|
G |
Ache |
acetylcholinesterase |
multiple interactions |
ISO |
acanthoside B inhibits the reaction [Scopolamine results in increased expression of ACHE protein] |
CTD |
PMID:31077737 |
|
NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
multiple interactions |
ISO |
[acanthoside B co-treated with Scopolamine] results in increased expression of BDNF protein |
CTD |
PMID:31077737 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
acanthoside B inhibits the reaction [Scopolamine results in decreased activity of CAT protein] |
CTD |
PMID:31077737 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
ISO |
acanthoside B inhibits the reaction [Scopolamine results in decreased phosphorylation of CREB1 protein] |
CTD |
PMID:31077737 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
ISO |
acanthoside B inhibits the reaction [Scopolamine results in decreased expression of IL10 protein] |
CTD |
PMID:31077737 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
acanthoside B inhibits the reaction [Scopolamine results in increased expression of IL1B protein] |
CTD |
PMID:31077737 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
acanthoside B inhibits the reaction [Scopolamine results in increased expression of IL6 protein] |
CTD |
PMID:31077737 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
acanthoside B inhibits the reaction [Scopolamine results in increased expression of NOS2 protein] |
CTD |
PMID:31077737 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Ntrk2 |
neurotrophic receptor tyrosine kinase 2 |
multiple interactions |
ISO |
[acanthoside B co-treated with Scopolamine] results in increased phosphorylation of NTRK2 protein |
CTD |
PMID:31077737 |
|
NCBI chr17:5,558,992...5,870,299
Ensembl chr17:5,559,043...5,869,136
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
acanthoside B inhibits the reaction [Scopolamine results in increased expression of PTGS2 protein] |
CTD |
PMID:31077737 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
acanthoside B inhibits the reaction [Scopolamine results in increased expression of TNF protein] |
CTD |
PMID:31077737 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
increases expression |
ISO |
ginsenoside Rh1 results in increased expression of FOS mRNA |
CTD |
PMID:16204943 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO |
ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of ICAM1 protein] |
CTD |
PMID:21875580 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
ginsenoside Rh1 inhibits the reaction [Oxazolone results in increased expression of IL1B mRNA]; ginsenoside Rh1 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of IL1B mRNA] |
CTD |
PMID:16557482 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il4 |
interleukin 4 |
decreases expression |
ISO |
ginsenoside Rh1 results in decreased expression of IL4 |
CTD |
PMID:22855946 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
ginsenoside Rh1 inhibits the reaction [Galactose results in increased secretion of IL6 protein] |
CTD |
PMID:29412148 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Itga4 |
integrin subunit alpha 4 |
multiple interactions |
ISO |
ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of [ITGA4 protein binds to ITGB1 protein]] |
CTD |
PMID:21875580 |
|
NCBI chr 3:64,162,764...64,235,010
Ensembl chr 3:64,163,085...64,233,715
|
|
G |
Itgal |
integrin subunit alpha L |
multiple interactions |
ISO |
ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of [ITGAL protein binds to ITGB2 protein]] |
CTD |
PMID:21875580 |
|
NCBI chr 1:181,918,183...181,955,735
Ensembl chr 1:181,918,183...181,955,732
|
|
G |
Itgb1 |
integrin subunit beta 1 |
multiple interactions |
ISO |
ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of [ITGA4 protein binds to ITGB1 protein]] |
CTD |
PMID:21875580 |
|
NCBI chr19:56,705,123...56,753,199
Ensembl chr19:56,705,171...56,753,195
|
|
G |
Itgb2 |
integrin subunit beta 2 |
multiple interactions |
ISO |
ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of [ITGAL protein binds to ITGB2 protein]] |
CTD |
PMID:21875580 |
|
NCBI chr20:11,061,394...11,097,656
Ensembl chr20:11,061,430...11,097,600
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
decreases activity |
ISO |
ginsenoside Rh1 results in decreased activity of JUN protein |
CTD |
PMID:22855946 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Lpl |
lipoprotein lipase |
increases secretion |
ISO |
ginsenoside Rh1 results in increased secretion of LPL protein |
CTD |
PMID:8988629 |
|
NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249
|
|
G |
Pgr |
progesterone receptor |
increases expression |
ISO |
ginsenoside Rh1 results in increased expression of PGR protein |
CTD |
PMID:16204943 |
|
NCBI chr 8:6,072,673...6,131,552
Ensembl chr 8:6,072,673...6,131,344
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
ISO |
ginsenoside Rh1 inhibits the reaction [bisphenol A results in increased expression of PPARG mRNA]; ginsenoside Rh1 inhibits the reaction [bisphenol A results in increased expression of PPARG protein] |
CTD |
PMID:32623698 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
ginsenoside Rh1 inhibits the reaction [Oxazolone results in increased expression of PTGS2 mRNA]; ginsenoside Rh1 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 mRNA] |
CTD |
PMID:16557482 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Sele |
selectin E |
multiple interactions |
ISO |
ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of SELE protein] |
CTD |
PMID:21875580 |
|
NCBI chr13:76,402,841...76,412,741
Ensembl chr13:76,403,304...76,412,741
|
|
G |
Tff1 |
trefoil factor 1 |
increases expression |
ISO |
ginsenoside Rh1 results in increased expression of TFF1 mRNA |
CTD |
PMID:16204943 |
|
NCBI chr20:9,235,736...9,239,597
Ensembl chr20:9,235,736...9,239,597
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions decreases expression decreases response to substance |
ISO |
ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of [ITGA4 protein binds to ITGB1 protein]]; ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of [ITGAL protein binds to ITGB2 protein]]; ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]; ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of SELE protein]; ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of VCAM1 protein] ginsenoside Rh1 inhibits the reaction [Oxazolone results in increased expression of TNF mRNA]; ginsenoside Rh1 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of TNF mRNA] ginsenoside Rh1 results in decreased expression of TNF ginsenoside Rh1 results in decreased susceptibility to TNF protein |
CTD |
PMID:16557482 PMID:21875580 PMID:22855946 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
multiple interactions |
ISO |
ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of VCAM1 protein] |
CTD |
PMID:21875580 |
|
NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958
|
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
decreases phosphorylation |
ISO |
ginsenoside Rh2 results in decreased phosphorylation of AKT1 protein |
CTD |
PMID:32762018 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
ISO |
ginsenoside Rh2 results in increased expression of BAX protein |
CTD |
PMID:26482938 PMID:32762018 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression |
ISO |
ginsenoside Rh2 results in decreased expression of BCL2 protein |
CTD |
PMID:26482938 PMID:32762018 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Casp3 |
caspase 3 |
increases cleavage decreases expression |
ISO |
ginsenoside Rh2 results in increased cleavage of CASP3 protein ginsenoside Rh2 results in decreased expression of CASP3 protein |
CTD |
PMID:26482938 PMID:32762018 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
decreases expression |
ISO |
ginsenoside Rh2 results in decreased expression of CASP9 protein |
CTD |
PMID:32762018 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression |
ISO |
ginsenoside Rh2 results in decreased expression of CCND1 protein |
CTD |
PMID:26482938 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Hdac1 |
histone deacetylase 1 |
decreases expression |
ISO |
ginsenoside Rh2 results in decreased expression of HDAC1 protein |
CTD |
PMID:26482938 |
|
NCBI chr 5:141,853,992...141,881,057
Ensembl chr 5:141,853,989...141,881,111
|
|
G |
Hdac2 |
histone deacetylase 2 |
decreases expression |
ISO |
ginsenoside Rh2 results in decreased expression of HDAC2 protein |
CTD |
PMID:26482938 |
|
NCBI chr20:40,548,244...40,571,609
Ensembl chr20:40,548,250...40,571,609
|
|
G |
Hdac6 |
histone deacetylase 6 |
decreases expression |
ISO |
ginsenoside Rh2 results in decreased expression of HDAC6 protein |
CTD |
PMID:26482938 |
|
NCBI chr X:14,550,645...14,572,445
Ensembl chr X:14,551,044...14,572,441
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
ginsenoside Rh2 inhibits the reaction [Galactose results in increased secretion of IL6 protein] |
CTD |
PMID:29412148 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
decreases phosphorylation increases phosphorylation |
ISO |
ginsenoside Rh2 results in decreased phosphorylation of MAPK1 protein ginsenoside Rh2 results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:26482938 PMID:32762018 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
decreases phosphorylation increases phosphorylation |
ISO |
ginsenoside Rh2 results in decreased phosphorylation of MAPK3 protein ginsenoside Rh2 results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:26482938 PMID:32762018 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
decreases phosphorylation |
ISO |
ginsenoside Rh2 results in decreased phosphorylation of MTOR protein |
CTD |
PMID:32762018 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
increases expression |
ISO |
ginsenoside Rh2 results in increased expression of NFKBIA protein |
CTD |
PMID:32762018 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
ginsenoside Rh2 results in increased expression of and results in decreased phosphorylation of RELA protein |
CTD |
PMID:32762018 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
ISO |
Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA]; Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein] |
CTD |
PMID:36457260 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Fn1 |
fibronectin 1 |
multiple interactions |
ISO |
Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of FN1 mRNA]; Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of FN1 protein] |
CTD |
PMID:36457260 |
|
NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678
|
|
G |
Hpse |
heparanase |
multiple interactions |
ISO |
Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of HPSE protein] Amygdalin inhibits the reaction [Ovalbumin results in increased expression of HPSE protein]; Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of HPSE protein] |
CTD |
PMID:36457260 |
|
NCBI chr14:8,896,593...8,937,011
Ensembl chr14:8,896,593...8,937,010
|
|
G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
multiple interactions |
ISO |
[peoniflorin co-treated with benzoylpaeoniflorin co-treated with Amygdalin] inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS1 mRNA]; Amygdalin inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS1 mRNA] |
CTD |
PMID:33149750 |
|
NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
[peoniflorin co-treated with benzoylpaeoniflorin co-treated with Amygdalin] inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]; Amygdalin inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA] |
CTD |
PMID:33149750 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA]; Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]; Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of FN1 mRNA]; Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of FN1 protein]; Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of HPSE protein]; Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of VIM mRNA]; Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of VIM protein]; Amygdalin inhibits the reaction [TGFB1 protein results in increased secretion of TGFB1 protein] Amygdalin inhibits the reaction [Ovalbumin results in increased secretion of TGFB1 protein]; Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA]; Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]; Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of FN1 mRNA]; Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of FN1 protein]; Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of HPSE protein]; Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of VIM mRNA]; Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of VIM protein]; Amygdalin inhibits the reaction [TGFB1 protein results in increased secretion of TGFB1 protein] |
CTD |
PMID:36457260 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Vim |
vimentin |
multiple interactions |
ISO |
Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of VIM mRNA]; Amygdalin inhibits the reaction [TGFB1 protein results in increased expression of VIM protein] |
CTD |
PMID:36457260 |
|
NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187
|
|
|
G |
Aacs |
acetoacetyl-CoA synthetase |
increases expression |
ISO |
Glucosamine results in increased expression of AACS mRNA |
CTD |
PMID:17178593 |
|
NCBI chr12:31,113,098...31,156,411
Ensembl chr12:31,113,098...31,160,954
|
|
G |
Abcg1 |
ATP binding cassette subfamily G member 1 |
increases expression |
EXP |
Glucosamine results in increased expression of ABCG1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr20:9,126,687...9,182,948
Ensembl chr20:9,126,687...9,182,948
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
increases expression |
ISO |
Glucosamine results in increased expression of ACACA mRNA |
CTD |
PMID:22096489 |
|
NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
|
|
G |
Acan |
aggrecan |
multiple interactions increases expression decreases expression affects expression |
ISO EXP |
Glucosamine analog affects the reaction [IL1B results in decreased expression of ACAN mRNA]; Glucosamine inhibits the reaction [IL1B protein results in decreased expression of ACAN mRNA]; Glucosamine results in decreased cleavage of and results in decreased secretion of ACAN protein Glucosamine results in increased expression of ACAN mRNA Glucosamine inhibits the reaction [IL1B results in decreased expression of ACAN mRNA] Glucosamine analog results in increased expression of ACAN protein; Glucosamine results in increased expression of ACAN mRNA; Glucosamine results in increased expression of ACAN protein Glucosamine analog results in decreased expression of ACAN mRNA Glucosamine analog affects the expression of ACAN mRNA |
CTD |
PMID:12801482 PMID:16300972 PMID:16872674 PMID:17109745 PMID:17337215 PMID:18321735 PMID:19909832 More...
|
|
NCBI chr 1:132,981,582...133,044,416
Ensembl chr 1:132,981,582...133,043,627
|
|
G |
Acot1 |
acyl-CoA thioesterase 1 |
increases expression |
ISO |
Glucosamine results in increased expression of ACOT1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 6:103,636,173...103,644,167
Ensembl chr 6:103,636,041...103,644,163
|
|
G |
Acox2 |
acyl-CoA oxidase 2 |
decreases expression |
ISO |
Glucosamine results in decreased expression of ACOX2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr15:16,660,584...16,692,160
Ensembl chr15:16,660,272...16,692,160
|
|
G |
Acss2 |
acyl-CoA synthetase short-chain family member 2 |
increases expression |
ISO |
Glucosamine results in increased expression of ACSS2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 3:144,003,808...144,047,452
Ensembl chr 3:144,004,336...144,059,675
|
|
G |
Adam15 |
ADAM metallopeptidase domain 15 |
multiple interactions decreases expression |
EXP |
Glucosamine affects the reaction [IL1B results in decreased expression of ADAM15 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of ADAM15 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 2:174,754,629...174,765,136
Ensembl chr 2:174,754,633...174,765,113
|
|
G |
Adam17 |
ADAM metallopeptidase domain 17 |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of ADAM17 mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of ADAM17 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 6:40,872,936...40,920,700
Ensembl chr 6:40,872,856...40,920,639
|
|
G |
Adamts1 |
ADAM metallopeptidase with thrombospondin type 1 motif, 1 |
decreases expression multiple interactions |
ISO EXP |
Glucosamine analog results in decreased expression of ADAMTS1 mRNA Glucosamine results in decreased expression of ADAMTS1 mRNA Glucosamine inhibits the reaction [IL1B results in increased expression of ADAMTS1 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of ADAMTS1 mRNA] |
CTD |
PMID:16300972 PMID:17109745 |
|
NCBI chr11:24,932,227...24,941,068
Ensembl chr11:24,931,761...24,941,103
|
|
G |
Adamts20 |
ADAM metallopeptidase with thrombospondin type 1 motif, 20 |
decreases cleavage |
ISO |
Glucosamine results in decreased cleavage of ADAMTS20 protein alternative form |
CTD |
PMID:19909832 |
|
NCBI chr 7:125,396,227...125,528,020
Ensembl chr 7:125,397,734...125,527,777
|
|
G |
Adamts4 |
ADAM metallopeptidase with thrombospondin type 1 motif, 4 |
increases expression |
EXP |
Glucosamine results in increased expression of ADAMTS4 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr13:83,670,556...83,680,045
Ensembl chr13:83,670,183...83,680,065
|
|
G |
Adamts5 |
ADAM metallopeptidase with thrombospondin type 1 motif, 5 |
decreases expression multiple interactions |
ISO |
Glucosamine analog results in decreased expression of ADAMTS5 mRNA Glucosamine results in decreased cleavage of and results in decreased activity of ADAMTS5 protein alternative form |
CTD |
PMID:16300972 PMID:19909832 |
|
NCBI chr11:25,000,627...25,047,205
Ensembl chr11:25,000,637...25,047,205
|
|
G |
Adamts9 |
ADAM metallopeptidase with thrombospondin type 1 motif, 9 |
decreases cleavage |
ISO |
Glucosamine results in decreased cleavage of ADAMTS9 protein alternative form |
CTD |
PMID:19909832 |
|
NCBI chr 4:125,290,633...125,462,988
Ensembl chr 4:125,291,490...125,462,929
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
increases expression |
ISO EXP |
Glucosamine results in increased expression of ADIPOQ mRNA |
CTD |
PMID:15694357 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Afp |
alpha-fetoprotein |
increases expression |
ISO |
Glucosamine results in increased expression of AFP mRNA |
CTD |
PMID:17178593 |
|
NCBI chr14:17,573,412...17,591,476
Ensembl chr14:17,573,412...17,591,480
|
|
G |
Agt |
angiotensinogen |
increases expression |
ISO |
Glucosamine results in increased expression of AGT mRNA |
CTD |
PMID:17178593 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Ahi1 |
Abelson helper integration site 1 |
decreases expression |
ISO |
Glucosamine results in decreased expression of AHI1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 1:15,762,485...15,891,213
Ensembl chr 1:15,762,462...15,891,041
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
affects phosphorylation multiple interactions |
ISO |
Glucosamine analog affects the phosphorylation of AKT1 protein Glucosamine inhibits the reaction [INS1 protein results in increased phosphorylation of AKT1 protein]; OSTN protein affects the reaction [Glucosamine inhibits the reaction [INS1 protein results in increased phosphorylation of AKT1 protein]] Glucosamine analog affects the reaction [IL1B results in increased phosphorylation of AKT1 protein]; Glucosamine promotes the reaction [IL1B results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:18080321 PMID:18340449 PMID:30602124 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alb |
albumin |
multiple interactions |
EXP |
[LEPR protein affects the susceptibility to Glucosamine] which affects the expression of ALB protein |
CTD |
PMID:33345901 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Alg12 |
ALG12, alpha-1,6-mannosyltransferase |
decreases expression |
ISO |
Glucosamine results in decreased expression of ALG12 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 7:119,895,112...119,909,488
Ensembl chr 7:119,895,120...119,909,458
|
|
G |
Alpl |
alkaline phosphatase, biomineralization associated |
multiple interactions increases expression increases activity |
ISO |
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [Glucosamine analog results in increased activity of ALPL protein] Glucosamine analog results in increased expression of ALPL mRNA |
CTD |
PMID:20458730 |
|
NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446
|
|
G |
Apoa1 |
apolipoprotein A1 |
increases secretion increases stability |
ISO |
Glucosamine results in increased secretion of APOA1 protein Glucosamine results in increased stability of APOA1 mRNA |
CTD |
PMID:15164326 |
|
NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035
|
|
G |
Apob |
apolipoprotein B |
multiple interactions increases degradation increases ubiquitination decreases secretion decreases localization decreases expression |
ISO EXP |
acetylleucyl-leucyl-norleucinal inhibits the reaction [Glucosamine results in decreased expression of and results in decreased secretion of APOB protein]; Glucosamine results in decreased expression of and results in decreased secretion of APOB protein; Oleic Acid inhibits the reaction [Glucosamine results in decreased secretion of APOB protein] Oleic Acid inhibits the reaction [Glucosamine results in increased degradation of APOB protein] Glucosamine results in increased ubiquitination of APOB protein Glucosamine results in decreased localization of APOB protein Glucosamine results in decreased expression of APOB protein |
CTD |
PMID:15618547 PMID:19383982 |
|
NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:30,844,368...30,892,497
|
|
G |
Apoe |
apolipoprotein E |
multiple interactions |
ISO |
[Streptozocin co-treated with APOE mutant form] results in increased abundance of Glucosamine; INS1 inhibits the reaction [[Streptozocin co-treated with APOE mutant form] results in increased abundance of Glucosamine] |
CTD |
PMID:16380481 |
|
NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932
|
|
G |
Ass1 |
argininosuccinate synthase 1 |
multiple interactions |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of ASS1 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 3:14,747,355...14,796,909
Ensembl chr 3:14,747,368...14,796,903
|
|
G |
Atf3 |
activating transcription factor 3 |
decreases expression |
ISO |
Glucosamine results in decreased expression of ATF3 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631
|
|
G |
Atf4 |
activating transcription factor 4 |
multiple interactions increases expression |
ISO |
4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of ATF4 mRNA]; 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of ATF4 protein]; EIF2AK3 protein affects the reaction [Glucosamine results in increased expression of ATF4 mRNA]; GSK2656157 inhibits the reaction [Glucosamine results in increased expression of ATF4 mRNA] NUS1 protein inhibits the reaction [Glucosamine results in increased expression of ATF4 mRNA] Glucosamine results in increased expression of ATF4 mRNA; Glucosamine results in increased expression of ATF4 protein |
CTD |
PMID:30602124 PMID:33812996 |
|
NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
|
|
G |
Atf6 |
activating transcription factor 6 |
multiple interactions increases expression decreases expression |
ISO EXP |
4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of ATF6 mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of MEF2A mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of MEF2A protein]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of PPARGC1A mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of PPARGC1A protein]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of SLC2A4 mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of SLC2A4 protein]; NUS1 protein inhibits the reaction [Glucosamine results in increased expression of ATF6 mRNA]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in increased expression of ATF6 mRNA] ATF6 protein affects the reaction [Glucosamine results in increased expression of OSTN mRNA] Glucosamine results in increased expression of ATF6 protein 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of ATF6 mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of MEF2A mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of MEF2A protein]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of PPARGC1A mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of PPARGC1A protein]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of SLC2A4 mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of SLC2A4 protein]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in increased expression of ATF6 mRNA] Glucosamine results in decreased expression of ATF6 mRNA |
CTD |
PMID:17178593 PMID:19383982 PMID:20165829 PMID:30602124 PMID:33812996 |
|
NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177
|
|
G |
Atf7ip |
activating transcription factor 7 interacting protein |
increases expression |
ISO |
Glucosamine results in increased expression of ATF7IP mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 4:169,385,872...169,471,652
Ensembl chr 4:169,385,872...169,471,650
|
|
G |
Atp2a2 |
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2 |
decreases expression |
ISO |
Glucosamine results in decreased expression of ATP2A2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr12:34,072,710...34,122,142
Ensembl chr12:34,072,683...34,122,101
|
|
G |
Azin1 |
antizyme inhibitor 1 |
decreases expression multiple interactions |
EXP |
Glucosamine results in decreased expression of AZIN1 mRNA IL1B promotes the reaction [Glucosamine results in increased expression of AZIN1 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 7:69,654,773...69,681,578
Ensembl chr 7:69,654,663...69,681,578
|
|
G |
B3gat3 |
beta-1,3-glucuronyltransferase 3 |
multiple interactions increases expression |
EXP |
[XDH protein co-treated with Hypoxanthine] inhibits the reaction [Glucosamine results in increased expression of B3GAT3 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in decreased activity of B3GAT3 protein]; Glucosamine inhibits the reaction [IL1B protein results in decreased expression of B3GAT3 mRNA] |
CTD |
PMID:11229466 PMID:11801247 |
|
NCBI chr 1:205,817,374...205,823,928
Ensembl chr 1:205,817,378...205,837,807
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
decreases expression multiple interactions |
ISO |
Glucosamine results in decreased expression of BCL2L1 protein pepstatin inhibits the reaction [Glucosamine results in decreased expression of BCL2L1 protein] |
CTD |
PMID:15972124 PMID:16850161 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
decreases expression |
ISO |
Glucosamine results in decreased expression of BDNF mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
increases expression |
ISO |
Glucosamine analog results in increased expression of BGLAP mRNA |
CTD |
PMID:20458730 |
|
NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495
|
|
G |
Bgn |
biglycan |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of BGN mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of BGN mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr X:151,197,296...151,209,458
Ensembl chr X:151,197,273...151,209,461
|
|
G |
Bmal1 |
basic helix-loop-helix ARNT like 1 |
decreases expression |
ISO |
Glucosamine results in decreased expression of BMAL1 mRNA; Glucosamine results in decreased expression of BMAL1 protein |
CTD |
PMID:24442997 |
|
NCBI chr 1:167,331,756...167,430,235
Ensembl chr 1:167,331,633...167,430,231
|
|
G |
Bmp2 |
bone morphogenetic protein 2 |
multiple interactions |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of BMP2 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 3:120,812,660...120,822,579
Ensembl chr 3:120,812,882...120,821,397
|
|
G |
Bmp4 |
bone morphogenetic protein 4 |
decreases expression multiple interactions |
EXP |
Glucosamine results in decreased expression of BMP4 mRNA Glucosamine promotes the reaction [IL1B results in decreased expression of BMP4 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr15:19,618,538...19,633,494
Ensembl chr15:19,618,542...19,623,306
|
|
G |
Bmp6 |
bone morphogenetic protein 6 |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of BMP6 mRNA] Glucosamine results in decreased expression of BMP6 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr17:26,318,121...26,469,691
Ensembl chr17:26,318,569...26,470,365
|
|
G |
Bmp7 |
bone morphogenetic protein 7 |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of BMP7 mRNA] Glucosamine results in increased expression of BMP7 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 3:161,639,915...161,716,938
Ensembl chr 3:161,516,462...161,716,788
|
|
G |
Calr |
calreticulin |
decreases expression |
ISO |
Glucosamine results in decreased expression of CALR mRNA |
CTD |
PMID:17178593 |
|
NCBI chr19:23,308,525...23,313,420
Ensembl chr19:23,308,351...23,313,414
|
|
G |
Car3 |
carbonic anhydrase 3 |
decreases expression |
EXP |
Glucosamine results in decreased expression of CAR3 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 2:86,770,418...86,780,011
Ensembl chr 2:86,770,420...86,784,280
|
|
G |
Casp3 |
caspase 3 |
increases cleavage multiple interactions |
ISO |
Glucosamine results in increased cleavage of CASP3 protein Glucosamine results in increased activity of and results in increased cleavage of CASP3 protein |
CTD |
PMID:16850161 PMID:22020377 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp4 |
caspase 4 |
decreases expression |
ISO |
Glucosamine results in decreased expression of CASP4 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 8:2,599,017...2,635,097
Ensembl chr 8:2,598,876...2,635,092
|
|
G |
Cbr2 |
carbonyl reductase 2 |
increases expression |
ISO |
Glucosamine results in increased expression of CBR2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr10:106,008,535...106,012,838
Ensembl chr10:105,991,589...106,013,001
|
|
G |
Cbr3 |
carbonyl reductase 3 |
increases expression |
ISO |
Glucosamine results in increased expression of CBR3 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr11:33,008,615...33,016,877
Ensembl chr11:33,008,615...33,016,875
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions increases expression |
ISO EXP |
Alloxan inhibits the reaction [Glucosamine inhibits the reaction [Cathelicidins results in increased expression of CCL2 protein]]; Glucosamine analog inhibits the reaction [IL1B results in increased secretion of CCL2 protein]; Glucosamine inhibits the reaction [Cathelicidins results in increased expression of CCL2 mRNA]; Glucosamine inhibits the reaction [Cathelicidins results in increased expression of CCL2 protein]; Glucosamine inhibits the reaction [TNF results in increased expression of CCL2 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of CCL2 protein] Glucosamine results in increased expression of CCL2 mRNA Glucosamine inhibits the reaction [IL1B results in increased expression of CCL2 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of CCL2 mRNA] |
CTD |
PMID:17109745 PMID:18080321 PMID:18949387 PMID:19020780 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl20 |
C-C motif chemokine ligand 20 |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of CCL20 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of CCL20 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 9:84,389,031...84,391,629
Ensembl chr 9:84,388,904...84,391,629
|
|
G |
Ccl22 |
C-C motif chemokine ligand 22 |
multiple interactions |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of CCL22 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr19:10,257,602...10,264,373
Ensembl chr19:10,257,601...10,264,400
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
multiple interactions |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of CCL3 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions |
ISO EXP |
Glucosamine analog inhibits the reaction [IL1B results in increased secretion of CCL5 protein] Glucosamine inhibits the reaction [IL1B results in increased expression of CCL5 mRNA] |
CTD |
PMID:17109745 PMID:18080321 |
|
NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Ccl7 |
C-C motif chemokine ligand 7 |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of CCL7 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of CCL7 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr10:67,016,446...67,018,296
Ensembl chr10:67,016,446...67,018,303
|
|
G |
Ccn2 |
cellular communication network factor 2 |
increases expression |
EXP |
Glucosamine analog results in increased expression of CCN2 mRNA |
CTD |
PMID:21466783 |
|
NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734
|
|
G |
Ccnb1 |
cyclin B1 |
decreases expression |
EXP |
Glucosamine results in decreased expression of CCNB1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Cd24 |
CD24 molecule |
increases expression |
ISO |
Glucosamine results in increased expression of CD24A mRNA |
CTD |
PMID:17178593 |
|
NCBI chr20:47,074,353...47,079,662
Ensembl chr20:47,073,512...47,079,662
|
|
G |
Cd28 |
Cd28 molecule |
increases expression |
EXP |
Glucosamine results in increased expression of CD28 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 9:62,166,324...62,194,674
Ensembl chr 9:62,166,192...62,194,685
|
|
G |
Cdc20 |
cell division cycle 20 |
decreases expression |
EXP |
Glucosamine results in decreased expression of CDC20 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 5:131,966,203...131,970,406
Ensembl chr 5:131,966,215...131,970,512
|
|
G |
Cdc23 |
cell division cycle 23 |
decreases expression |
EXP |
Glucosamine results in decreased expression of CDC23 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr18:26,236,891...26,260,611
Ensembl chr18:26,236,890...26,291,163
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
decreases expression |
EXP |
Glucosamine results in decreased expression of CDK1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression |
EXP ISO |
Glucosamine results in increased expression of CDKN1A protein Glucosamine results in increased expression of CDKN1A mRNA |
CTD |
PMID:15654767 PMID:17178593 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
decreases expression |
EXP |
Glucosamine results in decreased expression of CDKN1B protein |
CTD |
PMID:15654767 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cdkn3 |
cyclin-dependent kinase inhibitor 3 |
decreases expression |
EXP |
Glucosamine results in decreased expression of CDKN3 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr15:20,022,522...20,033,948
Ensembl chr15:20,022,664...20,033,945
|
|
G |
Cenpf |
centromere protein F |
decreases expression |
EXP |
Glucosamine results in decreased expression of CENPF mRNA |
CTD |
PMID:17109745 |
|
NCBI chr13:101,184,127...101,229,714
Ensembl chr13:101,184,127...101,229,669
|
|
G |
Chi3l1 |
chitinase 3 like 1 |
decreases expression |
ISO |
Glucosamine analog results in decreased expression of CHI3L1 mRNA |
CTD |
PMID:16142878 |
|
NCBI chr13:45,641,802...45,649,787
Ensembl chr13:45,641,802...45,649,787
|
|
G |
Chuk |
component of inhibitor of nuclear factor kappa B kinase complex |
multiple interactions decreases activity |
ISO |
Glucosamine analog results in decreased activity of and results in decreased localization of CHUK protein Glucosamine analog results in decreased activity of CHUK protein |
CTD |
PMID:20113495 |
|
NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065
|
|
G |
Ckap2 |
cytoskeleton associated protein 2 |
decreases expression |
EXP |
Glucosamine results in decreased expression of CKAP2 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr16:69,839,668...69,864,852
Ensembl chr16:69,839,630...69,864,913
|
|
G |
Clock |
clock circadian regulator |
decreases expression |
ISO |
Glucosamine results in decreased expression of CLOCK mRNA; Glucosamine results in decreased expression of CLOCK protein |
CTD |
PMID:24442997 |
|
NCBI chr14:31,908,542...31,992,673
Ensembl chr14:31,908,566...31,990,400
|
|
G |
Clta |
clathrin, light chain A |
decreases expression |
EXP |
Glucosamine results in decreased expression of CLTA mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 5:58,244,253...58,263,480
Ensembl chr 5:58,245,442...58,263,472
|
|
G |
Col11a1 |
collagen type XI alpha 1 chain |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in decreased expression of COL11A1 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of COL11A1 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 2:201,820,715...202,013,853
Ensembl chr 2:201,820,715...202,013,853
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions decreases expression |
ISO |
Glucosamine inhibits the reaction [IL1B protein results in increased expression of COL1A1 mRNA] Glucosamine results in decreased expression of COL1A1 mRNA |
CTD |
PMID:18321735 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Col2a1 |
collagen type II alpha 1 chain |
multiple interactions affects expression increases expression |
ISO EXP |
Glucosamine analog affects the reaction [IL1B results in decreased expression of COL2A1 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in decreased expression of COL2A1 mRNA] Glucosamine inhibits the reaction [IL1B results in decreased expression of COL2A1 mRNA] Glucosamine analog affects the expression of COL2A1 mRNA Glucosamine analog results in increased expression of COL2A1 mRNA; Glucosamine results in increased expression of COL2A1 mRNA |
CTD |
PMID:16300972 PMID:17109745 PMID:17337215 PMID:18321735 |
|
NCBI chr 7:129,098,489...129,127,560
Ensembl chr 7:129,098,786...129,127,546
|
|
G |
Col3a1 |
collagen type III alpha 1 chain |
multiple interactions |
EXP |
Glucosamine inhibits the reaction [IL1B results in decreased expression of COL3A1 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547
|
|
G |
Col8a1 |
collagen type VIII alpha 1 chain |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of COL8A1 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of COL8A1 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr11:42,776,851...42,906,432
Ensembl chr11:42,777,628...42,906,424
|
|
G |
Csf1 |
colony stimulating factor 1 |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of CSF1 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of CSF1 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 2:195,377,215...195,396,608
Ensembl chr 2:195,377,215...195,411,704
|
|
G |
Csf2 |
colony stimulating factor 2 |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of CSF2 mRNA] Glucosamine results in increased expression of CSF2 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199
|
|
G |
Csf3 |
colony stimulating factor 3 |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of CSF3 mRNA] Glucosamine results in increased expression of CSF3 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr10:83,660,787...83,664,569
Ensembl chr10:83,661,207...83,663,603
|
|
G |
Ctsd |
cathepsin D |
affects localization multiple interactions increases activity decreases expression |
ISO |
Glucosamine affects the localization of CTSD protein pepstatin inhibits the reaction [Glucosamine results in decreased expression of CTSD protein alternative form] Glucosamine results in increased activity of CTSD protein |
CTD |
PMID:15972124 PMID:16850161 |
|
NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488
|
|
G |
Cul2 |
cullin 2 |
multiple interactions |
ISO |
Glucosamine analog inhibits the reaction [TNF results in increased expression of CUL2 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of CUL2 mRNA] |
CTD |
PMID:18173918 |
|
NCBI chr17:54,169,093...54,210,197
Ensembl chr17:54,169,086...54,209,968
|
|
G |
Cxcl1 |
C-X-C motif chemokine ligand 1 |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL1 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of CXCL1 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr14:17,193,364...17,195,143
Ensembl chr14:17,193,365...17,195,215
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
multiple interactions |
ISO EXP |
Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL10 mRNA] Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL10 mRNA] |
CTD |
PMID:17109745 PMID:20737476 |
|
NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975
|
|
G |
Cxcl11 |
C-X-C motif chemokine ligand 11 |
multiple interactions |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL11 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr14:15,689,432...15,692,207
Ensembl chr14:15,689,424...15,692,271
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
multiple interactions decreases expression |
EXP |
Glucosamine promotes the reaction [IL1B results in decreased expression of CXCL12 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of CXCL12 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL2 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of CXCL2 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL3 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of CXCL3 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511
|
|
G |
Cxcl6 |
C-X-C motif chemokine ligand 6 |
multiple interactions |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL5 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr14:17,310,790...17,312,250
Ensembl chr14:17,310,426...17,313,093
|
|
G |
Cyba |
cytochrome b-245 alpha chain |
decreases expression |
ISO |
Glucosamine results in decreased expression of CYBA mRNA |
CTD |
PMID:18077487 |
|
NCBI chr19:50,487,598...50,495,669
Ensembl chr19:50,487,597...50,495,721
|
|
G |
Cycs |
cytochrome c, somatic |
affects localization |
ISO |
Glucosamine affects the localization of CYCS protein |
CTD |
PMID:15972124 PMID:22020377 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054 Ensembl chr18:79,651,378...79,654,054
|
|
G |
Cyp51 |
cytochrome P450, family 51 |
increases expression |
ISO |
Glucosamine results in increased expression of CYP51 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 4:30,036,956...30,055,410
Ensembl chr 4:30,036,865...30,055,410
|
|
G |
Dbi |
diazepam binding inhibitor |
increases expression |
ISO |
Glucosamine results in increased expression of DBI mRNA |
CTD |
PMID:17178593 |
|
NCBI chr13:31,241,466...31,249,853
Ensembl chr13:31,206,988...31,268,693
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression multiple interactions decreases expression |
ISO |
Glucosamine results in increased expression of DDIT3 mRNA; Glucosamine results in increased expression of DDIT3 protein NUS1 protein inhibits the reaction [Glucosamine results in increased expression of DDIT3 mRNA] 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of DDIT3 mRNA]; 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of DDIT3 protein] Glucosamine results in decreased expression of DDIT3 mRNA |
CTD |
PMID:16380481 PMID:17178593 PMID:30602124 PMID:33812996 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Ddit4l |
DNA-damage-inducible transcript 4-like |
increases expression |
EXP |
Glucosamine results in increased expression of DDIT4L mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 2:226,128,273...226,131,044
Ensembl chr 2:226,128,276...226,131,375
|
|
G |
Dhcr7 |
7-dehydrocholesterol reductase |
increases expression |
ISO |
Glucosamine results in increased expression of DHCR7 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 1:199,015,081...199,031,055
Ensembl chr 1:199,015,081...199,031,055
|
|
G |
Dnajb11 |
DnaJ heat shock protein family (Hsp40) member B11 |
decreases expression |
ISO |
Glucosamine results in decreased expression of DNAJB11 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr11:78,151,750...78,168,259
Ensembl chr11:78,150,429...78,180,407
|
|
G |
Dnajb9 |
DnaJ heat shock protein family (Hsp40) member B9 |
decreases expression |
ISO |
Glucosamine results in decreased expression of DNAJB9 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 6:61,270,385...61,276,795
Ensembl chr 6:61,269,913...61,275,063
|
|
G |
Dnajc3 |
DnaJ heat shock protein family (Hsp40) member C3 |
decreases expression |
ISO |
Glucosamine results in decreased expression of DNAJC3 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr15:96,025,605...96,068,585
Ensembl chr15:96,025,624...96,065,181
|
|
G |
Dspp |
dentin sialophosphoprotein |
decreases expression |
ISO |
Glucosamine analog results in decreased expression of DSPP mRNA |
CTD |
PMID:20458730 |
|
NCBI chr14:5,565,562...5,571,669
Ensembl chr14:5,565,629...5,571,672
|
|
G |
Dusp5 |
dual specificity phosphatase 5 |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of DUSP5 mRNA] Glucosamine results in increased expression of DUSP5 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 1:252,538,408...252,555,320
Ensembl chr 1:252,538,449...252,551,818
|
|
G |
Dusp7 |
dual specificity phosphatase 7 |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of DUSP7 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of DUSP7 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 8:107,009,369...107,016,404
Ensembl chr 8:107,008,528...107,016,404
|
|
G |
Dync1i1 |
dynein cytoplasmic 1 intermediate chain 1 |
decreases expression |
EXP |
Glucosamine results in decreased expression of DYNC1I1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 4:33,852,597...34,166,159
Ensembl chr 4:33,852,927...34,166,149
|
|
G |
Edem1 |
ER degradation enhancing alpha-mannosidase like protein 1 |
decreases expression |
ISO |
Glucosamine results in decreased expression of EDEM1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 4:141,797,631...141,829,717
Ensembl chr 4:141,797,701...141,829,717
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
multiple interactions increases expression increases phosphorylation |
EXP ISO |
EIF2AK3 gene mutant form inhibits the reaction [Glucosamine results in increased phosphorylation of EIF2S1 protein] Glucosamine results in increased expression of EIF2AK3 protein NUS1 protein inhibits the reaction [Glucosamine results in increased expression of EIF2AK3 protein] EIF2AK3 protein affects the reaction [Glucosamine results in increased expression of ATF4 mRNA]; EIF2AK3 protein affects the reaction [Glucosamine results in increased expression of OSTN mRNA]; EIF2AK3 protein affects the reaction [Glucosamine results in increased phosphorylation of EIF2S1 protein] Glucosamine results in increased phosphorylation of EIF2AK3 protein |
CTD |
PMID:16324875 PMID:19383982 PMID:30602124 PMID:33812996 |
|
NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2 subunit alpha |
increases phosphorylation multiple interactions |
ISO EXP |
Glucosamine results in increased phosphorylation of EIF2S1 protein NUS1 protein inhibits the reaction [Glucosamine results in increased phosphorylation of EIF2S1 protein] 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased phosphorylation of EIF2S1 protein]; EIF2AK3 protein affects the reaction [Glucosamine results in increased phosphorylation of EIF2S1 protein]; GSK2656157 inhibits the reaction [Glucosamine results in increased phosphorylation of EIF2S1 protein] EIF2AK3 gene mutant form inhibits the reaction [Glucosamine results in increased phosphorylation of EIF2S1 protein] |
CTD |
PMID:16324875 PMID:19383982 PMID:30602124 PMID:33812996 |
|
NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225
|
|
G |
Elovl6 |
ELOVL fatty acid elongase 6 |
increases expression |
ISO |
Glucosamine results in increased expression of ELOVL6 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 2:218,063,682...218,174,767
Ensembl chr 2:218,063,804...218,171,186
|
|
G |
Epas1 |
endothelial PAS domain protein 1 |
decreases expression multiple interactions |
EXP |
Glucosamine results in decreased expression of EPAS1 mRNA Glucosamine inhibits the reaction [IL1B results in increased expression of EPAS1 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of EPAS1 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 6:7,790,236...7,871,717
Ensembl chr 6:7,790,647...7,871,228
|
|
G |
Eprs1 |
glutamyl-prolyl-tRNA synthetase 1 |
decreases expression |
ISO |
Glucosamine results in decreased expression of EPRS1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr13:96,901,548...96,971,966
Ensembl chr13:96,901,575...96,971,966
|
|
G |
Ern1 |
endoplasmic reticulum to nucleus signaling 1 |
multiple interactions increases expression |
ISO |
ERN1 protein affects the reaction [Glucosamine results in increased expression of OSTN mRNA]; ERN1 protein affects the reaction [Glucosamine results in increased splicing of XBP1 mRNA] NUS1 protein inhibits the reaction [Glucosamine results in increased expression of ERN1 mRNA] |
CTD |
PMID:30602124 PMID:33812996 |
|
NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
increases expression |
ISO EXP |
Glucosamine results in increased expression of FABP4 mRNA |
CTD |
PMID:15694357 |
|
NCBI chr 2:91,580,879...91,585,567
Ensembl chr 2:91,580,885...91,585,578
|
|
G |
Fasn |
fatty acid synthase |
increases expression |
ISO |
Glucosamine results in increased expression of FASN mRNA |
CTD |
PMID:22096489 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Fbp2 |
fructose-bisphosphatase 2 |
increases expression |
ISO |
Glucosamine results in increased expression of FBP2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr17:2,236,088...2,253,702
Ensembl chr17:2,236,336...2,253,698
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
multiple interactions |
EXP |
Glucosamine promotes the reaction [Glucose results in increased expression of FGF2 mRNA] |
CTD |
PMID:1518840 |
|
NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221
|
|
G |
Fgf7 |
fibroblast growth factor 7 |
decreases expression multiple interactions |
EXP |
Glucosamine results in decreased expression of FGF7 mRNA IL1B inhibits the reaction [Glucosamine results in decreased expression of FGF7 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 3:113,280,448...113,333,279
Ensembl chr 3:113,281,283...113,332,929
|
|
G |
Fgf9 |
fibroblast growth factor 9 |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of FGF9 mRNA] Glucosamine results in increased expression of FGF9 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr15:32,208,993...32,254,952
Ensembl chr15:32,210,074...32,253,309
|
|
G |
Fgfr1 |
Fibroblast growth factor receptor 1 |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in decreased expression of FGFR1 mRNA] Glucosamine results in increased expression of FGFR1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr16:66,491,930...66,547,161
Ensembl chr16:66,494,042...66,547,350
|
|
G |
Fkbp11 |
FKBP prolyl isomerase 11 |
decreases expression |
ISO |
Glucosamine results in decreased expression of FKBP11 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 7:129,871,870...129,877,760
Ensembl chr 7:129,871,870...129,875,303
|
|
G |
Fn1 |
fibronectin 1 |
decreases expression |
ISO EXP |
Glucosamine results in decreased expression of FN1 protein |
CTD |
PMID:17178593 |
|
NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
Glucosamine analog inhibits the reaction [Buthionine Sulfoximine results in increased expression of FOS mRNA] Glucosamine analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of FOS protein] |
CTD |
PMID:19375915 PMID:21825963 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Furin |
furin (paired basic amino acid cleaving enzyme) |
decreases cleavage multiple interactions |
ISO |
Glucosamine results in decreased cleavage of FURIN protein alternative form Glucosamine results in decreased glycosylation of and results in decreased activity of FURIN protein |
CTD |
PMID:19909832 |
|
NCBI chr 1:134,348,142...134,361,182
Ensembl chr 1:134,348,144...134,364,314
|
|
G |
Fxyd2 |
FXYD domain-containing ion transport regulator 2 |
increases expression |
EXP |
Glucosamine results in increased expression of FXYD2 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 8:45,712,901...45,720,032
Ensembl chr 8:45,712,903...45,720,203
|
|
G |
Gatm |
glycine amidinotransferase |
decreases expression |
EXP |
Glucosamine results in decreased expression of GATM mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 3:109,658,919...109,675,508
Ensembl chr 3:109,658,951...109,684,129
|
|
G |
Gck |
glucokinase |
decreases expression |
EXP |
Glucosamine results in decreased expression of GCK mRNA |
CTD |
PMID:11893929 |
|
NCBI chr14:80,785,060...80,829,842
Ensembl chr14:80,785,060...80,826,995
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
increases expression |
ISO |
Glucosamine analog results in increased expression of GCLC mRNA |
CTD |
PMID:21825963 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gfpt1 |
glutamine fructose-6-phosphate transaminase 1 |
multiple interactions |
EXP |
[Glucosamine co-treated with INS1 protein] affects the localization of GFPT1 protein |
CTD |
PMID:9453242 |
|
NCBI chr 4:119,496,691...119,546,472
Ensembl chr 4:119,496,714...119,546,471
|
|
G |
Glrx |
glutaredoxin |
increases expression |
ISO |
Glucosamine results in increased expression of GLRX mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 2:5,341,873...5,351,686
Ensembl chr 2:5,341,885...5,351,680
|
|
G |
Gnpnat1 |
glucosamine-phosphate N-acetyltransferase 1 |
decreases expression |
ISO |
Glucosamine results in decreased expression of GNPNAT1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr15:18,596,180...18,608,854
Ensembl chr15:18,596,442...18,608,739
|
|
G |
Gnptab |
N-acetylglucosamine-1-phosphate transferase subunits alpha and beta |
increases expression |
ISO |
Glucosamine results in increased expression of GNPTAB mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 7:22,800,502...22,866,336
Ensembl chr 7:22,800,485...22,866,933
|
|
G |
Gpd1l1 |
glycerol-3-phosphate dehydrogenase 1 like 1 |
increases expression |
ISO |
Glucosamine results in increased expression of GPD1L mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 8:114,591,103...114,620,771
Ensembl chr 8:114,588,487...114,620,723
|
|
G |
Grem1 |
gremlin 1, DAN family BMP antagonist |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of GREM1 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of GREM1 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 3:100,512,317...100,524,001
Ensembl chr 3:100,512,313...100,524,082
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions decreases phosphorylation |
ISO |
Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]; NUS1 protein inhibits the reaction [Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]]; PRKAA1 protein promotes the reaction [Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]]; PRKAA1 protein promotes the reaction [NUS1 protein inhibits the reaction [Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]]] Glucosamine results in decreased phosphorylation of GSK3B protein |
CTD |
PMID:33812996 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Gspt1 |
G1 to S phase transition 1 |
multiple interactions |
ISO |
Glucosamine analog inhibits the reaction [TNF results in increased expression of GSPT1 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of GSPT1 mRNA] |
CTD |
PMID:18173918 |
|
NCBI chr10:4,362,528...4,397,215
Ensembl chr10:4,362,510...4,397,198
|
|
G |
Gstt1 |
glutathione S-transferase theta 1 |
increases expression |
ISO |
Glucosamine results in increased expression of GSTT1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr20:12,856,613...12,873,586
Ensembl chr20:12,856,669...12,873,585
|
|
G |
Hapln1 |
hyaluronan and proteoglycan link protein 1 |
decreases expression multiple interactions |
EXP |
Glucosamine results in decreased expression of HAPLN1 mRNA Glucosamine inhibits the reaction [IL1B results in decreased expression of HAPLN1 mRNA]; IL1B promotes the reaction [Glucosamine results in decreased expression of HAPLN1 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 2:20,631,640...20,696,388
Ensembl chr 2:20,631,640...20,693,777
|
|
G |
Herpud1 |
homocysteine inducible ER protein with ubiquitin like domain 1 |
decreases expression |
ISO |
Glucosamine results in decreased expression of HERPUD1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr19:10,598,411...10,609,002
Ensembl chr19:10,598,417...10,618,424
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions decreases expression |
ISO |
Glucosamine affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of HIF1A protein]; Glucosamine inhibits the reaction [Oxygen deficiency results in increased expression of HIF1A protein] Glucosamine results in decreased expression of HIF1A mRNA; Glucosamine results in decreased expression of HIF1A protein |
CTD |
PMID:19254699 PMID:22020377 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hk1 |
hexokinase 1 |
increases expression |
ISO EXP |
Glucosamine results in increased expression of HK1 mRNA |
CTD |
PMID:11893929 PMID:17178593 |
|
NCBI chr20:30,230,488...30,332,099
Ensembl chr20:30,230,486...30,332,131
|
|
G |
Hmga1 |
high mobility group AT-hook 1 |
increases expression |
EXP |
Glucosamine results in increased expression of HMGA1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr20:5,611,088...5,618,755
Ensembl chr20:5,611,694...5,618,752
|
|
G |
Hmgcs1 |
3-hydroxy-3-methylglutaryl-CoA synthase 1 |
increases expression |
ISO |
Glucosamine results in increased expression of HMGCS1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 2:51,649,368...51,667,100
Ensembl chr 2:51,649,497...51,667,100
|
|
G |
Hmmr |
hyaluronan-mediated motility receptor |
decreases expression |
EXP |
Glucosamine results in decreased expression of HMMR mRNA |
CTD |
PMID:17109745 |
|
NCBI chr10:25,132,933...25,163,029
Ensembl chr10:25,132,977...25,163,060
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in decreased expression of HMOX1 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of HMOX1 protein] Glucosamine results in increased expression of HMOX1 mRNA; Glucosamine results in increased expression of HMOX1 protein |
CTD |
PMID:18077487 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hoxa1 |
homeobox A1 |
decreases expression |
ISO |
Glucosamine results in decreased expression of HOXA1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 4:81,255,814...81,258,587
Ensembl chr 4:81,255,883...81,258,504
|
|
G |
Hpgd |
15-hydroxyprostaglandin dehydrogenase |
decreases expression |
EXP |
Glucosamine results in decreased expression of HPGD mRNA |
CTD |
PMID:17109745 |
|
NCBI chr16:33,986,265...34,024,228
Ensembl chr16:33,986,266...34,024,228
|
|
G |
Hsp90b1 |
heat shock protein 90 beta family member 1 |
decreases expression increases expression |
ISO EXP |
Glucosamine results in decreased expression of HSP90B1 mRNA Glucosamine results in increased expression of HSP90B1 protein |
CTD |
PMID:15618547 PMID:17109745 PMID:17178593 |
|
NCBI chr 7:21,110,431...21,124,762
Ensembl chr 7:21,110,457...21,124,788
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions increases expression decreases expression |
ISO EXP |
4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of HSPA5 mRNA]; NUS1 protein inhibits the reaction [Glucosamine results in increased expression of HSPA5 mRNA]; NUS1 protein inhibits the reaction [Glucosamine results in increased expression of HSPA5 protein]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in increased expression of HSPA5 mRNA] Glucosamine results in increased expression of HSPA5 mRNA; Glucosamine results in increased expression of HSPA5 protein 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of HSPA5 mRNA]; 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of HSPA5 protein] 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of HSPA5 mRNA]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in increased expression of HSPA5 mRNA] Glucosamine results in decreased expression of HSPA5 mRNA |
CTD |
PMID:15618547 PMID:16380481 PMID:17178593 PMID:19383982 PMID:20165829 PMID:22020377 PMID:30602124 PMID:33812996 More...
|
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Hyou1 |
hypoxia up-regulated 1 |
decreases expression |
ISO |
Glucosamine results in decreased expression of HYOU1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 8:44,706,073...44,718,189
Ensembl chr 8:44,706,263...44,718,186
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions decreases activity |
ISO EXP |
Alloxan inhibits the reaction [Glucosamine inhibits the reaction [Cathelicidins results in increased expression of ICAM1 protein]]; Glucosamine inhibits the reaction [[IL6 co-treated with TNF] results in increased expression of ICAM1 protein]; Glucosamine inhibits the reaction [Cathelicidins results in increased expression of ICAM1 mRNA]; Glucosamine inhibits the reaction [Cathelicidins results in increased expression of ICAM1 protein]; Glucosamine inhibits the reaction [IFNG promotes the reaction [TNF results in increased expression of ICAM1 protein]]; Glucosamine inhibits the reaction [IFNG results in increased expression of ICAM1 mRNA]; Glucosamine inhibits the reaction [IFNG results in increased expression of ICAM1 protein]; Glucosamine inhibits the reaction [IL1B promotes the reaction [TNF results in increased expression of ICAM1 protein]]; Glucosamine inhibits the reaction [IL1B results in increased expression of ICAM1 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of ICAM1 protein]; Glucosamine inhibits the reaction [IL6 results in increased expression of ICAM1 protein]; Glucosamine inhibits the reaction [TNF promotes the reaction [IFNG results in increased expression of ICAM1 protein]]; Glucosamine inhibits the reaction [TNF promotes the reaction [IL1B results in increased expression of ICAM1 protein]]; Glucosamine inhibits the reaction [TNF results in increased expression of ICAM1 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of ICAM1 protein] Glucosamine results in decreased activity of ICAM1 protein Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of ICAM1 protein] |
CTD |
PMID:16431966 PMID:16822504 PMID:17238806 PMID:18949387 PMID:19020780 PMID:19098112 More...
|
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Id1 |
inhibitor of DNA binding 1 |
increases expression |
ISO |
Glucosamine results in increased expression of ID1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 3:141,210,666...141,212,420
Ensembl chr 3:141,211,267...141,212,419
|
|
G |
Id2 |
inhibitor of DNA binding 2 |
increases expression |
ISO |
Glucosamine results in increased expression of ID2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 6:41,740,556...41,742,393
Ensembl chr 6:41,728,946...41,744,400
|
|
G |
Id3 |
inhibitor of DNA binding 3 |
increases expression |
ISO |
Glucosamine results in increased expression of ID3 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 5:148,372,784...148,374,353
Ensembl chr 5:148,372,762...148,374,349
|
|
G |
Idh1 |
isocitrate dehydrogenase (NADP(+)) 1 |
increases expression |
ISO |
Glucosamine results in increased expression of IDH1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 9:66,534,146...66,563,703
Ensembl chr 9:66,534,146...66,563,708
|
|
G |
Ifit3 |
interferon-induced protein with tetratricopeptide repeats 3 |
increases expression |
ISO |
Glucosamine results in increased expression of IFIT3 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 1:232,114,166...232,119,311
Ensembl chr 1:232,114,166...232,119,307
|
|
G |
Ifng |
interferon gamma |
decreases secretion multiple interactions |
ISO |
Glucosamine results in decreased secretion of IFNG protein Glucosamine inhibits the reaction [IFNG promotes the reaction [TNF results in increased expression of ICAM1 protein]]; Glucosamine inhibits the reaction [IFNG results in increased expression of ICAM1 mRNA]; Glucosamine inhibits the reaction [IFNG results in increased expression of ICAM1 protein]; Glucosamine inhibits the reaction [IFNG results in increased localization of STAT1 protein modified form]; Glucosamine inhibits the reaction [IFNG results in increased phosphorylation of and results in increased localization of STAT1 protein]; Glucosamine inhibits the reaction [TNF promotes the reaction [IFNG results in increased expression of ICAM1 protein]] |
CTD |
PMID:14507305 PMID:16431966 PMID:16822504 PMID:17238806 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Igfbp3 |
insulin-like growth factor binding protein 3 |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of IGFBP3 mRNA]; IL1B inhibits the reaction [Glucosamine results in increased expression of IGFBP3 mRNA] Glucosamine results in decreased expression of IGFBP3 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr14:82,056,347...82,064,083
Ensembl chr14:82,056,347...82,064,083
|
|
G |
Igfbp4 |
insulin-like growth factor binding protein 4 |
decreases expression |
ISO |
Glucosamine results in decreased expression of IGFBP4 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr10:83,995,253...84,007,272
Ensembl chr10:83,989,591...84,007,225
|
|
G |
Igfbp5 |
insulin-like growth factor binding protein 5 |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of IGFBP5 mRNA] Glucosamine results in increased expression of IGFBP5 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 9:74,452,371...74,464,953
Ensembl chr 9:74,448,382...74,465,156
|
|
G |
Ikbkb |
inhibitor of nuclear factor kappa B kinase subunit beta |
multiple interactions |
ISO |
Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of IKBKB protein] |
CTD |
PMID:18786831 |
|
NCBI chr16:69,319,487...69,373,251
Ensembl chr16:69,319,554...69,373,250
|
|
G |
Ikbkg |
inhibitor of nuclear factor kappa B kinase regulatory subunit gamma |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of IKBKG mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of IKBKG mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr X:152,216,485...152,241,476
Ensembl chr X:152,216,596...152,239,499
|
|
G |
Il11 |
interleukin 11 |
multiple interactions |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of IL11 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 1:69,069,829...69,076,129
Ensembl chr 1:69,068,137...69,076,129
|
|
G |
Il13ra1 |
interleukin 13 receptor subunit alpha 1 |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of IL13RA1 mRNA] Glucosamine results in decreased expression of IL13RA1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr X:115,348,822...115,408,682
Ensembl chr X:115,348,860...115,408,681 Ensembl chr11:115,348,860...115,408,681
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of IL1A mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of IL1A mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases expression decreases expression |
ISO EXP |
[Glucosamine co-treated with Chondroitin Sulfates co-treated with IL1B protein] results in decreased expression of NOS2 protein; [Glucosamine co-treated with Chondroitin Sulfates co-treated with IL1B protein] results in decreased expression of PTGES protein; [Glucosamine co-treated with Chondroitin Sulfates co-treated with IL1B protein] results in decreased expression of PTGS2 protein; [Glucosamine co-treated with Chondroitin Sulfates co-treated with IL1B protein] results in increased expression of TIMP3 mRNA; [Glucosamine co-treated with Chondroitin Sulfates] inhibits the reaction [IL1B protein results in increased secretion of Dinoprostone]; [Glucosamine co-treated with Chondroitin Sulfates] inhibits the reaction [IL1B protein results in increased secretion of Nitrites]; Glucosamine analog affects the reaction [IL1B protein results in increased abundance of Nitric Oxide]; Glucosamine analog affects the reaction [IL1B results in decreased expression of ACAN mRNA]; Glucosamine analog affects the reaction [IL1B results in decreased expression of COL2A1 mRNA]; Glucosamine analog affects the reaction [IL1B results in increased phosphorylation of AKT1 protein]; Glucosamine analog inhibits the reaction [IL1B protein results in increased abundance of Dinoprostone]; Glucosamine analog inhibits the reaction [IL1B protein results in increased expression of MMP13]; Glucosamine analog inhibits the reaction [IL1B protein results in increased expression of MMP1]; Glucosamine analog inhibits the reaction [IL1B protein results in increased expression of MMP3]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of and results in increased secretion of MMP1 protein]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of and results in increased secretion of MMP13 protein]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of and results in increased secretion of MMP3 protein]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of CXCL8 mRNA]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of MMP1 mRNA]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of MMP13 mRNA]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of MMP3 mRNA]; Glucosamine analog inhibits the reaction [IL1B results in increased localization of RELA protein]; Glucosamine analog inhibits the reaction [IL1B results in increased phosphorylation of and results in increased degradation of NFKBIA protein]; Glucosamine analog inhibits the reaction [IL1B results in increased secretion of CCL2 protein]; Glucosamine analog inhibits the reaction [IL1B results in increased secretion of CCL5 protein]; Glucosamine analog inhibits the reaction [IL1B results in increased secretion of CXCL8 protein]; Glucosamine analog promotes the reaction [IL1B results in increased phosphorylation of MAPK1 protein]; Glucosamine analog promotes the reaction [IL1B results in increased phosphorylation of MAPK3 protein]; Glucosamine analog promotes the reaction [IL1B results in increased phosphorylation of MAPK8 protein]; Glucosamine inhibits the reaction [[OSM protein co-treated with IL1B protein] results in decreased methylation of IL1B promoter]; Glucosamine inhibits the reaction [[OSM protein co-treated with IL1B protein] results in increased expression of IL1B mRNA]; Glucosamine inhibits the reaction [IL1B promotes the reaction [TNF results in increased expression of ICAM1 protein]]; Glucosamine inhibits the reaction [IL1B protein results in decreased expression of ACAN mRNA]; Glucosamine inhibits the reaction [IL1B protein results in decreased expression of COL2A1 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased activity of JUN protein]; Glucosamine inhibits the reaction [IL1B protein results in increased activity of JUND protein]; Glucosamine inhibits the reaction [IL1B protein results in increased degradation of NFKBIA protein]; Glucosamine inhibits the reaction [IL1B protein results in increased expression of COL1A1 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased expression of MMP1 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased expression of MMP13 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased expression of MMP3 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased expression of PTGS2 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased expression of PTGS2 protein]; Glucosamine inhibits the reaction [IL1B protein results in increased localization of NFKB1 protein]; Glucosamine inhibits the reaction [IL1B protein results in increased localization of RELA protein]; Glucosamine inhibits the reaction [IL1B protein results in increased secretion of Dinoprostone]; Glucosamine inhibits the reaction [IL1B protein results in increased secretion of MMP1 protein]; Glucosamine inhibits the reaction [IL1B protein results in increased secretion of MMP13 protein]; Glucosamine inhibits the reaction [IL1B protein results in increased secretion of MMP3 protein]; Glucosamine inhibits the reaction [IL1B results in decreased expression of HMOX1 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of HMOX1 protein]; Glucosamine inhibits the reaction [IL1B results in increased abundance of Dinoprostone]; Glucosamine inhibits the reaction [IL1B results in increased abundance of Nitric Oxide]; Glucosamine inhibits the reaction [IL1B results in increased abundance of Nitrites]; Glucosamine inhibits the reaction [IL1B results in increased degradation of NFKB1 protein]; Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL8 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL8 protein]; Glucosamine inhibits the reaction [IL1B results in increased expression of ICAM1 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of ICAM1 protein]; Glucosamine inhibits the reaction [IL1B results in increased expression of MMP3 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of MMP3 protein]; Glucosamine inhibits the reaction [IL1B results in increased expression of NOS2 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of PTGES mRNA]; Glucosamine inhibits the reaction [IL1B results in increased localization of RELA protein]; Glucosamine inhibits the reaction [IL1B results in increased phosphorylation of MAPK1 protein]; Glucosamine inhibits the reaction [IL1B results in increased phosphorylation of MAPK14 protein]; Glucosamine inhibits the reaction [IL1B results in increased phosphorylation of MAPK3 protein]; Glucosamine inhibits the reaction [IL1B results in increased phosphorylation of MAPK8 protein]; Glucosamine inhibits the reaction [IL1B results in increased secretion of CXCL8 protein]; Glucosamine inhibits the reaction [TNF promotes the reaction [IL1B results in increased expression of ICAM1 protein]]; Glucosamine promotes the reaction [IL1B results in increased expression of PPARG]; Glucosamine promotes the reaction [IL1B results in increased phosphorylation of AKT1 protein] Glucosamine results in increased expression of IL1B mRNA Glucosamine results in decreased expression of IL1B mRNA [IL1B protein co-treated with Glucosamine] results in increased expression of IL1R2 mRNA; Glucosamine affects the reaction [IL1B results in decreased expression of ADAM15 mRNA]; Glucosamine affects the reaction [IL1B results in decreased expression of OAT mRNA]; Glucosamine inhibits the reaction [IL1B protein results in decreased activity of B3GAT3 protein]; Glucosamine inhibits the reaction [IL1B protein results in decreased expression of B3GAT3 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased abundance of Dinoprostone]; Glucosamine inhibits the reaction [IL1B protein results in increased abundance of Nitric Oxide]; Glucosamine inhibits the reaction [IL1B protein results in increased expression of MMP3 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of ACAN mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of COL11A1 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of COL2A1 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of COL3A1 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of FGFR1 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of HAPLN1 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of LAMA4 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of SDC2 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of SOX4 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of THBS4 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of TIMP2 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of TIMP3 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of ADAM17 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of ADAMTS1 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of ASS1 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of BGN mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of BMP2 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of BMP6 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of BMP7 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CCL2 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CCL20 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CCL22 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CCL3 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CCL5 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CCL7 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of COL8A1 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CSF1 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CSF2 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CSF3 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL1 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL10 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL11 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL2 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL3 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL5 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of DUSP5 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of DUSP7 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of EPAS1 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of FGF9 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of GREM1 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of IGFBP3 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of IGFBP5 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of IKBKG mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of IL11 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of IL13RA1 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of IL1A mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of IL1B mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of IL23R mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of IL6 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of JAK2 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of JUNB mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of MMP10 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of MMP12 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of MMP13 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of MMP3 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of MMP9 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of NFKBIA mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of NFKBIB mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of NGF mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of NOS2 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of PDGFA mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of PLA2G2A mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of PLA2G4A mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of PLA2G5 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of RELB mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of SDC4 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of SLC7A8 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of TIMP1 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of TNFAIP6 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of TNK2 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of VCAN mRNA]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; Glucosamine promotes the reaction [IL1B results in decreased expression of BMP4 mRNA]; Glucosamine promotes the reaction [IL1B results in decreased expression of CXCL12 mRNA]; IL1B affects the reaction [Glucosamine affects the expression of PDGFA mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of ADAM15 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of BGN mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of COL11A1 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of CXCL12 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of DUSP7 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of EPAS1 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of IKBKG mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of JUNB mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of TNFAIP6 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of VCAN mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of ADAM17 mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of IL1A mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of JAK2 mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of LAMA4 mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of MMP9 mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of NFKBIB mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of TIMP3 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of ADAMTS1 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of COL8A1 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of CSF1 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of CXCL1 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of FGF7 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of GREM1 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of NFKBIA mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of PLA2G2A mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of PLA2G5 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of SDC4 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of SLC7A8 mRNA]; IL1B inhibits the reaction [Glucosamine results in increased expression of IGFBP3 mRNA]; IL1B promotes the reaction [Glucosamine results in decreased expression of HAPLN1 mRNA]; IL1B promotes the reaction [Glucosamine results in decreased expression of SDC2 mRNA]; IL1B promotes the reaction [Glucosamine results in decreased expression of THBS4 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of AZIN1 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of CCL2 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of CCL20 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of CCL7 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of CXCL2 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of CXCL3 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of MMP10 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of MMP12 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of MMP13 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of MMP2 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of MMP3 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of NOS2 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of TIMP1 mRNA] Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of IL1B protein]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA] |
CTD |
PMID:11229466 PMID:11801247 PMID:12681956 PMID:15144122 PMID:16822504 PMID:17109745 PMID:17238806 PMID:17337215 PMID:17605605 PMID:17925024 PMID:18026701 PMID:18077487 PMID:18080321 PMID:18321735 PMID:18340449 PMID:18786831 PMID:19626664 PMID:19656660 PMID:20737476 PMID:21219853 PMID:22089456 More...
|
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il1r2 |
interleukin 1 receptor type 2 |
multiple interactions |
EXP |
[IL1B protein co-treated with Glucosamine] results in increased expression of IL1R2 mRNA |
CTD |
PMID:11801247 |
|
NCBI chr 9:42,384,280...42,424,726
Ensembl chr 9:42,384,433...42,424,725
|
|
G |
Il2 |
interleukin 2 |
decreases secretion |
ISO |
Glucosamine results in decreased secretion of IL2 protein |
CTD |
PMID:14507305 |
|
NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
|
|
G |
Il23r |
interleukin 23 receptor |
multiple interactions |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of IL23R mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 4:96,580,568...96,672,540
Ensembl chr 4:96,580,714...96,674,021
|
|
G |
Il33 |
interleukin 33 |
decreases expression |
EXP |
Glucosamine results in decreased expression of IL33 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 1:227,701,964...227,736,374
Ensembl chr 1:227,721,435...227,736,373
|
|
G |
Il4 |
interleukin 4 |
decreases secretion decreases expression |
ISO |
Glucosamine results in decreased secretion of IL4 protein Glucosamine results in decreased expression of IL4 |
CTD |
PMID:14507305 PMID:21284687 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il5 |
interleukin 5 |
decreases secretion decreases expression |
ISO |
Glucosamine results in decreased secretion of IL5 protein Glucosamine results in decreased expression of IL5 |
CTD |
PMID:14507305 PMID:21284687 |
|
NCBI chr10:37,874,342...37,877,213
Ensembl chr10:37,874,342...37,877,213
|
|
G |
Il6 |
interleukin 6 |
multiple interactions decreases expression |
ISO EXP |
Glucosamine analog inhibits the reaction [TNF results in increased expression of IL6 mRNA]; Glucosamine inhibits the reaction [[IL6 co-treated with TNF] results in increased expression of ICAM1 protein]; Glucosamine inhibits the reaction [IL6 results in increased expression of ICAM1 protein]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of IL6 protein]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of IL6 mRNA] Glucosamine inhibits the reaction [IL1B results in increased expression of IL6 mRNA]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein] Glucosamine analog results in decreased expression of IL6 mRNA; Glucosamine results in decreased expression of IL6 mRNA Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of IL6 protein]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA] |
CTD |
PMID:16822504 PMID:17109745 PMID:18786831 PMID:19098112 PMID:20093129 PMID:20113495 PMID:20307528 PMID:20737476 More...
|
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Inpp5k |
inositol polyphosphate-5-phosphatase K |
multiple interactions increases expression |
ISO |
NUS1 protein inhibits the reaction [Glucosamine results in increased expression of INPP5K mRNA] |
CTD |
PMID:33812996 |
|
NCBI chr10:60,474,262...60,495,813
Ensembl chr10:60,475,897...60,496,773
|
|
G |
Ins1 |
insulin 1 |
multiple interactions |
EXP ISO |
4-phenylbutyric acid inhibits the reaction [Glucosamine inhibits the reaction [INS1 results in increased uptake of Deoxyglucose]]; [Glucosamine co-treated with INS1 protein] affects the localization of GFPT1 protein; Glucosamine inhibits the reaction [Glucose results in increased secretion of INS1 protein]; Glucosamine inhibits the reaction [INS1 protein results in increased uptake of Deoxyglucose]; Glucosamine inhibits the reaction [INS1 results in increased uptake of Deoxyglucose]; ursodoxicoltaurine inhibits the reaction [Glucosamine inhibits the reaction [INS1 results in increased uptake of Deoxyglucose]] [INS1 protein co-treated with Glucosamine] results in increased expression of OSTN mRNA; Glucosamine inhibits the reaction [INS1 protein results in increased phosphorylation of AKT1 protein]; Glucosamine inhibits the reaction [INS1 protein results in increased uptake of 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose]; INS1 inhibits the reaction [[Streptozocin co-treated with APOE mutant form] results in increased abundance of Glucosamine]; OSTN protein affects the reaction [Glucosamine inhibits the reaction [INS1 protein results in increased phosphorylation of AKT1 protein]]; OSTN protein affects the reaction [Glucosamine inhibits the reaction [INS1 protein results in increased uptake of 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose]] |
CTD |
PMID:9453242 PMID:11893929 PMID:16380481 PMID:20165829 PMID:30602124 |
|
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Ins2 |
insulin 2 |
multiple interactions |
ISO |
4-phenylbutyric acid inhibits the reaction [Glucosamine inhibits the reaction [INS results in increased uptake of Deoxyglucose]]; Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]; Glucosamine inhibits the reaction [INS results in increased uptake of Deoxyglucose]; NUS1 protein inhibits the reaction [Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]]; PRKAA1 protein promotes the reaction [Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]]; PRKAA1 protein promotes the reaction [NUS1 protein inhibits the reaction [Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]]]; ursodoxicoltaurine inhibits the reaction [Glucosamine inhibits the reaction [INS results in increased uptake of Deoxyglucose]] |
CTD |
PMID:20165829 PMID:33812996 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Irf1 |
interferon regulatory factor 1 |
multiple interactions |
ISO |
Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of IRF1 mRNA] |
CTD |
PMID:20737476 |
|
NCBI chr10:37,917,155...37,924,166
Ensembl chr10:37,916,670...37,924,166
|
|
G |
Isyna1 |
inositol-3-phosphate synthase 1 |
increases expression |
EXP |
Glucosamine results in increased expression of ISYNA1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr16:18,839,143...18,841,979
Ensembl chr16:18,839,145...18,841,979
|
|
G |
Jak2 |
Janus kinase 2 |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of JAK2 mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of JAK2 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 1:226,995,334...227,054,381
Ensembl chr 1:226,995,334...227,054,189
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
Glucosamine inhibits the reaction [IL1B protein results in increased activity of JUN protein] Glucosamine analog inhibits the reaction [Buthionine Sulfoximine results in increased expression of JUN mRNA] |
CTD |
PMID:17925024 PMID:21825963 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Junb |
JunB proto-oncogene, AP-1 transcription factor subunit |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of JUNB mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of JUNB mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr19:23,176,265...23,178,049
Ensembl chr19:23,176,294...23,178,035
|
|
G |
Jund |
JunD proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
Glucosamine inhibits the reaction [IL1B protein results in increased activity of JUND protein] |
CTD |
PMID:17925024 |
|
NCBI chr16:18,734,121...18,735,799
Ensembl chr16:18,734,122...18,735,799
|
|
G |
Kcnj16 |
potassium inwardly-rectifying channel, subfamily J, member 16 |
increases expression |
ISO |
Glucosamine results in increased expression of KCNJ16 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr10:95,990,009...96,021,356
Ensembl chr10:95,960,725...96,021,702
|
|
G |
Kif11 |
kinesin family member 11 |
decreases expression |
EXP |
Glucosamine results in decreased expression of KIF11 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 1:235,124,371...235,176,760
Ensembl chr 1:235,124,316...235,176,766
|
|
G |
Kif4a |
kinesin family member 4A |
decreases expression |
EXP |
Glucosamine results in decreased expression of KIF4A mRNA |
CTD |
PMID:17109745 |
|
NCBI chr X:65,721,746...65,824,277
Ensembl chr X:65,721,779...65,824,139
|
|
G |
Klf10 |
KLF transcription factor 10 |
increases expression |
ISO |
Glucosamine results in increased expression of KLF10 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 7:69,467,658...69,473,726
Ensembl chr 7:69,465,619...69,473,994
|
|
G |
Lama4 |
laminin subunit alpha 4 |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in decreased expression of LAMA4 mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of LAMA4 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr20:42,392,268...42,533,347
Ensembl chr20:42,392,268...42,533,347
|
|
G |
Lamb1 |
laminin subunit beta 1 |
multiple interactions |
ISO |
TXNIP promotes the reaction [Glucosamine results in increased expression of LAMB1 mRNA] |
CTD |
PMID:17178593 |
|
NCBI chr 6:47,835,492...47,902,585
Ensembl chr 6:47,835,525...47,902,585
|
|
G |
Lamc1 |
laminin subunit gamma 1 |
multiple interactions |
ISO |
TXNIP promotes the reaction [Glucosamine results in increased expression of LAMC1 mRNA] |
CTD |
PMID:17178593 |
|
NCBI chr13:65,374,372...65,501,492
Ensembl chr13:65,374,372...65,501,492
|
|
G |
Lcn2 |
lipocalin 2 |
decreases expression |
ISO |
Glucosamine results in decreased expression of LCN2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 3:15,680,688...15,684,033
Ensembl chr 3:15,680,687...15,684,095
|
|
G |
Lepr |
leptin receptor |
affects response to substance multiple interactions |
EXP |
LEPR protein affects the susceptibility to Glucosamine [LEPR protein affects the susceptibility to Glucosamine] which affects the expression of ALB protein |
CTD |
PMID:33345901 |
|
NCBI chr 5:116,294,409...116,477,904
Ensembl chr 5:116,289,823...116,475,908
|
|
G |
Lpin1 |
lipin 1 |
increases expression |
ISO |
Glucosamine results in increased expression of LPIN1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 6:39,309,198...39,417,034
Ensembl chr 6:39,312,748...39,417,097
|
|
G |
Ly6a |
lymphocyte antigen 6 family member A |
increases expression |
ISO |
Glucosamine results in increased expression of LY6A mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 7:107,177,191...107,189,436
Ensembl chr 7:107,183,469...107,189,981
|
|
G |
Mafb |
MAF bZIP transcription factor B |
increases expression |
EXP |
Glucosamine results in increased expression of MAFB mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 3:148,998,111...149,000,031
Ensembl chr 3:148,998,122...149,000,031
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation |
ISO |
Glucosamine analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MAPK1 protein]; Glucosamine analog promotes the reaction [IL1B results in increased phosphorylation of MAPK1 protein]; Glucosamine inhibits the reaction [IL1B results in increased phosphorylation of MAPK1 protein]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK1 protein] Glucosamine analog results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:18080321 PMID:18340449 PMID:19375915 PMID:19626664 PMID:20307528 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
multiple interactions |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased phosphorylation of MAPK14 protein] |
CTD |
PMID:19626664 |
|
NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
ISO |
Glucosamine analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MAPK3 protein]; Glucosamine analog promotes the reaction [IL1B results in increased phosphorylation of MAPK3 protein]; Glucosamine inhibits the reaction [IL1B results in increased phosphorylation of MAPK3 protein]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK3 protein] Glucosamine analog results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:18080321 PMID:18340449 PMID:19375915 PMID:19626664 PMID:20307528 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions increases phosphorylation |
ISO |
Glucosamine analog promotes the reaction [IL1B results in increased phosphorylation of MAPK8 protein]; Glucosamine inhibits the reaction [IL1B results in increased phosphorylation of MAPK8 protein]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK8 protein] Glucosamine analog results in increased phosphorylation of MAPK8 protein |
CTD |
PMID:18080321 PMID:19626664 PMID:20307528 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mcl1 |
MCL1 apoptosis regulator, BCL2 family member |
decreases expression |
ISO |
Glucosamine results in decreased expression of MCL1 mRNA; Glucosamine results in decreased expression of MCL1 protein |
CTD |
PMID:22020377 |
|
NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303
|
|
G |
Mef2a |
myocyte enhancer factor 2a |
multiple interactions decreases expression |
ISO EXP |
4-phenylbutyric acid inhibits the reaction [Glucosamine results in decreased expression of MEF2A mRNA]; 4-phenylbutyric acid inhibits the reaction [Glucosamine results in decreased expression of MEF2A protein]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of MEF2A mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of MEF2A protein]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in decreased expression of MEF2A mRNA]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in decreased expression of MEF2A protein] Glucosamine results in decreased expression of MEF2A mRNA; Glucosamine results in decreased expression of MEF2A protein |
CTD |
PMID:20165829 |
|
NCBI chr 1:120,847,874...120,982,488
Ensembl chr 1:120,850,080...120,981,948
|
|
G |
Mettl1 |
methyltransferase 1, tRNA methylguanosine |
decreases expression |
ISO |
Glucosamine results in decreased expression of METTL1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 7:62,864,860...62,869,202
Ensembl chr 7:62,864,853...62,869,202
|
|
G |
Mfap3l |
microfibril associated protein 3 like |
increases expression |
ISO |
Glucosamine results in increased expression of MFAP3L mRNA |
CTD |
PMID:17178593 |
|
NCBI chr16:29,411,643...29,454,665
Ensembl chr16:29,415,849...29,430,863
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
decreases expression |
EXP |
Glucosamine results in decreased expression of MKI67 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762
|
|
G |
Mmp1 |
matrix metallopeptidase 1 |
multiple interactions |
ISO |
Glucosamine analog inhibits the reaction [IL1B protein results in increased expression of MMP1]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of and results in increased secretion of MMP1 protein]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of MMP1 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased expression of MMP1 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased secretion of MMP1 protein] |
CTD |
PMID:15144122 PMID:17925024 PMID:18080321 |
|
NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097
|
|
G |
Mmp10 |
matrix metallopeptidase 10 |
increases expression multiple interactions |
EXP |
Glucosamine results in increased expression of MMP10 mRNA Glucosamine inhibits the reaction [IL1B results in increased expression of MMP10 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of MMP10 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 8:4,689,840...4,697,748
Ensembl chr 8:4,689,840...4,697,748
|
|
G |
Mmp12 |
matrix metallopeptidase 12 |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of MMP12 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of MMP12 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 8:4,581,785...4,591,687
Ensembl chr 8:4,581,785...4,599,611
|
|
G |
Mmp13 |
matrix metallopeptidase 13 |
affects expression multiple interactions increases expression |
ISO EXP |
Glucosamine analog affects the expression of MMP13 mRNA Glucosamine inhibits the reaction [IL1B results in increased expression of MMP13 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of MMP13 mRNA] Glucosamine analog inhibits the reaction [IL1B protein results in increased expression of MMP13]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of and results in increased secretion of MMP13 protein]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of MMP13 mRNA]; Glucosamine analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP13 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased expression of MMP13 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased secretion of MMP13 protein] |
CTD |
PMID:15144122 PMID:17109745 PMID:17337215 PMID:17925024 PMID:18080321 PMID:19656660 More...
|
|
NCBI chr 8:4,497,960...4,508,239
Ensembl chr 8:4,497,960...4,508,239
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions increases expression |
ISO EXP |
Glucosamine analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of and results in increased activity of MMP2 protein]; Glucosamine analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP2 mRNA]; Glucosamine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP2 mRNA]; Glucosamine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP2 protein] IL1B promotes the reaction [Glucosamine results in increased expression of MMP2 mRNA] |
CTD |
PMID:17109745 PMID:17498959 PMID:19375915 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp3 |
matrix metallopeptidase 3 |
multiple interactions increases expression decreases expression |
ISO EXP |
[Glucosamine co-treated with Chondroitin Sulfates] results in decreased expression of MMP3 mRNA; [Glucosamine co-treated with Chondroitin Sulfates] results in decreased secretion of MMP3 protein; Glucosamine analog inhibits the reaction [IL1B protein results in increased expression of MMP3]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of and results in increased secretion of MMP3 protein]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of MMP3 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased expression of MMP3 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased secretion of MMP3 protein]; Glucosamine inhibits the reaction [IL1B results in increased expression of MMP3 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of MMP3 protein]; Glucosamine results in decreased expression of and results in decreased activity of MMP3 protein Glucosamine results in increased expression of MMP3 mRNA Glucosamine inhibits the reaction [IL1B protein results in increased expression of MMP3 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of MMP3 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of MMP3 mRNA] Glucosamine analog results in decreased expression of MMP3 mRNA |
CTD |
PMID:11229466 PMID:12801482 PMID:15144122 PMID:16300972 PMID:17109745 PMID:17925024 PMID:18080321 PMID:18340449 PMID:20110869 More...
|
|
NCBI chr 8:4,640,397...4,653,963
Ensembl chr 8:4,640,416...4,653,961
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions increases expression |
ISO EXP |
Glucosamine analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of and results in increased activity of MMP9 protein]; Glucosamine analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP9 mRNA]; Glucosamine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP9 mRNA]; Glucosamine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP9 protein] Glucosamine results in increased expression of MMP9 mRNA Glucosamine inhibits the reaction [IL1B results in increased expression of MMP9 mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of MMP9 mRNA] |
CTD |
PMID:17109745 PMID:17498959 PMID:19375915 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mnda |
myeloid cell nuclear differentiation antigen |
increases expression |
ISO |
Glucosamine results in increased expression of IFI204 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr13:86,017,888...86,035,556
Ensembl chr13:86,017,892...86,034,201
|
|
G |
Mpo |
myeloperoxidase |
decreases activity |
EXP |
Glucosamine results in decreased activity of MPO protein |
CTD |
PMID:19098112 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Mvd |
mevalonate diphosphate decarboxylase |
increases expression |
ISO |
Glucosamine results in increased expression of MVD mRNA |
CTD |
PMID:17178593 |
|
NCBI chr19:50,496,366...50,506,429
Ensembl chr19:50,496,367...50,507,971
|
|
G |
Ndufa4 |
Ndufa4, mitochondrial complex associated |
increases expression |
EXP |
Glucosamine results in increased expression of NDUFA4 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 4:40,002,216...40,009,384
Ensembl chr 4:40,002,216...40,023,920
|
|
G |
Nedd4 |
NEDD4 E3 ubiquitin protein ligase |
decreases expression |
EXP |
Glucosamine results in decreased expression of NEDD4 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 8:73,384,095...73,468,951
Ensembl chr 8:73,383,695...73,468,951
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions decreases activity |
ISO EXP |
Glucosamine inhibits the reaction [Hydrogen Peroxide results in increased expression of and results in increased localization of NFKB1 protein]; Glucosamine inhibits the reaction [IL1B protein results in increased localization of NFKB1 protein]; Glucosamine inhibits the reaction [IL1B results in increased degradation of NFKB1 protein]; Glucosamine inhibits the reaction [NFKB1 results in increased degradation of RELA protein]; Glucosamine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of NFKB1 protein] Glucosamine results in decreased activity of NFKB1 protein Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of NFKB1 protein] |
CTD |
PMID:12681956 PMID:16431966 PMID:16822504 PMID:17498959 PMID:18036590 PMID:18205790 PMID:20737476 More...
|
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions decreases phosphorylation decreases expression |
ISO EXP |
Glucosamine analog inhibits the reaction [IL1B results in increased phosphorylation of and results in increased degradation of NFKBIA protein]; Glucosamine inhibits the reaction [IL1B protein results in increased degradation of NFKBIA protein] Glucosamine results in decreased phosphorylation of NFKBIA protein Glucosamine results in decreased expression of NFKBIA mRNA Glucosamine inhibits the reaction [IL1B results in increased expression of NFKBIA mRNA]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein]; IL1B inhibits the reaction [Glucosamine results in decreased expression of NFKBIA mRNA] Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of NFKBIA protein modified form]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:12681956 PMID:17109745 PMID:18080321 PMID:18205790 PMID:19098112 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nfkbib |
NFKB inhibitor beta |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of NFKBIB mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of NFKBIB mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 1:84,046,292...84,053,862
Ensembl chr 1:84,046,295...84,053,862
|
|
G |
Ngef |
neuronal guanine nucleotide exchange factor |
increases expression |
ISO |
Glucosamine results in increased expression of NGEF mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 9:88,146,956...88,244,454
Ensembl chr 9:88,146,956...88,244,914
|
|
G |
Ngf |
nerve growth factor |
multiple interactions |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of NGF mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions increases expression decreases expression |
ISO EXP |
[Glucosamine co-treated with Chondroitin Sulfates co-treated with IL1B protein] results in decreased expression of NOS2 protein; Glucosamine inhibits the reaction [IL1B results in increased expression of NOS2 mRNA] Glucosamine results in increased expression of NOS2 mRNA Glucosamine inhibits the reaction [IL1B results in increased expression of NOS2 mRNA]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of NOS2 mRNA] Glucosamine results in decreased expression of NOS2 mRNA Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]; Glucosamine inhibits the reaction [Lipopolysaccharides promotes the reaction [RELA protein binds to NOS2 promoter]]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] |
CTD |
PMID:17109745 PMID:17440993 PMID:17605605 PMID:18077487 PMID:18205790 PMID:19098112 PMID:20737476 More...
|
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
affects expression |
EXP |
Glucosamine affects the expression of NR1H4 |
CTD |
PMID:19373748 |
|
NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
|
|
G |
Nsdhl |
NAD(P) dependent steroid dehydrogenase-like |
increases expression |
ISO |
Glucosamine results in increased expression of NSDHL mRNA |
CTD |
PMID:17178593 |
|
NCBI chr X:150,775,034...150,807,161
Ensembl chr X:150,775,080...150,807,142
|
|
G |
Nucb2 |
nucleobindin 2 |
decreases expression |
ISO |
Glucosamine results in decreased expression of NUCB2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 1:170,750,830...170,787,356
Ensembl chr 1:170,750,877...170,787,353
|
|
G |
Nuf2 |
NUF2 component of NDC80 kinetochore complex |
decreases expression |
EXP |
Glucosamine results in decreased expression of NUF2 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr13:81,693,675...81,722,765
Ensembl chr13:81,693,598...81,722,766
|
|
G |
Nus1 |
NUS1 dehydrodolichyl diphosphate synthase subunit |
multiple interactions |
ISO |
NUS1 protein inhibits the reaction [Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]]; NUS1 protein inhibits the reaction [Glucosamine results in increased expression of ATF4 mRNA]; NUS1 protein inhibits the reaction [Glucosamine results in increased expression of ATF6 mRNA]; NUS1 protein inhibits the reaction [Glucosamine results in increased expression of DDIT3 mRNA]; NUS1 protein inhibits the reaction [Glucosamine results in increased expression of EIF2AK3 protein]; NUS1 protein inhibits the reaction [Glucosamine results in increased expression of ERN1 mRNA]; NUS1 protein inhibits the reaction [Glucosamine results in increased expression of HSPA5 mRNA]; NUS1 protein inhibits the reaction [Glucosamine results in increased expression of HSPA5 protein]; NUS1 protein inhibits the reaction [Glucosamine results in increased expression of INPP5K mRNA]; NUS1 protein inhibits the reaction [Glucosamine results in increased phosphorylation of EIF2S1 protein]; NUS1 protein inhibits the reaction [Glucosamine results in increased splicing of XBP1 mRNA]; PRKAA1 protein promotes the reaction [NUS1 protein inhibits the reaction [Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]]] |
CTD |
PMID:33812996 |
|
NCBI chr20:31,811,817...31,838,562
Ensembl chr20:31,811,817...31,838,561
|
|
G |
Oat |
ornithine aminotransferase |
multiple interactions |
EXP |
Glucosamine affects the reaction [IL1B results in decreased expression of OAT mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 1:187,347,862...187,367,644
Ensembl chr 1:187,347,865...187,367,682
|
|
G |
Ogt |
O-linked N-acetylglucosamine (GlcNAc) transferase |
decreases expression |
ISO |
Glucosamine results in decreased expression of OGT mRNA |
CTD |
PMID:17178593 |
|
NCBI chr X:66,771,278...66,816,148
Ensembl chr X:66,771,349...66,816,146
|
|
G |
Orc2 |
origin recognition complex, subunit 2 |
decreases expression |
ISO |
Glucosamine results in decreased expression of ORC2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 9:60,001,631...60,038,301
Ensembl chr 9:60,001,910...60,038,195
|
|
G |
Osm |
oncostatin M |
multiple interactions |
ISO |
Glucosamine inhibits the reaction [[OSM protein co-treated with IL1B protein] results in decreased methylation of IL1B promoter]; Glucosamine inhibits the reaction [[OSM protein co-treated with IL1B protein] results in increased expression of IL1B mRNA] |
CTD |
PMID:21219853 |
|
NCBI chr14:79,103,638...79,108,500
Ensembl chr14:79,104,344...79,108,313
|
|
G |
Ostn |
osteocrin |
increases expression multiple interactions |
ISO |
Glucosamine results in increased expression of OSTN mRNA 4-methylumbelliferone 8-carbaldehyde inhibits the reaction [Glucosamine results in increased expression of OSTN mRNA]; 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of OSTN mRNA]; [INS1 protein co-treated with Glucosamine] results in increased expression of OSTN mRNA; ATF6 protein affects the reaction [Glucosamine results in increased expression of OSTN mRNA]; EIF2AK3 protein affects the reaction [Glucosamine results in increased expression of OSTN mRNA]; ERN1 protein affects the reaction [Glucosamine results in increased expression of OSTN mRNA]; GSK2656157 inhibits the reaction [Glucosamine results in increased expression of OSTN mRNA]; OSTN protein affects the reaction [Glucosamine inhibits the reaction [INS1 protein results in increased phosphorylation of AKT1 protein]]; OSTN protein affects the reaction [Glucosamine inhibits the reaction [INS1 protein results in increased uptake of 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose]] |
CTD |
PMID:30602124 |
|
NCBI chr11:73,442,167...73,478,498
Ensembl chr11:73,442,487...73,468,603
|
|
G |
Oxr1 |
oxidation resistance 1 |
decreases expression |
ISO |
Glucosamine results in decreased expression of OXR1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 7:72,528,750...72,965,666
Ensembl chr 7:72,528,786...72,965,666
|
|
G |
Pank1 |
pantothenate kinase 1 |
increases expression |
ISO |
Glucosamine results in increased expression of PANK1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 1:232,324,718...232,395,445
Ensembl chr 1:232,328,430...232,396,829
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage multiple interactions |
ISO |
Glucosamine results in increased cleavage of PARP1 protein pepstatin inhibits the reaction [Glucosamine results in increased cleavage of PARP1 protein] |
CTD |
PMID:16850161 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pdgfa |
platelet derived growth factor subunit A |
affects expression multiple interactions |
EXP |
Glucosamine affects the expression of PDGFA mRNA Glucosamine inhibits the reaction [IL1B results in increased expression of PDGFA mRNA]; IL1B affects the reaction [Glucosamine affects the expression of PDGFA mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr12:15,645,549...15,667,056
Ensembl chr12:15,645,541...15,666,497
|
|
G |
Pdia4 |
protein disulfide isomerase family A, member 4 |
decreases expression |
ISO |
Glucosamine results in decreased expression of PDIA4 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 4:76,803,198...76,822,245
Ensembl chr 4:76,803,198...76,822,107
|
|
G |
Pdia6 |
protein disulfide isomerase family A, member 6 |
decreases expression |
ISO |
Glucosamine results in decreased expression of PDIA6 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 6:40,062,980...40,080,223
Ensembl chr 6:40,062,926...40,080,613
|
|
G |
Pdk4 |
pyruvate dehydrogenase kinase 4 |
increases expression |
ISO |
Glucosamine results in increased expression of PDK4 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 4:33,591,796...33,601,798
Ensembl chr 4:33,589,799...33,601,850
|
|
G |
Pfkp |
phosphofructokinase, platelet |
increases expression |
ISO |
Glucosamine results in increased expression of PFKP mRNA |
CTD |
PMID:17178593 |
|
NCBI chr17:63,729,743...63,794,026
Ensembl chr17:63,729,780...63,794,018
|
|
G |
Piga |
phosphatidylinositol glycan anchor biosynthesis, class A |
decreases expression |
ISO |
Glucosamine results in decreased expression of PIGA mRNA |
CTD |
PMID:17178593 |
|
NCBI chr X:30,043,033...30,055,861
Ensembl chr X:30,042,343...30,055,804
|
|
G |
Pla2g2a |
phospholipase A2 group IIA |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of PLA2G2A mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of PLA2G2A mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 5:151,076,442...151,079,019
Ensembl chr 5:151,076,442...151,079,014
|
|
G |
Pla2g4a |
phospholipase A2 group IVA |
affects expression multiple interactions |
EXP |
Glucosamine affects the expression of PLA2G4A mRNA Glucosamine inhibits the reaction [IL1B results in increased expression of PLA2G4A mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr13:61,877,818...62,022,261
Ensembl chr13:61,877,813...62,022,266
|
|
G |
Pla2g5 |
phospholipase A2, group V |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of PLA2G5 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of PLA2G5 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 5:151,041,339...151,109,433
Ensembl chr 5:151,041,340...151,062,658
|
|
G |
Plat |
plasminogen activator, tissue type |
increases expression |
ISO |
Glucosamine results in increased expression of PLAT mRNA |
CTD |
PMID:17178593 |
|
NCBI chr16:69,240,582...69,265,177
Ensembl chr16:69,240,585...69,268,223
|
|
G |
Plk1 |
polo-like kinase 1 |
increases expression decreases expression |
ISO EXP |
Glucosamine results in increased expression of PLK1 mRNA Glucosamine results in decreased expression of PLK1 mRNA |
CTD |
PMID:17109745 PMID:17178593 |
|
NCBI chr 1:176,716,420...176,726,400
Ensembl chr 1:176,716,420...176,726,400
|
|
G |
Plpp3 |
phospholipid phosphatase 3 |
decreases expression |
EXP |
Glucosamine results in decreased expression of PLPP3 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 5:119,927,085...120,002,206
Ensembl chr 5:119,927,085...120,002,205
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions increases expression |
ISO EXP |
Glucosamine promotes the reaction [IL1B results in increased expression of PPARG] Glucosamine results in increased expression of PPARG mRNA |
CTD |
PMID:15694357 PMID:22089456 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
multiple interactions decreases expression |
ISO EXP |
4-phenylbutyric acid inhibits the reaction [Glucosamine results in decreased expression of PPARGC1A mRNA]; 4-phenylbutyric acid inhibits the reaction [Glucosamine results in decreased expression of PPARGC1A protein]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of PPARGC1A mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of PPARGC1A protein]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in decreased expression of PPARGC1A mRNA]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in decreased expression of PPARGC1A protein] Glucosamine results in decreased expression of PPARGC1A mRNA; Glucosamine results in decreased expression of PPARGC1A protein |
CTD |
PMID:20165829 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Ppm1a |
protein phosphatase, Mg2+/Mn2+ dependent, 1A |
decreases expression |
ISO |
Glucosamine results in decreased expression of PPM1A mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 6:91,439,094...91,486,139
Ensembl chr 6:91,438,834...91,480,697
|
|
G |
Ppp1r15a |
protein phosphatase 1, regulatory subunit 15A |
decreases expression |
ISO |
Glucosamine results in decreased expression of PPP1R15A mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 1:96,000,053...96,003,128
Ensembl chr 1:96,000,058...96,003,171
|
|
G |
Prc1 |
protein regulator of cytokinesis 1 |
decreases expression |
EXP |
Glucosamine results in decreased expression of PRC1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 1:134,250,086...134,271,765
Ensembl chr 1:134,250,081...134,271,765
|
|
G |
Prkaa1 |
protein kinase AMP-activated catalytic subunit alpha 1 |
multiple interactions |
ISO |
PRKAA1 protein promotes the reaction [Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]]; PRKAA1 protein promotes the reaction [NUS1 protein inhibits the reaction [Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]]] |
CTD |
PMID:33812996 |
|
NCBI chr 2:54,240,298...54,275,978
Ensembl chr 2:54,240,137...54,275,978
|
|
G |
Psme3 |
proteasome activator subunit 3 |
decreases expression |
ISO |
Glucosamine results in decreased expression of PSME3 |
CTD |
PMID:21697645 |
|
NCBI chr10:86,257,672...86,265,458
Ensembl chr10:86,257,668...86,333,804
|
|
G |
Ptges |
prostaglandin E synthase |
multiple interactions |
ISO |
[Glucosamine co-treated with Chondroitin Sulfates co-treated with IL1B protein] results in decreased expression of PTGES protein; Glucosamine inhibits the reaction [IL1B results in increased expression of PTGES mRNA] |
CTD |
PMID:17605605 PMID:22089456 |
|
NCBI chr 3:14,177,892...14,189,236
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression decreases expression multiple interactions decreases glycosylation |
ISO EXP |
Glucosamine analog results in increased expression of PTGS2 protein alternative form Glucosamine results in decreased expression of PTGS2 mRNA Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA] Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]; Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]; Glucosamine inhibits the reaction [[Lipopolysaccharides results in increased expression of PTGS2 protein] which results in increased secretion of Dinoprostone]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein] Glucosamine results in decreased glycosylation of PTGS2 protein [Glucosamine co-treated with Chondroitin Sulfates co-treated with IL1B protein] results in decreased expression of PTGS2 protein; Glucosamine inhibits the reaction [IL1B protein results in increased expression of PTGS2 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased expression of PTGS2 protein] |
CTD |
PMID:12681956 PMID:17440993 PMID:17605605 PMID:18205790 PMID:19656660 PMID:20737476 PMID:22089456 More...
|
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Pttg1 |
PTTG1 regulator of sister chromatid separation, securin |
decreases expression |
EXP |
Glucosamine results in decreased expression of PTTG1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr10:27,893,466...27,904,965
Ensembl chr10:27,893,689...27,904,837
|
|
G |
Rab32 |
RAB32, member RAS oncogene family |
increases expression |
ISO |
Glucosamine results in increased expression of RAB32 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 1:4,946,193...4,961,003
Ensembl chr 1:4,945,036...4,960,934
|
|
G |
Racgap1 |
Rac GTPase-activating protein 1 |
decreases expression |
EXP |
Glucosamine results in decreased expression of RACGAP1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 7:130,750,936...130,780,891
Ensembl chr 7:130,750,936...130,780,831
|
|
G |
Rbm39 |
RNA binding motif protein 39 |
decreases expression |
ISO |
Glucosamine results in decreased expression of RBM39 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 3:144,662,998...144,696,222
Ensembl chr 3:144,663,001...144,696,213
|
|
G |
Recql4 |
RecQ like helicase 4 |
increases expression |
ISO |
Glucosamine results in increased expression of RECQL4 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 7:108,423,453...108,430,790
Ensembl chr 7:108,423,455...108,430,619
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions decreases activity increases localization |
ISO EXP |
Alloxan inhibits the reaction [Glucosamine inhibits the reaction [TNF results in increased phosphorylation of RELA protein]]; Glucosamine analog inhibits the reaction [IL1B results in increased localization of RELA protein]; Glucosamine analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of RELA protein]; Glucosamine inhibits the reaction [Hydrogen Peroxide results in increased expression of and results in increased localization of RELA protein]; Glucosamine inhibits the reaction [IL1B protein results in increased localization of RELA protein]; Glucosamine inhibits the reaction [IL1B results in increased localization of RELA protein]; Glucosamine inhibits the reaction [NFKB1 results in increased degradation of RELA protein]; Glucosamine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of RELA protein]; Glucosamine inhibits the reaction [TNF results in increased localization of RELA protein]; Glucosamine inhibits the reaction [TNF results in increased phosphorylation of RELA protein] Glucosamine results in decreased activity of RELA protein Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of RELA protein]; Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased localization of RELA protein]; Glucosamine inhibits the reaction [Lipopolysaccharides promotes the reaction [RELA protein binds to NOS2 promoter]]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of RELA mRNA]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased localization of RELA protein] Glucosamine results in increased localization of RELA protein |
CTD |
PMID:12681956 PMID:16431966 PMID:16822504 PMID:17238806 PMID:17498959 PMID:18036590 PMID:18080321 PMID:18205790 PMID:18340449 PMID:18786831 PMID:19020780 PMID:19375915 PMID:20307528 PMID:20737476 More...
|
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Relb |
RELB proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of RELB mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 1:79,257,738...79,285,490
Ensembl chr 1:79,257,725...79,285,507
|
|
G |
Rhob |
ras homolog family member B |
increases expression |
ISO |
Glucosamine results in increased expression of RHOB mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 6:31,363,752...31,365,926
Ensembl chr 6:31,363,548...31,366,108
|
|
G |
Rhoc |
ras homolog family member C |
decreases expression |
ISO |
Glucosamine analog results in decreased expression of RHOC mRNA |
CTD |
PMID:16142878 |
|
NCBI chr 2:192,287,065...192,293,292
Ensembl chr 2:192,287,130...192,295,306
|
|
G |
Rnd1 |
Rho family GTPase 1 |
multiple interactions decreases expression |
ISO |
Glucosamine analog inhibits the reaction [TNF results in increased expression of RND1 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of RND1 mRNA] Glucosamine results in decreased expression of RND1 mRNA |
CTD |
PMID:17178593 PMID:18173918 |
|
NCBI chr 7:129,821,311...129,828,385
Ensembl chr 7:129,821,311...129,828,399
|
|
G |
Rps6 |
ribosomal protein S6 |
decreases phosphorylation |
ISO |
Glucosamine results in decreased phosphorylation of RPS6 protein |
CTD |
PMID:19254699 |
|
NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602 Ensembl chr 5:101,371,136...101,374,602
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
decreases phosphorylation |
ISO |
Glucosamine results in decreased phosphorylation of RPS6KB1 protein |
CTD |
PMID:19254699 |
|
NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
|
|
G |
Runx2 |
RUNX family transcription factor 2 |
increases phosphorylation increases expression multiple interactions |
ISO |
Glucosamine analog results in increased phosphorylation of RUNX2 protein Glucosamine analog results in increased expression of RUNX2 mRNA 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [Glucosamine analog results in increased phosphorylation of RUNX2 protein] |
CTD |
PMID:20458730 |
|
NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167
|
|
G |
Scd2 |
stearoyl-Coenzyme A desaturase 2 |
increases expression |
ISO |
Glucosamine results in increased expression of SCD2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 1:243,169,171...243,182,231
Ensembl chr 1:243,169,236...243,182,232
|
|
G |
Sdc2 |
syndecan 2 |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in decreased expression of SDC2 mRNA]; IL1B promotes the reaction [Glucosamine results in decreased expression of SDC2 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 7:64,127,185...64,239,885
Ensembl chr 7:64,127,110...64,241,081
|
|
G |
Sdc4 |
syndecan 4 |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of SDC4 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of SDC4 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 3:153,154,888...153,173,576
Ensembl chr 3:153,154,896...153,173,580
|
|
G |
Selenbp1 |
selenium binding protein 1 |
decreases expression |
EXP |
Glucosamine results in decreased expression of SELENBP1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 2:182,494,004...182,504,594
Ensembl chr 2:182,493,978...182,504,594
|
|
G |
Serpinb2 |
serpin family B member 2 |
increases expression |
EXP |
Glucosamine results in increased expression of SERPINB2 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr13:23,537,312...23,551,823
Ensembl chr13:23,541,400...23,550,408
|
|
G |
Serpinh1 |
serpin family H member 1 |
increases expression |
ISO |
Glucosamine results in increased expression of SERPINH1 protein |
CTD |
PMID:16380481 |
|
NCBI chr 1:153,643,500...153,650,853
Ensembl chr 1:153,643,510...153,650,801
|
|
G |
Sfrp2 |
secreted frizzled-related protein 2 |
decreases expression |
EXP |
Glucosamine results in decreased expression of SFRP2 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 2:169,089,517...169,097,064
Ensembl chr 2:169,089,517...169,097,063
|
|
G |
Sgk1 |
serum/glucocorticoid regulated kinase 1 |
decreases expression |
ISO |
Glucosamine results in decreased expression of SGK1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 1:22,980,257...23,098,122
Ensembl chr 1:22,980,261...23,098,283
|
|
G |
Shcbp1 |
SHC binding and spindle associated 1 |
decreases expression |
EXP |
Glucosamine results in decreased expression of SHCBP1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr16:84,672,277...84,703,843
Ensembl chr16:84,672,321...84,703,844
|
|
G |
Slc17a1 |
solute carrier family 17 member 1 |
increases expression |
ISO |
Glucosamine results in increased expression of SLC17A1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr17:41,219,461...41,255,199
Ensembl chr17:41,222,049...41,253,304
|
|
G |
Slc23a2 |
solute carrier family 23 member 2 |
increases expression |
EXP |
Glucosamine results in increased expression of SLC23A2 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 3:119,302,651...119,395,289
Ensembl chr 3:119,302,666...119,460,343
|
|
G |
Slc2a2 |
solute carrier family 2 member 2 |
decreases expression |
EXP |
Glucosamine results in decreased expression of SLC2A2 mRNA |
CTD |
PMID:11893929 |
|
NCBI chr 2:111,609,798...111,639,930
Ensembl chr 2:111,611,774...111,639,933
|
|
G |
Slc2a4 |
solute carrier family 2 member 4 |
multiple interactions decreases expression increases uptake |
ISO EXP |
4-phenylbutyric acid inhibits the reaction [Glucosamine results in decreased expression of SLC2A4 mRNA]; 4-phenylbutyric acid inhibits the reaction [Glucosamine results in decreased expression of SLC2A4 protein]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of SLC2A4 mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of SLC2A4 protein]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in decreased expression of SLC2A4 mRNA]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in decreased expression of SLC2A4 protein] Glucosamine results in decreased expression of SLC2A4 mRNA; Glucosamine results in decreased expression of SLC2A4 protein SLC2A4 protein results in increased uptake of Glucosamine Glucosamine inhibits the reaction [SLC2A4 protein results in increased uptake of Glucose]; Glucose inhibits the reaction [SLC2A4 protein results in increased uptake of Glucosamine] |
CTD |
PMID:19373748 PMID:20165829 |
|
NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565
|
|
G |
Slc2a6 |
solute carrier family 2 member 6 |
decreases expression |
ISO |
Glucosamine results in decreased expression of SLC2A6 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 3:10,348,395...10,355,208
Ensembl chr 3:10,348,395...10,355,208
|
|
G |
Slc37a4 |
solute carrier family 37 member 4 |
increases expression |
ISO |
Glucosamine results in increased expression of SLC37A4 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 8:44,723,216...44,729,301
Ensembl chr 8:44,723,339...44,729,301
|
|
G |
Slc4a4 |
solute carrier family 4 member 4 |
decreases expression |
EXP |
Glucosamine results in decreased expression of SLC4A4 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr14:18,841,289...19,293,297
Ensembl chr14:18,845,159...19,272,883
|
|
G |
Slc7a8 |
solute carrier family 7 member 8 |
increases expression multiple interactions |
EXP |
Glucosamine results in increased expression of SLC7A8 mRNA Glucosamine inhibits the reaction [IL1B results in increased expression of SLC7A8 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of SLC7A8 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr15:28,183,013...28,242,717
Ensembl chr15:28,183,015...28,242,717
|
|
G |
Smad2 |
SMAD family member 2 |
multiple interactions increases phosphorylation |
ISO |
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [Glucosamine analog results in increased phosphorylation of SMAD2 protein] |
CTD |
PMID:20458730 |
|
NCBI chr18:69,849,884...69,918,926
Ensembl chr18:69,850,377...69,912,323
|
|
G |
Smpd3 |
sphingomyelin phosphodiesterase 3 |
decreases expression |
EXP |
Glucosamine results in decreased expression of SMPD3 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr19:34,162,337...34,245,786
Ensembl chr19:34,162,341...34,245,749
|
|
G |
Sox4 |
SRY-box transcription factor 4 |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in decreased expression of SOX4 mRNA] Glucosamine results in decreased expression of SOX4 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr17:35,667,809...35,672,515
Ensembl chr17:35,667,537...35,673,665
|
|
G |
Srsf3 |
serine and arginine rich splicing factor 3 |
decreases expression |
ISO |
Glucosamine results in decreased expression of SRSF3 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr20:7,091,928...7,101,860
Ensembl chr20:7,091,910...7,101,078
|
|
G |
St6gal1 |
ST6 beta-galactoside alpha-2,6-sialyltransferase 1 |
increases expression |
ISO |
Glucosamine results in increased expression of ST6GAL1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr11:77,526,837...77,653,474
Ensembl chr11:77,526,837...77,653,310
|
|
G |
Stat1 |
signal transducer and activator of transcription 1 |
multiple interactions |
ISO |
Glucosamine inhibits the reaction [IFNG results in increased localization of STAT1 protein modified form]; Glucosamine inhibits the reaction [IFNG results in increased phosphorylation of and results in increased localization of STAT1 protein] |
CTD |
PMID:16431966 PMID:17238806 |
|
NCBI chr 9:49,419,561...49,459,969
Ensembl chr 9:49,419,340...49,588,540
|
|
G |
Tacc3 |
transforming, acidic coiled-coil containing protein 3 |
decreases expression |
EXP |
Glucosamine results in decreased expression of TACC3 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr14:77,051,209...77,065,343
Ensembl chr14:77,051,215...77,065,219
|
|
G |
Testin |
testin gene |
decreases expression |
EXP |
Glucosamine results in decreased expression of TESTIN mRNA |
CTD |
PMID:17109745 |
|
NCBI chr17:3,824,222...3,859,385
Ensembl chr17:3,846,899...3,859,385
|
|
G |
Tgfa |
transforming growth factor alpha |
multiple interactions |
EXP |
[Glucose co-treated with Glucosamine] results in increased expression of TGFA protein; Glucosamine promotes the reaction [Glucose results in increased expression of TGFA mRNA] |
CTD |
PMID:1518840 |
|
NCBI chr 4:118,618,043...118,700,897
Ensembl chr 4:118,618,269...118,700,894
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
increases expression |
EXP |
Glucosamine analog results in increased expression of TGFB1 mRNA |
CTD |
PMID:21466783 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tgfbr1 |
transforming growth factor, beta receptor 1 |
increases expression multiple interactions |
ISO |
Glucosamine analog results in increased expression of TGFBR1 protein 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [Glucosamine analog results in increased expression of TGFBR1 protein] |
CTD |
PMID:20458730 |
|
NCBI chr 5:61,653,773...61,710,777
Ensembl chr 5:61,653,233...61,710,777
|
|
G |
Thbs4 |
thrombospondin 4 |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in decreased expression of THBS4 mRNA]; IL1B promotes the reaction [Glucosamine results in decreased expression of THBS4 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 2:23,983,158...24,025,289
Ensembl chr 2:23,983,158...24,026,313
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of TIMP1 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of TIMP1 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Timp2 |
TIMP metallopeptidase inhibitor 2 |
affects expression multiple interactions |
EXP |
Glucosamine affects the expression of TIMP2 mRNA Glucosamine inhibits the reaction [IL1B results in decreased expression of TIMP2 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr10:103,541,199...103,590,611
Ensembl chr10:103,531,505...103,590,611
|
|
G |
Timp3 |
TIMP metallopeptidase inhibitor 3 |
multiple interactions increases expression |
ISO EXP |
[Glucosamine co-treated with Chondroitin Sulfates co-treated with IL1B protein] results in increased expression of TIMP3 mRNA Glucosamine results in increased expression of TIMP3 mRNA Glucosamine inhibits the reaction [IL1B results in decreased expression of TIMP3 mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of TIMP3 mRNA] |
CTD |
PMID:17109745 PMID:17605605 |
|
NCBI chr 7:17,520,827...17,571,850
Ensembl chr 7:17,521,919...17,571,839
|
|
G |
Tinag |
tubulointerstitial nephritis antigen |
increases expression |
ISO |
Glucosamine results in increased expression of TINAG mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 8:77,800,031...77,885,077
Ensembl chr 8:77,800,032...77,885,077
|
|
G |
Tk1 |
thymidine kinase 1 |
decreases expression |
EXP |
Glucosamine results in decreased expression of TK1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr10:103,034,755...103,046,125
Ensembl chr10:103,031,521...103,046,920
|
|
G |
Tlr1 |
toll-like receptor 1 |
increases expression |
ISO |
Glucosamine results in increased expression of TLR1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr14:43,384,127...43,396,765
Ensembl chr14:43,384,932...43,397,125
|
|
G |
Tnf |
tumor necrosis factor |
decreases secretion multiple interactions decreases expression |
ISO EXP |
Glucosamine results in decreased secretion of TNF protein Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein] Glucosamine analog results in decreased expression of TNF mRNA; Glucosamine results in decreased expression of TNF mRNA Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of TNF protein]; Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA] [Glucosamine co-treated with Chondroitin Sulfates] results in decreased expression of TNF; Alloxan inhibits the reaction [Glucosamine inhibits the reaction [TNF results in increased phosphorylation of RELA protein]]; Glucosamine analog inhibits the reaction [TNF results in increased expression of CUL2 mRNA]; Glucosamine analog inhibits the reaction [TNF results in increased expression of CXCL8 mRNA]; Glucosamine analog inhibits the reaction [TNF results in increased expression of GSPT1 mRNA]; Glucosamine analog inhibits the reaction [TNF results in increased expression of IL6 mRNA]; Glucosamine analog inhibits the reaction [TNF results in increased expression of RND1 mRNA]; Glucosamine analog inhibits the reaction [TNF results in increased expression of TNFRSF1A mRNA]; Glucosamine analog inhibits the reaction [TNF results in increased expression of TNFRSF1B mRNA]; Glucosamine analog inhibits the reaction [TNF results in increased expression of TRAF6 mRNA]; Glucosamine inhibits the reaction [[IL6 co-treated with TNF] results in increased expression of ICAM1 protein]; Glucosamine inhibits the reaction [IFNG promotes the reaction [TNF results in increased expression of ICAM1 protein]]; Glucosamine inhibits the reaction [IL1B promotes the reaction [TNF results in increased expression of ICAM1 protein]]; Glucosamine inhibits the reaction [TNF promotes the reaction [IFNG results in increased expression of ICAM1 protein]]; Glucosamine inhibits the reaction [TNF promotes the reaction [IL1B results in increased expression of ICAM1 protein]]; Glucosamine inhibits the reaction [TNF results in increased expression of CCL2 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of CCL2 protein]; Glucosamine inhibits the reaction [TNF results in increased expression of CUL2 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of CXCL8 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of GSPT1 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of ICAM1 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of ICAM1 protein]; Glucosamine inhibits the reaction [TNF results in increased expression of IL6 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of RND1 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of TNFRSF1A mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of TNFRSF1B mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of TRAF6 mRNA]; Glucosamine inhibits the reaction [TNF results in increased localization of RELA protein]; Glucosamine inhibits the reaction [TNF results in increased phosphorylation of RELA protein] |
CTD |
PMID:14507305 PMID:16431966 PMID:16445576 PMID:16822504 PMID:17238806 PMID:18173918 PMID:18205790 PMID:18786831 PMID:19020780 PMID:19098112 PMID:20093129 PMID:20110869 PMID:20113495 PMID:20737476 More...
|
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfaip6 |
TNF alpha induced protein 6 |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of TNFAIP6 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of TNFAIP6 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 3:36,502,250...36,521,652
Ensembl chr 3:36,502,188...36,521,649
|
|
G |
Tnfrsf11b |
TNF receptor superfamily member 11B |
multiple interactions |
ISO |
[Chondroitin Sulfates co-treated with Glucosamine co-treated with Cholecalciferol] results in increased expression of TNFRSF11B mRNA; [Chondroitin Sulfates co-treated with Glucosamine co-treated with Cholecalciferol] results in increased expression of TNFRSF11B protein; [Chondroitin Sulfates co-treated with Glucosamine] results in increased expression of TNFRSF11B mRNA; [Chondroitin Sulfates co-treated with Glucosamine] results in increased expression of TNFRSF11B protein |
CTD |
PMID:17996099 |
|
NCBI chr 7:85,566,520...85,594,526
Ensembl chr 7:85,566,520...85,594,538
|
|
G |
Tnfrsf1a |
TNF receptor superfamily member 1A |
multiple interactions |
ISO |
Glucosamine analog inhibits the reaction [TNF results in increased expression of TNFRSF1A mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of TNFRSF1A mRNA] |
CTD |
PMID:18173918 |
|
NCBI chr 4:158,150,815...158,163,592
Ensembl chr 4:158,150,820...158,163,591
|
|
G |
Tnfrsf1b |
TNF receptor superfamily member 1B |
multiple interactions |
ISO |
Glucosamine analog inhibits the reaction [TNF results in increased expression of TNFRSF1B mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of TNFRSF1B mRNA] |
CTD |
PMID:18173918 |
|
NCBI chr 5:157,070,642...157,104,216
Ensembl chr 5:157,070,642...157,104,206
|
|
G |
Tnfsf11 |
TNF superfamily member 11 |
multiple interactions increases expression |
ISO |
[Chondroitin Sulfates co-treated with Glucosamine] inhibits the reaction [Cholecalciferol results in increased expression of TNFSF11 mRNA]; Chondroitin Sulfates inhibits the reaction [Glucosamine results in increased expression of TNFSF11 mRNA] |
CTD |
PMID:17996099 |
|
NCBI chr15:53,673,850...53,705,325
Ensembl chr15:53,673,877...53,705,445
|
|
G |
Tnk2 |
tyrosine kinase, non-receptor, 2 |
multiple interactions |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of TNK2 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr11:68,114,725...68,154,254
Ensembl chr11:68,114,726...68,154,009
|
|
G |
Top2a |
DNA topoisomerase II alpha |
decreases expression |
EXP |
Glucosamine results in decreased expression of TOP2A mRNA |
CTD |
PMID:17109745 |
|
NCBI chr10:83,945,731...83,976,874
Ensembl chr10:83,945,735...83,976,874
|
|
G |
Traf6 |
TNF receptor associated factor 6 |
multiple interactions |
ISO |
Glucosamine analog inhibits the reaction [TNF results in increased expression of TRAF6 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of TRAF6 mRNA] |
CTD |
PMID:18173918 |
|
NCBI chr 3:87,963,517...87,988,316
Ensembl chr 3:87,963,514...87,983,507
|
|
G |
Trpv4 |
transient receptor potential cation channel, subfamily V, member 4 |
increases expression |
ISO |
Glucosamine results in increased expression of TRPV4 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr12:41,938,533...41,977,517
Ensembl chr12:41,938,560...41,977,517
|
|
G |
Txn1 |
thioredoxin 1 |
decreases expression |
EXP ISO |
Glucosamine results in decreased expression of TXN1 protein |
CTD |
PMID:17178593 |
|
NCBI chr 5:72,712,334...72,724,564
Ensembl chr 5:72,711,933...72,724,629
|
|
G |
Txnip |
thioredoxin interacting protein |
increases expression multiple interactions |
EXP ISO |
Glucosamine results in increased expression of TXNIP protein Glucosamine results in increased expression of TXNIP mRNA; Glucosamine results in increased expression of TXNIP protein Glucosamine promotes the reaction [TXNIP results in increased abundance of Reactive Oxygen Species]; TXNIP promotes the reaction [Glucosamine results in increased expression of LAMB1 mRNA]; TXNIP promotes the reaction [Glucosamine results in increased expression of LAMC1 mRNA] |
CTD |
PMID:17178593 |
|
NCBI chr 2:184,093,079...184,096,882
Ensembl chr 2:184,092,991...184,096,886
|
|
G |
Ucp2 |
uncoupling protein 2 |
decreases expression |
EXP |
Glucosamine results in decreased expression of UCP2 mRNA |
CTD |
PMID:11893929 |
|
NCBI chr 1:154,839,242...154,845,612
Ensembl chr 1:154,839,209...154,845,611
|
|
G |
Uqcrh |
ubiquinol-cytochrome c reductase hinge protein |
increases expression |
ISO |
Glucosamine results in increased expression of UQCRH mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 5:129,545,978...129,554,173
Ensembl chr 5:129,545,984...129,554,242
|
|
G |
Vamp1 |
vesicle-associated membrane protein 1 |
increases expression |
EXP |
Glucosamine results in increased expression of VAMP1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 4:158,012,634...158,019,350
Ensembl chr 4:158,012,663...158,019,349
|
|
G |
Vcan |
versican |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of VCAN mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of VCAN mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 2:20,761,718...20,860,637
Ensembl chr 2:20,761,718...20,860,637
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions increases expression decreases expression |
ISO EXP |
Glucosamine inhibits the reaction [Oxygen deficiency results in increased expression of VEGFA protein] Glucosamine results in increased expression of VEGFA protein Glucosamine results in decreased expression of VEGFA protein |
CTD |
PMID:16324875 PMID:19254699 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Vegfd |
vascular endothelial growth factor D |
increases expression decreases expression |
ISO EXP |
Glucosamine results in increased expression of VEGFD mRNA Glucosamine results in decreased expression of VEGFD mRNA |
CTD |
PMID:17109745 PMID:17178593 |
|
NCBI chr X:30,073,122...30,108,413
Ensembl chr X:30,074,163...30,108,295
|
|
G |
Vnn1 |
vanin 1 |
increases expression |
ISO |
Glucosamine results in increased expression of VNN1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 1:21,537,084...21,547,395
Ensembl chr 1:21,537,094...21,547,395
|
|
G |
Xbp1 |
X-box binding protein 1 |
multiple interactions increases splicing increases expression decreases splicing |
ISO EXP |
4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of XBP1 mRNA]; NUS1 protein inhibits the reaction [Glucosamine results in increased splicing of XBP1 mRNA]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in increased expression of XBP1 mRNA] 4-methylumbelliferone 8-carbaldehyde affects the reaction [Glucosamine results in increased expression of XBP1 protein alternative form]; 4-methylumbelliferone 8-carbaldehyde inhibits the reaction [Glucosamine results in increased splicing of XBP1 mRNA]; 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of XBP1 protein alternative form]; 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased splicing of XBP1 mRNA]; ERN1 protein affects the reaction [Glucosamine results in increased splicing of XBP1 mRNA] 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of XBP1 mRNA]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in increased expression of XBP1 mRNA] Glucosamine results in decreased splicing of XBP1 mRNA |
CTD |
PMID:19383982 PMID:20165829 PMID:30602124 PMID:33812996 |
|
NCBI chr14:80,390,629...80,395,713
Ensembl chr14:80,390,643...80,395,693
|
|
G |
Xdh |
xanthine dehydrogenase |
multiple interactions |
EXP |
[XDH protein co-treated with Hypoxanthine] inhibits the reaction [Glucosamine results in increased abundance of Proteoglycans]; [XDH protein co-treated with Hypoxanthine] inhibits the reaction [Glucosamine results in increased expression of B3GAT3 mRNA] |
CTD |
PMID:11801247 |
|
NCBI chr 6:21,530,463...21,592,172
Ensembl chr 6:21,530,113...21,592,268
|
|
G |
Zfp467 |
zinc finger protein 467 |
increases expression |
ISO |
Glucosamine results in increased expression of ZFP467 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 4:77,385,752...77,394,709
Ensembl chr 4:77,385,758...77,392,229
|
|
|
G |
A2m |
alpha-2-macroglobulin |
increases uptake multiple interactions |
ISO |
A2M protein modified form results in increased uptake of Deoxyglucose HSPA5 protein affects the reaction [A2M protein modified form results in increased uptake of Deoxyglucose] |
CTD |
PMID:25720493 |
|
NCBI chr 4:154,897,770...154,947,787
Ensembl chr 4:154,897,877...154,947,786
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions |
ISO |
Deoxyglucose inhibits the reaction [ABCB1 protein results in increased export of Diazinon] |
CTD |
PMID:16221533 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcc9 |
ATP binding cassette subfamily C member 9 |
multiple interactions |
ISO |
[Oligomycins co-treated with Deoxyglucose] results in increased activity of [KCNJ11 protein binds to ABCC9 protein]; Glyburide inhibits the reaction [[Oligomycins co-treated with Deoxyglucose] results in increased activity of [KCNJ11 protein binds to ABCC9 protein]] |
CTD |
PMID:28842488 |
|
NCBI chr 4:175,531,854...175,655,849
Ensembl chr 4:175,532,547...175,655,356
|
|
G |
Abra |
actin-binding Rho activating protein |
multiple interactions increases uptake |
EXP |
CCG 1423 promotes the reaction [ABRA mutant form promotes the reaction [INS1 protein results in increased uptake of Deoxyglucose]]; CCG 1423 promotes the reaction [ABRA mutant form results in increased uptake of Deoxyglucose]; CCG 1423 promotes the reaction [INS1 protein promotes the reaction [ABRA mutant form results in increased uptake of Deoxyglucose]]; INS1 protein promotes the reaction [ABRA mutant form results in increased uptake of Deoxyglucose] |
CTD |
PMID:21393865 |
|
NCBI chr 7:72,970,187...72,974,255
Ensembl chr 7:72,970,186...72,974,255
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
increases uptake multiple interactions |
ISO |
ADIPOQ protein modified form results in increased uptake of Deoxyglucose Indinavir inhibits the reaction [ADIPOQ protein modified form results in increased uptake of Deoxyglucose] |
CTD |
PMID:29991592 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Agrp |
agouti related neuropeptide |
increases expression |
EXP |
Deoxyglucose results in increased expression of AGRP mRNA |
CTD |
PMID:10683841 |
|
NCBI chr19:33,447,992...33,481,602
Ensembl chr19:33,447,992...33,449,584
|
|
G |
Ap5s1 |
adaptor related protein complex 5 subunit sigma 1 |
increases expression |
ISO |
Deoxyglucose results in increased expression of AP5S1 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr 3:118,429,618...118,432,929
Ensembl chr 3:118,429,637...118,432,926
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
ISO |
[Sodium Azide co-treated with Deoxyglucose] affects the cleavage of and affects the localization of APP protein |
CTD |
PMID:17405930 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Atg3 |
autophagy related 3 |
multiple interactions |
ISO |
Deoxyglucose affects the reaction [demycarosyl-3D-digitoxosylmithramycin SK affects the expression of ATG3 mRNA] |
CTD |
PMID:26079942 |
|
NCBI chr11:55,624,914...55,653,249
Ensembl chr11:55,624,917...55,653,224
|
|
G |
Atg4b |
autophagy related 4B, cysteine peptidase |
multiple interactions |
ISO |
[demycarosyl-3D-digitoxosylmithramycin SK co-treated with Deoxyglucose] results in increased expression of ATG4B mRNA |
CTD |
PMID:26079942 |
|
NCBI chr 9:94,282,417...94,314,109
Ensembl chr 9:94,282,509...94,314,103
|
|
G |
Atg7 |
autophagy related 7 |
multiple interactions |
ISO |
ATG7 protein inhibits the reaction [Deoxyglucose results in increased cleavage of CASP3 protein]; ATG7 protein inhibits the reaction [Deoxyglucose results in increased expression of DDIT3 protein]; ATG7 protein inhibits the reaction [Deoxyglucose results in increased expression of HSPA5 protein]; ATG7 protein promotes the reaction [Deoxyglucose results in increased prenylation of MAP1LC3B protein] |
CTD |
PMID:20593179 |
|
NCBI chr 4:147,718,663...147,925,656
Ensembl chr 4:147,718,752...147,925,593
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions decreases expression |
ISO |
Deoxyglucose promotes the reaction [arsenic trioxide results in increased localization of and results in increased activity of BAX protein]; Deoxyglucose results in increased localization of and results in increased activity of BAX protein Deoxyglucose results in decreased expression of BAX mRNA |
CTD |
PMID:23041229 PMID:26079942 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO |
Deoxyglucose affects the reaction [demycarosyl-3D-digitoxosylmithramycin SK affects the expression of BCL2 mRNA] |
CTD |
PMID:26079942 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
decreases response to substance |
ISO |
BCL2L1 protein results in decreased susceptibility to Deoxyglucose |
CTD |
PMID:10679475 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Becn1 |
beclin 1 |
multiple interactions |
ISO |
[bafilomycin A co-treated with Deoxyglucose co-treated with demycarosyl-3D-digitoxosylmithramycin SK] results in decreased expression of BECN1 protein; [demycarosyl-3D-digitoxosylmithramycin SK co-treated with Deoxyglucose] results in increased expression of BECN1 mRNA |
CTD |
PMID:26079942 |
|
NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742
|
|
G |
Bid |
BH3 interacting domain death agonist |
multiple interactions |
ISO |
Deoxyglucose promotes the reaction [arsenic trioxide results in increased cleavage of and results in increased activity of BID protein]; Deoxyglucose results in increased cleavage of and results in increased activity of BID protein |
CTD |
PMID:23041229 |
|
NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity increases cleavage |
ISO EXP |
ATG7 protein inhibits the reaction [Deoxyglucose results in increased cleavage of CASP3 protein]; Deoxyglucose promotes the reaction [Arsenic Trioxide results in increased cleavage of and results in increased activity of CASP3 protein]; Deoxyglucose results in increased cleavage of and results in increased activity of CASP3 protein Deoxyglucose promotes the reaction [Metformin inhibits the reaction [Arsenic Trioxide results in increased expression of CASP3 protein modified form]] Deoxyglucose results in increased activity of CASP3 protein Corticosterone inhibits the reaction [Deoxyglucose results in increased activity of CASP3 protein]; GPX4 protein inhibits the reaction [Deoxyglucose results in increased activity of CASP3 protein] |
CTD |
PMID:10506188 PMID:15755911 PMID:20593179 PMID:23041229 PMID:29095437 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
ISO |
[Deoxyglucose co-treated with Cisplatin] results in increased activity of CASP9 protein; Deoxyglucose promotes the reaction [arsenic trioxide results in increased cleavage of and results in increased activity of CASP9 protein]; Deoxyglucose results in increased cleavage of and results in increased activity of CASP9 protein |
CTD |
PMID:20138251 PMID:23041229 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions |
ISO |
[demycarosyl-3D-digitoxosylmithramycin SK co-treated with Deoxyglucose] results in increased expression of CDKN1A mRNA |
CTD |
PMID:26079942 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cemip2 |
cell migration inducing hyaluronidase 2 |
decreases expression |
ISO |
Deoxyglucose results in decreased expression of CEMIP2 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr 1:219,330,295...219,407,760
Ensembl chr 1:219,337,985...219,407,760
|
|
G |
Chrm3 |
cholinergic receptor, muscarinic 3 |
affects response to substance |
ISO |
CHRM3 protein affects the susceptibility to Deoxyglucose |
CTD |
PMID:14724830 |
|
NCBI chr17:60,005,137...60,467,250
Ensembl chr17:60,005,202...60,467,278
|
|
G |
Chuk |
component of inhibitor of nuclear factor kappa B kinase complex |
affects localization |
ISO |
Deoxyglucose analog affects the localization of CHUK protein |
CTD |
PMID:27931795 |
|
NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065
|
|
G |
Ctsd |
cathepsin D |
increases expression |
EXP |
Deoxyglucose results in increased expression of CTSD protein |
CTD |
PMID:20026095 |
|
NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488
|
|
G |
Cul7 |
cullin 7 |
multiple interactions |
ISO |
[INS1 protein co-treated with CUL7 mutant form] results in increased uptake of Deoxyglucose |
CTD |
PMID:24219910 |
|
NCBI chr 9:14,319,102...14,333,035
Ensembl chr 9:14,319,108...14,332,741
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions increases expression |
ISO |
ATG7 protein inhibits the reaction [Deoxyglucose results in increased expression of DDIT3 protein]; Mannose inhibits the reaction [Deoxyglucose results in increased expression of DDIT3 protein] |
CTD |
PMID:20593179 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions increases import |
ISO |
AICA ribonucleotide inhibits the reaction [EGFR protein results in increased import of Deoxyglucose] EGFR protein mutant form results in increased import of Deoxyglucose |
CTD |
PMID:19625624 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
multiple interactions |
ISO |
Deoxyglucose results in decreased phosphorylation of and results in increased expression of EIF4EBP1 protein |
CTD |
PMID:23363784 |
|
NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984
|
|
G |
Erbb2 |
erb-b2 receptor tyrosine kinase 2 |
multiple interactions |
ISO |
[Deoxyglucose co-treated with Quercetin] results in increased ubiquitination of ERBB2 protein; Deoxyglucose inhibits the reaction [Quercetin promotes the reaction [ERBB2 protein binds to HSP90AA1 protein]] |
CTD |
PMID:18655187 |
|
NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078
|
|
G |
Errfi1 |
ERBB receptor feedback inhibitor 1 |
decreases expression |
ISO |
Deoxyglucose results in decreased expression of ERRFI1 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr 5:161,323,981...161,337,289
Ensembl chr 5:161,323,998...161,337,282
|
|
G |
Fam117a |
family with sequence similarity 117, member A |
decreases expression |
ISO |
Deoxyglucose results in decreased expression of FAM117A mRNA |
CTD |
PMID:33770205 |
|
NCBI chr10:80,281,411...80,325,345
Ensembl chr10:80,281,408...80,325,343
|
|
G |
Fxyd2 |
FXYD domain-containing ion transport regulator 2 |
multiple interactions increases transport |
ISO |
Calcium inhibits the reaction [FXYD2 protein results in increased transport of Deoxyglucose] |
CTD |
PMID:11533133 |
|
NCBI chr 8:45,712,901...45,720,032
Ensembl chr 8:45,712,903...45,720,203
|
|
G |
G3bp1 |
G3BP stress granule assembly factor 1 |
multiple interactions |
ISO |
Deoxyglucose inhibits the reaction [G3BP1 protein results in increased abundance of Lactic Acid]; Deoxyglucose inhibits the reaction [G3BP1 protein results in increased expression of HK2 protein]; Deoxyglucose inhibits the reaction [G3BP1 protein results in increased expression of LDHA protein]; Deoxyglucose inhibits the reaction [G3BP1 protein results in increased expression of PKM protein]; Deoxyglucose inhibits the reaction [G3BP1 protein results in increased uptake of Glucose] |
CTD |
PMID:35945655 |
|
NCBI chr10:39,586,864...39,620,268
Ensembl chr10:39,586,864...39,620,268
|
|
G |
Galr1 |
galanin receptor 1 |
increases expression |
EXP |
Deoxyglucose results in increased expression of GALR1 mRNA |
CTD |
PMID:9858361 PMID:9928191 |
|
NCBI chr18:75,772,021...75,787,577
Ensembl chr18:75,772,023...75,787,577
|
|
G |
Gcg |
glucagon |
multiple interactions increases secretion |
ISO |
Capsaicin inhibits the reaction [Deoxyglucose results in increased secretion of GCG protein] |
CTD |
PMID:1378463 |
|
NCBI chr 3:47,113,914...47,122,958
Ensembl chr 3:47,113,914...47,122,929
|
|
G |
Gpx4 |
glutathione peroxidase 4 |
multiple interactions |
EXP |
GPX4 protein inhibits the reaction [Deoxyglucose results in increased activity of CASP3 protein] |
CTD |
PMID:10506188 |
|
NCBI chr 7:9,650,186...9,652,982
Ensembl chr 7:9,650,185...9,652,982
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions |
ISO |
Deoxyglucose inhibits the reaction [arsenic trioxide results in increased phosphorylation of GSK3B protein]; Deoxyglucose inhibits the reaction [Fenretinide results in increased phosphorylation of GSK3B protein] |
CTD |
PMID:25246272 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
H2ax |
H2A.X variant histone |
decreases expression |
ISO |
Deoxyglucose results in decreased expression of H2AX protein |
CTD |
PMID:23363784 |
|
NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239
|
|
G |
Hk2 |
hexokinase 2 |
multiple interactions |
ISO |
[Lactic Acid co-treated with Deoxyglucose] inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of HK2 protein]; Deoxyglucose inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of HK2 protein]; Deoxyglucose inhibits the reaction [G3BP1 protein results in increased expression of HK2 protein]; Deoxyglucose inhibits the reaction [HMGA2 protein results in increased expression of HK2 protein]; Deoxyglucose results in decreased expression of and results in decreased activity of HK2 protein |
CTD |
PMID:32619556 PMID:34481905 PMID:35945655 PMID:36336208 |
|
NCBI chr 4:115,234,509...115,283,530
Ensembl chr 4:115,234,509...115,283,530
|
|
G |
Hmga2 |
high mobility group AT-hook 2 |
multiple interactions |
ISO |
Deoxyglucose inhibits the reaction [HMGA2 protein results in decreased expression of COX4 protein]; Deoxyglucose inhibits the reaction [HMGA2 protein results in decreased expression of ND1 protein]; Deoxyglucose inhibits the reaction [HMGA2 protein results in increased expression of HK2 protein]; Deoxyglucose inhibits the reaction [HMGA2 protein results in increased expression of MMP2 protein]; Deoxyglucose inhibits the reaction [HMGA2 protein results in increased expression of MMP9 protein] |
CTD |
PMID:34481905 |
|
NCBI chr 7:55,877,145...55,998,813
Ensembl chr 7:55,880,112...55,994,784
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
ISO |
Deoxyglucose inhibits the reaction [arsenic trioxide results in increased expression of HMOX1 protein]; Deoxyglucose inhibits the reaction [Fenretinide results in increased expression of HMOX1 protein] |
CTD |
PMID:25246272 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hsp90aa1 |
heat shock protein 90 alpha family class A member 1 |
multiple interactions |
ISO |
Deoxyglucose inhibits the reaction [Quercetin promotes the reaction [ERBB2 protein binds to HSP90AA1 protein]] |
CTD |
PMID:18655187 |
|
NCBI chr 6:129,702,376...129,707,907
Ensembl chr 6:129,702,383...129,707,268
|
|
G |
Hsp90b1 |
heat shock protein 90 beta family member 1 |
increases expression multiple interactions |
ISO |
Deoxyglucose results in increased expression of HSP90B1 protein 4-Quinolones analog inhibits the reaction [Deoxyglucose results in increased expression of HSP90B1 protein] |
CTD |
PMID:31022492 |
|
NCBI chr 7:21,110,431...21,124,762
Ensembl chr 7:21,110,457...21,124,788
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions increases expression |
ISO |
4-Quinolones analog inhibits the reaction [Deoxyglucose results in increased expression of HSPA5 mRNA]; 4-Quinolones analog inhibits the reaction [Deoxyglucose results in increased expression of HSPA5 protein]; ATG7 protein inhibits the reaction [Deoxyglucose results in increased expression of HSPA5 protein]; HSPA5 protein affects the reaction [A2M protein modified form results in increased uptake of Deoxyglucose]; HSPA5 protein affects the reaction [INS protein results in increased uptake of Deoxyglucose]; Mannose inhibits the reaction [Deoxyglucose results in increased expression of HSPA5 protein]; Oxygen deficiency inhibits the reaction [Deoxyglucose results in increased expression of HSPA5 protein] Deoxyglucose results in increased expression of HSPA5 mRNA; Deoxyglucose results in increased expression of HSPA5 protein |
CTD |
PMID:20593179 PMID:25720493 PMID:31022492 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Htra2 |
HtrA serine peptidase 2 |
multiple interactions decreases localization |
ISO |
Deoxyglucose promotes the reaction [arsenic trioxide results in decreased localization of HTRA2 protein] Deoxyglucose results in decreased localization of HTRA2 protein |
CTD |
PMID:23041229 |
|
NCBI chr 4:115,556,914...115,560,202
Ensembl chr 4:115,556,916...115,560,095
|
|
G |
Igf1r |
insulin-like growth factor 1 receptor |
multiple interactions |
ISO |
Deoxyglucose results in increased phosphorylation of and results in increased activity of IGF1R protein |
CTD |
PMID:23041229 |
|
NCBI chr 1:121,549,831...121,838,548
Ensembl chr 1:121,550,743...121,831,777
|
|
G |
Il1b |
interleukin 1 beta |
decreases response to substance multiple interactions |
ISO |
Deoxyglucose results in decreased susceptibility to IL1B protein Deoxyglucose inhibits the reaction [bisphenol F results in increased secretion of IL1B protein] Deoxyglucose inhibits the reaction [IL1B protein results in increased expression of MMP13 protein] |
CTD |
PMID:21211511 PMID:34147605 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
Deoxyglucose inhibits the reaction [bisphenol F results in increased secretion of IL6 protein] |
CTD |
PMID:34147605 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ins1 |
insulin 1 |
multiple interactions increases uptake increases transport increases secretion affects transport |
EXP ISO |
4-phenylbutyric acid inhibits the reaction [Glucosamine inhibits the reaction [INS1 results in increased uptake of Deoxyglucose]]; CCG 1423 promotes the reaction [ABRA mutant form promotes the reaction [INS1 protein results in increased uptake of Deoxyglucose]]; CCG 1423 promotes the reaction [INS1 protein promotes the reaction [ABRA mutant form results in increased uptake of Deoxyglucose]]; CCG 1423 promotes the reaction [INS1 protein results in increased uptake of Deoxyglucose]; Diethylhexyl Phthalate inhibits the reaction [INS1 protein results in increased uptake of Deoxyglucose]; Glucosamine inhibits the reaction [INS1 protein results in increased uptake of Deoxyglucose]; Glucosamine inhibits the reaction [INS1 results in increased uptake of Deoxyglucose]; Glucose inhibits the reaction [INS1 protein results in increased uptake of Deoxyglucose]; glyceryl 2-arachidonate promotes the reaction [INS1 protein results in increased uptake of Deoxyglucose]; INS1 protein promotes the reaction [ABRA mutant form results in increased uptake of Deoxyglucose]; INS1 protein promotes the reaction [CCG 1423 results in increased uptake of Deoxyglucose]; mono-(2-ethylhexyl)phthalate inhibits the reaction [INS1 protein results in increased uptake of Deoxyglucose]; N-(3-methoxyphenyl)-4-chlorocinnamanilide inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [INS1 protein results in increased uptake of Deoxyglucose]]; oxophenylarsine inhibits the reaction [INS1 protein results in increased uptake of Deoxyglucose]; Palmitic Acid inhibits the reaction [INS1 protein results in increased uptake of Deoxyglucose]; Quercetin inhibits the reaction [Palmitic Acid inhibits the reaction [INS1 protein results in increased uptake of Deoxyglucose]]; Quercetin inhibits the reaction [TNF protein inhibits the reaction [INS1 protein results in increased uptake of Deoxyglucose]]; Quercetin promotes the reaction [INS1 protein results in increased uptake of Deoxyglucose]; Raffinose promotes the reaction [INS1 protein results in increased uptake of Deoxyglucose]; SLC2A4 promotes the reaction [INS1 protein results in increased uptake of Deoxyglucose]; TNF protein inhibits the reaction [INS1 protein results in increased uptake of Deoxyglucose]; ursodoxicoltaurine inhibits the reaction [Glucosamine inhibits the reaction [INS1 results in increased uptake of Deoxyglucose]] [INS1 protein co-treated with CUL7 mutant form] results in increased uptake of Deoxyglucose; acetylaminophenylarsine oxide inhibits the reaction [INS1 protein results in increased transport of Deoxyglucose]; Apigenin inhibits the reaction [INS1 protein results in increased uptake of Deoxyglucose]; Dimercaprol inhibits the reaction [oxophenylarsine inhibits the reaction [INS1 protein results in increased transport of Deoxyglucose]]; Dimercaprol inhibits the reaction [oxophenylarsine inhibits the reaction [INS1 protein results in increased uptake of Deoxyglucose]]; Dimercaprol inhibits the reaction [p-aminophenylarsine oxide inhibits the reaction [INS1 protein results in increased transport of Deoxyglucose]]; dorsomorphin inhibits the reaction [Quercetin inhibits the reaction [INS1 protein results in increased uptake of Deoxyglucose]]; epigallocatechin gallate inhibits the reaction [INS1 protein results in increased uptake of Deoxyglucose]; fisetin inhibits the reaction [INS1 protein results in increased uptake of Deoxyglucose]; Genistein inhibits the reaction [INS1 protein results in increased uptake of Deoxyglucose]; Genistein inhibits the reaction [Raffinose promotes the reaction [INS1 protein results in increased uptake of Deoxyglucose]]; kaempferol inhibits the reaction [INS1 protein results in increased uptake of Deoxyglucose]; Luteolin inhibits the reaction [INS1 protein results in increased uptake of Deoxyglucose]; oxophenylarsine inhibits the reaction [INS1 protein results in increased transport of Deoxyglucose]; oxophenylarsine inhibits the reaction [INS1 protein results in increased uptake of Deoxyglucose]; p-aminophenylarsine oxide inhibits the reaction [INS1 protein results in increased transport of Deoxyglucose]; Quercetin inhibits the reaction [INS1 protein results in increased uptake of Deoxyglucose]; Quercetin inhibits the reaction [TNF protein inhibits the reaction [INS1 protein results in increased uptake of Deoxyglucose]]; Raffinose promotes the reaction [INS1 protein results in increased uptake of Deoxyglucose]; Ro 31-8220 inhibits the reaction [INS1 protein results in increased uptake of Deoxyglucose]; Silybin inhibits the reaction [INS1 protein results in increased uptake of Deoxyglucose]; theaflavin inhibits the reaction [INS1 protein results in increased uptake of Deoxyglucose]; TNF protein inhibits the reaction [INS1 protein results in increased uptake of Deoxyglucose]; tyrphostin 25 inhibits the reaction [INS1 protein results in increased uptake of Deoxyglucose]; Wortmannin inhibits the reaction [Raffinose promotes the reaction [INS1 protein results in increased uptake of Deoxyglucose]] INS1 protein results in increased uptake of Deoxyglucose; INS1 results in increased uptake of Deoxyglucose Deoxyglucose results in increased secretion of INS1 protein INS1 protein affects the transport of Deoxyglucose |
CTD |
PMID:1378463 PMID:1536656 PMID:1847587 PMID:1918056 PMID:2202293 PMID:2877896 PMID:3882699 PMID:9453242 PMID:14511371 PMID:18591783 PMID:20165829 PMID:20206685 PMID:21393865 PMID:22713545 PMID:23439570 PMID:24219910 PMID:24287560 PMID:24343960 PMID:26627467 PMID:28298333 PMID:28526321 PMID:29458019 PMID:31408376 More...
|
|
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Ins2 |
insulin 2 |
increases uptake multiple interactions |
ISO |
INS protein results in increased uptake of Deoxyglucose; INS results in increased uptake of Deoxyglucose METRNL protein inhibits the reaction [INS protein results in increased uptake of Deoxyglucose]; PPARA protein promotes the reaction [GW 7647 promotes the reaction [INS protein results in increased uptake of Deoxyglucose]] 3,3',4,5'-tetrahydroxystilbene inhibits the reaction [Palmitic Acid inhibits the reaction [INS protein results in increased uptake of Deoxyglucose]]; 4-phenylbutyric acid inhibits the reaction [Glucosamine inhibits the reaction [INS results in increased uptake of Deoxyglucose]]; Glucosamine inhibits the reaction [INS results in increased uptake of Deoxyglucose]; GW 7647 promotes the reaction [INS protein results in increased uptake of Deoxyglucose]; HSPA5 protein affects the reaction [INS protein results in increased uptake of Deoxyglucose]; Palmitates inhibits the reaction [INS protein results in increased uptake of Deoxyglucose]; Palmitic Acid inhibits the reaction [INS protein results in increased uptake of Deoxyglucose]; SLC2A1 protein inhibits the reaction [INS protein results in increased uptake of Deoxyglucose]; tin protoporphyrin IX inhibits the reaction [3,3',4,5'-tetrahydroxystilbene inhibits the reaction [Palmitic Acid inhibits the reaction [INS protein results in increased uptake of Deoxyglucose]]]; TNF protein inhibits the reaction [INS protein results in increased uptake of Deoxyglucose]; Troglitazone inhibits the reaction [TNF protein inhibits the reaction [INS protein results in increased uptake of Deoxyglucose]]; ursodoxicoltaurine inhibits the reaction [Glucosamine inhibits the reaction [INS results in increased uptake of Deoxyglucose]] |
CTD |
PMID:2173694 PMID:16483873 PMID:20165829 PMID:21324916 PMID:25720493 PMID:25815690 PMID:30213948 PMID:31877369 More...
|
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Itgb1 |
integrin subunit beta 1 |
decreases expression |
ISO |
Deoxyglucose analog results in decreased expression of ITGB1 protein |
CTD |
PMID:27931795 |
|
NCBI chr19:56,705,123...56,753,199
Ensembl chr19:56,705,171...56,753,195
|
|
G |
Jade2 |
jade family PHD finger 2 |
increases expression |
ISO |
Deoxyglucose results in increased expression of JADE2 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr10:36,075,239...36,124,210
Ensembl chr10:36,078,917...36,116,984
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
multiple interactions decreases activity |
ISO |
[Deoxyglucose co-treated with Glucose deficiency] results in decreased activity of KCNH2 protein; Deoxyglucose inhibits the reaction [Glucose results in decreased activity of KCNH2 protein]; Deoxyglucose promotes the reaction [Glucose deficiency results in decreased activity of KCNH2 protein]; Pyruvic Acid inhibits the reaction [[Deoxyglucose co-treated with Glucose deficiency] results in decreased activity of KCNH2 protein] Deoxyglucose results in decreased activity of KCNH2 protein |
CTD |
PMID:12531891 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Kcnj11 |
potassium inwardly-rectifying channel, subfamily J, member 11 |
multiple interactions |
ISO |
[Oligomycins co-treated with Deoxyglucose] results in increased activity of [KCNJ11 protein binds to ABCC9 protein]; Glyburide inhibits the reaction [[Oligomycins co-treated with Deoxyglucose] results in increased activity of [KCNJ11 protein binds to ABCC9 protein]] |
CTD |
PMID:28842488 |
|
NCBI chr 1:96,591,048...96,594,574
Ensembl chr 1:96,591,049...96,594,082
|
|
G |
Klhl42 |
kelch-like family, member 42 |
increases expression |
ISO |
Deoxyglucose results in increased expression of KLHL42 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr 4:179,999,655...180,027,283
Ensembl chr 4:180,004,580...180,027,283
|
|
G |
Ldha |
lactate dehydrogenase A |
multiple interactions |
ISO |
Deoxyglucose inhibits the reaction [G3BP1 protein results in increased expression of LDHA protein] |
CTD |
PMID:35945655 |
|
NCBI chr 1:97,371,823...97,381,247
Ensembl chr 1:97,366,021...97,433,472
|
|
G |
Lep |
leptin |
multiple interactions decreases secretion |
EXP |
[Deoxyglucose results in decreased abundance of Adenosine Triphosphate] which results in decreased secretion of LEP protein Deoxyglucose results in decreased secretion of LEP protein |
CTD |
PMID:10780946 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Liph |
lipase H |
decreases expression |
ISO |
Deoxyglucose results in decreased expression of LIPH mRNA |
CTD |
PMID:33770205 |
|
NCBI chr11:79,032,229...79,081,625
Ensembl chr11:79,033,312...79,081,625
|
|
G |
Map1lc3a |
microtubule-associated protein 1 light chain 3 alpha |
multiple interactions |
ISO |
Deoxyglucose affects the reaction [demycarosyl-3D-digitoxosylmithramycin SK affects the expression of MAP1LC3A mRNA] |
CTD |
PMID:26079942 |
|
NCBI chr 3:143,783,024...143,784,670
Ensembl chr 3:143,783,024...143,784,670
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
multiple interactions increases prenylation |
ISO |
ATG7 protein promotes the reaction [Deoxyglucose results in increased prenylation of MAP1LC3B protein]; Mannose inhibits the reaction [Deoxyglucose results in increased prenylation of MAP1LC3B protein]; Oxygen deficiency inhibits the reaction [Deoxyglucose results in increased prenylation of MAP1LC3B protein] |
CTD |
PMID:20593179 |
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
arsenic trioxide inhibits the reaction [Deoxyglucose results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Deoxyglucose results in increased phosphorylation of and results in increased activity of MAPK1 protein; PQ 401 inhibits the reaction [Deoxyglucose results in increased phosphorylation of and results in increased activity of MAPK1 protein]; U 0126 inhibits the reaction [Deoxyglucose results in increased phosphorylation of and results in increased activity of MAPK1 protein] |
CTD |
PMID:23041229 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
EXP ISO |
MAPK3 protein affects the reaction [AICA ribonucleotide results in increased uptake of Deoxyglucose] Arsenic Trioxide inhibits the reaction [Deoxyglucose results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Deoxyglucose results in increased phosphorylation of and results in increased activity of MAPK3 protein; PQ 401 inhibits the reaction [Deoxyglucose results in increased phosphorylation of and results in increased activity of MAPK3 protein]; U 0126 inhibits the reaction [Deoxyglucose results in increased phosphorylation of and results in increased activity of MAPK3 protein] |
CTD |
PMID:11978788 PMID:23041229 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mepce |
methylphosphate capping enzyme |
increases expression |
ISO |
Deoxyglucose results in increased expression of MEPCE mRNA |
CTD |
PMID:33770205 |
|
NCBI chr12:18,911,796...18,916,515
Ensembl chr12:18,911,796...18,916,514
|
|
G |
Metrnl |
meteorin-like, glial cell differentiation regulator |
multiple interactions |
ISO |
METRNL protein inhibits the reaction [INS protein results in increased uptake of Deoxyglucose] |
CTD |
PMID:30213948 |
|
NCBI chr10:106,963,880...106,977,875
Ensembl chr10:106,963,880...106,977,869
|
|
G |
Mmp13 |
matrix metallopeptidase 13 |
multiple interactions decreases expression |
ISO |
Deoxyglucose inhibits the reaction [IL1B protein results in increased expression of MMP13 protein]; Deoxyglucose inhibits the reaction [TNF protein results in increased expression of MMP13 protein] Deoxyglucose analog results in decreased expression of MMP13 protein |
CTD |
PMID:21211511 PMID:27931795 |
|
NCBI chr 8:4,497,960...4,508,239
Ensembl chr 8:4,497,960...4,508,239
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions |
ISO |
Deoxyglucose inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of MMP2 protein]; Deoxyglucose inhibits the reaction [HMGA2 protein results in increased expression of MMP2 protein] |
CTD |
PMID:34481905 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
decreases expression multiple interactions |
ISO |
Deoxyglucose analog results in decreased expression of MMP9 protein Deoxyglucose inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of MMP9 protein]; Deoxyglucose inhibits the reaction [HMGA2 protein results in increased expression of MMP9 protein] |
CTD |
PMID:27931795 PMID:34481905 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mt-nd1 |
mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 1 |
multiple interactions |
ISO |
Deoxyglucose inhibits the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone results in decreased expression of ND1 protein]; Deoxyglucose inhibits the reaction [HMGA2 protein results in decreased expression of ND1 protein] |
CTD |
PMID:34481905 |
|
NCBI chr MT:2,740...3,694 NCBI chr MT:2,740...3,694 NCBI chr MT:2,740...3,694
Ensembl chr MT:2,740...3,694
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
multiple interactions |
ISO |
Deoxyglucose results in decreased phosphorylation of and results in increased expression of MTOR protein; Deoxyglucose results in increased phosphorylation of and results in increased activity of MTOR protein |
CTD |
PMID:23041229 PMID:23363784 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Mxi1 |
MAX interactor 1, dimerization protein |
decreases expression |
ISO |
Deoxyglucose results in decreased expression of MXI1 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr 1:252,323,915...252,383,682
Ensembl chr 1:252,323,303...252,383,681
|
|
G |
Myo1e |
myosin IE |
decreases expression |
ISO |
Deoxyglucose results in decreased expression of MYO1E mRNA |
CTD |
PMID:33770205 |
|
NCBI chr 8:70,887,934...71,080,180
Ensembl chr 8:70,887,870...71,080,169
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions decreases expression |
ISO |
[demycarosyl-3D-digitoxosylmithramycin SK co-treated with Deoxyglucose] affects the expression of NFKB1 mRNA Deoxyglucose results in decreased expression of NFKB1 mRNA |
CTD |
PMID:26079942 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
Deoxyglucose promotes the reaction [STO 609 inhibits the reaction [Histamine results in increased phosphorylation of NOS2 protein]] |
CTD |
PMID:21145922 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Npy |
neuropeptide Y |
increases expression |
EXP |
Deoxyglucose results in increased expression of NPY mRNA |
CTD |
PMID:10683841 |
|
NCBI chr 4:78,881,294...78,888,495
Ensembl chr 4:78,881,264...78,888,495
|
|
G |
Oat |
ornithine aminotransferase |
multiple interactions |
EXP |
Deoxyglucose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein] |
CTD |
PMID:2827574 |
|
NCBI chr 1:187,347,862...187,367,644
Ensembl chr 1:187,347,865...187,367,682
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions increases cleavage |
ISO |
Deoxyglucose inhibits the reaction [arsenic trioxide results in increased cleavage of PARP1 protein]; Deoxyglucose inhibits the reaction [Fenretinide results in increased cleavage of PARP1 protein] Deoxyglucose promotes the reaction [Metformin inhibits the reaction [Arsenic Trioxide results in increased expression of PARP1 protein modified form]] Deoxyglucose results in increased cleavage of PARP1 protein |
CTD |
PMID:25246272 PMID:29095437 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pkm |
pyruvate kinase M1/2 |
multiple interactions |
ISO |
Deoxyglucose inhibits the reaction [G3BP1 protein results in increased expression of PKM protein] |
CTD |
PMID:35945655 |
|
NCBI chr 8:60,057,629...60,079,600
Ensembl chr 8:60,057,402...60,079,599
|
|
G |
Pmch |
pro-melanin-concentrating hormone |
increases expression |
EXP |
Deoxyglucose results in increased expression of PMCH mRNA |
CTD |
PMID:10683841 |
|
NCBI chr 7:22,511,934...22,513,250
Ensembl chr 7:22,511,934...22,513,250
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
PPARA protein promotes the reaction [GW 7647 promotes the reaction [INS protein results in increased uptake of Deoxyglucose]] |
CTD |
PMID:21324916 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
affects uptake increases uptake |
ISO |
PPARG protein affects the uptake of Deoxyglucose PPARG gene polymorphism results in increased uptake of Deoxyglucose |
CTD |
PMID:18083318 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppp3ca |
protein phosphatase 3 catalytic subunit alpha |
decreases response to substance |
ISO |
PPP3CA protein results in decreased susceptibility to Deoxyglucose |
CTD |
PMID:10679475 |
|
NCBI chr 2:225,165,981...225,440,978
Ensembl chr 2:225,165,766...225,438,974
|
|
G |
Pym1 |
PYM homolog 1, exon junction complex associated factor |
increases expression |
ISO |
Deoxyglucose results in increased expression of PYM1 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr 7:1,177,746...1,200,899
Ensembl chr 7:1,178,008...1,198,937
|
|
G |
Raf1 |
Raf-1 proto-oncogene, serine/threonine kinase |
multiple interactions |
EXP |
RAF1 protein affects the reaction [AICA ribonucleotide results in increased uptake of Deoxyglucose] |
CTD |
PMID:11978788 |
|
NCBI chr 4:148,679,534...148,740,265
Ensembl chr 4:148,679,530...148,740,317
|
|
G |
Rnf24 |
ring finger protein 24 |
decreases expression |
ISO |
Deoxyglucose results in decreased expression of RNF24 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr 3:118,520,459...118,575,213
Ensembl chr 3:118,525,349...118,541,080
|
|
G |
Rps6 |
ribosomal protein S6 |
decreases phosphorylation |
ISO |
Deoxyglucose results in decreased phosphorylation of RPS6 protein |
CTD |
PMID:23363784 |
|
NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602 Ensembl chr 5:101,371,136...101,374,602
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
decreases phosphorylation multiple interactions |
ISO |
Deoxyglucose results in decreased phosphorylation of RPS6KB1 protein Deoxyglucose results in increased phosphorylation of and results in increased activity of RPS6KB1 protein; oxophenylarsine inhibits the reaction [Deoxyglucose results in decreased phosphorylation of RPS6KB1 protein] |
CTD |
PMID:16183647 PMID:23041229 |
|
NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
|
|
G |
Serpinb5 |
serpin family B member 5 |
increases expression |
ISO |
Deoxyglucose analog results in increased expression of SERPINB5 protein |
CTD |
PMID:27931795 |
|
NCBI chr13:22,985,557...23,005,756
Ensembl chr13:22,985,557...23,005,756
|
|
G |
Slc16a1 |
solute carrier family 16 member 1 |
multiple interactions |
ISO |
[Lactic Acid co-treated with Deoxyglucose] promotes the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of SLC16A1 protein] |
CTD |
PMID:36336208 |
|
NCBI chr 2:192,123,755...192,144,617
Ensembl chr 2:192,124,289...192,144,611
|
|
G |
Slc2a1 |
solute carrier family 2 member 1 |
multiple interactions increases uptake |
ISO |
[arsenite affects the localization of SLC2A1 protein] which results in increased uptake of Deoxyglucose SLC2A1 protein results in increased uptake of Deoxyglucose [Deoxyglucose results in increased abundance of Glucose] which affects the localization of SLC2A1 protein; [sodium arsenite results in increased abundance of Arsenic] inhibits the reaction [[Deoxyglucose results in increased abundance of Glucose] which affects the localization of SLC2A1 protein]; SLC2A1 protein inhibits the reaction [INS protein results in increased uptake of Deoxyglucose] |
CTD |
PMID:2173694 PMID:14511371 PMID:31398423 |
|
NCBI chr 5:132,717,196...132,745,416
Ensembl chr 5:132,717,196...132,745,416
|
|
G |
Slc2a2 |
solute carrier family 2 member 2 |
multiple interactions increases transport |
ISO |
Cytochalasin B inhibits the reaction [SLC2A2 protein results in increased transport of Deoxyglucose]; Fructose inhibits the reaction [SLC2A2 protein results in increased transport of Deoxyglucose]; Glucose inhibits the reaction [SLC2A2 protein results in increased transport of Deoxyglucose]; Maltose inhibits the reaction [SLC2A2 protein results in increased transport of Deoxyglucose] |
CTD |
PMID:8457197 |
|
NCBI chr 2:111,609,798...111,639,930
Ensembl chr 2:111,611,774...111,639,933
|
|
G |
Slc2a3 |
solute carrier family 2 member 3 |
increases transport multiple interactions |
ISO |
SLC2A3 protein results in increased transport of Deoxyglucose Cytochalasin B inhibits the reaction [SLC2A3 protein results in increased transport of Deoxyglucose]; Galactose inhibits the reaction [SLC2A3 protein results in increased transport of Deoxyglucose]; Glucose inhibits the reaction [SLC2A3 protein results in increased transport of Deoxyglucose]; Maltose inhibits the reaction [SLC2A3 protein results in increased transport of Deoxyglucose] |
CTD |
PMID:8457197 |
|
NCBI chr 4:155,960,944...156,026,000
Ensembl chr 4:155,960,946...156,025,472
|
|
G |
Slc2a4 |
solute carrier family 2 member 4 |
multiple interactions increases uptake |
ISO EXP |
2-chloro-5-nitrobenzanilide inhibits the reaction [mangiferin promotes the reaction [SLC2A4 protein results in increased uptake of Deoxyglucose]]; [arsenite affects the localization of SLC2A4 protein] which results in increased uptake of Deoxyglucose; mangiferin promotes the reaction [SLC2A4 protein results in increased uptake of Deoxyglucose]; Plant Extracts promotes the reaction [SLC2A4 protein results in increased uptake of Deoxyglucose] [Indinavir results in decreased activity of SLC2A4 protein] inhibits the reaction [resveratrol results in increased uptake of Deoxyglucose]; SLC2A4 promotes the reaction [INS1 protein results in increased uptake of Deoxyglucose]; SLC2A4 protein promotes the reaction [resveratrol results in increased uptake of Deoxyglucose] |
CTD |
PMID:14511371 PMID:18601907 PMID:19477051 PMID:20206685 |
|
NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565
|
|
G |
Slc2a8 |
solute carrier family 2 member 8 |
increases uptake |
EXP ISO |
SLC2A8 protein results in increased uptake of Deoxyglucose |
CTD |
PMID:23396969 |
|
NCBI chr 3:16,274,918...16,284,536
Ensembl chr 3:16,274,925...16,284,464
|
|
G |
Smim14 |
small integral membrane protein 14 |
decreases expression |
ISO |
Deoxyglucose results in decreased expression of SMIM14 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr14:42,783,361...42,829,762
Ensembl chr14:42,783,332...42,829,760
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions |
ISO |
Deoxyglucose inhibits the reaction [manganese chloride results in increased expression of SOD2 mRNA]; Deoxyglucose inhibits the reaction [manganese chloride results in increased expression of SOD2 protein] |
CTD |
PMID:10328827 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions |
ISO |
[bafilomycin A co-treated with Deoxyglucose co-treated with demycarosyl-3D-digitoxosylmithramycin SK] affects the expression of SQSTM1 protein; [bafilomycin A co-treated with Deoxyglucose] affects the expression of SQSTM1 protein; Deoxyglucose inhibits the reaction [demycarosyl-3D-digitoxosylmithramycin SK results in decreased expression of SQSTM1 mRNA]; Deoxyglucose promotes the reaction [demycarosyl-3D-digitoxosylmithramycin SK results in decreased expression of SQSTM1 mRNA] |
CTD |
PMID:26079942 |
|
NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
increases expression |
ISO |
Deoxyglucose results in increased expression of SREBF1 mRNA |
CTD |
PMID:10913129 |
|
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
|
|
G |
Srgap3 |
SLIT-ROBO Rho GTPase activating protein 3 |
decreases expression |
ISO |
Deoxyglucose results in decreased expression of SRGAP3 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr 4:145,839,369...146,070,556
Ensembl chr 4:145,840,078...146,070,575
|
|
G |
Stk11 |
serine/threonine kinase 11 |
decreases phosphorylation |
ISO |
Deoxyglucose results in decreased phosphorylation of STK11 protein |
CTD |
PMID:23041229 |
|
NCBI chr 7:9,574,553...9,591,315
Ensembl chr 7:9,575,269...9,591,315
|
|
G |
Tent4b |
terminal nucleotidyltransferase 4B |
decreases expression |
ISO |
Deoxyglucose results in decreased expression of TENT4B mRNA |
CTD |
PMID:33770205 |
|
NCBI chr19:18,807,616...18,868,969
Ensembl chr19:18,807,525...18,869,537
|
|
G |
Tmcc3 |
transmembrane and coiled-coil domain family 3 |
decreases expression |
ISO |
Deoxyglucose results in decreased expression of TMCC3 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr 7:28,893,972...29,171,935
Ensembl chr 7:28,893,967...29,171,926
|
|
G |
Tmem250 |
transmembrane protein 250 |
increases expression |
ISO |
Deoxyglucose results in increased expression of TMEM250 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr 3:8,962,657...8,966,349
Ensembl chr 3:8,962,657...8,966,349
|
|
G |
Tmem87a |
transmembrane protein 87A |
increases expression |
ISO |
Deoxyglucose results in increased expression of TMEM87A mRNA |
CTD |
PMID:33770205 |
|
NCBI chr 3:107,307,726...107,353,571
Ensembl chr 3:107,307,726...107,353,551
|
|
G |
Tnf |
tumor necrosis factor |
decreases expression multiple interactions decreases response to substance |
ISO EXP |
Deoxyglucose results in decreased expression of TNF protein Quercetin inhibits the reaction [TNF protein inhibits the reaction [INS1 protein results in increased uptake of Deoxyglucose]]; TNF protein inhibits the reaction [INS1 protein results in increased uptake of Deoxyglucose] Deoxyglucose inhibits the reaction [bisphenol F results in increased secretion of TNF protein]; Quercetin inhibits the reaction [TNF protein inhibits the reaction [INS1 protein results in increased uptake of Deoxyglucose]]; TNF protein inhibits the reaction [INS1 protein results in increased uptake of Deoxyglucose] Deoxyglucose results in decreased susceptibility to TNF protein Deoxyglucose inhibits the reaction [TNF protein results in increased expression of MMP13 protein]; TNF protein inhibits the reaction [INS protein results in increased uptake of Deoxyglucose]; troglitazone inhibits the reaction [TNF protein inhibits the reaction [INS protein results in increased uptake of Deoxyglucose]] |
CTD |
PMID:16483873 PMID:21211511 PMID:21778228 PMID:22713545 PMID:23439570 PMID:34147605 More...
|
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
ISO |
[Deoxyglucose co-treated with demycarosyl-3D-digitoxosylmithramycin SK] results in increased expression of TP53 mRNA; Deoxyglucose promotes the reaction [demycarosyl-3D-digitoxosylmithramycin SK results in increased expression of TP53 mRNA]; TP53 protein inhibits the reaction [Deoxyglucose results in decreased abundance of Adenosine Triphosphate] |
CTD |
PMID:21042727 PMID:26079942 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Xiap |
X-linked inhibitor of apoptosis |
multiple interactions |
ISO |
[arsenic trioxide co-treated with Deoxyglucose] results in decreased expression of XIAP protein |
CTD |
PMID:23041229 |
|
NCBI chr X:120,890,537...120,938,413
Ensembl chr X:120,897,907...120,934,700
|
|
G |
Yars2 |
tyrosyl-tRNA synthetase 2 |
increases expression |
ISO |
Deoxyglucose results in increased expression of YARS2 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr11:84,632,350...84,638,138
Ensembl chr11:84,624,369...84,638,125
|
|
G |
Yes1 |
YES proto-oncogene 1, Src family tyrosine kinase |
decreases expression |
ISO |
Deoxyglucose results in decreased expression of YES1 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr 9:113,200,256...113,275,942
Ensembl chr 9:113,200,256...113,299,837
|
|
G |
Zbtb1 |
zinc finger and BTB domain containing 1 |
increases expression |
ISO |
Deoxyglucose results in increased expression of ZBTB1 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr 6:95,096,838...95,125,811
Ensembl chr 6:95,096,387...95,118,996
|
|
G |
Zfx |
zinc finger protein X-linked |
increases expression |
ISO |
Deoxyglucose results in increased expression of ZFX mRNA |
CTD |
PMID:33770205 |
|
NCBI chr X:58,804,690...58,853,155
Ensembl chr X:58,804,691...58,853,265
|
|
|
G |
Gaa |
alpha glucosidase |
multiple interactions increases metabolic processing |
ISO |
GAA gene SNP inhibits the reaction [GAA protein results in increased metabolism of 4-methylumbelliferyl glucoside] |
CTD |
PMID:21963784 |
|
NCBI chr10:104,529,673...104,546,836
Ensembl chr10:104,529,747...104,546,836
|
|
|
G |
Drd2 |
dopamine receptor D2 |
affects expression |
EXP |
albiflorin affects the expression of DRD2 |
CTD |
PMID:26475043 |
|
NCBI chr 8:49,708,927...49,772,876
Ensembl chr 8:49,708,927...49,772,875
|
|
G |
Htr1a |
5-hydroxytryptamine receptor 1A |
affects expression |
EXP |
albiflorin affects the expression of HTR1A |
CTD |
PMID:26475043 |
|
NCBI chr 2:36,693,462...36,698,026
Ensembl chr 2:36,694,174...36,695,442
|
|
G |
Htr2a |
5-hydroxytryptamine receptor 2A |
affects expression |
EXP |
albiflorin affects the expression of HTR2A |
CTD |
PMID:26475043 |
|
NCBI chr15:49,950,035...50,022,188
Ensembl chr15:49,950,804...50,020,928
|
|
G |
Map3k7 |
mitogen activated protein kinase kinase kinase 7 |
multiple interactions |
ISO |
Albiflorin inhibits the reaction [oxidized LDL increases phosphorylation of MAP3K7 protein in umbilical vein endothelial cells] |
RGD |
PMID:35601145 |
RGD:155804296 |
NCBI chr 5:46,356,973...46,415,597
Ensembl chr 5:46,357,931...46,415,597
|
|
G |
Slc6a3 |
solute carrier family 6 member 3 |
affects expression |
EXP |
albiflorin affects the expression of SLC6A3 |
CTD |
PMID:26475043 |
|
NCBI chr 1:29,709,443...29,750,413
Ensembl chr 1:29,709,443...29,750,413
|
|
G |
Th |
tyrosine hydroxylase |
affects expression |
EXP |
albiflorin affects the expression of TH |
CTD |
PMID:26475043 |
|
NCBI chr 1:198,071,500...198,078,832
Ensembl chr 1:198,071,503...198,109,767
|
|
|
G |
Idh2 |
isocitrate dehydrogenase (NADP(+)) 2 |
increases abundance multiple interactions |
ISO |
IDH2 protein mutant form results in increased abundance of glucose-1-phosphate Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of glucose-1-phosphate] |
CTD |
PMID:27469509 |
|
NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025
|
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
decreases expression |
EXP |
Amikacin results in decreased expression of ABCC3 mRNA |
CTD |
PMID:27765674 |
|
NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Abcc4 |
ATP binding cassette subfamily C member 4 |
decreases expression |
EXP |
Amikacin results in decreased expression of ABCC4 mRNA |
CTD |
PMID:27765674 |
|
NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283
|
|
G |
Casr |
calcium-sensing receptor |
increases activity |
ISO |
Amikacin results in increased activity of CASR protein |
CTD |
PMID:19884751 |
|
NCBI chr11:64,235,251...64,304,811
Ensembl chr11:64,235,251...64,304,811
|
|
G |
Cat |
catalase |
decreases activity multiple interactions |
ISO |
Amikacin results in decreased activity of CAT protein cefepime inhibits the reaction [Amikacin results in decreased activity of CAT protein] |
CTD |
PMID:18781908 PMID:23416261 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Il1a |
interleukin 1 alpha |
decreases expression |
ISO |
Amikacin results in decreased expression of IL1A mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
decreases expression |
ISO |
Amikacin results in decreased expression of IL1B mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il24 |
interleukin 24 |
decreases expression |
ISO |
Amikacin results in decreased expression of IL24 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr13:42,353,089...42,358,487
Ensembl chr13:42,353,090...42,358,487
|
|
G |
Pgd |
phosphogluconate dehydrogenase |
decreases activity |
EXP |
Amikacin results in decreased activity of PGD protein |
CTD |
PMID:15558954 |
|
NCBI chr 5:159,582,746...159,598,945
Ensembl chr 5:159,561,271...159,742,778
|
|
G |
Pid1 |
phosphotyrosine interaction domain containing 1 |
increases expression |
ISO |
Amikacin results in increased expression of PID1 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 9:85,284,335...85,503,035
Ensembl chr 9:85,284,335...85,503,044
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
decreases expression |
ISO |
Amikacin results in decreased expression of PTGS2 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Slc7a11 |
solute carrier family 7 member 11 |
decreases expression |
ISO |
Amikacin results in decreased expression of SLC7A11 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536
|
|
G |
Slpi |
secretory leukocyte peptidase inhibitor |
increases expression |
ISO |
Amikacin results in increased expression of SLPI mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 3:153,082,208...153,084,457
Ensembl chr 3:153,082,369...153,084,453
|
|
G |
Tyr |
tyrosinase |
decreases activity |
ISO |
Amikacin results in decreased activity of TYR protein |
CTD |
PMID:23416261 |
|
NCBI chr 1:141,115,036...141,210,207
Ensembl chr 1:141,115,036...141,210,207
|
|
|
G |
Gypa |
glycophorin A |
increases expression |
ISO |
apigetrin results in increased expression of GYPA protein |
CTD |
PMID:25058688 |
|
NCBI chr19:27,450,304...27,465,940
Ensembl chr19:27,450,308...27,465,822
|
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
ISO |
[lipopolysaccharide, E coli O55-B5 co-treated with asperuloside] results in increased expression of HMOX1 protein; asperuloside inhibits the reaction [Dextran Sulfate results in decreased expression of HMOX1 protein] |
CTD |
PMID:33974900 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
ISO |
asperuloside inhibits the reaction [Dextran Sulfate results in decreased expression of IL10 protein] |
CTD |
PMID:33974900 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
asperuloside inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; asperuloside inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL6 mRNA]; asperuloside inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL6 protein] |
CTD |
PMID:33974900 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
ISO |
asperuloside inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein] |
CTD |
PMID:33974900 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions affects localization |
ISO |
[asperuloside co-treated with Dextran Sulfate] results in increased expression of NFE2L2 protein; [lipopolysaccharide, E coli O55-B5 co-treated with asperuloside] results in increased expression of NFE2L2 protein; asperuloside affects the reaction [NFE2L2 protein affects the expression of NQO1 mRNA]; asperuloside inhibits the reaction [lipopolysaccharide, E coli O55-B5 affects the localization of NFE2L2 protein] asperuloside affects the localization of NFE2L2 protein |
CTD |
PMID:33974900 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
ISO |
asperuloside affects the reaction [NFE2L2 protein affects the expression of NQO1 mRNA] |
CTD |
PMID:33974900 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
asperuloside inhibits the reaction [Dextran Sulfate results in increased phosphorylation of RELA protein] |
CTD |
PMID:33974900 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
asperuloside inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; asperuloside inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of TNF mRNA]; asperuloside inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of TNF protein]; asperuloside inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein] |
CTD |
PMID:16508180 PMID:33974900 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
ganglioside, GD1b analog inhibits the reaction [[lipopolysaccharide, E. coli O26-B6 results in increased activity of NOS2 protein] which results in increased secretion of Nitrites]; ganglioside, GD1b inhibits the reaction [[lipopolysaccharide, E. coli O26-B6 results in increased activity of NOS2 protein] which results in increased secretion of Nitrites] |
CTD |
PMID:31202640 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
|
G |
Aacs |
acetoacetyl-CoA synthetase |
increases expression |
ISO |
Glucosamine results in increased expression of AACS mRNA |
CTD |
PMID:17178593 |
|
NCBI chr12:31,113,098...31,156,411
Ensembl chr12:31,113,098...31,160,954
|
|
G |
Abcg1 |
ATP binding cassette subfamily G member 1 |
increases expression |
EXP |
Glucosamine results in increased expression of ABCG1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr20:9,126,687...9,182,948
Ensembl chr20:9,126,687...9,182,948
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
increases expression |
ISO |
Glucosamine results in increased expression of ACACA mRNA |
CTD |
PMID:22096489 |
|
NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
|
|
G |
Acan |
aggrecan |
multiple interactions increases expression decreases expression affects expression |
ISO EXP |
Glucosamine analog affects the reaction [IL1B results in decreased expression of ACAN mRNA]; Glucosamine inhibits the reaction [IL1B protein results in decreased expression of ACAN mRNA]; Glucosamine results in decreased cleavage of and results in decreased secretion of ACAN protein Glucosamine results in increased expression of ACAN mRNA Glucosamine inhibits the reaction [IL1B results in decreased expression of ACAN mRNA] Glucosamine analog results in increased expression of ACAN protein; Glucosamine results in increased expression of ACAN mRNA; Glucosamine results in increased expression of ACAN protein Glucosamine analog results in decreased expression of ACAN mRNA Glucosamine analog affects the expression of ACAN mRNA |
CTD |
PMID:12801482 PMID:16300972 PMID:16872674 PMID:17109745 PMID:17337215 PMID:18321735 PMID:19909832 More...
|
|
NCBI chr 1:132,981,582...133,044,416
Ensembl chr 1:132,981,582...133,043,627
|
|
G |
Acot1 |
acyl-CoA thioesterase 1 |
increases expression |
ISO |
Glucosamine results in increased expression of ACOT1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 6:103,636,173...103,644,167
Ensembl chr 6:103,636,041...103,644,163
|
|
G |
Acox2 |
acyl-CoA oxidase 2 |
decreases expression |
ISO |
Glucosamine results in decreased expression of ACOX2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr15:16,660,584...16,692,160
Ensembl chr15:16,660,272...16,692,160
|
|
G |
Acss2 |
acyl-CoA synthetase short-chain family member 2 |
increases expression |
ISO |
Glucosamine results in increased expression of ACSS2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 3:144,003,808...144,047,452
Ensembl chr 3:144,004,336...144,059,675
|
|
G |
Adam15 |
ADAM metallopeptidase domain 15 |
multiple interactions decreases expression |
EXP |
Glucosamine affects the reaction [IL1B results in decreased expression of ADAM15 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of ADAM15 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 2:174,754,629...174,765,136
Ensembl chr 2:174,754,633...174,765,113
|
|
G |
Adam17 |
ADAM metallopeptidase domain 17 |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of ADAM17 mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of ADAM17 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 6:40,872,936...40,920,700
Ensembl chr 6:40,872,856...40,920,639
|
|
G |
Adamts1 |
ADAM metallopeptidase with thrombospondin type 1 motif, 1 |
decreases expression multiple interactions |
ISO EXP |
Glucosamine analog results in decreased expression of ADAMTS1 mRNA Glucosamine results in decreased expression of ADAMTS1 mRNA Glucosamine inhibits the reaction [IL1B results in increased expression of ADAMTS1 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of ADAMTS1 mRNA] |
CTD |
PMID:16300972 PMID:17109745 |
|
NCBI chr11:24,932,227...24,941,068
Ensembl chr11:24,931,761...24,941,103
|
|
G |
Adamts20 |
ADAM metallopeptidase with thrombospondin type 1 motif, 20 |
decreases cleavage |
ISO |
Glucosamine results in decreased cleavage of ADAMTS20 protein alternative form |
CTD |
PMID:19909832 |
|
NCBI chr 7:125,396,227...125,528,020
Ensembl chr 7:125,397,734...125,527,777
|
|
G |
Adamts4 |
ADAM metallopeptidase with thrombospondin type 1 motif, 4 |
increases expression |
EXP |
Glucosamine results in increased expression of ADAMTS4 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr13:83,670,556...83,680,045
Ensembl chr13:83,670,183...83,680,065
|
|
G |
Adamts5 |
ADAM metallopeptidase with thrombospondin type 1 motif, 5 |
decreases expression multiple interactions |
ISO |
Glucosamine analog results in decreased expression of ADAMTS5 mRNA Glucosamine results in decreased cleavage of and results in decreased activity of ADAMTS5 protein alternative form |
CTD |
PMID:16300972 PMID:19909832 |
|
NCBI chr11:25,000,627...25,047,205
Ensembl chr11:25,000,637...25,047,205
|
|
G |
Adamts9 |
ADAM metallopeptidase with thrombospondin type 1 motif, 9 |
decreases cleavage |
ISO |
Glucosamine results in decreased cleavage of ADAMTS9 protein alternative form |
CTD |
PMID:19909832 |
|
NCBI chr 4:125,290,633...125,462,988
Ensembl chr 4:125,291,490...125,462,929
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
increases expression |
ISO EXP |
Glucosamine results in increased expression of ADIPOQ mRNA |
CTD |
PMID:15694357 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Afp |
alpha-fetoprotein |
increases expression |
ISO |
Glucosamine results in increased expression of AFP mRNA |
CTD |
PMID:17178593 |
|
NCBI chr14:17,573,412...17,591,476
Ensembl chr14:17,573,412...17,591,480
|
|
G |
Agt |
angiotensinogen |
increases expression |
ISO |
Glucosamine results in increased expression of AGT mRNA |
CTD |
PMID:17178593 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Ahi1 |
Abelson helper integration site 1 |
decreases expression |
ISO |
Glucosamine results in decreased expression of AHI1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 1:15,762,485...15,891,213
Ensembl chr 1:15,762,462...15,891,041
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
affects phosphorylation multiple interactions |
ISO |
Glucosamine analog affects the phosphorylation of AKT1 protein Glucosamine inhibits the reaction [INS1 protein results in increased phosphorylation of AKT1 protein]; OSTN protein affects the reaction [Glucosamine inhibits the reaction [INS1 protein results in increased phosphorylation of AKT1 protein]] Glucosamine analog affects the reaction [IL1B results in increased phosphorylation of AKT1 protein]; Glucosamine promotes the reaction [IL1B results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:18080321 PMID:18340449 PMID:30602124 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alb |
albumin |
multiple interactions |
EXP |
[LEPR protein affects the susceptibility to Glucosamine] which affects the expression of ALB protein |
CTD |
PMID:33345901 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Alg12 |
ALG12, alpha-1,6-mannosyltransferase |
decreases expression |
ISO |
Glucosamine results in decreased expression of ALG12 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 7:119,895,112...119,909,488
Ensembl chr 7:119,895,120...119,909,458
|
|
G |
Alpl |
alkaline phosphatase, biomineralization associated |
multiple interactions increases expression increases activity |
ISO |
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [Glucosamine analog results in increased activity of ALPL protein] Glucosamine analog results in increased expression of ALPL mRNA |
CTD |
PMID:20458730 |
|
NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446
|
|
G |
Apoa1 |
apolipoprotein A1 |
increases secretion increases stability |
ISO |
Glucosamine results in increased secretion of APOA1 protein Glucosamine results in increased stability of APOA1 mRNA |
CTD |
PMID:15164326 |
|
NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035
|
|
G |
Apob |
apolipoprotein B |
multiple interactions increases degradation increases ubiquitination decreases secretion decreases localization decreases expression |
ISO EXP |
acetylleucyl-leucyl-norleucinal inhibits the reaction [Glucosamine results in decreased expression of and results in decreased secretion of APOB protein]; Glucosamine results in decreased expression of and results in decreased secretion of APOB protein; Oleic Acid inhibits the reaction [Glucosamine results in decreased secretion of APOB protein] Oleic Acid inhibits the reaction [Glucosamine results in increased degradation of APOB protein] Glucosamine results in increased ubiquitination of APOB protein Glucosamine results in decreased localization of APOB protein Glucosamine results in decreased expression of APOB protein |
CTD |
PMID:15618547 PMID:19383982 |
|
NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:30,844,368...30,892,497
|
|
G |
Apoe |
apolipoprotein E |
multiple interactions |
ISO |
[Streptozocin co-treated with APOE mutant form] results in increased abundance of Glucosamine; INS1 inhibits the reaction [[Streptozocin co-treated with APOE mutant form] results in increased abundance of Glucosamine] |
CTD |
PMID:16380481 |
|
NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932
|
|
G |
Ass1 |
argininosuccinate synthase 1 |
multiple interactions |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of ASS1 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 3:14,747,355...14,796,909
Ensembl chr 3:14,747,368...14,796,903
|
|
G |
Atf3 |
activating transcription factor 3 |
decreases expression |
ISO |
Glucosamine results in decreased expression of ATF3 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631
|
|
G |
Atf4 |
activating transcription factor 4 |
increases expression multiple interactions |
ISO |
Glucosamine results in increased expression of ATF4 mRNA; Glucosamine results in increased expression of ATF4 protein NUS1 protein inhibits the reaction [Glucosamine results in increased expression of ATF4 mRNA] 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of ATF4 mRNA]; 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of ATF4 protein]; EIF2AK3 protein affects the reaction [Glucosamine results in increased expression of ATF4 mRNA]; GSK2656157 inhibits the reaction [Glucosamine results in increased expression of ATF4 mRNA] |
CTD |
PMID:30602124 PMID:33812996 |
|
NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
|
|
G |
Atf6 |
activating transcription factor 6 |
multiple interactions increases expression decreases expression |
ISO EXP |
4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of ATF6 mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of MEF2A mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of MEF2A protein]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of PPARGC1A mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of PPARGC1A protein]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of SLC2A4 mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of SLC2A4 protein]; NUS1 protein inhibits the reaction [Glucosamine results in increased expression of ATF6 mRNA]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in increased expression of ATF6 mRNA] Glucosamine results in increased expression of ATF6 protein ATF6 protein affects the reaction [Glucosamine results in increased expression of OSTN mRNA] 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of ATF6 mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of MEF2A mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of MEF2A protein]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of PPARGC1A mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of PPARGC1A protein]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of SLC2A4 mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of SLC2A4 protein]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in increased expression of ATF6 mRNA] Glucosamine results in decreased expression of ATF6 mRNA |
CTD |
PMID:17178593 PMID:19383982 PMID:20165829 PMID:30602124 PMID:33812996 |
|
NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177
|
|
G |
Atf7ip |
activating transcription factor 7 interacting protein |
increases expression |
ISO |
Glucosamine results in increased expression of ATF7IP mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 4:169,385,872...169,471,652
Ensembl chr 4:169,385,872...169,471,650
|
|
G |
Atp2a2 |
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2 |
decreases expression |
ISO |
Glucosamine results in decreased expression of ATP2A2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr12:34,072,710...34,122,142
Ensembl chr12:34,072,683...34,122,101
|
|
G |
Azin1 |
antizyme inhibitor 1 |
decreases expression multiple interactions |
EXP |
Glucosamine results in decreased expression of AZIN1 mRNA IL1B promotes the reaction [Glucosamine results in increased expression of AZIN1 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 7:69,654,773...69,681,578
Ensembl chr 7:69,654,663...69,681,578
|
|
G |
B3gat3 |
beta-1,3-glucuronyltransferase 3 |
multiple interactions increases expression |
EXP |
[XDH protein co-treated with Hypoxanthine] inhibits the reaction [Glucosamine results in increased expression of B3GAT3 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in decreased activity of B3GAT3 protein]; Glucosamine inhibits the reaction [IL1B protein results in decreased expression of B3GAT3 mRNA] |
CTD |
PMID:11229466 PMID:11801247 |
|
NCBI chr 1:205,817,374...205,823,928
Ensembl chr 1:205,817,378...205,837,807
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
decreases expression multiple interactions |
ISO |
Glucosamine results in decreased expression of BCL2L1 protein pepstatin inhibits the reaction [Glucosamine results in decreased expression of BCL2L1 protein] |
CTD |
PMID:15972124 PMID:16850161 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
decreases expression |
ISO |
Glucosamine results in decreased expression of BDNF mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
increases expression |
ISO |
Glucosamine analog results in increased expression of BGLAP mRNA |
CTD |
PMID:20458730 |
|
NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495
|
|
G |
Bgn |
biglycan |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of BGN mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of BGN mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr X:151,197,296...151,209,458
Ensembl chr X:151,197,273...151,209,461
|
|
G |
Bmal1 |
basic helix-loop-helix ARNT like 1 |
decreases expression |
ISO |
Glucosamine results in decreased expression of BMAL1 mRNA; Glucosamine results in decreased expression of BMAL1 protein |
CTD |
PMID:24442997 |
|
NCBI chr 1:167,331,756...167,430,235
Ensembl chr 1:167,331,633...167,430,231
|
|
G |
Bmp2 |
bone morphogenetic protein 2 |
multiple interactions |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of BMP2 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 3:120,812,660...120,822,579
Ensembl chr 3:120,812,882...120,821,397
|
|
G |
Bmp4 |
bone morphogenetic protein 4 |
decreases expression multiple interactions |
EXP |
Glucosamine results in decreased expression of BMP4 mRNA Glucosamine promotes the reaction [IL1B results in decreased expression of BMP4 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr15:19,618,538...19,633,494
Ensembl chr15:19,618,542...19,623,306
|
|
G |
Bmp6 |
bone morphogenetic protein 6 |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of BMP6 mRNA] Glucosamine results in decreased expression of BMP6 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr17:26,318,121...26,469,691
Ensembl chr17:26,318,569...26,470,365
|
|
G |
Bmp7 |
bone morphogenetic protein 7 |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of BMP7 mRNA] Glucosamine results in increased expression of BMP7 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 3:161,639,915...161,716,938
Ensembl chr 3:161,516,462...161,716,788
|
|
G |
Calr |
calreticulin |
decreases expression |
ISO |
Glucosamine results in decreased expression of CALR mRNA |
CTD |
PMID:17178593 |
|
NCBI chr19:23,308,525...23,313,420
Ensembl chr19:23,308,351...23,313,414
|
|
G |
Car3 |
carbonic anhydrase 3 |
decreases expression |
EXP |
Glucosamine results in decreased expression of CAR3 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 2:86,770,418...86,780,011
Ensembl chr 2:86,770,420...86,784,280
|
|
G |
Casp3 |
caspase 3 |
increases cleavage multiple interactions |
ISO |
Glucosamine results in increased cleavage of CASP3 protein Glucosamine results in increased activity of and results in increased cleavage of CASP3 protein |
CTD |
PMID:16850161 PMID:22020377 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp4 |
caspase 4 |
decreases expression |
ISO |
Glucosamine results in decreased expression of CASP4 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 8:2,599,017...2,635,097
Ensembl chr 8:2,598,876...2,635,092
|
|
G |
Cbr2 |
carbonyl reductase 2 |
increases expression |
ISO |
Glucosamine results in increased expression of CBR2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr10:106,008,535...106,012,838
Ensembl chr10:105,991,589...106,013,001
|
|
G |
Cbr3 |
carbonyl reductase 3 |
increases expression |
ISO |
Glucosamine results in increased expression of CBR3 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr11:33,008,615...33,016,877
Ensembl chr11:33,008,615...33,016,875
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions increases expression |
ISO EXP |
Alloxan inhibits the reaction [Glucosamine inhibits the reaction [Cathelicidins results in increased expression of CCL2 protein]]; Glucosamine analog inhibits the reaction [IL1B results in increased secretion of CCL2 protein]; Glucosamine inhibits the reaction [Cathelicidins results in increased expression of CCL2 mRNA]; Glucosamine inhibits the reaction [Cathelicidins results in increased expression of CCL2 protein]; Glucosamine inhibits the reaction [TNF results in increased expression of CCL2 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of CCL2 protein] Glucosamine results in increased expression of CCL2 mRNA Glucosamine inhibits the reaction [IL1B results in increased expression of CCL2 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of CCL2 mRNA] |
CTD |
PMID:17109745 PMID:18080321 PMID:18949387 PMID:19020780 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl20 |
C-C motif chemokine ligand 20 |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of CCL20 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of CCL20 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 9:84,389,031...84,391,629
Ensembl chr 9:84,388,904...84,391,629
|
|
G |
Ccl22 |
C-C motif chemokine ligand 22 |
multiple interactions |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of CCL22 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr19:10,257,602...10,264,373
Ensembl chr19:10,257,601...10,264,400
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
multiple interactions |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of CCL3 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions |
ISO EXP |
Glucosamine analog inhibits the reaction [IL1B results in increased secretion of CCL5 protein] Glucosamine inhibits the reaction [IL1B results in increased expression of CCL5 mRNA] |
CTD |
PMID:17109745 PMID:18080321 |
|
NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Ccl7 |
C-C motif chemokine ligand 7 |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of CCL7 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of CCL7 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr10:67,016,446...67,018,296
Ensembl chr10:67,016,446...67,018,303
|
|
G |
Ccn2 |
cellular communication network factor 2 |
increases expression |
EXP |
Glucosamine analog results in increased expression of CCN2 mRNA |
CTD |
PMID:21466783 |
|
NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734
|
|
G |
Ccnb1 |
cyclin B1 |
decreases expression |
EXP |
Glucosamine results in decreased expression of CCNB1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Cd24 |
CD24 molecule |
increases expression |
ISO |
Glucosamine results in increased expression of CD24A mRNA |
CTD |
PMID:17178593 |
|
NCBI chr20:47,074,353...47,079,662
Ensembl chr20:47,073,512...47,079,662
|
|
G |
Cd28 |
Cd28 molecule |
increases expression |
EXP |
Glucosamine results in increased expression of CD28 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 9:62,166,324...62,194,674
Ensembl chr 9:62,166,192...62,194,685
|
|
G |
Cdc20 |
cell division cycle 20 |
decreases expression |
EXP |
Glucosamine results in decreased expression of CDC20 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 5:131,966,203...131,970,406
Ensembl chr 5:131,966,215...131,970,512
|
|
G |
Cdc23 |
cell division cycle 23 |
decreases expression |
EXP |
Glucosamine results in decreased expression of CDC23 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr18:26,236,891...26,260,611
Ensembl chr18:26,236,890...26,291,163
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
decreases expression |
EXP |
Glucosamine results in decreased expression of CDK1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression |
EXP ISO |
Glucosamine results in increased expression of CDKN1A protein Glucosamine results in increased expression of CDKN1A mRNA |
CTD |
PMID:15654767 PMID:17178593 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
decreases expression |
EXP |
Glucosamine results in decreased expression of CDKN1B protein |
CTD |
PMID:15654767 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cdkn3 |
cyclin-dependent kinase inhibitor 3 |
decreases expression |
EXP |
Glucosamine results in decreased expression of CDKN3 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr15:20,022,522...20,033,948
Ensembl chr15:20,022,664...20,033,945
|
|
G |
Cenpf |
centromere protein F |
decreases expression |
EXP |
Glucosamine results in decreased expression of CENPF mRNA |
CTD |
PMID:17109745 |
|
NCBI chr13:101,184,127...101,229,714
Ensembl chr13:101,184,127...101,229,669
|
|
G |
Chi3l1 |
chitinase 3 like 1 |
decreases expression |
ISO |
Glucosamine analog results in decreased expression of CHI3L1 mRNA |
CTD |
PMID:16142878 |
|
NCBI chr13:45,641,802...45,649,787
Ensembl chr13:45,641,802...45,649,787
|
|
G |
Chuk |
component of inhibitor of nuclear factor kappa B kinase complex |
multiple interactions decreases activity |
ISO |
Glucosamine analog results in decreased activity of and results in decreased localization of CHUK protein Glucosamine analog results in decreased activity of CHUK protein |
CTD |
PMID:20113495 |
|
NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065
|
|
G |
Ckap2 |
cytoskeleton associated protein 2 |
decreases expression |
EXP |
Glucosamine results in decreased expression of CKAP2 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr16:69,839,668...69,864,852
Ensembl chr16:69,839,630...69,864,913
|
|
G |
Clock |
clock circadian regulator |
decreases expression |
ISO |
Glucosamine results in decreased expression of CLOCK mRNA; Glucosamine results in decreased expression of CLOCK protein |
CTD |
PMID:24442997 |
|
NCBI chr14:31,908,542...31,992,673
Ensembl chr14:31,908,566...31,990,400
|
|
G |
Clta |
clathrin, light chain A |
decreases expression |
EXP |
Glucosamine results in decreased expression of CLTA mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 5:58,244,253...58,263,480
Ensembl chr 5:58,245,442...58,263,472
|
|
G |
Col11a1 |
collagen type XI alpha 1 chain |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in decreased expression of COL11A1 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of COL11A1 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 2:201,820,715...202,013,853
Ensembl chr 2:201,820,715...202,013,853
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions decreases expression |
ISO |
Glucosamine inhibits the reaction [IL1B protein results in increased expression of COL1A1 mRNA] Glucosamine results in decreased expression of COL1A1 mRNA |
CTD |
PMID:18321735 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Col2a1 |
collagen type II alpha 1 chain |
multiple interactions affects expression increases expression |
ISO EXP |
Glucosamine analog affects the reaction [IL1B results in decreased expression of COL2A1 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in decreased expression of COL2A1 mRNA] Glucosamine inhibits the reaction [IL1B results in decreased expression of COL2A1 mRNA] Glucosamine analog affects the expression of COL2A1 mRNA Glucosamine analog results in increased expression of COL2A1 mRNA; Glucosamine results in increased expression of COL2A1 mRNA |
CTD |
PMID:16300972 PMID:17109745 PMID:17337215 PMID:18321735 |
|
NCBI chr 7:129,098,489...129,127,560
Ensembl chr 7:129,098,786...129,127,546
|
|
G |
Col3a1 |
collagen type III alpha 1 chain |
multiple interactions |
EXP |
Glucosamine inhibits the reaction [IL1B results in decreased expression of COL3A1 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547
|
|
G |
Col8a1 |
collagen type VIII alpha 1 chain |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of COL8A1 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of COL8A1 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr11:42,776,851...42,906,432
Ensembl chr11:42,777,628...42,906,424
|
|
G |
Csf1 |
colony stimulating factor 1 |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of CSF1 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of CSF1 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 2:195,377,215...195,396,608
Ensembl chr 2:195,377,215...195,411,704
|
|
G |
Csf2 |
colony stimulating factor 2 |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of CSF2 mRNA] Glucosamine results in increased expression of CSF2 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199
|
|
G |
Csf3 |
colony stimulating factor 3 |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of CSF3 mRNA] Glucosamine results in increased expression of CSF3 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr10:83,660,787...83,664,569
Ensembl chr10:83,661,207...83,663,603
|
|
G |
Ctsd |
cathepsin D |
affects localization multiple interactions increases activity decreases expression |
ISO |
Glucosamine affects the localization of CTSD protein pepstatin inhibits the reaction [Glucosamine results in decreased expression of CTSD protein alternative form] Glucosamine results in increased activity of CTSD protein |
CTD |
PMID:15972124 PMID:16850161 |
|
NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488
|
|
G |
Cul2 |
cullin 2 |
multiple interactions |
ISO |
Glucosamine analog inhibits the reaction [TNF results in increased expression of CUL2 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of CUL2 mRNA] |
CTD |
PMID:18173918 |
|
NCBI chr17:54,169,093...54,210,197
Ensembl chr17:54,169,086...54,209,968
|
|
G |
Cxcl1 |
C-X-C motif chemokine ligand 1 |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL1 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of CXCL1 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr14:17,193,364...17,195,143
Ensembl chr14:17,193,365...17,195,215
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
multiple interactions |
ISO EXP |
Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL10 mRNA] Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL10 mRNA] |
CTD |
PMID:17109745 PMID:20737476 |
|
NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975
|
|
G |
Cxcl11 |
C-X-C motif chemokine ligand 11 |
multiple interactions |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL11 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr14:15,689,432...15,692,207
Ensembl chr14:15,689,424...15,692,271
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
multiple interactions decreases expression |
EXP |
Glucosamine promotes the reaction [IL1B results in decreased expression of CXCL12 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of CXCL12 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL2 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of CXCL2 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL3 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of CXCL3 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511
|
|
G |
Cxcl6 |
C-X-C motif chemokine ligand 6 |
multiple interactions |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL5 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr14:17,310,790...17,312,250
Ensembl chr14:17,310,426...17,313,093
|
|
G |
Cyba |
cytochrome b-245 alpha chain |
decreases expression |
ISO |
Glucosamine results in decreased expression of CYBA mRNA |
CTD |
PMID:18077487 |
|
NCBI chr19:50,487,598...50,495,669
Ensembl chr19:50,487,597...50,495,721
|
|
G |
Cycs |
cytochrome c, somatic |
affects localization |
ISO |
Glucosamine affects the localization of CYCS protein |
CTD |
PMID:15972124 PMID:22020377 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054 Ensembl chr18:79,651,378...79,654,054
|
|
G |
Cyp51 |
cytochrome P450, family 51 |
increases expression |
ISO |
Glucosamine results in increased expression of CYP51 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 4:30,036,956...30,055,410
Ensembl chr 4:30,036,865...30,055,410
|
|
G |
Dbi |
diazepam binding inhibitor |
increases expression |
ISO |
Glucosamine results in increased expression of DBI mRNA |
CTD |
PMID:17178593 |
|
NCBI chr13:31,241,466...31,249,853
Ensembl chr13:31,206,988...31,268,693
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression multiple interactions decreases expression |
ISO |
Glucosamine results in increased expression of DDIT3 mRNA; Glucosamine results in increased expression of DDIT3 protein NUS1 protein inhibits the reaction [Glucosamine results in increased expression of DDIT3 mRNA] 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of DDIT3 mRNA]; 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of DDIT3 protein] Glucosamine results in decreased expression of DDIT3 mRNA |
CTD |
PMID:16380481 PMID:17178593 PMID:30602124 PMID:33812996 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Ddit4l |
DNA-damage-inducible transcript 4-like |
increases expression |
EXP |
Glucosamine results in increased expression of DDIT4L mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 2:226,128,273...226,131,044
Ensembl chr 2:226,128,276...226,131,375
|
|
G |
Dhcr7 |
7-dehydrocholesterol reductase |
increases expression |
ISO |
Glucosamine results in increased expression of DHCR7 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 1:199,015,081...199,031,055
Ensembl chr 1:199,015,081...199,031,055
|
|
G |
Dnajb11 |
DnaJ heat shock protein family (Hsp40) member B11 |
decreases expression |
ISO |
Glucosamine results in decreased expression of DNAJB11 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr11:78,151,750...78,168,259
Ensembl chr11:78,150,429...78,180,407
|
|
G |
Dnajb9 |
DnaJ heat shock protein family (Hsp40) member B9 |
decreases expression |
ISO |
Glucosamine results in decreased expression of DNAJB9 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 6:61,270,385...61,276,795
Ensembl chr 6:61,269,913...61,275,063
|
|
G |
Dnajc3 |
DnaJ heat shock protein family (Hsp40) member C3 |
decreases expression |
ISO |
Glucosamine results in decreased expression of DNAJC3 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr15:96,025,605...96,068,585
Ensembl chr15:96,025,624...96,065,181
|
|
G |
Dspp |
dentin sialophosphoprotein |
decreases expression |
ISO |
Glucosamine analog results in decreased expression of DSPP mRNA |
CTD |
PMID:20458730 |
|
NCBI chr14:5,565,562...5,571,669
Ensembl chr14:5,565,629...5,571,672
|
|
G |
Dusp5 |
dual specificity phosphatase 5 |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of DUSP5 mRNA] Glucosamine results in increased expression of DUSP5 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 1:252,538,408...252,555,320
Ensembl chr 1:252,538,449...252,551,818
|
|
G |
Dusp7 |
dual specificity phosphatase 7 |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of DUSP7 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of DUSP7 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 8:107,009,369...107,016,404
Ensembl chr 8:107,008,528...107,016,404
|
|
G |
Dync1i1 |
dynein cytoplasmic 1 intermediate chain 1 |
decreases expression |
EXP |
Glucosamine results in decreased expression of DYNC1I1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 4:33,852,597...34,166,159
Ensembl chr 4:33,852,927...34,166,149
|
|
G |
Edem1 |
ER degradation enhancing alpha-mannosidase like protein 1 |
decreases expression |
ISO |
Glucosamine results in decreased expression of EDEM1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 4:141,797,631...141,829,717
Ensembl chr 4:141,797,701...141,829,717
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
multiple interactions increases expression increases phosphorylation |
EXP ISO |
EIF2AK3 gene mutant form inhibits the reaction [Glucosamine results in increased phosphorylation of EIF2S1 protein] Glucosamine results in increased expression of EIF2AK3 protein NUS1 protein inhibits the reaction [Glucosamine results in increased expression of EIF2AK3 protein] EIF2AK3 protein affects the reaction [Glucosamine results in increased expression of ATF4 mRNA]; EIF2AK3 protein affects the reaction [Glucosamine results in increased expression of OSTN mRNA]; EIF2AK3 protein affects the reaction [Glucosamine results in increased phosphorylation of EIF2S1 protein] Glucosamine results in increased phosphorylation of EIF2AK3 protein |
CTD |
PMID:16324875 PMID:19383982 PMID:30602124 PMID:33812996 |
|
NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2 subunit alpha |
increases phosphorylation multiple interactions |
ISO EXP |
Glucosamine results in increased phosphorylation of EIF2S1 protein NUS1 protein inhibits the reaction [Glucosamine results in increased phosphorylation of EIF2S1 protein] 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased phosphorylation of EIF2S1 protein]; EIF2AK3 protein affects the reaction [Glucosamine results in increased phosphorylation of EIF2S1 protein]; GSK2656157 inhibits the reaction [Glucosamine results in increased phosphorylation of EIF2S1 protein] EIF2AK3 gene mutant form inhibits the reaction [Glucosamine results in increased phosphorylation of EIF2S1 protein] |
CTD |
PMID:16324875 PMID:19383982 PMID:30602124 PMID:33812996 |
|
NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225
|
|
G |
Elovl6 |
ELOVL fatty acid elongase 6 |
increases expression |
ISO |
Glucosamine results in increased expression of ELOVL6 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 2:218,063,682...218,174,767
Ensembl chr 2:218,063,804...218,171,186
|
|
G |
Epas1 |
endothelial PAS domain protein 1 |
decreases expression multiple interactions |
EXP |
Glucosamine results in decreased expression of EPAS1 mRNA Glucosamine inhibits the reaction [IL1B results in increased expression of EPAS1 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of EPAS1 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 6:7,790,236...7,871,717
Ensembl chr 6:7,790,647...7,871,228
|
|
G |
Eprs1 |
glutamyl-prolyl-tRNA synthetase 1 |
decreases expression |
ISO |
Glucosamine results in decreased expression of EPRS1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr13:96,901,548...96,971,966
Ensembl chr13:96,901,575...96,971,966
|
|
G |
Ern1 |
endoplasmic reticulum to nucleus signaling 1 |
multiple interactions increases expression |
ISO |
ERN1 protein affects the reaction [Glucosamine results in increased expression of OSTN mRNA]; ERN1 protein affects the reaction [Glucosamine results in increased splicing of XBP1 mRNA] NUS1 protein inhibits the reaction [Glucosamine results in increased expression of ERN1 mRNA] |
CTD |
PMID:30602124 PMID:33812996 |
|
NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
increases expression |
ISO EXP |
Glucosamine results in increased expression of FABP4 mRNA |
CTD |
PMID:15694357 |
|
NCBI chr 2:91,580,879...91,585,567
Ensembl chr 2:91,580,885...91,585,578
|
|
G |
Fasn |
fatty acid synthase |
increases expression |
ISO |
Glucosamine results in increased expression of FASN mRNA |
CTD |
PMID:22096489 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Fbp2 |
fructose-bisphosphatase 2 |
increases expression |
ISO |
Glucosamine results in increased expression of FBP2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr17:2,236,088...2,253,702
Ensembl chr17:2,236,336...2,253,698
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
multiple interactions |
EXP |
Glucosamine promotes the reaction [Glucose results in increased expression of FGF2 mRNA] |
CTD |
PMID:1518840 |
|
NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221
|
|
G |
Fgf7 |
fibroblast growth factor 7 |
decreases expression multiple interactions |
EXP |
Glucosamine results in decreased expression of FGF7 mRNA IL1B inhibits the reaction [Glucosamine results in decreased expression of FGF7 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 3:113,280,448...113,333,279
Ensembl chr 3:113,281,283...113,332,929
|
|
G |
Fgf9 |
fibroblast growth factor 9 |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of FGF9 mRNA] Glucosamine results in increased expression of FGF9 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr15:32,208,993...32,254,952
Ensembl chr15:32,210,074...32,253,309
|
|
G |
Fgfr1 |
Fibroblast growth factor receptor 1 |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in decreased expression of FGFR1 mRNA] Glucosamine results in increased expression of FGFR1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr16:66,491,930...66,547,161
Ensembl chr16:66,494,042...66,547,350
|
|
G |
Fkbp11 |
FKBP prolyl isomerase 11 |
decreases expression |
ISO |
Glucosamine results in decreased expression of FKBP11 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 7:129,871,870...129,877,760
Ensembl chr 7:129,871,870...129,875,303
|
|
G |
Fn1 |
fibronectin 1 |
decreases expression |
ISO EXP |
Glucosamine results in decreased expression of FN1 protein |
CTD |
PMID:17178593 |
|
NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
Glucosamine analog inhibits the reaction [Buthionine Sulfoximine results in increased expression of FOS mRNA] Glucosamine analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of FOS protein] |
CTD |
PMID:19375915 PMID:21825963 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Furin |
furin (paired basic amino acid cleaving enzyme) |
decreases cleavage multiple interactions |
ISO |
Glucosamine results in decreased cleavage of FURIN protein alternative form Glucosamine results in decreased glycosylation of and results in decreased activity of FURIN protein |
CTD |
PMID:19909832 |
|
NCBI chr 1:134,348,142...134,361,182
Ensembl chr 1:134,348,144...134,364,314
|
|
G |
Fxyd2 |
FXYD domain-containing ion transport regulator 2 |
increases expression |
EXP |
Glucosamine results in increased expression of FXYD2 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 8:45,712,901...45,720,032
Ensembl chr 8:45,712,903...45,720,203
|
|
G |
Gatm |
glycine amidinotransferase |
decreases expression |
EXP |
Glucosamine results in decreased expression of GATM mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 3:109,658,919...109,675,508
Ensembl chr 3:109,658,951...109,684,129
|
|
G |
Gck |
glucokinase |
decreases expression |
EXP |
Glucosamine results in decreased expression of GCK mRNA |
CTD |
PMID:11893929 |
|
NCBI chr14:80,785,060...80,829,842
Ensembl chr14:80,785,060...80,826,995
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
increases expression |
ISO |
Glucosamine analog results in increased expression of GCLC mRNA |
CTD |
PMID:21825963 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gfpt1 |
glutamine fructose-6-phosphate transaminase 1 |
multiple interactions |
EXP |
[Glucosamine co-treated with INS1 protein] affects the localization of GFPT1 protein |
CTD |
PMID:9453242 |
|
NCBI chr 4:119,496,691...119,546,472
Ensembl chr 4:119,496,714...119,546,471
|
|
G |
Glrx |
glutaredoxin |
increases expression |
ISO |
Glucosamine results in increased expression of GLRX mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 2:5,341,873...5,351,686
Ensembl chr 2:5,341,885...5,351,680
|
|
G |
Gnpnat1 |
glucosamine-phosphate N-acetyltransferase 1 |
decreases expression |
ISO |
Glucosamine results in decreased expression of GNPNAT1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr15:18,596,180...18,608,854
Ensembl chr15:18,596,442...18,608,739
|
|
G |
Gnptab |
N-acetylglucosamine-1-phosphate transferase subunits alpha and beta |
increases expression |
ISO |
Glucosamine results in increased expression of GNPTAB mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 7:22,800,502...22,866,336
Ensembl chr 7:22,800,485...22,866,933
|
|
G |
Gpd1l1 |
glycerol-3-phosphate dehydrogenase 1 like 1 |
increases expression |
ISO |
Glucosamine results in increased expression of GPD1L mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 8:114,591,103...114,620,771
Ensembl chr 8:114,588,487...114,620,723
|
|
G |
Grem1 |
gremlin 1, DAN family BMP antagonist |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of GREM1 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of GREM1 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 3:100,512,317...100,524,001
Ensembl chr 3:100,512,313...100,524,082
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
decreases phosphorylation multiple interactions |
ISO |
Glucosamine results in decreased phosphorylation of GSK3B protein Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]; NUS1 protein inhibits the reaction [Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]]; PRKAA1 protein promotes the reaction [Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]]; PRKAA1 protein promotes the reaction [NUS1 protein inhibits the reaction [Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]]] |
CTD |
PMID:33812996 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Gspt1 |
G1 to S phase transition 1 |
multiple interactions |
ISO |
Glucosamine analog inhibits the reaction [TNF results in increased expression of GSPT1 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of GSPT1 mRNA] |
CTD |
PMID:18173918 |
|
NCBI chr10:4,362,528...4,397,215
Ensembl chr10:4,362,510...4,397,198
|
|
G |
Gstt1 |
glutathione S-transferase theta 1 |
increases expression |
ISO |
Glucosamine results in increased expression of GSTT1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr20:12,856,613...12,873,586
Ensembl chr20:12,856,669...12,873,585
|
|
G |
Hapln1 |
hyaluronan and proteoglycan link protein 1 |
decreases expression multiple interactions |
EXP |
Glucosamine results in decreased expression of HAPLN1 mRNA Glucosamine inhibits the reaction [IL1B results in decreased expression of HAPLN1 mRNA]; IL1B promotes the reaction [Glucosamine results in decreased expression of HAPLN1 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 2:20,631,640...20,696,388
Ensembl chr 2:20,631,640...20,693,777
|
|
G |
Herpud1 |
homocysteine inducible ER protein with ubiquitin like domain 1 |
decreases expression |
ISO |
Glucosamine results in decreased expression of HERPUD1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr19:10,598,411...10,609,002
Ensembl chr19:10,598,417...10,618,424
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions decreases expression |
ISO |
Glucosamine affects the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of HIF1A protein]; Glucosamine inhibits the reaction [Oxygen deficiency results in increased expression of HIF1A protein] Glucosamine results in decreased expression of HIF1A mRNA; Glucosamine results in decreased expression of HIF1A protein |
CTD |
PMID:19254699 PMID:22020377 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hk1 |
hexokinase 1 |
increases expression |
ISO EXP |
Glucosamine results in increased expression of HK1 mRNA |
CTD |
PMID:11893929 PMID:17178593 |
|
NCBI chr20:30,230,488...30,332,099
Ensembl chr20:30,230,486...30,332,131
|
|
G |
Hmga1 |
high mobility group AT-hook 1 |
increases expression |
EXP |
Glucosamine results in increased expression of HMGA1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr20:5,611,088...5,618,755
Ensembl chr20:5,611,694...5,618,752
|
|
G |
Hmgcs1 |
3-hydroxy-3-methylglutaryl-CoA synthase 1 |
increases expression |
ISO |
Glucosamine results in increased expression of HMGCS1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 2:51,649,368...51,667,100
Ensembl chr 2:51,649,497...51,667,100
|
|
G |
Hmmr |
hyaluronan-mediated motility receptor |
decreases expression |
EXP |
Glucosamine results in decreased expression of HMMR mRNA |
CTD |
PMID:17109745 |
|
NCBI chr10:25,132,933...25,163,029
Ensembl chr10:25,132,977...25,163,060
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression |
ISO |
Glucosamine inhibits the reaction [IL1B results in decreased expression of HMOX1 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of HMOX1 protein] Glucosamine results in increased expression of HMOX1 mRNA; Glucosamine results in increased expression of HMOX1 protein |
CTD |
PMID:18077487 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hoxa1 |
homeobox A1 |
decreases expression |
ISO |
Glucosamine results in decreased expression of HOXA1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 4:81,255,814...81,258,587
Ensembl chr 4:81,255,883...81,258,504
|
|
G |
Hpgd |
15-hydroxyprostaglandin dehydrogenase |
decreases expression |
EXP |
Glucosamine results in decreased expression of HPGD mRNA |
CTD |
PMID:17109745 |
|
NCBI chr16:33,986,265...34,024,228
Ensembl chr16:33,986,266...34,024,228
|
|
G |
Hsp90b1 |
heat shock protein 90 beta family member 1 |
decreases expression increases expression |
ISO EXP |
Glucosamine results in decreased expression of HSP90B1 mRNA Glucosamine results in increased expression of HSP90B1 protein |
CTD |
PMID:15618547 PMID:17109745 PMID:17178593 |
|
NCBI chr 7:21,110,431...21,124,762
Ensembl chr 7:21,110,457...21,124,788
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions increases expression decreases expression |
ISO EXP |
4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of HSPA5 mRNA]; NUS1 protein inhibits the reaction [Glucosamine results in increased expression of HSPA5 mRNA]; NUS1 protein inhibits the reaction [Glucosamine results in increased expression of HSPA5 protein]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in increased expression of HSPA5 mRNA] 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of HSPA5 mRNA]; 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of HSPA5 protein] Glucosamine results in increased expression of HSPA5 mRNA; Glucosamine results in increased expression of HSPA5 protein 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of HSPA5 mRNA]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in increased expression of HSPA5 mRNA] Glucosamine results in decreased expression of HSPA5 mRNA |
CTD |
PMID:15618547 PMID:16380481 PMID:17178593 PMID:19383982 PMID:20165829 PMID:22020377 PMID:30602124 PMID:33812996 More...
|
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Hyou1 |
hypoxia up-regulated 1 |
decreases expression |
ISO |
Glucosamine results in decreased expression of HYOU1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 8:44,706,073...44,718,189
Ensembl chr 8:44,706,263...44,718,186
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions decreases activity |
ISO EXP |
Alloxan inhibits the reaction [Glucosamine inhibits the reaction [Cathelicidins results in increased expression of ICAM1 protein]]; Glucosamine inhibits the reaction [[IL6 co-treated with TNF] results in increased expression of ICAM1 protein]; Glucosamine inhibits the reaction [Cathelicidins results in increased expression of ICAM1 mRNA]; Glucosamine inhibits the reaction [Cathelicidins results in increased expression of ICAM1 protein]; Glucosamine inhibits the reaction [IFNG promotes the reaction [TNF results in increased expression of ICAM1 protein]]; Glucosamine inhibits the reaction [IFNG results in increased expression of ICAM1 mRNA]; Glucosamine inhibits the reaction [IFNG results in increased expression of ICAM1 protein]; Glucosamine inhibits the reaction [IL1B promotes the reaction [TNF results in increased expression of ICAM1 protein]]; Glucosamine inhibits the reaction [IL1B results in increased expression of ICAM1 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of ICAM1 protein]; Glucosamine inhibits the reaction [IL6 results in increased expression of ICAM1 protein]; Glucosamine inhibits the reaction [TNF promotes the reaction [IFNG results in increased expression of ICAM1 protein]]; Glucosamine inhibits the reaction [TNF promotes the reaction [IL1B results in increased expression of ICAM1 protein]]; Glucosamine inhibits the reaction [TNF results in increased expression of ICAM1 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of ICAM1 protein] Glucosamine results in decreased activity of ICAM1 protein Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of ICAM1 protein] |
CTD |
PMID:16431966 PMID:16822504 PMID:17238806 PMID:18949387 PMID:19020780 PMID:19098112 More...
|
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Id1 |
inhibitor of DNA binding 1 |
increases expression |
ISO |
Glucosamine results in increased expression of ID1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 3:141,210,666...141,212,420
Ensembl chr 3:141,211,267...141,212,419
|
|
G |
Id2 |
inhibitor of DNA binding 2 |
increases expression |
ISO |
Glucosamine results in increased expression of ID2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 6:41,740,556...41,742,393
Ensembl chr 6:41,728,946...41,744,400
|
|
G |
Id3 |
inhibitor of DNA binding 3 |
increases expression |
ISO |
Glucosamine results in increased expression of ID3 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 5:148,372,784...148,374,353
Ensembl chr 5:148,372,762...148,374,349
|
|
G |
Idh1 |
isocitrate dehydrogenase (NADP(+)) 1 |
increases expression |
ISO |
Glucosamine results in increased expression of IDH1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 9:66,534,146...66,563,703
Ensembl chr 9:66,534,146...66,563,708
|
|
G |
Ifit3 |
interferon-induced protein with tetratricopeptide repeats 3 |
increases expression |
ISO |
Glucosamine results in increased expression of IFIT3 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 1:232,114,166...232,119,311
Ensembl chr 1:232,114,166...232,119,307
|
|
G |
Ifng |
interferon gamma |
decreases secretion multiple interactions |
ISO |
Glucosamine results in decreased secretion of IFNG protein Glucosamine inhibits the reaction [IFNG promotes the reaction [TNF results in increased expression of ICAM1 protein]]; Glucosamine inhibits the reaction [IFNG results in increased expression of ICAM1 mRNA]; Glucosamine inhibits the reaction [IFNG results in increased expression of ICAM1 protein]; Glucosamine inhibits the reaction [IFNG results in increased localization of STAT1 protein modified form]; Glucosamine inhibits the reaction [IFNG results in increased phosphorylation of and results in increased localization of STAT1 protein]; Glucosamine inhibits the reaction [TNF promotes the reaction [IFNG results in increased expression of ICAM1 protein]] |
CTD |
PMID:14507305 PMID:16431966 PMID:16822504 PMID:17238806 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Igfbp3 |
insulin-like growth factor binding protein 3 |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of IGFBP3 mRNA]; IL1B inhibits the reaction [Glucosamine results in increased expression of IGFBP3 mRNA] Glucosamine results in decreased expression of IGFBP3 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr14:82,056,347...82,064,083
Ensembl chr14:82,056,347...82,064,083
|
|
G |
Igfbp4 |
insulin-like growth factor binding protein 4 |
decreases expression |
ISO |
Glucosamine results in decreased expression of IGFBP4 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr10:83,995,253...84,007,272
Ensembl chr10:83,989,591...84,007,225
|
|
G |
Igfbp5 |
insulin-like growth factor binding protein 5 |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of IGFBP5 mRNA] Glucosamine results in increased expression of IGFBP5 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 9:74,452,371...74,464,953
Ensembl chr 9:74,448,382...74,465,156
|
|
G |
Ikbkb |
inhibitor of nuclear factor kappa B kinase subunit beta |
multiple interactions |
ISO |
Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of IKBKB protein] |
CTD |
PMID:18786831 |
|
NCBI chr16:69,319,487...69,373,251
Ensembl chr16:69,319,554...69,373,250
|
|
G |
Ikbkg |
inhibitor of nuclear factor kappa B kinase regulatory subunit gamma |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of IKBKG mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of IKBKG mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr X:152,216,485...152,241,476
Ensembl chr X:152,216,596...152,239,499
|
|
G |
Il11 |
interleukin 11 |
multiple interactions |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of IL11 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 1:69,069,829...69,076,129
Ensembl chr 1:69,068,137...69,076,129
|
|
G |
Il13ra1 |
interleukin 13 receptor subunit alpha 1 |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of IL13RA1 mRNA] Glucosamine results in decreased expression of IL13RA1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr X:115,348,822...115,408,682
Ensembl chr X:115,348,860...115,408,681 Ensembl chr11:115,348,860...115,408,681
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of IL1A mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of IL1A mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases expression decreases expression |
ISO EXP |
[Glucosamine co-treated with Chondroitin Sulfates co-treated with IL1B protein] results in decreased expression of NOS2 protein; [Glucosamine co-treated with Chondroitin Sulfates co-treated with IL1B protein] results in decreased expression of PTGES protein; [Glucosamine co-treated with Chondroitin Sulfates co-treated with IL1B protein] results in decreased expression of PTGS2 protein; [Glucosamine co-treated with Chondroitin Sulfates co-treated with IL1B protein] results in increased expression of TIMP3 mRNA; [Glucosamine co-treated with Chondroitin Sulfates] inhibits the reaction [IL1B protein results in increased secretion of Dinoprostone]; [Glucosamine co-treated with Chondroitin Sulfates] inhibits the reaction [IL1B protein results in increased secretion of Nitrites]; Glucosamine analog affects the reaction [IL1B protein results in increased abundance of Nitric Oxide]; Glucosamine analog affects the reaction [IL1B results in decreased expression of ACAN mRNA]; Glucosamine analog affects the reaction [IL1B results in decreased expression of COL2A1 mRNA]; Glucosamine analog affects the reaction [IL1B results in increased phosphorylation of AKT1 protein]; Glucosamine analog inhibits the reaction [IL1B protein results in increased abundance of Dinoprostone]; Glucosamine analog inhibits the reaction [IL1B protein results in increased expression of MMP13]; Glucosamine analog inhibits the reaction [IL1B protein results in increased expression of MMP1]; Glucosamine analog inhibits the reaction [IL1B protein results in increased expression of MMP3]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of and results in increased secretion of MMP1 protein]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of and results in increased secretion of MMP13 protein]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of and results in increased secretion of MMP3 protein]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of CXCL8 mRNA]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of MMP1 mRNA]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of MMP13 mRNA]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of MMP3 mRNA]; Glucosamine analog inhibits the reaction [IL1B results in increased localization of RELA protein]; Glucosamine analog inhibits the reaction [IL1B results in increased phosphorylation of and results in increased degradation of NFKBIA protein]; Glucosamine analog inhibits the reaction [IL1B results in increased secretion of CCL2 protein]; Glucosamine analog inhibits the reaction [IL1B results in increased secretion of CCL5 protein]; Glucosamine analog inhibits the reaction [IL1B results in increased secretion of CXCL8 protein]; Glucosamine analog promotes the reaction [IL1B results in increased phosphorylation of MAPK1 protein]; Glucosamine analog promotes the reaction [IL1B results in increased phosphorylation of MAPK3 protein]; Glucosamine analog promotes the reaction [IL1B results in increased phosphorylation of MAPK8 protein]; Glucosamine inhibits the reaction [[OSM protein co-treated with IL1B protein] results in decreased methylation of IL1B promoter]; Glucosamine inhibits the reaction [[OSM protein co-treated with IL1B protein] results in increased expression of IL1B mRNA]; Glucosamine inhibits the reaction [IL1B promotes the reaction [TNF results in increased expression of ICAM1 protein]]; Glucosamine inhibits the reaction [IL1B protein results in decreased expression of ACAN mRNA]; Glucosamine inhibits the reaction [IL1B protein results in decreased expression of COL2A1 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased activity of JUN protein]; Glucosamine inhibits the reaction [IL1B protein results in increased activity of JUND protein]; Glucosamine inhibits the reaction [IL1B protein results in increased degradation of NFKBIA protein]; Glucosamine inhibits the reaction [IL1B protein results in increased expression of COL1A1 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased expression of MMP1 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased expression of MMP13 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased expression of MMP3 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased expression of PTGS2 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased expression of PTGS2 protein]; Glucosamine inhibits the reaction [IL1B protein results in increased localization of NFKB1 protein]; Glucosamine inhibits the reaction [IL1B protein results in increased localization of RELA protein]; Glucosamine inhibits the reaction [IL1B protein results in increased secretion of Dinoprostone]; Glucosamine inhibits the reaction [IL1B protein results in increased secretion of MMP1 protein]; Glucosamine inhibits the reaction [IL1B protein results in increased secretion of MMP13 protein]; Glucosamine inhibits the reaction [IL1B protein results in increased secretion of MMP3 protein]; Glucosamine inhibits the reaction [IL1B results in decreased expression of HMOX1 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of HMOX1 protein]; Glucosamine inhibits the reaction [IL1B results in increased abundance of Dinoprostone]; Glucosamine inhibits the reaction [IL1B results in increased abundance of Nitric Oxide]; Glucosamine inhibits the reaction [IL1B results in increased abundance of Nitrites]; Glucosamine inhibits the reaction [IL1B results in increased degradation of NFKB1 protein]; Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL8 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL8 protein]; Glucosamine inhibits the reaction [IL1B results in increased expression of ICAM1 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of ICAM1 protein]; Glucosamine inhibits the reaction [IL1B results in increased expression of MMP3 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of MMP3 protein]; Glucosamine inhibits the reaction [IL1B results in increased expression of NOS2 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of PTGES mRNA]; Glucosamine inhibits the reaction [IL1B results in increased localization of RELA protein]; Glucosamine inhibits the reaction [IL1B results in increased phosphorylation of MAPK1 protein]; Glucosamine inhibits the reaction [IL1B results in increased phosphorylation of MAPK14 protein]; Glucosamine inhibits the reaction [IL1B results in increased phosphorylation of MAPK3 protein]; Glucosamine inhibits the reaction [IL1B results in increased phosphorylation of MAPK8 protein]; Glucosamine inhibits the reaction [IL1B results in increased secretion of CXCL8 protein]; Glucosamine inhibits the reaction [TNF promotes the reaction [IL1B results in increased expression of ICAM1 protein]]; Glucosamine promotes the reaction [IL1B results in increased expression of PPARG]; Glucosamine promotes the reaction [IL1B results in increased phosphorylation of AKT1 protein] Glucosamine results in increased expression of IL1B mRNA Glucosamine results in decreased expression of IL1B mRNA [IL1B protein co-treated with Glucosamine] results in increased expression of IL1R2 mRNA; Glucosamine affects the reaction [IL1B results in decreased expression of ADAM15 mRNA]; Glucosamine affects the reaction [IL1B results in decreased expression of OAT mRNA]; Glucosamine inhibits the reaction [IL1B protein results in decreased activity of B3GAT3 protein]; Glucosamine inhibits the reaction [IL1B protein results in decreased expression of B3GAT3 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased abundance of Dinoprostone]; Glucosamine inhibits the reaction [IL1B protein results in increased abundance of Nitric Oxide]; Glucosamine inhibits the reaction [IL1B protein results in increased expression of MMP3 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of ACAN mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of COL11A1 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of COL2A1 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of COL3A1 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of FGFR1 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of HAPLN1 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of LAMA4 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of SDC2 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of SOX4 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of THBS4 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of TIMP2 mRNA]; Glucosamine inhibits the reaction [IL1B results in decreased expression of TIMP3 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of ADAM17 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of ADAMTS1 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of ASS1 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of BGN mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of BMP2 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of BMP6 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of BMP7 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CCL2 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CCL20 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CCL22 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CCL3 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CCL5 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CCL7 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of COL8A1 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CSF1 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CSF2 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CSF3 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL1 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL10 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL11 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL2 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL3 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of CXCL5 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of DUSP5 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of DUSP7 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of EPAS1 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of FGF9 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of GREM1 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of IGFBP3 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of IGFBP5 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of IKBKG mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of IL11 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of IL13RA1 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of IL1A mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of IL1B mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of IL23R mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of IL6 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of JAK2 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of JUNB mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of MMP10 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of MMP12 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of MMP13 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of MMP3 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of MMP9 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of NFKBIA mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of NFKBIB mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of NGF mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of NOS2 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of PDGFA mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of PLA2G2A mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of PLA2G4A mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of PLA2G5 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of RELB mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of SDC4 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of SLC7A8 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of TIMP1 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of TNFAIP6 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of TNK2 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of VCAN mRNA]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; Glucosamine promotes the reaction [IL1B results in decreased expression of BMP4 mRNA]; Glucosamine promotes the reaction [IL1B results in decreased expression of CXCL12 mRNA]; IL1B affects the reaction [Glucosamine affects the expression of PDGFA mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of ADAM15 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of BGN mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of COL11A1 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of CXCL12 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of DUSP7 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of EPAS1 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of IKBKG mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of JUNB mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of TNFAIP6 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of VCAN mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of ADAM17 mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of IL1A mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of JAK2 mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of LAMA4 mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of MMP9 mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of NFKBIB mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of TIMP3 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of ADAMTS1 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of COL8A1 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of CSF1 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of CXCL1 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of FGF7 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of GREM1 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of NFKBIA mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of PLA2G2A mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of PLA2G5 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of SDC4 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of SLC7A8 mRNA]; IL1B inhibits the reaction [Glucosamine results in increased expression of IGFBP3 mRNA]; IL1B promotes the reaction [Glucosamine results in decreased expression of HAPLN1 mRNA]; IL1B promotes the reaction [Glucosamine results in decreased expression of SDC2 mRNA]; IL1B promotes the reaction [Glucosamine results in decreased expression of THBS4 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of AZIN1 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of CCL2 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of CCL20 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of CCL7 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of CXCL2 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of CXCL3 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of MMP10 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of MMP12 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of MMP13 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of MMP2 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of MMP3 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of NOS2 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of TIMP1 mRNA] Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of IL1B protein]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA] |
CTD |
PMID:11229466 PMID:11801247 PMID:12681956 PMID:15144122 PMID:16822504 PMID:17109745 PMID:17238806 PMID:17337215 PMID:17605605 PMID:17925024 PMID:18026701 PMID:18077487 PMID:18080321 PMID:18321735 PMID:18340449 PMID:18786831 PMID:19626664 PMID:19656660 PMID:20737476 PMID:21219853 PMID:22089456 More...
|
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il1r2 |
interleukin 1 receptor type 2 |
multiple interactions |
EXP |
[IL1B protein co-treated with Glucosamine] results in increased expression of IL1R2 mRNA |
CTD |
PMID:11801247 |
|
NCBI chr 9:42,384,280...42,424,726
Ensembl chr 9:42,384,433...42,424,725
|
|
G |
Il2 |
interleukin 2 |
decreases secretion |
ISO |
Glucosamine results in decreased secretion of IL2 protein |
CTD |
PMID:14507305 |
|
NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
|
|
G |
Il23r |
interleukin 23 receptor |
multiple interactions |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of IL23R mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 4:96,580,568...96,672,540
Ensembl chr 4:96,580,714...96,674,021
|
|
G |
Il33 |
interleukin 33 |
decreases expression |
EXP |
Glucosamine results in decreased expression of IL33 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 1:227,701,964...227,736,374
Ensembl chr 1:227,721,435...227,736,373
|
|
G |
Il4 |
interleukin 4 |
decreases secretion decreases expression |
ISO |
Glucosamine results in decreased secretion of IL4 protein Glucosamine results in decreased expression of IL4 |
CTD |
PMID:14507305 PMID:21284687 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il5 |
interleukin 5 |
decreases secretion decreases expression |
ISO |
Glucosamine results in decreased secretion of IL5 protein Glucosamine results in decreased expression of IL5 |
CTD |
PMID:14507305 PMID:21284687 |
|
NCBI chr10:37,874,342...37,877,213
Ensembl chr10:37,874,342...37,877,213
|
|
G |
Il6 |
interleukin 6 |
multiple interactions decreases expression |
ISO EXP |
Glucosamine analog inhibits the reaction [TNF results in increased expression of IL6 mRNA]; Glucosamine inhibits the reaction [[IL6 co-treated with TNF] results in increased expression of ICAM1 protein]; Glucosamine inhibits the reaction [IL6 results in increased expression of ICAM1 protein]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of IL6 protein]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of IL6 mRNA] Glucosamine inhibits the reaction [IL1B results in increased expression of IL6 mRNA]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein] Glucosamine analog results in decreased expression of IL6 mRNA; Glucosamine results in decreased expression of IL6 mRNA Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of IL6 protein]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA] |
CTD |
PMID:16822504 PMID:17109745 PMID:18786831 PMID:19098112 PMID:20093129 PMID:20113495 PMID:20307528 PMID:20737476 More...
|
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Inpp5k |
inositol polyphosphate-5-phosphatase K |
multiple interactions increases expression |
ISO |
NUS1 protein inhibits the reaction [Glucosamine results in increased expression of INPP5K mRNA] |
CTD |
PMID:33812996 |
|
NCBI chr10:60,474,262...60,495,813
Ensembl chr10:60,475,897...60,496,773
|
|
G |
Ins1 |
insulin 1 |
multiple interactions |
EXP ISO |
4-phenylbutyric acid inhibits the reaction [Glucosamine inhibits the reaction [INS1 results in increased uptake of Deoxyglucose]]; [Glucosamine co-treated with INS1 protein] affects the localization of GFPT1 protein; Glucosamine inhibits the reaction [Glucose results in increased secretion of INS1 protein]; Glucosamine inhibits the reaction [INS1 protein results in increased uptake of Deoxyglucose]; Glucosamine inhibits the reaction [INS1 results in increased uptake of Deoxyglucose]; ursodoxicoltaurine inhibits the reaction [Glucosamine inhibits the reaction [INS1 results in increased uptake of Deoxyglucose]] [INS1 protein co-treated with Glucosamine] results in increased expression of OSTN mRNA; Glucosamine inhibits the reaction [INS1 protein results in increased phosphorylation of AKT1 protein]; Glucosamine inhibits the reaction [INS1 protein results in increased uptake of 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose]; INS1 inhibits the reaction [[Streptozocin co-treated with APOE mutant form] results in increased abundance of Glucosamine]; OSTN protein affects the reaction [Glucosamine inhibits the reaction [INS1 protein results in increased phosphorylation of AKT1 protein]]; OSTN protein affects the reaction [Glucosamine inhibits the reaction [INS1 protein results in increased uptake of 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose]] |
CTD |
PMID:9453242 PMID:11893929 PMID:16380481 PMID:20165829 PMID:30602124 |
|
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Ins2 |
insulin 2 |
multiple interactions |
ISO |
4-phenylbutyric acid inhibits the reaction [Glucosamine inhibits the reaction [INS results in increased uptake of Deoxyglucose]]; Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]; Glucosamine inhibits the reaction [INS results in increased uptake of Deoxyglucose]; NUS1 protein inhibits the reaction [Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]]; PRKAA1 protein promotes the reaction [Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]]; PRKAA1 protein promotes the reaction [NUS1 protein inhibits the reaction [Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]]]; ursodoxicoltaurine inhibits the reaction [Glucosamine inhibits the reaction [INS results in increased uptake of Deoxyglucose]] |
CTD |
PMID:20165829 PMID:33812996 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Irf1 |
interferon regulatory factor 1 |
multiple interactions |
ISO |
Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of IRF1 mRNA] |
CTD |
PMID:20737476 |
|
NCBI chr10:37,917,155...37,924,166
Ensembl chr10:37,916,670...37,924,166
|
|
G |
Isyna1 |
inositol-3-phosphate synthase 1 |
increases expression |
EXP |
Glucosamine results in increased expression of ISYNA1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr16:18,839,143...18,841,979
Ensembl chr16:18,839,145...18,841,979
|
|
G |
Jak2 |
Janus kinase 2 |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of JAK2 mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of JAK2 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 1:226,995,334...227,054,381
Ensembl chr 1:226,995,334...227,054,189
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
Glucosamine inhibits the reaction [IL1B protein results in increased activity of JUN protein] Glucosamine analog inhibits the reaction [Buthionine Sulfoximine results in increased expression of JUN mRNA] |
CTD |
PMID:17925024 PMID:21825963 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Junb |
JunB proto-oncogene, AP-1 transcription factor subunit |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of JUNB mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of JUNB mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr19:23,176,265...23,178,049
Ensembl chr19:23,176,294...23,178,035
|
|
G |
Jund |
JunD proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
Glucosamine inhibits the reaction [IL1B protein results in increased activity of JUND protein] |
CTD |
PMID:17925024 |
|
NCBI chr16:18,734,121...18,735,799
Ensembl chr16:18,734,122...18,735,799
|
|
G |
Kcnj16 |
potassium inwardly-rectifying channel, subfamily J, member 16 |
increases expression |
ISO |
Glucosamine results in increased expression of KCNJ16 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr10:95,990,009...96,021,356
Ensembl chr10:95,960,725...96,021,702
|
|
G |
Kif11 |
kinesin family member 11 |
decreases expression |
EXP |
Glucosamine results in decreased expression of KIF11 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 1:235,124,371...235,176,760
Ensembl chr 1:235,124,316...235,176,766
|
|
G |
Kif4a |
kinesin family member 4A |
decreases expression |
EXP |
Glucosamine results in decreased expression of KIF4A mRNA |
CTD |
PMID:17109745 |
|
NCBI chr X:65,721,746...65,824,277
Ensembl chr X:65,721,779...65,824,139
|
|
G |
Klf10 |
KLF transcription factor 10 |
increases expression |
ISO |
Glucosamine results in increased expression of KLF10 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 7:69,467,658...69,473,726
Ensembl chr 7:69,465,619...69,473,994
|
|
G |
Lama4 |
laminin subunit alpha 4 |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in decreased expression of LAMA4 mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of LAMA4 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr20:42,392,268...42,533,347
Ensembl chr20:42,392,268...42,533,347
|
|
G |
Lamb1 |
laminin subunit beta 1 |
multiple interactions |
ISO |
TXNIP promotes the reaction [Glucosamine results in increased expression of LAMB1 mRNA] |
CTD |
PMID:17178593 |
|
NCBI chr 6:47,835,492...47,902,585
Ensembl chr 6:47,835,525...47,902,585
|
|
G |
Lamc1 |
laminin subunit gamma 1 |
multiple interactions |
ISO |
TXNIP promotes the reaction [Glucosamine results in increased expression of LAMC1 mRNA] |
CTD |
PMID:17178593 |
|
NCBI chr13:65,374,372...65,501,492
Ensembl chr13:65,374,372...65,501,492
|
|
G |
Lcn2 |
lipocalin 2 |
decreases expression |
ISO |
Glucosamine results in decreased expression of LCN2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 3:15,680,688...15,684,033
Ensembl chr 3:15,680,687...15,684,095
|
|
G |
Lepr |
leptin receptor |
multiple interactions affects response to substance |
EXP |
[LEPR protein affects the susceptibility to Glucosamine] which affects the expression of ALB protein |
CTD |
PMID:33345901 |
|
NCBI chr 5:116,294,409...116,477,904
Ensembl chr 5:116,289,823...116,475,908
|
|
G |
Lpin1 |
lipin 1 |
increases expression |
ISO |
Glucosamine results in increased expression of LPIN1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 6:39,309,198...39,417,034
Ensembl chr 6:39,312,748...39,417,097
|
|
G |
Ly6a |
lymphocyte antigen 6 family member A |
increases expression |
ISO |
Glucosamine results in increased expression of LY6A mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 7:107,177,191...107,189,436
Ensembl chr 7:107,183,469...107,189,981
|
|
G |
Mafb |
MAF bZIP transcription factor B |
increases expression |
EXP |
Glucosamine results in increased expression of MAFB mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 3:148,998,111...149,000,031
Ensembl chr 3:148,998,122...149,000,031
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation |
ISO |
Glucosamine analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MAPK1 protein]; Glucosamine analog promotes the reaction [IL1B results in increased phosphorylation of MAPK1 protein]; Glucosamine inhibits the reaction [IL1B results in increased phosphorylation of MAPK1 protein]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK1 protein] Glucosamine analog results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:18080321 PMID:18340449 PMID:19375915 PMID:19626664 PMID:20307528 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
multiple interactions |
ISO |
Glucosamine inhibits the reaction [IL1B results in increased phosphorylation of MAPK14 protein] |
CTD |
PMID:19626664 |
|
NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
ISO |
Glucosamine analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MAPK3 protein]; Glucosamine analog promotes the reaction [IL1B results in increased phosphorylation of MAPK3 protein]; Glucosamine inhibits the reaction [IL1B results in increased phosphorylation of MAPK3 protein]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK3 protein] Glucosamine analog results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:18080321 PMID:18340449 PMID:19375915 PMID:19626664 PMID:20307528 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions increases phosphorylation |
ISO |
Glucosamine analog promotes the reaction [IL1B results in increased phosphorylation of MAPK8 protein]; Glucosamine inhibits the reaction [IL1B results in increased phosphorylation of MAPK8 protein]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK8 protein] Glucosamine analog results in increased phosphorylation of MAPK8 protein |
CTD |
PMID:18080321 PMID:19626664 PMID:20307528 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mcl1 |
MCL1 apoptosis regulator, BCL2 family member |
decreases expression |
ISO |
Glucosamine results in decreased expression of MCL1 mRNA; Glucosamine results in decreased expression of MCL1 protein |
CTD |
PMID:22020377 |
|
NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303
|
|
G |
Mef2a |
myocyte enhancer factor 2a |
multiple interactions decreases expression |
ISO EXP |
4-phenylbutyric acid inhibits the reaction [Glucosamine results in decreased expression of MEF2A mRNA]; 4-phenylbutyric acid inhibits the reaction [Glucosamine results in decreased expression of MEF2A protein]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of MEF2A mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of MEF2A protein]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in decreased expression of MEF2A mRNA]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in decreased expression of MEF2A protein] Glucosamine results in decreased expression of MEF2A mRNA; Glucosamine results in decreased expression of MEF2A protein |
CTD |
PMID:20165829 |
|
NCBI chr 1:120,847,874...120,982,488
Ensembl chr 1:120,850,080...120,981,948
|
|
G |
Mettl1 |
methyltransferase 1, tRNA methylguanosine |
decreases expression |
ISO |
Glucosamine results in decreased expression of METTL1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 7:62,864,860...62,869,202
Ensembl chr 7:62,864,853...62,869,202
|
|
G |
Mfap3l |
microfibril associated protein 3 like |
increases expression |
ISO |
Glucosamine results in increased expression of MFAP3L mRNA |
CTD |
PMID:17178593 |
|
NCBI chr16:29,411,643...29,454,665
Ensembl chr16:29,415,849...29,430,863
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
decreases expression |
EXP |
Glucosamine results in decreased expression of MKI67 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762
|
|
G |
Mmp1 |
matrix metallopeptidase 1 |
multiple interactions |
ISO |
Glucosamine analog inhibits the reaction [IL1B protein results in increased expression of MMP1]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of and results in increased secretion of MMP1 protein]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of MMP1 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased expression of MMP1 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased secretion of MMP1 protein] |
CTD |
PMID:15144122 PMID:17925024 PMID:18080321 |
|
NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097
|
|
G |
Mmp10 |
matrix metallopeptidase 10 |
increases expression multiple interactions |
EXP |
Glucosamine results in increased expression of MMP10 mRNA Glucosamine inhibits the reaction [IL1B results in increased expression of MMP10 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of MMP10 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 8:4,689,840...4,697,748
Ensembl chr 8:4,689,840...4,697,748
|
|
G |
Mmp12 |
matrix metallopeptidase 12 |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of MMP12 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of MMP12 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 8:4,581,785...4,591,687
Ensembl chr 8:4,581,785...4,599,611
|
|
G |
Mmp13 |
matrix metallopeptidase 13 |
affects expression multiple interactions increases expression |
ISO EXP |
Glucosamine analog affects the expression of MMP13 mRNA Glucosamine inhibits the reaction [IL1B results in increased expression of MMP13 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of MMP13 mRNA] Glucosamine analog inhibits the reaction [IL1B protein results in increased expression of MMP13]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of and results in increased secretion of MMP13 protein]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of MMP13 mRNA]; Glucosamine analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP13 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased expression of MMP13 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased secretion of MMP13 protein] |
CTD |
PMID:15144122 PMID:17109745 PMID:17337215 PMID:17925024 PMID:18080321 PMID:19656660 More...
|
|
NCBI chr 8:4,497,960...4,508,239
Ensembl chr 8:4,497,960...4,508,239
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions increases expression |
ISO EXP |
Glucosamine analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of and results in increased activity of MMP2 protein]; Glucosamine analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP2 mRNA]; Glucosamine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP2 mRNA]; Glucosamine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP2 protein] IL1B promotes the reaction [Glucosamine results in increased expression of MMP2 mRNA] |
CTD |
PMID:17109745 PMID:17498959 PMID:19375915 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp3 |
matrix metallopeptidase 3 |
multiple interactions increases expression decreases expression |
ISO EXP |
[Glucosamine co-treated with Chondroitin Sulfates] results in decreased expression of MMP3 mRNA; [Glucosamine co-treated with Chondroitin Sulfates] results in decreased secretion of MMP3 protein; Glucosamine analog inhibits the reaction [IL1B protein results in increased expression of MMP3]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of and results in increased secretion of MMP3 protein]; Glucosamine analog inhibits the reaction [IL1B results in increased expression of MMP3 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased expression of MMP3 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased secretion of MMP3 protein]; Glucosamine inhibits the reaction [IL1B results in increased expression of MMP3 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of MMP3 protein]; Glucosamine results in decreased expression of and results in decreased activity of MMP3 protein Glucosamine results in increased expression of MMP3 mRNA Glucosamine inhibits the reaction [IL1B protein results in increased expression of MMP3 mRNA]; Glucosamine inhibits the reaction [IL1B results in increased expression of MMP3 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of MMP3 mRNA] Glucosamine analog results in decreased expression of MMP3 mRNA |
CTD |
PMID:11229466 PMID:12801482 PMID:15144122 PMID:16300972 PMID:17109745 PMID:17925024 PMID:18080321 PMID:18340449 PMID:20110869 More...
|
|
NCBI chr 8:4,640,397...4,653,963
Ensembl chr 8:4,640,416...4,653,961
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions increases expression |
ISO EXP |
Glucosamine analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of and results in increased activity of MMP9 protein]; Glucosamine analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP9 mRNA]; Glucosamine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP9 mRNA]; Glucosamine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP9 protein] Glucosamine results in increased expression of MMP9 mRNA Glucosamine inhibits the reaction [IL1B results in increased expression of MMP9 mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of MMP9 mRNA] |
CTD |
PMID:17109745 PMID:17498959 PMID:19375915 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mnda |
myeloid cell nuclear differentiation antigen |
increases expression |
ISO |
Glucosamine results in increased expression of IFI204 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr13:86,017,888...86,035,556
Ensembl chr13:86,017,892...86,034,201
|
|
G |
Mpo |
myeloperoxidase |
decreases activity |
EXP |
Glucosamine results in decreased activity of MPO protein |
CTD |
PMID:19098112 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Mvd |
mevalonate diphosphate decarboxylase |
increases expression |
ISO |
Glucosamine results in increased expression of MVD mRNA |
CTD |
PMID:17178593 |
|
NCBI chr19:50,496,366...50,506,429
Ensembl chr19:50,496,367...50,507,971
|
|
G |
Ndufa4 |
Ndufa4, mitochondrial complex associated |
increases expression |
EXP |
Glucosamine results in increased expression of NDUFA4 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 4:40,002,216...40,009,384
Ensembl chr 4:40,002,216...40,023,920
|
|
G |
Nedd4 |
NEDD4 E3 ubiquitin protein ligase |
decreases expression |
EXP |
Glucosamine results in decreased expression of NEDD4 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 8:73,384,095...73,468,951
Ensembl chr 8:73,383,695...73,468,951
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions decreases activity |
ISO EXP |
Glucosamine inhibits the reaction [Hydrogen Peroxide results in increased expression of and results in increased localization of NFKB1 protein]; Glucosamine inhibits the reaction [IL1B protein results in increased localization of NFKB1 protein]; Glucosamine inhibits the reaction [IL1B results in increased degradation of NFKB1 protein]; Glucosamine inhibits the reaction [NFKB1 results in increased degradation of RELA protein]; Glucosamine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of NFKB1 protein] Glucosamine results in decreased activity of NFKB1 protein Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of NFKB1 protein] |
CTD |
PMID:12681956 PMID:16431966 PMID:16822504 PMID:17498959 PMID:18036590 PMID:18205790 PMID:20737476 More...
|
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions decreases phosphorylation decreases expression |
ISO EXP |
Glucosamine analog inhibits the reaction [IL1B results in increased phosphorylation of and results in increased degradation of NFKBIA protein]; Glucosamine inhibits the reaction [IL1B protein results in increased degradation of NFKBIA protein] Glucosamine results in decreased phosphorylation of NFKBIA protein Glucosamine results in decreased expression of NFKBIA mRNA Glucosamine inhibits the reaction [IL1B results in increased expression of NFKBIA mRNA]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein]; IL1B inhibits the reaction [Glucosamine results in decreased expression of NFKBIA mRNA] Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of NFKBIA protein modified form]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:12681956 PMID:17109745 PMID:18080321 PMID:18205790 PMID:19098112 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nfkbib |
NFKB inhibitor beta |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of NFKBIB mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of NFKBIB mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 1:84,046,292...84,053,862
Ensembl chr 1:84,046,295...84,053,862
|
|
G |
Ngef |
neuronal guanine nucleotide exchange factor |
increases expression |
ISO |
Glucosamine results in increased expression of NGEF mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 9:88,146,956...88,244,454
Ensembl chr 9:88,146,956...88,244,914
|
|
G |
Ngf |
nerve growth factor |
multiple interactions |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of NGF mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions increases expression decreases expression |
ISO EXP |
[Glucosamine co-treated with Chondroitin Sulfates co-treated with IL1B protein] results in decreased expression of NOS2 protein; Glucosamine inhibits the reaction [IL1B results in increased expression of NOS2 mRNA] Glucosamine results in increased expression of NOS2 mRNA Glucosamine inhibits the reaction [IL1B results in increased expression of NOS2 mRNA]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of NOS2 mRNA] Glucosamine results in decreased expression of NOS2 mRNA Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]; Glucosamine inhibits the reaction [Lipopolysaccharides promotes the reaction [RELA protein binds to NOS2 promoter]]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] |
CTD |
PMID:17109745 PMID:17440993 PMID:17605605 PMID:18077487 PMID:18205790 PMID:19098112 PMID:20737476 More...
|
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
affects expression |
EXP |
Glucosamine affects the expression of NR1H4 |
CTD |
PMID:19373748 |
|
NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
|
|
G |
Nsdhl |
NAD(P) dependent steroid dehydrogenase-like |
increases expression |
ISO |
Glucosamine results in increased expression of NSDHL mRNA |
CTD |
PMID:17178593 |
|
NCBI chr X:150,775,034...150,807,161
Ensembl chr X:150,775,080...150,807,142
|
|
G |
Nucb2 |
nucleobindin 2 |
decreases expression |
ISO |
Glucosamine results in decreased expression of NUCB2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 1:170,750,830...170,787,356
Ensembl chr 1:170,750,877...170,787,353
|
|
G |
Nuf2 |
NUF2 component of NDC80 kinetochore complex |
decreases expression |
EXP |
Glucosamine results in decreased expression of NUF2 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr13:81,693,675...81,722,765
Ensembl chr13:81,693,598...81,722,766
|
|
G |
Nus1 |
NUS1 dehydrodolichyl diphosphate synthase subunit |
multiple interactions |
ISO |
NUS1 protein inhibits the reaction [Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]]; NUS1 protein inhibits the reaction [Glucosamine results in increased expression of ATF4 mRNA]; NUS1 protein inhibits the reaction [Glucosamine results in increased expression of ATF6 mRNA]; NUS1 protein inhibits the reaction [Glucosamine results in increased expression of DDIT3 mRNA]; NUS1 protein inhibits the reaction [Glucosamine results in increased expression of EIF2AK3 protein]; NUS1 protein inhibits the reaction [Glucosamine results in increased expression of ERN1 mRNA]; NUS1 protein inhibits the reaction [Glucosamine results in increased expression of HSPA5 mRNA]; NUS1 protein inhibits the reaction [Glucosamine results in increased expression of HSPA5 protein]; NUS1 protein inhibits the reaction [Glucosamine results in increased expression of INPP5K mRNA]; NUS1 protein inhibits the reaction [Glucosamine results in increased phosphorylation of EIF2S1 protein]; NUS1 protein inhibits the reaction [Glucosamine results in increased splicing of XBP1 mRNA]; PRKAA1 protein promotes the reaction [NUS1 protein inhibits the reaction [Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]]] |
CTD |
PMID:33812996 |
|
NCBI chr20:31,811,817...31,838,562
Ensembl chr20:31,811,817...31,838,561
|
|
G |
Oat |
ornithine aminotransferase |
multiple interactions |
EXP |
Glucosamine affects the reaction [IL1B results in decreased expression of OAT mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 1:187,347,862...187,367,644
Ensembl chr 1:187,347,865...187,367,682
|
|
G |
Ogt |
O-linked N-acetylglucosamine (GlcNAc) transferase |
decreases expression |
ISO |
Glucosamine results in decreased expression of OGT mRNA |
CTD |
PMID:17178593 |
|
NCBI chr X:66,771,278...66,816,148
Ensembl chr X:66,771,349...66,816,146
|
|
G |
Orc2 |
origin recognition complex, subunit 2 |
decreases expression |
ISO |
Glucosamine results in decreased expression of ORC2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 9:60,001,631...60,038,301
Ensembl chr 9:60,001,910...60,038,195
|
|
G |
Osm |
oncostatin M |
multiple interactions |
ISO |
Glucosamine inhibits the reaction [[OSM protein co-treated with IL1B protein] results in decreased methylation of IL1B promoter]; Glucosamine inhibits the reaction [[OSM protein co-treated with IL1B protein] results in increased expression of IL1B mRNA] |
CTD |
PMID:21219853 |
|
NCBI chr14:79,103,638...79,108,500
Ensembl chr14:79,104,344...79,108,313
|
|
G |
Ostn |
osteocrin |
increases expression multiple interactions |
ISO |
Glucosamine results in increased expression of OSTN mRNA 4-methylumbelliferone 8-carbaldehyde inhibits the reaction [Glucosamine results in increased expression of OSTN mRNA]; 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of OSTN mRNA]; [INS1 protein co-treated with Glucosamine] results in increased expression of OSTN mRNA; ATF6 protein affects the reaction [Glucosamine results in increased expression of OSTN mRNA]; EIF2AK3 protein affects the reaction [Glucosamine results in increased expression of OSTN mRNA]; ERN1 protein affects the reaction [Glucosamine results in increased expression of OSTN mRNA]; GSK2656157 inhibits the reaction [Glucosamine results in increased expression of OSTN mRNA]; OSTN protein affects the reaction [Glucosamine inhibits the reaction [INS1 protein results in increased phosphorylation of AKT1 protein]]; OSTN protein affects the reaction [Glucosamine inhibits the reaction [INS1 protein results in increased uptake of 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose]] |
CTD |
PMID:30602124 |
|
NCBI chr11:73,442,167...73,478,498
Ensembl chr11:73,442,487...73,468,603
|
|
G |
Oxr1 |
oxidation resistance 1 |
decreases expression |
ISO |
Glucosamine results in decreased expression of OXR1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 7:72,528,750...72,965,666
Ensembl chr 7:72,528,786...72,965,666
|
|
G |
Pank1 |
pantothenate kinase 1 |
increases expression |
ISO |
Glucosamine results in increased expression of PANK1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 1:232,324,718...232,395,445
Ensembl chr 1:232,328,430...232,396,829
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage multiple interactions |
ISO |
Glucosamine results in increased cleavage of PARP1 protein pepstatin inhibits the reaction [Glucosamine results in increased cleavage of PARP1 protein] |
CTD |
PMID:16850161 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pdgfa |
platelet derived growth factor subunit A |
affects expression multiple interactions |
EXP |
Glucosamine affects the expression of PDGFA mRNA Glucosamine inhibits the reaction [IL1B results in increased expression of PDGFA mRNA]; IL1B affects the reaction [Glucosamine affects the expression of PDGFA mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr12:15,645,549...15,667,056
Ensembl chr12:15,645,541...15,666,497
|
|
G |
Pdia4 |
protein disulfide isomerase family A, member 4 |
decreases expression |
ISO |
Glucosamine results in decreased expression of PDIA4 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 4:76,803,198...76,822,245
Ensembl chr 4:76,803,198...76,822,107
|
|
G |
Pdia6 |
protein disulfide isomerase family A, member 6 |
decreases expression |
ISO |
Glucosamine results in decreased expression of PDIA6 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 6:40,062,980...40,080,223
Ensembl chr 6:40,062,926...40,080,613
|
|
G |
Pdk4 |
pyruvate dehydrogenase kinase 4 |
increases expression |
ISO |
Glucosamine results in increased expression of PDK4 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 4:33,591,796...33,601,798
Ensembl chr 4:33,589,799...33,601,850
|
|
G |
Pfkp |
phosphofructokinase, platelet |
increases expression |
ISO |
Glucosamine results in increased expression of PFKP mRNA |
CTD |
PMID:17178593 |
|
NCBI chr17:63,729,743...63,794,026
Ensembl chr17:63,729,780...63,794,018
|
|
G |
Piga |
phosphatidylinositol glycan anchor biosynthesis, class A |
decreases expression |
ISO |
Glucosamine results in decreased expression of PIGA mRNA |
CTD |
PMID:17178593 |
|
NCBI chr X:30,043,033...30,055,861
Ensembl chr X:30,042,343...30,055,804
|
|
G |
Pla2g2a |
phospholipase A2 group IIA |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of PLA2G2A mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of PLA2G2A mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 5:151,076,442...151,079,019
Ensembl chr 5:151,076,442...151,079,014
|
|
G |
Pla2g4a |
phospholipase A2 group IVA |
affects expression multiple interactions |
EXP |
Glucosamine affects the expression of PLA2G4A mRNA Glucosamine inhibits the reaction [IL1B results in increased expression of PLA2G4A mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr13:61,877,818...62,022,261
Ensembl chr13:61,877,813...62,022,266
|
|
G |
Pla2g5 |
phospholipase A2, group V |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of PLA2G5 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of PLA2G5 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 5:151,041,339...151,109,433
Ensembl chr 5:151,041,340...151,062,658
|
|
G |
Plat |
plasminogen activator, tissue type |
increases expression |
ISO |
Glucosamine results in increased expression of PLAT mRNA |
CTD |
PMID:17178593 |
|
NCBI chr16:69,240,582...69,265,177
Ensembl chr16:69,240,585...69,268,223
|
|
G |
Plk1 |
polo-like kinase 1 |
increases expression decreases expression |
ISO EXP |
Glucosamine results in increased expression of PLK1 mRNA Glucosamine results in decreased expression of PLK1 mRNA |
CTD |
PMID:17109745 PMID:17178593 |
|
NCBI chr 1:176,716,420...176,726,400
Ensembl chr 1:176,716,420...176,726,400
|
|
G |
Plpp3 |
phospholipid phosphatase 3 |
decreases expression |
EXP |
Glucosamine results in decreased expression of PLPP3 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 5:119,927,085...120,002,206
Ensembl chr 5:119,927,085...120,002,205
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions increases expression |
ISO EXP |
Glucosamine promotes the reaction [IL1B results in increased expression of PPARG] Glucosamine results in increased expression of PPARG mRNA |
CTD |
PMID:15694357 PMID:22089456 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
multiple interactions decreases expression |
ISO EXP |
4-phenylbutyric acid inhibits the reaction [Glucosamine results in decreased expression of PPARGC1A mRNA]; 4-phenylbutyric acid inhibits the reaction [Glucosamine results in decreased expression of PPARGC1A protein]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of PPARGC1A mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of PPARGC1A protein]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in decreased expression of PPARGC1A mRNA]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in decreased expression of PPARGC1A protein] Glucosamine results in decreased expression of PPARGC1A mRNA; Glucosamine results in decreased expression of PPARGC1A protein |
CTD |
PMID:20165829 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Ppm1a |
protein phosphatase, Mg2+/Mn2+ dependent, 1A |
decreases expression |
ISO |
Glucosamine results in decreased expression of PPM1A mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 6:91,439,094...91,486,139
Ensembl chr 6:91,438,834...91,480,697
|
|
G |
Ppp1r15a |
protein phosphatase 1, regulatory subunit 15A |
decreases expression |
ISO |
Glucosamine results in decreased expression of PPP1R15A mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 1:96,000,053...96,003,128
Ensembl chr 1:96,000,058...96,003,171
|
|
G |
Prc1 |
protein regulator of cytokinesis 1 |
decreases expression |
EXP |
Glucosamine results in decreased expression of PRC1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 1:134,250,086...134,271,765
Ensembl chr 1:134,250,081...134,271,765
|
|
G |
Prkaa1 |
protein kinase AMP-activated catalytic subunit alpha 1 |
multiple interactions |
ISO |
PRKAA1 protein promotes the reaction [Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]]; PRKAA1 protein promotes the reaction [NUS1 protein inhibits the reaction [Glucosamine inhibits the reaction [INS protein results in increased phosphorylation of GSK3B protein]]] |
CTD |
PMID:33812996 |
|
NCBI chr 2:54,240,298...54,275,978
Ensembl chr 2:54,240,137...54,275,978
|
|
G |
Psme3 |
proteasome activator subunit 3 |
decreases expression |
ISO |
Glucosamine results in decreased expression of PSME3 |
CTD |
PMID:21697645 |
|
NCBI chr10:86,257,672...86,265,458
Ensembl chr10:86,257,668...86,333,804
|
|
G |
Ptges |
prostaglandin E synthase |
multiple interactions |
ISO |
[Glucosamine co-treated with Chondroitin Sulfates co-treated with IL1B protein] results in decreased expression of PTGES protein; Glucosamine inhibits the reaction [IL1B results in increased expression of PTGES mRNA] |
CTD |
PMID:17605605 PMID:22089456 |
|
NCBI chr 3:14,177,892...14,189,236
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression decreases expression multiple interactions decreases glycosylation |
ISO EXP |
Glucosamine analog results in increased expression of PTGS2 protein alternative form Glucosamine results in decreased expression of PTGS2 mRNA Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA] Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]; Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]; Glucosamine inhibits the reaction [[Lipopolysaccharides results in increased expression of PTGS2 protein] which results in increased secretion of Dinoprostone]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein] Glucosamine results in decreased glycosylation of PTGS2 protein [Glucosamine co-treated with Chondroitin Sulfates co-treated with IL1B protein] results in decreased expression of PTGS2 protein; Glucosamine inhibits the reaction [IL1B protein results in increased expression of PTGS2 mRNA]; Glucosamine inhibits the reaction [IL1B protein results in increased expression of PTGS2 protein] |
CTD |
PMID:12681956 PMID:17440993 PMID:17605605 PMID:18205790 PMID:19656660 PMID:20737476 PMID:22089456 More...
|
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Pttg1 |
PTTG1 regulator of sister chromatid separation, securin |
decreases expression |
EXP |
Glucosamine results in decreased expression of PTTG1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr10:27,893,466...27,904,965
Ensembl chr10:27,893,689...27,904,837
|
|
G |
Rab32 |
RAB32, member RAS oncogene family |
increases expression |
ISO |
Glucosamine results in increased expression of RAB32 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 1:4,946,193...4,961,003
Ensembl chr 1:4,945,036...4,960,934
|
|
G |
Racgap1 |
Rac GTPase-activating protein 1 |
decreases expression |
EXP |
Glucosamine results in decreased expression of RACGAP1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 7:130,750,936...130,780,891
Ensembl chr 7:130,750,936...130,780,831
|
|
G |
Rbm39 |
RNA binding motif protein 39 |
decreases expression |
ISO |
Glucosamine results in decreased expression of RBM39 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 3:144,662,998...144,696,222
Ensembl chr 3:144,663,001...144,696,213
|
|
G |
Recql4 |
RecQ like helicase 4 |
increases expression |
ISO |
Glucosamine results in increased expression of RECQL4 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 7:108,423,453...108,430,790
Ensembl chr 7:108,423,455...108,430,619
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions decreases activity increases localization |
ISO EXP |
Alloxan inhibits the reaction [Glucosamine inhibits the reaction [TNF results in increased phosphorylation of RELA protein]]; Glucosamine analog inhibits the reaction [IL1B results in increased localization of RELA protein]; Glucosamine analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of RELA protein]; Glucosamine inhibits the reaction [Hydrogen Peroxide results in increased expression of and results in increased localization of RELA protein]; Glucosamine inhibits the reaction [IL1B protein results in increased localization of RELA protein]; Glucosamine inhibits the reaction [IL1B results in increased localization of RELA protein]; Glucosamine inhibits the reaction [NFKB1 results in increased degradation of RELA protein]; Glucosamine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of RELA protein]; Glucosamine inhibits the reaction [TNF results in increased localization of RELA protein]; Glucosamine inhibits the reaction [TNF results in increased phosphorylation of RELA protein] Glucosamine results in decreased activity of RELA protein Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of RELA protein]; Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased localization of RELA protein]; Glucosamine inhibits the reaction [Lipopolysaccharides promotes the reaction [RELA protein binds to NOS2 promoter]]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of RELA mRNA]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased localization of RELA protein] Glucosamine results in increased localization of RELA protein |
CTD |
PMID:12681956 PMID:16431966 PMID:16822504 PMID:17238806 PMID:17498959 PMID:18036590 PMID:18080321 PMID:18205790 PMID:18340449 PMID:18786831 PMID:19020780 PMID:19375915 PMID:20307528 PMID:20737476 More...
|
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Relb |
RELB proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of RELB mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 1:79,257,738...79,285,490
Ensembl chr 1:79,257,725...79,285,507
|
|
G |
Rhob |
ras homolog family member B |
increases expression |
ISO |
Glucosamine results in increased expression of RHOB mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 6:31,363,752...31,365,926
Ensembl chr 6:31,363,548...31,366,108
|
|
G |
Rhoc |
ras homolog family member C |
decreases expression |
ISO |
Glucosamine analog results in decreased expression of RHOC mRNA |
CTD |
PMID:16142878 |
|
NCBI chr 2:192,287,065...192,293,292
Ensembl chr 2:192,287,130...192,295,306
|
|
G |
Rnd1 |
Rho family GTPase 1 |
multiple interactions decreases expression |
ISO |
Glucosamine analog inhibits the reaction [TNF results in increased expression of RND1 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of RND1 mRNA] Glucosamine results in decreased expression of RND1 mRNA |
CTD |
PMID:17178593 PMID:18173918 |
|
NCBI chr 7:129,821,311...129,828,385
Ensembl chr 7:129,821,311...129,828,399
|
|
G |
Rps6 |
ribosomal protein S6 |
decreases phosphorylation |
ISO |
Glucosamine results in decreased phosphorylation of RPS6 protein |
CTD |
PMID:19254699 |
|
NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602 Ensembl chr 5:101,371,136...101,374,602
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
decreases phosphorylation |
ISO |
Glucosamine results in decreased phosphorylation of RPS6KB1 protein |
CTD |
PMID:19254699 |
|
NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
|
|
G |
Runx2 |
RUNX family transcription factor 2 |
increases phosphorylation increases expression multiple interactions |
ISO |
Glucosamine analog results in increased phosphorylation of RUNX2 protein Glucosamine analog results in increased expression of RUNX2 mRNA 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [Glucosamine analog results in increased phosphorylation of RUNX2 protein] |
CTD |
PMID:20458730 |
|
NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167
|
|
G |
Scd2 |
stearoyl-Coenzyme A desaturase 2 |
increases expression |
ISO |
Glucosamine results in increased expression of SCD2 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 1:243,169,171...243,182,231
Ensembl chr 1:243,169,236...243,182,232
|
|
G |
Sdc2 |
syndecan 2 |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in decreased expression of SDC2 mRNA]; IL1B promotes the reaction [Glucosamine results in decreased expression of SDC2 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 7:64,127,185...64,239,885
Ensembl chr 7:64,127,110...64,241,081
|
|
G |
Sdc4 |
syndecan 4 |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of SDC4 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of SDC4 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 3:153,154,888...153,173,576
Ensembl chr 3:153,154,896...153,173,580
|
|
G |
Selenbp1 |
selenium binding protein 1 |
decreases expression |
EXP |
Glucosamine results in decreased expression of SELENBP1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 2:182,494,004...182,504,594
Ensembl chr 2:182,493,978...182,504,594
|
|
G |
Serpinb2 |
serpin family B member 2 |
increases expression |
EXP |
Glucosamine results in increased expression of SERPINB2 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr13:23,537,312...23,551,823
Ensembl chr13:23,541,400...23,550,408
|
|
G |
Serpinh1 |
serpin family H member 1 |
increases expression |
ISO |
Glucosamine results in increased expression of SERPINH1 protein |
CTD |
PMID:16380481 |
|
NCBI chr 1:153,643,500...153,650,853
Ensembl chr 1:153,643,510...153,650,801
|
|
G |
Sfrp2 |
secreted frizzled-related protein 2 |
decreases expression |
EXP |
Glucosamine results in decreased expression of SFRP2 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 2:169,089,517...169,097,064
Ensembl chr 2:169,089,517...169,097,063
|
|
G |
Sgk1 |
serum/glucocorticoid regulated kinase 1 |
decreases expression |
ISO |
Glucosamine results in decreased expression of SGK1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 1:22,980,257...23,098,122
Ensembl chr 1:22,980,261...23,098,283
|
|
G |
Shcbp1 |
SHC binding and spindle associated 1 |
decreases expression |
EXP |
Glucosamine results in decreased expression of SHCBP1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr16:84,672,277...84,703,843
Ensembl chr16:84,672,321...84,703,844
|
|
G |
Slc17a1 |
solute carrier family 17 member 1 |
increases expression |
ISO |
Glucosamine results in increased expression of SLC17A1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr17:41,219,461...41,255,199
Ensembl chr17:41,222,049...41,253,304
|
|
G |
Slc23a2 |
solute carrier family 23 member 2 |
increases expression |
EXP |
Glucosamine results in increased expression of SLC23A2 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 3:119,302,651...119,395,289
Ensembl chr 3:119,302,666...119,460,343
|
|
G |
Slc2a2 |
solute carrier family 2 member 2 |
decreases expression |
EXP |
Glucosamine results in decreased expression of SLC2A2 mRNA |
CTD |
PMID:11893929 |
|
NCBI chr 2:111,609,798...111,639,930
Ensembl chr 2:111,611,774...111,639,933
|
|
G |
Slc2a4 |
solute carrier family 2 member 4 |
multiple interactions decreases expression increases uptake |
ISO EXP |
4-phenylbutyric acid inhibits the reaction [Glucosamine results in decreased expression of SLC2A4 mRNA]; 4-phenylbutyric acid inhibits the reaction [Glucosamine results in decreased expression of SLC2A4 protein]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of SLC2A4 mRNA]; ATF6 mutant form inhibits the reaction [Glucosamine results in decreased expression of SLC2A4 protein]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in decreased expression of SLC2A4 mRNA]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in decreased expression of SLC2A4 protein] Glucosamine results in decreased expression of SLC2A4 mRNA; Glucosamine results in decreased expression of SLC2A4 protein SLC2A4 protein results in increased uptake of Glucosamine Glucosamine inhibits the reaction [SLC2A4 protein results in increased uptake of Glucose]; Glucose inhibits the reaction [SLC2A4 protein results in increased uptake of Glucosamine] |
CTD |
PMID:19373748 PMID:20165829 |
|
NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565
|
|
G |
Slc2a6 |
solute carrier family 2 member 6 |
decreases expression |
ISO |
Glucosamine results in decreased expression of SLC2A6 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 3:10,348,395...10,355,208
Ensembl chr 3:10,348,395...10,355,208
|
|
G |
Slc37a4 |
solute carrier family 37 member 4 |
increases expression |
ISO |
Glucosamine results in increased expression of SLC37A4 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 8:44,723,216...44,729,301
Ensembl chr 8:44,723,339...44,729,301
|
|
G |
Slc4a4 |
solute carrier family 4 member 4 |
decreases expression |
EXP |
Glucosamine results in decreased expression of SLC4A4 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr14:18,841,289...19,293,297
Ensembl chr14:18,845,159...19,272,883
|
|
G |
Slc7a8 |
solute carrier family 7 member 8 |
increases expression multiple interactions |
EXP |
Glucosamine results in increased expression of SLC7A8 mRNA Glucosamine inhibits the reaction [IL1B results in increased expression of SLC7A8 mRNA]; IL1B inhibits the reaction [Glucosamine results in decreased expression of SLC7A8 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr15:28,183,013...28,242,717
Ensembl chr15:28,183,015...28,242,717
|
|
G |
Smad2 |
SMAD family member 2 |
multiple interactions increases phosphorylation |
ISO |
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [Glucosamine analog results in increased phosphorylation of SMAD2 protein] |
CTD |
PMID:20458730 |
|
NCBI chr18:69,849,884...69,918,926
Ensembl chr18:69,850,377...69,912,323
|
|
G |
Smpd3 |
sphingomyelin phosphodiesterase 3 |
decreases expression |
EXP |
Glucosamine results in decreased expression of SMPD3 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr19:34,162,337...34,245,786
Ensembl chr19:34,162,341...34,245,749
|
|
G |
Sox4 |
SRY-box transcription factor 4 |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in decreased expression of SOX4 mRNA] Glucosamine results in decreased expression of SOX4 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr17:35,667,809...35,672,515
Ensembl chr17:35,667,537...35,673,665
|
|
G |
Srsf3 |
serine and arginine rich splicing factor 3 |
decreases expression |
ISO |
Glucosamine results in decreased expression of SRSF3 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr20:7,091,928...7,101,860
Ensembl chr20:7,091,910...7,101,078
|
|
G |
St6gal1 |
ST6 beta-galactoside alpha-2,6-sialyltransferase 1 |
increases expression |
ISO |
Glucosamine results in increased expression of ST6GAL1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr11:77,526,837...77,653,474
Ensembl chr11:77,526,837...77,653,310
|
|
G |
Stat1 |
signal transducer and activator of transcription 1 |
multiple interactions |
ISO |
Glucosamine inhibits the reaction [IFNG results in increased localization of STAT1 protein modified form]; Glucosamine inhibits the reaction [IFNG results in increased phosphorylation of and results in increased localization of STAT1 protein] |
CTD |
PMID:16431966 PMID:17238806 |
|
NCBI chr 9:49,419,561...49,459,969
Ensembl chr 9:49,419,340...49,588,540
|
|
G |
Tacc3 |
transforming, acidic coiled-coil containing protein 3 |
decreases expression |
EXP |
Glucosamine results in decreased expression of TACC3 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr14:77,051,209...77,065,343
Ensembl chr14:77,051,215...77,065,219
|
|
G |
Testin |
testin gene |
decreases expression |
EXP |
Glucosamine results in decreased expression of TESTIN mRNA |
CTD |
PMID:17109745 |
|
NCBI chr17:3,824,222...3,859,385
Ensembl chr17:3,846,899...3,859,385
|
|
G |
Tgfa |
transforming growth factor alpha |
multiple interactions |
EXP |
[Glucose co-treated with Glucosamine] results in increased expression of TGFA protein; Glucosamine promotes the reaction [Glucose results in increased expression of TGFA mRNA] |
CTD |
PMID:1518840 |
|
NCBI chr 4:118,618,043...118,700,897
Ensembl chr 4:118,618,269...118,700,894
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
increases expression |
EXP |
Glucosamine analog results in increased expression of TGFB1 mRNA |
CTD |
PMID:21466783 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tgfbr1 |
transforming growth factor, beta receptor 1 |
increases expression multiple interactions |
ISO |
Glucosamine analog results in increased expression of TGFBR1 protein 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [Glucosamine analog results in increased expression of TGFBR1 protein] |
CTD |
PMID:20458730 |
|
NCBI chr 5:61,653,773...61,710,777
Ensembl chr 5:61,653,233...61,710,777
|
|
G |
Thbs4 |
thrombospondin 4 |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in decreased expression of THBS4 mRNA]; IL1B promotes the reaction [Glucosamine results in decreased expression of THBS4 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 2:23,983,158...24,025,289
Ensembl chr 2:23,983,158...24,026,313
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
multiple interactions increases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of TIMP1 mRNA]; IL1B promotes the reaction [Glucosamine results in increased expression of TIMP1 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Timp2 |
TIMP metallopeptidase inhibitor 2 |
affects expression multiple interactions |
EXP |
Glucosamine affects the expression of TIMP2 mRNA Glucosamine inhibits the reaction [IL1B results in decreased expression of TIMP2 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr10:103,541,199...103,590,611
Ensembl chr10:103,531,505...103,590,611
|
|
G |
Timp3 |
TIMP metallopeptidase inhibitor 3 |
multiple interactions increases expression |
ISO EXP |
[Glucosamine co-treated with Chondroitin Sulfates co-treated with IL1B protein] results in increased expression of TIMP3 mRNA Glucosamine results in increased expression of TIMP3 mRNA Glucosamine inhibits the reaction [IL1B results in decreased expression of TIMP3 mRNA]; IL1B affects the reaction [Glucosamine results in increased expression of TIMP3 mRNA] |
CTD |
PMID:17109745 PMID:17605605 |
|
NCBI chr 7:17,520,827...17,571,850
Ensembl chr 7:17,521,919...17,571,839
|
|
G |
Tinag |
tubulointerstitial nephritis antigen |
increases expression |
ISO |
Glucosamine results in increased expression of TINAG mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 8:77,800,031...77,885,077
Ensembl chr 8:77,800,032...77,885,077
|
|
G |
Tk1 |
thymidine kinase 1 |
decreases expression |
EXP |
Glucosamine results in decreased expression of TK1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr10:103,034,755...103,046,125
Ensembl chr10:103,031,521...103,046,920
|
|
G |
Tlr1 |
toll-like receptor 1 |
increases expression |
ISO |
Glucosamine results in increased expression of TLR1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr14:43,384,127...43,396,765
Ensembl chr14:43,384,932...43,397,125
|
|
G |
Tnf |
tumor necrosis factor |
decreases secretion multiple interactions decreases expression |
ISO EXP |
Glucosamine results in decreased secretion of TNF protein Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein] Glucosamine analog results in decreased expression of TNF mRNA; Glucosamine results in decreased expression of TNF mRNA Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of TNF protein]; Glucosamine analog inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Glucosamine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA] [Glucosamine co-treated with Chondroitin Sulfates] results in decreased expression of TNF; Alloxan inhibits the reaction [Glucosamine inhibits the reaction [TNF results in increased phosphorylation of RELA protein]]; Glucosamine analog inhibits the reaction [TNF results in increased expression of CUL2 mRNA]; Glucosamine analog inhibits the reaction [TNF results in increased expression of CXCL8 mRNA]; Glucosamine analog inhibits the reaction [TNF results in increased expression of GSPT1 mRNA]; Glucosamine analog inhibits the reaction [TNF results in increased expression of IL6 mRNA]; Glucosamine analog inhibits the reaction [TNF results in increased expression of RND1 mRNA]; Glucosamine analog inhibits the reaction [TNF results in increased expression of TNFRSF1A mRNA]; Glucosamine analog inhibits the reaction [TNF results in increased expression of TNFRSF1B mRNA]; Glucosamine analog inhibits the reaction [TNF results in increased expression of TRAF6 mRNA]; Glucosamine inhibits the reaction [[IL6 co-treated with TNF] results in increased expression of ICAM1 protein]; Glucosamine inhibits the reaction [IFNG promotes the reaction [TNF results in increased expression of ICAM1 protein]]; Glucosamine inhibits the reaction [IL1B promotes the reaction [TNF results in increased expression of ICAM1 protein]]; Glucosamine inhibits the reaction [TNF promotes the reaction [IFNG results in increased expression of ICAM1 protein]]; Glucosamine inhibits the reaction [TNF promotes the reaction [IL1B results in increased expression of ICAM1 protein]]; Glucosamine inhibits the reaction [TNF results in increased expression of CCL2 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of CCL2 protein]; Glucosamine inhibits the reaction [TNF results in increased expression of CUL2 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of CXCL8 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of GSPT1 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of ICAM1 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of ICAM1 protein]; Glucosamine inhibits the reaction [TNF results in increased expression of IL6 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of RND1 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of TNFRSF1A mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of TNFRSF1B mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of TRAF6 mRNA]; Glucosamine inhibits the reaction [TNF results in increased localization of RELA protein]; Glucosamine inhibits the reaction [TNF results in increased phosphorylation of RELA protein] |
CTD |
PMID:14507305 PMID:16431966 PMID:16445576 PMID:16822504 PMID:17238806 PMID:18173918 PMID:18205790 PMID:18786831 PMID:19020780 PMID:19098112 PMID:20093129 PMID:20110869 PMID:20113495 PMID:20737476 More...
|
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfaip6 |
TNF alpha induced protein 6 |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of TNFAIP6 mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of TNFAIP6 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 3:36,502,250...36,521,652
Ensembl chr 3:36,502,188...36,521,649
|
|
G |
Tnfrsf11b |
TNF receptor superfamily member 11B |
multiple interactions |
ISO |
[Chondroitin Sulfates co-treated with Glucosamine co-treated with Cholecalciferol] results in increased expression of TNFRSF11B mRNA; [Chondroitin Sulfates co-treated with Glucosamine co-treated with Cholecalciferol] results in increased expression of TNFRSF11B protein; [Chondroitin Sulfates co-treated with Glucosamine] results in increased expression of TNFRSF11B mRNA; [Chondroitin Sulfates co-treated with Glucosamine] results in increased expression of TNFRSF11B protein |
CTD |
PMID:17996099 |
|
NCBI chr 7:85,566,520...85,594,526
Ensembl chr 7:85,566,520...85,594,538
|
|
G |
Tnfrsf1a |
TNF receptor superfamily member 1A |
multiple interactions |
ISO |
Glucosamine analog inhibits the reaction [TNF results in increased expression of TNFRSF1A mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of TNFRSF1A mRNA] |
CTD |
PMID:18173918 |
|
NCBI chr 4:158,150,815...158,163,592
Ensembl chr 4:158,150,820...158,163,591
|
|
G |
Tnfrsf1b |
TNF receptor superfamily member 1B |
multiple interactions |
ISO |
Glucosamine analog inhibits the reaction [TNF results in increased expression of TNFRSF1B mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of TNFRSF1B mRNA] |
CTD |
PMID:18173918 |
|
NCBI chr 5:157,070,642...157,104,216
Ensembl chr 5:157,070,642...157,104,206
|
|
G |
Tnfsf11 |
TNF superfamily member 11 |
multiple interactions increases expression |
ISO |
[Chondroitin Sulfates co-treated with Glucosamine] inhibits the reaction [Cholecalciferol results in increased expression of TNFSF11 mRNA]; Chondroitin Sulfates inhibits the reaction [Glucosamine results in increased expression of TNFSF11 mRNA] |
CTD |
PMID:17996099 |
|
NCBI chr15:53,673,850...53,705,325
Ensembl chr15:53,673,877...53,705,445
|
|
G |
Tnk2 |
tyrosine kinase, non-receptor, 2 |
multiple interactions |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of TNK2 mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr11:68,114,725...68,154,254
Ensembl chr11:68,114,726...68,154,009
|
|
G |
Top2a |
DNA topoisomerase II alpha |
decreases expression |
EXP |
Glucosamine results in decreased expression of TOP2A mRNA |
CTD |
PMID:17109745 |
|
NCBI chr10:83,945,731...83,976,874
Ensembl chr10:83,945,735...83,976,874
|
|
G |
Traf6 |
TNF receptor associated factor 6 |
multiple interactions |
ISO |
Glucosamine analog inhibits the reaction [TNF results in increased expression of TRAF6 mRNA]; Glucosamine inhibits the reaction [TNF results in increased expression of TRAF6 mRNA] |
CTD |
PMID:18173918 |
|
NCBI chr 3:87,963,517...87,988,316
Ensembl chr 3:87,963,514...87,983,507
|
|
G |
Trpv4 |
transient receptor potential cation channel, subfamily V, member 4 |
increases expression |
ISO |
Glucosamine results in increased expression of TRPV4 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr12:41,938,533...41,977,517
Ensembl chr12:41,938,560...41,977,517
|
|
G |
Txn1 |
thioredoxin 1 |
decreases expression |
EXP ISO |
Glucosamine results in decreased expression of TXN1 protein |
CTD |
PMID:17178593 |
|
NCBI chr 5:72,712,334...72,724,564
Ensembl chr 5:72,711,933...72,724,629
|
|
G |
Txnip |
thioredoxin interacting protein |
increases expression multiple interactions |
EXP ISO |
Glucosamine results in increased expression of TXNIP protein Glucosamine results in increased expression of TXNIP mRNA; Glucosamine results in increased expression of TXNIP protein Glucosamine promotes the reaction [TXNIP results in increased abundance of Reactive Oxygen Species]; TXNIP promotes the reaction [Glucosamine results in increased expression of LAMB1 mRNA]; TXNIP promotes the reaction [Glucosamine results in increased expression of LAMC1 mRNA] |
CTD |
PMID:17178593 |
|
NCBI chr 2:184,093,079...184,096,882
Ensembl chr 2:184,092,991...184,096,886
|
|
G |
Ucp2 |
uncoupling protein 2 |
decreases expression |
EXP |
Glucosamine results in decreased expression of UCP2 mRNA |
CTD |
PMID:11893929 |
|
NCBI chr 1:154,839,242...154,845,612
Ensembl chr 1:154,839,209...154,845,611
|
|
G |
Uqcrh |
ubiquinol-cytochrome c reductase hinge protein |
increases expression |
ISO |
Glucosamine results in increased expression of UQCRH mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 5:129,545,978...129,554,173
Ensembl chr 5:129,545,984...129,554,242
|
|
G |
Vamp1 |
vesicle-associated membrane protein 1 |
increases expression |
EXP |
Glucosamine results in increased expression of VAMP1 mRNA |
CTD |
PMID:17109745 |
|
NCBI chr 4:158,012,634...158,019,350
Ensembl chr 4:158,012,663...158,019,349
|
|
G |
Vcan |
versican |
multiple interactions decreases expression |
EXP |
Glucosamine inhibits the reaction [IL1B results in increased expression of VCAN mRNA]; IL1B affects the reaction [Glucosamine results in decreased expression of VCAN mRNA] |
CTD |
PMID:17109745 |
|
NCBI chr 2:20,761,718...20,860,637
Ensembl chr 2:20,761,718...20,860,637
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions increases expression decreases expression |
ISO EXP |
Glucosamine inhibits the reaction [Oxygen deficiency results in increased expression of VEGFA protein] Glucosamine results in increased expression of VEGFA protein Glucosamine results in decreased expression of VEGFA protein |
CTD |
PMID:16324875 PMID:19254699 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Vegfd |
vascular endothelial growth factor D |
increases expression decreases expression |
ISO EXP |
Glucosamine results in increased expression of VEGFD mRNA Glucosamine results in decreased expression of VEGFD mRNA |
CTD |
PMID:17109745 PMID:17178593 |
|
NCBI chr X:30,073,122...30,108,413
Ensembl chr X:30,074,163...30,108,295
|
|
G |
Vnn1 |
vanin 1 |
increases expression |
ISO |
Glucosamine results in increased expression of VNN1 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 1:21,537,084...21,547,395
Ensembl chr 1:21,537,094...21,547,395
|
|
G |
Xbp1 |
X-box binding protein 1 |
multiple interactions increases splicing increases expression decreases splicing |
ISO EXP |
4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of XBP1 mRNA]; NUS1 protein inhibits the reaction [Glucosamine results in increased splicing of XBP1 mRNA]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in increased expression of XBP1 mRNA] Glucosamine results in increased expression of XBP1 protein alternative form 4-methylumbelliferone 8-carbaldehyde affects the reaction [Glucosamine results in increased expression of XBP1 protein alternative form]; 4-methylumbelliferone 8-carbaldehyde inhibits the reaction [Glucosamine results in increased splicing of XBP1 mRNA]; 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of XBP1 protein alternative form]; 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased splicing of XBP1 mRNA]; ERN1 protein affects the reaction [Glucosamine results in increased splicing of XBP1 mRNA] 4-phenylbutyric acid inhibits the reaction [Glucosamine results in increased expression of XBP1 mRNA]; ursodoxicoltaurine inhibits the reaction [Glucosamine results in increased expression of XBP1 mRNA] Glucosamine results in decreased splicing of XBP1 mRNA |
CTD |
PMID:19383982 PMID:20165829 PMID:30602124 PMID:33812996 |
|
NCBI chr14:80,390,629...80,395,713
Ensembl chr14:80,390,643...80,395,693
|
|
G |
Xdh |
xanthine dehydrogenase |
multiple interactions |
EXP |
[XDH protein co-treated with Hypoxanthine] inhibits the reaction [Glucosamine results in increased abundance of Proteoglycans]; [XDH protein co-treated with Hypoxanthine] inhibits the reaction [Glucosamine results in increased expression of B3GAT3 mRNA] |
CTD |
PMID:11801247 |
|
NCBI chr 6:21,530,463...21,592,172
Ensembl chr 6:21,530,113...21,592,268
|
|
G |
Zfp467 |
zinc finger protein 467 |
increases expression |
ISO |
Glucosamine results in increased expression of ZFP467 mRNA |
CTD |
PMID:17178593 |
|
NCBI chr 4:77,385,752...77,394,709
Ensembl chr 4:77,385,758...77,392,229
|
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression |
ISO |
TXN protein affects the reaction [calycosin-7-O-beta-D-glucoside results in increased expression of BAX mRNA]; TXN protein affects the reaction [calycosin-7-O-beta-D-glucoside results in increased expression of BAX protein] calycosin-7-O-beta-D-glucoside results in increased expression of BAX mRNA; calycosin-7-O-beta-D-glucoside results in increased expression of BAX protein |
CTD |
PMID:36812960 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions decreases expression |
ISO |
TXN protein affects the reaction [calycosin-7-O-beta-D-glucoside results in decreased expression of BCL2 mRNA]; TXN protein affects the reaction [calycosin-7-O-beta-D-glucoside results in decreased expression of BCL2 protein] calycosin-7-O-beta-D-glucoside results in decreased expression of BCL2 mRNA; calycosin-7-O-beta-D-glucoside results in decreased expression of BCL2 protein |
CTD |
PMID:36812960 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Casp3 |
caspase 3 |
increases cleavage multiple interactions increases expression |
ISO |
calycosin-7-O-beta-D-glucoside results in increased cleavage of CASP3 protein TXN protein affects the reaction [calycosin-7-O-beta-D-glucoside results in increased cleavage of CASP3 protein]; TXN protein affects the reaction [calycosin-7-O-beta-D-glucoside results in increased expression of CASP3 mRNA] |
CTD |
PMID:36812960 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cat |
catalase |
decreases expression |
ISO |
calycosin-7-O-beta-D-glucoside results in decreased expression of CAT protein |
CTD |
PMID:36812960 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Epo |
erythropoietin |
increases expression |
ISO |
calycosin-7-O-beta-D-glucoside results in increased expression of EPO mRNA |
CTD |
PMID:21309574 PMID:37348668 |
|
NCBI chr12:19,204,258...19,207,948
Ensembl chr12:19,204,508...19,207,946
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
decreases expression |
ISO |
calycosin-7-O-beta-D-glucoside results in decreased expression of GPT protein |
CTD |
PMID:36812960 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions increases expression |
ISO |
calycosin-7-O-beta-D-glucoside results in decreased degradation of and results in increased expression of HIF1A protein modified form; calycosin-7-O-beta-D-glucoside results in increased expression of and results in decreased degradation of HIF1A protein calycosin-7-O-beta-D-glucoside results in increased expression of HIF1A mRNA; calycosin-7-O-beta-D-glucoside results in increased expression of HIF1A protein |
CTD |
PMID:21309574 PMID:37348668 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Txn1 |
thioredoxin 1 |
multiple interactions decreases expression |
ISO |
TXN protein affects the reaction [calycosin-7-O-beta-D-glucoside results in decreased expression of BCL2 mRNA]; TXN protein affects the reaction [calycosin-7-O-beta-D-glucoside results in decreased expression of BCL2 protein]; TXN protein affects the reaction [calycosin-7-O-beta-D-glucoside results in increased cleavage of CASP3 protein]; TXN protein affects the reaction [calycosin-7-O-beta-D-glucoside results in increased expression of BAX mRNA]; TXN protein affects the reaction [calycosin-7-O-beta-D-glucoside results in increased expression of BAX protein]; TXN protein affects the reaction [calycosin-7-O-beta-D-glucoside results in increased expression of CASP3 mRNA] calycosin-7-O-beta-D-glucoside results in decreased expression of TXN protein calycosin-7-O-beta-D-glucoside results in decreased expression of TXN mRNA; calycosin-7-O-beta-D-glucoside results in decreased expression of TXN protein |
CTD |
PMID:36812960 |
|
NCBI chr 5:72,712,334...72,724,564
Ensembl chr 5:72,711,933...72,724,629
|
|
|
G |
Fbp1 |
fructose-bisphosphatase 1 |
multiple interactions |
ISO |
[Enzyme Inhibitors results in decreased activity of FBP1 protein] which results in decreased abundance of Glucose-6-Phosphate |
CTD |
PMID:31974165 |
|
NCBI chr17:2,207,271...2,230,076
Ensembl chr17:2,208,031...2,230,071
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
multiple interactions |
ISO |
[Fluoxetine results in decreased expression of G6PC1 protein] which results in increased abundance of Glucose-6-Phosphate |
CTD |
PMID:33179799 |
|
NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804
|
|
G |
G6pc2 |
glucose-6-phosphatase catalytic subunit 2 |
increases hydrolysis |
ISO |
G6PC2 protein results in increased hydrolysis of Glucose-6-Phosphate |
CTD |
PMID:14722102 |
|
NCBI chr 3:53,999,821...54,005,539
|
|
G |
Gpd2 |
glycerol-3-phosphate dehydrogenase 2 |
multiple interactions |
ISO |
GPD2 protein inhibits the reaction [Dihydroxyacetone results in increased abundance of Glucose-6-Phosphate]; GPD2 protein inhibits the reaction [Glucose results in increased abundance of Glucose-6-Phosphate]; GPD2 protein inhibits the reaction [Glycerol results in increased abundance of Glucose-6-Phosphate] |
CTD |
PMID:31974165 |
|
NCBI chr 3:41,800,552...41,937,729
Ensembl chr 3:41,801,930...41,936,901
|
|
G |
Nr4a1 |
nuclear receptor subfamily 4, group A, member 1 |
multiple interactions |
ISO |
[Glycerol co-treated with Succinic Acid co-treated with Glucose-6-Phosphate co-treated with Pantothenic Acid co-treated with Niacinamide] results in increased expression of NR4A1 mRNA |
CTD |
PMID:20505214 |
|
NCBI chr 7:132,368,399...132,389,300
Ensembl chr 7:132,374,840...132,389,297
|
|
G |
Pfkfb1 |
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 1 |
increases abundance multiple interactions |
ISO |
PFKFB1 gene mutant form results in increased abundance of Glucose-6-Phosphate PFKFB1 gene mutant form inhibits the reaction [Metformin results in decreased abundance of Glucose-6-Phosphate metabolite] |
CTD |
PMID:31974165 |
|
NCBI chr X:19,508,522...19,562,165
Ensembl chr X:19,508,546...19,562,182
|
|
G |
Prkaa1 |
protein kinase AMP-activated catalytic subunit alpha 1 |
multiple interactions |
ISO |
[[PRKAA1 gene co-treated with PRKAA2 gene] affects the susceptibility to 4-hydroxy-3-(4-(2-hydroxyphenyl)phenyl)-6-oxo-7H-thieno(2,3-b)pyridine-5-carbonitrile] which results in increased abundance of Glucose-6-Phosphate; [[PRKAA1 gene mutant form co-treated with PRKAA2 gene mutant form] affects the susceptibility to [Glucose co-treated with S 4048]] which results in increased abundance of Glucose-6-Phosphate; [[PRKAA1 gene mutant form co-treated with PRKAA2 gene mutant form] affects the susceptibility to Metformin] which results in increased abundance of Glucose-6-Phosphate |
CTD |
PMID:31974165 |
|
NCBI chr 2:54,240,298...54,275,978
Ensembl chr 2:54,240,137...54,275,978
|
|
G |
Prkaa2 |
protein kinase AMP-activated catalytic subunit alpha 2 |
multiple interactions |
ISO |
[[PRKAA1 gene co-treated with PRKAA2 gene] affects the susceptibility to 4-hydroxy-3-(4-(2-hydroxyphenyl)phenyl)-6-oxo-7H-thieno(2,3-b)pyridine-5-carbonitrile] which results in increased abundance of Glucose-6-Phosphate; [[PRKAA1 gene mutant form co-treated with PRKAA2 gene mutant form] affects the susceptibility to [Glucose co-treated with S 4048]] which results in increased abundance of Glucose-6-Phosphate; [[PRKAA1 gene mutant form co-treated with PRKAA2 gene mutant form] affects the susceptibility to Metformin] which results in increased abundance of Glucose-6-Phosphate |
CTD |
PMID:31974165 |
|
NCBI chr 5:119,807,992...119,879,987
Ensembl chr 5:119,813,226...119,879,543
|
|
|
G |
Ache |
acetylcholinesterase |
increases expression multiple interactions |
EXP |
daidzin results in increased expression of ACHE mRNA 4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline inhibits the reaction [daidzin results in increased expression of ACHE mRNA]; 4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline inhibits the reaction [daidzin results in increased expression of and results in increased activity of ACHE protein]; daidzin results in increased expression of and results in increased activity of ACHE protein |
CTD |
PMID:31034797 |
|
NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Acsl3 |
acyl-CoA synthetase long-chain family member 3 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of ACSL3 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 9:80,115,164...80,164,636
Ensembl chr 9:80,115,112...80,164,627
|
|
G |
Aldh1a2 |
aldehyde dehydrogenase 1 family, member A2 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of ALDH1A2 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 8:71,877,850...71,957,107
Ensembl chr 8:71,877,850...71,957,107
|
|
G |
Aldh2 |
aldehyde dehydrogenase 2 family member |
multiple interactions |
ISO |
daidzin inhibits the reaction [ALDH2 protein results in increased hydrolysis of 4-nitrophenyl acetate]; daidzin inhibits the reaction [ALDH2 protein results in increased oxidation of propionaldehyde] |
CTD |
PMID:21349255 |
|
NCBI chr12:34,949,549...34,982,527
Ensembl chr12:34,901,219...34,982,521
|
|
G |
Anpep |
alanyl aminopeptidase, membrane |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of ANPEP mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 1:133,767,332...133,810,137
Ensembl chr 1:133,767,332...133,785,789
|
|
G |
Atoh8 |
atonal bHLH transcription factor 8 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of ATOH8 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 4:104,259,992...104,292,168
Ensembl chr 4:104,259,992...104,292,168
|
|
G |
Bckdk |
branched chain ketoacid dehydrogenase kinase |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of BCKDK mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 1:182,515,335...182,520,007
Ensembl chr 1:182,515,327...182,536,633
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
multiple interactions |
ISO |
daidzin inhibits the reaction [Pentylenetetrazole results in decreased expression of BDNF protein] |
CTD |
PMID:32450180 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Bpgm |
bisphosphoglycerate mutase |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of BPGM mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 4:63,139,730...63,168,581
Ensembl chr 4:63,140,018...63,168,581
|
|
G |
Cabp5 |
calcium binding protein 5 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of CABP5 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 1:74,350,811...74,363,830
Ensembl chr 1:74,350,811...74,363,830
|
|
G |
Cacybp |
calcyclin binding protein |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of CACYBP mRNA |
CTD |
PMID:27424125 |
|
NCBI chr13:72,437,485...72,447,810
Ensembl chr13:72,437,490...72,450,177
|
|
G |
Casp8ap2 |
caspase 8 associated protein 2 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of CASP8AP2 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 5:47,014,501...47,052,276
Ensembl chr 5:47,014,667...47,052,275
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
daidzin inhibits the reaction [Pentylenetetrazole results in decreased activity of CAT protein] |
CTD |
PMID:32450180 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cd200r1 |
CD200 receptor 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of CD200R1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr11:55,886,937...55,921,217
Ensembl chr11:55,887,717...55,921,285
|
|
G |
Cfap251 |
cilia and flagella associated protein 251 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of CFAP251 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr12:33,261,622...33,337,028
Ensembl chr12:33,261,476...33,293,932
|
|
G |
Cybrd1 |
cytochrome b reductase 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of CYBRD1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 3:55,934,874...55,962,132
Ensembl chr 3:55,934,874...55,962,108
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
multiple interactions |
EXP |
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of CYP11A1 mRNA |
CTD |
PMID:28964809 |
|
NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338
|
|
G |
Dennd2d |
DENN domain containing 2D |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of DENND2D mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 2:193,973,231...193,992,275
Ensembl chr 2:193,973,231...193,992,270
|
|
G |
Dnmt1 |
DNA methyltransferase 1 |
multiple interactions |
EXP |
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in increased expression of DNMT1 mRNA |
CTD |
PMID:28964809 |
|
NCBI chr 8:19,440,611...19,486,659
Ensembl chr 8:19,440,611...19,486,659
|
|
G |
Dnmt3a |
DNA methyltransferase 3 alpha |
multiple interactions |
EXP |
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in increased expression of DNMT3A mRNA |
CTD |
PMID:28964809 |
|
NCBI chr 6:26,791,517...26,902,161
Ensembl chr 6:26,822,609...26,896,687
|
|
G |
Dpp9 |
dipeptidyl peptidase 9 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of DPP9 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 9:1,011,347...1,046,337
Ensembl chr 9:1,011,351...1,046,541
|
|
G |
Edrf1 |
erythroid differentiation regulatory factor 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of EDRF1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 1:188,441,514...188,478,743
Ensembl chr 1:188,441,634...188,478,701
|
|
G |
Efhd1 |
EF-hand domain family, member D1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of EFHD1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 9:87,938,259...87,984,917
Ensembl chr 9:87,938,284...87,984,917
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions |
EXP |
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in increased expression of ESR2 mRNA |
CTD |
PMID:28964809 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Fam171a2 |
family with sequence similarity 171, member A2 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of FAM171A2 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr10:87,393,888...87,404,051
Ensembl chr10:87,394,007...87,404,053
|
|
G |
Fam180a |
family with sequence similarity 180, member A |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of FAM180A mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 4:63,992,867...64,008,047
Ensembl chr 4:63,992,867...64,008,047
|
|
G |
Fam210b |
family with sequence similarity 210, member B |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of FAM210B mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 3:161,118,228...161,128,400
Ensembl chr 3:161,118,239...161,128,397
|
|
G |
Fam241b |
family with sequence similarity 241 member B |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of FAM241B mRNA |
CTD |
PMID:27424125 |
|
NCBI chr20:30,052,315...30,055,247
Ensembl chr20:30,052,324...30,055,084
|
|
G |
Fgd6 |
FYVE, RhoGEF and PH domain containing 6 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of FGD6 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 7:28,597,609...28,712,908
Ensembl chr 7:28,597,609...28,712,456
|
|
G |
Fhl2 |
four and a half LIM domains 2 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of FHL2 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 9:45,388,979...45,462,421
Ensembl chr 9:45,388,981...45,431,192
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
increases expression |
ISO |
daidzin results in increased expression of FOS mRNA |
CTD |
PMID:17142977 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Galnt15 |
polypeptide N-acetylgalactosaminyltransferase 15 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of GALNT15 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr16:7,227,232...7,267,002
Ensembl chr16:7,227,271...7,267,014
|
|
G |
Gng5 |
G protein subunit gamma 5 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of GNG5 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 2:235,394,680...235,403,177
Ensembl chr 1:77,292,043...77,292,513
|
|
G |
Hipk4 |
homeodomain interacting protein kinase 4 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of HIPK4 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 1:82,810,708...82,821,080
Ensembl chr 1:82,810,708...82,821,077
|
|
G |
Hmcn1 |
hemicentin 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of HMCN1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr13:62,615,461...63,084,524
Ensembl chr13:62,615,461...63,084,524
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
ISO |
daidzin inhibits the reaction [Pentylenetetrazole results in decreased expression of HMOX1 protein] |
CTD |
PMID:32450180 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hsd3b1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
multiple interactions |
EXP |
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of HSD3B1 mRNA |
CTD |
PMID:28964809 |
|
NCBI chr 2:186,169,864...186,175,984
Ensembl chr 2:186,169,863...186,175,999
|
|
G |
Il6r |
interleukin 6 receptor |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of IL6R mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 2:175,289,157...175,347,719
Ensembl chr 2:175,298,686...175,347,536
|
|
G |
Isg20l2 |
interferon stimulated exonuclease gene 20-like 2 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of ISG20L2 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 2:173,396,780...173,407,102
Ensembl chr 2:173,396,780...173,406,614
|
|
G |
Kdm5a |
lysine demethylase 5A |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of KDM5A mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 4:153,565,909...153,643,912
Ensembl chr 4:153,565,846...153,642,422
|
|
G |
Kitlg |
KIT ligand |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of KITLG mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 7:34,896,075...34,977,215
Ensembl chr 7:34,896,053...34,977,214
|
|
G |
Knstrn |
kinetochore-localized astrin/SPAG5 binding protein |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of KNSTRN mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 3:105,800,762...105,820,555
Ensembl chr 3:105,800,954...105,820,715
|
|
G |
Ldlrap1 |
low density lipoprotein receptor adaptor protein 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of LDLRAP1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 5:146,955,607...146,978,601
Ensembl chr 5:146,955,607...146,978,601
|
|
G |
Lmod1 |
leiomodin 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of LMOD1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr13:46,754,048...46,796,186
Ensembl chr13:46,754,033...46,794,900
|
|
G |
Lrg1 |
leucine-rich alpha-2-glycoprotein 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of LRG1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 9:947,516...949,773
Ensembl chr 9:947,516...949,813
|
|
G |
Lsr |
lipolysis stimulated lipoprotein receptor |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of LSR mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 1:86,185,769...86,201,952
Ensembl chr 1:86,186,431...86,201,952
|
|
G |
Mrpl33 |
mitochondrial ribosomal protein L33 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of MRPL33 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 6:24,825,800...24,833,994
Ensembl chr 6:24,825,827...24,833,834
|
|
G |
Mtmr11 |
myotubularin related protein 11 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of MTMR11 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 2:183,721,983...183,732,148
Ensembl chr 2:183,723,530...183,732,148
|
|
G |
Myof |
myoferlin |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of MYOF mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 1:235,673,666...235,822,413
Ensembl chr 1:235,673,666...235,822,334
|
|
G |
Nefh |
neurofilament heavy chain |
increases expression |
EXP |
daidzin results in increased expression of NEFH mRNA; daidzin results in increased expression of NEFH protein |
CTD |
PMID:31034797 |
|
NCBI chr14:79,830,362...79,840,347
Ensembl chr14:79,830,362...79,840,351
|
|
G |
Nefl |
neurofilament light chain |
increases expression |
EXP |
daidzin results in increased expression of NEFL mRNA; daidzin results in increased expression of NEFL protein |
CTD |
PMID:31034797 |
|
NCBI chr15:42,301,920...42,305,793
Ensembl chr15:42,301,916...42,305,793
|
|
G |
Nr4a1 |
nuclear receptor subfamily 4, group A, member 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of NR4A1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 7:132,368,399...132,389,300
Ensembl chr 7:132,374,840...132,389,297
|
|
G |
Nr5a1 |
nuclear receptor subfamily 5, group A, member 1 |
multiple interactions |
EXP |
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of NR5A1 mRNA; [Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of NR5A1 protein; [Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in increased methylation of NR5A1 promoter; decitabine inhibits the reaction [[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of NR5A1 mRNA] |
CTD |
PMID:28964809 |
|
NCBI chr 3:22,464,786...22,486,328
Ensembl chr 3:22,465,502...22,486,328
|
|
G |
Pgr |
progesterone receptor |
increases expression |
ISO |
daidzin results in increased expression of PGR protein |
CTD |
PMID:17142977 |
|
NCBI chr 8:6,072,673...6,131,552
Ensembl chr 8:6,072,673...6,131,344
|
|
G |
Prima1 |
proline rich membrane anchor 1 |
increases expression multiple interactions |
EXP |
daidzin results in increased expression of PRIMA1 mRNA 4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline inhibits the reaction [daidzin results in increased expression of PRIMA1 mRNA] |
CTD |
PMID:31034797 |
|
NCBI chr 6:122,338,365...122,390,955
Ensembl chr 6:122,338,370...122,389,921
|
|
G |
Prkaca |
protein kinase cAMP-activated catalytic subunit alpha |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of PRKACA mRNA |
CTD |
PMID:27424125 |
|
NCBI chr19:24,155,081...24,178,430
Ensembl chr19:24,155,090...24,178,430
|
|
G |
Prpf40a |
pre-mRNA processing factor 40 homolog A |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of PRPF40A mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 3:37,625,585...37,689,859
Ensembl chr 3:37,627,690...37,690,886
|
|
G |
Pspc1 |
paraspeckle component 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of PSPC1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr15:30,828,617...30,911,315
Ensembl chr15:30,828,626...30,911,202
|
|
G |
Pth1r |
parathyroid hormone 1 receptor |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of PTH1R mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 8:110,693,910...110,725,458
Ensembl chr 8:110,697,485...110,719,729
|
|
G |
Rassf5 |
Ras association domain family member 5 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of RASSF5 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr13:42,637,513...42,703,024
Ensembl chr13:42,637,549...42,703,024
|
|
G |
Rgs22 |
regulator of G-protein signaling 22 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of RGS22 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 7:67,188,531...67,308,805
Ensembl chr 7:67,188,519...67,308,875
|
|
G |
S1pr3 |
sphingosine-1-phosphate receptor 3 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of S1PR3 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr17:13,781,050...13,794,408
Ensembl chr17:13,781,050...13,794,505
|
|
G |
Selplg |
selectin P ligand |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of SELPLG mRNA |
CTD |
PMID:27424125 |
|
NCBI chr12:42,796,690...42,809,908
Ensembl chr12:42,796,580...42,812,585
|
|
G |
Siglec10 |
sialic acid binding Ig-like lectin 10 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of SIGLEC10 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 1:93,817,301...93,826,376
Ensembl chr 1:93,817,335...93,825,931
|
|
G |
Slc16a1 |
solute carrier family 16 member 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of SLC16A1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 2:192,123,755...192,144,617
Ensembl chr 2:192,124,289...192,144,611
|
|
G |
Snx30 |
sorting nexin family member 30 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of SNX30 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 5:74,683,902...74,813,013
Ensembl chr 5:74,684,015...74,792,631
|
|
G |
Ssc5d |
scavenger receptor cysteine rich family member with 5 domains |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of SSC5D mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 1:68,891,942...68,910,462
Ensembl chr 1:68,891,949...68,909,743
|
|
G |
Star |
steroidogenic acute regulatory protein |
multiple interactions |
EXP |
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of STAR mRNA; [Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of STAR protein |
CTD |
PMID:28964809 |
|
NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672
|
|
G |
Styxl1 |
serine/threonine/tyrosine interacting-like 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of STYXL1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr12:20,907,410...20,940,232
Ensembl chr12:20,907,435...20,939,752
|
|
G |
Sumo1 |
small ubiquitin-like modifier 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of SUMO1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 9:61,078,790...61,108,697
Ensembl chr 9:61,077,435...61,108,761
|
|
G |
Tc2n |
tandem C2 domains, nuclear |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of TC2N mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 6:120,761,112...120,856,835
Ensembl chr 6:120,761,119...120,849,326
|
|
G |
Tp53i11 |
tumor protein p53 inducible protein 11 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of TP53I11 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 3:79,144,824...79,160,056
Ensembl chr 3:79,144,895...79,160,050
|
|
G |
Vcpip1 |
valosin containing protein interacting protein 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of VCPIP1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 5:9,534,247...9,560,889
Ensembl chr 5:9,534,129...9,562,040
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO |
daidzin inhibits the reaction [Pentylenetetrazole results in increased expression of VEGFA protein] |
CTD |
PMID:32450180 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
affects response to substance multiple interactions increases expression |
ISO |
ABCB1 exon polymorphism affects the susceptibility to Etoposide [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [Celecoxib results in decreased expression of ABCB1] which results in increased susceptibility to Etoposide Etoposide results in increased expression of ABCB1 mRNA; Etoposide results in increased expression of ABCB1 protein |
CTD |
PMID:12969965 PMID:15239124 PMID:19047049 PMID:19562670 PMID:27570640 PMID:27840903 More...
|
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
affects response to substance multiple interactions increases expression decreases uptake decreases response to substance |
ISO |
ABCC1 protein affects the susceptibility to Etoposide Glucose inhibits the reaction [Sodium Azide inhibits the reaction [ABCC1 protein results in decreased uptake of Etoposide]]; Sodium Azide inhibits the reaction [ABCC1 protein results in decreased uptake of Etoposide]; Verapamil inhibits the reaction [ABCC1 protein results in decreased susceptibility to Etoposide]; Verapamil inhibits the reaction [ABCC1 protein results in decreased uptake of Etoposide] Etoposide results in increased expression of ABCC1 mRNA ABCC1 protein results in decreased susceptibility to Etoposide; ABCC1 results in decreased susceptibility to Etoposide [GCLC protein co-treated with GCLM protein] promotes the reaction [ABCC1 protein results in decreased susceptibility to Etoposide]; [MYCN protein affects the expression of ABCC1 mRNA] which affects the susceptibility to Etoposide; GSTP1 protein promotes the reaction [ABCC1 protein results in decreased susceptibility to Etoposide]; hesperetin inhibits the reaction [ABCC1 protein results in decreased susceptibility to Etoposide]; naringenin inhibits the reaction [ABCC1 protein results in decreased susceptibility to Etoposide]; Resveratrol inhibits the reaction [ABCC1 protein results in decreased susceptibility to Etoposide]; Silymarin inhibits the reaction [ABCC1 protein results in decreased susceptibility to Etoposide]; Tocopherols inhibits the reaction [ABCC1 protein affects the export of Etoposide]; verlukast inhibits the reaction [ABCC1 protein results in decreased susceptibility to Etoposide] |
CTD |
PMID:7954421 PMID:8968083 PMID:9334814 PMID:10348353 PMID:10856430 PMID:10900222 PMID:11778547 PMID:15180633 PMID:15460906 PMID:15617835 PMID:15999103 PMID:16156793 PMID:16217747 More...
|
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
affects transport multiple interactions |
ISO |
ABCC2 protein affects the transport of Etoposide Probenecid promotes the reaction [ABCC2 protein affects the transport of Etoposide] |
CTD |
PMID:15751272 PMID:15849751 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
decreases response to substance |
ISO |
ABCC3 protein results in decreased susceptibility to Etoposide |
CTD |
PMID:15884115 |
|
NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions |
ISO |
[ERBB2 results in increased expression of ABCG2] which results in decreased susceptibility to Etoposide; ABCG2 mutant form inhibits the reaction [ERBB2 results in decreased susceptibility to Etoposide] |
CTD |
PMID:21712253 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Abhd4 |
abhydrolase domain containing 4, N-acyl phospholipase B |
increases expression |
ISO |
Etoposide results in increased expression of ABHD4 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr15:27,697,384...27,716,013
Ensembl chr15:27,704,113...27,716,966
|
|
G |
Abra |
actin-binding Rho activating protein |
increases expression |
ISO |
Etoposide results in increased expression of ABRA mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 7:72,970,187...72,974,255
Ensembl chr 7:72,970,186...72,974,255
|
|
G |
Acadm |
acyl-CoA dehydrogenase medium chain |
affects response to substance |
ISO |
ACADM protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 2:242,858,865...242,883,036
Ensembl chr 2:242,858,865...242,883,147
|
|
G |
Ace2 |
angiotensin converting enzyme 2 |
increases expression decreases expression |
ISO EXP |
Etoposide results in increased expression of ACE2 mRNA Etoposide results in decreased expression of ACE2 mRNA |
CTD |
PMID:29397400 PMID:32808185 |
|
NCBI chr X:30,293,597...30,340,961
Ensembl chr X:30,293,589...30,340,977
|
|
G |
Aco1 |
aconitase 1 |
increases expression |
ISO |
Etoposide results in increased expression of ACO1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 5:55,259,841...55,315,872
Ensembl chr 5:55,259,827...55,316,391
|
|
G |
Acsl3 |
acyl-CoA synthetase long-chain family member 3 |
affects response to substance |
ISO |
ACSL3 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 9:80,115,164...80,164,636
Ensembl chr 9:80,115,112...80,164,627
|
|
G |
Acta1 |
actin, alpha 1, skeletal muscle |
decreases expression |
ISO |
Etoposide results in decreased expression of ACTA1 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr19:51,883,709...51,886,735
Ensembl chr19:51,883,715...51,886,742
|
|
G |
Agrn |
agrin |
increases expression |
ISO |
Etoposide results in increased expression of AGRN mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 5:166,749,306...166,782,212
Ensembl chr 5:166,749,310...166,786,003
|
|
G |
Ahcyl1 |
adenosylhomocysteinase-like 1 |
affects response to substance |
ISO |
AHCYL1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 2:195,294,149...195,328,586
Ensembl chr 2:195,294,153...195,345,815
|
|
G |
Ahi1 |
Abelson helper integration site 1 |
increases expression |
ISO |
Etoposide results in increased expression of AHI1 protein alternative form |
CTD |
PMID:19379585 |
|
NCBI chr 1:15,762,485...15,891,213
Ensembl chr 1:15,762,462...15,891,041
|
|
G |
Akap12 |
A-kinase anchoring protein 12 |
affects response to substance |
ISO |
AKAP12 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 1:40,730,123...40,819,863
Ensembl chr 1:40,730,123...40,819,886
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
increases response to substance increases phosphorylation multiple interactions |
ISO |
AKT1 protein modified form results in increased susceptibility to Etoposide Etoposide results in increased phosphorylation of AKT1 protein Etoposide results in increased phosphorylation of and results in increased activity of AKT1 protein; NFKB1 protein affects the reaction [Etoposide results in increased phosphorylation of AKT1 protein]; pepstatin inhibits the reaction [AKT1 protein modified form results in increased susceptibility to Etoposide]; PTEN protein inhibits the reaction [Etoposide results in increased phosphorylation of and results in increased activity of AKT1 protein] |
CTD |
PMID:17699715 PMID:17935137 PMID:23396362 PMID:27769712 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alad |
aminolevulinate dehydratase |
multiple interactions |
ISO |
[Cyclophosphamide co-treated with Carmustine co-treated with Etoposide] results in decreased activity of ALAD protein |
CTD |
PMID:19162187 |
|
NCBI chr 5:75,961,993...75,972,334
Ensembl chr 5:75,961,993...75,972,474
|
|
G |
Alas1 |
5'-aminolevulinate synthase 1 |
increases expression |
ISO |
Etoposide results in increased expression of ALAS1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 8:106,876,514...106,889,917
Ensembl chr 8:106,876,514...106,889,917
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
increases expression multiple interactions |
ISO |
Etoposide results in increased expression of ALDH1A1 mRNA; Etoposide results in increased expression of ALDH1A1 protein FTL protein affects the reaction [Etoposide results in increased expression of ALDH1A1 protein] |
CTD |
PMID:33969609 |
|
NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961
|
|
G |
Aldh3a1 |
aldehyde dehydrogenase 3 family, member A1 |
affects response to substance |
ISO |
ALDH3A1 protein affects the susceptibility to Etoposide |
CTD |
PMID:15905174 |
|
NCBI chr10:45,892,993...45,902,680
Ensembl chr10:45,892,924...45,902,681
|
|
G |
Aldoc |
aldolase, fructose-bisphosphate C |
affects response to substance multiple interactions |
ISO |
ALDOC protein affects the susceptibility to Etoposide [Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in decreased expression of ALDOC protein |
CTD |
PMID:16217747 PMID:29733421 |
|
NCBI chr10:63,217,477...63,221,066
Ensembl chr10:63,217,451...63,221,066
|
|
G |
Alpg |
alkaline phosphatase, germ cell |
affects response to substance |
ISO |
ALPG protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 9:87,748,721...87,761,500
Ensembl chr 9:87,753,648...87,757,836
|
|
G |
Alpp |
alkaline phosphatase, placental |
affects response to substance |
ISO |
ALPP protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 9:87,765,846...87,768,606
Ensembl chr 9:87,765,860...87,768,606
|
|
G |
Ank1 |
ankyrin 1 |
increases expression |
ISO |
Etoposide results in increased expression of ANK1 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr16:68,876,294...69,054,963
Ensembl chr16:68,877,504...69,054,759
|
|
G |
Ankrd10 |
ankyrin repeat domain 10 |
decreases expression |
ISO |
Etoposide results in decreased expression of ANKRD10 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr16:77,866,489...77,889,745
Ensembl chr16:77,864,261...77,889,745
|
|
G |
Ankrd27 |
ankyrin repeat domain 27 |
decreases expression |
ISO |
Etoposide results in decreased expression of ANKRD27 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 1:88,251,216...88,303,615
Ensembl chr 1:88,251,226...88,303,615
|
|
G |
Ankrd28 |
ankyrin repeat domain 28 |
affects response to substance |
ISO |
ANKRD28 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr16:6,918,487...7,050,244
Ensembl chr16:6,914,336...7,050,249
|
|
G |
Anxa4 |
annexin A4 |
increases expression |
ISO |
Etoposide results in increased expression of ANXA4 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 4:119,184,378...119,241,183
Ensembl chr 4:119,184,374...119,241,161
|
|
G |
Anxa7 |
annexin A7 |
multiple interactions |
ISO |
[Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in decreased expression of ANXA7 protein |
CTD |
PMID:29733421 |
|
NCBI chr15:3,821,798...3,849,659
Ensembl chr15:3,821,845...3,849,385
|
|
G |
Apaf1 |
apoptotic peptidase activating factor 1 |
increases expression |
ISO |
Etoposide results in increased expression of APAF1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 7:25,494,143...25,579,540
Ensembl chr 7:25,494,609...25,579,540
|
|
G |
Apex1 |
apurinic/apyrimidinic endodeoxyribonuclease 1 |
decreases response to substance |
ISO |
APEX1 protein results in decreased susceptibility to Etoposide |
CTD |
PMID:20856196 |
|
NCBI chr15:24,144,595...24,146,785
Ensembl chr15:24,144,362...24,146,785
|
|
G |
Aplp1 |
amyloid beta precursor like protein 1 |
decreases expression |
ISO |
Etoposide results in decreased expression of APLP1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 1:85,696,880...85,707,215
Ensembl chr 1:85,696,882...85,707,155
|
|
G |
Apol2 |
apolipoprotein L, 2 |
increases expression |
ISO |
Etoposide results in increased expression of APOL8 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 7:109,331,367...109,338,632
Ensembl chr 7:109,331,392...109,338,558
|
|
G |
Aqp1 |
aquaporin 1 |
decreases expression |
ISO |
Etoposide results in decreased expression of AQP1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 4:84,482,512...84,494,690
Ensembl chr 4:84,482,512...84,494,690
|
|
G |
Ar |
androgen receptor |
multiple interactions increases degradation |
ISO |
calpain inhibitor 2 inhibits the reaction [Etoposide results in increased degradation of AR protein]; CAST inhibits the reaction [Etoposide results in increased degradation of AR protein]; Etoposide inhibits the reaction [Androgens results in increased activity of AR protein]; Etoposide inhibits the reaction [Metribolone results in increased activity of AR protein] |
CTD |
PMID:18726991 PMID:28377212 PMID:30818834 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Areg |
amphiregulin |
increases expression decreases expression |
ISO |
Etoposide results in increased expression of AREG mRNA; Etoposide results in increased expression of AREG protein Etoposide results in decreased expression of AREG mRNA |
CTD |
PMID:15228094 PMID:25270620 |
|
NCBI chr14:16,972,185...16,981,443
Ensembl chr14:16,972,187...16,981,535
|
|
G |
Arg2 |
arginase 2 |
decreases expression |
ISO |
Etoposide results in decreased expression of ARG2 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 6:97,936,002...97,961,379
Ensembl chr 6:97,936,002...97,961,378
|
|
G |
Arhgdib |
Rho GDP dissociation inhibitor beta |
increases expression |
ISO |
Etoposide results in increased expression of ARHGDIB mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 4:169,822,951...169,841,884
Ensembl chr 4:169,822,952...169,841,658
|
|
G |
Arih1 |
ariadne RBR E3 ubiquitin protein ligase 1 |
increases response to substance |
ISO |
ARIH1 mutant form results in increased susceptibility to Etoposide |
CTD |
PMID:25624349 |
|
NCBI chr 8:59,777,378...59,879,762
Ensembl chr 8:59,777,379...59,880,245
|
|
G |
Arl6ip5 |
ADP-ribosylation factor like GTPase 6 interacting protein 5 |
increases response to substance decreases expression |
ISO |
ARL6IP5 protein results in increased susceptibility to Etoposide Etoposide results in decreased expression of ARL6IP5 |
CTD |
PMID:19492242 |
|
NCBI chr 4:129,810,650...129,838,628
Ensembl chr 4:129,810,645...129,838,608
|
|
G |
Arnt |
aryl hydrocarbon receptor nuclear translocator |
multiple interactions |
ISO |
ARNT protein affects the reaction [Etoposide results in increased expression of FTL protein] |
CTD |
PMID:33969609 |
|
NCBI chr 2:182,997,731...183,056,584
Ensembl chr 2:182,997,736...183,056,580
|
|
G |
Arsa |
arylsulfatase A |
decreases expression |
ISO |
Etoposide results in decreased expression of ARSA mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 7:120,542,788...120,547,577
Ensembl chr 7:120,543,362...120,548,783
|
|
G |
Asah1 |
N-acylsphingosine amidohydrolase 1 |
affects response to substance |
ISO |
ASAH1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr16:50,966,404...50,997,827
Ensembl chr16:50,966,229...51,008,233
|
|
G |
Atf2 |
activating transcription factor 2 |
multiple interactions |
ISO |
Etoposide results in increased phosphorylation of and results in increased activity of ATF2 protein |
CTD |
PMID:12663670 |
|
NCBI chr 3:58,718,323...58,795,280
Ensembl chr 3:58,718,332...58,795,236
|
|
G |
Atf4 |
activating transcription factor 4 |
decreases expression |
ISO |
Etoposide results in decreased expression of ATF4 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
|
|
G |
Atm |
ATM serine/threonine kinase |
multiple interactions increases phosphorylation |
ISO |
Etoposide results in increased phosphorylation of and results in increased activity of ATM protein Etoposide results in increased phosphorylation of ATM protein Etoposide results in increased phosphorylation of and affects the localization of ATM protein; pifithrin inhibits the reaction [Etoposide results in increased phosphorylation of and affects the localization of ATM protein] |
CTD |
PMID:22242153 PMID:26259609 PMID:37451322 |
|
NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437
|
|
G |
Atp13a4 |
ATPase 13A4 |
decreases expression |
ISO |
Etoposide results in decreased expression of ATP13A4 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr11:71,222,196...71,359,933
Ensembl chr11:71,226,161...71,359,933
|
|
G |
Atp1a1 |
ATPase Na+/K+ transporting subunit alpha 1 |
affects response to substance |
ISO |
ATP1A1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 2:189,020,722...189,048,826
Ensembl chr 2:189,020,722...189,048,837
|
|
G |
Atp1a2 |
ATPase Na+/K+ transporting subunit alpha 2 |
decreases expression |
ISO |
Etoposide results in decreased expression of ATP1A2 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr13:84,729,597...84,754,544
Ensembl chr13:84,729,601...84,754,544
|
|
G |
Atp1b4 |
ATPase Na+/K+ transporting family member beta 4 |
increases expression |
ISO |
Etoposide results in increased expression of ATP1B4 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr X:117,087,284...117,108,023
Ensembl chr X:117,057,423...117,108,020
|
|
G |
Atp5me |
ATP synthase membrane subunit e |
multiple interactions |
ISO |
[Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in increased expression of ATP5ME protein |
CTD |
PMID:29733421 |
|
NCBI chr14:1,319,868...1,320,996
Ensembl chr14:1,319,868...1,321,013
|
|
G |
Atp5po |
ATP synthase peripheral stalk subunit OSCP |
decreases expression |
ISO |
Etoposide results in decreased expression of ATP5PO protein |
CTD |
PMID:29733421 |
|
NCBI chr11:31,165,218...31,171,530
Ensembl chr11:31,165,217...31,171,592
|
|
G |
Atp6v0a4 |
ATPase H+ transporting V0 subunit a4 |
affects response to substance |
ISO |
ATP6V0A4 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 4:66,760,163...66,842,126
Ensembl chr 4:66,760,159...66,842,110
|
|
G |
Atp6v1a |
ATPase H+ transporting V1 subunit A |
multiple interactions decreases expression |
ISO |
[Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in decreased expression of ATP6V1A protein Etoposide results in decreased expression of ATP6V1A protein |
CTD |
PMID:29733421 |
|
NCBI chr11:56,561,444...56,614,694
Ensembl chr11:56,560,974...56,614,694
|
|
G |
Atp7a |
ATPase copper transporting alpha |
decreases response to substance |
ISO |
ATP7A protein results in decreased susceptibility to Etoposide |
CTD |
PMID:17510416 |
|
NCBI chr X:71,094,144...71,201,550
Ensembl chr X:71,094,202...71,198,354
|
|
G |
Atr |
ATR serine/threonine kinase |
increases phosphorylation |
ISO |
Etoposide results in increased phosphorylation of ATR protein |
CTD |
PMID:22242153 |
|
NCBI chr 8:96,426,704...96,524,152
Ensembl chr 8:96,426,724...96,524,136
|
|
G |
Atxn1 |
ataxin 1 |
decreases expression |
ISO |
Etoposide results in decreased expression of ATXN1 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr17:18,737,491...19,142,360
Ensembl chr17:18,737,533...19,142,360
|
|
G |
Aurka |
aurora kinase A |
decreases expression |
ISO |
Etoposide results in decreased expression of AURKA mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 3:161,128,309...161,144,524
Ensembl chr 3:161,128,313...161,144,390
|
|
G |
Avpi1 |
arginine vasopressin-induced 1 |
affects response to substance |
ISO |
AVPI1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 1:240,930,236...240,936,154
Ensembl chr 1:240,930,236...240,936,154
|
|
G |
Avpr1a |
arginine vasopressin receptor 1A |
increases expression |
ISO |
Etoposide results in increased expression of AVPR1A mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 7:58,114,306...58,118,230
Ensembl chr 7:58,114,284...58,122,215
|
|
G |
Axl |
Axl receptor tyrosine kinase |
increases expression |
ISO |
Etoposide results in increased expression of AXL mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 1:81,265,088...81,296,278
Ensembl chr 1:81,265,088...81,296,265
|
|
G |
Bace2 |
beta-secretase 2 |
affects response to substance |
ISO |
BACE2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr11:36,707,447...36,789,550
Ensembl chr11:36,707,458...36,789,546
|
|
G |
Bag2 |
BAG cochaperone 2 |
affects response to substance |
ISO |
BAG2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 9:35,970,033...35,980,677
Ensembl chr 9:35,970,033...35,980,721
|
|
G |
Bak1 |
BCL2-antagonist/killer 1 |
increases activity increases response to substance affects response to substance multiple interactions affects expression |
ISO |
Etoposide results in increased activity of BAK1 protein BAK1 protein results in increased susceptibility to Etoposide BAK1 protein affects the susceptibility to Etoposide nimesulide inhibits the reaction [Etoposide results in increased activity of BAK1 protein] Etoposide affects the expression of BAK1 protein |
CTD |
PMID:15215046 PMID:16077961 PMID:17688235 PMID:21745461 |
|
NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264
|
|
G |
Bambi |
BMP and activin membrane-bound inhibitor |
affects response to substance |
ISO |
BAMBI protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr17:54,121,251...54,125,816
Ensembl chr17:54,121,255...54,126,060
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression decreases folding affects response to substance |
ISO |
[ABT-737 co-treated with Etoposide] affects the folding of and results in increased activity of BAX protein; [Cisplatin co-treated with Etoposide] affects the localization of BAX protein; [Doxorubicin co-treated with Vincristine co-treated with Etoposide co-treated with Mitotane] results in decreased expression of BAX protein; [IL4 protein co-treated with VCAM1 protein] inhibits the reaction [Etoposide results in decreased folding of BAX protein]; [RASSF1 co-treated with Etoposide] affects the folding of and results in increased activity of BAX protein; [trigonelline co-treated with Etoposide] results in increased expression of BAX protein; [VCAM1 protein co-treated with IL4 protein] inhibits the reaction [Etoposide inhibits the reaction [BAX protein binds to BCL2L1 protein]]; Etoposide inhibits the reaction [BAX protein binds to BCL2L1 protein]; Etoposide results in increased activity of and affects the localization of BAX protein; Etoposide results in increased cleavage of and results in increased expression of BAX protein; Nicotine inhibits the reaction [[Cisplatin co-treated with Etoposide] affects the localization of BAX protein]; nimesulide inhibits the reaction [Etoposide results in increased activity of and affects the localization of BAX protein] Etoposide results in increased expression of BAX mRNA; Etoposide results in increased expression of BAX protein BAX protein affects the susceptibility to Etoposide |
CTD |
PMID:9815696 PMID:10620629 PMID:15131059 PMID:16077961 PMID:16120219 PMID:18676776 PMID:21527772 PMID:21745461 PMID:21880625 PMID:29397400 PMID:33148531 More...
|
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bbc3 |
Bcl-2 binding component 3 |
increases expression multiple interactions affects response to substance |
ISO |
Etoposide results in increased expression of BBC3 mRNA; Etoposide results in increased expression of BBC3 protein entinostat promotes the reaction [Etoposide results in increased expression of BBC3 protein]; Etoposide promotes the reaction [entinostat results in increased expression of BBC3 protein]; Etoposide promotes the reaction [trichostatin A results in increased expression of BBC3 protein]; Etoposide promotes the reaction [UF010 compound results in increased expression of BBC3 protein]; TP53 protein modified form inhibits the reaction [Etoposide results in increased expression of BBC3 protein]; trichostatin A promotes the reaction [Etoposide results in increased expression of BBC3 protein]; UF010 compound promotes the reaction [Etoposide results in increased expression of BBC3 protein] BBC3 protein affects the susceptibility to Etoposide |
CTD |
PMID:20477944 PMID:21801448 PMID:25699604 PMID:37956312 |
|
NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions decreases expression |
ISO |
[Doxorubicin co-treated with Vincristine co-treated with Etoposide co-treated with Mitotane] results in decreased expression of BCL2 protein; [Etoposide co-treated with Ciprofloxacin] results in decreased expression of BCL2 protein; [trigonelline co-treated with Etoposide] results in decreased expression of BCL2 protein; BCL2 protein inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; BCL2 protein inhibits the reaction [Etoposide results in increased degradation of PARP1 protein]; BCL2 protein results in decreased susceptibility to [Cisplatin co-treated with Etoposide] Etoposide results in decreased expression of BCL2 mRNA; Etoposide results in decreased expression of BCL2 protein [G(M3) Ganglioside results in increased expression of BCL2 protein] which results in decreased susceptibility to Etoposide; BCL2 protein affects the reaction [[Etoposide results in increased activity of GSK3B protein] which results in increased activity of CASP3 protein]; Lithium Chloride inhibits the reaction [Etoposide results in decreased expression of BCL2 mRNA]; Lithium Chloride inhibits the reaction [Etoposide results in decreased expression of BCL2 protein] |
CTD |
PMID:8840993 PMID:9815696 PMID:12063570 PMID:15917659 PMID:16571667 PMID:19408126 PMID:33148531 More...
|
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions affects expression decreases response to substance |
ISO |
[[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [VCAM1 protein co-treated with IL4 protein] inhibits the reaction [Etoposide inhibits the reaction [BAX protein binds to BCL2L1 protein]]; BCL2L1 protein inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; BCL2L1 protein inhibits the reaction [Etoposide results in increased degradation of PARP1 protein]; BCL2L1 protein results in decreased susceptibility to [Cisplatin co-treated with Etoposide]; Etoposide inhibits the reaction [BAX protein binds to BCL2L1 protein] Etoposide affects the expression of BCL2L1 protein BCL2L1 protein results in decreased susceptibility to Etoposide |
CTD |
PMID:8840993 PMID:10620629 PMID:11468182 PMID:15215046 PMID:15917659 PMID:19047049 More...
|
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Bcl2l2 |
Bcl2-like 2 |
decreases response to substance |
ISO |
BCL2L2 results in decreased susceptibility to Etoposide |
CTD |
PMID:14973057 |
|
NCBI chr15:28,346,449...28,361,627
Ensembl chr15:28,356,807...28,361,624
|
|
G |
Bcl6b |
BCL6B, transcription repressor |
multiple interactions |
ISO |
[Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in decreased expression of BCL6B mRNA |
CTD |
PMID:29733421 |
|
NCBI chr10:54,940,908...54,947,022
Ensembl chr10:54,940,909...54,945,974
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
increases expression multiple interactions |
ISO |
Etoposide results in increased expression of BDNF mRNA HIPK2 mutant form inhibits the reaction [Etoposide results in increased expression of BDNF mRNA] |
CTD |
PMID:20573984 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Bid |
BH3 interacting domain death agonist |
multiple interactions increases expression increases cleavage |
ISO |
CASP9 mutant form inhibits the reaction [Etoposide results in increased cleavage of BID protein]; Estradiol inhibits the reaction [Etoposide results in increased expression of BID mRNA] |
CTD |
PMID:19426747 PMID:21801448 |
|
NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720
|
|
G |
Bik |
BCL2-interacting killer |
increases response to substance |
ISO |
BIK protein results in increased susceptibility to Etoposide |
CTD |
PMID:16007125 |
|
NCBI chr 7:114,672,277...114,691,296
Ensembl chr 7:114,672,277...114,691,296
|
|
G |
Bin1 |
bridging integrator 1 |
increases response to substance |
ISO |
BIN1 protein results in increased susceptibility to Etoposide |
CTD |
PMID:21447800 |
|
NCBI chr18:24,009,731...24,067,267
Ensembl chr18:24,009,653...24,067,263
|
|
G |
Bin3 |
bridging integrator 3 |
affects response to substance |
ISO |
BIN3 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr15:45,173,725...45,212,607
Ensembl chr15:45,173,732...45,212,604
|
|
G |
Birc2 |
baculoviral IAP repeat-containing 2 |
affects response to substance decreases response to substance increases expression |
ISO |
BIRC2 protein affects the susceptibility to Etoposide BIRC2 protein results in decreased susceptibility to Etoposide Etoposide results in increased expression of BIRC2 mRNA |
CTD |
PMID:10815900 PMID:14970392 PMID:15050749 PMID:16217747 |
|
NCBI chr 8:4,968,856...4,989,325
Ensembl chr 8:4,968,842...4,988,732
|
|
G |
Birc3 |
baculoviral IAP repeat-containing 3 |
decreases response to substance decreases expression multiple interactions |
ISO |
BIRC3 protein results in decreased susceptibility to Etoposide Etoposide results in decreased expression of BIRC3 mRNA [Etoposide co-treated with KN 62] results in decreased expression of BIRC3 protein |
CTD |
PMID:14666661 PMID:15050749 PMID:16120219 |
|
NCBI chr 8:5,000,844...5,028,470
Ensembl chr 8:5,000,845...5,015,802
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
multiple interactions decreases response to substance increases expression |
ISO |
[FOXO3 protein results in decreased expression of BIRC5 protein] which results in increased susceptibility to Etoposide; BIRC5 protein inhibits the reaction [FOXO3 protein results in increased susceptibility to Etoposide]; BIRC5 protein results in decreased susceptibility to [Cisplatin co-treated with Etoposide]; Estradiol inhibits the reaction [Etoposide results in increased expression of BIRC5 mRNA] BIRC5 protein results in decreased susceptibility to Etoposide |
CTD |
PMID:15917659 PMID:16322251 PMID:16364925 PMID:16382892 PMID:19211844 PMID:19426747 More...
|
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Birc7 |
baculoviral IAP repeat-containing 7 |
decreases response to substance |
ISO |
BIRC7 protein results in decreased susceptibility to Etoposide |
CTD |
PMID:17437058 |
|
NCBI chr 3:168,047,824...168,052,606
Ensembl chr 3:168,047,824...168,052,606
|
|
G |
Blm |
BLM RecQ like helicase |
decreases expression |
ISO |
Etoposide results in decreased expression of BLM mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 1:134,409,832...134,496,073
Ensembl chr 1:134,409,857...134,484,312
|
|
G |
Bmp6 |
bone morphogenetic protein 6 |
multiple interactions |
ISO |
Etoposide inhibits the reaction [BMP6 protein results in increased expression of HAMP mRNA] |
CTD |
PMID:25633564 |
|
NCBI chr17:26,318,121...26,469,691
Ensembl chr17:26,318,569...26,470,365
|
|
G |
Brca1 |
BRCA1, DNA repair associated |
multiple interactions increases expression decreases expression |
ISO |
BRCA1 protein mutant form inhibits the reaction [Etoposide results in increased expression of CDK2 protein]; BRCA1 protein mutant form inhibits the reaction [Etoposide results in increased expression of RAD52 protein]; BRCA1 protein mutant form inhibits the reaction [Etoposide results in increased expression of RAD54L protein]; BRCA1 protein mutant form inhibits the reaction [Etoposide results in increased expression of XRCC2 protein]; BRCA1 protein mutant form inhibits the reaction [Etoposide results in increased expression of XRCC3 protein]; BRCA1 protein mutant form inhibits the reaction [Etoposide results in increased expression of XRCC4 protein]; pifithrin inhibits the reaction [Etoposide results in increased expression of and affects the localization of BRCA1 protein] Etoposide results in increased expression of BRCA1 protein Etoposide results in decreased expression of BRCA1 mRNA |
CTD |
PMID:15607317 PMID:16417649 PMID:26259609 |
|
NCBI chr10:86,417,441...86,477,762
Ensembl chr10:86,418,000...86,477,304
|
|
G |
Bscl2 |
BSCL2 lipid droplet biogenesis associated, seipin |
increases expression |
ISO |
Etoposide results in increased expression of BSCL2 mRNA |
CTD |
PMID:22003191 PMID:25270620 |
|
NCBI chr 1:205,731,828...205,743,430
Ensembl chr 1:205,733,872...205,743,421
|
|
G |
Btg2 |
BTG anti-proliferation factor 2 |
multiple interactions increases expression |
ISO |
TRP53 protein affects the reaction [Etoposide results in increased expression of BTG2 mRNA] TP53 promotes the reaction [Etoposide results in increased expression of BTG2 protein] Etoposide results in increased expression of BTG2 mRNA; Etoposide results in increased expression of BTG2 protein |
CTD |
PMID:21382384 PMID:22003191 PMID:24211769 PMID:27358234 |
|
NCBI chr13:45,531,881...45,535,642
Ensembl chr13:45,531,925...45,535,628
|
|
G |
Btg3 |
BTG anti-proliferation factor 3 |
decreases expression |
ISO |
Etoposide results in decreased expression of BTG3 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr11:17,030,156...17,046,069
Ensembl chr11:17,030,160...17,046,170
|
|
G |
Bub1 |
BUB1 mitotic checkpoint serine/threonine kinase |
decreases expression |
ISO |
Etoposide results in decreased expression of BUB1 mRNA |
CTD |
PMID:16120219 |
|
NCBI chr 3:115,020,254...115,051,650
Ensembl chr 3:115,020,254...115,051,650
|
|
G |
Bub1b |
BUB1 mitotic checkpoint serine/threonine kinase B |
decreases expression |
ISO |
Etoposide results in decreased expression of BUB1B mRNA |
CTD |
PMID:16120219 |
|
NCBI chr 3:105,563,089...105,615,547
Ensembl chr 3:105,563,138...105,615,547
|
|
G |
C14h4orf19 |
similar to human chromosome 4 open reading frame 19 |
affects response to substance |
ISO |
C4ORF19 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr14:44,387,386...44,478,344
Ensembl chr14:44,387,393...44,478,041
|
|
G |
C1qbp |
complement C1q binding protein |
decreases response to substance |
ISO |
C1QBP protein results in decreased susceptibility to Etoposide |
CTD |
PMID:25354864 |
|
NCBI chr10:55,699,954...55,704,605
Ensembl chr10:55,699,954...55,704,649
|
|
G |
C2h5orf22 |
similar to human chromosome 5 open reading frame 22 |
affects response to substance |
ISO |
C5ORF22 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 2:61,848,790...61,864,762
Ensembl chr 2:61,849,363...61,864,738
|
|
G |
Cab39 |
calcium binding protein 39 |
decreases expression |
ISO |
Etoposide results in decreased expression of CAB39 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 9:86,463,095...86,524,545
Ensembl chr 9:86,463,095...86,524,544
|
|
G |
Cadps2 |
calcium dependent secretion activator 2 |
affects response to substance |
ISO |
CADPS2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 4:51,780,415...52,309,641
Ensembl chr 4:51,781,053...52,309,829
|
|
G |
Calca |
calcitonin-related polypeptide alpha |
multiple interactions decreases response to substance |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [CALCA protein results in decreased susceptibility to Etoposide] |
CTD |
PMID:16222118 |
|
NCBI chr 1:168,878,212...168,883,176
Ensembl chr 1:168,878,214...168,883,105
|
|
G |
Calm1 |
calmodulin 1 |
increases expression |
ISO |
Etoposide results in increased expression of CALM1 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 6:119,487,691...119,495,759
Ensembl chr 6:119,487,621...119,498,227
|
|
G |
Card10 |
caspase recruitment domain family, member 10 |
multiple interactions increases expression |
ISO |
Estradiol inhibits the reaction [Etoposide results in increased expression of CARD10 mRNA] |
CTD |
PMID:19426747 |
|
NCBI chr 7:110,330,460...110,371,551
Ensembl chr 7:110,330,408...110,359,224
|
|
G |
Casp2 |
caspase 2 |
increases expression increases splicing |
ISO |
Etoposide results in increased expression of CASP2 mRNA alternative form Etoposide results in increased splicing of CASP2 mRNA |
CTD |
PMID:14757846 |
|
NCBI chr 4:71,149,632...71,167,388
Ensembl chr 4:71,149,669...71,167,379
|
|
G |
Casp3 |
caspase 3 |
affects expression increases cleavage multiple interactions increases activity increases expression |
ISO EXP |
Etoposide affects the expression of CASP3 protein Etoposide results in increased cleavage of CASP3 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Etoposide results in increased cleavage of CASP3 protein]; 3',4'-dihydroxyflavone analog inhibits the reaction [Etoposide results in increased cleavage of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [CASP8 co-treated with TP53] affects the reaction [Etoposide results in increased cleavage of CASP3 protein]; [Etoposide co-treated with Mifepristone] results in increased activity of CASP3 protein; [RASSF1 co-treated with Etoposide] results in increased cleavage of CASP3 protein; [STAT1 protein results in increased activity of CASP3 protein] which results in increased susceptibility to Etoposide; [trigonelline co-treated with Etoposide] results in increased cleavage of CASP3 protein; Acetylcysteine inhibits the reaction [Etoposide results in increased cleavage of CASP3 protein]; Aspirin inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; BCL2 protein inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; BCL2L1 protein inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; benzyloxycarbonyl-leucyl-glutamyl-histidyl-aspartic acid fluoromethyl ketone inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; benzyloxycarbonyl-valyl-alanyl-aspartyl-fluoromethane inhibits the reaction [Etoposide results in increased cleavage of CASP3 protein]; CASP8 mutant form inhibits the reaction [Etoposide results in increased cleavage of CASP3 protein]; CD40LG protein inhibits the reaction [Etoposide promotes the reaction [CASP3 protein results in increased cleavage of PARP1 protein]]; CDKN1A mutant form inhibits the reaction [Aspirin inhibits the reaction [Etoposide results in increased activity of CASP3 protein]]; Dehydroascorbic Acid promotes the reaction [Etoposide results in increased activity of CASP3 protein]; Etoposide promotes the reaction [CASP3 protein results in increased cleavage of PARP1 protein]; Etoposide promotes the reaction [Gold results in increased activity of CASP3 protein]; Etoposide promotes the reaction [Nanotubes, Carbon results in increased activity of CASP3 protein]; Etoposide promotes the reaction [Silver results in increased activity of CASP3 protein]; Etoposide results in increased cleavage of and results in increased activity of CASP3 protein; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Etoposide results in increased cleavage of CASP3 protein]; nimesulide inhibits the reaction [Etoposide results in increased cleavage of CASP3 protein]; Oxygen deficiency inhibits the reaction [Etoposide results in increased expression of CASP3 protein]; palbociclib inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; pifithrin promotes the reaction [Etoposide results in increased activity of CASP3 protein]; pifithrin promotes the reaction [Etoposide results in increased cleavage of CASP3 protein]; Tetrachlorodibenzodioxin inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; TMSB4X protein inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; TP73 mutant form inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; TP73 mutant form inhibits the reaction [Etoposide results in increased cleavage of CASP3 protein]; Wortmannin promotes the reaction [Etoposide results in increased cleavage of and results in increased activity of CASP3 protein] Etoposide results in increased expression of CASP3 protein; Etoposide results in increased expression of CASP3 protein modified form [Etoposide results in increased activity of GSK3B protein] which results in increased activity of CASP3 protein; Etoposide results in increased activity of CASP3 protein 2-tert-butylhydroquinone inhibits the reaction [Etoposide results in increased cleavage of and results in increased activity of CASP3 protein]; BCL2 protein affects the reaction [[Etoposide results in increased activity of GSK3B protein] which results in increased activity of CASP3 protein]; Etoposide results in increased cleavage of and results in increased activity of CASP3 protein; HIPK2 gene mutant form promotes the reaction [Etoposide results in increased activity of CASP3 protein]; Metoclopramide inhibits the reaction [Etoposide results in increased activity of CASP3 protein] |
CTD |
PMID:8840993 PMID:10759716 PMID:12871656 PMID:15215046 PMID:15924153 PMID:16014620 PMID:16192531 PMID:16364925 PMID:16545138 PMID:16844113 PMID:16951922 PMID:17516866 PMID:17935137 PMID:18056177 PMID:18649362 PMID:19047049 PMID:19408126 PMID:19662097 PMID:19760634 PMID:20299546 PMID:20573984 PMID:21617849 PMID:21745461 PMID:21745629 PMID:21801448 PMID:21880625 PMID:22275372 PMID:22302033 PMID:23144690 PMID:25447644 PMID:26259609 PMID:29027213 PMID:30217652 PMID:30890322 PMID:33148531 PMID:35065218 More...
|
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp7 |
caspase 7 |
multiple interactions increases activity |
ISO |
[STAT1 protein results in increased activity of CASP7 protein] which results in increased susceptibility to Etoposide; benzyloxycarbonyl-leucyl-glutamyl-histidyl-aspartic acid fluoromethyl ketone inhibits the reaction [Etoposide results in increased activity of CASP7 protein]; palbociclib inhibits the reaction [Etoposide results in increased activity of CASP7 protein]; pifithrin promotes the reaction [Etoposide results in increased activity of CASP7 protein]; Tetrachlorodibenzodioxin inhibits the reaction [Etoposide results in increased activity of CASP7 protein]; TP73 mutant form inhibits the reaction [Etoposide results in increased activity of CASP7 protein] 2-tert-butylhydroquinone inhibits the reaction [Etoposide results in increased activity of CASP7 protein] |
CTD |
PMID:18056177 PMID:18649362 PMID:20299546 PMID:21801448 PMID:22275372 PMID:22302033 PMID:26259609 More...
|
|
NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Casp8 |
caspase 8 |
multiple interactions increases response to substance increases cleavage increases activity |
ISO |
3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione inhibits the reaction [Etoposide results in increased activity of CASP8 protein]; [CASP8 co-treated with TP53] affects the reaction [Etoposide results in increased cleavage of and results in increased activity of CASP9 protein]; [CASP8 co-treated with TP53] affects the reaction [Etoposide results in increased cleavage of CASP3 protein]; [CASP8 co-treated with TP53] affects the reaction [Etoposide results in increased cleavage of PARP1 protein]; [CASP8 co-treated with TP53] inhibits the reaction [CASP8 protein mutant form results in decreased susceptibility to Etoposide]; acetyl-leucyl-glutamyl-histidyl-aspartal inhibits the reaction [Etoposide results in increased activity of CASP8 protein]; CASP8 mutant form inhibits the reaction [Etoposide results in increased cleavage of CASP3 protein]; CASP8 mutant form inhibits the reaction [Etoposide results in increased cleavage of CASP9 protein]; Etoposide results in increased cleavage of and results in increased activity of CASP8 protein; Etoposide results in increased expression of and results in increased cleavage of CASP8 protein; Lithium inhibits the reaction [Etoposide results in increased activity of CASP8 protein]; nimesulide inhibits the reaction [Etoposide results in increased cleavage of and results in increased activity of CASP8 protein]; TP73 mutant form inhibits the reaction [Etoposide results in increased cleavage of CASP8 protein] CASP8 protein results in increased susceptibility to Etoposide |
CTD |
PMID:15475000 PMID:21745461 PMID:21801448 PMID:22010212 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
multiple interactions increases cleavage increases activity affects expression |
ISO |
[CASP8 co-treated with TP53] affects the reaction [Etoposide results in increased cleavage of and results in increased activity of CASP9 protein]; [Cisplatin co-treated with Etoposide] results in increased activity of CASP9 protein; CASP8 mutant form inhibits the reaction [Etoposide results in increased cleavage of CASP9 protein]; CASP9 mutant form inhibits the reaction [Etoposide results in increased cleavage of BID protein]; Etoposide results in increased cleavage of and results in increased activity of CASP9 protein; HTATIP2 protein promotes the reaction [Etoposide results in increased activity of CASP9 protein]; MYC protein promotes the reaction [Etoposide results in increased cleavage of CASP9 protein]; Nicotine inhibits the reaction [[Cisplatin co-treated with Etoposide] results in increased activity of CASP9 protein]; nimesulide inhibits the reaction [Etoposide results in increased cleavage of and results in increased activity of CASP9 protein]; TMSB4X protein inhibits the reaction [Etoposide results in increased cleavage of and results in increased activity of CASP9 protein]; Wortmannin promotes the reaction [Etoposide results in increased cleavage of CASP9 protein] Etoposide affects the expression of CASP9 protein |
CTD |
PMID:12925536 PMID:15215046 PMID:16364925 PMID:16799960 PMID:17935137 PMID:18056177 PMID:18676776 PMID:21324178 PMID:21745461 PMID:21801448 More...
|
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Casq2 |
calsequestrin 2 |
decreases expression |
ISO |
Etoposide results in decreased expression of CASQ2 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 2:189,526,003...189,582,276
Ensembl chr 2:189,525,960...189,582,267
|
|
G |
Cast |
calpastatin |
multiple interactions |
ISO |
CAST inhibits the reaction [Etoposide results in increased degradation of AR protein] |
CTD |
PMID:18726991 |
|
NCBI chr 2:3,973,112...4,082,658
Ensembl chr 2:3,973,112...4,082,659
|
|
G |
Cat |
catalase |
increases response to substance multiple interactions increases activity |
ISO EXP |
CAT results in increased susceptibility to Etoposide EPO protein inhibits the reaction [Etoposide results in increased activity of CAT protein] |
CTD |
PMID:21689642 PMID:25451571 PMID:29069929 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccdc51 |
coiled-coil domain containing 51 |
decreases expression |
ISO |
Etoposide results in decreased expression of CCDC51 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 8:109,722,595...109,741,478
Ensembl chr 8:109,722,557...109,741,472
|
|
G |
Ccdc6 |
coiled-coil domain containing 6 |
increases response to substance decreases response to substance |
ISO |
CCDC6 results in increased susceptibility to Etoposide CCDC6 results in decreased susceptibility to Etoposide |
CTD |
PMID:22363533 PMID:22655027 |
|
NCBI chr20:18,432,177...18,528,186
Ensembl chr20:18,433,695...18,528,658
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
increases expression |
ISO |
Etoposide results in increased expression of CCL3 protein |
CTD |
PMID:10540334 |
|
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Ccn2 |
cellular communication network factor 2 |
increases expression |
ISO |
Etoposide results in increased expression of CCN2 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734
|
|
G |
Ccna2 |
cyclin A2 |
multiple interactions decreases expression |
ISO |
Etoposide affects the expression of and affects the localization of CCNA2 protein Etoposide results in decreased expression of CCNA2 mRNA; Etoposide results in decreased expression of CCNA2 protein |
CTD |
PMID:16120219 PMID:17390037 |
|
NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577
|
|
G |
Ccnb1 |
cyclin B1 |
decreases expression |
ISO |
Etoposide results in decreased expression of CCNB1 mRNA; Etoposide results in decreased expression of CCNB1 protein |
CTD |
PMID:16120219 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Ccnd1 |
cyclin D1 |
increases expression |
ISO |
Etoposide results in increased expression of CCND1 mRNA |
CTD |
PMID:16120219 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccng1 |
cyclin G1 |
increases expression |
ISO |
Etoposide results in increased expression of CCNG1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr10:25,176,231...25,182,604
Ensembl chr10:25,176,234...25,181,641
|
|
G |
Ccng2 |
cyclin G2 |
increases expression |
ISO |
Etoposide results in increased expression of CCNG2 mRNA |
CTD |
PMID:18754885 |
|
NCBI chr14:14,804,321...14,812,819
Ensembl chr14:14,804,322...14,812,830
|
|
G |
Ccs |
copper chaperone for superoxide dismutase |
increases expression |
ISO |
Etoposide results in increased expression of CCS mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 1:202,113,792...202,134,931
Ensembl chr 1:202,113,804...202,134,915
|
|
G |
Cct8 |
chaperonin containing TCP1 subunit 8 |
multiple interactions |
ISO |
[Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in decreased expression of CCT8 protein |
CTD |
PMID:29733421 |
|
NCBI chr11:26,710,370...26,722,079
Ensembl chr11:26,710,370...26,722,079
|
|
G |
Cd274 |
CD274 molecule |
increases expression |
ISO |
Etoposide results in increased expression of CD274 protein |
CTD |
PMID:17920123 |
|
NCBI chr 1:227,116,674...227,137,379
Ensembl chr 1:227,116,649...227,134,450
|
|
G |
Cd40lg |
CD40 ligand |
multiple interactions decreases response to substance |
ISO |
CD40LG protein inhibits the reaction [Etoposide promotes the reaction [CASP3 protein results in increased cleavage of PARP1 protein]] CD40LG protein results in decreased susceptibility to Etoposide |
CTD |
PMID:16545138 |
|
NCBI chr X:135,127,052...135,138,768
Ensembl chr X:135,126,969...135,138,306
|
|
G |
Cd44 |
CD44 molecule |
affects response to substance multiple interactions |
ISO |
CD44 protein affects the susceptibility to Etoposide [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in decreased susceptibility to Etoposide; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in decreased susceptibility to Etoposide; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in decreased susceptibility to Etoposide]; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in decreased susceptibility to Etoposide] |
CTD |
PMID:15215046 PMID:19047049 |
|
NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620
|
|
G |
Cd55 |
CD55 molecule (Cromer blood group) |
affects response to substance |
ISO |
CD55 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr13:41,857,242...41,885,966
Ensembl chr13:41,857,395...41,885,831
|
|
G |
Cd59b |
CD59b molecule |
multiple interactions |
ISO |
[Cisplatin co-treated with Etoposide] results in decreased expression of CD59 protein |
CTD |
PMID:21826740 |
|
NCBI chr 3:90,459,085...90,477,571
Ensembl chr 3:90,459,162...90,478,847
|
|
G |
Cdc25a |
cell division cycle 25A |
decreases expression |
ISO |
Etoposide results in decreased expression of CDC25A mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 8:109,864,356...109,882,734
Ensembl chr 8:109,864,478...109,882,701
|
|
G |
Cdc25c |
cell division cycle 25C |
decreases expression |
ISO |
Etoposide results in decreased expression of CDC25C mRNA |
CTD |
PMID:16120219 |
|
NCBI chr18:26,335,156...26,356,199
Ensembl chr18:26,335,834...26,356,185
|
|
G |
Cdc42bpg |
CDC42 binding protein kinase gamma |
increases expression |
ISO |
Etoposide results in increased expression of CDC42BPG mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 1:203,608,339...203,628,502
Ensembl chr 1:203,608,574...203,628,502
|
|
G |
Cdc45 |
cell division cycle 45 |
decreases expression |
ISO |
Etoposide results in decreased expression of CDC45 mRNA |
CTD |
PMID:16120219 |
|
NCBI chr11:82,185,427...82,210,630
Ensembl chr11:82,185,473...82,210,619
|
|
G |
Cdc6 |
cell division cycle 6 |
decreases expression |
ISO |
Etoposide results in decreased expression of CDC6 mRNA |
CTD |
PMID:16120219 |
|
NCBI chr10:83,864,189...83,878,011
Ensembl chr10:83,864,638...83,878,011
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
multiple interactions increases expression affects response to substance |
ISO |
BRCA1 protein mutant form inhibits the reaction [Etoposide results in increased expression of CDK2 protein]; CDK2 affects the reaction [Etoposide results in increased phosphorylation of TPI1 protein] CDK2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 PMID:16417649 PMID:20149834 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions increases expression |
ISO EXP |
[Etoposide results in increased susceptibility to Benzo(a)pyrene] which results in increased expression of CDKN1A protein; [RASSF1 co-treated with Etoposide] results in increased expression of CDKN1A protein; CDKN1A mutant form inhibits the reaction [Aspirin inhibits the reaction [Etoposide results in increased activity of CASP3 protein]]; CDKN1A protein affects the reaction [Etoposide results in decreased expression of UBE2C protein]; entinostat promotes the reaction [Etoposide results in increased expression of CDKN1A protein]; Etoposide promotes the reaction [entinostat results in increased expression of CDKN1A protein]; Etoposide promotes the reaction [trichostatin A results in increased expression of CDKN1A protein]; Etoposide promotes the reaction [UF010 compound results in increased expression of CDKN1A protein]; KEAP1 protein affects the reaction [Etoposide results in increased expression of CDKN1A protein]; resveratrol inhibits the reaction [Etoposide results in increased expression of CDKN1A mRNA]; TP53 affects the reaction [Etoposide results in increased expression of CDKN1A mRNA]; TP53 promotes the reaction [Etoposide results in increased expression of CDKN1A protein]; TP53 protein promotes the reaction [[Etoposide results in increased susceptibility to Benzo(a)pyrene] which results in increased expression of CDKN1A protein]; TP53 protein promotes the reaction [Etoposide results in increased expression of CDKN1A protein]; trichostatin A promotes the reaction [Etoposide results in increased expression of CDKN1A protein]; UF010 compound promotes the reaction [Etoposide results in increased expression of CDKN1A protein] Etoposide results in increased expression of CDKN1A mRNA; Etoposide results in increased expression of CDKN1A protein [CDKN2A gene mutant form results in increased expression of CDKN2A protein alternative form] inhibits the reaction [Etoposide results in increased expression of CDKN1A protein]; TRP53 affects the reaction [Etoposide results in increased expression of CDKN1A mRNA] cordycepin inhibits the reaction [Etoposide results in increased expression of CDKN1A mRNA]; Etoposide promotes the reaction [Niacin deficiency results in increased expression of CDKN1A protein]; mithramycin A inhibits the reaction [Etoposide results in increased expression of CDKN1A mRNA]; salubrinal inhibits the reaction [Etoposide results in increased expression of CDKN1A mRNA] |
CTD |
PMID:14601052 PMID:16120219 PMID:16882877 PMID:17516866 PMID:21212465 PMID:21526190 PMID:21527772 PMID:21617849 PMID:21801448 PMID:21880625 PMID:23690541 PMID:24067374 PMID:24211769 PMID:25078064 PMID:25699604 PMID:25914138 PMID:26055805 PMID:27129209 PMID:27358234 PMID:27982581 PMID:29471073 More...
|
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
increases expression multiple interactions |
ISO |
Etoposide results in increased expression of CDKN1B protein wortmannin promotes the reaction [Etoposide results in increased expression of CDKN1B protein] |
CTD |
PMID:17935137 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
increases expression multiple interactions |
EXP ISO |
Etoposide results in increased expression of CDKN2A mRNA [CDKN2A gene mutant form results in increased expression of CDKN2A protein alternative form] inhibits the reaction [Etoposide results in increased expression of CDKN1A protein]; [CDKN2A gene mutant form results in increased expression of CDKN2A protein alternative form] inhibits the reaction [Etoposide results in increased expression of TRP53 protein] cordycepin inhibits the reaction [Etoposide results in increased expression of CDKN2A mRNA]; mithramycin A inhibits the reaction [Etoposide results in increased expression of CDKN2A mRNA]; salubrinal inhibits the reaction [Etoposide results in increased expression of CDKN2A mRNA] |
CTD |
PMID:21526190 PMID:23690541 |
|
NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149
|
|
G |
Cdkn3 |
cyclin-dependent kinase inhibitor 3 |
decreases expression |
ISO |
Etoposide results in decreased expression of CDKN3 mRNA |
CTD |
PMID:16120219 |
|
NCBI chr15:20,022,522...20,033,948
Ensembl chr15:20,022,664...20,033,945
|
|
G |
Ceacam1 |
CEA cell adhesion molecule 1 |
increases expression |
ISO |
Etoposide results in increased expression of CEACAM1 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 1:81,043,595...81,060,050
Ensembl chr 1:81,043,595...81,059,992
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
decreases expression increases degradation |
ISO |
Etoposide results in decreased expression of CEBPA mRNA; Etoposide results in decreased expression of CEBPA protein Etoposide results in increased degradation of CEBPA protein |
CTD |
PMID:19662097 |
|
NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412
|
|
G |
Cebpz |
CCAAT/enhancer binding protein zeta |
decreases expression |
ISO |
Etoposide results in decreased expression of CEBPZ mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 6:16,119,871...16,137,600
Ensembl chr 6:16,119,872...16,137,600
|
|
G |
Cel |
carboxyl ester lipase |
increases expression |
ISO |
Etoposide results in increased expression of CEL mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 3:11,883,532...11,891,035
Ensembl chr 3:11,883,532...11,891,035
|
|
G |
Cenpf |
centromere protein F |
decreases expression |
ISO |
Etoposide results in decreased expression of CENPF mRNA |
CTD |
PMID:16120219 |
|
NCBI chr13:101,184,127...101,229,714
Ensembl chr13:101,184,127...101,229,669
|
|
G |
Cercam |
cerebral endothelial cell adhesion molecule |
increases expression |
ISO |
Etoposide results in increased expression of CERCAM mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 3:13,118,150...13,155,960
Ensembl chr 3:13,142,107...13,155,956
|
|
G |
Ces1d |
carboxylesterase 1D |
increases expression |
ISO |
Etoposide results in increased expression of CES1D mRNA |
CTD |
PMID:25270620 |
|
NCBI chr19:13,873,490...13,912,035
Ensembl chr19:13,796,623...13,912,035
|
|
G |
Ces2e |
carboxylesterase 2E |
increases expression |
ISO |
Etoposide results in increased expression of CES2E mRNA |
CTD |
PMID:25270620 |
|
NCBI chr19:157,447...172,822
Ensembl chr19:157,407...172,856
|
|
G |
Cflar |
CASP8 and FADD-like apoptosis regulator |
increases expression |
ISO |
Etoposide results in increased expression of CFLAR protein |
CTD |
PMID:14601052 |
|
NCBI chr 9:60,185,338...60,236,173
Ensembl chr 9:60,185,452...60,237,034
|
|
G |
Cgref1 |
cell growth regulator with EF hand domain 1 |
increases expression |
ISO |
Etoposide results in increased expression of CGREF1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 6:25,431,846...25,443,853
Ensembl chr 6:25,431,799...25,443,852
|
|
G |
Chac1 |
ChaC glutathione-specific gamma-glutamylcyclotransferase 1 |
decreases expression |
ISO |
Etoposide results in decreased expression of CHAC1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 3:106,342,302...106,345,526
Ensembl chr 3:106,342,302...106,345,526
|
|
G |
Chaf1a |
chromatin assembly factor 1 subunit A |
decreases expression |
ISO |
Etoposide results in decreased expression of CHAF1A mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 9:873,953...900,701
Ensembl chr 9:874,051...900,654
|
|
G |
Chek1 |
checkpoint kinase 1 |
affects response to substance multiple interactions |
ISO |
CHEK1 protein affects the susceptibility to Etoposide TP53 protein affects the reaction [CHEK1 protein affects the susceptibility to Etoposide] |
CTD |
PMID:18698031 |
|
NCBI chr 8:36,420,565...36,443,477
Ensembl chr 8:36,420,569...36,441,009
|
|
G |
Chek2 |
checkpoint kinase 2 |
increases phosphorylation multiple interactions |
ISO |
Etoposide results in increased phosphorylation of CHEK2 protein 4-fluoro-2-(4-(4-(2-hydroxypropan-2-yl)pyrrolidin-3-ylamino)-6,7-dimethoxyquinazolin-2-yl)phenol inhibits the reaction [Etoposide results in increased phosphorylation of CHEK2 protein]; pifithrin inhibits the reaction [Etoposide results in increased phosphorylation of CHEK2 protein] |
CTD |
PMID:21186793 PMID:22242153 PMID:26259609 |
|
NCBI chr12:45,788,823...45,821,382
Ensembl chr12:45,788,827...45,821,286
|
|
G |
Chi3l1 |
chitinase 3 like 1 |
decreases response to substance |
ISO |
CHI3L1 results in decreased susceptibility to Etoposide |
CTD |
PMID:20506295 |
|
NCBI chr13:45,641,802...45,649,787
Ensembl chr13:45,641,802...45,649,787
|
|
G |
Chuk |
component of inhibitor of nuclear factor kappa B kinase complex |
decreases expression |
ISO |
Etoposide results in decreased expression of CHUK protein |
CTD |
PMID:30177839 |
|
NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065
|
|
G |
Ciapin1 |
cytokine induced apoptosis inhibitor 1 |
decreases response to substance |
ISO |
CIAPIN1 protein results in decreased susceptibility to Etoposide |
CTD |
PMID:18389626 |
|
NCBI chr19:10,179,963...10,195,511
Ensembl chr19:10,180,100...10,195,503
|
|
G |
Ckm |
creatine kinase, M-type |
decreases expression |
ISO |
Etoposide results in decreased expression of CKM mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 1:79,061,390...79,071,721
Ensembl chr 1:79,061,456...79,071,720
|
|
G |
Ckmt1 |
creatine kinase, mitochondrial 1 |
affects response to substance |
ISO |
CKMT1B protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 3:108,329,859...108,335,760
Ensembl chr 3:108,330,705...108,335,758
|
|
G |
Coa7 |
cytochrome c oxidase assembly factor 7 |
decreases expression |
ISO |
Etoposide results in decreased expression of COA7 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 5:123,069,356...123,080,942
Ensembl chr 5:123,069,371...123,080,199
|
|
G |
Cobl |
cordon-bleu WH2 repeat protein |
decreases expression |
ISO |
Etoposide results in decreased expression of COBL mRNA |
CTD |
PMID:25270620 |
|
NCBI chr14:86,828,137...87,060,682
Ensembl chr14:86,828,139...87,060,800
|
|
G |
Col15a1 |
collagen type XV alpha 1 chain |
affects response to substance |
ISO |
COL15A1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 5:61,501,963...61,607,591
Ensembl chr 5:61,501,963...61,607,591
|
|
G |
Col4a1 |
collagen type IV alpha 1 chain |
decreases expression |
ISO |
Etoposide results in decreased expression of COL4A1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr16:78,183,533...78,294,412
Ensembl chr16:78,183,533...78,294,412
|
|
G |
Col9a3 |
collagen type IX alpha 3 chain |
affects response to substance |
ISO |
COL9A3 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 3:167,711,776...167,734,468
Ensembl chr 3:167,711,840...167,734,465
|
|
G |
Cox6a2 |
cytochrome c oxidase subunit 6A2 |
decreases expression |
ISO |
Etoposide results in decreased expression of COX6A2 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 1:182,788,528...182,790,746
Ensembl chr 1:182,788,528...182,789,274
|
|
G |
Cps1 |
carbamoyl-phosphate synthase 1 |
affects response to substance |
ISO |
CPS1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 9:68,614,153...68,737,037
Ensembl chr 9:68,614,153...68,737,033
|
|
G |
Cpt2 |
carnitine palmitoyltransferase 2 |
decreases expression |
ISO |
Etoposide results in decreased expression of CPT2 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 5:122,664,677...122,682,126
Ensembl chr 5:122,664,677...122,682,095
|
|
G |
Crabp2 |
cellular retinoic acid binding protein 2 |
increases expression |
ISO |
Etoposide results in increased expression of CRABP2 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 2:173,417,004...173,421,352
Ensembl chr 2:173,416,857...173,421,379
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
ISO |
Etoposide results in increased expression of and results in increased phosphorylation of CREB1 protein; HIPK2 gene mutant form inhibits the reaction [Etoposide results in increased expression of and results in increased phosphorylation of CREB1 protein] |
CTD |
PMID:20573984 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Crem |
cAMP responsive element modulator |
affects response to substance |
ISO |
CREM protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr17:54,238,889...54,305,989
Ensembl chr17:54,239,030...54,305,989
|
|
G |
Crip2 |
cysteine-rich protein 2 |
increases expression |
ISO |
Etoposide results in increased expression of CRIP2 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 6:132,221,120...132,226,066
Ensembl chr 6:132,221,082...132,226,065
|
|
G |
Csgalnact1 |
chondroitin sulfate N-acetylgalactosaminyltransferase 1 |
affects response to substance |
ISO |
CSGALNACT1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr16:20,995,210...21,330,586
Ensembl chr16:21,235,784...21,330,319
|
|
G |
Cth |
cystathionine gamma-lyase |
affects response to substance |
ISO |
CTH protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 2:246,975,888...247,002,234
Ensembl chr 2:246,975,894...247,002,234
|
|
G |
Ctnnb1 |
catenin beta 1 |
multiple interactions |
ISO |
[[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in decreased susceptibility to Etoposide; resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in decreased susceptibility to Etoposide] |
CTD |
PMID:19047049 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
decreases expression |
ISO |
Etoposide results in decreased expression of CXCL12 mRNA; Etoposide results in decreased expression of CXCL12 protein |
CTD |
PMID:22363485 |
|
NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168
|
|
G |
Cycs |
cytochrome c, somatic |
affects localization |
ISO |
Etoposide affects the localization of CYCS protein |
CTD |
PMID:10759716 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054 Ensembl chr18:79,651,378...79,654,054
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases expression multiple interactions |
ISO |
Etoposide results in increased expression of CYP1A1 mRNA; Etoposide results in increased expression of CYP1A1 protein Etoposide promotes the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 protein]; TP53 protein promotes the reaction [Etoposide promotes the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 protein]]; TP53 protein promotes the reaction [Etoposide results in increased expression of CYP1A1 protein] |
CTD |
PMID:29471073 PMID:31542801 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
increases expression |
ISO |
Etoposide results in increased expression of CYP1A2 mRNA |
CTD |
PMID:31542801 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp26a1 |
cytochrome P450, family 26, subfamily a, polypeptide 1 |
decreases response to substance |
ISO |
CYP26A1 protein results in decreased susceptibility to Etoposide |
CTD |
PMID:15703382 |
|
NCBI chr 1:235,471,368...235,475,204
Ensembl chr 1:235,471,298...235,475,204
|
|
G |
Cyp27b1 |
cytochrome P450, family 27, subfamily b, polypeptide 1 |
increases expression |
ISO |
Etoposide results in increased expression of CYP27B1 mRNA |
CTD |
PMID:17716971 |
|
NCBI chr 7:62,869,340...62,876,242
Ensembl chr 7:62,871,297...62,876,241
|
|
G |
Cyp2c24 |
cytochrome P450, family 2, subfamily c, polypeptide 24 |
increases expression |
ISO |
Etoposide results in increased expression of CYP2C55 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 1:236,873,967...236,936,238
Ensembl chr 1:236,873,967...236,936,238
|
|
G |
Cyp2c6 |
cytochrome P450, family 2, subfamily C, polypeptide 6 |
increases expression |
ISO |
Etoposide results in increased expression of CYP2C29 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Cyp2s1 |
cytochrome P450, family 2, subfamily s, polypeptide 1 |
decreases expression |
ISO |
Etoposide results in decreased expression of CYP2S1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 1:81,309,948...81,325,303
Ensembl chr 1:81,310,451...81,325,303
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
decreases methylation increases expression multiple interactions affects response to substance |
ISO |
CYP3A4 protein results in decreased methylation of Etoposide Etoposide results in increased expression of CYP3A4 mRNA [Etoposide results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; Cyclosporine inhibits the reaction [CYP3A4 protein results in decreased methylation of Etoposide]; Dexamethasone inhibits the reaction [CYP3A4 protein results in decreased methylation of Etoposide]; Erythromycin inhibits the reaction [CYP3A4 protein results in decreased methylation of Etoposide]; Midazolam inhibits the reaction [CYP3A4 protein results in decreased methylation of Etoposide] CYP3A4 gene polymorphism affects the susceptibility to Etoposide; CYP3A4 protein affects the susceptibility to Etoposide |
CTD |
PMID:8114683 PMID:12969965 PMID:17279585 PMID:25455453 PMID:31542801 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
affects response to substance decreases methylation |
ISO |
CYP3A5 gene polymorphism affects the susceptibility to Etoposide CYP3A5 protein results in decreased methylation of Etoposide |
CTD |
PMID:8114683 PMID:12969965 |
|
NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422
|
|
G |
Cyren |
cell cycle regulator of NHEJ |
affects localization |
ISO |
Etoposide affects the localization of CYREN protein alternative form |
CTD |
PMID:24610814 |
|
NCBI chr 4:63,547,311...63,553,394
Ensembl chr 4:63,547,335...63,551,602
|
|
G |
Dab2 |
DAB adaptor protein 2 |
affects response to substance |
ISO |
DAB2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 2:55,514,692...55,567,476
Ensembl chr 2:55,514,700...55,567,476
|
|
G |
Dapk1 |
death associated protein kinase 1 |
increases expression multiple interactions |
ISO |
Etoposide results in increased expression of DAPK1 protein; Etoposide results in increased expression of DAPK1 protein modified form DAPK1 protein promotes the reaction [Etoposide results in decreased expression of IKBKB protein]; DAPK1 protein promotes the reaction [Etoposide results in increased expression of ETS1 protein]; DAPK1 protein promotes the reaction [Etoposide results in increased expression of TP53 protein modified form]; DAPK1 protein promotes the reaction [Etoposide results in increased expression of TP53 protein] |
CTD |
PMID:30177839 |
|
NCBI chr17:3,930,223...4,090,991
Ensembl chr17:3,930,213...4,090,991
|
|
G |
Dbf4 |
DBF4-CDC7 kinase regulatory subunit |
decreases expression |
ISO |
Etoposide results in decreased expression of DBF4 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 4:25,676,570...25,701,152
Ensembl chr 4:25,676,634...25,701,066
|
|
G |
Dbn1 |
drebrin 1 |
affects response to substance |
ISO |
DBN1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr17:9,150,608...9,164,982
Ensembl chr17:9,150,659...9,164,984
|
|
G |
Dcaf4 |
DDB1 and CUL4 associated factor 4 |
increases expression |
ISO |
Etoposide results in increased expression of DCAF4 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 6:103,154,847...103,180,992
Ensembl chr 6:103,154,867...103,180,982
|
|
G |
Dct |
dopachrome tautomerase |
affects response to substance |
ISO |
DCT protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr15:95,062,006...95,100,863
Ensembl chr15:95,062,003...95,100,836
|
|
G |
Ddit4 |
DNA-damage-inducible transcript 4 |
affects response to substance |
ISO |
DDIT4 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr20:27,891,989...27,894,088
Ensembl chr20:27,891,998...27,894,105
|
|
G |
Ddr1 |
discoidin domain receptor tyrosine kinase 1 |
increases expression |
ISO |
Etoposide results in increased expression of DDR1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr20:3,042,494...3,064,442
Ensembl chr20:3,044,320...3,064,468
|
|
G |
Des |
desmin |
decreases expression |
ISO |
Etoposide results in decreased expression of DES mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 9:76,850,979...76,858,695
Ensembl chr 9:76,850,982...76,858,699
|
|
G |
Dkk3 |
dickkopf WNT signaling pathway inhibitor 3 |
affects response to substance |
ISO |
DKK3 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 1:166,237,969...166,281,271
Ensembl chr 1:166,238,238...166,280,590
|
|
G |
Dmd |
dystrophin |
affects response to substance decreases expression |
ISO |
DMD protein affects the susceptibility to Etoposide Etoposide results in decreased expression of DMD mRNA |
CTD |
PMID:16217747 PMID:29397400 |
|
NCBI chr X:47,272,324...49,504,219
Ensembl chr X:47,272,331...49,504,207
|
|
G |
Dmrt1 |
doublesex and mab-3 related transcription factor 1 |
decreases expression |
ISO |
Etoposide results in decreased expression of DMRT1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 1:223,142,859...223,241,333
Ensembl chr 1:223,142,859...223,241,333
|
|
G |
Dnmt1 |
DNA methyltransferase 1 |
decreases response to substance |
EXP ISO |
DNMT1 protein results in decreased susceptibility to Etoposide |
CTD |
PMID:18314485 |
|
NCBI chr 8:19,440,611...19,486,659
Ensembl chr 8:19,440,611...19,486,659
|
|
G |
Dnmt3b |
DNA methyltransferase 3 beta |
decreases response to substance |
ISO |
DNMT3B protein results in decreased susceptibility to Etoposide |
CTD |
PMID:18314485 |
|
NCBI chr 3:142,130,588...142,169,128
Ensembl chr 3:142,130,592...142,169,124
|
|
G |
Dpp7 |
dipeptidylpeptidase 7 |
multiple interactions |
ISO |
Etoposide promotes the reaction [[DPP7 protein results in increased cleavage of Dipeptides] which results in increased abundance of 4-nitroaniline] |
CTD |
PMID:16725115 |
|
NCBI chr 3:8,165,091...8,169,343
Ensembl chr 3:8,165,091...8,169,355
|
|
G |
Dpysl2 |
dihydropyrimidinase-like 2 |
decreases expression |
ISO |
Etoposide results in decreased expression of DPYSL2 protein |
CTD |
PMID:29733421 |
|
NCBI chr15:41,005,551...41,111,724
Ensembl chr15:41,005,551...41,111,829
|
|
G |
Dpysl4 |
dihydropyrimidinase-like 4 |
increases expression |
ISO |
Etoposide results in increased expression of DPYSL4 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 1:193,883,039...193,898,916
Ensembl chr 1:193,883,106...193,898,914
|
|
G |
Dusp2 |
dual specificity phosphatase 2 |
affects response to substance |
ISO |
DUSP2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 3:114,556,325...114,558,510
Ensembl chr 3:114,556,325...114,558,499
|
|
G |
Dusp4 |
dual specificity phosphatase 4 |
affects response to substance increases expression |
ISO |
DUSP4 protein affects the susceptibility to Etoposide Etoposide results in increased expression of DUSP4 mRNA |
CTD |
PMID:16217747 PMID:29397400 |
|
NCBI chr16:57,376,659...57,398,161
Ensembl chr16:57,377,229...57,398,138
|
|
G |
E2f1 |
E2F transcription factor 1 |
multiple interactions |
ISO |
E2F1 protein affects the reaction [Etoposide results in increased expression of HIC1 mRNA]; Etoposide promotes the reaction [E2F1 protein binds to HIC1 promoter] |
CTD |
PMID:19491197 |
|
NCBI chr 3:143,064,535...143,075,362
Ensembl chr 3:143,049,478...143,075,361
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions |
ISO |
EDN1 mutant form inhibits the reaction [VEGFC protein results in decreased susceptibility to Etoposide] |
CTD |
PMID:24184161 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Ednrb |
endothelin receptor type B |
decreases expression |
ISO |
Etoposide results in decreased expression of EDNRB mRNA |
CTD |
PMID:25270620 |
|
NCBI chr15:80,640,839...80,672,115
Ensembl chr15:80,643,043...80,672,115
|
|
G |
Efs |
embryonal Fyn-associated substrate |
increases expression |
ISO |
Etoposide results in increased expression of EFS mRNA |
CTD |
PMID:25270620 |
|
NCBI chr15:28,392,417...28,403,016
Ensembl chr15:28,392,187...28,401,902
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
ISO |
[EGF protein results in decreased expression of TOP2A protein] which results in decreased susceptibility to Etoposide |
CTD |
PMID:16969495 |
|
NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Egfl8 |
EGF-like-domain, multiple 8 |
affects response to substance |
ISO |
EGFL8 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr20:4,132,930...4,136,024
Ensembl chr20:4,133,629...4,136,018
|
|
G |
Egfr |
epidermal growth factor receptor |
decreases expression |
ISO |
Etoposide results in decreased expression of EGFR mRNA; Etoposide results in decreased expression of EGFR protein |
CTD |
PMID:15228094 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Ei24 |
EI24, autophagy associated transmembrane protein |
increases expression |
ISO |
Etoposide results in increased expression of EI24 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 8:36,494,289...36,510,653
Ensembl chr 8:36,494,289...36,510,571
|
|
G |
Eif2s2 |
eukaryotic translation initiation factor 2 subunit beta |
decreases expression |
ISO |
Etoposide results in decreased expression of EIF2S2 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 3:143,374,652...143,395,460
Ensembl chr 3:143,373,686...143,395,432
|
|
G |
Eif3a |
eukaryotic translation initiation factor 3, subunit A |
increases response to substance |
ISO |
EIF3A results in increased susceptibility to Etoposide |
CTD |
PMID:21610145 |
|
NCBI chr 1:259,902,767...259,932,976
Ensembl chr 1:259,902,680...259,932,976
|
|
G |
Emp1 |
epithelial membrane protein 1 |
increases expression |
ISO |
Etoposide results in increased expression of EMP1 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 4:168,212,901...168,233,039
Ensembl chr 4:168,212,861...168,232,904
|
|
G |
Emp2 |
epithelial membrane protein 2 |
affects response to substance |
ISO |
EMP2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr10:5,360,073...5,394,734
Ensembl chr10:5,360,073...5,394,733
|
|
G |
Emp3 |
epithelial membrane protein 3 |
increases expression |
ISO |
Etoposide results in increased expression of EMP3 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 1:96,388,651...96,391,946
Ensembl chr 1:96,388,652...96,391,988
|
|
G |
En2 |
engrailed homeobox 2 |
affects response to substance |
ISO |
EN2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 4:7,221,096...7,226,943
Ensembl chr 4:7,221,096...7,226,943
|
|
G |
Eno1 |
enolase 1 |
decreases expression |
ISO |
Etoposide results in decreased expression of ENO1 protein |
CTD |
PMID:29733421 |
|
NCBI chr 5:160,719,951...160,731,337
Ensembl chr 5:160,719,951...160,731,336
|
|
G |
Entpd2 |
ectonucleoside triphosphate diphosphohydrolase 2 |
decreases expression |
ISO |
Etoposide results in decreased expression of ENTPD2 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 3:8,213,575...8,219,094
Ensembl chr 3:8,213,663...8,226,866
|
|
G |
Ep300 |
E1A binding protein p300 |
multiple interactions |
ISO |
[[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in decreased susceptibility to Etoposide; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in decreased susceptibility to Etoposide; resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in decreased susceptibility to Etoposide]; resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in decreased susceptibility to Etoposide] |
CTD |
PMID:19047049 |
|
NCBI chr 7:113,108,476...113,178,529
Ensembl chr 7:113,106,247...113,136,088 Ensembl chr 7:113,106,247...113,136,088
|
|
G |
Epb41l3 |
erythrocyte membrane protein band 4.1-like 3 |
affects response to substance |
ISO |
EPB41L3 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 9:109,056,178...109,260,607
Ensembl chr 9:109,016,113...109,260,607
|
|
G |
Ephx1 |
epoxide hydrolase 1 |
increases expression |
ISO |
Etoposide results in increased expression of EPHX1 mRNA |
CTD |
PMID:21382384 PMID:25270620 |
|
NCBI chr13:92,714,315...92,744,105
Ensembl chr13:92,714,315...92,790,235
|
|
G |
Epm2aip1 |
EPM2A interacting protein 1 |
increases expression |
ISO |
Etoposide results in increased expression of EPM2AIP1 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 8:111,233,871...111,241,219
Ensembl chr 8:111,233,826...111,241,871
|
|
G |
Epo |
erythropoietin |
multiple interactions |
ISO |
EPO protein inhibits the reaction [Etoposide results in increased activity of CAT protein]; EPO protein results in increased susceptibility to [Organoplatinum Compounds co-treated with Etoposide] |
CTD |
PMID:18403296 PMID:29069929 |
|
NCBI chr12:19,204,258...19,207,948
Ensembl chr12:19,204,508...19,207,946
|
|
G |
Erbb2 |
erb-b2 receptor tyrosine kinase 2 |
multiple interactions decreases expression decreases response to substance affects response to substance |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ERBB2 results in decreased susceptibility to Etoposide]; 3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [ERBB2 results in decreased susceptibility to Etoposide]; [ERBB2 results in increased expression of ABCG2] which results in decreased susceptibility to Etoposide; ABCG2 mutant form inhibits the reaction [ERBB2 results in decreased susceptibility to Etoposide]; Curcumin analog inhibits the reaction [ERBB2 protein results in decreased susceptibility to Etoposide] Etoposide results in decreased expression of ERBB2 mRNA ERBB2 protein results in decreased susceptibility to Etoposide; ERBB2 results in decreased susceptibility to Etoposide ERBB2 protein affects the susceptibility to Etoposide |
CTD |
PMID:10327070 PMID:15228094 PMID:21712253 PMID:25866362 |
|
NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078
|
|
G |
Erbb3 |
erb-b2 receptor tyrosine kinase 3 |
affects response to substance decreases expression |
ISO |
ERBB3 protein affects the susceptibility to Etoposide Etoposide results in decreased expression of ERBB3 mRNA |
CTD |
PMID:15228094 PMID:16217747 PMID:29397400 |
|
NCBI chr 7:994,549...1,015,876
Ensembl chr 7:996,225...1,015,525
|
|
G |
Erbb4 |
erb-b2 receptor tyrosine kinase 4 |
decreases expression |
ISO |
Etoposide results in decreased expression of ERBB4 mRNA |
CTD |
PMID:15228094 |
|
NCBI chr 9:69,523,733...70,596,743
Ensembl chr 9:69,531,481...70,596,595
|
|
G |
Ereg |
epiregulin |
increases expression |
ISO |
Etoposide results in increased expression of EREG mRNA |
CTD |
PMID:15228094 |
|
NCBI chr14:17,027,287...17,041,062
Ensembl chr14:17,027,287...17,041,062
|
|
G |
Ervfrd-1 |
endogenous retrovirus group FRD member 1, envelope |
affects response to substance |
ISO |
ERVFRD-1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr12:22,151,211...22,158,264
Ensembl chr12:22,151,211...22,158,264
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions |
ISO |
Etoposide inhibits the reaction [Estradiol results in increased activity of ESR1 protein] |
CTD |
PMID:30818834 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
increases response to substance multiple interactions |
ISO |
ESR2 protein results in increased susceptibility to Etoposide TP53 protein inhibits the reaction [ESR2 protein results in increased susceptibility to Etoposide] |
CTD |
PMID:20623183 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Esrp1 |
epithelial splicing regulatory protein 1 |
affects response to substance |
ISO |
ESRP1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 5:24,427,611...24,482,157
Ensembl chr 5:24,428,717...24,482,062
|
|
G |
Esrra |
estrogen related receptor, alpha |
multiple interactions |
ISO |
Etoposide inhibits the reaction [XCT790 results in decreased activity of ESRRA protein]; Etoposide promotes the reaction [PPARGC1A protein results in increased activity of ESRRA protein] |
CTD |
PMID:30818834 |
|
NCBI chr 1:204,104,100...204,114,182
Ensembl chr 1:204,104,101...204,114,268
|
|
G |
Ets1 |
ETS proto-oncogene 1, transcription factor |
multiple interactions increases expression |
ISO |
DAPK1 protein promotes the reaction [Etoposide results in increased expression of ETS1 protein]; ETS1 protein promotes the reaction [Etoposide results in decreased expression of IKBKB protein]; TP53 protein promotes the reaction [Etoposide results in increased expression of ETS1 protein] |
CTD |
PMID:30177839 |
|
NCBI chr 8:31,045,909...31,168,010
Ensembl chr 8:31,045,945...31,168,010
|
|
G |
Etv6 |
ETS variant transcription factor 6 |
increases response to substance increases mutagenesis |
ISO |
ETV6 gene mutant form results in increased susceptibility to Etoposide Etoposide results in increased mutagenesis of ETV6 gene |
CTD |
PMID:15217836 PMID:28624474 |
|
NCBI chr 4:166,849,031...167,085,211
Ensembl chr 4:166,847,686...167,084,992
|
|
G |
Exoc4 |
exocyst complex component 4 |
increases expression |
ISO |
Etoposide results in increased expression of EXOC4 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 4:61,807,706...62,584,316
Ensembl chr 4:61,807,761...62,585,723
|
|
G |
F11r |
F11 receptor |
increases expression |
ISO |
Etoposide results in increased expression of F11R mRNA |
CTD |
PMID:29397400 |
|
NCBI chr13:83,873,797...83,897,388
Ensembl chr13:83,873,797...83,897,402
|
|
G |
F2r |
coagulation factor II (thrombin) receptor |
affects response to substance |
ISO |
F2R protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 2:26,869,343...26,885,856
Ensembl chr 2:26,868,404...26,885,870
|
|
G |
F3 |
coagulation factor III, tissue factor |
increases expression |
ISO |
Etoposide results in increased expression of F3 mRNA |
CTD |
PMID:12542493 |
|
NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668
|
|
G |
Fads3 |
fatty acid desaturase 3 |
increases expression |
ISO |
Etoposide results in increased expression of FADS3 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 1:206,685,667...206,702,538
Ensembl chr 1:206,685,894...206,704,769
|
|
G |
Fam171a1 |
family with sequence similarity 171, member A1 |
affects response to substance |
ISO |
FAM171A1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr17:75,024,582...75,148,348
Ensembl chr17:75,024,575...75,150,255
|
|
G |
Fas |
Fas cell surface death receptor |
multiple interactions increases expression |
ISO |
3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione inhibits the reaction [Etoposide results in increased expression of and affects the localization of FAS protein]; Etoposide results in increased expression of and affects the localization of FAS protein; Lithium inhibits the reaction [Etoposide results in increased expression of and affects the localization of FAS protein] Etoposide results in increased expression of FAS mRNA Etoposide results in increased expression of FAS mRNA; Etoposide results in increased expression of FAS protein |
CTD |
PMID:12513834 PMID:15475000 PMID:16192531 PMID:29397400 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Faslg |
Fas ligand |
multiple interactions increases expression increases activity |
ISO |
[linsidomine results in increased abundance of Nitric Oxide] inhibits the reaction [Etoposide results in increased activity of FASLG promoter]; [S-Nitroso-N-Acetylpenicillamine results in increased abundance of Nitric Oxide] inhibits the reaction [Etoposide results in increased activity of FASLG promoter]; [S-Nitrosoglutathione results in increased abundance of Nitric Oxide] inhibits the reaction [Etoposide results in increased activity of FASLG promoter]; [spermine nitric oxide complex results in increased abundance of Nitric Oxide] inhibits the reaction [Etoposide results in increased activity of FASLG promoter]; Nitric Oxide inhibits the reaction [Etoposide results in increased activity of FASLG promoter] Etoposide results in increased expression of FASL mRNA |
CTD |
PMID:10811113 PMID:12513834 |
|
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Fasn |
fatty acid synthase |
increases expression |
ISO |
Etoposide results in increased expression of FASN mRNA |
CTD |
PMID:17089011 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Fbl |
fibrillarin |
affects localization |
ISO |
Etoposide analog affects the localization of FBL protein |
CTD |
PMID:10942594 |
|
NCBI chr 1:83,469,832...83,478,932
Ensembl chr 1:83,469,832...83,478,932
|
|
G |
Fdft1 |
farnesyl diphosphate farnesyl transferase 1 |
affects response to substance |
ISO |
FDFT1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr15:37,412,143...37,440,198
Ensembl chr15:37,412,146...37,440,287
|
|
G |
Fdxr |
ferredoxin reductase |
increases expression |
ISO |
Etoposide results in increased expression of FDXR mRNA |
CTD |
PMID:17374387 |
|
NCBI chr10:100,507,863...100,516,649
Ensembl chr10:100,507,865...100,516,658
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
affects response to substance |
ISO |
FGF2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221
|
|
G |
Fhl1 |
four and a half LIM domains 1 |
affects response to substance |
ISO |
FHL1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr X:134,555,399...134,614,930
Ensembl chr X:134,555,479...134,614,928
|
|
G |
Fhl2 |
four and a half LIM domains 2 |
decreases expression |
ISO |
Etoposide results in decreased expression of FHL2 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 9:45,388,979...45,462,421
Ensembl chr 9:45,388,981...45,431,192
|
|
G |
Flnc |
filamin C |
increases expression |
ISO |
Etoposide results in increased expression of FLNC mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 4:58,034,088...58,061,882
Ensembl chr 4:58,034,189...58,061,844
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
decreases response to substance increases expression multiple interactions |
EXP ISO |
FOS protein results in decreased susceptibility to Etoposide Etoposide results in increased expression of FOS [Etoposide co-treated with Cyclic AMP] results in increased expression of FOS mRNA; Acetylcysteine inhibits the reaction [Etoposide results in increased expression of FOS] |
CTD |
PMID:10711420 PMID:18314485 PMID:23824011 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Fosl1 |
FOS like 1, AP-1 transcription factor subunit |
increases expression |
ISO |
Etoposide results in increased expression of FOSL1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 1:202,754,549...202,763,057
Ensembl chr 1:202,754,529...202,764,930
|
|
G |
Foxf2 |
forkhead box F2 |
affects response to substance |
ISO |
FOXF2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr17:32,835,730...32,842,547
Ensembl chr17:32,836,777...32,842,176
|
|
G |
Foxj2 |
forkhead box J2 |
decreases expression |
ISO |
Etoposide results in decreased expression of FOXJ2 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 4:156,047,043...156,073,540
Ensembl chr 4:156,046,969...156,073,518
|
|
G |
Foxo1 |
forkhead box O1 |
increases phosphorylation multiple interactions |
ISO |
Etoposide results in increased phosphorylation of FOXO1 protein wortmannin inhibits the reaction [Etoposide results in increased phosphorylation of FOXO1 protein] |
CTD |
PMID:17935137 |
|
NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790
|
|
G |
Foxo3 |
forkhead box O3 |
increases phosphorylation increases response to substance multiple interactions |
ISO |
Etoposide results in increased phosphorylation of FOXO3 protein FOXO3 protein results in increased susceptibility to Etoposide [FOXO3 protein results in decreased expression of BIRC5 protein] which results in increased susceptibility to Etoposide; BIRC5 protein inhibits the reaction [FOXO3 protein results in increased susceptibility to Etoposide]; Wortmannin inhibits the reaction [Etoposide results in increased phosphorylation of FOXO3 protein] |
CTD |
PMID:17935137 PMID:19211844 |
|
NCBI chr20:45,669,708...45,764,606
Ensembl chr20:45,672,995...45,764,561
|
|
G |
Fth1 |
ferritin heavy chain 1 |
multiple interactions increases expression |
ISO |
HIPK2 protein promotes the reaction [Etoposide results in increased expression of FTH1 mRNA] |
CTD |
PMID:20980392 |
|
NCBI chr 1:206,627,142...206,629,430
Ensembl chr 1:206,627,103...206,725,424
|
|
G |
Ftl1 |
ferritin light chain 1 |
increases expression multiple interactions |
ISO |
Etoposide results in increased expression of FTL mRNA; Etoposide results in increased expression of FTL protein 1-cyclopropyl-4-(4-((5-methyl-3-(3-(4-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)methyl)pyridin-2-yl)piperazine inhibits the reaction [Etoposide results in increased expression of FTL protein]; ARNT protein affects the reaction [Etoposide results in increased expression of FTL protein]; Etoposide promotes the reaction [HIF1A protein binds to FTL promoter]; FTL protein affects the reaction [Etoposide results in increased expression of ALDH1A1 protein]; FTL protein affects the reaction [Etoposide results in increased expression of KLF4 protein]; FTL protein affects the reaction [Etoposide results in increased expression of SOX2 protein]; HIF1A protein affects the reaction [Etoposide results in increased expression of FTL protein] |
CTD |
PMID:33969609 |
|
NCBI chr 1:95,936,387...95,938,234
Ensembl chr 1:95,936,387...95,939,725 Ensembl chr10:95,936,387...95,939,725
|
|
G |
Fut8 |
fucosyltransferase 8 |
affects response to substance |
ISO |
FUT8 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 6:95,949,246...96,176,677
Ensembl chr 6:95,949,991...96,176,677
|
|
G |
Fyn |
FYN proto-oncogene, Src family tyrosine kinase |
affects response to substance decreases expression |
ISO |
FYN protein affects the susceptibility to Etoposide Etoposide results in decreased expression of FYN mRNA |
CTD |
PMID:16217747 PMID:25270620 |
|
NCBI chr20:42,767,733...42,960,903
Ensembl chr20:42,766,369...42,959,911
|
|
G |
Fzd1 |
frizzled class receptor 1 |
decreases expression |
ISO |
Etoposide results in decreased expression of FZD1 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 4:29,310,303...29,314,701
Ensembl chr 4:29,310,091...29,312,643 Ensembl chr 4:29,310,091...29,312,643
|
|
G |
Fzd5 |
frizzled class receptor 5 |
decreases expression |
ISO |
Etoposide results in decreased expression of FZD5 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 9:66,113,096...66,120,276
Ensembl chr 9:66,113,112...66,121,457
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible, alpha |
increases response to substance multiple interactions increases expression |
ISO |
GADD45A protein results in increased susceptibility to Etoposide IKBKB protein inhibits the reaction [Etoposide results in increased expression of GADD45A protein] Etoposide results in increased expression of GADD45A mRNA; Etoposide results in increased expression of GADD45A protein |
CTD |
PMID:19003803 PMID:21527772 PMID:29397400 PMID:30177839 PMID:31542801 |
|
NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115
|
|
G |
Ganab |
glucosidase II alpha subunit |
multiple interactions decreases expression |
ISO |
[Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in decreased expression of GANAB protein Etoposide results in decreased expression of GANAB protein |
CTD |
PMID:29733421 |
|
NCBI chr 1:205,793,910...205,813,704
Ensembl chr 1:205,793,895...205,813,695
|
|
G |
Gapdh |
glyceraldehyde-3-phosphate dehydrogenase |
increases expression |
ISO |
Etoposide results in increased expression of GAPDH protein |
CTD |
PMID:29733421 |
|
NCBI chr 4:157,962,312...157,967,158
Ensembl chr 4:157,962,343...157,966,235
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
multiple interactions |
ISO |
[GCLC protein co-treated with GCLM protein] promotes the reaction [ABCC1 protein results in decreased susceptibility to Etoposide]; [GCLC protein co-treated with GCLM protein] results in decreased susceptibility to Etoposide |
CTD |
PMID:10900222 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
multiple interactions |
ISO |
[GCLC protein co-treated with GCLM protein] promotes the reaction [ABCC1 protein results in decreased susceptibility to Etoposide]; [GCLC protein co-treated with GCLM protein] results in decreased susceptibility to Etoposide |
CTD |
PMID:10900222 |
|
NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
|
|
G |
Gdf15 |
growth differentiation factor 15 |
multiple interactions increases expression |
ISO |
Etoposide promotes the reaction [[TP53 protein binds to GDF15 promoter] which results in increased expression of GDF15 mRNA] [Etoposide results in increased expression of TP53 protein] which results in increased expression of GDF15 protein; Etoposide results in increased expression of GDF15 mRNA; Etoposide results in increased expression of GDF15 protein |
CTD |
PMID:11895857 PMID:16120219 PMID:24211769 PMID:29397400 |
|
NCBI chr16:18,804,457...18,808,043
Ensembl chr16:18,805,239...18,808,055
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
multiple interactions increases response to substance |
ISO |
GJA1 protein affects the reaction [Simvastatin results in increased susceptibility to Etoposide]; Tetradecanoylphorbol Acetate affects the reaction [GJA1 protein results in increased susceptibility to Etoposide] |
CTD |
PMID:23978459 |
|
NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582
|
|
G |
Gja5 |
gap junction protein, alpha 5 |
decreases expression |
ISO |
Etoposide results in decreased expression of GJA5 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 2:184,602,407...184,621,952
Ensembl chr 2:184,564,475...184,621,952
|
|
G |
Gls2 |
glutaminase 2 |
increases expression |
ISO |
Etoposide results in increased expression of GLS2 mRNA |
CTD |
PMID:21527772 PMID:29397400 |
|
NCBI chr 7:617,252...633,424
Ensembl chr 7:617,288...633,426
|
|
G |
Gpihbp1 |
glycosylphosphatidylinositol anchored high density lipoprotein binding protein 1 |
decreases expression |
ISO |
Etoposide results in decreased expression of GPIHBP1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 7:107,285,584...107,288,702
Ensembl chr 7:107,285,654...107,288,702
|
|
G |
Gpm6b |
glycoprotein m6b |
affects response to substance |
ISO |
GPM6B protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr X:28,057,788...28,204,409
Ensembl chr X:28,059,450...28,204,211
|
|
G |
Gpnmb |
glycoprotein nmb |
increases expression |
ISO |
Etoposide results in increased expression of GPNMB mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 4:78,010,247...78,031,491
Ensembl chr 4:78,010,197...78,049,367
|
|
G |
Gpr37 |
G protein-coupled receptor 37 |
affects response to substance |
ISO |
GPR37 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 4:54,138,860...54,160,927
Ensembl chr 4:54,138,870...54,161,001
|
|
G |
Gpsm2 |
G-protein signaling modulator 2 |
affects response to substance |
ISO |
GPSM2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 2:196,327,149...196,375,322
Ensembl chr 2:196,327,149...196,375,154
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
increases expression |
ISO |
Etoposide results in increased expression of GPX1 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gpx3 |
glutathione peroxidase 3 |
increases expression |
ISO |
Etoposide results in increased expression of GPX3 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr10:39,028,624...39,036,695
Ensembl chr10:39,028,570...39,037,035
|
|
G |
Gria3 |
glutamate ionotropic receptor AMPA type subunit 3 |
increases expression |
ISO |
Etoposide results in increased expression of GRIA3 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr X:120,238,515...120,504,106
Ensembl chr X:120,238,534...120,504,096
|
|
G |
Grpel1 |
GrpE-like 1, mitochondrial |
decreases expression |
ISO |
Etoposide results in decreased expression of GRPEL1 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr14:74,292,023...74,298,243
Ensembl chr14:74,292,023...74,298,200
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions increases activity |
ISO |
BCL2 protein affects the reaction [[Etoposide results in increased activity of GSK3B protein] which results in increased activity of CASP3 protein] [Etoposide results in increased activity of GSK3B protein] which results in increased activity of CASP3 protein; Etoposide results in increased activity of GSK3B protein |
CTD |
PMID:19408126 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Gstm1 |
glutathione S-transferase mu 1 |
affects response to substance |
ISO |
GSTM1 gene polymorphism affects the susceptibility to Etoposide |
CTD |
PMID:15713801 |
|
NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411
|
|
G |
Gstm4 |
glutathione S-transferase mu 4 |
affects response to substance |
ISO |
GSTM4 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 2:195,667,940...195,685,315
Ensembl chr 2:195,680,004...195,685,323
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
multiple interactions decreases response to substance affects response to substance |
ISO |
Curcumin inhibits the reaction [GSTP1 protein results in decreased susceptibility to Etoposide]; Ethacrynic Acid inhibits the reaction [GSTP1 protein results in decreased susceptibility to Etoposide]; GSTP1 protein promotes the reaction [ABCC1 protein results in decreased susceptibility to Etoposide]; Sulfinpyrazone inhibits the reaction [GSTP1 protein results in decreased susceptibility to Etoposide]; verlukast inhibits the reaction [GSTP1 protein results in decreased susceptibility to Etoposide] GSTP1 gene polymorphism affects the susceptibility to Etoposide |
CTD |
PMID:10900222 PMID:12969965 PMID:15999103 |
|
NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
|
|
G |
Gstt2 |
glutathione S-transferase theta 2 |
affects response to substance |
ISO |
GSTT2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr20:12,819,617...12,823,288
Ensembl chr20:12,819,170...12,823,288
|
|
G |
H2ax |
H2A.X variant histone |
multiple interactions increases expression decreases response to substance increases phosphorylation |
ISO EXP |
Celecoxib inhibits the reaction [Etoposide results in increased phosphorylation of H2AX protein]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Etoposide results in increased phosphorylation of H2AX protein]; nimesulide inhibits the reaction [Etoposide results in increased phosphorylation of H2AX protein]; palbociclib inhibits the reaction [Etoposide results in increased expression of H2AX protein]; pifithrin promotes the reaction [Etoposide results in increased expression of H2AX protein] 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Etoposide results in increased expression of H2AX protein]; RAD54B protein affects the reaction [Etoposide results in increased expression of H2AX protein]; TOP2B protein affects the reaction [Etoposide results in increased expression of H2AX protein] 4,4'-(1,2-dimethyl-1,2-ethanediyl)bis-2,6-piperazinedione inhibits the reaction [Etoposide results in increased expression of H2AX protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Etoposide results in increased expression of H2AX protein]; Bortezomib inhibits the reaction [Etoposide results in increased expression of H2AX protein]; Razoxane inhibits the reaction [Etoposide results in increased expression of H2AX protein] H2AX protein results in decreased susceptibility to Etoposide Etoposide results in increased expression of H2AX protein; Etoposide results in increased expression of H2AX protein modified form |
CTD |
PMID:17875725 PMID:20643100 PMID:20978201 PMID:21555580 PMID:21745461 PMID:22302033 PMID:25078064 PMID:26259609 PMID:28343997 PMID:32482060 PMID:33823233 PMID:34510228 PMID:35690182 PMID:37451322 More...
|
|
NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239
|
|
G |
Hal |
histidine ammonia lyase |
decreases expression |
ISO |
Etoposide results in decreased expression of HAL mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 7:28,007,449...28,037,701
Ensembl chr 7:28,006,972...28,037,701
|
|
G |
Hamp |
hepcidin antimicrobial peptide |
decreases expression multiple interactions |
ISO |
Etoposide results in decreased expression of HAMP mRNA Etoposide inhibits the reaction [BMP6 protein results in increased expression of HAMP mRNA] |
CTD |
PMID:25270620 PMID:25633564 |
|
NCBI chr 1:86,170,926...86,172,865
Ensembl chr 1:86,170,901...86,172,891
|
|
G |
Hbegf |
heparin-binding EGF-like growth factor |
increases expression |
ISO |
Etoposide results in increased expression of HBEGF mRNA |
CTD |
PMID:15228094 |
|
NCBI chr18:28,106,284...28,116,167
Ensembl chr18:28,105,760...28,116,441
|
|
G |
Hbp1 |
HMG-box transcription factor 1 |
decreases expression |
ISO |
Etoposide results in decreased expression of HBP1 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 6:48,529,633...48,555,775
Ensembl chr 6:48,529,372...48,555,787
|
|
G |
Hdac4 |
histone deacetylase 4 |
affects response to substance |
ISO |
HDAC4 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 9:92,503,467...92,750,164
Ensembl chr 9:92,507,611...92,750,164
|
|
G |
Heph |
hephaestin |
affects response to substance |
ISO |
HEPH protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr X:61,151,131...61,402,980
Ensembl chr X:61,296,345...61,402,980
|
|
G |
Hic1 |
HIC ZBTB transcriptional repressor 1 |
multiple interactions increases expression |
ISO |
E2F1 protein affects the reaction [Etoposide results in increased expression of HIC1 mRNA]; Etoposide promotes the reaction [E2F1 protein binds to HIC1 promoter] |
CTD |
PMID:19491197 |
|
NCBI chr10:60,014,520...60,019,475
Ensembl chr10:60,011,528...60,019,475
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions |
ISO |
Etoposide promotes the reaction [HIF1A protein binds to FTL promoter]; HIF1A mutant form inhibits the reaction [Oxygen deficiency results in decreased susceptibility to Etoposide]; HIF1A protein affects the reaction [Etoposide results in increased expression of FTL protein] |
CTD |
PMID:23144690 PMID:33969609 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hipk2 |
homeodomain interacting protein kinase 2 |
increases activity multiple interactions decreases response to substance |
ISO |
Etoposide results in increased activity of HIPK2 protein HIPK2 gene mutant form inhibits the reaction [Etoposide results in increased expression of and results in increased phosphorylation of CREB1 protein]; HIPK2 gene mutant form promotes the reaction [Etoposide results in increased activity of CASP3 protein]; HIPK2 protein promotes the reaction [Etoposide results in increased expression of FTH1 mRNA]; HIPK2 protein promotes the reaction [Etoposide results in increased expression of NQO1 mRNA] HIPK2 results in decreased susceptibility to Etoposide HIPK2 mutant form inhibits the reaction [Etoposide results in increased expression of BDNF mRNA] |
CTD |
PMID:20573984 PMID:20980392 |
|
NCBI chr 4:67,439,327...67,619,223
Ensembl chr 4:67,440,501...67,619,223
|
|
G |
Hmces |
5-hydroxymethylcytosine binding, ES cell specific |
decreases expression |
ISO |
Etoposide results in decreased expression of HMCES mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 4:120,392,812...120,415,616
Ensembl chr 4:120,366,542...120,415,616
|
|
G |
Hmg20b |
high mobility group 20 B |
affects response to substance |
ISO |
HMG20B protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 7:8,368,934...8,373,650
Ensembl chr 7:8,368,990...8,373,640
|
|
G |
Hmga2 |
high mobility group AT-hook 2 |
affects response to substance |
ISO |
HMGA2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 7:55,877,145...55,998,813
Ensembl chr 7:55,880,112...55,994,784
|
|
G |
Hmgb1 |
high mobility group box 1 |
increases secretion decreases response to substance |
ISO |
Etoposide results in increased secretion of HMGB1 protein HMGB1 protein results in decreased susceptibility to Etoposide |
CTD |
PMID:27807322 |
|
NCBI chr12:5,972,950...5,979,658
Ensembl chr12:5,901,586...5,978,565 Ensembl chr16:5,901,586...5,978,565
|
|
G |
Hnrnph2 |
heterogeneous nuclear ribonucleoprotein H2 |
decreases expression |
ISO |
Etoposide results in decreased expression of HNRNPH2 protein |
CTD |
PMID:29733421 |
|
NCBI chr X:97,780,890...97,786,846
Ensembl chr X:97,780,785...97,787,041
|
|
G |
Hoxa5 |
homeo box A5 |
affects response to substance |
ISO |
HOXA5 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 4:81,302,341...81,306,234
Ensembl chr 4:81,302,353...81,306,234
|
|
G |
Hsp90aa1 |
heat shock protein 90 alpha family class A member 1 |
multiple interactions |
EXP |
[Bleomycin co-treated with Cisplatin co-treated with Etoposide] results in increased expression of HSP90AA1 protein |
CTD |
PMID:24478030 |
|
NCBI chr 6:129,702,376...129,707,907
Ensembl chr 6:129,702,383...129,707,268
|
|
G |
Hsp90b1 |
heat shock protein 90 beta family member 1 |
multiple interactions |
EXP |
[Bleomycin co-treated with Cisplatin co-treated with Etoposide] results in increased expression of HSP90B1 protein |
CTD |
PMID:24478030 |
|
NCBI chr 7:21,110,431...21,124,762
Ensembl chr 7:21,110,457...21,124,788
|
|
G |
Hspa2 |
heat shock protein family A (Hsp70) member 2 |
affects response to substance |
ISO |
HSPA2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 6:95,128,504...95,131,281
Ensembl chr 6:95,128,350...95,131,287
|
|
G |
Hspe1 |
heat shock protein family E (Hsp10) member 1 |
increases expression |
ISO |
Etoposide results in increased expression of HSPE1 protein |
CTD |
PMID:29733421 |
|
NCBI chr 9:56,589,912...56,593,000
Ensembl chr 9:56,589,789...56,593,089
|
|
G |
Htatip2 |
HIV-1 Tat interactive protein 2 |
affects response to substance increases response to substance multiple interactions |
ISO |
HTATIP2 protein affects the susceptibility to Etoposide HTATIP2 protein results in increased susceptibility to Etoposide HTATIP2 protein promotes the reaction [Etoposide results in increased activity of CASP9 protein]; HTATIP2 protein promotes the reaction [Etoposide results in increased activity of PARP1 protein] |
CTD |
PMID:16217747 PMID:16799960 |
|
NCBI chr 1:99,473,411...99,488,632
Ensembl chr 1:99,469,245...99,488,629
|
|
G |
Htr4 |
5-hydroxytryptamine receptor 4 |
affects response to substance |
ISO |
HTR4 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr18:55,765,981...55,949,921
Ensembl chr18:55,766,725...55,949,321
|
|
G |
Ier5 |
immediate early response 5 |
increases expression |
ISO |
Etoposide results in increased expression of IER5 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr13:67,270,134...67,272,226
Ensembl chr13:67,270,135...67,272,227
|
|
G |
Ifitm1 |
interferon induced transmembrane protein 1 |
affects response to substance |
ISO |
IFITM1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 1:196,067,163...196,069,169
Ensembl chr 1:196,067,963...196,069,169
|
|
G |
Igdcc4 |
immunoglobulin superfamily, DCC subclass, member 4 |
increases expression |
ISO |
Etoposide results in increased expression of IGDCC4 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 8:65,621,893...65,657,651
Ensembl chr 8:65,621,897...65,657,648
|
|
G |
Igf1r |
insulin-like growth factor 1 receptor |
affects response to substance |
ISO |
IGF1R protein affects the susceptibility to Etoposide |
CTD |
PMID:15499378 |
|
NCBI chr 1:121,549,831...121,838,548
Ensembl chr 1:121,550,743...121,831,777
|
|
G |
Igfbp7 |
insulin-like growth factor binding protein 7 |
affects response to substance |
ISO |
IGFBP7 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr14:30,737,414...30,797,317
Ensembl chr14:30,737,164...30,797,314
|
|
G |
Igsf11 |
immunoglobulin superfamily, member 11 |
decreases expression |
ISO |
Etoposide results in decreased expression of IGSF11 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr11:61,733,139...61,884,059
Ensembl chr11:61,733,144...61,868,348
|
|
G |
Ikbkb |
inhibitor of nuclear factor kappa B kinase subunit beta |
affects response to substance multiple interactions decreases expression |
ISO |
IKBKB protein affects the susceptibility to Etoposide DAPK1 protein promotes the reaction [Etoposide results in decreased expression of IKBKB protein]; ETS1 protein promotes the reaction [Etoposide results in decreased expression of IKBKB protein]; IKBKB protein inhibits the reaction [Etoposide results in increased expression of GADD45A protein]; IKBKB protein promotes the reaction [Etoposide results in increased expression of MDM2 protein modified form]; IKBKB protein promotes the reaction [Etoposide results in increased expression of MDM2 protein]; TP53 protein promotes the reaction [Etoposide results in decreased expression of IKBKB protein] |
CTD |
PMID:20159942 PMID:30177839 |
|
NCBI chr16:69,319,487...69,373,251
Ensembl chr16:69,319,554...69,373,250
|
|
G |
Il1b |
interleukin 1 beta |
increases expression |
ISO |
Etoposide results in increased expression of IL1B mRNA |
CTD |
PMID:18523641 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il4 |
interleukin 4 |
decreases response to substance multiple interactions |
ISO |
IL4 protein results in decreased susceptibility to Etoposide [IL4 protein co-treated with VCAM1 protein] inhibits the reaction [Etoposide results in decreased folding of BAX protein]; [VCAM1 protein co-treated with IL4 protein] inhibits the reaction [Etoposide inhibits the reaction [BAX protein binds to BCL2L1 protein]]; [VCAM1 protein co-treated with IL4 protein] results in decreased susceptibility to Etoposide |
CTD |
PMID:10620629 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il6 |
interleukin 6 |
multiple interactions increases expression increases secretion |
ISO EXP |
(4-(5-(4-fluorophenyl)-2-methylsulfanyl-3H-imidazol-4-yl)pyridin-2-yl)-(1-phenylethyl)amine inhibits the reaction [Etoposide results in increased expression of IL6 mRNA]; (4-(5-(4-fluorophenyl)-2-methylsulfanyl-3H-imidazol-4-yl)pyridin-2-yl)-(1-phenylethyl)amine inhibits the reaction [Etoposide results in increased secretion of IL6 protein] Etoposide results in increased expression of IL6 mRNA; Etoposide results in increased expression of IL6 protein |
CTD |
PMID:15135310 PMID:17003255 PMID:18523641 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Inka2 |
inka box actin regulator 2 |
increases expression |
ISO |
Etoposide results in increased expression of INKA2 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 2:193,185,275...193,200,643
Ensembl chr 2:193,185,275...193,200,642
|
|
G |
Insig1 |
insulin induced gene 1 |
affects response to substance |
ISO |
INSIG1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 4:7,315,494...7,323,972
Ensembl chr 4:7,315,495...7,323,952
|
|
G |
Ints15 |
integrator complex subunit 15 |
decreases expression |
ISO |
Etoposide results in decreased expression of INTS15 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr12:11,245,045...11,260,170
Ensembl chr12:11,245,842...11,260,166
|
|
G |
Ireb2 |
iron responsive element binding protein 2 |
multiple interactions decreases expression |
ISO |
1-cyclopropyl-4-(4-((5-methyl-3-(3-(4-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)methyl)pyridin-2-yl)piperazine inhibits the reaction [Etoposide results in decreased expression of IREB2 protein] Etoposide results in decreased expression of IREB2 mRNA; Etoposide results in decreased expression of IREB2 protein |
CTD |
PMID:33969609 |
|
NCBI chr 8:55,228,080...55,311,613
Ensembl chr 8:55,228,085...55,311,611
|
|
G |
Irs2 |
insulin receptor substrate 2 |
affects response to substance |
ISO |
IRS2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr16:78,488,249...78,512,482
Ensembl chr16:78,485,045...78,512,482
|
|
G |
Irx4 |
iroquois homeobox 4 |
decreases expression |
ISO |
Etoposide results in decreased expression of IRX4 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 1:30,030,561...30,039,549
Ensembl chr 1:30,030,561...30,039,549
|
|
G |
Isg15 |
ISG15 ubiquitin-like modifier |
increases expression |
ISO |
Etoposide results in increased expression of ISG15 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 5:166,784,148...166,785,435
Ensembl chr 5:166,784,148...166,785,435
|
|
G |
Isg20 |
interferon stimulated exonuclease gene 20 |
affects response to substance |
ISO |
ISG20 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 1:132,829,303...132,837,027
Ensembl chr 1:132,815,123...132,837,027
|
|
G |
Isg20l2 |
interferon stimulated exonuclease gene 20-like 2 |
decreases expression |
ISO |
Etoposide results in decreased expression of ISG20L2 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 2:173,396,780...173,407,102
Ensembl chr 2:173,396,780...173,406,614
|
|
G |
Itga2b |
integrin subunit alpha 2b |
increases expression |
ISO |
Etoposide results in increased expression of ITGA2B mRNA |
CTD |
PMID:21527772 |
|
NCBI chr10:87,408,532...87,426,055
Ensembl chr10:87,408,536...87,426,168
|
|
G |
Itgb3 |
integrin subunit beta 3 |
increases response to substance |
ISO |
ITGB3 protein results in increased susceptibility to Etoposide |
CTD |
PMID:21332719 |
|
NCBI chr10:89,509,917...89,564,679
Ensembl chr10:89,509,989...89,564,679
|
|
G |
Itpr1 |
inositol 1,4,5-trisphosphate receptor, type 1 |
affects response to substance |
ISO |
ITPR1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 4:141,187,377...141,554,240
Ensembl chr 4:141,187,418...141,510,491
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
[Etoposide co-treated with Cyclic AMP] results in increased expression of JUN mRNA |
CTD |
PMID:10711420 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Kcnab2 |
potassium voltage-gated channel subfamily A regulatory beta subunit 2 |
affects response to substance |
ISO |
KCNAB2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 5:162,899,511...162,988,057
Ensembl chr 5:162,901,896...162,988,243
|
|
G |
Kcne3 |
potassium voltage-gated channel subfamily E regulatory subunit 3 |
decreases expression |
ISO |
Etoposide results in decreased expression of KCNE3 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 1:154,523,903...154,530,865
Ensembl chr 1:154,523,830...154,532,020
|
|
G |
Kcnn2 |
potassium calcium-activated channel subfamily N member 2 |
decreases expression |
ISO |
Etoposide results in decreased expression of KCNN2 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr18:37,817,966...38,258,347
Ensembl chr18:37,817,957...38,258,347
|
|
G |
Keap1 |
Kelch-like ECH-associated protein 1 |
decreases response to substance multiple interactions increases response to substance |
ISO |
KEAP1 protein results in decreased susceptibility to Etoposide KEAP1 protein affects the reaction [Etoposide results in increased expression of CDKN1A protein] KEAP1 mRNA results in increased susceptibility to Etoposide |
CTD |
PMID:22684020 PMID:26708503 PMID:27982581 |
|
NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862
|
|
G |
Kif1a |
kinesin family member 1A |
increases expression |
ISO |
Etoposide results in increased expression of KIF1A mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 9:93,563,033...93,647,412
Ensembl chr 9:93,563,045...93,647,480
|
|
G |
Kif20a |
kinesin family member 20A |
decreases expression |
ISO |
Etoposide results in decreased expression of KIF20A mRNA |
CTD |
PMID:24211769 |
|
NCBI chr18:26,230,294...26,238,780
Ensembl chr18:26,230,230...26,238,780
|
|
G |
Kif23 |
kinesin family member 23 |
decreases expression |
ISO |
Etoposide results in decreased expression of KIF23 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 8:62,397,908...62,425,162
Ensembl chr 8:62,397,948...62,425,072
|
|
G |
Kit |
KIT proto-oncogene receptor tyrosine kinase |
multiple interactions increases expression |
ISO |
[Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in increased expression of KIT protein Etoposide results in increased expression of KIT protein |
CTD |
PMID:29733421 |
|
NCBI chr14:32,547,459...32,624,694
Ensembl chr14:32,548,877...32,624,652
|
|
G |
Klf4 |
KLF transcription factor 4 |
increases expression multiple interactions |
ISO |
Etoposide results in increased expression of KLF4 mRNA; Etoposide results in increased expression of KLF4 protein FTL protein affects the reaction [Etoposide results in increased expression of KLF4 protein] |
CTD |
PMID:33969609 |
|
NCBI chr 5:70,278,843...70,283,751
Ensembl chr 5:70,278,972...70,283,602
|
|
G |
Klf5 |
KLF transcription factor 5 |
increases expression |
ISO |
Etoposide results in increased expression of KLF5 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr15:76,060,320...76,079,445
Ensembl chr15:76,064,258...76,079,445
|
|
G |
Klf6 |
KLF transcription factor 6 |
decreases expression |
ISO |
Etoposide results in decreased expression of KLF6 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr17:64,539,456...64,548,451
Ensembl chr17:64,531,463...64,588,570
|
|
G |
Klhl26 |
kelch-like family member 26 |
increases expression |
ISO |
Etoposide results in increased expression of KLHL26 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr16:18,952,123...18,977,328
Ensembl chr16:18,952,234...18,977,328
|
|
G |
Klk1c10 |
kallikrein 1-related peptidase C10 |
multiple interactions |
ISO |
Etoposide inhibits the reaction [Dihydrotestosterone results in increased expression of KLK3 mRNA] |
CTD |
PMID:20601956 |
|
NCBI chr 1:94,402,993...94,407,052
Ensembl chr 1:94,402,993...94,407,052
|
|
G |
Kmt2a |
lysine methyltransferase 2A |
increases response to substance increases mutagenesis increases cleavage |
ISO |
KMT2A gene mutant form results in increased susceptibility to Etoposide Etoposide results in increased mutagenesis of KMT2A gene Etoposide results in increased cleavage of KMT2A gene |
CTD |
PMID:14712291 PMID:24086652 PMID:28624474 |
|
NCBI chr 8:45,116,763...45,193,320
Ensembl chr 8:45,118,814...45,193,181
|
|
G |
Krt19 |
keratin 19 |
increases expression |
ISO |
Etoposide results in increased expression of KRT19 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr10:85,075,835...85,080,552
Ensembl chr10:85,066,802...85,171,799
|
|
G |
Krt80 |
keratin 80 |
increases expression |
ISO |
Etoposide results in increased expression of KRT80 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 7:132,463,216...132,485,134
Ensembl chr 7:132,463,218...132,485,508
|
|
G |
Kynu |
kynureninase |
affects response to substance |
ISO |
KYNU protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 3:27,778,646...27,929,470
Ensembl chr 3:27,778,772...27,929,488
|
|
G |
Lancl1 |
LanC like glutathione S-transferase 1 |
affects response to substance |
ISO |
LANCL1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 9:68,515,052...68,548,646
Ensembl chr 9:68,518,574...68,548,628
|
|
G |
Lap3 |
leucine aminopeptidase 3 |
decreases expression |
ISO |
Etoposide results in decreased expression of LAP3 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr14:65,608,375...65,627,359
Ensembl chr14:65,608,376...65,627,359
|
|
G |
Lcn2 |
lipocalin 2 |
increases response to substance |
EXP |
LCN2 protein results in increased susceptibility to Etoposide |
CTD |
PMID:19860839 |
|
NCBI chr 3:15,680,688...15,684,033
Ensembl chr 3:15,680,687...15,684,095
|
|
G |
Ldb3 |
LIM domain binding 3 |
decreases expression |
ISO |
Etoposide results in decreased expression of LDB3 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr16:9,855,768...9,920,108
Ensembl chr16:9,855,927...9,918,532
|
|
G |
Lgals3 |
galectin 3 |
affects response to substance |
ISO |
LGALS3 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr15:20,620,083...20,632,019
Ensembl chr15:20,607,692...20,632,025
|
|
G |
Lgals7 |
galectin 7 |
increases expression |
ISO |
Etoposide results in increased expression of LGALS7 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 1:84,148,612...84,152,016
Ensembl chr 1:84,150,252...84,152,015
|
|
G |
Lhx1 |
LIM homeobox 1 |
multiple interactions decreases expression |
ISO |
[Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in decreased expression of LHX1 mRNA Etoposide results in decreased expression of LHX1 mRNA |
CTD |
PMID:29733421 |
|
NCBI chr10:69,396,829...69,403,617
Ensembl chr10:69,396,829...69,403,617
|
|
G |
Lhx2 |
LIM homeobox 2 |
decreases expression |
ISO |
Etoposide results in decreased expression of LHX2 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 3:22,113,619...22,143,909
Ensembl chr 3:22,126,007...22,143,908
|
|
G |
Lif |
LIF, interleukin 6 family cytokine |
increases expression |
ISO |
Etoposide results in increased expression of LIF mRNA |
CTD |
PMID:29397400 |
|
NCBI chr14:79,131,049...79,140,486
Ensembl chr14:79,134,574...79,140,482
|
|
G |
Limch1 |
LIM and calponin homology domains 1 |
affects response to substance |
ISO |
LIMCH1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr14:41,112,579...41,425,001
Ensembl chr14:41,114,803...41,425,191
|
|
G |
Lipa |
lipase A, lysosomal acid type |
affects response to substance |
ISO |
LIPA protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 1:232,024,351...232,057,735
Ensembl chr 1:232,024,356...232,057,633
|
|
G |
Lrrc47 |
leucine rich repeat containing 47 |
decreases expression |
ISO |
Etoposide results in decreased expression of LRRC47 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 5:164,570,539...164,580,174
Ensembl chr 5:164,570,435...164,580,174
|
|
G |
Ltbr |
lymphotoxin beta receptor |
multiple interactions increases expression |
ISO |
Estradiol inhibits the reaction [Etoposide results in increased expression of LTBR mRNA] |
CTD |
PMID:19426747 |
|
NCBI chr 4:158,108,884...158,115,339
Ensembl chr 4:158,108,886...158,121,539
|
|
G |
Lxn |
latexin |
increases response to substance |
ISO |
LXN protein results in increased susceptibility to Etoposide |
CTD |
PMID:25341047 |
|
NCBI chr 2:151,727,556...151,733,426
Ensembl chr 2:151,727,102...151,733,460
|
|
G |
Ly6e |
lymphocyte antigen 6 family member E |
affects response to substance |
ISO |
LY6E protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 7:106,935,530...106,939,689
Ensembl chr 7:106,935,761...106,939,689
|
|
G |
Macf1 |
microtubule-actin crosslinking factor 1 |
affects response to substance |
ISO |
MACF1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 5:135,623,734...135,949,097
Ensembl chr 5:135,623,742...135,945,905
|
|
G |
Man2b1 |
mannosidase, alpha, class 2B, member 1 |
increases expression |
ISO |
Etoposide results in increased expression of MAN2B1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr19:23,055,092...23,074,398
Ensembl chr19:23,055,097...23,074,389
|
|
G |
Map2k3 |
mitogen activated protein kinase kinase 3 |
increases expression |
ISO |
Etoposide results in increased expression of MAP2K3 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr10:45,608,145...45,629,492
Ensembl chr10:45,607,163...45,629,492
|
|
G |
Map3k5 |
mitogen-activated protein kinase kinase kinase 5 |
decreases expression |
ISO |
Etoposide results in decreased expression of MAP3K5 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 1:14,685,776...14,904,935
Ensembl chr 1:14,685,492...14,904,800
|
|
G |
Map7 |
microtubule-associated protein 7 |
affects response to substance |
ISO |
MAP7 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 1:14,910,433...15,037,574
Ensembl chr 1:14,910,551...15,037,574
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation |
ISO |
3',4'-dihydroxyflavone analog inhibits the reaction [Etoposide results in increased phosphorylation of MAPK1 protein]; Acetylcysteine inhibits the reaction [Etoposide results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [Etoposide results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:16014620 PMID:19720055 PMID:26046675 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk12 |
mitogen-activated protein kinase 12 |
increases activity affects response to substance multiple interactions |
ISO |
Etoposide results in increased activity of MAPK12 protein MAPK12 protein affects the susceptibility to Etoposide [MAPK12 protein results in increased phosphorylation of TOP2A protein] which results in increased susceptibility to Etoposide; [MAPK12 protein results in increased stability of TOP2A protein] which results in increased susceptibility to Etoposide |
CTD |
PMID:21878638 |
|
NCBI chr 7:120,206,005...120,216,711
Ensembl chr 7:120,206,271...120,216,664
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
ISO |
3',4'-dihydroxyflavone analog inhibits the reaction [Etoposide results in increased phosphorylation of MAPK3 protein]; Acetylcysteine inhibits the reaction [Etoposide results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [Etoposide results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:16014620 PMID:19720055 PMID:26046675 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapkapk2 |
MAPK activated protein kinase 2 |
multiple interactions increases phosphorylation |
ISO |
(4-(5-(4-fluorophenyl)-2-methylsulfanyl-3H-imidazol-4-yl)pyridin-2-yl)-(1-phenylethyl)amine inhibits the reaction [Etoposide results in increased phosphorylation of MAPKAPK2 protein] |
CTD |
PMID:17003255 |
|
NCBI chr13:42,513,762...42,560,061
Ensembl chr13:42,513,762...42,560,457
|
|
G |
Matn2 |
matrilin 2 |
affects response to substance |
ISO |
MATN2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 7:65,494,996...65,644,613
Ensembl chr 7:65,494,834...65,645,113
|
|
G |
Mbp |
myelin basic protein |
affects response to substance |
ISO |
MBP protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr18:75,855,878...75,966,404
Ensembl chr18:75,855,878...75,966,404
|
|
G |
Mcam |
melanoma cell adhesion molecule |
increases expression |
ISO |
Etoposide results in increased expression of MCAM mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 8:44,479,391...44,487,575
Ensembl chr 8:44,479,376...44,487,571
|
|
G |
Mcl1 |
MCL1 apoptosis regulator, BCL2 family member |
multiple interactions decreases expression |
ISO |
wortmannin promotes the reaction [Etoposide results in decreased expression of MCL1 protein] |
CTD |
PMID:17935137 |
|
NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303
|
|
G |
Mcm10 |
minichromosome maintenance 10 replication initiation factor |
decreases expression |
ISO |
Etoposide results in decreased expression of MCM10 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr17:73,263,788...73,288,346
Ensembl chr17:73,266,095...73,287,364
|
|
G |
Mcm2 |
minichromosome maintenance complex component 2 |
decreases expression |
ISO |
Etoposide results in decreased expression of MCM2 mRNA |
CTD |
PMID:16120219 |
|
NCBI chr 4:121,346,434...121,360,962
Ensembl chr 4:121,346,434...121,360,847
|
|
G |
Mcm6 |
minichromosome maintenance complex component 6 |
decreases expression |
ISO |
Etoposide results in decreased expression of MCM6 mRNA |
CTD |
PMID:16120219 |
|
NCBI chr13:39,826,745...39,851,937
Ensembl chr13:39,826,763...39,851,960
|
|
G |
Mcm7 |
minichromosome maintenance complex component 7 |
decreases expression |
ISO |
Etoposide results in decreased expression of MCM7 mRNA |
CTD |
PMID:16120219 |
|
NCBI chr12:17,042,207...17,049,470
Ensembl chr12:17,042,212...17,050,063
|
|
G |
Mcm8 |
minichromosome maintenance 8 homologous recombination repair factor |
decreases expression |
ISO |
Etoposide results in decreased expression of MCM8 mRNA |
CTD |
PMID:16120219 |
|
NCBI chr 3:120,086,741...120,117,008
Ensembl chr 3:120,086,763...120,117,008
|
|
G |
Mdfic |
MyoD family inhibitor domain containing |
affects response to substance |
ISO |
MDFIC protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 4:43,972,310...44,052,162
Ensembl chr 4:43,972,507...44,052,161
|
|
G |
Mdh2 |
malate dehydrogenase 2 |
multiple interactions |
ISO |
[Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in decreased expression of MDH2 protein |
CTD |
PMID:29733421 |
|
NCBI chr12:20,894,269...20,907,225
Ensembl chr12:20,894,262...20,907,271
|
|
G |
Mdm2 |
MDM2 proto-oncogene |
multiple interactions decreases expression increases phosphorylation increases expression decreases response to substance |
ISO EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Etoposide promotes the reaction [MDM2 protein binds to TOP2A protein]]; Cadmium Chloride affects the reaction [Etoposide results in increased phosphorylation of MDM2 protein]; Etoposide promotes the reaction [MDM2 protein binds to TOP2A protein]; IKBKB protein promotes the reaction [Etoposide results in increased expression of MDM2 protein modified form]; IKBKB protein promotes the reaction [Etoposide results in increased expression of MDM2 protein]; Wortmannin promotes the reaction [Etoposide results in increased phosphorylation of MDM2 protein] Etoposide results in decreased expression of MDM2 protein Etoposide results in increased expression of MDM2 mRNA; Etoposide results in increased expression of MDM2 protein; Etoposide results in increased expression of MDM2 protein modified form Tetrachlorodibenzodioxin inhibits the reaction [Etoposide results in increased expression of MDM2 protein] MDM2 promoter SNP results in decreased susceptibility to Etoposide |
CTD |
PMID:15459018 PMID:16120219 PMID:17575151 PMID:17935137 PMID:18096571 PMID:25078064 PMID:25744307 PMID:26259609 PMID:30177839 PMID:31542801 More...
|
|
NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915
|
|
G |
Me2 |
malic enzyme 2 |
decreases expression |
ISO |
Etoposide results in decreased expression of ME2 protein |
CTD |
PMID:29733421 |
|
NCBI chr18:67,350,833...67,400,987
Ensembl chr18:67,355,795...67,400,987
|
|
G |
Mir135b |
microRNA 135b |
increases expression |
ISO |
Etoposide results in increased expression of MIR135B mRNA |
CTD |
PMID:27570640 |
|
NCBI chr13:43,638,857...43,638,953
Ensembl chr13:43,638,857...43,638,953
|
|
G |
Mir139 |
microRNA 139 |
increases expression |
ISO |
Etoposide results in increased expression of MIR139 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 1:155,878,828...155,878,895
Ensembl chr 1:155,878,825...155,878,902
|
|
G |
Mir196b |
microRNA 196b |
increases expression |
ISO |
Etoposide results in increased expression of MIR196B mRNA |
CTD |
PMID:27570640 |
|
NCBI chr 4:81,330,487...81,330,571
Ensembl chr 4:81,330,487...81,330,571
|
|
G |
Mir34c |
microRNA 34c |
increases expression |
ISO |
Etoposide results in increased expression of MIR34C mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 8:51,409,726...51,409,802
Ensembl chr 8:51,409,726...51,409,802
|
|
G |
Mlana |
melan-A |
affects response to substance |
ISO |
MLANA protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 1:227,469,537...227,483,343
Ensembl chr 1:227,469,537...227,483,343
|
|
G |
Mllt11 |
MLLT11, transcription factor 7 cofactor |
affects response to substance |
ISO |
MLLT11 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 2:182,795,790...182,804,960
Ensembl chr 2:182,795,790...182,797,199
|
|
G |
Mmp1 |
matrix metallopeptidase 1 |
decreases expression multiple interactions |
ISO |
Etoposide results in decreased expression of MMP1 protein pifithrin inhibits the reaction [Etoposide results in decreased expression of MMP1 protein] |
CTD |
PMID:18557930 |
|
NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097
|
|
G |
Mocos |
molybdenum cofactor sulfurase |
affects response to substance |
ISO |
MOCOS protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr18:15,931,659...15,977,415
Ensembl chr18:15,931,654...15,977,187
|
|
G |
Mpo |
myeloperoxidase |
increases metabolic processing |
ISO |
MPO protein results in increased metabolism of Etoposide |
CTD |
PMID:16841962 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Mpzl1 |
myelin protein zero-like 1 |
decreases expression |
ISO |
Etoposide results in decreased expression of MPZL1 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr13:77,852,467...77,889,305
Ensembl chr13:77,852,467...77,896,616
|
|
G |
Mr1 |
major histocompatibility complex, class I-related |
increases expression affects expression |
ISO |
Etoposide results in increased expression of MR1 mRNA Etoposide affects the expression of MR1 mRNA |
CTD |
PMID:21527772 PMID:25811541 |
|
NCBI chr13:67,298,362...67,317,985
Ensembl chr13:67,299,585...67,317,970
|
|
G |
Mras |
muscle RAS oncogene homolog |
decreases expression |
ISO |
Etoposide results in decreased expression of MRAS mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 8:99,944,036...100,006,771
Ensembl chr 8:99,944,036...99,996,408
|
|
G |
Mrc1 |
mannose receptor, C type 1 |
decreases expression |
ISO |
Etoposide results in decreased expression of MRC1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr17:77,249,187...77,330,857
Ensembl chr17:77,249,187...77,330,857
|
|
G |
Mrm2 |
mitochondrial rRNA methyltransferase 2 |
decreases expression |
ISO |
Etoposide results in decreased expression of MRM2 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr12:14,309,556...14,314,759
Ensembl chr12:14,251,941...14,314,118
|
|
G |
Msc |
musculin |
decreases expression |
ISO |
Etoposide results in decreased expression of MSC mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 5:4,547,335...4,553,206
Ensembl chr 5:4,547,405...4,553,203
|
|
G |
Msh6 |
mutS homolog 6 |
decreases expression |
ISO |
Etoposide results in decreased expression of MSH6 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 6:6,562,631...6,579,995
Ensembl chr 6:6,562,632...6,579,956
|
|
G |
Mt-nd4 |
mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4 |
increases expression |
ISO |
Etoposide results in increased expression of ND4 mRNA |
CTD |
PMID:26259609 |
|
NCBI chr MT:10,160...11,537 NCBI chr MT:10,160...11,537 NCBI chr MT:10,160...11,537
Ensembl chr MT:10,160...11,537
|
|
G |
Mt2A |
metallothionein 2A |
decreases expression multiple interactions |
ISO |
Etoposide results in decreased expression of MT2A protein XAF1 protein affects the reaction [Etoposide results in decreased expression of MT2A protein] |
CTD |
PMID:28507149 |
|
NCBI chr19:10,832,009...10,832,783
Ensembl chr19:10,832,002...10,832,784
|
|
G |
Mthfd2 |
methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase |
decreases expression |
ISO |
Etoposide results in decreased expression of MTHFD2 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 4:115,811,135...115,822,663
Ensembl chr 4:115,811,139...115,822,608
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
increases phosphorylation |
ISO |
Etoposide results in increased phosphorylation of MTOR protein |
CTD |
PMID:27769712 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Mtus1 |
microtubule associated scaffold protein 1 |
affects response to substance |
ISO |
MTUS1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr16:51,202,497...51,347,794
Ensembl chr16:51,253,562...51,347,793
|
|
G |
Mxi1 |
MAX interactor 1, dimerization protein |
affects response to substance |
ISO |
MXI1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 1:252,323,915...252,383,682
Ensembl chr 1:252,323,303...252,383,681
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
decreases expression increases response to substance multiple interactions |
ISO |
Etoposide results in decreased expression of MYC; Etoposide results in decreased expression of MYC mRNA MYC protein results in increased susceptibility to Etoposide MYC protein promotes the reaction [Etoposide results in increased cleavage of CASP9 protein] |
CTD |
PMID:9454737 PMID:21324178 PMID:21527772 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Mycn |
MYCN proto-oncogene, bHLH transcription factor |
multiple interactions decreases response to substance |
ISO |
[MYCN protein affects the expression of ABCC1 mRNA] which affects the susceptibility to Etoposide MYCN protein results in decreased susceptibility to Etoposide |
CTD |
PMID:10348353 |
|
NCBI chr 6:35,717,764...35,723,590
Ensembl chr 6:35,717,764...35,723,590
|
|
G |
Myh7 |
myosin heavy chain 7 |
decreases expression |
ISO |
Etoposide results in decreased expression of MYH7 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr15:28,446,550...28,469,888
Ensembl chr15:28,446,550...28,468,217
|
|
G |
Myl2 |
myosin light chain 2 |
decreases expression |
ISO |
Etoposide results in decreased expression of MYL2 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr12:34,454,223...34,468,554
Ensembl chr12:34,454,218...34,468,983
|
|
G |
Myl3 |
myosin light chain 3 |
decreases expression |
ISO |
Etoposide results in decreased expression of MYL3 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 8:110,738,669...110,744,814
Ensembl chr 8:110,738,661...110,744,816
|
|
G |
Myom2 |
myomesin 2 |
decreases expression |
ISO |
Etoposide results in decreased expression of MYOM2 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr16:74,520,148...74,592,658
Ensembl chr16:74,520,157...74,592,772
|
|
G |
Myot |
myotilin |
increases expression |
ISO |
Etoposide results in increased expression of MYOT mRNA |
CTD |
PMID:29397400 |
|
NCBI chr18:36,705,244...36,724,849
Ensembl chr18:36,705,314...36,724,841
|
|
G |
Myt1 |
myelin transcription factor 1 |
decreases expression |
ISO |
Etoposide results in decreased expression of MYT1 mRNA |
CTD |
PMID:16120219 |
|
NCBI chr 3:168,890,466...168,950,341
Ensembl chr 3:168,886,089...168,950,341
|
|
G |
Nabp2 |
nucleic acid binding protein 2 |
multiple interactions increases acetylation |
ISO |
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid inhibits the reaction [Etoposide results in increased acetylation of NABP2 protein] |
CTD |
PMID:26170237 |
|
NCBI chr 7:830,949...836,551
Ensembl chr 7:830,949...838,027
|
|
G |
Nap1l1 |
nucleosome assembly protein 1-like 1 |
affects response to substance |
ISO |
NAP1L1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 7:46,933,278...46,957,853
Ensembl chr 7:46,933,356...46,956,593
|
|
G |
Nck2 |
NCK adaptor protein 2 |
decreases expression |
ISO |
Etoposide results in decreased expression of NCK2 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 9:45,713,979...45,840,330
Ensembl chr 9:45,714,883...45,840,307
|
|
G |
Nectin2 |
nectin cell adhesion molecule 2 |
decreases expression |
ISO |
Etoposide results in decreased expression of NECTIN2 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 1:79,372,123...79,407,379
Ensembl chr 1:79,372,119...79,407,360
|
|
G |
Nedd9 |
neural precursor cell expressed, developmentally down-regulated 9 |
affects response to substance |
ISO |
NEDD9 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr17:23,289,793...23,468,026
Ensembl chr17:23,282,326...23,468,019
|
|
G |
Nek2 |
NIMA-related kinase 2 |
decreases expression |
ISO |
Etoposide results in decreased expression of NEK2 mRNA |
CTD |
PMID:16120219 |
|
NCBI chr13:103,405,818...103,419,063
Ensembl chr13:103,405,819...103,419,051
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
decreases response to substance multiple interactions |
ISO |
NFE2L2 mRNA results in decreased susceptibility to Etoposide; NFE2L2 protein results in decreased susceptibility to Etoposide NFE2L2 protein affects the reaction [Etoposide results in increased expression of SRXN1 protein]; NFE2L2 protein affects the reaction [Etoposide results in increased expression of TP53 protein]; trigonelline inhibits the reaction [NFE2L2 protein results in decreased susceptibility to Etoposide] |
CTD |
PMID:26708503 PMID:27982581 PMID:33148531 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO |
NFKB1 protein affects the reaction [Etoposide results in increased expression of TP53 protein]; NFKB1 protein affects the reaction [Etoposide results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:23396362 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions increases degradation |
ISO |
wortmannin inhibits the reaction [Etoposide results in increased degradation of NFKBIA protein] |
CTD |
PMID:12637521 PMID:17935137 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nherf1 |
NHERF family PDZ scaffold protein 1 |
increases expression |
ISO |
Etoposide results in increased expression of NHERF1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr10:100,403,189...100,420,290
Ensembl chr10:100,403,069...100,420,598
|
|
G |
Niban1 |
niban apoptosis regulator 1 |
affects response to substance |
ISO |
NIBAN1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr13:63,674,240...63,827,748
Ensembl chr13:63,674,171...63,827,729
|
|
G |
Nit2 |
nitrilase family, member 2 |
multiple interactions |
ISO |
[Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in decreased expression of NIT2 protein |
CTD |
PMID:29733421 |
|
NCBI chr11:43,363,839...43,378,713
Ensembl chr11:43,363,985...43,375,024
|
|
G |
Nmt2 |
N-myristoyltransferase 2 |
affects response to substance |
ISO |
NMT2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr17:74,917,833...74,964,788
Ensembl chr17:74,917,833...74,961,080
|
|
G |
Nos2 |
nitric oxide synthase 2 |
increases expression |
EXP ISO |
Etoposide results in increased expression of NOS2 mRNA Etoposide results in increased expression of NOS2 protein |
CTD |
PMID:15135310 PMID:26259609 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Npas1 |
neuronal PAS domain protein 1 |
increases expression |
ISO |
Etoposide results in increased expression of NPAS1 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 1:77,167,375...77,187,887
Ensembl chr 1:77,167,381...77,186,762
|
|
G |
Npnt |
nephronectin |
increases expression |
ISO |
Etoposide results in increased expression of NPNT mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 2:221,391,151...221,459,527
Ensembl chr 2:221,391,153...221,459,401
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
affects response to substance increases expression multiple interactions |
ISO |
NQO1 protein affects the susceptibility to Etoposide Etoposide results in increased expression of NQO1 mRNA HIPK2 protein promotes the reaction [Etoposide results in increased expression of NQO1 mRNA] |
CTD |
PMID:16217747 PMID:20980392 PMID:29397400 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr0b1 |
nuclear receptor subfamily 0, group B, member 1 |
decreases expression |
ISO |
Etoposide results in decreased expression of NR0B1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr X:50,756,886...50,761,014
Ensembl chr X:50,756,886...50,761,011
|
|
G |
Nr1h2 |
nuclear receptor subfamily 1, group H, member 2 |
affects localization affects response to substance multiple interactions |
ISO |
Etoposide affects the localization of NR1H2 protein NR1H2 protein affects the susceptibility to Etoposide Etoposide promotes the reaction [NR1H2 protein results in increased expression of CETP mRNA]; NR1H2 mutant form inhibits the reaction [Etoposide results in increased expression of CETP mRNA] |
CTD |
PMID:25914138 |
|
NCBI chr 1:95,041,967...95,047,358
Ensembl chr 1:95,041,967...95,047,377
|
|
G |
Nr1h3 |
nuclear receptor subfamily 1, group H, member 3 |
multiple interactions affects response to substance increases expression |
ISO |
Etoposide promotes the reaction [NR1H3 protein results in increased expression of CETP mRNA]; Etoposide results in increased expression of and affects the localization of NR1H3 protein; NR1H3 mutant form inhibits the reaction [Etoposide results in increased expression of CETP mRNA] NR1H3 protein affects the susceptibility to Etoposide Etoposide results in increased expression of NR1H3 mRNA |
CTD |
PMID:25914138 |
|
NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
affects response to substance multiple interactions increases activity |
ISO |
NR1I2 protein affects the susceptibility to Etoposide [Etoposide results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA |
CTD |
PMID:17279585 PMID:25455453 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
multiple interactions |
ISO |
Etoposide inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased activity of NR1I3 protein] |
CTD |
PMID:30818834 |
|
NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
|
|
G |
Nrap |
nebulin-related anchoring protein |
decreases expression |
ISO |
Etoposide results in decreased expression of NRAP mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 1:255,350,113...255,427,704
Ensembl chr 1:255,350,113...255,427,693
|
|
G |
Nrg1 |
neuregulin 1 |
increases expression |
ISO |
Etoposide results in increased expression of NRG1 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr16:59,250,658...60,304,519
Ensembl chr16:59,250,854...60,296,884
|
|
G |
Nrip1 |
nuclear receptor interacting protein 1 |
affects response to substance decreases expression |
ISO |
NRIP1 protein affects the susceptibility to Etoposide Etoposide results in decreased expression of NRIP1 mRNA; Etoposide results in decreased expression of NRIP1 protein |
CTD |
PMID:16217747 PMID:25914138 |
|
NCBI chr11:14,895,843...14,979,490
Ensembl chr11:14,895,553...14,981,761
|
|
G |
Nupr1 |
nuclear protein 1, transcriptional regulator |
affects response to substance decreases expression |
ISO |
NUPR1 protein affects the susceptibility to Etoposide Etoposide results in decreased expression of NUPR1 mRNA |
CTD |
PMID:16217747 PMID:25270620 |
|
NCBI chr 1:181,213,292...181,215,327
Ensembl chr 1:181,213,368...181,215,281
|
|
G |
Oat |
ornithine aminotransferase |
multiple interactions |
ISO |
[Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in decreased expression of OAT protein |
CTD |
PMID:29733421 |
|
NCBI chr 1:187,347,862...187,367,644
Ensembl chr 1:187,347,865...187,367,682
|
|
G |
Oca2 |
OCA2 melanosomal transmembrane protein |
affects response to substance |
ISO |
OCA2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 1:107,116,278...107,446,093
Ensembl chr 1:107,116,278...107,446,074
|
|
G |
Ogg1 |
8-oxoguanine DNA glycosylase |
decreases expression multiple interactions |
ISO |
Etoposide results in decreased expression of OGG1 mRNA wogonin inhibits the reaction [Etoposide results in decreased expression of OGG1 mRNA] |
CTD |
PMID:23872129 |
|
NCBI chr 4:146,474,701...146,481,959
Ensembl chr 4:146,474,750...146,484,766
|
|
G |
P2rx7 |
purinergic receptor P2X 7 |
increases expression |
ISO |
Etoposide results in increased expression of P2RX7 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr12:33,889,709...33,934,168
Ensembl chr12:33,879,745...33,934,619
|
|
G |
Pabpc1 |
poly(A) binding protein, cytoplasmic 1 |
decreases expression |
ISO |
Etoposide results in decreased expression of PABPC1 protein |
CTD |
PMID:29733421 |
|
NCBI chr 7:67,777,438...67,789,731
Ensembl chr 7:67,777,381...67,789,744
|
|
G |
Palb2 |
partner and localizer of BRCA2 |
decreases expression |
ISO |
Etoposide results in decreased expression of PALB2 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 1:176,665,076...176,689,053
Ensembl chr 1:176,665,076...176,688,990
|
|
G |
Papss2 |
3'-phosphoadenosine 5'-phosphosulfate synthase 2 |
increases expression |
ISO |
Etoposide results in increased expression of PAPSS2 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 1:230,454,314...230,539,332
Ensembl chr 1:230,454,426...230,539,331
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage multiple interactions increases degradation |
EXP ISO |
Etoposide results in increased cleavage of PARP1 protein 3',4'-dihydroxyflavone analog inhibits the reaction [Etoposide results in increased cleavage of PARP1 protein]; [CASP8 co-treated with TP53] affects the reaction [Etoposide results in increased cleavage of PARP1 protein]; [Colforsin co-treated with Theophylline] inhibits the reaction [Etoposide results in increased cleavage of PARP1 protein]; [trigonelline co-treated with Etoposide] results in increased cleavage of PARP1 protein; BCL2 protein inhibits the reaction [Etoposide results in increased degradation of PARP1 protein]; BCL2L1 protein inhibits the reaction [Etoposide results in increased degradation of PARP1 protein]; benzyloxycarbonyl-valyl-alanyl-aspartyl-fluoromethane inhibits the reaction [Etoposide results in increased cleavage of PARP1 protein]; CD40LG protein inhibits the reaction [Etoposide promotes the reaction [CASP3 protein results in increased cleavage of PARP1 protein]]; Etoposide promotes the reaction [CASP3 protein results in increased cleavage of PARP1 protein]; HTATIP2 protein promotes the reaction [Etoposide results in increased activity of PARP1 protein]; Nicotine inhibits the reaction [Etoposide results in increased cleavage of PARP1 protein]; PTEN protein modified form promotes the reaction [Etoposide results in increased cleavage of PARP1 protein]; PTEN protein promotes the reaction [Etoposide results in increased cleavage of PARP1 protein]; Wortmannin promotes the reaction [Etoposide results in increased cleavage of PARP1 protein]; XAF1 protein affects the reaction [Etoposide results in increased cleavage of PARP1 protein] Niacin deficiency affects the reaction [Etoposide results in increased cleavage of PARP1 protein] |
CTD |
PMID:8840993 PMID:9454737 PMID:12690110 PMID:16014620 PMID:16545138 PMID:16799960 PMID:16807353 PMID:16844113 PMID:17516866 PMID:17935137 PMID:20457658 PMID:21801448 PMID:25447644 PMID:26259609 PMID:28507149 PMID:30890322 PMID:33148531 More...
|
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pbk |
PDZ binding kinase |
affects response to substance |
ISO |
PBK protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr15:40,022,873...40,034,014
Ensembl chr15:40,023,002...40,034,014
|
|
G |
Pcbp2 |
poly(rC) binding protein 2 |
multiple interactions |
ISO |
[Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in decreased expression of PCBP2 protein |
CTD |
PMID:29733421 |
|
NCBI chr 7:133,605,375...133,631,312
Ensembl chr 7:133,605,573...133,629,863
|
|
G |
Pcbp4 |
poly(rC) binding protein 4 |
decreases expression |
ISO |
Etoposide results in decreased expression of PCBP4 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 8:107,092,688...107,103,276
Ensembl chr 8:107,093,013...107,103,276
|
|
G |
Pck2 |
phosphoenolpyruvate carboxykinase 2 (mitochondrial) |
decreases expression |
ISO |
Etoposide results in decreased expression of PCK2 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr15:29,027,891...29,036,729
Ensembl chr15:29,027,894...29,037,283
|
|
G |
Pde2a |
phosphodiesterase 2A |
decreases expression |
ISO |
Etoposide results in decreased expression of PDE2A mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 1:155,823,590...155,915,434
Ensembl chr 1:155,813,180...155,915,434
|
|
G |
Pde4b |
phosphodiesterase 4B |
affects response to substance |
ISO |
PDE4B protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 5:116,799,819...117,369,155
Ensembl chr 5:116,799,971...117,367,696
|
|
G |
Pdgfc |
platelet derived growth factor C |
affects response to substance |
ISO |
PDGFC protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 2:166,316,870...166,493,449
Ensembl chr 2:166,316,803...166,493,433
|
|
G |
Pdia3 |
protein disulfide isomerase family A, member 3 |
multiple interactions |
EXP |
[Bleomycin co-treated with Cisplatin co-treated with Etoposide] results in increased expression of PDIA3 protein |
CTD |
PMID:24478030 |
|
NCBI chr 3:108,388,189...108,412,013
Ensembl chr 3:108,388,245...108,413,236
|
|
G |
Pdk1 |
pyruvate dehydrogenase kinase 1 |
decreases expression |
ISO |
Etoposide results in decreased expression of PDK1 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 3:56,705,824...56,733,040
Ensembl chr 3:56,705,871...56,733,038
|
|
G |
Pdk4 |
pyruvate dehydrogenase kinase 4 |
increases expression |
ISO |
Etoposide results in increased expression of PDK4 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 4:33,591,796...33,601,798
Ensembl chr 4:33,589,799...33,601,850
|
|
G |
Pdlim3 |
PDZ and LIM domain 3 |
increases expression |
ISO |
Etoposide results in increased expression of PDLIM3 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr16:46,352,460...46,383,680
Ensembl chr16:46,352,467...46,383,657
|
|
G |
Pelo |
pelota mRNA surveillance and ribosome rescue factor |
decreases expression |
ISO |
Etoposide results in decreased expression of PELO mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 2:46,797,853...46,799,621
Ensembl chr 2:46,797,853...46,799,746
|
|
G |
Perp |
p53 apoptosis effector related to PMP22 |
increases expression |
ISO |
Etoposide results in increased expression of PERP mRNA |
CTD |
PMID:21382384 PMID:25270620 |
|
NCBI chr 1:13,542,067...13,554,514
Ensembl chr 1:13,542,067...13,554,511
|
|
G |
Phgdh |
phosphoglycerate dehydrogenase |
affects response to substance |
ISO |
PHGDH protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 2:185,906,962...185,936,054
Ensembl chr 2:185,906,966...185,935,944
|
|
G |
Phlda3 |
pleckstrin homology-like domain, family A, member 3 |
increases expression |
ISO |
Etoposide results in increased expression of PHLDA3 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr13:47,193,250...47,196,335
Ensembl chr13:47,193,086...47,196,335
|
|
G |
Piga |
phosphatidylinositol glycan anchor biosynthesis, class A |
multiple interactions |
ISO |
[Cisplatin co-treated with Etoposide] results in increased mutagenesis of PIGA |
CTD |
PMID:21826740 |
|
NCBI chr X:30,043,033...30,055,861
Ensembl chr X:30,042,343...30,055,804
|
|
G |
Pip5k1b |
phosphatidylinositol-4-phosphate 5-kinase type 1 beta |
affects response to substance |
ISO |
PIP5K1B protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 1:221,907,220...222,183,672
Ensembl chr 1:221,914,159...222,183,672
|
|
G |
Plau |
plasminogen activator, urokinase |
increases expression |
ISO |
Etoposide results in increased expression of PLAU mRNA |
CTD |
PMID:21527772 |
|
NCBI chr15:3,456,230...3,462,732
Ensembl chr15:3,456,232...3,462,775
|
|
G |
Plk1 |
polo-like kinase 1 |
decreases expression |
ISO |
Etoposide results in decreased expression of PLK1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 1:176,716,420...176,726,400
Ensembl chr 1:176,716,420...176,726,400
|
|
G |
Plk2 |
polo-like kinase 2 |
increases expression |
ISO |
Etoposide results in increased expression of PLK2 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 2:41,969,176...41,974,945
Ensembl chr 2:41,969,176...41,974,947
|
|
G |
Plk3 |
polo-like kinase 3 |
increases expression |
ISO |
Etoposide results in increased expression of PLK3 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 5:130,607,142...130,612,317
Ensembl chr 5:130,607,142...130,612,317
|
|
G |
Plp1 |
proteolipid protein 1 |
affects response to substance |
ISO |
PLP1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr X:100,184,039...100,201,035
Ensembl chr X:100,185,767...100,201,032
|
|
G |
Plpp2 |
phospholipid phosphatase 2 |
decreases expression |
ISO |
Etoposide results in decreased expression of PLPP2 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 7:10,175,918...10,184,032
Ensembl chr 7:10,175,948...10,184,071
|
|
G |
Pm20d1 |
peptidase M20 domain containing 1 |
increases expression |
ISO |
Etoposide results in increased expression of PM20D1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr13:43,237,954...43,259,999
Ensembl chr13:43,237,971...43,259,999
|
|
G |
Pmaip1 |
phorbol-12-myristate-13-acetate-induced protein 1 |
increases expression |
ISO |
Etoposide results in increased expression of PMAIP1 mRNA |
CTD |
PMID:21801448 |
|
NCBI chr18:59,986,020...59,992,434
Ensembl chr18:59,986,017...59,992,429
|
|
G |
Pmel |
premelanosome protein |
affects response to substance |
ISO |
PMEL protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 7:1,138,202...1,148,735
Ensembl chr 7:1,138,586...1,148,746
|
|
G |
Pmp2 |
peripheral myelin protein 2 |
affects response to substance |
ISO |
PMP2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 2:91,611,334...91,615,252
Ensembl chr 2:91,611,334...91,615,252
|
|
G |
Pmp22 |
peripheral myelin protein 22 |
affects response to substance |
ISO |
PMP22 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr10:47,795,709...47,825,715
Ensembl chr10:47,795,709...47,825,714
|
|
G |
Polq |
DNA polymerase theta |
decreases response to substance |
ISO |
POLQ results in decreased susceptibility to Etoposide |
CTD |
PMID:21883722 |
|
NCBI chr11:63,673,796...63,775,905
Ensembl chr11:63,673,816...63,775,878
|
|
G |
Polr1h |
RNA polymerase I subunit H |
decreases response to substance multiple interactions |
ISO |
POLR1H protein results in decreased susceptibility to Etoposide Verapamil inhibits the reaction [POLR1H protein results in decreased susceptibility to Etoposide] |
CTD |
PMID:14726695 |
|
NCBI chr20:1,594,936...1,598,854
Ensembl chr20:1,594,936...1,598,854
|
|
G |
Postn |
periostin |
increases expression |
ISO |
Etoposide results in increased expression of POSTN mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 2:138,527,714...138,559,098
Ensembl chr 2:138,527,696...138,559,099
|
|
G |
Pou5f1 |
POU class 5 homeobox 1 |
increases expression |
ISO |
Etoposide results in increased expression of POU5F1 mRNA; Etoposide results in increased expression of POU5F1 protein |
CTD |
PMID:33969609 |
|
NCBI chr20:3,223,128...3,227,891
Ensembl chr20:3,223,129...3,227,891
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
increases expression multiple interactions |
ISO |
Etoposide results in increased expression of PPARGC1A mRNA Etoposide promotes the reaction [PPARGC1A protein results in increased activity of ESRRA protein] |
CTD |
PMID:26259609 PMID:30818834 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Ppargc1b |
PPARG coactivator 1 beta |
increases expression |
ISO |
Etoposide results in increased expression of PPARGC1B mRNA |
CTD |
PMID:26259609 |
|
NCBI chr18:54,758,891...54,861,103
Ensembl chr18:54,758,902...54,861,194
|
|
G |
Ppm1d |
protein phosphatase, Mg2+/Mn2+ dependent, 1D |
increases expression |
ISO |
Etoposide results in increased expression of PPM1D protein |
CTD |
PMID:25078064 |
|
NCBI chr10:70,172,603...70,208,607
Ensembl chr10:70,172,603...70,208,607
|
|
G |
Ppp1r13l |
protein phosphatase 1, regulatory subunit 13 like |
increases expression multiple interactions decreases response to substance |
ISO |
Etoposide results in increased expression of PPP1R13L mRNA Etoposide results in increased expression of and results in increased localization of PPP1R13L protein PPP1R13L results in decreased susceptibility to Etoposide |
CTD |
PMID:17570360 PMID:19299014 |
|
NCBI chr 1:79,010,997...79,030,714
Ensembl chr 1:79,011,745...79,030,712
|
|
G |
Prc1 |
protein regulator of cytokinesis 1 |
decreases expression |
ISO |
Etoposide results in decreased expression of PRC1 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 1:134,250,086...134,271,765
Ensembl chr 1:134,250,081...134,271,765
|
|
G |
Prdx1 |
peroxiredoxin 1 |
decreases expression |
ISO |
Etoposide results in decreased expression of PRDX1 protein |
CTD |
PMID:29733421 |
|
NCBI chr 5:130,147,258...130,162,856
Ensembl chr 5:130,147,204...130,162,856
|
|
G |
Prkab1 |
protein kinase AMP-activated non-catalytic subunit beta 1 |
increases expression |
ISO |
Etoposide results in increased expression of PRKAB1 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr12:40,588,140...40,598,673
Ensembl chr12:40,588,211...40,598,661
|
|
G |
Prkcd |
protein kinase C, delta |
multiple interactions |
ISO |
Etoposide results in increased cleavage of and results in increased activity of PRKCD protein |
CTD |
PMID:19662097 |
|
NCBI chr16:5,769,217...5,799,380
Ensembl chr16:5,769,215...5,799,352
|
|
G |
Prkcz |
protein kinase C, zeta |
increases response to substance |
ISO |
PRKCZ protein results in increased susceptibility to Etoposide |
CTD |
PMID:21863889 |
|
NCBI chr 5:165,817,786...165,930,386
Ensembl chr 5:165,819,466...165,930,367
|
|
G |
Prkdc |
protein kinase, DNA-activated, catalytic subunit |
increases phosphorylation multiple interactions |
ISO |
Etoposide results in increased phosphorylation of PRKDC protein PRKDC protein promotes the reaction [Etoposide results in increased phosphorylation of SP1 protein] |
CTD |
PMID:17441964 |
|
NCBI chr11:85,040,790...85,258,357
Ensembl chr11:85,040,792...85,257,952
|
|
G |
Prkx |
protein kinase cAMP-dependent X-linked catalytic subunit |
increases expression |
ISO |
Etoposide results in increased expression of PRKX mRNA |
CTD |
PMID:29397400 |
|
NCBI chr X:41,823,349...41,866,844
Ensembl chr X:41,823,355...41,866,669
|
|
G |
Prnp |
prion protein |
decreases response to substance |
ISO |
PRNP protein results in decreased susceptibility to Etoposide |
CTD |
PMID:15386405 |
|
NCBI chr 3:119,186,073...119,201,513
Ensembl chr 3:119,177,485...119,203,937
|
|
G |
Procr |
protein C receptor |
increases expression |
ISO |
Etoposide results in increased expression of PROCR mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 3:144,254,596...144,258,863
Ensembl chr 3:144,254,380...144,258,903
|
|
G |
Psmd13 |
proteasome 26S subunit, non-ATPase 13 |
multiple interactions |
ISO |
[Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in decreased expression of PSMD13 protein |
CTD |
PMID:29733421 |
|
NCBI chr 1:195,964,617...195,976,895
Ensembl chr 1:195,964,138...195,976,905
|
|
G |
Pten |
phosphatase and tensin homolog |
multiple interactions increases response to substance |
ISO |
PTEN protein inhibits the reaction [Etoposide results in increased phosphorylation of and results in increased activity of AKT1 protein]; PTEN protein modified form promotes the reaction [Etoposide results in increased cleavage of PARP1 protein]; PTEN protein promotes the reaction [Etoposide results in increased cleavage of PARP1 protein]; Wortmannin inhibits the reaction [PTEN protein results in increased susceptibility to Etoposide] |
CTD |
PMID:16807353 PMID:17935137 |
|
NCBI chr 1:230,630,443...230,697,070
Ensembl chr 1:230,630,338...230,696,838
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression multiple interactions |
ISO |
Etoposide results in increased expression of PTGS2 protein PTGS2 mutant form inhibits the reaction [VEGFC protein results in decreased susceptibility to Etoposide] |
CTD |
PMID:24184161 PMID:26259609 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Pus3 |
pseudouridine synthase 3 |
decreases expression |
ISO |
Etoposide results in decreased expression of PUS3 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 8:33,910,461...33,918,716
Ensembl chr 8:33,911,357...33,918,714
|
|
G |
Pygm |
glycogen phosphorylase, muscle associated |
decreases expression |
ISO |
Etoposide results in decreased expression of PYGM mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 1:203,690,550...203,705,369
Ensembl chr 1:203,690,533...203,705,368
|
|
G |
Rab17 |
RAB17, member RAS oncogene family |
affects response to substance |
ISO |
RAB17 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 9:91,552,924...91,566,759
Ensembl chr 9:91,553,464...91,566,451
|
|
G |
Rab20 |
RAB20, member RAS oncogene family |
affects response to substance |
ISO |
RAB20 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr16:78,019,337...78,043,529
Ensembl chr16:78,019,337...78,043,529
|
|
G |
Rad51 |
RAD51 recombinase |
affects localization |
EXP |
Etoposide affects the localization of RAD51 protein |
CTD |
PMID:9885240 |
|
NCBI chr 3:106,099,753...106,125,038
Ensembl chr 3:106,100,381...106,125,035
|
|
G |
Rad52 |
RAD52 homolog, DNA repair protein |
multiple interactions increases expression |
ISO |
BRCA1 protein mutant form inhibits the reaction [Etoposide results in increased expression of RAD52 protein] Etoposide results in increased expression of RAD52 mRNA; Etoposide results in increased expression of RAD52 protein |
CTD |
PMID:16417649 PMID:19799994 |
|
NCBI chr 4:153,106,062...153,128,598
Ensembl chr 4:153,106,062...153,128,207
|
|
G |
Rad54b |
RAD54 homolog B |
multiple interactions |
ISO |
RAD54B protein affects the reaction [Etoposide results in increased expression of H2AX protein] |
CTD |
PMID:33823233 |
|
NCBI chr 5:25,032,112...25,104,630
Ensembl chr 5:25,032,066...25,104,616
|
|
G |
Rad54l |
RAD54 like |
multiple interactions increases expression |
ISO |
BRCA1 protein mutant form inhibits the reaction [Etoposide results in increased expression of RAD54L protein] |
CTD |
PMID:16417649 |
|
NCBI chr 5:129,575,431...129,605,100
Ensembl chr 5:129,575,378...129,605,070
|
|
G |
Rasip1 |
Ras interacting protein 1 |
affects response to substance |
ISO |
RASIP1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 1:96,097,135...96,109,564
Ensembl chr 1:96,091,074...96,109,562
|
|
G |
Rassf1 |
Ras association domain family member 1 |
multiple interactions increases response to substance |
ISO |
[RASSF1 co-treated with Etoposide] affects the folding of and results in increased activity of BAX protein; [RASSF1 co-treated with Etoposide] results in increased cleavage of CASP3 protein; [RASSF1 co-treated with Etoposide] results in increased expression of CDKN1A protein; ABT-737 promotes the reaction [RASSF1 results in increased susceptibility to Etoposide] |
CTD |
PMID:21880625 |
|
NCBI chr 8:108,225,023...108,236,164
Ensembl chr 8:108,225,023...108,236,164
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
affects response to substance decreases phosphorylation multiple interactions |
ISO |
RB1 protein affects the susceptibility to Etoposide Etoposide results in decreased phosphorylation of RB1 protein [Colforsin co-treated with Theophylline] inhibits the reaction [Etoposide results in decreased phosphorylation of RB1 protein] |
CTD |
PMID:9454737 PMID:17640669 |
|
NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
|
|
G |
Rbm17 |
RNA binding motif protein 17 |
decreases response to substance |
ISO |
RBM17 protein results in decreased susceptibility to Etoposide |
CTD |
PMID:16061639 |
|
NCBI chr17:66,937,140...66,954,034
Ensembl chr17:66,937,140...66,954,014
|
|
G |
Rbm34 |
RNA binding motif protein 34 |
decreases expression |
ISO |
Etoposide results in decreased expression of RBM34 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr19:54,936,516...54,956,810
Ensembl chr19:54,936,531...54,956,715
|
|
G |
Rcan1 |
regulator of calcineurin 1 |
affects response to substance |
ISO |
RCAN1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr11:31,622,208...31,702,150
Ensembl chr11:31,622,210...31,702,045
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
[[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in decreased susceptibility to Etoposide; resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in decreased susceptibility to Etoposide] |
CTD |
PMID:19047049 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Retsat |
retinol saturase |
increases expression |
ISO |
Etoposide results in increased expression of RETSAT mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 4:104,653,306...104,662,069
Ensembl chr 4:104,653,155...104,668,310
|
|
G |
Rfc1 |
replication factor C subunit 1 |
decreases expression |
ISO |
Etoposide results in decreased expression of RFC1 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr14:42,966,279...43,041,372
Ensembl chr14:42,966,324...43,041,370
|
|
G |
Rgcc |
regulator of cell cycle |
increases expression |
ISO |
Etoposide results in increased expression of RGCC mRNA |
CTD |
PMID:29397400 |
|
NCBI chr15:54,662,483...54,675,320
Ensembl chr15:54,662,483...54,681,141
|
|
G |
Ripk2 |
receptor-interacting serine-threonine kinase 2 |
multiple interactions increases expression |
ISO |
Estradiol inhibits the reaction [Etoposide results in increased expression of RIPK2 mRNA] |
CTD |
PMID:19426747 |
|
NCBI chr 5:29,630,806...29,662,804
Ensembl chr 5:29,631,570...29,662,657
|
|
G |
Ripply3 |
ripply transcriptional repressor 3 |
increases expression |
ISO |
Etoposide results in increased expression of RIPPLY3 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr11:33,648,471...33,656,587
Ensembl chr11:33,648,486...33,656,584
|
|
G |
Rnf113a1 |
ring finger protein 113A1 |
decreases expression |
ISO |
Etoposide results in decreased expression of RNF113A mRNA |
CTD |
PMID:24211769 |
|
NCBI chr X:116,427,941...116,429,164
Ensembl chr X:116,427,684...116,433,762
|
|
G |
Robo1 |
roundabout guidance receptor 1 |
affects response to substance |
ISO |
ROBO1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr11:10,580,863...11,621,675
Ensembl chr11:10,580,908...11,620,203
|
|
G |
Robo3 |
roundabout guidance receptor 3 |
increases expression |
ISO |
Etoposide results in increased expression of ROBO3 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 8:37,133,542...37,151,674
Ensembl chr 8:37,133,916...37,151,315
|
|
G |
Ropn1 |
rhophilin associated tail protein 1 |
affects response to substance |
ISO |
ROPN1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr11:66,097,854...66,127,148
Ensembl chr11:66,097,856...66,127,148
|
|
G |
Rpl6 |
ribosomal protein L6 |
decreases response to substance |
ISO |
RPL6 protein results in decreased susceptibility to Etoposide |
CTD |
PMID:15846068 |
|
NCBI chr12:35,347,493...35,352,011
Ensembl chr12:35,347,497...35,351,921
|
|
G |
Rps27l |
ribosomal protein S27-like |
increases expression |
ISO |
Etoposide results in increased expression of RPS27L protein |
CTD |
PMID:18056458 |
|
NCBI chr 8:67,562,483...67,567,418
Ensembl chr 8:67,562,483...67,567,418
|
|
G |
Rps6 |
ribosomal protein S6 |
increases phosphorylation |
ISO |
Etoposide results in increased phosphorylation of RPS6 protein |
CTD |
PMID:23396362 |
|
NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602 Ensembl chr 5:101,371,136...101,374,602
|
|
G |
Rras |
RAS related |
increases expression |
ISO |
Etoposide results in increased expression of RRAS mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 1:95,500,582...95,504,362
Ensembl chr 1:95,500,566...95,504,357
|
|
G |
Rrm2b |
ribonucleotide reductase regulatory TP53 inducible subunit M2B |
increases expression |
ISO |
Etoposide results in increased expression of RRM2B mRNA |
CTD |
PMID:21704725 |
|
NCBI chr 7:69,077,024...69,108,742
Ensembl chr 7:69,078,291...69,108,633
|
|
G |
RT1-A2 |
RT1 class Ia, locus A2 |
affects expression |
ISO |
Etoposide affects the expression of HLA-E mRNA |
CTD |
PMID:25811541 |
|
NCBI chr20:4,870,939...4,910,183
|
|
G |
RT1-CE16 |
RT1 class I, locus CE16 |
affects expression |
ISO |
Etoposide affects the expression of HLA-A mRNA |
CTD |
PMID:25811541 |
|
NCBI chr20:3,257,109...3,260,747
Ensembl chr20:3,257,123...3,279,563
|
|
G |
Rtkn |
rhotekin |
increases expression |
ISO |
Etoposide results in increased expression of RTKN mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 4:115,640,813...115,657,952
Ensembl chr 4:115,640,774...115,657,952
|
|
G |
Runx1 |
RUNX family transcription factor 1 |
increases mutagenesis increases response to substance |
ISO |
Etoposide results in increased mutagenesis of RUNX1 gene RUNX1 gene mutant form results in increased susceptibility to Etoposide |
CTD |
PMID:15217836 PMID:28624474 |
|
NCBI chr11:31,839,880...32,074,427
Ensembl chr11:31,843,764...32,074,542
|
|
G |
Runx3 |
RUNX family transcription factor 3 |
increases response to substance |
ISO |
RUNX3 protein results in increased susceptibility to Etoposide |
CTD |
PMID:15756676 |
|
NCBI chr 5:147,360,587...147,419,161
Ensembl chr 5:147,360,994...147,419,156
|
|
G |
Rxra |
retinoid X receptor alpha |
multiple interactions |
ISO |
Etoposide promotes the reaction [RXRA protein results in increased expression of CETP mRNA]; Tretinoin promotes the reaction [Etoposide promotes the reaction [RXRA protein results in increased expression of CETP mRNA]] |
CTD |
PMID:25914138 |
|
NCBI chr 3:10,989,832...11,076,366
Ensembl chr 3:10,989,832...11,073,712
|
|
G |
Ryr2 |
ryanodine receptor 2 |
decreases expression |
ISO |
Etoposide results in decreased expression of RYR2 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr17:58,389,925...58,975,641
Ensembl chr17:58,389,925...58,975,142
|
|
G |
Scn3b |
sodium voltage-gated channel beta subunit 3 |
increases expression |
ISO |
Etoposide results in increased expression of SCN3B mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 8:40,630,372...40,652,869
Ensembl chr 8:40,630,455...40,652,868
|
|
G |
Scn4b |
sodium voltage-gated channel beta subunit 4 |
increases expression |
ISO |
Etoposide results in increased expression of SCN4B mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 8:45,446,580...45,462,294
Ensembl chr 8:45,446,215...45,462,292
|
|
G |
Sdc1 |
syndecan 1 |
increases expression |
ISO |
Etoposide results in increased expression of SDC1 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 6:31,562,799...31,585,267
Ensembl chr 6:31,562,739...31,585,264
|
|
G |
Sdhaf1 |
succinate dehydrogenase complex assembly factor 1 |
decreases expression |
ISO |
Etoposide results in decreased expression of SDHAF1 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 1:85,576,207...85,577,156
Ensembl chr 1:85,576,041...85,577,366 Ensembl chr 1:85,576,041...85,577,366
|
|
G |
Serpine2 |
serpin family E member 2 |
increases expression |
ISO |
Etoposide results in increased expression of SERPINE2 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 9:81,124,746...81,188,866
Ensembl chr 9:81,124,804...81,188,826
|
|
G |
Sesn1 |
sestrin 1 |
increases expression |
ISO |
Etoposide results in increased expression of SESN1 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr20:45,294,876...45,387,698
Ensembl chr20:45,294,871...45,387,697
|
|
G |
Sfn |
stratifin |
increases expression |
ISO |
Etoposide results in increased expression of SFN mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 5:145,826,722...145,827,994
Ensembl chr 5:145,826,201...145,831,314
|
|
G |
Slbp |
stem-loop histone mRNA binding protein |
decreases expression |
ISO |
Etoposide results in decreased expression of SLBP mRNA |
CTD |
PMID:24211769 |
|
NCBI chr14:77,071,441...77,081,911
Ensembl chr14:77,071,632...77,081,906
|
|
G |
Slc16a6 |
solute carrier family 16, member 6 |
affects response to substance |
ISO |
SLC16A6 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr10:94,424,377...94,447,482
Ensembl chr10:94,426,244...94,448,779
|
|
G |
Slc1a5 |
solute carrier family 1 member 5 |
decreases expression |
ISO |
Etoposide results in decreased expression of SLC1A5 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 1:77,456,849...77,470,952
Ensembl chr 1:77,456,694...77,470,952
|
|
G |
Slc22a18 |
solute carrier family 22, member 18 |
affects response to substance |
ISO |
SLC22A18 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 1:198,670,626...198,694,977
Ensembl chr 1:198,671,731...198,694,975
|
|
G |
Slc27a3 |
solute carrier family 27 member 3 |
affects response to substance |
ISO |
SLC27A3 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 2:175,853,241...175,857,909
Ensembl chr 2:175,853,241...175,857,909
|
|
G |
Slc2a6 |
solute carrier family 2 member 6 |
increases expression |
ISO |
Etoposide results in increased expression of SLC2A6 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 3:10,348,395...10,355,208
Ensembl chr 3:10,348,395...10,355,208
|
|
G |
Slc35f2 |
solute carrier family 35, member F2 |
decreases expression |
ISO |
Etoposide results in decreased expression of SLC35F2 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 8:54,159,970...54,203,614
Ensembl chr 8:54,159,970...54,203,612
|
|
G |
Slc45a3 |
solute carrier family 45, member 3 |
multiple interactions |
ISO |
Etoposide inhibits the reaction [Dihydrotestosterone results in increased expression of SLC45A3 mRNA] |
CTD |
PMID:20601956 |
|
NCBI chr13:43,407,293...43,427,588
Ensembl chr13:43,407,293...43,427,588
|
|
G |
Slc4a11 |
solute carrier family 4 member 11 |
increases expression |
ISO |
Etoposide results in increased expression of SLC4A11 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 3:117,900,223...117,912,787
Ensembl chr 3:117,900,223...117,912,674
|
|
G |
Slc7a11 |
solute carrier family 7 member 11 |
affects response to substance |
ISO |
SLC7A11 protein affects the susceptibility to Etoposide |
CTD |
PMID:31226288 |
|
NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536
|
|
G |
Slc7a3 |
solute carrier family 7 member 3 |
decreases expression |
ISO |
Etoposide results in decreased expression of SLC7A3 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr X:66,210,071...66,216,482
Ensembl chr X:66,210,081...66,215,708
|
|
G |
Slc7a5 |
solute carrier family 7 member 5 |
affects response to substance |
ISO |
SLC7A5 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr19:49,935,220...49,963,823
Ensembl chr19:49,935,220...49,963,823
|
|
G |
Slc8a1 |
solute carrier family 8 member A1 |
decreases expression |
ISO |
Etoposide results in decreased expression of SLC8A1 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 6:13,194,609...13,547,369
Ensembl chr 6:13,194,662...13,535,628
|
|
G |
Slco2b1 |
solute carrier organic anion transporter family, member 2b1 |
multiple interactions |
ISO |
Etoposide inhibits the reaction [SLCO2B1 protein results in increased uptake of Cascade Blue] |
CTD |
PMID:30863990 |
|
NCBI chr 1:153,959,288...154,007,294
Ensembl chr 1:153,959,293...154,007,353
|
|
G |
Smad2 |
SMAD family member 2 |
multiple interactions increases phosphorylation |
ISO |
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [Etoposide results in increased phosphorylation of SMAD2 protein] |
CTD |
PMID:22363485 |
|
NCBI chr18:69,849,884...69,918,926
Ensembl chr18:69,850,377...69,912,323
|
|
G |
Smpdl3a |
sphingomyelin phosphodiesterase, acid-like 3A |
affects response to substance |
ISO |
SMPDL3A protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr20:37,132,592...37,155,567
Ensembl chr20:37,132,592...37,155,567
|
|
G |
Sod2 |
superoxide dismutase 2 |
increases expression decreases response to substance |
ISO |
Etoposide results in increased expression of SOD2 protein SOD2 protein results in decreased susceptibility to Etoposide |
CTD |
PMID:10759716 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Sohlh1 |
spermatogenesis and oogenesis specific basic helix-loop-helix 1 |
decreases expression |
ISO |
Etoposide results in decreased expression of SOHLH1 mRNA |
CTD |
PMID:29733421 |
|
NCBI chr 3:8,662,995...8,667,521
Ensembl chr 3:8,663,318...8,667,388
|
|
G |
Sorbs1 |
sorbin and SH3 domain containing 1 |
affects response to substance |
ISO |
SORBS1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 1:239,107,882...239,330,276
Ensembl chr 1:239,108,777...239,330,169
|
|
G |
Sorbs2 |
sorbin and SH3 domain containing 2 |
affects response to substance |
ISO |
SORBS2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr16:46,435,220...46,748,743
Ensembl chr16:46,435,237...46,626,514
|
|
G |
Sort1 |
sortilin 1 |
affects response to substance |
ISO |
SORT1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 2:195,924,033...196,002,354
Ensembl chr 2:195,924,099...196,002,354
|
|
G |
Sox10 |
SRY-box transcription factor 10 |
affects response to substance |
ISO |
SOX10 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 7:110,725,274...110,734,651
Ensembl chr 7:110,725,274...110,735,544
|
|
G |
Sox2 |
SRY-box transcription factor 2 |
multiple interactions |
ISO |
FTL protein affects the reaction [Etoposide results in increased expression of SOX2 protein] |
CTD |
PMID:33969609 |
|
NCBI chr 2:117,536,929...117,539,340
Ensembl chr 2:117,536,929...117,539,338
|
|
G |
Sp1 |
Sp1 transcription factor |
increases phosphorylation increases expression increases activity multiple interactions |
ISO EXP |
Etoposide results in increased phosphorylation of SP1 protein Etoposide results in increased expression of SP1 mRNA Etoposide results in increased activity of SP1 protein cordycepin inhibits the reaction [Etoposide results in increased activity of SP1 protein]; cordycepin inhibits the reaction [Etoposide results in increased expression of SP1 mRNA] PRKDC protein promotes the reaction [Etoposide results in increased phosphorylation of SP1 protein]; wortmannin inhibits the reaction [Etoposide results in increased phosphorylation of SP1 protein] |
CTD |
PMID:17441964 PMID:23690541 |
|
NCBI chr 7:133,541,302...133,571,961
Ensembl chr 7:133,541,491...133,571,961
|
|
G |
Spata18 |
spermatogenesis associated 18 |
increases expression |
ISO |
Etoposide results in increased expression of SPATA18 mRNA |
CTD |
PMID:21527772 PMID:29397400 |
|
NCBI chr14:34,531,931...34,558,671
Ensembl chr14:34,531,061...34,558,687
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
affects response to substance decreases expression |
ISO |
SPP1 protein affects the susceptibility to Etoposide Etoposide results in decreased expression of SPP1 mRNA |
CTD |
PMID:16217747 PMID:25270620 |
|
NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162
|
|
G |
Sptssa |
serine palmitoyltransferase, small subunit A |
affects response to substance |
ISO |
SPTSSA protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 6:72,144,714...72,156,130
Ensembl chr 6:72,144,714...72,156,214
|
|
G |
Srxn1 |
sulfiredoxin 1 |
increases expression multiple interactions |
ISO |
Etoposide results in increased expression of SRXN1 mRNA; Etoposide results in increased expression of SRXN1 protein NFE2L2 protein affects the reaction [Etoposide results in increased expression of SRXN1 protein]; TP53 protein affects the reaction [Etoposide results in increased expression of SRXN1 protein] |
CTD |
PMID:22003191 PMID:27358234 PMID:27982581 |
|
NCBI chr 3:140,604,490...140,610,050
Ensembl chr 3:140,599,608...140,628,448
|
|
G |
St3gal5 |
ST3 beta-galactoside alpha-2,3-sialyltransferase 5 |
decreases response to substance |
ISO |
ST3GAL5 protein results in decreased susceptibility to Etoposide |
CTD |
PMID:16571667 |
|
NCBI chr 4:104,134,613...104,192,558
Ensembl chr 4:104,134,613...104,192,558
|
|
G |
St6galnac2 |
ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 2 |
affects response to substance |
ISO |
ST6GALNAC2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr10:101,910,220...101,928,412
Ensembl chr10:101,909,971...101,915,008 Ensembl chr10:101,909,971...101,915,008
|
|
G |
ST7 |
suppression of tumorigenicity 7 |
affects response to substance |
ISO |
ST7 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 4:46,041,655...46,289,745
Ensembl chr 4:46,042,236...46,289,740
|
|
G |
Stat1 |
signal transducer and activator of transcription 1 |
multiple interactions |
ISO |
[STAT1 protein results in increased activity of CASP3 protein] which results in increased susceptibility to Etoposide; [STAT1 protein results in increased activity of CASP7 protein] which results in increased susceptibility to Etoposide |
CTD |
PMID:18649362 |
|
NCBI chr 9:49,419,561...49,459,969
Ensembl chr 9:49,419,340...49,588,540
|
|
G |
Stc1 |
stanniocalcin 1 |
increases expression |
ISO |
Etoposide results in increased expression of STC1 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr15:44,299,591...44,311,695
Ensembl chr15:44,299,621...44,310,264
|
|
G |
Stip1 |
stress-induced phosphoprotein 1 |
increases expression |
ISO |
Etoposide results in increased expression of STIP1 protein |
CTD |
PMID:29733421 |
|
NCBI chr 1:204,209,433...204,228,452
Ensembl chr 1:204,178,932...204,228,476
|
|
G |
Stmn1 |
stathmin 1 |
affects response to substance |
ISO |
STMN1 affects the susceptibility to Etoposide |
CTD |
PMID:17172428 |
|
NCBI chr 5:146,680,757...146,687,154
Ensembl chr 5:146,681,436...146,687,154
|
|
G |
Stmn2 |
stathmin 2 |
decreases expression |
ISO |
Etoposide results in decreased expression of STMN2 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 2:93,204,690...93,252,011
Ensembl chr 2:93,204,692...93,252,011
|
|
G |
Stom |
stomatin |
increases expression |
ISO |
Etoposide results in increased expression of STOM mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 3:18,645,058...18,667,343
Ensembl chr 3:18,644,378...18,667,354
|
|
G |
Sytl1 |
synaptotagmin-like 1 |
increases expression |
ISO |
Etoposide results in increased expression of SYTL1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 5:145,452,524...145,462,940
Ensembl chr 5:145,422,669...145,462,940
|
|
G |
Tap1 |
transporter 1, ATP binding cassette subfamily B member |
increases expression |
ISO |
Etoposide results in increased expression of TAP1 mRNA |
CTD |
PMID:17374387 PMID:21527772 |
|
NCBI chr20:4,656,262...4,666,634
Ensembl chr20:4,656,263...4,666,901
|
|
G |
Tax1bp3 |
Tax1 binding protein 3 |
increases expression |
ISO |
Etoposide results in increased expression of TAX1BP3 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr10:57,795,845...57,800,363
Ensembl chr10:57,795,382...57,800,363
|
|
G |
Tbc1d8 |
TBC1 domain family, member 8 |
increases expression |
ISO |
Etoposide results in increased expression of TBC1D8 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 9:41,651,394...41,761,432
Ensembl chr 9:41,651,395...41,761,409
|
|
G |
Tbl1x |
transducin (beta)-like 1 X-linked |
decreases expression |
ISO |
Etoposide results in decreased expression of TBL1X mRNA |
CTD |
PMID:25270620 |
|
NCBI chr X:41,574,558...41,731,117
Ensembl chr X:41,576,047...41,731,101
|
|
G |
Tbpl1 |
TATA-box binding protein like 1 |
affects localization |
ISO |
Etoposide affects the localization of TBPL1 protein |
CTD |
PMID:17085973 |
|
NCBI chr 1:22,777,892...22,803,305
Ensembl chr 1:22,778,459...22,803,122 Ensembl chr 1:22,778,459...22,803,122
|
|
G |
Tcap |
titin-cap |
decreases expression |
ISO |
Etoposide results in decreased expression of TCAP mRNA |
CTD |
PMID:29397400 |
|
NCBI chr10:83,381,719...83,382,887
Ensembl chr10:83,381,719...83,382,887
|
|
G |
Tcfl5 |
transcription factor like 5 |
affects response to substance |
ISO |
TCFL5 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 3:167,734,471...167,754,174
Ensembl chr 3:167,734,473...167,754,282
|
|
G |
Tcp1 |
t-complex 1 |
multiple interactions |
ISO |
[Etoposide co-treated with Cisplatin co-treated with Bleomycin] results in decreased expression of TCP1 protein |
CTD |
PMID:29733421 |
|
NCBI chr 1:47,829,061...47,836,809
Ensembl chr 1:47,828,652...47,836,839
|
|
G |
Tdrd3 |
tudor domain containing 3 |
affects response to substance |
ISO |
TDRD3 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr15:63,340,531...63,497,208
Ensembl chr15:63,341,235...63,476,110
|
|
G |
Tent5a |
terminal nucleotidyltransferase 5A |
affects response to substance |
ISO |
TENT5A protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 8:86,222,294...86,229,045
Ensembl chr 8:86,225,357...86,229,045
|
|
G |
Tex264 |
testis expressed 264 |
decreases expression |
ISO |
Etoposide results in decreased expression of TEX264 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 8:107,295,806...107,322,858
Ensembl chr 8:107,295,806...107,323,232
|
|
G |
Tfam |
transcription factor A, mitochondrial |
increases expression |
ISO |
Etoposide results in increased expression of TFAM mRNA |
CTD |
PMID:26259609 |
|
NCBI chr20:17,356,243...17,368,293
Ensembl chr20:17,356,197...17,368,292
|
|
G |
Tfap2a |
transcription factor AP-2 alpha |
affects response to substance increases response to substance |
ISO |
TFAP2A protein affects the susceptibility to Etoposide TFAP2A protein results in increased susceptibility to Etoposide |
CTD |
PMID:16204029 PMID:16217747 |
|
NCBI chr17:24,028,716...24,047,507
Ensembl chr17:24,024,432...24,047,507
|
|
G |
Tfec |
transcription factor EC |
decreases expression |
ISO |
Etoposide results in decreased expression of TFEC mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 4:45,106,129...45,180,236
Ensembl chr 4:45,107,641...45,180,236
|
|
G |
Tff3 |
trefoil factor 3 |
affects response to substance |
ISO |
TFF3 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr20:9,193,259...9,197,969
Ensembl chr20:9,193,262...9,198,054
|
|
G |
Tfpi |
tissue factor pathway inhibitor |
affects response to substance |
ISO |
TFPI protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 3:69,533,156...69,582,547
Ensembl chr 3:69,533,156...69,576,880
|
|
G |
Tfpi2 |
tissue factor pathway inhibitor 2 |
affects response to substance |
ISO |
TFPI2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 4:31,981,786...31,986,707
Ensembl chr 4:31,982,178...31,986,600
|
|
G |
Tfrc |
transferrin receptor |
multiple interactions decreases expression |
ISO |
1-cyclopropyl-4-(4-((5-methyl-3-(3-(4-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)methyl)pyridin-2-yl)piperazine inhibits the reaction [Etoposide results in decreased expression of TFRC protein] Etoposide results in decreased expression of TFRC mRNA; Etoposide results in decreased expression of TFRC protein |
CTD |
PMID:33969609 |
|
NCBI chr11:68,163,413...68,185,257
Ensembl chr11:68,163,413...68,185,257
|
|
G |
Tgds |
TDP-glucose 4,6-dehydratase |
affects response to substance |
ISO |
TGDS protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr15:95,175,064...95,195,555
Ensembl chr15:95,174,608...95,195,554
|
|
G |
Tgfa |
transforming growth factor alpha |
increases expression |
ISO |
Etoposide results in increased expression of TGFA mRNA |
CTD |
PMID:15228094 |
|
NCBI chr 4:118,618,043...118,700,897
Ensembl chr 4:118,618,269...118,700,894
|
|
G |
Tgif2 |
TGFB-induced factor homeobox 2 |
decreases expression |
ISO |
Etoposide results in decreased expression of TGIF2 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 3:145,333,152...145,348,599
Ensembl chr 3:145,333,418...145,348,596
|
|
G |
Thbs4 |
thrombospondin 4 |
increases expression |
ISO |
Etoposide results in increased expression of THBS4 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 2:23,983,158...24,025,289
Ensembl chr 2:23,983,158...24,026,313
|
|
G |
Tipin |
timeless interacting protein |
decreases expression |
ISO |
Etoposide results in decreased expression of TIPIN mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 8:64,780,813...64,801,358
Ensembl chr 8:64,780,828...64,801,352
|
|
G |
Tm7sf3 |
transmembrane 7 superfamily member 3 |
increases expression |
ISO |
Etoposide results in increased expression of TM7SF3 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 4:179,518,127...179,550,154
Ensembl chr 4:179,518,130...179,550,154
|
|
G |
Tmbim4 |
transmembrane BAX inhibitor motif containing 4 |
increases expression |
ISO |
Etoposide results in increased expression of TMBIM4 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 7:55,718,690...55,733,277
Ensembl chr 7:55,718,699...55,742,773
|
|
G |
Tmc6 |
transmembrane channel like 6 |
affects response to substance |
ISO |
TMC6 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr10:102,982,059...102,999,509
Ensembl chr10:102,971,229...102,998,960
|
|
G |
Tmem185b |
transmembrane protein 185B |
decreases expression |
ISO |
Etoposide results in decreased expression of TMEM185B mRNA |
CTD |
PMID:24211769 |
|
NCBI chr13:30,647,533...30,650,864
Ensembl chr13:30,647,482...30,650,858
|
|
G |
Tmem204 |
transmembrane protein 204 |
decreases expression |
ISO |
Etoposide results in decreased expression of TMEM204 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr10:14,076,518...14,104,849
Ensembl chr10:14,076,519...14,101,920
|
|
G |
Tmem47 |
transmembrane protein 47 |
affects response to substance |
ISO |
TMEM47 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr X:45,421,405...45,447,900
Ensembl chr X:45,421,405...45,447,900
|
|
G |
Tmem97 |
transmembrane protein 97 |
affects response to substance |
ISO |
TMEM97 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr10:63,438,228...63,447,311
Ensembl chr10:63,438,222...63,589,730
|
|
G |
Tmsb4x |
thymosin beta 4, X-linked |
decreases response to substance multiple interactions |
ISO |
TMSB4X protein results in decreased susceptibility to Etoposide TMSB4X protein inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; TMSB4X protein inhibits the reaction [Etoposide results in increased cleavage of and results in increased activity of CASP9 protein] |
CTD |
PMID:16364925 |
|
NCBI chr X:27,144,666...27,146,667
Ensembl chr X:27,128,610...27,146,667
|
|
G |
Tnf |
tumor necrosis factor |
increases expression |
ISO EXP |
Etoposide results in increased expression of TNF mRNA |
CTD |
PMID:15135310 PMID:18523641 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfrsf11b |
TNF receptor superfamily member 11B |
increases expression |
ISO |
Etoposide results in increased expression of TNFRSF11B mRNA |
CTD |
PMID:11459812 |
|
NCBI chr 7:85,566,520...85,594,526
Ensembl chr 7:85,566,520...85,594,538
|
|
G |
Tnfrsf12a |
TNF receptor superfamily member 12A |
multiple interactions increases expression |
ISO |
Estradiol inhibits the reaction [Etoposide results in increased expression of TNFRSF12A mRNA] |
CTD |
PMID:19426747 |
|
NCBI chr10:12,707,077...12,709,071
Ensembl chr10:12,689,890...12,709,045
|
|
G |
Tnfrsf14 |
TNF receptor superfamily member 14 |
increases expression |
ISO |
Etoposide results in increased expression of TNFRSF14 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 5:165,486,069...165,494,421
Ensembl chr 5:165,484,262...165,493,703
|
|
G |
Tnfrsf1a |
TNF receptor superfamily member 1A |
affects response to substance |
ISO |
TNFRSF1A protein affects the susceptibility to Etoposide |
CTD |
PMID:20159942 |
|
NCBI chr 4:158,150,815...158,163,592
Ensembl chr 4:158,150,820...158,163,591
|
|
G |
Tnfsf11 |
TNF superfamily member 11 |
decreases expression |
ISO |
Etoposide results in decreased expression of TNFSF11 mRNA |
CTD |
PMID:11459812 |
|
NCBI chr15:53,673,850...53,705,325
Ensembl chr15:53,673,877...53,705,445
|
|
G |
Tnfsf9 |
TNF superfamily member 9 |
increases expression |
ISO |
Etoposide results in increased expression of TNFSF9 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 9:1,944,017...1,946,351
Ensembl chr 9:1,944,017...1,946,345
|
|
G |
Tnks |
tankyrase |
affects response to substance |
ISO |
TNKS protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr16:57,223,174...57,370,740
Ensembl chr16:57,225,094...57,366,260
|
|
G |
Top2a |
DNA topoisomerase II alpha |
affects binding decreases activity multiple interactions affects activity decreases expression increases response to substance affects response to substance decreases response to substance |
ISO |
Etoposide binds to TOP2A protein Etoposide analog results in decreased activity of TOP2A protein; Etoposide metabolite results in decreased activity of TOP2A protein; Etoposide results in decreased activity of TOP2A protein [Ciprofloxacin binds to TOP2A protein] inhibits the reaction [Etoposide binds to TOP2A protein]; [EGF protein results in decreased expression of TOP2A protein] which results in decreased susceptibility to Etoposide; [MAPK12 protein results in increased phosphorylation of TOP2A protein] which results in increased susceptibility to Etoposide; [MAPK12 protein results in increased stability of TOP2A protein] which results in increased susceptibility to Etoposide; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Etoposide promotes the reaction [MDM2 protein binds to TOP2A protein]]; delphinidin results in decreased susceptibility to [Etoposide affects the activity of TOP2A protein]; Etoposide metabolite inhibits the reaction [TOP2A protein binds to Nucleic Acids, Nucleotides, and Nucleosides]; Etoposide metabolite inhibits the reaction [TOP2A protein results in increased hydrolysis of Adenosine Triphosphate]; Etoposide promotes the reaction [MDM2 protein binds to TOP2A protein]; TOP2A results in decreased susceptibility to [Carboplatin co-treated with Etoposide co-treated with Ifosfamide]; TOP2A results in decreased susceptibility to [Cisplatin co-treated with Etoposide] Etoposide results in decreased expression of TOP2A protein TOP2A protein results in increased susceptibility to Etoposide TOP2A protein modified form affects the susceptibility to Etoposide TOP2A gene mutant form results in decreased susceptibility to Etoposide; TOP2A protein mutant form results in decreased susceptibility to Etoposide |
CTD |
PMID:10856430 PMID:11325482 PMID:11470519 PMID:11531262 PMID:11676865 PMID:12569090 PMID:15211611 PMID:16969495 PMID:17575151 PMID:19182879 PMID:21056033 PMID:21413765 PMID:21878638 PMID:24650156 PMID:26198043 PMID:27422292 PMID:27533850 PMID:31512855 PMID:33760604 PMID:34635930 More...
|
|
NCBI chr10:83,945,731...83,976,874
Ensembl chr10:83,945,735...83,976,874
|
|
G |
Top2b |
DNA topoisomerase II beta |
decreases response to substance decreases activity affects response to substance decreases expression multiple interactions increases response to substance |
ISO |
TOP2B protein mutant form results in decreased susceptibility to Etoposide Etoposide results in decreased activity of TOP2B protein TOP2B protein affects the susceptibility to Etoposide Etoposide results in decreased expression of TOP2B protein TOP2B protein affects the reaction [Etoposide results in increased expression of H2AX protein] TOP2B protein mutant form results in increased susceptibility to Etoposide |
CTD |
PMID:10856430 PMID:15322234 PMID:16239602 PMID:17875725 PMID:26198043 PMID:27422292 More...
|
|
NCBI chr15:9,051,340...9,111,721
Ensembl chr15:9,051,341...9,112,085
|
|
G |
Top3a |
DNA topoisomerase III alpha |
decreases expression |
ISO |
Etoposide results in decreased expression of TOP3A mRNA |
CTD |
PMID:24211769 |
|
NCBI chr10:45,419,219...45,457,356
Ensembl chr10:45,419,217...45,457,559
|
|
G |
Tor1a |
torsin family 1, member A |
decreases expression |
ISO |
Etoposide results in decreased expression of TOR1A mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 3:14,250,667...14,257,704
Ensembl chr 3:14,250,676...14,257,691
|
|
G |
Tp53 |
tumor protein p53 |
increases acetylation affects activity increases expression multiple interactions increases activity increases phosphorylation affects response to substance increases response to substance |
ISO EXP |
Etoposide results in increased acetylation of TP53 protein; Etoposide results in increased acetylation of TP53 protein mutant form Etoposide affects the activity of TP53 protein; Etoposide metabolite affects the activity of TP53 protein Etoposide results in increased expression of TRP53 protein [CDKN2A gene mutant form results in increased expression of CDKN2A protein alternative form] inhibits the reaction [Etoposide results in increased expression of TRP53 protein]; Etoposide results in increased phosphorylation of and results in increased activity of TRP53 protein; TRP53 affects the reaction [Etoposide results in increased expression of CDKN1A mRNA]; TRP53 affects the reaction [Etoposide results in increased expression of TPT1 mRNA]; TRP53 affects the reaction [Etoposide results in increased expression of TPT1 protein]; TRP53 protein affects the reaction [Etoposide results in increased expression of BTG2 mRNA] Etoposide results in increased activity of TP53 protein Etoposide results in increased phosphorylation of TP53 protein TRP53 protein affects the susceptibility to Etoposide Etoposide results in increased expression of TP53 protein [Etoposide results in increased expression of TP53 protein] which results in increased expression of GDF15 protein; Etoposide results in increased expression of TP53 protein 2,4,4'-trichlorobiphenyl inhibits the reaction [Etoposide results in increased expression of TP53 protein]; 2,4,5,2',5'-pentachlorobiphenyl inhibits the reaction [Etoposide results in increased expression of TP53 protein]; 3,4,5,3',4'-pentachlorobiphenyl inhibits the reaction [Etoposide results in increased expression of TP53 protein]; [CASP8 co-treated with TP53] affects the reaction [Etoposide results in increased cleavage of and results in increased activity of CASP9 protein]; [CASP8 co-treated with TP53] affects the reaction [Etoposide results in increased cleavage of CASP3 protein]; [CASP8 co-treated with TP53] affects the reaction [Etoposide results in increased cleavage of PARP1 protein]; [CASP8 co-treated with TP53] inhibits the reaction [CASP8 protein mutant form results in decreased susceptibility to Etoposide]; [Doxorubicin co-treated with Vincristine co-treated with Etoposide co-treated with Mitotane] results in decreased expression of TP53 protein; [Etoposide results in increased acetylation of TP53 protein mutant form] which results in increased expression of UBE2C protein; [TP53 protein results in increased susceptibility to Etoposide] which results in decreased chemical synthesis of benzo(a)pyrene 7,8-dihydrodiol; Cadmium Chloride affects the reaction [Etoposide results in increased phosphorylation of TP53 protein]; DAPK1 protein promotes the reaction [Etoposide results in increased expression of TP53 protein modified form]; DAPK1 protein promotes the reaction [Etoposide results in increased expression of TP53 protein]; entinostat promotes the reaction [Etoposide results in increased expression of and results in increased acetylation of TP53 protein]; Etoposide promotes the reaction [[TP53 protein binds to GDF15 promoter] which results in increased expression of GDF15 mRNA]; Etoposide promotes the reaction [entinostat results in increased expression of TP53 protein]; Etoposide promotes the reaction [TP53 protein binds to TNFRSF10B promoter]; Etoposide promotes the reaction [TP53 protein results in increased chemical synthesis of benzo(a)pyrene 7,8-dihydrodiol]; Etoposide promotes the reaction [trichostatin A results in increased expression of TP53 protein]; Etoposide promotes the reaction [UF010 compound results in increased expression of TP53 protein]; Etoposide results in increased expression of and results in increased acetylation of TP53 protein; Etoposide results in increased phosphorylation of and affects the localization of TP53 protein; Etoposide results in increased phosphorylation of and results in increased activity of TP53 protein; NFE2L2 protein affects the reaction [Etoposide results in increased expression of TP53 protein]; NFKB1 protein affects the reaction [Etoposide results in increased expression of TP53 protein]; Oxygen deficiency inhibits the reaction [Etoposide results in increased phosphorylation of TP53 protein]; pifithrin inhibits the reaction [Etoposide results in increased activity of TP53 protein]; Tetrachlorodibenzodioxin inhibits the reaction [Etoposide results in increased acetylation of TP53 protein]; Tetrachlorodibenzodioxin inhibits the reaction [Etoposide results in increased phosphorylation of and results in increased activity of TP53 protein]; TP53 affects the reaction [Etoposide results in increased expression of CDKN1A mRNA]; TP53 affects the reaction [Etoposide results in increased expression of TPT1 mRNA]; TP53 promotes the reaction [Etoposide results in increased expression of BTG2 protein]; TP53 promotes the reaction [Etoposide results in increased expression of CDKN1A protein]; TP53 protein affects the reaction [CHEK1 protein affects the susceptibility to Etoposide]; TP53 protein affects the reaction [Etoposide results in decreased expression of UBE2C mRNA]; TP53 protein affects the reaction [Etoposide results in increased expression of SRXN1 protein]; TP53 protein inhibits the reaction [ESR2 protein results in increased susceptibility to Etoposide]; TP53 protein inhibits the reaction [Etoposide results in decreased expression of UBE2C protein]; TP53 protein modified form inhibits the reaction [Etoposide results in increased expression of BBC3 protein]; TP53 protein promotes the reaction [[Etoposide results in increased susceptibility to Benzo(a)pyrene] which results in increased expression of CDKN1A protein]; TP53 protein promotes the reaction [Etoposide promotes the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 protein]]; TP53 protein promotes the reaction [Etoposide results in decreased expression of IKBKB protein]; TP53 protein promotes the reaction [Etoposide results in increased expression of CDKN1A protein]; TP53 protein promotes the reaction [Etoposide results in increased expression of CYP1A1 protein]; TP53 protein promotes the reaction [Etoposide results in increased expression of ETS1 protein]; trichostatin A promotes the reaction [Etoposide results in increased expression of and results in increased acetylation of TP53 protein]; UF010 compound promotes the reaction [Etoposide results in increased expression of and results in increased acetylation of TP53 protein] cordycepin promotes the reaction [Etoposide results in increased expression of TP53 protein]; Etoposide promotes the reaction [Acetaminophen results in increased phosphorylation of TP53 protein]; Etoposide results in increased expression of and results in increased phosphorylation of TP53 protein; Niacin deficiency inhibits the reaction [Etoposide results in increased expression of TP53 protein]; Tetrachlorodibenzodioxin inhibits the reaction [Etoposide results in increased expression of and results in increased phosphorylation of TP53 protein] TP53 protein results in increased susceptibility to Etoposide; TP53 results in increased susceptibility to Etoposide |
CTD |
PMID:9815696 PMID:11895857 PMID:12082016 PMID:15131059 PMID:15459018 PMID:15964798 PMID:16120219 PMID:16330492 PMID:16882877 PMID:17516866 PMID:18698031 PMID:19751709 PMID:20299546 PMID:20477944 PMID:20623183 PMID:20655369 PMID:21212465 PMID:21526190 PMID:21552291 PMID:21801448 PMID:22003191 PMID:22010212 PMID:22242153 PMID:23144690 PMID:23396362 PMID:23690541 PMID:24067374 PMID:25078064 PMID:25699604 PMID:25744307 PMID:26259609 PMID:27129209 PMID:27358234 PMID:27982581 PMID:29471073 PMID:30177839 PMID:30818834 PMID:31542801 PMID:35435491 PMID:37956312 More...
|
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tp53bp1 |
tumor protein p53 binding protein 1 |
increases expression multiple interactions |
ISO |
Etoposide results in increased expression of TP53BP1 protein pifithrin inhibits the reaction [Etoposide results in increased expression of and affects the localization of TP53BP1 protein] |
CTD |
PMID:26259609 PMID:27358234 |
|
NCBI chr 3:108,166,574...108,270,229
Ensembl chr 3:108,169,980...108,269,822
|
|
G |
Tp53i3 |
tumor protein p53 inducible protein 3 |
increases expression |
ISO |
Etoposide results in increased expression of TP53I3 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 6:27,818,327...27,825,753
|
|
G |
Tp73 |
tumor protein p73 |
multiple interactions increases expression |
ISO |
[[Etoposide results in increased expression of TP73 protein] which results in increased expression of VDR protein] which results in increased susceptibility to Calcitriol; TP73 mutant form inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; TP73 mutant form inhibits the reaction [Etoposide results in increased activity of CASP7 protein]; TP73 mutant form inhibits the reaction [Etoposide results in increased cleavage of CASP3 protein]; TP73 mutant form inhibits the reaction [Etoposide results in increased cleavage of CASP8 protein]; TP73 protein affects the reaction [Etoposide results in increased expression of VDR mRNA] Etoposide results in increased expression of TP73 mRNA; Etoposide results in increased expression of TP73 protein |
CTD |
PMID:17716971 PMID:21801448 |
|
NCBI chr 5:164,621,377...164,703,958
Ensembl chr 5:164,621,377...164,681,128
|
|
G |
Tpi1 |
triosephosphate isomerase 1 |
multiple interactions increases phosphorylation |
ISO |
CDK2 affects the reaction [Etoposide results in increased phosphorylation of TPI1 protein] |
CTD |
PMID:20149834 |
|
NCBI chr 4:157,615,283...157,618,813
Ensembl chr 4:157,615,386...157,619,541
|
|
G |
Tpp2 |
tripeptidyl peptidase 2 |
multiple interactions affects localization |
ISO |
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Etoposide affects the localization of TPP2 protein]; SB 203580 inhibits the reaction [Etoposide affects the localization of TPP2 protein]; U 0126 inhibits the reaction [Etoposide affects the localization of TPP2 protein] 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Etoposide affects the localization of TPP2 protein]; Sirolimus promotes the reaction [Etoposide affects the localization of TPP2 protein]; U 0126 inhibits the reaction [Etoposide affects the localization of TPP2 protein]; wortmannin promotes the reaction [Etoposide affects the localization of TPP2 protein] |
CTD |
PMID:20643100 |
|
NCBI chr 9:46,046,712...46,128,157
Ensembl chr 9:46,046,632...46,128,157
|
|
G |
Tpt1 |
tumor protein, translationally-controlled 1 |
increases expression multiple interactions |
ISO |
Etoposide results in increased expression of TPT1 mRNA TRP53 affects the reaction [Etoposide results in increased expression of TPT1 mRNA]; TRP53 affects the reaction [Etoposide results in increased expression of TPT1 protein] Etoposide results in increased expression of TPT1 mRNA; Etoposide results in increased expression of TPT1 protein TP53 affects the reaction [Etoposide results in increased expression of TPT1 mRNA] |
CTD |
PMID:24067374 |
|
NCBI chr15:51,156,728...51,159,629
Ensembl chr15:51,146,154...51,159,625
|
|
G |
Traf2 |
Tnf receptor-associated factor 2 |
affects response to substance |
ISO |
TRAF2 protein affects the susceptibility to Etoposide |
CTD |
PMID:20159942 |
|
NCBI chr 3:8,341,950...8,366,609
Ensembl chr 3:8,341,951...8,366,538
|
|
G |
Trib2 |
tribbles pseudokinase 2 |
affects response to substance |
ISO |
TRIB2 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 6:38,545,971...38,570,349
Ensembl chr 6:38,545,975...38,569,370
|
|
G |
Trib3 |
tribbles pseudokinase 3 |
decreases expression |
ISO |
Etoposide results in decreased expression of TRIB3 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 3:140,809,634...140,815,230
Ensembl chr 3:140,809,043...140,814,497
|
|
G |
Trim2 |
tripartite motif-containing 2 |
affects response to substance decreases expression |
ISO |
TRIM2 protein affects the susceptibility to Etoposide Etoposide results in decreased expression of TRIM2 mRNA |
CTD |
PMID:16217747 PMID:25270620 |
|
NCBI chr 2:169,500,628...169,652,855
Ensembl chr 2:169,500,634...169,652,927
|
|
G |
Trim38 |
tripartite motif containing 38 |
decreases expression |
ISO |
Etoposide results in decreased expression of TRIM38 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr17:41,351,857...41,365,021
|
|
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
increases expression |
ISO |
Etoposide results in increased expression of TRPV1 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr10:57,851,428...57,876,513
Ensembl chr10:57,851,428...57,876,513
|
|
G |
Ttk |
Ttk protein kinase |
decreases expression |
ISO |
Etoposide results in decreased expression of TTK mRNA |
CTD |
PMID:16120219 |
|
NCBI chr 8:84,754,329...84,792,653
Ensembl chr 8:84,754,315...84,792,651
|
|
G |
Tuba4a |
tubulin, alpha 4A |
increases expression |
ISO |
Etoposide results in increased expression of TUBA4A mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 9:76,709,617...76,714,327
Ensembl chr 9:76,709,614...76,713,918
|
|
G |
Tufm |
Tu translation elongation factor, mitochondrial |
decreases expression |
ISO |
Etoposide results in decreased expression of TUFM protein |
CTD |
PMID:29733421 |
|
NCBI chr 1:181,073,788...181,077,395
Ensembl chr 1:181,073,788...181,077,395
|
|
G |
Txn2 |
thioredoxin 2 |
decreases response to substance |
ISO |
TXN2 protein results in decreased susceptibility to Etoposide |
CTD |
PMID:12080052 |
|
NCBI chr 7:109,496,772...109,510,378
Ensembl chr 7:109,496,761...109,510,359
|
|
G |
Txnip |
thioredoxin interacting protein |
increases expression |
ISO |
Etoposide results in increased expression of TXNIP protein |
CTD |
PMID:18270325 |
|
NCBI chr 2:184,093,079...184,096,882
Ensembl chr 2:184,092,991...184,096,886
|
|
G |
Txnl1 |
thioredoxin-like 1 |
decreases expression |
ISO |
Etoposide results in decreased expression of TXNL1 protein |
CTD |
PMID:29733421 |
|
NCBI chr18:57,125,362...57,155,167
Ensembl chr18:57,125,369...57,165,266
|
|
G |
Tyms |
thymidylate synthetase |
affects response to substance |
ISO |
TYMS gene polymorphism affects the susceptibility to Etoposide |
CTD |
PMID:15713801 |
|
NCBI chr 9:113,313,454...113,329,551
Ensembl chr 9:113,313,452...113,329,536
|
|
G |
Tyrp1 |
tyrosinase-related protein 1 |
affects response to substance |
ISO |
TYRP1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 5:95,280,982...95,299,516
Ensembl chr 5:95,280,982...95,299,516
|
|
G |
Ube2c |
ubiquitin-conjugating enzyme E2C |
decreases expression multiple interactions |
ISO |
Etoposide results in decreased expression of UBE2C mRNA; Etoposide results in decreased expression of UBE2C protein [Etoposide results in increased acetylation of TP53 protein mutant form] which results in increased expression of UBE2C protein; CDKN1A protein affects the reaction [Etoposide results in decreased expression of UBE2C protein]; TP53 protein affects the reaction [Etoposide results in decreased expression of UBE2C mRNA]; TP53 protein inhibits the reaction [Etoposide results in decreased expression of UBE2C protein] |
CTD |
PMID:17374387 PMID:27129209 |
|
NCBI chr 3:153,506,636...153,509,036
Ensembl chr 3:153,506,636...153,513,339
|
|
G |
Ubl3 |
ubiquitin-like 3 |
affects response to substance |
ISO |
UBL3 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr12:6,473,684...6,518,331
Ensembl chr12:6,473,460...6,518,862
|
|
G |
Ucp2 |
uncoupling protein 2 |
decreases expression |
ISO |
Etoposide results in decreased expression of UCP2 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 1:154,839,242...154,845,612
Ensembl chr 1:154,839,209...154,845,611
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
affects response to substance increases glucuronidation |
ISO |
UGT1A1 gene polymorphism affects the susceptibility to Etoposide UGT1A1 protein results in increased glucuronidation of Etoposide |
CTD |
PMID:12969965 PMID:17151191 |
|
NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a2 |
UDP glucuronosyltransferase 1 family, polypeptide A2 |
increases glucuronidation |
ISO |
UGT1A3 protein results in increased glucuronidation of Etoposide |
CTD |
PMID:17151191 |
|
NCBI chr 9:88,791,216...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Unc5c |
unc-5 netrin receptor C |
increases response to substance |
ISO |
UNC5C results in increased susceptibility to Etoposide |
CTD |
PMID:21600761 |
|
NCBI chr 2:230,180,353...230,535,219
Ensembl chr 2:230,180,951...230,535,217
|
|
G |
Upp2 |
uridine phosphorylase 2 |
increases expression |
ISO |
Etoposide results in increased expression of UPP2 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 3:43,273,048...43,317,417
Ensembl chr 3:43,273,048...43,317,417
|
|
G |
Utp3 |
UTP3, small subunit processome component |
decreases expression |
ISO |
Etoposide results in decreased expression of UTP3 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr14:19,515,716...19,517,370
Ensembl chr14:19,515,669...19,517,396
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
multiple interactions decreases response to substance |
ISO |
[IL4 protein co-treated with VCAM1 protein] inhibits the reaction [Etoposide results in decreased folding of BAX protein]; [VCAM1 protein co-treated with IL4 protein] inhibits the reaction [Etoposide inhibits the reaction [BAX protein binds to BCL2L1 protein]]; [VCAM1 protein co-treated with IL4 protein] results in decreased susceptibility to Etoposide VCAM1 protein results in decreased susceptibility to Etoposide |
CTD |
PMID:10620629 |
|
NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958
|
|
G |
Vcan |
versican |
affects response to substance |
ISO |
VCAN protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 2:20,761,718...20,860,637
Ensembl chr 2:20,761,718...20,860,637
|
|
G |
Vdac1 |
voltage-dependent anion channel 1 |
multiple interactions |
EXP |
Etoposide promotes the reaction [VDAC1 protein binds to VDAC1 protein] |
CTD |
PMID:20937774 |
|
NCBI chr10:36,532,306...36,559,642
Ensembl chr10:36,532,244...36,559,640
|
|
G |
Vdr |
vitamin D receptor |
multiple interactions affects response to substance increases expression |
ISO |
[[Etoposide results in increased expression of TP73 protein] which results in increased expression of VDR protein] which results in increased susceptibility to Calcitriol; TP73 protein affects the reaction [Etoposide results in increased expression of VDR mRNA] VDR gene polymorphism affects the susceptibility to Etoposide; VDR intron polymorphism affects the susceptibility to Etoposide |
CTD |
PMID:12969965 PMID:15713801 PMID:17716971 |
|
NCBI chr 7:128,987,981...129,037,677
Ensembl chr 7:128,987,981...129,037,677
|
|
G |
Vegfa |
vascular endothelial growth factor A |
decreases response to substance |
ISO |
VEGFA mRNA results in decreased susceptibility to Etoposide |
CTD |
PMID:18494554 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Vegfc |
vascular endothelial growth factor C |
multiple interactions decreases response to substance |
ISO |
EDN1 mutant form inhibits the reaction [VEGFC protein results in decreased susceptibility to Etoposide]; PTGS2 mutant form inhibits the reaction [VEGFC protein results in decreased susceptibility to Etoposide] |
CTD |
PMID:24184161 |
|
NCBI chr16:37,712,251...37,827,845
Ensembl chr16:37,712,262...37,827,848
|
|
G |
Vkorc1 |
vitamin K epoxide reductase complex, subunit 1 |
increases expression |
ISO |
Etoposide results in increased expression of VKORC1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 1:182,502,491...182,505,012
Ensembl chr 1:182,500,844...182,505,008
|
|
G |
Wif1 |
Wnt inhibitory factor 1 |
increases response to substance |
ISO |
WIF1 protein results in increased susceptibility to Etoposide |
CTD |
PMID:15389810 |
|
NCBI chr 7:56,548,060...56,618,364
Ensembl chr 7:56,548,053...56,618,360
|
|
G |
Wipi1 |
WD repeat domain, phosphoinositide interacting 1 |
affects response to substance |
ISO |
WIPI1 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr10:94,542,946...94,580,174
Ensembl chr10:94,542,946...94,579,846
|
|
G |
Wnt3a |
Wnt family member 3A |
increases response to substance |
ISO |
WNT3A protein results in increased susceptibility to Etoposide |
CTD |
PMID:19864107 |
|
NCBI chr10:44,034,174...44,078,366
Ensembl chr10:44,034,194...44,078,324
|
|
G |
Wrn |
WRN RecQ like helicase |
increases response to substance |
ISO |
WRN gene mutant form results in increased susceptibility to Etoposide |
CTD |
PMID:10725663 |
|
NCBI chr16:58,763,517...58,898,604
Ensembl chr16:58,763,504...58,895,450
|
|
G |
Xaf1 |
XIAP associated factor 1 |
increases response to substance increases expression multiple interactions |
ISO |
XAF1 protein results in increased susceptibility to Etoposide Etoposide results in increased expression of XAF1 mRNA; Etoposide results in increased expression of XAF1 protein XAF1 protein affects the reaction [Etoposide results in decreased expression of MT2A protein]; XAF1 protein affects the reaction [Etoposide results in increased cleavage of PARP1 protein] |
CTD |
PMID:15843754 PMID:17570219 PMID:28507149 |
|
NCBI chr10:56,917,378...56,929,791
Ensembl chr10:56,917,121...56,929,770
|
|
G |
Xrcc1 |
X-ray repair cross complementing 1 |
multiple interactions affects response to substance increases expression |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Etoposide results in increased expression of XRCC1 mRNA]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Etoposide results in increased expression of XRCC1 protein]; resveratrol inhibits the reaction [Etoposide results in increased expression of XRCC1 mRNA]; resveratrol inhibits the reaction [Etoposide results in increased expression of XRCC1 protein]; U 0126 inhibits the reaction [Etoposide results in increased expression of XRCC1 mRNA]; U 0126 inhibits the reaction [Etoposide results in increased expression of XRCC1 protein] XRCC1 protein affects the susceptibility to Etoposide Etoposide results in increased expression of XRCC1 mRNA; Etoposide results in increased expression of XRCC1 protein |
CTD |
PMID:26046675 |
|
NCBI chr 1:80,140,495...80,168,705
Ensembl chr 1:80,141,207...80,168,701
|
|
G |
Xrcc2 |
X-ray repair cross complementing 2 |
multiple interactions increases expression |
ISO |
BRCA1 protein mutant form inhibits the reaction [Etoposide results in increased expression of XRCC2 protein] |
CTD |
PMID:16417649 |
|
NCBI chr 4:9,423,873...9,502,980
Ensembl chr 4:9,423,898...9,442,482
|
|
G |
Xrcc3 |
X-ray repair cross complementing 3 |
multiple interactions increases expression |
ISO |
BRCA1 protein mutant form inhibits the reaction [Etoposide results in increased expression of XRCC3 protein] |
CTD |
PMID:16417649 |
|
NCBI chr 6:130,863,405...130,873,765
Ensembl chr 6:130,863,959...130,872,444
|
|
G |
Xrcc4 |
X-ray repair cross complementing 4 |
multiple interactions decreases response to substance increases expression |
ISO |
BRCA1 protein mutant form inhibits the reaction [Etoposide results in increased expression of XRCC4 protein] XRCC4 results in decreased susceptibility to Etoposide |
CTD |
PMID:16417649 PMID:21785230 |
|
NCBI chr 2:20,948,464...21,197,705
Ensembl chr 2:20,951,200...21,197,808
|
|
G |
Xrcc5 |
X-ray repair cross complementing 5 |
affects response to substance |
ISO |
XRCC5 protein affects the susceptibility to Etoposide |
CTD |
PMID:12384553 |
|
NCBI chr 9:73,955,216...74,044,020
Ensembl chr 9:73,955,216...74,044,018
|
|
G |
Zbtb24 |
zinc finger and BTB domain containing 24 |
decreases expression |
ISO |
Etoposide results in decreased expression of ZBTB24 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr20:44,943,302...44,965,329
Ensembl chr20:44,947,297...44,963,963
|
|
G |
Zdhhc11 |
zinc finger, DHHC-type containing 11 |
affects response to substance |
ISO |
ZDHHC11 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 1:29,296,334...29,327,227
Ensembl chr 1:29,296,334...29,326,898
|
|
G |
Zfp202 |
zinc finger protein 202 |
decreases expression |
ISO |
Etoposide results in decreased expression of ZNF202 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 8:40,542,665...40,567,397
Ensembl chr 8:40,542,701...40,563,118
|
|
G |
Zfp365 |
zinc finger protein 365 |
increases expression |
ISO |
Etoposide results in increased expression of ZFP365 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr20:20,666,240...20,689,734
Ensembl chr20:20,666,240...20,691,238
|
|
G |
Zfp36l1 |
zinc finger protein 36, C3H type-like 1 |
decreases expression |
ISO |
Etoposide results in decreased expression of ZFP36L1 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 6:98,930,705...98,935,748
Ensembl chr 6:98,930,718...98,935,748
|
|
G |
Zfp637 |
zinc finger protein 637 |
affects response to substance |
ISO |
ZNF32 protein affects the susceptibility to Etoposide |
CTD |
PMID:16217747 |
|
NCBI chr 4:150,984,940...151,010,079
Ensembl chr 4:150,984,541...151,011,874
|
|
G |
Zfp94 |
zinc finger protein 94 |
decreases expression |
ISO |
Etoposide results in decreased expression of ZNF45 mRNA |
CTD |
PMID:24211769 |
|
NCBI chr 1:79,858,188...79,879,702
Ensembl chr 1:79,859,180...79,879,612
|
|
G |
Zmat3 |
zinc finger, matrin type 3 |
increases expression |
ISO |
Etoposide results in increased expression of ZMAT3 mRNA |
CTD |
PMID:29397400 |
|
NCBI chr 2:115,106,046...115,136,888
Ensembl chr 2:115,106,966...115,136,863
|
|
G |
Znf750 |
zinc finger protein 750 |
increases expression |
ISO |
Etoposide results in increased expression of ZFP750 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr10:106,772,162...106,781,186
Ensembl chr10:106,772,669...106,781,200
|
|
|
G |
Ache |
acetylcholinesterase |
increases expression multiple interactions |
EXP |
genistin results in increased expression of ACHE mRNA genistin results in increased expression of and results in increased activity of ACHE protein |
CTD |
PMID:27019979 |
|
NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Acsl3 |
acyl-CoA synthetase long-chain family member 3 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of ACSL3 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 9:80,115,164...80,164,636
Ensembl chr 9:80,115,112...80,164,627
|
|
G |
Aldh1a2 |
aldehyde dehydrogenase 1 family, member A2 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of ALDH1A2 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 8:71,877,850...71,957,107
Ensembl chr 8:71,877,850...71,957,107
|
|
G |
Anpep |
alanyl aminopeptidase, membrane |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of ANPEP mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 1:133,767,332...133,810,137
Ensembl chr 1:133,767,332...133,785,789
|
|
G |
Atoh8 |
atonal bHLH transcription factor 8 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of ATOH8 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 4:104,259,992...104,292,168
Ensembl chr 4:104,259,992...104,292,168
|
|
G |
Bckdk |
branched chain ketoacid dehydrogenase kinase |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of BCKDK mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 1:182,515,335...182,520,007
Ensembl chr 1:182,515,327...182,536,633
|
|
G |
Bpgm |
bisphosphoglycerate mutase |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of BPGM mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 4:63,139,730...63,168,581
Ensembl chr 4:63,140,018...63,168,581
|
|
G |
Cabp5 |
calcium binding protein 5 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of CABP5 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 1:74,350,811...74,363,830
Ensembl chr 1:74,350,811...74,363,830
|
|
G |
Cacybp |
calcyclin binding protein |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of CACYBP mRNA |
CTD |
PMID:27424125 |
|
NCBI chr13:72,437,485...72,447,810
Ensembl chr13:72,437,490...72,450,177
|
|
G |
Casp8ap2 |
caspase 8 associated protein 2 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of CASP8AP2 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 5:47,014,501...47,052,276
Ensembl chr 5:47,014,667...47,052,275
|
|
G |
Cd200r1 |
CD200 receptor 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of CD200R1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr11:55,886,937...55,921,217
Ensembl chr11:55,887,717...55,921,285
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
multiple interactions |
ISO |
genistin inhibits the reaction [Lipopolysaccharides results in increased activity of CEBPB protein] |
CTD |
PMID:15832817 |
|
NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473
|
|
G |
Cfap251 |
cilia and flagella associated protein 251 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of CFAP251 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr12:33,261,622...33,337,028
Ensembl chr12:33,261,476...33,293,932
|
|
G |
Cybrd1 |
cytochrome b reductase 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of CYBRD1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 3:55,934,874...55,962,132
Ensembl chr 3:55,934,874...55,962,108
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
multiple interactions |
EXP |
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of CYP11A1 mRNA |
CTD |
PMID:28964809 |
|
NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338
|
|
G |
Dennd2d |
DENN domain containing 2D |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of DENND2D mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 2:193,973,231...193,992,275
Ensembl chr 2:193,973,231...193,992,270
|
|
G |
Dnmt1 |
DNA methyltransferase 1 |
multiple interactions |
EXP |
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in increased expression of DNMT1 mRNA |
CTD |
PMID:28964809 |
|
NCBI chr 8:19,440,611...19,486,659
Ensembl chr 8:19,440,611...19,486,659
|
|
G |
Dnmt3a |
DNA methyltransferase 3 alpha |
multiple interactions |
EXP |
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in increased expression of DNMT3A mRNA |
CTD |
PMID:28964809 |
|
NCBI chr 6:26,791,517...26,902,161
Ensembl chr 6:26,822,609...26,896,687
|
|
G |
Dpp9 |
dipeptidyl peptidase 9 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of DPP9 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 9:1,011,347...1,046,337
Ensembl chr 9:1,011,351...1,046,541
|
|
G |
Edrf1 |
erythroid differentiation regulatory factor 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of EDRF1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 1:188,441,514...188,478,743
Ensembl chr 1:188,441,634...188,478,701
|
|
G |
Efhd1 |
EF-hand domain family, member D1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of EFHD1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 9:87,938,259...87,984,917
Ensembl chr 9:87,938,284...87,984,917
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions |
EXP |
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in increased expression of ESR2 mRNA |
CTD |
PMID:28964809 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Fam171a2 |
family with sequence similarity 171, member A2 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of FAM171A2 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr10:87,393,888...87,404,051
Ensembl chr10:87,394,007...87,404,053
|
|
G |
Fam180a |
family with sequence similarity 180, member A |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of FAM180A mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 4:63,992,867...64,008,047
Ensembl chr 4:63,992,867...64,008,047
|
|
G |
Fam210b |
family with sequence similarity 210, member B |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of FAM210B mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 3:161,118,228...161,128,400
Ensembl chr 3:161,118,239...161,128,397
|
|
G |
Fam241b |
family with sequence similarity 241 member B |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of FAM241B mRNA |
CTD |
PMID:27424125 |
|
NCBI chr20:30,052,315...30,055,247
Ensembl chr20:30,052,324...30,055,084
|
|
G |
Fgd6 |
FYVE, RhoGEF and PH domain containing 6 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of FGD6 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 7:28,597,609...28,712,908
Ensembl chr 7:28,597,609...28,712,456
|
|
G |
Fhl2 |
four and a half LIM domains 2 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of FHL2 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 9:45,388,979...45,462,421
Ensembl chr 9:45,388,981...45,431,192
|
|
G |
G6pd |
glucose-6-phosphate dehydrogenase |
increases expression |
ISO |
genistin analog results in increased expression of G6PD mRNA |
CTD |
PMID:16719502 |
|
NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801
|
|
G |
Galnt15 |
polypeptide N-acetylgalactosaminyltransferase 15 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of GALNT15 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr16:7,227,232...7,267,002
Ensembl chr16:7,227,271...7,267,014
|
|
G |
Gng5 |
G protein subunit gamma 5 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of GNG5 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 2:235,394,680...235,403,177
Ensembl chr 1:77,292,043...77,292,513
|
|
G |
Hipk4 |
homeodomain interacting protein kinase 4 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of HIPK4 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 1:82,810,708...82,821,080
Ensembl chr 1:82,810,708...82,821,077
|
|
G |
Hmcn1 |
hemicentin 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of HMCN1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr13:62,615,461...63,084,524
Ensembl chr13:62,615,461...63,084,524
|
|
G |
Hsd3b1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
multiple interactions |
EXP |
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of HSD3B1 mRNA |
CTD |
PMID:28964809 |
|
NCBI chr 2:186,169,864...186,175,984
Ensembl chr 2:186,169,863...186,175,999
|
|
G |
Il6r |
interleukin 6 receptor |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of IL6R mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 2:175,289,157...175,347,719
Ensembl chr 2:175,298,686...175,347,536
|
|
G |
Isg20l2 |
interferon stimulated exonuclease gene 20-like 2 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of ISG20L2 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 2:173,396,780...173,407,102
Ensembl chr 2:173,396,780...173,406,614
|
|
G |
Kdm5a |
lysine demethylase 5A |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of KDM5A mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 4:153,565,909...153,643,912
Ensembl chr 4:153,565,846...153,642,422
|
|
G |
Kitlg |
KIT ligand |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of KITLG mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 7:34,896,075...34,977,215
Ensembl chr 7:34,896,053...34,977,214
|
|
G |
Knstrn |
kinetochore-localized astrin/SPAG5 binding protein |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of KNSTRN mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 3:105,800,762...105,820,555
Ensembl chr 3:105,800,954...105,820,715
|
|
G |
Ldlrap1 |
low density lipoprotein receptor adaptor protein 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of LDLRAP1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 5:146,955,607...146,978,601
Ensembl chr 5:146,955,607...146,978,601
|
|
G |
Lmod1 |
leiomodin 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of LMOD1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr13:46,754,048...46,796,186
Ensembl chr13:46,754,033...46,794,900
|
|
G |
Lrg1 |
leucine-rich alpha-2-glycoprotein 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of LRG1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 9:947,516...949,773
Ensembl chr 9:947,516...949,813
|
|
G |
Lsr |
lipolysis stimulated lipoprotein receptor |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of LSR mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 1:86,185,769...86,201,952
Ensembl chr 1:86,186,431...86,201,952
|
|
G |
Ltf |
lactotransferrin |
increases expression |
ISO |
genistin results in increased expression of LTF mRNA |
CTD |
PMID:20049207 |
|
NCBI chr 8:110,999,948...111,022,795
Ensembl chr 8:110,999,948...111,022,795
|
|
G |
Mrpl33 |
mitochondrial ribosomal protein L33 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of MRPL33 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 6:24,825,800...24,833,994
Ensembl chr 6:24,825,827...24,833,834
|
|
G |
Mt1 |
metallothionein 1 |
increases expression |
ISO |
genistin analog results in increased expression of MT1A mRNA |
CTD |
PMID:16719502 |
|
NCBI chr19:10,826,032...10,827,048
Ensembl chr19:10,826,032...10,827,049 Ensembl chr17:10,826,032...10,827,049
|
|
G |
Mt1-ps3 |
metallothionein 1, pseudogene 3 |
increases expression |
ISO |
genistin analog results in increased expression of MT1E mRNA |
CTD |
PMID:16719502 |
|
NCBI chr17:74,786,652...74,787,040
Ensembl chr17:74,786,654...74,787,135
|
|
G |
Mt2A |
metallothionein 2A |
increases expression |
ISO |
genistin analog results in increased expression of MT2A mRNA |
CTD |
PMID:16719502 |
|
NCBI chr19:10,832,009...10,832,783
Ensembl chr19:10,832,002...10,832,784
|
|
G |
Mtmr11 |
myotubularin related protein 11 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of MTMR11 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 2:183,721,983...183,732,148
Ensembl chr 2:183,723,530...183,732,148
|
|
G |
Myof |
myoferlin |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of MYOF mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 1:235,673,666...235,822,413
Ensembl chr 1:235,673,666...235,822,334
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
genistin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] |
CTD |
PMID:15832817 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nr4a1 |
nuclear receptor subfamily 4, group A, member 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of NR4A1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 7:132,368,399...132,389,300
Ensembl chr 7:132,374,840...132,389,297
|
|
G |
Nr5a1 |
nuclear receptor subfamily 5, group A, member 1 |
multiple interactions |
EXP |
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of NR5A1 mRNA; [Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of NR5A1 protein; [Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in increased methylation of NR5A1 promoter; decitabine inhibits the reaction [[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of NR5A1 mRNA] |
CTD |
PMID:28964809 |
|
NCBI chr 3:22,464,786...22,486,328
Ensembl chr 3:22,465,502...22,486,328
|
|
G |
Prima1 |
proline rich membrane anchor 1 |
increases expression |
EXP |
genistin results in increased expression of PRIMA1 mRNA |
CTD |
PMID:27019979 |
|
NCBI chr 6:122,338,365...122,390,955
Ensembl chr 6:122,338,370...122,389,921
|
|
G |
Prkaca |
protein kinase cAMP-activated catalytic subunit alpha |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of PRKACA mRNA |
CTD |
PMID:27424125 |
|
NCBI chr19:24,155,081...24,178,430
Ensembl chr19:24,155,090...24,178,430
|
|
G |
Prpf40a |
pre-mRNA processing factor 40 homolog A |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of PRPF40A mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 3:37,625,585...37,689,859
Ensembl chr 3:37,627,690...37,690,886
|
|
G |
Pspc1 |
paraspeckle component 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of PSPC1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr15:30,828,617...30,911,315
Ensembl chr15:30,828,626...30,911,202
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
genistin inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA] |
CTD |
PMID:21341175 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Pth1r |
parathyroid hormone 1 receptor |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of PTH1R mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 8:110,693,910...110,725,458
Ensembl chr 8:110,697,485...110,719,729
|
|
G |
Rassf5 |
Ras association domain family member 5 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of RASSF5 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr13:42,637,513...42,703,024
Ensembl chr13:42,637,549...42,703,024
|
|
G |
Rgs22 |
regulator of G-protein signaling 22 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of RGS22 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 7:67,188,531...67,308,805
Ensembl chr 7:67,188,519...67,308,875
|
|
G |
S1pr3 |
sphingosine-1-phosphate receptor 3 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of S1PR3 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr17:13,781,050...13,794,408
Ensembl chr17:13,781,050...13,794,505
|
|
G |
Selplg |
selectin P ligand |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of SELPLG mRNA |
CTD |
PMID:27424125 |
|
NCBI chr12:42,796,690...42,809,908
Ensembl chr12:42,796,580...42,812,585
|
|
G |
Siglec10 |
sialic acid binding Ig-like lectin 10 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of SIGLEC10 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 1:93,817,301...93,826,376
Ensembl chr 1:93,817,335...93,825,931
|
|
G |
Slc16a1 |
solute carrier family 16 member 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of SLC16A1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 2:192,123,755...192,144,617
Ensembl chr 2:192,124,289...192,144,611
|
|
G |
Slc30a1 |
solute carrier family 30 member 1 |
increases expression |
ISO |
genistin analog results in increased expression of SLC30A1 mRNA |
CTD |
PMID:16719502 |
|
NCBI chr13:103,491,037...103,494,910
Ensembl chr13:103,491,037...103,494,910
|
|
G |
Snx30 |
sorting nexin family member 30 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of SNX30 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 5:74,683,902...74,813,013
Ensembl chr 5:74,684,015...74,792,631
|
|
G |
Ssc5d |
scavenger receptor cysteine rich family member with 5 domains |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of SSC5D mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 1:68,891,942...68,910,462
Ensembl chr 1:68,891,949...68,909,743
|
|
G |
Star |
steroidogenic acute regulatory protein |
multiple interactions |
EXP |
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of STAR mRNA; [Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of STAR protein |
CTD |
PMID:28964809 |
|
NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672
|
|
G |
Styxl1 |
serine/threonine/tyrosine interacting-like 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of STYXL1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr12:20,907,410...20,940,232
Ensembl chr12:20,907,435...20,939,752
|
|
G |
Sumo1 |
small ubiquitin-like modifier 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of SUMO1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 9:61,078,790...61,108,697
Ensembl chr 9:61,077,435...61,108,761
|
|
G |
Tc2n |
tandem C2 domains, nuclear |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of TC2N mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 6:120,761,112...120,856,835
Ensembl chr 6:120,761,119...120,849,326
|
|
G |
Tp53i11 |
tumor protein p53 inducible protein 11 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of TP53I11 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 3:79,144,824...79,160,056
Ensembl chr 3:79,144,895...79,160,050
|
|
G |
Vcpip1 |
valosin containing protein interacting protein 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of VCPIP1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 5:9,534,247...9,560,889
Ensembl chr 5:9,534,129...9,562,040
|
|
|
G |
Cxcr1 |
C-X-C motif chemokine receptor 1 |
multiple interactions |
ISO |
ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of CXCR1 protein] |
CTD |
PMID:21875580 |
|
NCBI chr 9:75,766,894...75,771,079
Ensembl chr 9:75,766,770...75,771,084
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO |
ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of ICAM1 protein] |
CTD |
PMID:21875580 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Ifng |
interferon gamma |
decreases expression |
ISO |
ginsenoside M1 results in decreased expression of IFNG mRNA |
CTD |
PMID:15914323 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il1b |
interleukin 1 beta |
decreases expression |
ISO |
ginsenoside M1 results in decreased expression of IL1B mRNA |
CTD |
PMID:15914323 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il4 |
interleukin 4 |
decreases expression |
ISO |
ginsenoside M1 results in decreased expression of IL4 mRNA |
CTD |
PMID:15914323 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
ginsenoside M1 inhibits the reaction [Galactose results in increased secretion of IL6 protein] |
CTD |
PMID:29412148 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Itga4 |
integrin subunit alpha 4 |
multiple interactions |
ISO |
ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of [ITGA4 protein binds to ITGB1 protein]] |
CTD |
PMID:21875580 |
|
NCBI chr 3:64,162,764...64,235,010
Ensembl chr 3:64,163,085...64,233,715
|
|
G |
Itgal |
integrin subunit alpha L |
multiple interactions |
ISO |
ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of [ITGAL protein binds to ITGB2 protein]] |
CTD |
PMID:21875580 |
|
NCBI chr 1:181,918,183...181,955,735
Ensembl chr 1:181,918,183...181,955,732
|
|
G |
Itgb1 |
integrin subunit beta 1 |
multiple interactions |
ISO |
ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of [ITGA4 protein binds to ITGB1 protein]] |
CTD |
PMID:21875580 |
|
NCBI chr19:56,705,123...56,753,199
Ensembl chr19:56,705,171...56,753,195
|
|
G |
Itgb2 |
integrin subunit beta 2 |
multiple interactions |
ISO |
ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of [ITGAL protein binds to ITGB2 protein]] |
CTD |
PMID:21875580 |
|
NCBI chr20:11,061,394...11,097,656
Ensembl chr20:11,061,430...11,097,600
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
decreases secretion |
ISO |
ginsenoside M1 results in decreased secretion of MMP9 protein |
CTD |
PMID:21875580 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
EXP |
ginsenoside M1 results in decreased activity of [NFKB1 protein binds to RELA protein] |
CTD |
PMID:15802804 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
EXP |
ginsenoside M1 results in decreased expression of and results in decreased activity of NOS2 protein |
CTD |
PMID:15802804 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
P2rx4 |
purinergic receptor P2X 4 |
multiple interactions |
ISO |
[ginsenoside M1 co-treated with Adenosine Triphosphate] results in increased activity of P2RX4 protein; ginsenoside M1 promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein] |
CTD |
PMID:30545933 |
|
NCBI chr12:33,844,609...33,862,265
Ensembl chr12:33,844,396...33,862,253
|
|
G |
P2rx7 |
purinergic receptor P2X 7 |
decreases response to substance |
ISO |
P2RX7 gene mutant form results in decreased susceptibility to ginsenoside M1 |
CTD |
PMID:30545933 |
|
NCBI chr12:33,889,709...33,934,168
Ensembl chr12:33,879,745...33,934,619
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
decreases expression |
ISO EXP |
ginsenoside M1 results in decreased expression of PTGS2 mRNA ginsenoside M1 results in decreased expression of PTGS2 protein |
CTD |
PMID:15802804 PMID:15914323 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
ginsenoside M1 results in decreased activity of [NFKB1 protein binds to RELA protein] |
CTD |
PMID:15802804 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Sele |
selectin E |
multiple interactions |
ISO |
ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of SELE protein] |
CTD |
PMID:21875580 |
|
NCBI chr13:76,402,841...76,412,741
Ensembl chr13:76,403,304...76,412,741
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions decreases expression decreases response to substance |
ISO |
ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of [ITGA4 protein binds to ITGB1 protein]]; ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of [ITGAL protein binds to ITGB2 protein]]; ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of CXCR1 protein]; ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]; ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of SELE protein]; ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]; ginsenoside M1 inhibits the reaction [TNF protein results in increased secretion of CXCL8 protein] ginsenoside M1 results in decreased expression of TNF mRNA ginsenoside M1 results in decreased susceptibility to TNF protein |
CTD |
PMID:15914323 PMID:21875580 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
multiple interactions |
ISO |
ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of VCAM1 protein] |
CTD |
PMID:21875580 |
|
NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958
|
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
ginsenoside F1 inhibits the reaction [Galactose results in increased secretion of IL6 protein] |
CTD |
PMID:29412148 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
ginsenoside F1 inhibits the reaction [Galactose affects the localization of RELA protein] |
CTD |
PMID:29412148 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions |
ISO |
ginsenoside F2 analog inhibits the reaction [ABCB1 protein results in increased transport of Digoxin] |
CTD |
PMID:24380838 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions increases phosphorylation |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rb1 results in increased phosphorylation of AKT1 protein]; Fulvestrant inhibits the reaction [ginsenoside Rb1 results in increased phosphorylation of AKT1 protein]; Pertussis Toxin inhibits the reaction [ginsenoside Rb1 results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:19781563 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Atp6v1a |
ATPase H+ transporting V1 subunit A |
multiple interactions |
ISO |
ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of ATP6V1A mRNA] |
CTD |
PMID:34812491 |
|
NCBI chr11:56,561,444...56,614,694
Ensembl chr11:56,560,974...56,614,694
|
|
G |
Atp6v1b2 |
ATPase H+ transporting V1 subunit B2 |
multiple interactions |
ISO |
ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of ATP6V1B2 mRNA] |
CTD |
PMID:34812491 |
|
NCBI chr16:20,617,515...20,641,651
Ensembl chr16:20,617,518...20,641,745
|
|
G |
Bmp2 |
bone morphogenetic protein 2 |
multiple interactions increases expression |
EXP |
ginsenoside Rb1 inhibits the reaction [aluminum chloride results in decreased expression of BMP2 mRNA] ginsenoside Rb1 results in increased expression of BMP2 mRNA |
CTD |
PMID:27470910 |
|
NCBI chr 3:120,812,660...120,822,579
Ensembl chr 3:120,812,882...120,821,397
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
ginsenoside Rb1 inhibits the reaction [Oxidopamine results in increased activity of CASP3 protein] |
CTD |
PMID:19781563 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Clcn7 |
chloride voltage-gated channel 7 |
multiple interactions |
ISO |
ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of CLCN7 mRNA] |
CTD |
PMID:34812491 |
|
NCBI chr10:14,151,758...14,177,130
Ensembl chr10:14,151,758...14,177,130
|
|
G |
Ctsb |
cathepsin B |
multiple interactions |
ISO |
ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of CTSB mRNA] |
CTD |
PMID:34812491 |
|
NCBI chr15:37,389,636...37,410,508
Ensembl chr15:37,389,629...37,410,500
|
|
G |
Ctsd |
cathepsin D |
multiple interactions |
ISO |
ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of CTSD mRNA] |
CTD |
PMID:34812491 |
|
NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
ginsenoside Rb1 inhibits the reaction [TNFSF11 protein results in increased expression of FOS mRNA] |
CTD |
PMID:22386813 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 protein]; Cycloheximide inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 mRNA]; Cycloheximide inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 protein]; Dactinomycin inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 mRNA]; Dactinomycin inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 protein]; fulvestrant inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 mRNA]; fulvestrant inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 protein]; ginsenoside Rb1 results in increased expression of and results in increased activity of HMOX1 protein; Pertussis Toxin inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 mRNA]; Pertussis Toxin inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 protein] [astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] results in increased expression of HMOX1 mRNA; [astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] results in increased expression of HMOX1 protein |
CTD |
PMID:19781563 PMID:25422538 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Igf1 |
insulin-like growth factor 1 |
multiple interactions increases expression |
EXP |
ginsenoside Rb1 inhibits the reaction [aluminum chloride results in decreased expression of IGF1 mRNA] ginsenoside Rb1 results in increased expression of IGF1 mRNA |
CTD |
PMID:27470910 |
|
NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP |
ginsenoside Rb1 inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein] |
CTD |
PMID:17655881 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Itgam |
integrin subunit alpha M |
multiple interactions |
EXP |
ginsenoside Rb1 inhibits the reaction [Lipopolysaccharides results in increased expression of ITGAM protein] |
CTD |
PMID:17655881 |
|
NCBI chr 1:182,659,047...182,709,501
Ensembl chr 1:182,659,000...182,709,503
|
|
G |
Itgb2 |
integrin subunit beta 2 |
multiple interactions |
EXP |
ginsenoside Rb1 inhibits the reaction [Lipopolysaccharides results in increased expression of ITGB2 protein] |
CTD |
PMID:17655881 |
|
NCBI chr20:11,061,394...11,097,656
Ensembl chr20:11,061,430...11,097,600
|
|
G |
Kcne1 |
potassium voltage-gated channel subfamily E regulatory subunit 1 |
increases expression |
ISO |
ginsenoside Rb1 results in increased expression of KCNE1 |
CTD |
PMID:24615935 |
|
NCBI chr11:31,580,951...31,594,116
Ensembl chr11:31,580,742...31,593,901
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
affects activity |
ISO |
ginsenoside Rb1 affects the activity of KCNH2 protein |
CTD |
PMID:15842772 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Lamp1 |
lysosomal-associated membrane protein 1 |
multiple interactions |
ISO |
ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of LAMP1 mRNA] |
CTD |
PMID:34812491 |
|
NCBI chr16:76,355,982...76,380,700
Ensembl chr16:76,355,984...76,381,883
|
|
G |
Map2 |
microtubule-associated protein 2 |
increases expression |
ISO |
ginsenoside Rb1 results in increased expression of MAP2 mRNA |
CTD |
PMID:24599032 |
|
NCBI chr 9:67,723,422...67,981,886
Ensembl chr 9:67,723,371...67,979,809
|
|
G |
Nfatc1 |
nuclear factor of activated T-cells 1 |
multiple interactions |
ISO |
ginsenoside Rb1 inhibits the reaction [TNFSF11 protein results in increased expression of NFATC1 mRNA] |
CTD |
PMID:22386813 |
|
NCBI chr18:74,046,422...74,156,041
Ensembl chr18:74,046,904...74,156,028
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions affects localization increases expression |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rb1 results in increased localization of NFE2L2 protein]; [ginsenoside Rb1 co-treated with ginsenoside 20S-protopanaxatriol] results in increased expression of NFE2L2 protein; fulvestrant inhibits the reaction [ginsenoside Rb1 results in increased localization of NFE2L2 protein]; ginsenoside Rb1 results in increased activity of and results in increased localization of NFE2L2 protein; Pertussis Toxin inhibits the reaction [ginsenoside Rb1 results in increased localization of NFE2L2 protein] ginsenoside Rb1 affects the localization of NFE2L2 protein [astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] affects the localization of NFE2L2 protein ginsenoside Rb1 results in increased expression of NFE2L2 mRNA |
CTD |
PMID:19781563 PMID:22780686 PMID:25422538 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
P2rx4 |
purinergic receptor P2X 4 |
multiple interactions |
ISO |
ginsenoside Rb1 promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein] |
CTD |
PMID:30545933 |
|
NCBI chr12:33,844,609...33,862,265
Ensembl chr12:33,844,396...33,862,253
|
|
G |
Pgr |
progesterone receptor |
increases expression |
ISO |
ginsenoside Rb1 results in increased expression of PGR protein |
CTD |
PMID:16204943 |
|
NCBI chr 8:6,072,673...6,131,552
Ensembl chr 8:6,072,673...6,131,344
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
ginsenoside Rb1 inhibits the reaction [TNFSF11 protein affects the localization of RELA protein] |
CTD |
PMID:22386813 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Runx2 |
RUNX family transcription factor 2 |
increases expression multiple interactions |
EXP |
ginsenoside Rb1 results in increased expression of RUNX2 mRNA ginsenoside Rb1 inhibits the reaction [aluminum chloride results in decreased expression of RUNX2 mRNA] |
CTD |
PMID:27470910 |
|
NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167
|
|
G |
Slco1b2 |
solute carrier organic anion transporter family member 1B2 |
multiple interactions |
ISO |
ginsenoside Rb1 binds to and results in decreased activity of SLCO1B3 protein |
CTD |
PMID:25297453 |
|
NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions decreases expression |
ISO |
ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased expression of SQSTM1 protein] ginsenoside Rb1 results in decreased expression of SQSTM1 protein |
CTD |
PMID:34812491 |
|
NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Tfeb |
transcription factor EB |
multiple interactions |
ISO |
[ginsenoside Rb1 co-treated with alpha-Chlorohydrin] affects the localization of TFEB protein; ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of TFEB mRNA] |
CTD |
PMID:34812491 |
|
NCBI chr 9:13,198,890...13,254,726
Ensembl chr 9:13,198,891...13,254,714
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions increases expression |
EXP |
ginsenoside Rb1 inhibits the reaction [aluminum chloride results in decreased expression of TGFB1 mRNA] ginsenoside Rb1 results in increased expression of TGFB1 mRNA |
CTD |
PMID:27470910 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
ginsenoside Rb1 inhibits the reaction [TNFSF11 protein results in increased expression of TNF mRNA] |
CTD |
PMID:22386813 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfsf11 |
TNF superfamily member 11 |
multiple interactions decreases response to substance |
ISO |
ginsenoside Rb1 inhibits the reaction [TNFSF11 protein affects the localization of RELA protein]; ginsenoside Rb1 inhibits the reaction [TNFSF11 protein results in increased expression of FOS mRNA]; ginsenoside Rb1 inhibits the reaction [TNFSF11 protein results in increased expression of NFATC1 mRNA]; ginsenoside Rb1 inhibits the reaction [TNFSF11 protein results in increased expression of TNF mRNA] ginsenoside Rb1 results in decreased susceptibility to TNFSF11 protein |
CTD |
PMID:22386813 |
|
NCBI chr15:53,673,850...53,705,325
Ensembl chr15:53,673,877...53,705,445
|
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
increases expression |
EXP |
ginsenoside Rb2 results in increased expression of ABCC2 mRNA |
CTD |
PMID:23835644 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Lpl |
lipoprotein lipase |
increases secretion decreases secretion |
ISO |
ginsenoside Rb2 results in increased secretion of LPL protein ginsenoside Rb2 results in decreased secretion of LPL protein |
CTD |
PMID:8988629 |
|
NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249
|
|
|
G |
Slco1b2 |
solute carrier organic anion transporter family member 1B2 |
multiple interactions |
ISO |
ginsenoside Rc binds to and results in decreased activity of SLCO1B3 protein |
CTD |
PMID:25297453 |
|
NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981
|
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
ginsenoside Rd results in increased phosphorylation of and results in increased activity of AKT1 protein |
CTD |
PMID:24599032 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
EXP |
ginsenoside Rd inhibits the reaction [APP protein modified form results in decreased expression of BCL2 mRNA]; ginsenoside Rd inhibits the reaction [APP protein modified form results in increased expression of BAX mRNA]; ginsenoside Rd inhibits the reaction [APP protein modified form results in increased expression of CASP3 protein modified form]; ginsenoside Rd inhibits the reaction [APP protein modified form results in increased expression of CYCS mRNA] |
CTD |
PMID:26111763 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
EXP |
ginsenoside Rd inhibits the reaction [APP protein modified form results in increased expression of BAX mRNA] |
CTD |
PMID:26111763 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
EXP |
ginsenoside Rd inhibits the reaction [APP protein modified form results in decreased expression of BCL2 mRNA] |
CTD |
PMID:26111763 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP |
ginsenoside Rd inhibits the reaction [APP protein modified form results in increased expression of CASP3 protein modified form] |
CTD |
PMID:26111763 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cat |
catalase |
increases expression |
EXP |
ginsenoside Rd results in increased expression of CAT protein |
CTD |
PMID:9933756 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression multiple interactions |
ISO |
ginsenoside Rd results in increased expression of CDKN1A mRNA staurosporine aglycone inhibits the reaction [ginsenoside Rd results in increased expression of CDKN1A mRNA] |
CTD |
PMID:24599032 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Chat |
choline O-acetyltransferase |
increases expression multiple interactions |
ISO |
ginsenoside Rd results in increased expression of CHAT mRNA; ginsenoside Rd results in increased expression of CHAT protein staurosporine aglycone inhibits the reaction [ginsenoside Rd results in increased expression of CHAT mRNA]; staurosporine aglycone inhibits the reaction [ginsenoside Rd results in increased expression of CHAT protein] |
CTD |
PMID:24599032 |
|
NCBI chr16:7,657,362...7,717,093
Ensembl chr16:7,657,362...7,717,093
|
|
G |
Cycs |
cytochrome c, somatic |
multiple interactions |
EXP |
ginsenoside Rd inhibits the reaction [APP protein modified form results in increased expression of CYCS mRNA] |
CTD |
PMID:26111763 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054 Ensembl chr18:79,651,378...79,654,054
|
|
G |
Lpl |
lipoprotein lipase |
decreases secretion |
ISO |
ginsenoside Rd results in decreased secretion of LPL protein |
CTD |
PMID:8988629 |
|
NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249
|
|
G |
Map2 |
microtubule-associated protein 2 |
increases expression |
ISO |
ginsenoside Rd results in increased expression of MAP2 mRNA; ginsenoside Rd results in increased expression of MAP2 protein |
CTD |
PMID:24599032 |
|
NCBI chr 9:67,723,422...67,981,886
Ensembl chr 9:67,723,371...67,979,809
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
ginsenoside Rd results in increased phosphorylation of and results in increased activity of MAPK1 protein |
CTD |
PMID:24599032 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
ginsenoside Rd results in increased phosphorylation of and results in increased activity of MAPK3 protein |
CTD |
PMID:24599032 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Ngf |
nerve growth factor |
increases expression |
ISO |
ginsenoside Rd results in increased expression of NGF mRNA |
CTD |
PMID:24599032 |
|
NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452
|
|
G |
Ngfr |
nerve growth factor receptor |
increases expression |
ISO |
ginsenoside Rd results in increased expression of NGFR mRNA; ginsenoside Rd results in increased expression of NGFR protein |
CTD |
PMID:24599032 |
|
NCBI chr10:80,515,287...80,533,518
Ensembl chr10:80,515,299...80,533,518
|
|
G |
P2rx4 |
purinergic receptor P2X 4 |
multiple interactions |
ISO |
ginsenoside Rd promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein] |
CTD |
PMID:30545933 |
|
NCBI chr12:33,844,609...33,862,265
Ensembl chr12:33,844,396...33,862,253
|
|
G |
P2rx7 |
purinergic receptor P2X 7 |
decreases response to substance |
ISO |
P2RX7 gene mutant form results in decreased susceptibility to ginsenoside Rd |
CTD |
PMID:30545933 |
|
NCBI chr12:33,889,709...33,934,168
Ensembl chr12:33,879,745...33,934,619
|
|
G |
Slc18a3 |
solute carrier family 18 member A3 |
increases expression |
ISO |
ginsenoside Rd results in increased expression of SLC18A3 mRNA |
CTD |
PMID:24599032 |
|
NCBI chr16:7,713,630...7,716,491
|
|
G |
Slc5a7 |
solute carrier family 5 member 7 |
increases expression |
ISO |
ginsenoside Rd results in increased expression of SLC5A7 mRNA |
CTD |
PMID:24599032 |
|
NCBI chr 9:7,595,440...7,626,258
Ensembl chr 9:7,595,444...7,626,258
|
|
G |
Slco1b2 |
solute carrier organic anion transporter family member 1B2 |
multiple interactions |
ISO |
ginsenoside Rd binds to and results in decreased activity of SLCO1B3 protein |
CTD |
PMID:25297453 |
|
NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
increases transport |
EXP ISO |
ABCB11 protein results in increased transport of ginsenoside Re |
CTD |
PMID:25297453 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
increases transport |
ISO |
ABCC1 protein results in increased transport of ginsenoside Re |
CTD |
PMID:25297453 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
increases transport |
EXP ISO |
ABCC2 protein results in increased transport of ginsenoside Re |
CTD |
PMID:25297453 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
increases transport |
EXP ISO |
ABCG2 protein results in increased transport of ginsenoside Re |
CTD |
PMID:25297453 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
increases expression multiple interactions |
ISO |
ginsenoside Re results in increased expression of ADIPOQ mRNA ginsenoside Re results in increased expression of and results in increased secretion of ADIPOQ protein |
CTD |
PMID:23545455 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Aif1 |
allograft inflammatory factor 1 |
multiple interactions decreases expression |
ISO |
3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of AIF1 protein]]]]; ginsenoside Re affects the reaction [GPX1 protein affects the expression of AIF1 protein]; ginsenoside Re inhibits the reaction [Methamphetamine results in increased expression of AIF1 protein]; ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of AIF1 protein]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of AIF1 protein]]] ginsenoside Re results in decreased expression of AIF1 protein |
CTD |
PMID:29467000 PMID:36682417 |
|
NCBI chr20:3,646,784...3,652,670
Ensembl chr20:3,646,777...3,652,668
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions increases phosphorylation |
ISO EXP |
ginsenoside Re results in increased phosphorylation of and results in increased activity of AKT1 protein ginsenoside Re results in increased phosphorylation of AKT1 protein |
CTD |
PMID:17878692 PMID:17885204 PMID:24599032 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Ar |
androgen receptor |
multiple interactions |
ISO |
ginsenoside Re binds to and affects the activity of AR protein |
CTD |
PMID:16985185 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
decreases expression multiple interactions |
ISO EXP |
ginsenoside Re results in decreased expression of BAX mRNA; ginsenoside Re results in decreased expression of BAX protein 3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of BAX protein]]]]; Acetylcysteine inhibits the reaction [ginsenoside Re inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in increased expression of BAX protein]]; Cyclosporine inhibits the reaction [ginsenoside Re inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in increased expression of BAX protein]]; ginsenoside Re inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in increased expression of BAX protein]; ginsenoside Re inhibits the reaction [Methamphetamine results in increased expression of BAX protein]; ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of BAX protein]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of BAX protein]]] |
CTD |
PMID:12674765 PMID:15621629 PMID:29467000 PMID:37308051 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
increases expression multiple interactions |
ISO |
ginsenoside Re results in increased expression of BCL2 mRNA; ginsenoside Re results in increased expression of BCL2 protein 3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of BCL2 protein]]]]; 3-nitropropionic acid inhibits the reaction [ginsenoside Re inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in decreased expression of BCL2 protein]]; ginsenoside Re inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in decreased expression of BCL2 protein]; ginsenoside Re inhibits the reaction [Methamphetamine results in decreased expression of BCL2 protein]; ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of BCL2 protein]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of BCL2 protein]]] |
CTD |
PMID:15621629 PMID:29467000 PMID:37308051 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions |
ISO |
3-nitropropionic acid inhibits the reaction [ginsenoside Re inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in decreased expression of BCL2L1 protein]]; ginsenoside Re inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in decreased expression of BCL2L1 protein] |
CTD |
PMID:37308051 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased cleavage of CASP3 protein]]]]; 3-nitropropionic acid inhibits the reaction [ginsenoside Re inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in increased cleavage of CASP3 protein]]; ginsenoside Re inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in increased cleavage of CASP3 protein]; ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased activity of CASP3 protein]; ginsenoside Re inhibits the reaction [Methamphetamine results in increased cleavage of CASP3 protein]; ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased cleavage of CASP3 protein]]; ginsenoside Re results in decreased cleavage of and results in decreased activity of CASP3 protein; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased cleavage of CASP3 protein]]] |
CTD |
PMID:15621629 PMID:23102375 PMID:25523949 PMID:29467000 PMID:37308051 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
ginsenoside Re inhibits the reaction [Methamphetamine results in increased activity of CAT protein]; PRKCD affects the reaction [ginsenoside Re inhibits the reaction [Methamphetamine results in increased activity of CAT protein]] |
CTD |
PMID:24430743 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression |
ISO |
ginsenoside Re results in increased expression of CDKN1A mRNA |
CTD |
PMID:24599032 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Chat |
choline O-acetyltransferase |
increases expression multiple interactions |
ISO |
ginsenoside Re results in increased expression of CHAT mRNA; ginsenoside Re results in increased expression of CHAT protein staurosporine aglycone inhibits the reaction [ginsenoside Re results in increased expression of CHAT mRNA]; staurosporine aglycone inhibits the reaction [ginsenoside Re results in increased expression of CHAT protein] |
CTD |
PMID:24599032 |
|
NCBI chr16:7,657,362...7,717,093
Ensembl chr16:7,657,362...7,717,093
|
|
G |
Chuk |
component of inhibitor of nuclear factor kappa B kinase complex |
multiple interactions |
ISO |
ginsenoside Re inhibits the reaction [TNF protein results in increased phosphorylation of CHUK protein] |
CTD |
PMID:17885204 |
|
NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065
|
|
G |
Cldn1 |
claudin 1 |
multiple interactions |
ISO |
ginsenoside Re inhibits the reaction [Trinitrobenzenesulfonic Acid results in decreased expression of CLDN1 protein] |
CTD |
PMID:22849695 |
|
NCBI chr11:74,421,569...74,436,728
Ensembl chr11:74,421,569...74,436,724
|
|
G |
Crp |
C-reactive protein |
increases expression |
EXP |
ginsenoside Re results in increased expression of CRP protein |
CTD |
PMID:16797897 |
|
NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178
|
|
G |
Cyba |
cytochrome b-245 alpha chain |
multiple interactions |
ISO |
ginsenoside Re inhibits the reaction [GPX1 protein affects the reaction [Phencyclidine results in increased activity of CYBA protein]]; ginsenoside Re inhibits the reaction [Phencyclidine results in increased activity of CYBA protein] |
CTD |
PMID:29037473 |
|
NCBI chr19:50,487,598...50,495,669
Ensembl chr19:50,487,597...50,495,721
|
|
G |
Cyp8b1 |
cytochrome P450 family 8 subfamily B member 1 |
increases expression |
EXP |
ginsenoside Re results in increased expression of CYP8B1 mRNA |
CTD |
PMID:23835644 |
|
NCBI chr 8:121,578,123...121,580,093
Ensembl chr 8:121,557,062...121,580,166
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions |
ISO |
ginsenoside Re binds to and affects the activity of ESR1 protein |
CTD |
PMID:16985185 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
increases expression |
ISO |
ginsenoside Re results in increased expression of FABP4 mRNA |
CTD |
PMID:23545455 |
|
NCBI chr 2:91,580,879...91,585,567
Ensembl chr 2:91,580,885...91,585,578
|
|
G |
Fas |
Fas cell surface death receptor |
decreases expression multiple interactions |
ISO |
ginsenoside Re results in decreased expression of FAS mRNA ginsenoside Re inhibits the reaction [Dietary Fats results in increased expression of FAS mRNA] |
CTD |
PMID:21971952 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
increases expression |
ISO |
ginsenoside Re results in increased expression of FOS mRNA |
CTD |
PMID:16204943 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
decreases expression |
ISO |
ginsenoside Re results in decreased expression of G6PC1 mRNA |
CTD |
PMID:21971952 |
|
NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804
|
|
G |
Gpam |
glycerol-3-phosphate acyltransferase, mitochondrial |
multiple interactions |
ISO |
ginsenoside Re inhibits the reaction [Dietary Fats results in increased expression of GPAM mRNA] |
CTD |
PMID:21971952 |
|
NCBI chr 1:254,106,323...254,170,755
Ensembl chr 1:254,106,331...254,142,639
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions |
ISO |
ginsenoside Re affects the reaction [GPX1 protein affects the expression of AIF1 protein]; ginsenoside Re affects the reaction [GPX1 protein affects the expression of and affects the localization of RELA protein]; ginsenoside Re affects the reaction [GPX1 protein affects the expression of PTAFR protein]; ginsenoside Re affects the reaction [GPX1 protein affects the phosphorylation of MAPK1 protein]; ginsenoside Re affects the reaction [GPX1 protein affects the phosphorylation of MAPK3 protein]; ginsenoside Re inhibits the reaction [GPX1 protein affects the reaction [Phencyclidine affects the localization of NCF1 protein]]; ginsenoside Re inhibits the reaction [GPX1 protein affects the reaction [Phencyclidine results in decreased activity of SOD2 protein]]; ginsenoside Re inhibits the reaction [GPX1 protein affects the reaction [Phencyclidine results in increased activity of CYBA protein]]; ginsenoside Re inhibits the reaction [GPX1 protein affects the reaction [Phencyclidine results in increased activity of SOD1 protein]] |
CTD |
PMID:29037473 PMID:36682417 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
increases phosphorylation |
ISO |
ginsenoside Re results in increased phosphorylation of GSK3B protein |
CTD |
PMID:17885204 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Hspd1 |
heat shock protein family D (Hsp60) member 1 |
increases expression |
ISO |
ginsenoside Re results in increased expression of HSPD1 protein |
CTD |
PMID:23144451 |
|
NCBI chr 9:56,579,195...56,590,011
Ensembl chr 9:56,579,201...56,589,662
|
|
G |
Ifng |
interferon gamma |
decreases expression |
ISO |
ginsenoside Re results in decreased expression of IFNG protein |
CTD |
PMID:20230918 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Ikbkb |
inhibitor of nuclear factor kappa B kinase subunit beta |
multiple interactions |
ISO |
ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of IKBKB protein] |
CTD |
PMID:22849695 |
|
NCBI chr16:69,319,487...69,373,251
Ensembl chr16:69,319,554...69,373,250
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]; ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]; ginsenoside Re metabolite inhibits the reaction [Oxazolone results in increased expression of IL1B mRNA]; ginsenoside Re metabolite inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of IL1B mRNA] |
CTD |
PMID:16557482 PMID:22494059 PMID:22849695 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
ginsenoside Re inhibits the reaction [TNF protein results in increased expression of IL6 mRNA] |
CTD |
PMID:17885204 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ins1 |
insulin 1 |
multiple interactions |
EXP |
ginsenoside Re inhibits the reaction [Dietary Fats inhibits the reaction [INS1 protein results in increased localization of SLC2A4 protein]] |
CTD |
PMID:22571876 |
|
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Irak1 |
interleukin-1 receptor-associated kinase 1 |
multiple interactions |
ISO |
ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased degradation of IRAK1 protein]; ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of IRAK1 protein] |
CTD |
PMID:22849695 |
|
NCBI chr X:151,768,621...151,778,521
Ensembl chr X:151,768,777...151,778,521
|
|
G |
Irak4 |
interleukin-1 receptor-associated kinase 4 |
multiple interactions |
ISO |
ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased degradation of IRAK4 protein] |
CTD |
PMID:22849695 |
|
NCBI chr 7:125,682,502...125,708,294
Ensembl chr 7:125,682,488...125,717,837
|
|
G |
Irgm |
immunity-related GTPase M |
decreases expression |
ISO |
ginsenoside Re results in decreased expression of IRGM protein |
CTD |
PMID:20230918 |
|
NCBI chr10:33,233,513...33,241,594
Ensembl chr10:33,233,455...33,241,578
|
|
G |
Irs1 |
insulin receptor substrate 1 |
multiple interactions increases expression increases phosphorylation |
ISO |
ginsenoside Re inhibits the reaction [TNF protein results in increased phosphorylation of IRS1 protein] ginsenoside Re results in increased expression of IRS1 mRNA ginsenoside Re results in increased phosphorylation of IRS1 protein |
CTD |
PMID:17885204 PMID:23545455 |
|
NCBI chr 9:83,552,964...83,605,797
Ensembl chr 9:83,548,944...83,606,122
|
|
G |
Kcne1 |
potassium voltage-gated channel subfamily E regulatory subunit 1 |
increases expression |
ISO |
ginsenoside Re results in increased expression of KCNE1 |
CTD |
PMID:24615935 |
|
NCBI chr11:31,580,951...31,594,116
Ensembl chr11:31,580,742...31,593,901
|
|
G |
Lpl |
lipoprotein lipase |
increases secretion |
ISO |
ginsenoside Re results in increased secretion of LPL protein |
CTD |
PMID:8988629 |
|
NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249
|
|
G |
Lrpprc |
leucine-rich pentatricopeptide repeat containing |
increases expression |
ISO |
ginsenoside Re results in increased expression of LRPPRC protein |
CTD |
PMID:23144451 |
|
NCBI chr 6:9,859,816...9,942,294
Ensembl chr 6:9,859,867...9,942,293
|
|
G |
Map2 |
microtubule-associated protein 2 |
increases expression |
ISO |
ginsenoside Re results in increased expression of MAP2 mRNA; ginsenoside Re results in increased expression of MAP2 protein |
CTD |
PMID:24599032 |
|
NCBI chr 9:67,723,422...67,981,886
Ensembl chr 9:67,723,371...67,979,809
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation |
ISO |
ginsenoside Re affects the reaction [GPX1 protein affects the phosphorylation of MAPK1 protein]; ginsenoside Re results in increased phosphorylation of and results in increased activity of MAPK1 protein ginsenoside Re results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:24599032 PMID:36682417 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
ISO |
ginsenoside Re affects the reaction [GPX1 protein affects the phosphorylation of MAPK3 protein]; ginsenoside Re results in increased phosphorylation of and results in increased activity of MAPK3 protein ginsenoside Re results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:24599032 PMID:36682417 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
ISO |
ginsenoside Re inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased activity of MPO protein] |
CTD |
PMID:22849695 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Myl9 |
myosin light chain 9 |
affects phosphorylation |
EXP |
ginsenoside Re affects the phosphorylation of MYL9 protein |
CTD |
PMID:24658813 |
|
NCBI chr 3:145,281,943...145,288,333
Ensembl chr 3:145,281,937...145,288,333
|
|
G |
Mylk |
myosin light chain kinase |
affects expression |
EXP |
ginsenoside Re affects the expression of MYLK mRNA; ginsenoside Re affects the expression of MYLK protein |
CTD |
PMID:24658813 |
|
NCBI chr11:65,783,008...66,030,239
Ensembl chr11:65,783,008...66,030,261
|
|
G |
Ncf1 |
neutrophil cytosolic factor 1 |
multiple interactions |
ISO |
ginsenoside Re inhibits the reaction [GPX1 protein affects the reaction [Phencyclidine affects the localization of NCF1 protein]]; ginsenoside Re inhibits the reaction [Phencyclidine affects the localization of NCF1 protein] |
CTD |
PMID:29037473 |
|
NCBI chr12:22,485,382...22,494,647
Ensembl chr12:22,485,451...22,494,646
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO EXP |
ginsenoside Re inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein] |
CTD |
PMID:17885204 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Ngf |
nerve growth factor |
increases expression |
ISO |
ginsenoside Re results in increased expression of NGF mRNA |
CTD |
PMID:24599032 |
|
NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452
|
|
G |
Ngfr |
nerve growth factor receptor |
increases expression |
ISO |
ginsenoside Re results in increased expression of NGFR mRNA; ginsenoside Re results in increased expression of NGFR protein |
CTD |
PMID:24599032 |
|
NCBI chr10:80,515,287...80,533,518
Ensembl chr10:80,515,299...80,533,518
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions decreases expression |
ISO |
ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] ginsenoside Re results in decreased expression of NOS2 protein |
CTD |
PMID:15621629 PMID:23102375 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nos3 |
nitric oxide synthase 3 |
multiple interactions increases phosphorylation |
ISO |
2-aminoethoxydiphenyl borate inhibits the reaction [ginsenoside Re results in increased phosphorylation of NOS3 protein]; Calcium deficiency inhibits the reaction [ginsenoside Re results in increased phosphorylation of NOS3 protein]; Mifepristone inhibits the reaction [ginsenoside Re results in increased phosphorylation of NOS3 protein] |
CTD |
PMID:17490654 |
|
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Nr0b2 |
nuclear receptor subfamily 0, group B, member 2 |
increases expression |
ISO |
ginsenoside Re results in increased expression of NR0B2 mRNA |
CTD |
PMID:21971952 |
|
NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609
|
|
G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
multiple interactions increases activity |
ISO |
[ginsenoside Re results in increased activity of NR3C1 protein] which results in increased abundance of Nitric Oxide |
CTD |
PMID:17490654 |
|
NCBI chr18:31,271,681...31,393,320
Ensembl chr18:31,271,681...31,393,375
|
|
G |
Ocln |
occludin |
multiple interactions |
ISO |
ginsenoside Re inhibits the reaction [Trinitrobenzenesulfonic Acid results in decreased expression of OCLN protein] |
CTD |
PMID:22849695 |
|
NCBI chr 2:31,657,217...31,707,466
Ensembl chr 2:31,657,220...31,764,150
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
ISO |
ginsenoside Re inhibits the reaction [Methamphetamine results in increased cleavage of PARP1 protein] |
CTD |
PMID:25523949 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pck1 |
phosphoenolpyruvate carboxykinase 1 |
multiple interactions decreases expression |
ISO |
ginsenoside Re inhibits the reaction [Dietary Fats results in increased expression of PCK1 mRNA] ginsenoside Re results in decreased expression of PCK1 mRNA |
CTD |
PMID:21971952 |
|
NCBI chr 3:161,930,256...161,936,205
Ensembl chr 3:161,930,256...161,936,191
|
|
G |
Pdyn |
prodynorphin |
multiple interactions |
ISO |
3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of BCL2 protein]]]]; 3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of TH protein]]]]; 3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased cleavage of CASP3 protein]]]]; 3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of AIF1 protein]]]]; 3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of BAX protein]]]]; ginsenoside Re inhibits the reaction [Methamphetamine results in decreased expression of PDYN mRNA]; ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of BCL2 protein]]; ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of TH protein]]; ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased cleavage of CASP3 protein]]; ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of AIF1 protein]]; ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of BAX protein]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of BCL2 protein]]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of TH protein]]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased cleavage of CASP3 protein]]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of AIF1 protein]]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of BAX protein]]] |
CTD |
PMID:29467000 |
|
NCBI chr 3:116,900,990...116,913,334
Ensembl chr 3:116,900,992...116,913,334
|
|
G |
Pgr |
progesterone receptor |
multiple interactions increases expression |
ISO |
ginsenoside Re binds to and affects the activity of PGR protein ginsenoside Re results in increased expression of PGR protein |
CTD |
PMID:16204943 PMID:16985185 |
|
NCBI chr 8:6,072,673...6,131,552
Ensembl chr 8:6,072,673...6,131,344
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
increases expression |
ISO |
ginsenoside Re results in increased expression of PPARG mRNA |
CTD |
PMID:23545455 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Prkaa1 |
protein kinase AMP-activated catalytic subunit alpha 1 |
increases phosphorylation multiple interactions |
ISO |
ginsenoside Re results in increased phosphorylation of PRKAA1 protein ginsenoside Re inhibits the reaction [Dietary Fats results in decreased phosphorylation of PRKAA1 protein] |
CTD |
PMID:21971952 |
|
NCBI chr 2:54,240,298...54,275,978
Ensembl chr 2:54,240,137...54,275,978
|
|
G |
Prkcd |
protein kinase C, delta |
multiple interactions increases response to substance |
ISO |
3-nitropropionic acid inhibits the reaction [ginsenoside Re inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in increased cleavage of and results in increased phosphorylation of PRKCD protein]]; ginsenoside Re inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in increased cleavage of and results in increased phosphorylation of PRKCD protein]; ginsenoside Re inhibits the reaction [Methamphetamine affects the localization of PRKCD protein]; PRKCD affects the reaction [ginsenoside Re inhibits the reaction [Methamphetamine results in increased activity of CAT protein]]; PRKCD affects the reaction [ginsenoside Re inhibits the reaction [Methamphetamine results in increased activity of SOD1 protein]] ginsenoside Re inhibits the reaction [Methamphetamine affects the localization of PRKCD protein]; ginsenoside Re inhibits the reaction [Methamphetamine results in increased expression of and results in increased cleavage of PRKCD protein] PRKCD results in increased susceptibility to ginsenoside Re |
CTD |
PMID:24430743 PMID:25523949 PMID:37308051 |
|
NCBI chr16:5,769,217...5,799,380
Ensembl chr16:5,769,215...5,799,352
|
|
G |
Ptafr |
platelet-activating factor receptor |
multiple interactions decreases expression |
ISO |
ginsenoside Re affects the reaction [GPX1 protein affects the expression of PTAFR protein] ginsenoside Re results in decreased expression of PTAFR protein |
CTD |
PMID:36682417 |
|
NCBI chr 5:144,765,770...144,795,057
Ensembl chr 5:144,765,976...144,795,251
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]; ginsenoside Re metabolite inhibits the reaction [Oxazolone results in increased expression of PTGS2 mRNA]; ginsenoside Re metabolite inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 mRNA] |
CTD |
PMID:16557482 PMID:23102375 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
ginsenoside Re affects the reaction [GPX1 protein affects the expression of and affects the localization of RELA protein]; ginsenoside Re results in decreased expression of and affects the localization of RELA protein |
CTD |
PMID:36682417 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
increases phosphorylation |
ISO |
ginsenoside Re results in increased phosphorylation of RPS6KB1 protein |
CTD |
PMID:17885204 |
|
NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
|
|
G |
Scd |
stearoyl-CoA desaturase |
decreases expression multiple interactions |
ISO |
ginsenoside Re results in decreased expression of SCD mRNA ginsenoside Re inhibits the reaction [Dietary Fats results in increased expression of SCD1 mRNA] |
CTD |
PMID:21971952 |
|
NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562
|
|
G |
Slc18a3 |
solute carrier family 18 member A3 |
increases expression |
ISO |
ginsenoside Re results in increased expression of SLC18A3 mRNA |
CTD |
PMID:24599032 |
|
NCBI chr16:7,713,630...7,716,491
|
|
G |
Slc2a4 |
solute carrier family 2 member 4 |
multiple interactions increases localization |
EXP ISO |
ginsenoside Re inhibits the reaction [Dietary Fats inhibits the reaction [INS1 protein results in increased localization of SLC2A4 protein]] ginsenoside Re results in increased localization of SLC2A4 protein |
CTD |
PMID:17885204 PMID:22571876 PMID:23545455 |
|
NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565
|
|
G |
Slc5a7 |
solute carrier family 5 member 7 |
increases expression |
ISO |
ginsenoside Re results in increased expression of SLC5A7 mRNA |
CTD |
PMID:24599032 |
|
NCBI chr 9:7,595,440...7,626,258
Ensembl chr 9:7,595,444...7,626,258
|
|
G |
Slco1b2 |
solute carrier organic anion transporter family member 1B2 |
multiple interactions |
EXP ISO |
SLCO1B2 protein binds to and results in increased transport of ginsenoside Re SLCO1B3 protein binds to and results in increased transport of ginsenoside Re |
CTD |
PMID:25297453 |
|
NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981
|
|
G |
Socs3 |
suppressor of cytokine signaling 3 |
multiple interactions |
ISO |
ginsenoside Re inhibits the reaction [TNF protein results in increased expression of SOCS3 mRNA] |
CTD |
PMID:17885204 |
|
NCBI chr10:103,193,909...103,197,322
Ensembl chr10:103,193,537...103,197,787
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions decreases activity |
ISO |
ginsenoside Re inhibits the reaction [GPX1 protein affects the reaction [Phencyclidine results in increased activity of SOD1 protein]]; ginsenoside Re inhibits the reaction [Methamphetamine results in increased activity of SOD1 protein]; PRKCD affects the reaction [ginsenoside Re inhibits the reaction [Methamphetamine results in increased activity of SOD1 protein]] ginsenoside Re results in decreased activity of SOD1 protein |
CTD |
PMID:24430743 PMID:29037473 PMID:36682417 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions |
ISO |
ginsenoside Re inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in decreased activity of SOD2 protein]; ginsenoside Re inhibits the reaction [GPX1 protein affects the reaction [Phencyclidine results in decreased activity of SOD2 protein]] |
CTD |
PMID:29037473 PMID:37308051 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions decreases expression |
ISO |
ginsenoside Re inhibits the reaction [Dietary Fats results in increased expression of SREBF1 mRNA] ginsenoside Re results in decreased expression of SREBF1 mRNA |
CTD |
PMID:21971952 |
|
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
|
|
G |
Stk11 |
serine/threonine kinase 11 |
increases phosphorylation |
ISO |
ginsenoside Re results in increased phosphorylation of STK11 protein |
CTD |
PMID:21971952 |
|
NCBI chr 7:9,574,553...9,591,315
Ensembl chr 7:9,575,269...9,591,315
|
|
G |
Tac1 |
tachykinin, precursor 1 |
multiple interactions |
ISO |
ginsenoside Re inhibits the reaction [Methamphetamine results in increased expression of TAC1 mRNA]; ginsenoside Re inhibits the reaction [Methamphetamine results in increased expression of TAC1 protein modified form]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [Methamphetamine results in increased expression of TAC1 mRNA]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [Methamphetamine results in increased expression of TAC1 protein modified form]] |
CTD |
PMID:29467000 |
|
NCBI chr 4:35,679,183...35,687,180
Ensembl chr 4:35,679,704...35,687,178
|
|
G |
Tbc1d4 |
TBC1 domain family, member 4 |
increases phosphorylation |
ISO |
ginsenoside Re results in increased phosphorylation of TBC1D4 protein |
CTD |
PMID:17885204 |
|
NCBI chr15:78,256,030...78,434,168
Ensembl chr15:78,257,121...78,434,265
|
|
G |
Tff1 |
trefoil factor 1 |
increases expression |
ISO |
ginsenoside Re results in increased expression of TFF1 mRNA |
CTD |
PMID:16204943 |
|
NCBI chr20:9,235,736...9,239,597
Ensembl chr20:9,235,736...9,239,597
|
|
G |
Th |
tyrosine hydroxylase |
multiple interactions |
ISO |
ginsenoside Re inhibits the reaction [Methamphetamine results in decreased expression of and results in decreased activity of TH protein] 3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of TH protein]]]]; ginsenoside Re inhibits the reaction [Methamphetamine results in decreased expression of TH protein]; ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of TH protein]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of TH protein]]] |
CTD |
PMID:25523949 PMID:29467000 |
|
NCBI chr 1:198,071,500...198,078,832
Ensembl chr 1:198,071,503...198,109,767
|
|
G |
Tjp1 |
tight junction protein 1 |
multiple interactions |
ISO |
ginsenoside Re inhibits the reaction [Trinitrobenzenesulfonic Acid results in decreased expression of TJP1 protein] |
CTD |
PMID:22849695 |
|
NCBI chr 1:118,849,838...119,094,492
Ensembl chr 1:118,849,838...119,094,432
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions |
ISO |
ginsenoside Re inhibits the reaction [Lipopolysaccharides binds to TLR4 protein] |
CTD |
PMID:22849695 |
|
NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO EXP |
ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; ginsenoside Re inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein]; ginsenoside Re inhibits the reaction [TNF protein results in increased expression of IL6 mRNA]; ginsenoside Re inhibits the reaction [TNF protein results in increased expression of SOCS3 mRNA]; ginsenoside Re inhibits the reaction [TNF protein results in increased phosphorylation of CHUK protein]; ginsenoside Re inhibits the reaction [TNF protein results in increased phosphorylation of IRS1 protein]; ginsenoside Re metabolite inhibits the reaction [Oxazolone results in increased expression of TNF mRNA]; ginsenoside Re metabolite inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of TNF mRNA]; ginsenoside Re results in decreased expression of and results in decreased secretion of TNF protein |
CTD |
PMID:16557482 PMID:17885204 PMID:22494059 PMID:22849695 PMID:23545455 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Apoa1 |
apolipoprotein A1 |
multiple interactions decreases expression |
ISO |
ginsenoside Rf inhibits the reaction [pirinixic acid results in decreased expression of APOA1 mRNA]; ginsenoside Rf inhibits the reaction [pirinixic acid results in decreased expression of APOA1 protein]; PPARA protein affects the reaction [ginsenoside Rf inhibits the reaction [pirinixic acid results in decreased expression of APOA1 mRNA]] ginsenoside Rf results in decreased expression of APOA1 protein |
CTD |
PMID:16297877 |
|
NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035
|
|
G |
Apoc3 |
apolipoprotein C3 |
multiple interactions decreases expression increases expression |
ISO |
ginsenoside Rf inhibits the reaction [pirinixic acid results in decreased expression of APOC3 mRNA]; ginsenoside Rf inhibits the reaction [pirinixic acid results in decreased expression of APOC3 protein]; PPARA protein affects the reaction [ginsenoside Rf inhibits the reaction [pirinixic acid results in decreased expression of APOC3 mRNA]]; PPARA protein affects the reaction [ginsenoside Rf results in increased expression of APOC3 mRNA] ginsenoside Rf results in decreased expression of APOC3 protein |
CTD |
PMID:16297877 |
|
NCBI chr 8:46,531,478...46,533,658
Ensembl chr 8:46,531,478...46,533,583
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
affects activity |
ISO |
ginsenoside Rf affects the activity of KCNH2 protein |
CTD |
PMID:15842772 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions decreases expression |
ISO |
ginsenoside Rf binds to and results in decreased activity of PPARA protein; ginsenoside Rf inhibits the reaction [pirinixic acid results in increased activity of PPARA protein]; ginsenoside Rf inhibits the reaction [pirinixic acid results in increased expression of PPARA mRNA]; PPARA protein affects the reaction [ginsenoside Rf inhibits the reaction [pirinixic acid results in decreased expression of APOA1 mRNA]]; PPARA protein affects the reaction [ginsenoside Rf inhibits the reaction [pirinixic acid results in decreased expression of APOC3 mRNA]]; PPARA protein affects the reaction [ginsenoside Rf results in increased expression of APOC3 mRNA] ginsenoside Rf results in decreased expression of PPARA mRNA |
CTD |
PMID:16297877 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
increases transport multiple interactions |
EXP ISO |
ABCB11 protein results in increased transport of ginsenoside Rg1 ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of ABCB11 mRNA]; ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of ABCB11 protein] ginsenoside Rg1 promotes the reaction [Carbon Tetrachloride results in increased expression of ABCB11 protein] |
CTD |
PMID:25297453 PMID:29964319 PMID:32198087 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
increases transport |
ISO |
ABCC1 protein results in increased transport of ginsenoside Rg1 |
CTD |
PMID:25297453 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
increases transport multiple interactions increases expression |
EXP ISO |
ABCC2 protein results in increased transport of ginsenoside Rg1 ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of ABCC2 mRNA]; ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of ABCC2 protein] ginsenoside Rg1 promotes the reaction [Carbon Tetrachloride results in increased expression of ABCC2 protein]; Tretinoin inhibits the reaction [ginsenoside Rg1 promotes the reaction [Carbon Tetrachloride results in increased expression of ABCC2 protein]] ginsenoside Rg1 results in increased expression of ABCC2 protein |
CTD |
PMID:25297453 PMID:29964319 PMID:32198087 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
increases expression multiple interactions |
ISO |
ginsenoside Rg1 results in increased expression of ABCC3 protein ginsenoside Rg1 promotes the reaction [Carbon Tetrachloride results in increased expression of ABCC3 protein]; Tretinoin inhibits the reaction [ginsenoside Rg1 promotes the reaction [Carbon Tetrachloride results in increased expression of ABCC3 protein]] |
CTD |
PMID:29964319 |
|
NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Abcc4 |
ATP binding cassette subfamily C member 4 |
increases expression multiple interactions |
ISO |
ginsenoside Rg1 results in increased expression of ABCC4 protein ginsenoside Rg1 promotes the reaction [Carbon Tetrachloride results in increased expression of ABCC4 protein] |
CTD |
PMID:29964319 |
|
NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
increases transport |
EXP ISO |
ABCG2 protein results in increased transport of ginsenoside Rg1 |
CTD |
PMID:25297453 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Ache |
acetylcholinesterase |
decreases activity |
ISO |
ginsenoside Rg1 results in decreased activity of ACHE protein |
CTD |
PMID:20564503 |
|
NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Adam10 |
ADAM metallopeptidase domain 10 |
multiple interactions |
EXP |
ginsenoside Rg1 inhibits the reaction [[APP protein alternative form co-treated with Dexamethasone] results in decreased expression of ADAM10 mRNA] |
CTD |
PMID:22484447 |
|
NCBI chr 8:71,346,008...71,477,889
Ensembl chr 8:71,345,837...71,477,889
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO EXP |
ginsenoside Rg1 inhibits the reaction [Chlorpyrifos results in decreased phosphorylation of AKT1 protein]; ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in decreased expression of AKT1 mRNA]; ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in decreased phosphorylation of AKT1 protein] 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in decreased phosphorylation of AKT1 protein]]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in decreased phosphorylation of AKT1 protein] ginsenoside Rg1 inhibits the reaction [Doxorubicin results in increased expression of AKT1 mRNA] |
CTD |
PMID:33331133 PMID:34783124 PMID:34859534 PMID:36811218 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Apaf1 |
apoptotic peptidase activating factor 1 |
multiple interactions |
ISO |
ginsenoside Rg1 promotes the reaction [Doxorubicin results in increased expression of APAF1 mRNA] |
CTD |
PMID:34783124 |
|
NCBI chr 7:25,494,143...25,579,540
Ensembl chr 7:25,494,609...25,579,540
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
EXP |
ginsenoside Rg1 inhibits the reaction [[APP protein alternative form co-treated with Dexamethasone] results in decreased expression of ADAM10 mRNA]; ginsenoside Rg1 inhibits the reaction [[APP protein alternative form co-treated with Dexamethasone] results in increased expression of APP mRNA]; ginsenoside Rg1 inhibits the reaction [[APP protein alternative form co-treated with Dexamethasone] results in increased expression of APP protein alternative form]; ginsenoside Rg1 inhibits the reaction [[APP protein alternative form co-treated with Dexamethasone] results in increased expression of APP protein]; ginsenoside Rg1 inhibits the reaction [[APP protein alternative form co-treated with Dexamethasone] results in increased expression of BACE1 mRNA]; ginsenoside Rg1 results in decreased susceptibility to [APP protein alternative form co-treated with Dexamethasone] |
CTD |
PMID:22484447 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Atf6 |
activating transcription factor 6 |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of ATF6 protein] |
CTD |
PMID:30918470 |
|
NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177
|
|
G |
Atm |
ATM serine/threonine kinase |
multiple interactions |
ISO |
ginsenoside Rg1 promotes the reaction [Doxorubicin results in increased expression of ATM mRNA] |
CTD |
PMID:34783124 |
|
NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437
|
|
G |
Bace1 |
beta-secretase 1 |
multiple interactions |
EXP |
ginsenoside Rg1 inhibits the reaction [[APP protein alternative form co-treated with Dexamethasone] results in increased expression of BACE1 mRNA] |
CTD |
PMID:22484447 |
|
NCBI chr 8:46,142,060...46,166,268
Ensembl chr 8:46,142,116...46,165,876
|
|
G |
Bad |
BCL2-associated agonist of cell death |
multiple interactions |
EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Rotenone results in increased phosphorylation of BAD protein]]; ginsenoside Rg1 inhibits the reaction [Rotenone results in increased phosphorylation of BAD protein]; Mifepristone inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Rotenone results in increased phosphorylation of BAD protein]]; SH-6 compound inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Rotenone results in increased phosphorylation of BAD protein]] |
CTD |
PMID:17123556 |
|
NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression multiple interactions |
ISO EXP |
ginsenoside Rg1 results in increased expression of BAX protein ginsenoside Rg1 inhibits the reaction [Chlorpyrifos results in increased expression of BAX protein] ginsenoside Rg1 promotes the reaction [Doxorubicin results in increased expression of BAX mRNA] 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of BAX protein]]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of BAX protein] |
CTD |
PMID:28371286 PMID:34783124 PMID:34859534 PMID:36811218 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression multiple interactions |
ISO EXP |
ginsenoside Rg1 results in decreased expression of BCL2 protein ginsenoside Rg1 inhibits the reaction [Chlorpyrifos results in decreased expression of BCL2 protein] 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]; ginsenoside Rg1 inhibits the reaction [Oxygen deficiency results in decreased expression of BCL2 protein] |
CTD |
PMID:26593335 PMID:28371286 PMID:34859534 PMID:36811218 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity |
ISO EXP |
ginsenoside Rg1 inhibits the reaction [cobaltous chloride results in increased activity of CASP3 protein]; ginsenoside Rg1 promotes the reaction [Doxorubicin results in increased expression of CASP3 mRNA] ginsenoside Rg1 inhibits the reaction [Chlorpyrifos results in increased cleavage of CASP3 protein] 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased cleavage of CASP3 protein]]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased cleavage of CASP3 protein] ginsenoside Rg1 results in increased activity of CASP3 protein |
CTD |
PMID:24386346 PMID:28371286 PMID:34783124 PMID:34859534 PMID:36811218 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
increases activity multiple interactions |
ISO EXP |
ginsenoside Rg1 results in increased activity of CASP9 protein ginsenoside Rg1 inhibits the reaction [Chlorpyrifos results in increased cleavage of CASP9 protein] ginsenoside Rg1 promotes the reaction [Doxorubicin results in increased expression of CASP9 mRNA] 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased cleavage of CASP9 protein]]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased cleavage of CASP9 protein] |
CTD |
PMID:28371286 PMID:34783124 PMID:34859534 PMID:36811218 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased activity of CAT protein] |
CTD |
PMID:29964319 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccne1 |
cyclin E1 |
multiple interactions |
ISO |
ginsenoside Rg1 affects the reaction [tert-Butylhydroperoxide affects the expression of CCNE1 protein] |
CTD |
PMID:15606011 |
|
NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101
|
|
G |
Cdh1 |
cadherin 1 |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in decreased expression of CDH1 mRNA]; ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in decreased expression of CDH1 protein] |
CTD |
PMID:33331133 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
multiple interactions |
ISO |
ginsenoside Rg1 affects the reaction [tert-Butylhydroperoxide affects the expression of CDK2 protein] |
CTD |
PMID:15606011 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions |
ISO |
ginsenoside Rg1 affects the reaction [tert-Butylhydroperoxide affects the expression of CDKN1A protein]; ginsenoside Rg1 promotes the reaction [Doxorubicin results in increased expression of CDKN1A mRNA] |
CTD |
PMID:15606011 PMID:34783124 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in decreased expression of CREB1 protein] |
CTD |
PMID:33331133 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
multiple interactions |
EXP |
ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of CYP2B10 mRNA]; ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of CYP2B10 protein] |
CTD |
PMID:32198087 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in increased expression of CYP2E1 mRNA] |
CTD |
PMID:29964319 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions |
EXP |
ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of CYP3A4 mRNA]; ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of CYP3A4 protein] |
CTD |
PMID:32198087 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of DDIT3 protein] |
CTD |
PMID:30918470 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Ern1 |
endoplasmic reticulum to nucleus signaling 1 |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of ERN1 protein] |
CTD |
PMID:30918470 |
|
NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
increases expression |
ISO |
ginsenoside Rg1 results in increased expression of FOS mRNA |
CTD |
PMID:16204943 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Fshb |
follicle stimulating hormone subunit beta |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in increased expression of FSHB protein] |
CTD |
PMID:33331133 |
|
NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370
|
|
G |
Fshr |
follicle stimulating hormone receptor |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in decreased expression of FSHR protein] |
CTD |
PMID:33331133 |
|
NCBI chr 6:5,198,825...5,406,785
Ensembl chr 6:5,198,825...5,406,785
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
increases expression multiple interactions |
ISO |
ginsenoside Rg1 results in increased expression of GCLC mRNA ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of GCLC mRNA]; NFE2L2 protein affects the reaction [ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of GCLC mRNA]] |
CTD |
PMID:29964319 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
increases expression multiple interactions |
ISO |
ginsenoside Rg1 results in increased expression of GCLM protein ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of GCLM protein] |
CTD |
PMID:29964319 |
|
NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in decreased expression of GJA1 mRNA]; ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in decreased expression of GJA1 protein] |
CTD |
PMID:33331133 |
|
NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582
|
|
G |
Glud1 |
glutamate dehydrogenase 1 |
multiple interactions |
EXP |
ginsenoside Rg1 inhibits the reaction [Oxygen deficiency results in increased expression of GLUD1 protein] |
CTD |
PMID:26593335 |
|
NCBI chr16:9,640,312...9,673,961
Ensembl chr16:9,640,312...9,673,957
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in increased expression of GPT protein] |
CTD |
PMID:29964319 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions |
EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in decreased phosphorylation of GSK3B protein]]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in decreased phosphorylation of GSK3B protein] |
CTD |
PMID:34859534 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
H2ax |
H2A.X variant histone |
multiple interactions |
ISO |
ginsenoside Rg1 promotes the reaction [Doxorubicin results in increased expression of H2AX mRNA] |
CTD |
PMID:34783124 |
|
NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression |
ISO |
[astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] results in increased expression of HMOX1 mRNA; [astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] results in increased expression of HMOX1 protein; ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of HMOX1 mRNA]; NFE2L2 protein affects the reaction [ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of HMOX1 mRNA]]; Tretinoin inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of HMOX1 mRNA]] ginsenoside Rg1 results in increased expression of HMOX1 mRNA; ginsenoside Rg1 results in increased expression of HMOX1 protein |
CTD |
PMID:25422538 PMID:29964319 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of HSPA5 protein] |
CTD |
PMID:30918470 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
EXP |
ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of IFNG protein] |
CTD |
PMID:32198087 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO EXP |
1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B]]; ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in increased expression of IL1B protein]; ginsenoside Rg1 inhibits the reaction [Chlorpyrifos results in increased expression of IL1B protein]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B] ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of IL1B protein] |
CTD |
PMID:22214447 PMID:29964319 PMID:32198087 PMID:36811218 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP ISO |
ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein] ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in increased expression of IL6 protein]; ginsenoside Rg1 inhibits the reaction [Chlorpyrifos results in increased expression of IL6 protein]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein] |
CTD |
PMID:17655881 PMID:29964319 PMID:30918470 PMID:36811218 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Inha |
inhibin subunit alpha |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in decreased expression of INHA protein] |
CTD |
PMID:33331133 |
|
NCBI chr 9:76,994,465...76,997,366
Ensembl chr 9:76,993,589...76,997,248
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
affects activity |
ISO |
ginsenoside Rg1 affects the activity of KCNH2 protein |
CTD |
PMID:15842772 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Keap1 |
Kelch-like ECH-associated protein 1 |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in increased expression of KEAP1 protein] |
CTD |
PMID:29964319 |
|
NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862
|
|
G |
Lhb |
luteinizing hormone subunit beta |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in decreased expression of LHB protein] |
CTD |
PMID:33331133 |
|
NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972 Ensembl chr 1:95,900,984...95,901,972
|
|
G |
Lpl |
lipoprotein lipase |
increases secretion |
ISO |
ginsenoside Rg1 results in increased secretion of LPL protein |
CTD |
PMID:8988629 |
|
NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249
|
|
G |
Map2 |
microtubule-associated protein 2 |
increases expression |
ISO |
ginsenoside Rg1 results in increased expression of MAP2 mRNA |
CTD |
PMID:24599032 |
|
NCBI chr 9:67,723,422...67,981,886
Ensembl chr 9:67,723,371...67,979,809
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions affects phosphorylation |
ISO |
PLCG1 affects the reaction [ginsenoside Rg1 affects the phosphorylation of MAPK1 protein] |
CTD |
PMID:22214447 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
affects phosphorylation multiple interactions |
ISO |
ginsenoside Rg1 affects the phosphorylation of MAPK3 protein PLCG1 affects the reaction [ginsenoside Rg1 affects the phosphorylation of MAPK3 protein] |
CTD |
PMID:22214447 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [cobaltous chloride results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:24386346 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [cobaltous chloride results in increased phosphorylation of MAPK9 protein] |
CTD |
PMID:24386346 |
|
NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178
|
|
G |
Met |
MET proto-oncogene, receptor tyrosine kinase |
multiple interactions increases expression |
ISO |
Mifepristone inhibits the reaction [ginsenoside Rg1 results in increased expression of MET protein]; MIR23A mRNA inhibits the reaction [ginsenoside Rg1 results in increased expression of MET protein] |
CTD |
PMID:26115870 |
|
NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876
|
|
G |
Mfn2 |
mitofusin 2 |
multiple interactions |
EXP |
ginsenoside Rg1 inhibits the reaction [Oxygen deficiency results in decreased expression of MFN2 mRNA]; ginsenoside Rg1 inhibits the reaction [Oxygen deficiency results in decreased expression of MFN2 protein] |
CTD |
PMID:26593335 |
|
NCBI chr 5:158,304,285...158,335,502
Ensembl chr 5:158,304,287...158,335,342
|
|
G |
Mir23a |
microRNA 23a |
decreases expression multiple interactions |
ISO |
ginsenoside Rg1 results in decreased expression of MIR23A mRNA Mifepristone inhibits the reaction [ginsenoside Rg1 results in decreased expression of MIR23A mRNA]; MIR23A mRNA inhibits the reaction [ginsenoside Rg1 results in increased expression of MET protein] |
CTD |
PMID:26115870 |
|
NCBI chr19:23,954,997...23,955,071
Ensembl chr19:23,954,997...23,955,071
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
increases expression |
EXP |
ginsenoside Rg1 results in increased expression of MMP2 protein |
CTD |
PMID:23738715 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
increases expression |
EXP |
ginsenoside Rg1 results in increased expression of MMP9 protein |
CTD |
PMID:23738715 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [cobaltous chloride results in decreased activity of [MTOR protein binds to RAPTOR protein]]; ginsenoside Rg1 results in increased activity of [MTOR protein binds to RAPTOR protein] ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in decreased expression of MTOR protein] |
CTD |
PMID:24386346 PMID:33331133 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions affects localization increases expression |
ISO |
[ginsenoside Rg1 co-treated with ginsenoside 20S-protopanaxatriol] results in increased expression of NFE2L2 protein ginsenoside Rg1 affects the localization of NFE2L2 protein [astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] affects the localization of NFE2L2 protein; ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of NFE2L2 protein]; NFE2L2 protein affects the reaction [ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of GCLC mRNA]]; NFE2L2 protein affects the reaction [ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of HMOX1 mRNA]]; NFE2L2 protein affects the reaction [ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of NQO1 mRNA]]; Tretinoin inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of NFE2L2 protein]] ginsenoside Rg1 results in increased expression of NFE2L2 mRNA |
CTD |
PMID:22780686 PMID:25422538 PMID:29964319 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
affects phosphorylation multiple interactions |
ISO |
ginsenoside Rg1 affects the phosphorylation of NFKBIA protein PLCG1 affects the reaction [ginsenoside Rg1 affects the phosphorylation of NFKBIA protein] |
CTD |
PMID:22214447 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2]]; ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in increased expression of NOS2 protein]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2] |
CTD |
PMID:22214447 PMID:29964319 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of NQO1 mRNA]; ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of NQO1 protein]; NFE2L2 protein affects the reaction [ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of NQO1 mRNA]]; Tretinoin inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of NQO1 mRNA]] |
CTD |
PMID:29964319 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
multiple interactions |
EXP |
ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of NR1H4 mRNA]; ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of NR1H4 protein] |
CTD |
PMID:32198087 |
|
NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
|
|
G |
Pgr |
progesterone receptor |
increases expression |
ISO |
ginsenoside Rg1 results in increased expression of PGR protein |
CTD |
PMID:16204943 |
|
NCBI chr 8:6,072,673...6,131,552
Ensembl chr 8:6,072,673...6,131,344
|
|
G |
Pik3ca |
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in decreased expression of PIK3CA mRNA] |
CTD |
PMID:33331133 |
|
NCBI chr 2:115,175,275...115,249,034
Ensembl chr 2:115,174,984...115,249,032
|
|
G |
Plcg1 |
phospholipase C, gamma 1 |
multiple interactions |
ISO |
PLCG1 affects the reaction [ginsenoside Rg1 affects the phosphorylation of MAPK1 protein]; PLCG1 affects the reaction [ginsenoside Rg1 affects the phosphorylation of MAPK3 protein]; PLCG1 affects the reaction [ginsenoside Rg1 affects the phosphorylation of NFKBIA protein] |
CTD |
PMID:22214447 |
|
NCBI chr 3:149,385,587...149,416,330
Ensembl chr 3:149,385,587...149,416,330
|
|
G |
Prkaa1 |
protein kinase AMP-activated catalytic subunit alpha 1 |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [cobaltous chloride results in increased phosphorylation of PRKAA1 protein] |
CTD |
PMID:24386346 |
|
NCBI chr 2:54,240,298...54,275,978
Ensembl chr 2:54,240,137...54,275,978
|
|
G |
Pten |
phosphatase and tensin homolog |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in increased expression of PTEN protein] |
CTD |
PMID:33331133 |
|
NCBI chr 1:230,630,443...230,697,070
Ensembl chr 1:230,630,338...230,696,838
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2]]; ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in increased expression of PTGS2 protein]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2] |
CTD |
PMID:22214447 PMID:29964319 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rad51 |
RAD51 recombinase |
multiple interactions |
ISO |
ginsenoside Rg1 promotes the reaction [Doxorubicin results in increased expression of RAD51 mRNA] |
CTD |
PMID:34783124 |
|
NCBI chr 3:106,099,753...106,125,038
Ensembl chr 3:106,100,381...106,125,035
|
|
G |
Rps6 |
ribosomal protein S6 |
increases phosphorylation |
ISO |
ginsenoside Rg1 results in increased phosphorylation of RPS6 protein |
CTD |
PMID:24386346 |
|
NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602 Ensembl chr 5:101,371,136...101,374,602
|
|
G |
Rptor |
regulatory associated protein of MTOR, complex 1 |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [cobaltous chloride results in decreased activity of [MTOR protein binds to RAPTOR protein]]; ginsenoside Rg1 results in increased activity of [MTOR protein binds to RAPTOR protein] |
CTD |
PMID:24386346 |
|
NCBI chr10:104,878,487...105,176,986
Ensembl chr10:104,878,487...105,176,983
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions |
ISO |
ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of SIRT1 protein] |
CTD |
PMID:30918470 |
|
NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260
|
|
G |
Slc10a1 |
solute carrier family 10 member 1 |
multiple interactions |
EXP |
ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of SLC10A1 mRNA]; ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of SLC10A1 protein] |
CTD |
PMID:32198087 |
|
NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670
|
|
G |
Slco1b2 |
solute carrier organic anion transporter family member 1B2 |
multiple interactions |
EXP ISO |
SLCO1B2 protein binds to and results in increased transport of ginsenoside Rg1 SLCO1B3 protein binds to and results in increased transport of ginsenoside Rg1 |
CTD |
PMID:25297453 |
|
NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981
|
|
G |
Sult2a1 |
sulfotransferase family 2A member 1 |
multiple interactions |
EXP |
ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of SULT2A1 mRNA]; ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of SULT2A1 protein] |
CTD |
PMID:32198087 |
|
NCBI chr 1:75,451,178...75,508,113
Ensembl chr 1:74,911,100...75,508,134
|
|
G |
Tff1 |
trefoil factor 1 |
increases expression |
ISO |
ginsenoside Rg1 results in increased expression of TFF1 mRNA |
CTD |
PMID:16204943 |
|
NCBI chr20:9,235,736...9,239,597
Ensembl chr20:9,235,736...9,239,597
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO EXP |
1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF]]; ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF protein]; ginsenoside Rg1 inhibits the reaction [Chlorpyrifos results in increased expression of TNF protein]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein] ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of TNF protein] |
CTD |
PMID:22214447 PMID:29964319 PMID:30918470 PMID:32198087 PMID:36811218 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
ISO |
ginsenoside Rg1 promotes the reaction [Doxorubicin results in increased expression of TP53 mRNA] |
CTD |
PMID:34783124 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
multiple interactions |
EXP |
ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of UGT1A1 mRNA]; ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of UGT1A1 protein] |
CTD |
PMID:32198087 |
|
NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Xrcc1 |
X-ray repair cross complementing 1 |
multiple interactions |
ISO |
ginsenoside Rg1 promotes the reaction [Doxorubicin results in increased expression of XRCC1 mRNA] |
CTD |
PMID:34783124 |
|
NCBI chr 1:80,140,495...80,168,705
Ensembl chr 1:80,141,207...80,168,701
|
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
increases expression |
EXP |
ginsenoside Rg2 results in increased expression of ABCC2 mRNA |
CTD |
PMID:23835644 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg2 inhibits the reaction [APP protein modified form results in decreased phosphorylation of AKT1 protein]]; ginsenoside Rg2 inhibits the reaction [APP protein modified form results in decreased phosphorylation of AKT1 protein] |
CTD |
PMID:28756148 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg2 inhibits the reaction [APP protein modified form results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg2 inhibits the reaction [APP protein modified form results in increased activity of CASP3 protein]]; ginsenoside Rg2 inhibits the reaction [APP protein modified form results in decreased expression of BCL2 protein]; ginsenoside Rg2 inhibits the reaction [APP protein modified form results in decreased phosphorylation of AKT1 protein]; ginsenoside Rg2 inhibits the reaction [APP protein modified form results in increased activity of and results in increased cleavage of CASP3 protein]; ginsenoside Rg2 inhibits the reaction [APP protein modified form results in increased expression of BAX protein] |
CTD |
PMID:28756148 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
EXP |
ginsenoside Rg2 inhibits the reaction [APP protein modified form results in increased expression of BAX protein] |
CTD |
PMID:28756148 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
EXP |
ginsenoside Rg2 inhibits the reaction [APP protein modified form results in decreased expression of BCL2 protein] |
CTD |
PMID:28756148 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Becn2 |
beclin 2 |
multiple interactions |
ISO |
ginsenoside Rg2 inhibits the reaction [BECN2 protein binds to GPRASP1 protein] |
CTD |
PMID:27305347 |
|
NCBI chr13:87,842,980...87,892,410
Ensembl chr13:87,844,531...87,845,787
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg2 inhibits the reaction [APP protein modified form results in increased activity of CASP3 protein]]; ginsenoside Rg2 inhibits the reaction [APP protein modified form results in increased activity of and results in increased cleavage of CASP3 protein] |
CTD |
PMID:28756148 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Crtc2 |
CREB regulated transcription coactivator 2 |
multiple interactions |
ISO |
[ginsenoside Rg2 results in increased activity of NR0B2 protein] which results in decreased activity of CRTC2 protein |
CTD |
PMID:22062806 |
|
NCBI chr 2:175,709,603...175,719,768
Ensembl chr 2:175,709,644...175,719,763
|
|
G |
G6pc3 |
glucose 6 phosphatase catalytic subunit 3 |
decreases expression multiple interactions |
ISO |
ginsenoside Rg2 results in decreased expression of G6PC3 mRNA dorsomorphin inhibits the reaction [ginsenoside Rg2 results in decreased expression of G6PC3 mRNA] |
CTD |
PMID:22062806 |
|
NCBI chr10:87,146,987...87,151,223
Ensembl chr10:87,146,901...87,151,221
|
|
G |
Gprasp1 |
G protein-coupled receptor associated sorting protein 1 |
multiple interactions |
ISO |
ginsenoside Rg2 inhibits the reaction [BECN2 protein binds to GPRASP1 protein] |
CTD |
PMID:27305347 |
|
NCBI chr X:98,764,853...98,772,685
Ensembl chr X:98,709,841...98,772,851
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
increases phosphorylation multiple interactions |
ISO |
ginsenoside Rg2 results in increased phosphorylation of GSK3B protein [[ginsenoside Rg2 results in increased phosphorylation of GSK3B protein] co-treated with [ginsenoside Rg2 results in increased expression of NR0B2 mRNA]] results in decreased chemical synthesis of Glucose; dorsomorphin inhibits the reaction [ginsenoside Rg2 results in increased phosphorylation of GSK3B protein] |
CTD |
PMID:22062806 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
multiple interactions increases expression |
ISO |
bafilomycin A1 promotes the reaction [ginsenoside Rg2 results in increased expression of MAP1LC3B protein modified form] |
CTD |
PMID:27305347 |
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
|
|
G |
Nr0b2 |
nuclear receptor subfamily 0, group B, member 2 |
multiple interactions increases expression increases activity |
ISO |
[[ginsenoside Rg2 results in increased phosphorylation of GSK3B protein] co-treated with [ginsenoside Rg2 results in increased expression of NR0B2 mRNA]] results in decreased chemical synthesis of Glucose; [ginsenoside Rg2 results in increased activity of NR0B2 protein] which results in decreased activity of CRTC2 protein |
CTD |
PMID:22062806 |
|
NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609
|
|
G |
Pck1 |
phosphoenolpyruvate carboxykinase 1 |
multiple interactions decreases expression |
ISO |
dorsomorphin inhibits the reaction [ginsenoside Rg2 results in decreased expression of PCK1 mRNA] |
CTD |
PMID:22062806 |
|
NCBI chr 3:161,930,256...161,936,205
Ensembl chr 3:161,930,256...161,936,191
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
multiple interactions decreases expression |
ISO |
dorsomorphin inhibits the reaction [ginsenoside Rg2 results in decreased expression of PPARGC1A mRNA] |
CTD |
PMID:22062806 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions decreases expression |
ISO |
bafilomycin A1 promotes the reaction [ginsenoside Rg2 results in decreased expression of SQSTM1 protein] |
CTD |
PMID:27305347 |
|
NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Stk11 |
serine/threonine kinase 11 |
increases phosphorylation multiple interactions |
ISO |
ginsenoside Rg2 results in increased phosphorylation of STK11 protein dorsomorphin inhibits the reaction [ginsenoside Rg2 results in increased phosphorylation of STK11 protein] |
CTD |
PMID:22062806 |
|
NCBI chr 7:9,574,553...9,591,315
Ensembl chr 7:9,575,269...9,591,315
|
|
|
G |
Gpx2 |
glutathione peroxidase 2 |
multiple interactions decreases expression |
ISO |
glucobrassicin analog inhibits the reaction [glucoraphanin analog results in increased expression of GPX2 mRNA] glucobrassicin analog results in decreased expression of GPX2 protein |
CTD |
PMID:20868228 |
|
NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions decreases activity |
ISO |
glucobrassicin analog inhibits the reaction [glucoraphanin results in increased activity of NQO1 protein] glucobrassicin analog results in decreased activity of NQO1 protein |
CTD |
PMID:20868228 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases expression |
EXP |
glucoerucin results in increased expression of CYP1A1 protein |
CTD |
PMID:20833222 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
increases expression |
EXP |
glucoerucin results in increased expression of CYP1A2 protein |
CTD |
PMID:20833222 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
increases expression |
EXP |
glucoerucin results in increased expression of CYP1B1 protein |
CTD |
PMID:20833222 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Ephx1 |
epoxide hydrolase 1 |
increases expression |
EXP |
glucoerucin results in increased expression of EPHX1 protein |
CTD |
PMID:21132492 |
|
NCBI chr13:92,714,315...92,744,105
Ensembl chr13:92,714,315...92,790,235
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases activity |
EXP |
glucoerucin results in increased activity of NQO1 protein |
CTD |
PMID:20833222 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases expression |
EXP |
glucoraphanin results in increased expression of CYP1A1 protein |
CTD |
PMID:20833222 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
increases expression |
EXP |
glucoraphanin results in increased expression of CYP1A2 protein |
CTD |
PMID:20833222 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
increases expression |
EXP |
glucoraphanin results in increased expression of CYP1B1 protein |
CTD |
PMID:20833222 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Ephx1 |
epoxide hydrolase 1 |
increases expression |
EXP |
glucoraphanin results in increased expression of EPHX1 protein |
CTD |
PMID:21132492 |
|
NCBI chr13:92,714,315...92,744,105
Ensembl chr13:92,714,315...92,790,235
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
decreases expression |
EXP |
Glucoraphanin decreases expression of Gpx1 mRNA in the jejunum |
RGD |
PMID:23271678 |
RGD:152998882 |
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gpx2 |
glutathione peroxidase 2 |
increases expression increases expression multiple interactions |
ISO EXP |
glucoraphanin analog results in increased expression of GPX2 mRNA; glucoraphanin analog results in increased expression of GPX2 protein Glucoraphanin increases expression of Gpx2 mRNA in the jejunum Benzo(a)pyrene inhibits the reaction [glucoraphanin results in increased expression of GPX2 mRNA]; glucobrassicin analog inhibits the reaction [glucoraphanin analog results in increased expression of GPX2 mRNA] |
CTD RGD |
PMID:20868228 PMID:23271678 |
RGD:152998882 |
NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
affects localization |
ISO |
glucoraphanin analog affects the localization of NFE2L2 protein |
CTD |
PMID:20868228 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions increases activity |
ISO EXP |
glucobrassicin analog inhibits the reaction [glucoraphanin results in increased activity of NQO1 protein] glucoraphanin analog results in increased activity of NQO1 protein |
CTD |
PMID:20833222 PMID:20868228 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
|
G |
Acsl3 |
acyl-CoA synthetase long-chain family member 3 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of ACSL3 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 9:80,115,164...80,164,636
Ensembl chr 9:80,115,112...80,164,627
|
|
G |
Aldh1a2 |
aldehyde dehydrogenase 1 family, member A2 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of ALDH1A2 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 8:71,877,850...71,957,107
Ensembl chr 8:71,877,850...71,957,107
|
|
G |
Anpep |
alanyl aminopeptidase, membrane |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of ANPEP mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 1:133,767,332...133,810,137
Ensembl chr 1:133,767,332...133,785,789
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
EXP |
glycitin inhibits the reaction [APP protein binds to APP protein] |
CTD |
PMID:17323972 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Atoh8 |
atonal bHLH transcription factor 8 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of ATOH8 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 4:104,259,992...104,292,168
Ensembl chr 4:104,259,992...104,292,168
|
|
G |
Bckdk |
branched chain ketoacid dehydrogenase kinase |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of BCKDK mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 1:182,515,335...182,520,007
Ensembl chr 1:182,515,327...182,536,633
|
|
G |
Bpgm |
bisphosphoglycerate mutase |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of BPGM mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 4:63,139,730...63,168,581
Ensembl chr 4:63,140,018...63,168,581
|
|
G |
Cabp5 |
calcium binding protein 5 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of CABP5 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 1:74,350,811...74,363,830
Ensembl chr 1:74,350,811...74,363,830
|
|
G |
Cacybp |
calcyclin binding protein |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of CACYBP mRNA |
CTD |
PMID:27424125 |
|
NCBI chr13:72,437,485...72,447,810
Ensembl chr13:72,437,490...72,450,177
|
|
G |
Casp8ap2 |
caspase 8 associated protein 2 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of CASP8AP2 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 5:47,014,501...47,052,276
Ensembl chr 5:47,014,667...47,052,275
|
|
G |
Cd200r1 |
CD200 receptor 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of CD200R1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr11:55,886,937...55,921,217
Ensembl chr11:55,887,717...55,921,285
|
|
G |
Cfap251 |
cilia and flagella associated protein 251 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of CFAP251 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr12:33,261,622...33,337,028
Ensembl chr12:33,261,476...33,293,932
|
|
G |
Cybrd1 |
cytochrome b reductase 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of CYBRD1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 3:55,934,874...55,962,132
Ensembl chr 3:55,934,874...55,962,108
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
multiple interactions |
EXP |
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of CYP11A1 mRNA |
CTD |
PMID:28964809 |
|
NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338
|
|
G |
Dennd2d |
DENN domain containing 2D |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of DENND2D mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 2:193,973,231...193,992,275
Ensembl chr 2:193,973,231...193,992,270
|
|
G |
Dnmt1 |
DNA methyltransferase 1 |
multiple interactions |
EXP |
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in increased expression of DNMT1 mRNA |
CTD |
PMID:28964809 |
|
NCBI chr 8:19,440,611...19,486,659
Ensembl chr 8:19,440,611...19,486,659
|
|
G |
Dnmt3a |
DNA methyltransferase 3 alpha |
multiple interactions |
EXP |
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in increased expression of DNMT3A mRNA |
CTD |
PMID:28964809 |
|
NCBI chr 6:26,791,517...26,902,161
Ensembl chr 6:26,822,609...26,896,687
|
|
G |
Dpp9 |
dipeptidyl peptidase 9 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of DPP9 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 9:1,011,347...1,046,337
Ensembl chr 9:1,011,351...1,046,541
|
|
G |
Edrf1 |
erythroid differentiation regulatory factor 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of EDRF1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 1:188,441,514...188,478,743
Ensembl chr 1:188,441,634...188,478,701
|
|
G |
Efhd1 |
EF-hand domain family, member D1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of EFHD1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 9:87,938,259...87,984,917
Ensembl chr 9:87,938,284...87,984,917
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions |
EXP |
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in increased expression of ESR2 mRNA |
CTD |
PMID:28964809 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Fam171a2 |
family with sequence similarity 171, member A2 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of FAM171A2 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr10:87,393,888...87,404,051
Ensembl chr10:87,394,007...87,404,053
|
|
G |
Fam180a |
family with sequence similarity 180, member A |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of FAM180A mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 4:63,992,867...64,008,047
Ensembl chr 4:63,992,867...64,008,047
|
|
G |
Fam210b |
family with sequence similarity 210, member B |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of FAM210B mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 3:161,118,228...161,128,400
Ensembl chr 3:161,118,239...161,128,397
|
|
G |
Fam241b |
family with sequence similarity 241 member B |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of FAM241B mRNA |
CTD |
PMID:27424125 |
|
NCBI chr20:30,052,315...30,055,247
Ensembl chr20:30,052,324...30,055,084
|
|
G |
Fgd6 |
FYVE, RhoGEF and PH domain containing 6 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of FGD6 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 7:28,597,609...28,712,908
Ensembl chr 7:28,597,609...28,712,456
|
|
G |
Fhl2 |
four and a half LIM domains 2 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of FHL2 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 9:45,388,979...45,462,421
Ensembl chr 9:45,388,981...45,431,192
|
|
G |
Galnt15 |
polypeptide N-acetylgalactosaminyltransferase 15 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of GALNT15 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr16:7,227,232...7,267,002
Ensembl chr16:7,227,271...7,267,014
|
|
G |
Gng5 |
G protein subunit gamma 5 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of GNG5 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 2:235,394,680...235,403,177
Ensembl chr 1:77,292,043...77,292,513
|
|
G |
Hipk4 |
homeodomain interacting protein kinase 4 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of HIPK4 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 1:82,810,708...82,821,080
Ensembl chr 1:82,810,708...82,821,077
|
|
G |
Hmcn1 |
hemicentin 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of HMCN1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr13:62,615,461...63,084,524
Ensembl chr13:62,615,461...63,084,524
|
|
G |
Hsd3b1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
multiple interactions |
EXP |
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of HSD3B1 mRNA |
CTD |
PMID:28964809 |
|
NCBI chr 2:186,169,864...186,175,984
Ensembl chr 2:186,169,863...186,175,999
|
|
G |
Il6r |
interleukin 6 receptor |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of IL6R mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 2:175,289,157...175,347,719
Ensembl chr 2:175,298,686...175,347,536
|
|
G |
Isg20l2 |
interferon stimulated exonuclease gene 20-like 2 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of ISG20L2 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 2:173,396,780...173,407,102
Ensembl chr 2:173,396,780...173,406,614
|
|
G |
Kdm5a |
lysine demethylase 5A |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of KDM5A mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 4:153,565,909...153,643,912
Ensembl chr 4:153,565,846...153,642,422
|
|
G |
Kitlg |
KIT ligand |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of KITLG mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 7:34,896,075...34,977,215
Ensembl chr 7:34,896,053...34,977,214
|
|
G |
Knstrn |
kinetochore-localized astrin/SPAG5 binding protein |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of KNSTRN mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 3:105,800,762...105,820,555
Ensembl chr 3:105,800,954...105,820,715
|
|
G |
Ldlrap1 |
low density lipoprotein receptor adaptor protein 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of LDLRAP1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 5:146,955,607...146,978,601
Ensembl chr 5:146,955,607...146,978,601
|
|
G |
Lmod1 |
leiomodin 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of LMOD1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr13:46,754,048...46,796,186
Ensembl chr13:46,754,033...46,794,900
|
|
G |
Lrg1 |
leucine-rich alpha-2-glycoprotein 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of LRG1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 9:947,516...949,773
Ensembl chr 9:947,516...949,813
|
|
G |
Lsr |
lipolysis stimulated lipoprotein receptor |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of LSR mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 1:86,185,769...86,201,952
Ensembl chr 1:86,186,431...86,201,952
|
|
G |
Mrpl33 |
mitochondrial ribosomal protein L33 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of MRPL33 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 6:24,825,800...24,833,994
Ensembl chr 6:24,825,827...24,833,834
|
|
G |
Mtmr11 |
myotubularin related protein 11 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of MTMR11 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 2:183,721,983...183,732,148
Ensembl chr 2:183,723,530...183,732,148
|
|
G |
Myof |
myoferlin |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of MYOF mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 1:235,673,666...235,822,413
Ensembl chr 1:235,673,666...235,822,334
|
|
G |
Nr4a1 |
nuclear receptor subfamily 4, group A, member 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of NR4A1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 7:132,368,399...132,389,300
Ensembl chr 7:132,374,840...132,389,297
|
|
G |
Nr5a1 |
nuclear receptor subfamily 5, group A, member 1 |
multiple interactions |
EXP |
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of NR5A1 mRNA; [Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of NR5A1 protein; [Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in increased methylation of NR5A1 promoter; decitabine inhibits the reaction [[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of NR5A1 mRNA] |
CTD |
PMID:28964809 |
|
NCBI chr 3:22,464,786...22,486,328
Ensembl chr 3:22,465,502...22,486,328
|
|
G |
Prkaca |
protein kinase cAMP-activated catalytic subunit alpha |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of PRKACA mRNA |
CTD |
PMID:27424125 |
|
NCBI chr19:24,155,081...24,178,430
Ensembl chr19:24,155,090...24,178,430
|
|
G |
Prpf40a |
pre-mRNA processing factor 40 homolog A |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of PRPF40A mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 3:37,625,585...37,689,859
Ensembl chr 3:37,627,690...37,690,886
|
|
G |
Pspc1 |
paraspeckle component 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of PSPC1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr15:30,828,617...30,911,315
Ensembl chr15:30,828,626...30,911,202
|
|
G |
Pth1r |
parathyroid hormone 1 receptor |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of PTH1R mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 8:110,693,910...110,725,458
Ensembl chr 8:110,697,485...110,719,729
|
|
G |
Rassf5 |
Ras association domain family member 5 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of RASSF5 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr13:42,637,513...42,703,024
Ensembl chr13:42,637,549...42,703,024
|
|
G |
Rgs22 |
regulator of G-protein signaling 22 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of RGS22 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 7:67,188,531...67,308,805
Ensembl chr 7:67,188,519...67,308,875
|
|
G |
S1pr3 |
sphingosine-1-phosphate receptor 3 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of S1PR3 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr17:13,781,050...13,794,408
Ensembl chr17:13,781,050...13,794,505
|
|
G |
Selplg |
selectin P ligand |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of SELPLG mRNA |
CTD |
PMID:27424125 |
|
NCBI chr12:42,796,690...42,809,908
Ensembl chr12:42,796,580...42,812,585
|
|
G |
Siglec10 |
sialic acid binding Ig-like lectin 10 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of SIGLEC10 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 1:93,817,301...93,826,376
Ensembl chr 1:93,817,335...93,825,931
|
|
G |
Slc16a1 |
solute carrier family 16 member 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of SLC16A1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 2:192,123,755...192,144,617
Ensembl chr 2:192,124,289...192,144,611
|
|
G |
Snx30 |
sorting nexin family member 30 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of SNX30 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 5:74,683,902...74,813,013
Ensembl chr 5:74,684,015...74,792,631
|
|
G |
Ssc5d |
scavenger receptor cysteine rich family member with 5 domains |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] affects the expression of SSC5D mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 1:68,891,942...68,910,462
Ensembl chr 1:68,891,949...68,909,743
|
|
G |
Star |
steroidogenic acute regulatory protein |
multiple interactions |
EXP |
[Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of STAR mRNA; [Genistein co-treated with daidzein co-treated with glycitin co-treated with genistin co-treated with daidzin co-treated with glycitein] results in decreased expression of STAR protein |
CTD |
PMID:28964809 |
|
NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672
|
|
G |
Styxl1 |
serine/threonine/tyrosine interacting-like 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of STYXL1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr12:20,907,410...20,940,232
Ensembl chr12:20,907,435...20,939,752
|
|
G |
Sumo1 |
small ubiquitin-like modifier 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of SUMO1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 9:61,078,790...61,108,697
Ensembl chr 9:61,077,435...61,108,761
|
|
G |
Tc2n |
tandem C2 domains, nuclear |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of TC2N mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 6:120,761,112...120,856,835
Ensembl chr 6:120,761,119...120,849,326
|
|
G |
Tp53i11 |
tumor protein p53 inducible protein 11 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in decreased expression of TP53I11 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 3:79,144,824...79,160,056
Ensembl chr 3:79,144,895...79,160,050
|
|
G |
Vcpip1 |
valosin containing protein interacting protein 1 |
multiple interactions |
ISO |
[daidzein co-treated with daidzin co-treated with genistin co-treated with Genistein co-treated with glycitin co-treated with glycitein] results in increased expression of VCPIP1 mRNA |
CTD |
PMID:27424125 |
|
NCBI chr 5:9,534,247...9,560,889
Ensembl chr 5:9,534,129...9,562,040
|
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
increases phosphorylation multiple interactions |
ISO |
gypenoside LXXV results in increased phosphorylation of AKT1 protein 2-chloro-5-nitrobenzanilide inhibits the reaction [gypenoside LXXV results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:35192202 PMID:36325883 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
gypenoside LXXV inhibits the reaction [LEPR gene mutant form results in increased expression of CCL2 protein] |
CTD |
PMID:35192202 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccn2 |
cellular communication network factor 2 |
multiple interactions increases expression |
ISO |
gypenoside LXXV results in increased expression of and results in increased secretion of CTGF protein gypenoside LXXV results in increased expression of CTGF mRNA |
CTD |
PMID:31018484 |
|
NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
gypenoside LXXV inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; gypenoside LXXV inhibits the reaction [LEPR gene mutant form results in increased expression of IL1B protein] |
CTD |
PMID:33050067 PMID:35192202 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
gypenoside LXXV inhibits the reaction [LEPR gene mutant form results in increased expression of IL6 protein] |
CTD |
PMID:35192202 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Irs1 |
insulin receptor substrate 1 |
decreases phosphorylation multiple interactions |
ISO |
gypenoside LXXV results in decreased phosphorylation of IRS1 protein 2-chloro-5-nitrobenzanilide inhibits the reaction [gypenoside LXXV results in decreased expression of and results in decreased phosphorylation of IRS1 protein]; gypenoside LXXV results in decreased expression of and results in decreased phosphorylation of IRS1 protein |
CTD |
PMID:35192202 PMID:36325883 |
|
NCBI chr 9:83,552,964...83,605,797
Ensembl chr 9:83,548,944...83,606,122
|
|
G |
Lepr |
leptin receptor |
multiple interactions |
ISO |
gypenoside LXXV inhibits the reaction [LEPR gene mutant form results in increased expression of CCL2 protein]; gypenoside LXXV inhibits the reaction [LEPR gene mutant form results in increased expression of IL1B protein]; gypenoside LXXV inhibits the reaction [LEPR gene mutant form results in increased expression of IL6 protein]; gypenoside LXXV inhibits the reaction [LEPR gene mutant form results in increased expression of TNF protein] |
CTD |
PMID:35192202 |
|
NCBI chr 5:116,294,409...116,477,904
Ensembl chr 5:116,289,823...116,475,908
|
|
G |
Nr3c2 |
nuclear receptor subfamily 3, group C, member 2 |
multiple interactions |
ISO |
gypenoside LXXV binds to and affects the localization of NR3C2 protein |
CTD |
PMID:31018484 |
|
NCBI chr19:30,715,634...31,059,885
Ensembl chr19:30,715,648...31,059,885
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
increases expression multiple interactions |
ISO EXP |
gypenoside LXXV results in increased expression of PPARG protein 2-chloro-5-nitrobenzanilide inhibits the reaction [gypenoside LXXV results in increased expression of PPARG protein] 2-chloro-5-nitrobenzanilide inhibits the reaction [gypenoside LXXV binds to and results in increased activity of PPARG protein]; gypenoside LXXV binds to and results in increased activity of PPARG protein |
CTD |
PMID:35192202 PMID:36325883 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
gypenoside LXXV results in decreased expression of and results in decreased phosphorylation of RELA protein |
CTD |
PMID:33050067 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Slc2a4 |
solute carrier family 2 member 4 |
affects localization increases expression multiple interactions |
ISO |
gypenoside LXXV affects the localization of SLC2A4 protein gypenoside LXXV results in increased expression of SLC2A4 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [gypenoside LXXV affects the localization of SLC2A4 protein]; 2-chloro-5-nitrobenzanilide inhibits the reaction [gypenoside LXXV affects the localization of SLC2A4 protein]; 2-chloro-5-nitrobenzanilide inhibits the reaction [gypenoside LXXV results in increased expression of SLC2A4 protein] |
CTD |
PMID:35192202 PMID:36325883 |
|
NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
decreases expression |
ISO |
gypenoside LXXV results in decreased expression of TGFB1 protein |
CTD |
PMID:33050067 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
gypenoside LXXV inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of TNF protein]; gypenoside LXXV inhibits the reaction [LEPR gene mutant form results in increased expression of TNF protein]; gypenoside LXXV inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA] |
CTD |
PMID:33050067 PMID:35192202 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Abca13 |
ATP binding cassette subfamily A member 13 |
decreases expression |
ISO |
Arbutin results in decreased expression of ABCA13 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr14:83,873,397...84,376,138
Ensembl chr14:83,873,940...84,375,075
|
|
G |
Abca8a |
ATP-binding cassette, subfamily A (ABC1), member 8a |
decreases expression |
ISO |
Arbutin results in decreased expression of ABCA10 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr10:95,002,334...95,072,315
Ensembl chr10:95,002,334...95,072,375
|
|
G |
Acmsd |
aminocarboxymuconate semialdehyde decarboxylase |
decreases expression |
ISO |
Arbutin results in decreased expression of ACMSD mRNA |
CTD |
PMID:17103032 |
|
NCBI chr13:39,200,412...39,245,954
Ensembl chr13:39,200,314...39,245,209
|
|
G |
Acvrl1 |
activin A receptor like type 1 |
decreases expression |
ISO |
Arbutin results in decreased expression of ACVRL1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 7:132,239,200...132,256,592
Ensembl chr 7:132,239,729...132,256,591
|
|
G |
Adam19 |
ADAM metallopeptidase domain 19 |
decreases expression |
ISO |
Arbutin results in decreased expression of ADAM19 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr10:30,491,362...30,583,115
Ensembl chr10:30,491,405...30,583,105
|
|
G |
Adam7 |
ADAM metallopeptidase domain 7 |
increases expression |
ISO |
Arbutin results in increased expression of ADAM7 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr15:42,833,796...42,882,201
Ensembl chr15:42,833,796...42,882,201
|
|
G |
Adamts3 |
ADAM metallopeptidase with thrombospondin type 1, motif 3 |
decreases expression |
ISO |
Arbutin results in decreased expression of ADAMTS3 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr14:18,231,128...18,437,771
Ensembl chr14:18,231,165...18,435,556
|
|
G |
Adamts9 |
ADAM metallopeptidase with thrombospondin type 1 motif, 9 |
decreases expression |
ISO |
Arbutin results in decreased expression of ADAMTS9 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 4:125,290,633...125,462,988
Ensembl chr 4:125,291,490...125,462,929
|
|
G |
Adrb3 |
adrenoceptor beta 3 |
decreases expression |
ISO |
Arbutin results in decreased expression of ADRB3 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr16:64,839,820...64,844,552
Ensembl chr16:64,841,788...64,844,552
|
|
G |
Aebp2 |
AE binding protein 2 |
increases expression |
ISO |
Arbutin results in increased expression of AEBP2 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 4:173,527,881...173,566,033
Ensembl chr 4:173,528,344...173,593,100
|
|
G |
Afap1 |
actin filament associated protein 1 |
decreases expression |
ISO |
Arbutin results in decreased expression of AFAP1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr14:74,743,322...74,856,300
Ensembl chr14:74,743,320...74,856,263
|
|
G |
Agbl4 |
AGBL carboxypeptidase 4 |
decreases expression |
ISO |
Arbutin results in decreased expression of AGBL4 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 5:125,254,963...126,534,367
Ensembl chr 5:125,254,956...126,534,367
|
|
G |
Agpat3 |
1-acylglycerol-3-phosphate O-acyltransferase 3 |
decreases expression |
ISO |
Arbutin results in decreased expression of AGPAT3 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr20:10,330,960...10,415,358
Ensembl chr20:10,384,507...10,415,358
|
|
G |
Ahnak |
AHNAK nucleoprotein |
decreases expression |
ISO |
Arbutin results in decreased expression of AHNAK mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 1:205,882,225...205,970,934
Ensembl chr 1:205,882,273...205,970,926
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
decreases expression |
ISO |
Arbutin results in decreased expression of AKT1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alb |
albumin |
multiple interactions |
ISO |
ALB protein binds to and affects the transport of Arbutin |
CTD |
PMID:8831264 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Amtn |
amelotin |
decreases expression |
ISO |
Arbutin results in decreased expression of AMTN mRNA |
CTD |
PMID:17103032 |
|
NCBI chr14:19,648,624...19,661,181
Ensembl chr14:19,648,625...19,661,181
|
|
G |
Ankrd17 |
ankyrin repeat domain 17 |
increases expression |
ISO |
Arbutin results in increased expression of ANKRD17 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr14:17,723,239...17,861,841
Ensembl chr14:17,721,932...17,862,617
|
|
G |
Ankrd23 |
ankyrin repeat domain 23 |
increases expression |
ISO |
Arbutin results in increased expression of ANKRD23 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 9:38,773,234...38,778,705
Ensembl chr 9:38,773,240...38,779,839
|
|
G |
Ap1s1 |
adaptor related protein complex 1 subunit sigma 1 |
decreases expression |
ISO |
Arbutin results in decreased expression of AP1S1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr12:19,625,267...19,635,792
Ensembl chr12:19,625,332...19,756,713
|
|
G |
Apom |
apolipoprotein M |
increases expression |
ISO |
Arbutin results in increased expression of APOM mRNA |
CTD |
PMID:17103032 |
|
NCBI chr20:3,690,950...3,693,550
Ensembl chr20:3,688,413...3,693,550
|
|
G |
Aptx |
aprataxin |
decreases expression |
ISO |
Arbutin results in decreased expression of APTX mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 5:55,798,896...55,822,963
Ensembl chr 5:55,800,248...55,822,855
|
|
G |
Arfip2 |
ADP-ribosylation factor interacting protein 2 |
decreases expression |
ISO |
Arbutin results in decreased expression of ARFIP2 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 1:159,974,255...159,980,398
Ensembl chr 1:159,974,201...159,980,336
|
|
G |
Arhgef2 |
Rho/Rac guanine nucleotide exchange factor 2 |
decreases expression |
ISO |
Arbutin results in decreased expression of ARHGEF2 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 2:174,061,126...174,118,355
Ensembl chr 2:174,062,976...174,118,355
|
|
G |
Arl2 |
ADP-ribosylation factor like GTPase 2 |
decreases expression |
ISO |
Arbutin results in decreased expression of ARL2 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 1:203,434,129...203,446,156
Ensembl chr 1:203,434,129...203,446,119
|
|
G |
Arl6ip1 |
ADP-ribosylation factor like GTPase 6 interacting protein 1 |
increases expression |
ISO |
Arbutin results in increased expression of ARL6IP1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 1:172,430,475...172,439,990
Ensembl chr 1:172,430,489...172,439,994
|
|
G |
Arx |
aristaless related homeobox |
decreases expression |
ISO |
Arbutin results in decreased expression of ARX mRNA |
CTD |
PMID:17103032 |
|
NCBI chr X:58,016,233...58,028,149
Ensembl chr X:58,016,233...58,028,142
|
|
G |
Asap1 |
ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 |
increases expression |
ISO |
Arbutin results in increased expression of ASAP1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 7:95,786,130...96,093,111
Ensembl chr 7:95,787,818...96,092,754
|
|
G |
Asap3 |
ArfGAP with SH3 domain, ankyrin repeat and PH domain 3 |
decreases expression |
ISO |
Arbutin results in decreased expression of ASAP3 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 5:148,433,382...148,476,027
Ensembl chr 5:148,433,494...148,474,073
|
|
G |
Atf6b |
activating transcription factor 6 beta |
decreases expression |
ISO |
Arbutin results in decreased expression of ATF6B mRNA |
CTD |
PMID:17103032 |
|
NCBI chr20:4,090,921...4,098,920
Ensembl chr20:4,090,921...4,098,894
|
|
G |
B4galnt4 |
beta-1,4-N-acetyl-galactosaminyl transferase 4 |
decreases expression |
ISO |
Arbutin results in decreased expression of B4GALNT4 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 1:196,171,394...196,182,294
Ensembl chr 1:196,171,394...196,182,294
|
|
G |
Bag5 |
BAG cochaperone 5 |
decreases expression |
ISO |
Arbutin results in decreased expression of BAG5 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 6:130,768,467...130,772,122
Ensembl chr 6:130,768,141...130,772,970
|
|
G |
Bcas2 |
BCAS2, pre-mRNA processing factor |
increases expression |
ISO |
Arbutin results in increased expression of BCAS2 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 2:190,692,503...190,700,386
Ensembl chr 2:190,692,461...190,700,389
|
|
G |
Bckdk |
branched chain ketoacid dehydrogenase kinase |
decreases expression |
ISO |
Arbutin results in decreased expression of BCKDK mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 1:182,515,335...182,520,007
Ensembl chr 1:182,515,327...182,536,633
|
|
G |
Bmpr1b |
bone morphogenetic protein receptor type 1B |
decreases expression |
ISO |
Arbutin results in decreased expression of BMPR1B mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 2:230,538,252...230,871,077
Ensembl chr 2:230,541,558...230,871,368
|
|
G |
Bnip2 |
BCL2 interacting protein 2 |
increases expression |
ISO |
Arbutin results in increased expression of BNIP2 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 8:70,640,436...70,661,782
Ensembl chr 8:70,640,445...70,675,590
|
|
G |
Brsk1 |
BR serine/threonine kinase 1 |
decreases expression |
ISO |
Arbutin results in decreased expression of BRSK1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 1:69,134,166...69,159,947
Ensembl chr 1:69,134,565...69,160,365
|
|
G |
Bst2 |
bone marrow stromal cell antigen 2 |
decreases expression |
ISO |
Arbutin results in decreased expression of BST2 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr16:18,216,605...18,220,979
Ensembl chr16:18,217,407...18,220,979
|
|
G |
C1h19orf33 |
similar to human chromosome 19 open reading frame 33 |
decreases expression |
ISO |
Arbutin results in decreased expression of C19ORF33 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 1:84,549,830...84,550,666
Ensembl chr 1:84,549,831...84,550,664
|
|
G |
C1qb |
complement C1q B chain |
decreases expression |
ISO |
Arbutin results in decreased expression of C1QB mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 5:149,118,843...149,124,394
Ensembl chr 5:149,118,846...149,124,407
|
|
G |
C5h1orf87 |
similar to human chromosome 1 open reading frame 87 |
decreases expression |
ISO |
Arbutin results in decreased expression of C1ORF87 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 5:111,342,381...111,411,576
Ensembl chr 5:111,342,387...111,411,590
|
|
G |
Cacng7 |
calcium voltage-gated channel auxiliary subunit gamma 7 |
decreases expression |
ISO |
Arbutin results in decreased expression of CACNG7 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 1:65,800,059...65,831,246
Ensembl chr 1:65,800,355...65,831,006
|
|
G |
Capns2 |
calpain, small subunit 2 |
increases expression |
ISO |
Arbutin results in increased expression of CAPNS2 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr19:14,104,334...14,105,276
|
|
G |
Casp8 |
caspase 8 |
decreases expression |
ISO |
Arbutin results in decreased expression of CASP8 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
Arbutin inhibits the reaction [potassium bromate results in decreased activity of CAT protein] |
CTD |
PMID:36284482 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cbx6 |
chromobox 6 |
decreases expression |
ISO |
Arbutin results in decreased expression of CBX6 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 7:111,372,979...111,383,026
Ensembl chr 7:111,372,980...111,383,091
|
|
G |
Ccar1 |
cell division cycle and apoptosis regulator 1 |
increases expression |
ISO |
Arbutin results in increased expression of CCAR1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr20:30,685,916...30,728,531
Ensembl chr20:30,685,916...30,728,526
|
|
G |
Ccdc170 |
coiled-coil domain containing 170 |
decreases expression |
ISO |
Arbutin results in decreased expression of CCDC170 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 1:40,945,607...41,050,010
Ensembl chr 1:40,945,961...41,085,040
|
|
G |
Ccdc28b |
coiled coil domain containing 28B |
decreases expression |
ISO |
Arbutin results in decreased expression of CCDC28B mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 5:141,962,275...141,967,278
Ensembl chr 5:141,962,276...141,967,382
|
|
G |
Ccnyl1 |
cyclin Y-like 1 |
increases expression |
ISO |
Arbutin results in increased expression of CCNYL1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 9:66,071,721...66,121,742
Ensembl chr 9:66,071,543...66,107,999
|
|
G |
Cct8 |
chaperonin containing TCP1 subunit 8 |
increases expression |
ISO |
Arbutin results in increased expression of CCT8 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr11:26,710,370...26,722,079
Ensembl chr11:26,710,370...26,722,079
|
|
G |
Cd151 |
CD151 molecule (Raph blood group) |
decreases expression |
ISO |
Arbutin results in decreased expression of CD151 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 1:196,564,744...196,568,753
Ensembl chr 1:196,565,181...196,568,753
|
|
G |
Cd160 |
CD160 molecule |
decreases expression |
ISO |
Arbutin results in decreased expression of CD160 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 2:184,340,820...184,383,421
Ensembl chr 2:184,340,599...184,375,834
|
|
G |
Cd2bp2 |
Cd2 (cytoplasmic tail) binding protein 2 |
decreases expression |
ISO |
Arbutin results in decreased expression of CD2BP2 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 1:181,809,399...181,815,269
Ensembl chr 1:181,809,406...181,813,448
|
|
G |
Cd3g |
CD3 gamma subunit of T-cell receptor complex |
decreases expression |
ISO |
Arbutin results in decreased expression of CD3G mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 8:45,280,797...45,287,271
Ensembl chr 8:45,281,204...45,287,147
|
|
G |
Cdin1 |
CDAN1 interacting nuclease 1 |
increases expression |
ISO |
Arbutin results in increased expression of CDIN1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 3:102,441,553...102,646,935
Ensembl chr 3:102,441,704...102,646,682
|
|
G |
Cdk16 |
cyclin-dependent kinase 16 |
decreases expression |
ISO |
Arbutin results in decreased expression of CDK16 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr X:1,492,814...1,504,309
Ensembl chr X:1,492,814...1,504,148
|
|
G |
Ceacam1 |
CEA cell adhesion molecule 1 |
decreases expression |
ISO |
Arbutin results in decreased expression of CEACAM1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 1:81,043,595...81,060,050
Ensembl chr 1:81,043,595...81,059,992
|
|
G |
Cfap161 |
cilia and flagella associated protein 161 |
decreases expression |
ISO |
Arbutin results in decreased expression of CFAP161 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 1:137,743,783...137,768,685
Ensembl chr 1:137,743,784...137,768,730
|
|
G |
Cfap70 |
cilia and flagella associated protein 70 |
decreases expression |
ISO |
Arbutin results in decreased expression of CFAP70 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr15:3,852,381...3,918,036
Ensembl chr15:3,852,509...3,918,014
|
|
G |
Clec2ml1 |
C-type lectin domain family 2, member M like 1 |
increases expression |
ISO |
Arbutin results in increased expression of KLRC4 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 4:162,768,988...162,779,951
Ensembl chr 4:162,768,994...162,779,899
|
|
G |
Clec4b2 |
C-type lectin domain family 4, member B2 |
decreases expression |
ISO |
Arbutin results in decreased expression of CLEC4C mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 4:156,462,742...156,486,240
Ensembl chr 4:156,462,742...156,486,240
|
|
G |
Cnksr2 |
connector enhancer of kinase suppressor of Ras 2 |
decreases expression |
ISO |
Arbutin results in decreased expression of CNKSR2 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr X:36,908,135...37,148,337
Ensembl chr X:36,907,850...37,150,555
|
|
G |
Col17a1 |
collagen type XVII alpha 1 chain |
decreases expression |
ISO |
Arbutin results in decreased expression of COL17A1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 1:246,530,589...246,577,559
Ensembl chr 1:246,531,367...246,577,632
|
|
G |
Cpb1 |
carboxypeptidase B1 |
decreases expression |
ISO |
Arbutin results in decreased expression of CPB1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 2:102,755,241...102,785,628
Ensembl chr 2:102,755,241...102,785,628
|
|
G |
Cpe |
carboxypeptidase E |
increases expression |
ISO |
Arbutin results in increased expression of CPE mRNA |
CTD |
PMID:17103032 |
|
NCBI chr16:25,030,276...25,142,231
Ensembl chr16:25,030,276...25,142,233
|
|
G |
Cpne5 |
copine 5 |
increases expression |
ISO |
Arbutin results in increased expression of CPNE5 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr20:7,206,742...7,289,309
Ensembl chr20:7,206,742...7,288,883
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
decreases expression |
EXP |
Arbutin results in decreased expression of CYP17A1 mRNA; Arbutin results in decreased expression of CYP17A1 protein |
CTD |
PMID:37783241 |
|
NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
|
|
G |
Cyp2u1 |
cytochrome P450, family 2, subfamily u, polypeptide 1 |
increases expression |
ISO |
Arbutin results in increased expression of CYP2U1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 2:219,849,403...219,866,959
Ensembl chr 2:219,849,407...219,866,882
|
|
G |
Cyrib |
CYFIP related Rac1 interactor B |
increases expression |
ISO |
Arbutin results in increased expression of CYRIB mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 7:95,633,876...95,760,588
Ensembl chr 7:95,633,876...95,697,686
|
|
G |
Ddx46 |
DEAD-box helicase 46 |
increases expression |
ISO |
Arbutin results in increased expression of DDX46 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr17:8,942,070...8,988,440
Ensembl chr17:8,944,454...8,988,439
|
|
G |
Diaph2 |
diaphanous-related formin 2 |
decreases expression |
ISO |
Arbutin results in decreased expression of DIAPH2 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr X:92,395,189...93,234,521
Ensembl chr X:92,395,251...93,229,869
|
|
G |
Dlgap4 |
DLG associated protein 4 |
increases expression |
ISO |
Arbutin results in increased expression of DLGAP4 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 3:145,124,189...145,271,791
Ensembl chr 3:145,175,479...145,270,490
|
|
G |
Dlx1 |
distal-less homeobox 1 |
decreases expression |
ISO |
Arbutin results in decreased expression of DLX1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 3:56,356,190...56,360,780
Ensembl chr 3:56,356,190...56,360,780
|
|
G |
Dmxl1 |
Dmx-like 1 |
decreases expression |
ISO |
Arbutin results in decreased expression of DMXL1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr18:42,993,292...43,163,457
Ensembl chr18:42,993,340...43,163,456
|
|
G |
Dnah7 |
dynein, axonemal, heavy chain 7 |
decreases expression |
ISO |
Arbutin results in decreased expression of DNAH7 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 9:54,960,235...55,266,529
Ensembl chr 9:54,960,440...55,262,297
|
|
G |
Dnai3 |
dynein axonemal intermediate chain 3 |
decreases expression |
ISO |
Arbutin results in decreased expression of DNAI3 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 2:234,947,910...235,006,173
Ensembl chr 2:234,929,677...235,006,173
|
|
G |
Dnajb9 |
DnaJ heat shock protein family (Hsp40) member B9 |
increases expression |
ISO |
Arbutin results in increased expression of DNAJB9 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 6:61,270,385...61,276,795
Ensembl chr 6:61,269,913...61,275,063
|
|
G |
Dpp7 |
dipeptidylpeptidase 7 |
decreases expression |
ISO |
Arbutin results in decreased expression of DPP7 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 3:8,165,091...8,169,343
Ensembl chr 3:8,165,091...8,169,355
|
|
G |
Dpysl2 |
dihydropyrimidinase-like 2 |
decreases expression |
ISO |
Arbutin results in decreased expression of DPYSL2 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr15:41,005,551...41,111,724
Ensembl chr15:41,005,551...41,111,829
|
|
G |
Ece1 |
endothelin converting enzyme 1 |
increases expression |
ISO |
Arbutin results in increased expression of ECE1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 5:150,077,679...150,179,375
Ensembl chr 5:150,077,644...150,179,371
|
|
G |
Eepd1 |
endonuclease/exonuclease/phosphatase family domain containing 1 |
increases expression |
ISO |
Arbutin results in increased expression of EEPD1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 8:23,957,258...24,064,343
Ensembl chr 8:23,957,255...24,064,340
|
|
G |
Efhc2 |
EF-hand domain containing 2 |
decreases expression |
ISO |
Arbutin results in decreased expression of EFHC2 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr X:5,360,499...5,564,004
Ensembl chr X:5,360,617...5,560,970
|
|
G |
Efl1 |
elongation factor like GTPase 1 |
increases expression |
ISO |
Arbutin results in increased expression of EFL1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 1:136,638,527...136,763,518
Ensembl chr 1:136,638,527...136,763,518
|
|
G |
Efna3 |
ephrin A3 |
decreases expression |
ISO |
Arbutin results in decreased expression of EFNA3 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 2:174,729,192...174,738,111
Ensembl chr 2:174,729,764...174,738,736
|
|
G |
Efs |
embryonal Fyn-associated substrate |
decreases expression |
ISO |
Arbutin results in decreased expression of EFS mRNA |
CTD |
PMID:17103032 |
|
NCBI chr15:28,392,417...28,403,016
Ensembl chr15:28,392,187...28,401,902
|
|
G |
Eid1 |
EP300 interacting inhibitor of differentiation 1 |
increases expression |
ISO |
Arbutin results in increased expression of EID1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 3:112,922,961...112,924,680
Ensembl chr 3:112,922,668...112,924,752
|
|
G |
Elane |
elastase, neutrophil expressed |
decreases expression |
ISO |
Arbutin results in decreased expression of ELANE mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 7:9,817,251...9,819,174
Ensembl chr 7:9,817,252...9,819,100
|
|
G |
Emx2 |
empty spiracles homeobox 2 |
decreases expression |
ISO |
Arbutin results in decreased expression of EMX2 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 1:258,626,584...258,633,594
Ensembl chr 1:258,626,584...258,633,594
|
|
G |
Enpp1 |
ectonucleotide pyrophosphatase/phosphodiesterase 1 |
decreases expression |
ISO |
Arbutin results in decreased expression of ENPP1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 1:20,698,746...20,763,741
Ensembl chr 1:20,698,764...20,763,715
|
|
G |
Eps8 |
EGFR pathway substrate 8, signaling adaptor |
increases expression |
ISO |
Arbutin results in increased expression of EPS8 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 4:170,388,378...170,486,873
Ensembl chr 4:170,388,378...170,486,873
|
|
G |
Epx |
eosinophil peroxidase |
increases expression |
ISO |
Arbutin results in increased expression of EPX mRNA |
CTD |
PMID:17103032 |
|
NCBI chr10:72,666,865...72,677,952
Ensembl chr10:72,666,865...72,677,952
|
|
G |
Erc1 |
ELKS/RAB6-interacting/CAST family member 1 |
increases expression |
ISO |
Arbutin results in increased expression of ERC1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 4:152,763,664...153,055,724
Ensembl chr 4:152,767,419...153,055,639
|
|
G |
Esr2 |
estrogen receptor 2 |
increases expression |
ISO |
Arbutin results in increased expression of ESR2 protein |
CTD |
PMID:29360751 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Evi2b |
ecotropic viral integration site 2B |
decreases expression |
ISO |
Arbutin results in decreased expression of EVI2B mRNA |
CTD |
PMID:17103032 |
|
NCBI chr10:64,472,693...64,474,311
Ensembl chr10:64,471,505...64,481,560
|
|
G |
Exd1 |
exonuclease 3'-5' domain containing 1 |
decreases expression |
ISO |
Arbutin results in decreased expression of EXD1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 3:106,507,839...106,535,922
Ensembl chr 3:106,508,076...106,535,922
|
|
G |
F13b |
coagulation factor XIII B chain |
decreases expression |
ISO |
Arbutin results in decreased expression of F13B mRNA |
CTD |
PMID:17103032 |
|
NCBI chr13:51,130,908...51,156,383
Ensembl chr13:51,130,920...51,156,381
|
|
G |
Fam3d |
FAM3 metabolism regulating signaling molecule D |
decreases expression |
ISO |
Arbutin results in decreased expression of FAM3D mRNA |
CTD |
PMID:17103032 |
|
NCBI chr15:16,538,881...16,574,468
Ensembl chr15:16,539,489...16,573,034
|
|
G |
Fancd2os |
FANCD2 opposite strand |
decreases expression |
ISO |
Arbutin results in decreased expression of FANCD2OS mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 4:146,740,863...146,747,547
Ensembl chr 4:146,740,863...146,747,569
|
|
G |
Faslg |
Fas ligand |
decreases expression |
ISO |
Arbutin results in decreased expression of FASLG mRNA |
CTD |
PMID:17103032 |
|
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Fbxo11 |
F-box protein 11 |
increases expression |
ISO |
Arbutin results in increased expression of FBXO11 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 6:6,486,761...6,562,664
Ensembl chr 6:6,486,015...6,562,662
|
|
G |
Fbxo16 |
F-box protein 16 |
increases expression |
ISO |
Arbutin results in increased expression of FBXO16 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr15:39,492,268...39,541,493
Ensembl chr15:39,492,377...39,541,480
|
|
G |
Fgf5 |
fibroblast growth factor 5 |
decreases expression |
ISO |
Arbutin results in decreased expression of FGF5 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr14:11,323,827...11,346,164
Ensembl chr14:11,325,334...11,345,997
|
|
G |
Fgfr3 |
fibroblast growth factor receptor 3 |
decreases expression |
ISO |
Arbutin results in decreased expression of FGFR3 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr14:76,987,242...77,002,671
Ensembl chr14:76,987,993...77,003,341
|
|
G |
Fmnl3 |
formin-like 3 |
decreases expression |
ISO |
Arbutin results in decreased expression of FMNL3 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 7:130,454,270...130,505,626
Ensembl chr 7:130,454,275...130,505,626
|
|
G |
Fpgt |
fucose-1-phosphate guanylyltransferase |
decreases expression |
ISO |
Arbutin results in decreased expression of FPGT mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 2:244,099,031...244,119,967
Ensembl chr 2:244,099,076...244,119,899
|
|
G |
Fras1 |
Fraser extracellular matrix complex subunit 1 |
decreases expression |
ISO |
Arbutin results in decreased expression of FRAS1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr14:12,791,407...13,200,862
Ensembl chr14:12,793,599...13,200,726
|
|
G |
Frmpd4 |
FERM and PDZ domain containing 4 |
decreases expression |
ISO |
Arbutin results in decreased expression of FRMPD4 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr X:25,853,849...26,814,642
Ensembl chr X:25,853,934...26,814,637
|
|
G |
Fshb |
follicle stimulating hormone subunit beta |
increases expression |
ISO |
Arbutin results in increased expression of FSHB protein |
CTD |
PMID:29360751 |
|
NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370
|
|
G |
Galc |
galactosylceramidase |
increases expression |
ISO |
Arbutin results in increased expression of GALC mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 6:117,452,888...117,522,281
Ensembl chr 6:117,452,895...117,515,830
|
|
G |
Garem1 |
GRB2 associated regulator of MAPK1 subtype 1 |
increases expression |
ISO |
Arbutin results in increased expression of GAREM1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr18:12,420,169...12,585,323
Ensembl chr18:12,423,882...12,585,345
|
|
G |
Get3 |
guided entry of tail-anchored proteins factor 3, ATPase |
decreases expression |
ISO |
Arbutin results in decreased expression of GET3 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr19:23,130,109...23,138,196
Ensembl chr19:23,130,109...23,138,193
|
|
G |
Gipc1 |
GIPC PDZ domain containing family, member 1 |
decreases expression |
ISO |
Arbutin results in decreased expression of GIPC1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr19:24,474,291...24,487,083
Ensembl chr19:24,453,123...24,486,997
|
|
G |
Glt8d2 |
glycosyltransferase 8 domain containing 2 |
decreases expression |
ISO |
Arbutin results in decreased expression of GLT8D2 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 7:21,029,534...21,081,081
Ensembl chr 7:21,029,525...21,081,080
|
|
G |
Gmpr |
guanosine monophosphate reductase |
decreases expression |
ISO |
Arbutin results in decreased expression of GMPR mRNA |
CTD |
PMID:17103032 |
|
NCBI chr17:19,151,820...19,189,626
Ensembl chr17:19,151,815...19,189,621
|
|
G |
Gnl2 |
G protein nucleolar 2 |
increases expression |
ISO |
Arbutin results in increased expression of GNL2 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 5:137,293,141...137,318,528
Ensembl chr 5:137,293,081...137,318,526
|
|
G |
Gpc3 |
glypican 3 |
decreases expression |
ISO |
Arbutin results in decreased expression of GPC3 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr X:131,868,986...132,236,824
Ensembl chr X:131,868,990...132,236,798
|
|
G |
Gpd2 |
glycerol-3-phosphate dehydrogenase 2 |
increases expression |
ISO |
Arbutin results in increased expression of GPD2 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 3:41,800,552...41,937,729
Ensembl chr 3:41,801,930...41,936,901
|
|
G |
Gper1 |
G protein-coupled estrogen receptor 1 |
increases expression |
ISO |
Arbutin results in increased expression of GPER1 protein |
CTD |
PMID:29360751 |
|
NCBI chr12:15,217,217...15,222,679
Ensembl chr12:15,217,442...15,221,889
|
|
G |
Gpr155 |
G protein-coupled receptor 155 |
decreases expression |
ISO |
Arbutin results in decreased expression of GPR155 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 3:58,216,422...58,270,350
Ensembl chr 3:58,216,423...58,270,275
|
|
G |
Gpr26 |
G protein-coupled receptor 26 |
decreases expression |
ISO |
Arbutin results in decreased expression of GPR26 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 1:186,766,001...186,805,435
Ensembl chr 1:186,767,062...186,784,568
|
|
G |
Gpr32 |
G protein-coupled receptor 32 |
increases expression |
ISO |
Arbutin results in increased expression of GPR32 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 1:94,756,863...94,757,895
|
|
G |
Gpr55 |
G protein-coupled receptor 55 |
decreases expression |
ISO |
Arbutin results in decreased expression of GPR55 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 9:86,584,906...86,640,601
Ensembl chr 9:86,590,885...86,640,613
|
|
G |
Gprc5d |
G protein-coupled receptor, class C, group 5, member D |
decreases expression |
ISO |
Arbutin results in decreased expression of GPRC5D mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 4:167,943,523...167,955,616
Ensembl chr 4:167,943,523...167,955,616
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
ISO EXP |
Arbutin inhibits the reaction [Ethanol results in increased expression of GPT protein] |
CTD |
PMID:34346143 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gsdma |
gasdermin A |
decreases expression |
ISO |
Arbutin results in decreased expression of GSDMA mRNA |
CTD |
PMID:17103032 |
|
NCBI chr10:83,614,336...83,639,543
Ensembl chr10:83,627,051...83,639,543
|
|
G |
Gucy1a2 |
guanylate cyclase 1 soluble subunit alpha 2 |
decreases expression |
ISO |
Arbutin results in decreased expression of GUCY1A2 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 8:500,212...900,201
Ensembl chr 8:500,212...889,203
|
|
G |
H1f1 |
H1.1 linker histone, cluster member |
increases expression |
ISO |
Arbutin results in increased expression of H1-1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr17:41,366,268...41,367,011
Ensembl chr17:41,366,268...41,367,011
|
|
G |
Hand1 |
heart and neural crest derivatives expressed 1 |
increases expression |
ISO |
Arbutin results in increased expression of HAND1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr10:42,006,646...42,009,213
Ensembl chr10:42,006,651...42,009,213
|
|
G |
Hist1h2al1 |
histone cluster 1 H2A family like 1 |
increases expression |
ISO |
Arbutin results in increased expression of H2AC6 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr17:42,707,954...42,708,420
|
|
G |
Hlf |
HLF transcription factor, PAR bZIP family member |
decreases expression |
ISO |
Arbutin results in decreased expression of HLF mRNA |
CTD |
PMID:17103032 |
|
NCBI chr10:75,154,244...75,211,884
Ensembl chr10:75,154,507...75,211,935
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
EXP |
Arbutin inhibits the reaction [Ethanol results in decreased expression of HMOX1 mRNA] |
CTD |
PMID:34346143 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hoxb8 |
homeo box B8 |
decreases expression |
ISO |
Arbutin results in decreased expression of HOXB8 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr10:81,248,313...81,251,261
Ensembl chr10:81,248,887...81,250,638
|
|
G |
Hps3 |
HPS3, biogenesis of lysosomal organelles complex 2 subunit 1 |
decreases expression |
ISO |
Arbutin results in decreased expression of HPS3 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 2:102,484,574...102,527,580
Ensembl chr 2:102,484,574...102,526,047
|
|
G |
Hsd3b1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
decreases expression |
ISO EXP |
Arbutin results in decreased expression of HSD3B1 mRNA Arbutin results in decreased expression of HSD3B1 mRNA; Arbutin results in decreased expression of HSD3B1 protein |
CTD |
PMID:17103032 PMID:37783241 |
|
NCBI chr 2:186,169,864...186,175,984
Ensembl chr 2:186,169,863...186,175,999
|
|
G |
Htatsf1 |
HIV-1 Tat specific factor 1 |
increases expression |
ISO |
Arbutin results in increased expression of HTATSF1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr X:134,935,426...134,949,607
Ensembl chr X:134,935,426...134,949,607
|
|
G |
Ifit3 |
interferon-induced protein with tetratricopeptide repeats 3 |
decreases expression |
ISO |
Arbutin results in decreased expression of IFIT3 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 1:232,114,166...232,119,311
Ensembl chr 1:232,114,166...232,119,307
|
|
G |
Igdcc3 |
immunoglobulin superfamily, DCC subclass, member 3 |
decreases expression |
ISO |
Arbutin results in decreased expression of IGDCC3 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 8:65,661,165...65,707,961
Ensembl chr 8:65,661,196...65,707,959
|
|
G |
Il23a |
interleukin 23 subunit alpha |
decreases expression |
ISO |
Arbutin results in decreased expression of IL23A mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 7:721,809...723,923
Ensembl chr 7:721,809...723,923
|
|
G |
Il3ra |
interleukin 3 receptor subunit alpha |
increases expression |
ISO |
Arbutin results in increased expression of IL3RA mRNA |
CTD |
PMID:17103032 |
|
NCBI chr12:16,318,081...16,323,781
Ensembl chr12:16,318,081...16,323,484
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP |
Arbutin inhibits the reaction [Ethanol results in increased expression of IL6 protein] |
CTD |
PMID:34346143 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Il6st |
interleukin 6 cytokine family signal transducer |
decreases expression |
ISO |
Arbutin results in decreased expression of IL6ST mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 2:44,065,979...44,106,255
Ensembl chr 2:44,066,130...44,109,936
|
|
G |
Ina |
internexin neuronal intermediate filament protein, alpha |
decreases expression |
ISO |
Arbutin results in decreased expression of INA mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 1:245,896,775...245,908,330
Ensembl chr 1:245,896,775...245,908,330
|
|
G |
Inpp4b |
inositol polyphosphate-4-phosphatase type II B |
increases expression |
ISO |
Arbutin results in increased expression of INPP4B mRNA |
CTD |
PMID:17103032 |
|
NCBI chr19:25,920,189...26,670,085
Ensembl chr19:25,925,358...26,280,634
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
decreases expression |
ISO |
Arbutin results in decreased expression of JUN mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Kcnab3 |
potassium voltage-gated channel subfamily A regulatory beta subunit 3 |
decreases expression |
ISO |
Arbutin results in decreased expression of KCNAB3 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr10:54,047,830...54,056,401
Ensembl chr10:54,047,825...54,054,174
|
|
G |
Kctd17 |
potassium channel tetramerization domain containing 17 |
decreases expression |
ISO |
Arbutin results in decreased expression of KCTD17 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 7:109,979,060...110,009,091
Ensembl chr 7:109,979,060...110,008,927
|
|
G |
Kif26b |
kinesin family member 26B |
decreases expression |
ISO |
Arbutin results in decreased expression of KIF26B mRNA |
CTD |
PMID:17103032 |
|
NCBI chr13:90,282,821...90,689,058
Ensembl chr13:90,283,404...90,682,811
|
|
G |
Klhl13 |
kelch-like family member 13 |
increases expression |
ISO |
Arbutin results in increased expression of KLHL13 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr X:113,942,309...114,107,299
Ensembl chr X:113,942,309...114,107,321
|
|
G |
Lctl |
lactase-like |
decreases expression |
ISO |
Arbutin results in decreased expression of LCTL mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 8:64,618,356...64,654,851
Ensembl chr 8:64,618,350...64,639,357
|
|
G |
Lhcgr |
luteinizing hormone/choriogonadotropin receptor |
decreases expression |
EXP |
Arbutin results in decreased expression of LHCGR mRNA; Arbutin results in decreased expression of LHCGR protein |
CTD |
PMID:37783241 |
|
NCBI chr 6:5,661,871...5,728,109
Ensembl chr 6:5,661,871...5,724,521
|
|
G |
Lrp5 |
LDL receptor related protein 5 |
decreases expression |
ISO |
Arbutin results in decreased expression of LRP5 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 1:200,814,247...200,917,581
Ensembl chr 1:200,814,250...200,917,581
|
|
G |
Lrp6 |
LDL receptor related protein 6 |
decreases expression |
ISO |
Arbutin results in decreased expression of LRP6 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 4:167,269,856...167,400,364
Ensembl chr 4:167,270,353...167,400,497
|
|
G |
Lrrc4 |
leucine rich repeat containing 4 |
decreases expression |
ISO |
Arbutin results in decreased expression of LRRC4 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 4:57,433,518...57,437,114
Ensembl chr 4:57,433,428...57,437,911
|
|
G |
Lrrtm4 |
leucine rich repeat transmembrane neuronal 4 |
decreases expression |
ISO |
Arbutin results in decreased expression of LRRTM4 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 4:112,545,874...113,338,713
Ensembl chr 4:112,545,917...113,335,865
|
|
G |
Mafk |
MAF bZIP transcription factor K |
decreases expression |
ISO |
Arbutin results in decreased expression of MAFK mRNA |
CTD |
PMID:17103032 |
|
NCBI chr12:14,834,628...14,856,414
Ensembl chr12:14,833,984...14,837,048 Ensembl chr12:14,833,984...14,837,048
|
|
G |
Map4k5 |
mitogen-activated protein kinase kinase kinase kinase 5 |
decreases expression |
ISO |
Arbutin results in decreased expression of MAP4K5 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 6:88,284,087...88,377,118
Ensembl chr 6:88,284,094...88,376,799
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
decreases expression |
ISO |
Arbutin results in decreased expression of MAPK8 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mcm8 |
minichromosome maintenance 8 homologous recombination repair factor |
increases expression |
ISO |
Arbutin results in increased expression of MCM8 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 3:120,086,741...120,117,008
Ensembl chr 3:120,086,763...120,117,008
|
|
G |
Mdfi |
MyoD family inhibitor |
decreases expression |
ISO |
Arbutin results in decreased expression of MDFI mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 9:13,156,806...13,175,218
Ensembl chr 9:13,156,866...13,175,217
|
|
G |
Mfap4 |
microfibril associated protein 4 |
decreases expression |
ISO |
Arbutin results in decreased expression of MFAP4 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr10:46,167,158...46,170,176
Ensembl chr10:46,167,217...46,170,155
|
|
G |
Midn |
midnolin |
decreases expression |
ISO |
Arbutin results in decreased expression of MIDN mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 7:9,548,100...9,559,605
Ensembl chr 7:9,549,650...9,559,752
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
increases expression |
ISO |
Arbutin results in increased expression of MKI67 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762
|
|
G |
Mmgt1 |
membrane magnesium transporter 1 |
increases expression |
ISO |
Arbutin results in increased expression of MMGT1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr X:134,408,463...134,420,798
Ensembl chr X:134,408,466...134,420,729
|
|
G |
Mthfd1l |
methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1-like |
decreases expression |
ISO |
Arbutin results in decreased expression of MTHFD1L mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 1:40,443,926...40,632,911
Ensembl chr 1:40,444,008...40,632,905
|
|
G |
Mvd |
mevalonate diphosphate decarboxylase |
decreases expression |
ISO |
Arbutin results in decreased expression of MVD mRNA |
CTD |
PMID:17103032 |
|
NCBI chr19:50,496,366...50,506,429
Ensembl chr19:50,496,367...50,507,971
|
|
G |
Myo3b |
myosin IIIB |
decreases expression |
ISO |
Arbutin results in decreased expression of MYO3B mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 3:54,820,225...55,228,518
Ensembl chr 3:54,820,251...55,227,373
|
|
G |
Ncald |
neurocalcin delta |
decreases expression |
ISO |
Arbutin results in decreased expression of NCALD mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 7:68,532,671...68,964,740
Ensembl chr 7:68,534,421...68,964,496
|
|
G |
Negr1 |
neuronal growth regulator 1 |
decreases expression |
ISO |
Arbutin results in decreased expression of NEGR1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 2:245,624,460...246,359,605
Ensembl chr 2:245,624,435...246,356,730
|
|
G |
Neu4 |
neuraminidase 4 |
increases expression |
ISO |
Arbutin results in increased expression of NEU4 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 9:94,396,920...94,402,576
Ensembl chr 9:94,396,920...94,402,576
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
EXP |
Arbutin inhibits the reaction [Ethanol results in decreased expression of NFE2L2 mRNA] |
CTD |
PMID:34346143 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nkd1 |
NKD inhibitor of WNT signaling pathway 1 |
decreases expression |
ISO |
Arbutin results in decreased expression of NKD1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr19:18,476,344...18,549,380
Ensembl chr19:18,476,344...18,549,380
|
|
G |
Nmi |
N-myc (and STAT) interactor |
increases expression |
ISO |
Arbutin results in increased expression of NMI mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 3:36,415,607...36,439,716
Ensembl chr 3:36,415,607...36,439,498
|
|
G |
Noxred1 |
NADP-dependent oxidoreductase domain containing 1 |
decreases expression |
ISO |
Arbutin results in decreased expression of NOXRED1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 6:106,862,350...106,888,113
Ensembl chr 6:106,862,343...106,884,712
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
EXP |
Arbutin inhibits the reaction [Ethanol results in increased expression of NQO1 mRNA] |
CTD |
PMID:34346143 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr2f1 |
nuclear receptor subfamily 2, group F, member 1 |
increases expression |
ISO |
Arbutin results in increased expression of NR2F1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 2:8,040,375...8,050,123
Ensembl chr 2:8,040,377...8,050,123
|
|
G |
Nrp2 |
neuropilin 2 |
increases expression |
ISO |
Arbutin results in increased expression of NRP2 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 9:64,122,815...64,238,007
Ensembl chr 9:64,123,132...64,237,958
|
|
G |
Ntf4 |
neurotrophin 4 |
decreases expression |
ISO |
Arbutin results in decreased expression of NTF4 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 1:95,893,560...95,896,391
Ensembl chr 1:95,893,457...95,897,243
|
|
G |
Olfml1 |
olfactomedin-like 1 |
decreases expression |
ISO |
Arbutin results in decreased expression of OLFML1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 1:161,478,129...161,502,541
Ensembl chr 1:161,478,242...161,502,537
|
|
G |
Osbp2 |
oxysterol binding protein 2 |
decreases expression |
ISO |
Arbutin results in decreased expression of OSBP2 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr14:78,585,088...78,746,785
Ensembl chr14:78,585,089...78,746,786
|
|
G |
Osbpl11 |
oxysterol binding protein-like 11 |
increases expression |
ISO |
Arbutin results in increased expression of OSBPL11 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr11:67,533,669...67,616,795
Ensembl chr11:67,533,672...67,596,444
|
|
G |
Otx1 |
orthodenticle homeobox 1 |
decreases expression |
ISO |
Arbutin results in decreased expression of OTX1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr14:96,082,146...96,089,161
Ensembl chr14:96,082,151...96,089,086
|
|
G |
Pacsin2 |
protein kinase C and casein kinase substrate in neurons 2 |
decreases expression |
ISO |
Arbutin results in decreased expression of PACSIN2 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 7:114,505,525...114,599,087
Ensembl chr 7:114,505,152...114,598,546
|
|
G |
Parg |
poly (ADP-ribose) glycohydrolase |
increases expression |
ISO |
Arbutin results in increased expression of PARG mRNA |
CTD |
PMID:17103032 |
|
NCBI chr16:7,436,429...7,544,276
Ensembl chr16:7,436,476...7,544,273
|
|
G |
Pcgf6 |
polycomb group ring finger 6 |
increases expression |
ISO |
Arbutin results in increased expression of PCGF6 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 1:245,925,354...245,944,964
Ensembl chr 1:245,925,360...245,944,914
|
|
G |
Pcmtd2 |
protein-L-isoaspartate (D-aspartate) O-methyltransferase domain containing 2 |
increases expression |
ISO |
Arbutin results in increased expression of PCMTD2 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 3:168,960,312...168,979,504
Ensembl chr 3:168,960,305...168,979,497
|
|
G |
Pcnx2 |
pecanex 2 |
decreases expression |
ISO |
Arbutin results in decreased expression of PCNX2 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr19:53,718,920...53,869,559
Ensembl chr19:53,718,655...53,871,364
|
|
G |
Pdzk1 |
PDZ domain containing 1 |
decreases expression |
ISO |
Arbutin results in decreased expression of PDZK1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 2:184,376,161...184,407,514
Ensembl chr 2:184,376,161...184,407,514
|
|
G |
Perm1 |
PPARGC1 and ESRR induced regulator, muscle 1 |
decreases expression |
ISO |
Arbutin results in decreased expression of PERM1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 5:166,800,030...166,805,323
Ensembl chr 5:166,800,030...166,805,323
|
|
G |
Pf4 |
platelet factor 4 |
decreases expression |
ISO |
Arbutin results in decreased expression of PF4 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr14:17,298,304...17,299,220
Ensembl chr14:17,298,308...17,299,365
|
|
G |
Pgm2 |
phosphoglucomutase 2 |
increases expression |
ISO |
Arbutin results in increased expression of PGM2 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr14:44,166,314...44,199,828
Ensembl chr14:44,164,425...44,199,967
|
|
G |
Pigq |
phosphatidylinositol glycan anchor biosynthesis, class Q |
decreases expression |
ISO |
Arbutin results in decreased expression of PIGQ mRNA |
CTD |
PMID:17103032 |
|
NCBI chr10:14,942,571...14,958,584
Ensembl chr10:14,942,577...14,958,584
|
|
G |
Pin1 |
peptidylprolyl cis/trans isomerase, NIMA-interacting 1 |
decreases expression |
ISO |
Arbutin results in decreased expression of PIN1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 8:19,189,408...19,200,785
Ensembl chr 8:19,189,373...19,200,785
|
|
G |
Pitpnb |
phosphatidylinositol transfer protein, beta |
increases expression |
ISO |
Arbutin results in increased expression of PITPNB mRNA |
CTD |
PMID:17103032 |
|
NCBI chr12:45,249,308...45,298,388
Ensembl chr12:45,249,333...45,298,314
|
|
G |
Pkhd1 |
PKHD1 ciliary IPT domain containing fibrocystin/polyductin |
decreases expression |
ISO |
Arbutin results in decreased expression of PKHD1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 9:22,547,396...23,037,443
Ensembl chr 9:22,549,513...23,037,381
|
|
G |
Poglut2 |
protein O-glucosyltransferase 2 |
increases expression |
ISO |
Arbutin results in increased expression of POGLUT2 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 9:46,256,388...46,268,714
Ensembl chr 9:46,256,390...46,268,532
|
|
G |
Pole2 |
DNA polymerase epsilon 2, accessory subunit |
increases expression |
ISO |
Arbutin results in increased expression of POLE2 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 6:87,674,702...87,712,723
Ensembl chr 6:87,674,702...87,699,305
|
|
G |
Pphln1 |
periphilin 1 |
increases expression |
ISO |
Arbutin results in increased expression of PPHLN1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 7:124,538,594...124,629,985
Ensembl chr 7:124,538,627...124,629,985
|
|
G |
Prg2 |
proteoglycan 2, pro eosinophil major basic protein |
decreases expression |
ISO |
Arbutin results in decreased expression of PRG2 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 3:70,062,535...70,066,102
Ensembl chr 3:70,062,535...70,066,101
|
|
G |
Prkx |
protein kinase cAMP-dependent X-linked catalytic subunit |
decreases expression |
ISO |
Arbutin results in decreased expression of PRKX mRNA |
CTD |
PMID:17103032 |
|
NCBI chr X:41,823,349...41,866,844
Ensembl chr X:41,823,355...41,866,669
|
|
G |
Prmt2 |
protein arginine methyltransferase 2 |
decreases expression |
ISO |
Arbutin results in decreased expression of PRMT2 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr20:12,394,748...12,420,643
Ensembl chr20:12,394,798...12,420,643
|
|
G |
Prr18 |
proline rich 18 |
decreases expression |
ISO |
Arbutin results in decreased expression of PRR18 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 1:52,400,215...52,403,998
Ensembl chr 1:52,400,215...52,404,309
|
|
G |
Prrx1 |
paired related homeobox 1 |
decreases expression |
ISO |
Arbutin results in decreased expression of PRRX1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr13:75,600,777...75,671,896
Ensembl chr13:75,601,706...75,670,866
|
|
G |
Psmd13 |
proteasome 26S subunit, non-ATPase 13 |
decreases expression |
ISO |
Arbutin results in decreased expression of PSMD13 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 1:195,964,617...195,976,895
Ensembl chr 1:195,964,138...195,976,905
|
|
G |
Psmd3 |
proteasome 26S subunit, non-ATPase 3 |
decreases expression |
ISO |
Arbutin results in decreased expression of PSMD3 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr10:83,643,473...83,655,620
Ensembl chr10:83,643,647...83,655,618
|
|
G |
Rab3gap1 |
RAB3 GTPase activating protein catalytic subunit 1 |
increases expression |
ISO |
Arbutin results in increased expression of RAB3GAP1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr13:39,355,698...39,429,154
Ensembl chr13:39,352,247...39,429,169
|
|
G |
Rab6b |
RAB6B, member RAS oncogene family |
decreases expression |
ISO |
Arbutin results in decreased expression of RAB6B mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 8:103,695,328...103,764,023
Ensembl chr 8:103,695,631...103,805,732
|
|
G |
Rasgef1b |
RasGEF domain family, member 1B |
decreases expression |
ISO |
Arbutin results in decreased expression of RASGEF1B mRNA |
CTD |
PMID:17103032 |
|
NCBI chr14:9,859,512...10,380,044
Ensembl chr14:9,860,247...10,379,741
|
|
G |
Rnf208 |
ring finger protein 208 |
decreases expression |
ISO |
Arbutin results in decreased expression of RNF208 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 3:8,057,808...8,059,721
Ensembl chr 3:8,043,685...8,059,844
|
|
G |
Rps6ka3 |
ribosomal protein S6 kinase A3 |
increases expression |
ISO |
Arbutin results in increased expression of RPS6KA3 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr X:35,517,306...35,623,296
Ensembl chr X:35,517,306...35,623,207
|
|
G |
Rsbn1 |
round spermatid basic protein 1 |
decreases expression |
ISO |
Arbutin results in decreased expression of RSBN1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 2:191,416,631...191,470,711
Ensembl chr 2:191,416,631...191,470,711
|
|
G |
Saa4 |
serum amyloid A4 |
decreases expression |
ISO |
Arbutin results in decreased expression of SAA4 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 1:97,247,580...97,251,882
|
|
G |
Sccpdh |
saccharopine dehydrogenase (putative) |
increases expression |
ISO |
Arbutin results in increased expression of SCCPDH mRNA |
CTD |
PMID:17103032 |
|
NCBI chr13:91,400,120...91,421,875
Ensembl chr13:91,400,190...91,422,222
|
|
G |
Scn1b |
sodium voltage-gated channel beta subunit 1 |
increases expression |
ISO |
Arbutin results in increased expression of SCN1B mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 1:86,353,917...86,363,820
Ensembl chr 1:86,353,917...86,363,739
|
|
G |
Sdc4 |
syndecan 4 |
decreases expression |
ISO |
Arbutin results in decreased expression of SDC4 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 3:153,154,888...153,173,576
Ensembl chr 3:153,154,896...153,173,580
|
|
G |
Semg1 |
semenogelin 1 |
decreases expression |
ISO |
Arbutin results in decreased expression of SEMG1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 3:152,910,033...152,912,882
Ensembl chr 3:152,910,034...152,912,882
|
|
G |
Serpina5 |
serpin family A member 5 |
decreases expression |
ISO |
Arbutin results in decreased expression of SERPINA5 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 6:123,009,224...123,028,412
Ensembl chr 6:123,023,306...123,028,407
|
|
G |
Serpind1 |
serpin family D member 1 |
decreases expression |
ISO |
Arbutin results in decreased expression of SERPIND1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr11:83,664,517...83,675,593
Ensembl chr11:83,664,518...83,675,519
|
|
G |
Sf3b1 |
splicing factor 3b, subunit 1 |
increases expression |
ISO |
Arbutin results in increased expression of SF3B1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 9:56,492,403...56,532,300
Ensembl chr 9:56,492,403...56,532,300
|
|
G |
Sfrp5 |
secreted frizzled-related protein 5 |
decreases expression |
ISO |
Arbutin results in decreased expression of SFRP5 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 1:241,006,762...241,011,224
Ensembl chr 1:241,006,762...241,011,224
|
|
G |
Sfxn2 |
sideroflexin 2 |
decreases expression |
ISO |
Arbutin results in decreased expression of SFXN2 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 1:245,447,014...245,459,312
Ensembl chr 1:245,447,015...245,468,411 Ensembl chr 1:245,447,015...245,468,411
|
|
G |
Sh3gl2 |
SH3 domain containing GRB2 like 2, endophilin A1 |
decreases expression |
ISO |
Arbutin results in decreased expression of SH3GL2 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 5:99,653,189...99,827,500
Ensembl chr 5:99,653,152...100,113,843
|
|
G |
Sin3b |
SIN3 transcription regulator family member B |
decreases expression |
ISO |
Arbutin results in decreased expression of SIN3B mRNA |
CTD |
PMID:17103032 |
|
NCBI chr16:17,123,277...17,159,978
Ensembl chr16:17,123,434...17,159,978
|
|
G |
Slc13a2 |
solute carrier family 13 member 2 |
decreases expression |
ISO |
Arbutin results in decreased expression of SLC13A2 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr10:63,291,813...63,319,127
Ensembl chr10:63,291,815...63,319,127
|
|
G |
Slc15a3 |
solute carrier family 15 member 3 |
decreases expression |
ISO |
Arbutin results in decreased expression of SLC15A3 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 1:207,492,365...207,507,158
Ensembl chr 1:207,492,365...207,507,157
|
|
G |
Slc18a2 |
solute carrier family 18 member A2 |
decreases expression |
ISO |
Arbutin results in decreased expression of SLC18A2 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 1:258,413,748...258,449,143
Ensembl chr 1:258,413,959...258,448,325
|
|
G |
Slc23a3 |
solute carrier family 23, member 3 |
increases expression |
ISO |
Arbutin results in increased expression of SLC23A3 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 9:76,622,621...76,633,188
Ensembl chr 9:76,622,800...76,631,366
|
|
G |
Slc25a2 |
solute carrier family 25 member 2 |
decreases expression |
ISO |
Arbutin results in decreased expression of SLC25A2 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr18:29,452,943...29,456,324
Ensembl chr18:29,453,582...29,460,383
|
|
G |
Slc27a4 |
solute carrier family 27 member 4 |
decreases expression |
ISO |
Arbutin results in decreased expression of SLC27A4 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 3:13,075,022...13,087,943
Ensembl chr 3:13,075,022...13,087,943
|
|
G |
Slc7a3 |
solute carrier family 7 member 3 |
decreases expression |
ISO |
Arbutin results in decreased expression of SLC7A3 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr X:66,210,071...66,216,482
Ensembl chr X:66,210,081...66,215,708
|
|
G |
Slco5a1 |
solute carrier organic anion transporter family, member 5A1 |
decreases expression |
ISO |
Arbutin results in decreased expression of SLCO5A1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 5:6,228,938...6,358,124
Ensembl chr 5:6,228,973...6,352,913
|
|
G |
Snip1 |
Smad nuclear interacting protein 1 |
decreases expression |
ISO |
Arbutin results in decreased expression of SNIP1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 5:137,328,371...137,335,846
Ensembl chr 5:137,328,371...137,335,845
|
|
G |
Socs4 |
suppressor of cytokine signaling 4 |
decreases expression |
ISO |
Arbutin results in decreased expression of SOCS4 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr15:20,523,406...20,537,889
Ensembl chr15:20,523,183...20,542,494
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions |
EXP |
Arbutin inhibits the reaction [potassium bromate results in decreased activity of SOD1 protein] |
CTD |
PMID:36284482 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Spata13 |
spermatogenesis associated 13 |
increases expression |
ISO |
Arbutin results in increased expression of SPATA13 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr15:34,778,479...34,907,645
Ensembl chr15:34,778,473...34,905,114
|
|
G |
Spata20 |
spermatogenesis associated 20 |
decreases expression |
ISO |
Arbutin results in decreased expression of SPATA20 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr10:79,427,525...79,435,472
Ensembl chr10:79,427,528...79,434,368
|
|
G |
Sptlc1 |
serine palmitoyltransferase, long chain base subunit 1 |
increases expression |
ISO |
Arbutin results in increased expression of SPTLC1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr17:11,877,249...11,916,295
Ensembl chr17:11,877,249...11,916,295
|
|
G |
Srd5a1 |
steroid 5 alpha-reductase 1 |
decreases activity decreases expression |
EXP |
Arbutin results in decreased activity of SRD5A1 protein Arbutin results in decreased expression of SRD5A1 mRNA; Arbutin results in decreased expression of SRD5A1 protein |
CTD |
PMID:37783241 |
|
NCBI chr 1:33,686,069...33,720,468
Ensembl chr 1:33,686,391...33,720,461
|
|
G |
Stard8 |
StAR-related lipid transfer domain containing 8 |
decreases expression |
ISO |
Arbutin results in decreased expression of STARD8 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr X:64,079,079...64,196,052
Ensembl chr X:64,124,574...64,196,052
|
|
G |
Syde1 |
synapse defective Rho GTPase homolog 1 |
decreases expression |
ISO |
Arbutin results in decreased expression of SYDE1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 7:11,032,931...11,038,917
Ensembl chr 7:11,032,898...11,039,869
|
|
G |
Sympk |
symplekin scaffold protein |
decreases expression |
ISO |
Arbutin results in decreased expression of SYMPK mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 1:78,672,372...78,700,684
Ensembl chr 1:78,672,378...78,700,684
|
|
G |
Tal1 |
TAL bHLH transcription factor 1, erythroid differentiation factor |
decreases expression |
ISO |
Arbutin results in decreased expression of TAL1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 5:128,586,776...128,600,976
Ensembl chr 5:128,587,701...128,600,976
|
|
G |
Tardbp |
TAR DNA binding protein |
increases expression |
ISO |
Arbutin results in increased expression of TARDBP mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 5:159,050,518...159,062,218
Ensembl chr 5:159,051,799...159,062,055
|
|
G |
Tcf12 |
transcription factor 12 |
increases expression |
ISO |
Arbutin results in increased expression of TCF12 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 8:72,490,447...72,799,265
Ensembl chr 8:72,492,567...72,799,201
|
|
G |
Tes |
testin LIM domain protein |
increases expression |
ISO |
Arbutin results in increased expression of TES mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 4:45,365,304...45,403,829
Ensembl chr 4:45,365,285...45,403,829
|
|
G |
Tex13b |
testis expressed 13B |
decreases expression |
ISO |
Arbutin results in decreased expression of TEX13B mRNA |
CTD |
PMID:17103032 |
|
NCBI chr X:104,490,937...104,511,224
Ensembl chr X:104,490,091...104,494,201
|
|
G |
Tgfb3 |
transforming growth factor, beta 3 |
decreases expression |
ISO |
Arbutin results in decreased expression of TGFB3 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 6:105,704,058...105,726,661
Ensembl chr 6:105,704,236...105,726,564
|
|
G |
Tll1 |
tolloid-like 1 |
decreases expression |
ISO |
Arbutin results in decreased expression of TLL1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr16:25,509,146...25,710,330
Ensembl chr16:25,509,146...25,709,543
|
|
G |
Tmem59l |
transmembrane protein 59-like |
decreases expression |
ISO |
Arbutin results in decreased expression of TMEM59L mRNA |
CTD |
PMID:17103032 |
|
NCBI chr16:18,941,370...18,945,381
Ensembl chr16:18,941,567...18,945,381
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP |
Arbutin inhibits the reaction [Ethanol results in increased expression of TNF protein] |
CTD |
PMID:34346143 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tor4a |
torsin family 4, member A |
decreases expression |
ISO |
Arbutin results in decreased expression of TOR4A mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 3:8,004,292...8,007,979
Ensembl chr 3:8,002,023...8,008,042
|
|
G |
Tram2 |
translocation associated membrane protein 2 |
decreases expression |
ISO |
Arbutin results in decreased expression of TRAM2 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 9:23,419,204...23,498,745
Ensembl chr 9:23,424,232...23,498,689
|
|
G |
Treh |
trehalase |
decreases expression |
ISO |
Arbutin results in decreased expression of TREH mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 8:44,990,182...45,003,881
Ensembl chr 8:44,990,182...45,003,540
|
|
G |
Tsc1 |
TSC complex subunit 1 |
increases expression |
ISO |
Arbutin results in increased expression of TSC1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 3:11,969,547...12,018,591
Ensembl chr 3:11,979,729...12,015,674
|
|
G |
Tsc22d2 |
TSC22 domain family, member 2 |
decreases expression |
ISO |
Arbutin results in decreased expression of TSC22D2 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 2:142,646,778...142,697,977
Ensembl chr 2:142,644,744...142,693,606
|
|
G |
Tshz2 |
teashirt zinc finger homeobox 2 |
decreases expression |
ISO |
Arbutin results in decreased expression of TSHZ2 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 3:158,405,469...158,666,915
Ensembl chr 3:158,405,423...158,850,128
|
|
G |
Tspoap1 |
TSPO associated protein 1 |
decreases expression |
ISO |
Arbutin results in decreased expression of TSPOAP1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr10:72,554,220...72,586,402
Ensembl chr10:72,560,980...72,586,412
|
|
G |
Ttc22 |
tetratricopeptide repeat domain 22 |
decreases expression |
ISO |
Arbutin results in decreased expression of TTC22 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 5:121,401,973...121,423,130
Ensembl chr 5:121,406,326...121,423,130
|
|
G |
Tulp3 |
TUB like protein 3 |
decreases expression |
ISO |
Arbutin results in decreased expression of TULP3 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 4:161,590,478...161,632,244
Ensembl chr 4:161,590,479...161,632,149
|
|
G |
Tyr |
tyrosinase |
decreases expression decreases activity |
ISO |
Arbutin results in decreased expression of TYR mRNA Arbutin results in decreased activity of TYR protein |
CTD |
PMID:21071833 PMID:22705713 |
|
NCBI chr 1:141,115,036...141,210,207
Ensembl chr 1:141,115,036...141,210,207
|
|
G |
Ube2d2b |
ubiquitin-conjugating enzyme E2D 2B |
decreases expression |
ISO |
Arbutin results in decreased expression of UBE2D4 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr14:1,915,999...1,917,473
Ensembl chr14:1,916,845...1,917,416
|
|
G |
Ube2m |
ubiquitin-conjugating enzyme E2M |
decreases expression |
ISO |
Arbutin results in decreased expression of UBE2M mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 1:73,662,576...73,666,113
Ensembl chr 1:73,662,576...73,666,026
|
|
G |
Ubqln1 |
ubiquilin 1 |
increases expression |
ISO |
Arbutin results in increased expression of UBQLN1 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr17:6,439,002...6,477,096
Ensembl chr17:6,439,002...6,477,090
|
|
G |
Usp44 |
ubiquitin specific peptidase 44 |
decreases expression |
ISO |
Arbutin results in decreased expression of USP44 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 7:28,364,169...28,412,039
Ensembl chr 7:28,364,033...28,410,053
|
|
G |
Utp11 |
UTP11, small subunit processome component |
increases expression |
ISO |
Arbutin results in increased expression of UTP11 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 5:136,931,279...136,946,164
Ensembl chr 5:136,931,008...136,946,191
|
|
G |
Vps13b |
vacuolar protein sorting 13 homolog B |
decreases expression |
ISO |
Arbutin results in decreased expression of VPS13B mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 7:66,557,862...67,128,429
Ensembl chr 7:66,558,471...67,128,429
|
|
G |
Vps39 |
VPS39 subunit of HOPS complex |
increases expression |
ISO |
Arbutin results in increased expression of VPS39 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 3:107,266,846...107,304,884
Ensembl chr 3:107,267,310...107,304,975
|
|
G |
Vwa3a |
von Willebrand factor A domain containing 3A |
decreases expression |
ISO |
Arbutin results in decreased expression of VWA3A mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 1:175,293,782...175,355,588
Ensembl chr 1:175,293,873...175,355,602
|
|
G |
Wnt10a |
Wnt family member 10A |
decreases expression |
ISO |
Arbutin results in decreased expression of WNT10A mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 9:76,349,931...76,362,400
Ensembl chr 9:76,349,931...76,362,400
|
|
G |
Zbtb20 |
zinc finger and BTB domain containing 20 |
increases expression |
ISO |
Arbutin results in increased expression of ZBTB20 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr11:57,052,129...57,791,214
Ensembl chr11:57,072,880...57,510,210
|
|
G |
Zbtb7b |
zinc finger and BTB domain containing 7B |
decreases expression |
ISO |
Arbutin results in decreased expression of ZBTB7B mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 2:174,795,831...174,811,980
Ensembl chr 2:174,797,453...174,814,236
|
|
G |
Zdhhc2 |
zinc finger DHHC-type palmitoyltransferase 2 |
decreases expression |
ISO |
Arbutin results in decreased expression of ZDHHC2 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr16:51,808,465...51,878,060
Ensembl chr16:51,808,468...51,878,060
|
|
G |
Zfp414 |
zinc finger protein 414 |
decreases expression |
ISO |
Arbutin results in decreased expression of ZNF414 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 7:14,420,232...14,422,939
Ensembl chr 7:14,420,165...14,438,166
|
|
G |
Zfp483 |
zinc finger protein 483 |
decreases expression |
ISO |
Arbutin results in decreased expression of ZNF483 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 5:73,763,201...73,780,511
Ensembl chr 5:73,763,179...73,776,223
|
|
G |
Zfp870 |
zinc finger protein 870 |
increases expression |
ISO |
Arbutin results in increased expression of ZNF670 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 7:11,990,146...12,003,813
Ensembl chr 7:11,990,148...12,003,813
|
|
G |
Zkscan7 |
zinc finger with KRAB and SCAN domains 7 |
decreases expression |
ISO |
Arbutin results in decreased expression of ZKSCAN7 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 8:122,501,938...122,519,600
Ensembl chr 8:122,502,218...122,519,600
|
|
G |
Znf354b |
zinc finger protein 354B |
decreases expression |
ISO |
Arbutin results in decreased expression of ZNF354B mRNA |
CTD |
PMID:17103032 |
|
NCBI chr10:35,233,783...35,251,110
Ensembl chr10:35,185,028...35,245,505
|
|
G |
Znf81L |
zinc finger protein 81 like |
decreases expression |
ISO |
Arbutin results in decreased expression of ZNF81 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr X:1,030,103...1,126,078
Ensembl chr X:1,036,153...1,126,102
|
|
G |
Zp2 |
zona pellucida glycoprotein 2 |
decreases expression |
ISO |
Arbutin results in decreased expression of ZP2 mRNA |
CTD |
PMID:17103032 |
|
NCBI chr 1:174,513,507...174,525,288
Ensembl chr 1:174,513,511...174,525,288
|
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
ISO |
astragalin inhibits the reaction [[Galactose co-treated with Aluminum Chloride] results in decreased expression of APP protein] |
CTD |
PMID:35537655 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
astragalin inhibits the reaction [[Galactose co-treated with Aluminum Chloride] results in decreased expression of CAT protein] |
CTD |
PMID:35537655 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
astragalin inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA] |
CTD |
PMID:22210036 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
multiple interactions |
ISO |
astragalin inhibits the reaction [Lipopolysaccharides results in increased expression of CCL3 mRNA] |
CTD |
PMID:22210036 |
|
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Hes1 |
hes family bHLH transcription factor 1 |
multiple interactions |
ISO |
astragalin inhibits the reaction [[Galactose co-treated with Aluminum Chloride] results in increased expression of HES1 protein] |
CTD |
PMID:35537655 |
|
NCBI chr11:70,705,763...70,708,176
Ensembl chr11:70,705,764...70,708,192
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
ISO |
astragalin inhibits the reaction [[Galactose co-treated with Aluminum Chloride] results in decreased expression of IL10 protein] |
CTD |
PMID:35537655 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
astragalin inhibits the reaction [[Galactose co-treated with Aluminum Chloride] results in increased expression of IL1B protein]; astragalin inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA] |
CTD |
PMID:22210036 PMID:35537655 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
astragalin inhibits the reaction [[Galactose co-treated with Aluminum Chloride] results in increased expression of IL6 protein]; astragalin inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA] |
CTD |
PMID:22210036 PMID:35537655 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
astragalin inhibits the reaction [Lipopolysaccharides results in increased degradation of NFKBIA protein] |
CTD |
PMID:22210036 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
astragalin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; astragalin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] |
CTD |
PMID:22210036 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Notch1 |
notch receptor 1 |
multiple interactions |
ISO |
astragalin inhibits the reaction [[Galactose co-treated with Aluminum Chloride] results in increased expression of NOTCH1 protein] |
CTD |
PMID:35537655 |
|
NCBI chr 3:9,277,955...9,323,531
Ensembl chr 3:9,278,086...9,323,531
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
astragalin inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]; astragalin inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein] |
CTD |
PMID:22210036 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rbpj |
recombination signal binding protein for immunoglobulin kappa J region |
multiple interactions |
ISO |
astragalin inhibits the reaction [[Galactose co-treated with Aluminum Chloride] results in increased expression of RBPJ protein] |
CTD |
PMID:35537655 |
|
NCBI chr14:57,338,493...57,523,330
Ensembl chr14:57,338,507...57,523,353
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
astragalin inhibits the reaction [[Galactose co-treated with Aluminum Chloride] results in increased expression of and results in increased phosphorylation of RELA protein]; astragalin inhibits the reaction [Lipopolysaccharides results in increased localization of RELA protein] |
CTD |
PMID:22210036 PMID:35537655 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
astragalin inhibits the reaction [[Galactose co-treated with Aluminum Chloride] results in increased expression of TNF protein]; astragalin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA] |
CTD |
PMID:22210036 PMID:35537655 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions |
ISO |
[liquiritin co-treated with 1-Naphthylisothiocyanate] results in increased expression of ABCB11 mRNA |
CTD |
PMID:36008890 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
multiple interactions |
ISO |
[liquiritin co-treated with 1-Naphthylisothiocyanate] results in decreased expression of ABCC2 mRNA |
CTD |
PMID:36008890 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
multiple interactions |
ISO |
[liquiritin co-treated with 1-Naphthylisothiocyanate] results in increased expression of ABCC3 mRNA |
CTD |
PMID:36008890 |
|
NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Abcc4 |
ATP binding cassette subfamily C member 4 |
multiple interactions |
ISO |
[liquiritin co-treated with 1-Naphthylisothiocyanate] results in increased expression of ABCC4 mRNA |
CTD |
PMID:36008890 |
|
NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
EXP ISO |
liquiritin inhibits the reaction [Monocrotaline results in increased expression of CCL2 mRNA] liquiritin inhibits the reaction [HSPD1 protein results in increased expression of CCL2 mRNA] |
CTD |
PMID:31589899 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
EXP |
[brucine co-treated with liquiritin] results in decreased activity of CYP2E1 protein |
CTD |
PMID:21800547 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
increases expression multiple interactions |
EXP |
liquiritin results in increased expression of GCLC protein liquiritin inhibits the reaction [Monocrotaline results in decreased expression of GCLC mRNA] |
CTD |
PMID:29908794 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
multiple interactions increases expression |
EXP |
liquiritin inhibits the reaction [Monocrotaline results in decreased expression of GCLM mRNA] liquiritin results in increased expression of GCLM protein |
CTD |
PMID:29908794 |
|
NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
EXP ISO |
liquiritin inhibits the reaction [Monocrotaline results in increased activity of GPT protein] liquiritin inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of GPT protein] |
CTD |
PMID:31589899 PMID:36008890 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
EXP |
liquiritin inhibits the reaction [Monocrotaline results in decreased expression of GSR mRNA]; liquiritin inhibits the reaction [Monocrotaline results in decreased expression of GSR protein] |
CTD |
PMID:29908794 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
EXP ISO |
liquiritin inhibits the reaction [Monocrotaline results in increased expression of HMOX1 mRNA] [liquiritin co-treated with 1-Naphthylisothiocyanate] results in increased expression of HMOX1 mRNA; liquiritin inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of HMOX1 protein] |
CTD |
PMID:29908794 PMID:36008890 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hspd1 |
heat shock protein family D (Hsp60) member 1 |
multiple interactions |
ISO EXP |
liquiritin inhibits the reaction [HSPD1 protein results in increased expression of CCL2 mRNA]; liquiritin inhibits the reaction [HSPD1 protein results in increased expression of IL6 mRNA]; liquiritin inhibits the reaction [HSPD1 protein results in increased expression of NOS2 mRNA]; liquiritin inhibits the reaction [HSPD1 protein results in increased expression of RELA protein] liquiritin inhibits the reaction [Monocrotaline affects the expression of HSPD1 protein] |
CTD |
PMID:31589899 |
|
NCBI chr 9:56,579,195...56,590,011
Ensembl chr 9:56,579,201...56,589,662
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
liquiritin inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of IL1B protein] |
CTD |
PMID:36008890 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO EXP |
liquiritin inhibits the reaction [HSPD1 protein results in increased expression of IL6 mRNA] liquiritin inhibits the reaction [Monocrotaline results in increased expression of IL6 mRNA] |
CTD |
PMID:31589899 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Keap1 |
Kelch-like ECH-associated protein 1 |
multiple interactions |
ISO |
liquiritin promotes the reaction [1-Naphthylisothiocyanate results in decreased expression of KEAP1 protein] |
CTD |
PMID:36008890 |
|
NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
EXP |
liquiritin inhibits the reaction [Monocrotaline results in increased expression of MMP9 protein] |
CTD |
PMID:29908794 PMID:31589899 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
liquiritin inhibits the reaction [Monocrotaline results in increased activity of MPO protein] |
CTD |
PMID:31589899 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
decreases response to substance multiple interactions |
ISO EXP |
NFE2L2 gene mutant form results in decreased susceptibility to liquiritin liquiritin promotes the reaction [1-Naphthylisothiocyanate results in increased expression of NFE2L2 protein] liquiritin inhibits the reaction [Monocrotaline results in decreased expression of NFE2L2 mRNA] |
CTD |
PMID:29908794 PMID:36008890 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
EXP ISO |
liquiritin inhibits the reaction [Monocrotaline results in increased expression of NOS2 mRNA] liquiritin inhibits the reaction [HSPD1 protein results in increased expression of NOS2 mRNA] |
CTD |
PMID:31589899 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
EXP ISO |
liquiritin inhibits the reaction [Monocrotaline results in decreased expression of NQO1 mRNA] [liquiritin co-treated with 1-Naphthylisothiocyanate] results in increased expression of NQO1 mRNA |
CTD |
PMID:29908794 PMID:36008890 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
multiple interactions |
ISO |
liquiritin inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of NR1H4 mRNA]; liquiritin inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of NR1H4 protein] |
CTD |
PMID:36008890 |
|
NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP ISO |
liquiritin inhibits the reaction [Monocrotaline results in increased expression of RELA protein] liquiritin inhibits the reaction [HSPD1 protein results in increased expression of RELA protein] |
CTD |
PMID:31589899 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions |
ISO |
liquiritin inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of SIRT1 mRNA]; liquiritin inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of SIRT1 protein] |
CTD |
PMID:36008890 |
|
NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260
|
|
G |
Slc10a1 |
solute carrier family 10 member 1 |
multiple interactions |
ISO |
liquiritin inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of SLC10A1 mRNA] |
CTD |
PMID:36008890 |
|
NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions |
EXP |
liquiritin inhibits the reaction [Monocrotaline results in increased expression of SQSTM1 protein] |
CTD |
PMID:29908794 |
|
NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions |
EXP |
liquiritin inhibits the reaction [Monocrotaline results in increased expression of TLR4 protein] |
CTD |
PMID:31589899 |
|
NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
liquiritin inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of TNF protein] |
CTD |
PMID:36008890 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Txn2 |
thioredoxin 2 |
multiple interactions |
EXP |
liquiritin inhibits the reaction [Monocrotaline results in decreased expression of TXN2 mRNA]; liquiritin inhibits the reaction [Monocrotaline results in decreased expression of TXN2 protein] |
CTD |
PMID:29908794 |
|
NCBI chr 7:109,496,772...109,510,378
Ensembl chr 7:109,496,761...109,510,359
|
|
G |
Txnrd2 |
thioredoxin reductase 2 |
multiple interactions |
EXP |
liquiritin inhibits the reaction [Monocrotaline results in decreased expression of TXNRD2 mRNA]; liquiritin inhibits the reaction [Monocrotaline results in decreased expression of TXNRD2 protein] |
CTD |
PMID:29908794 |
|
NCBI chr11:82,519,996...82,568,156
Ensembl chr11:82,519,999...82,568,156
|
|
|
G |
Ache |
acetylcholinesterase |
decreases activity |
ISO |
loganin results in decreased activity of ACHE protein |
CTD |
PMID:19666019 |
|
NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
ISO |
loganin inhibits the reaction [Bleomycin results in increased expression of ACTA2 mRNA]; loganin inhibits the reaction [Bleomycin results in increased expression of ACTA2 protein] |
CTD |
PMID:35279615 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
increases expression |
ISO |
loganin results in increased expression of BCL2 mRNA |
CTD |
PMID:20966881 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Casp1 |
caspase 1 |
multiple interactions |
ISO |
loganin inhibits the reaction [Glucose results in increased expression of CASP1 mRNA]; loganin inhibits the reaction [Glucose results in increased expression of CASP1 protein] loganin inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of CASP1 protein] |
CTD |
PMID:37473909 |
|
NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383
|
|
G |
Casp3 |
caspase 3 |
decreases expression |
ISO |
loganin results in decreased expression of CASP3 mRNA |
CTD |
PMID:20966881 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
decreases expression |
ISO |
loganin results in decreased expression of CASP9 mRNA |
CTD |
PMID:20966881 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
affects expression |
ISO |
loganin affects the expression of CCL2 protein |
CTD |
PMID:21864639 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Cyba |
cytochrome b-245 alpha chain |
affects expression |
ISO |
loganin affects the expression of CYBA protein |
CTD |
PMID:21864639 |
|
NCBI chr19:50,487,598...50,495,669
Ensembl chr19:50,487,597...50,495,721
|
|
G |
Gsdmd |
gasdermin D |
multiple interactions |
ISO |
loganin inhibits the reaction [Glucose results in increased expression of GSDMD mRNA]; loganin inhibits the reaction [Glucose results in increased expression of GSDMD protein] loganin inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of GSDMD mRNA]; loganin inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of GSDMD protein] |
CTD |
PMID:37473909 |
|
NCBI chr 7:107,542,489...107,547,051
Ensembl chr 7:107,542,083...107,547,055
|
|
G |
Hmox1 |
heme oxygenase 1 |
affects expression |
ISO |
loganin affects the expression of HMOX1 protein |
CTD |
PMID:21864639 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Il18 |
interleukin 18 |
multiple interactions |
ISO |
loganin inhibits the reaction [Glucose results in increased expression of IL18 mRNA]; loganin inhibits the reaction [Glucose results in increased expression of IL18 protein] loganin inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of and results in increased secretion of IL18 protein]; loganin inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of IL18 mRNA] |
CTD |
PMID:37473909 |
|
NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP ISO |
loganin inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA] loganin inhibits the reaction [Glucose results in increased expression of IL1B mRNA]; loganin inhibits the reaction [Glucose results in increased expression of IL1B protein] loganin inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of and results in increased secretion of IL1B protein]; loganin inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA] |
CTD |
PMID:35279615 PMID:37473909 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP ISO |
loganin inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA] |
CTD |
PMID:35279615 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Lep |
leptin |
affects expression |
ISO |
loganin affects the expression of LEP protein |
CTD |
PMID:21864639 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
affects expression |
ISO |
loganin affects the expression of NFE2L2 protein |
CTD |
PMID:21864639 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions |
ISO |
loganin inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of NLRP3 mRNA]; loganin inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of NLRP3 protein] loganin inhibits the reaction [Glucose results in increased expression of NLRP3 mRNA]; loganin inhibits the reaction [Glucose results in increased expression of NLRP3 protein] |
CTD |
PMID:37473909 |
|
NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811
|
|
G |
Nos2 |
nitric oxide synthase 2 |
affects expression |
ISO |
loganin affects the expression of NOS2 protein |
CTD |
PMID:21864639 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nox4 |
NADPH oxidase 4 |
affects expression |
ISO |
loganin affects the expression of NOX4 protein |
CTD |
PMID:21864639 |
|
NCBI chr 1:140,900,886...141,078,844
Ensembl chr 1:140,901,097...141,077,406
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
affects expression |
ISO |
loganin affects the expression of PTGS2 protein |
CTD |
PMID:21864639 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
affects expression multiple interactions |
ISO EXP |
loganin affects the expression of RELA protein loganin inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased phosphorylation of RELA protein] |
CTD |
PMID:21864639 PMID:35279615 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
ISO EXP |
loganin inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased phosphorylation of STAT3 protein] loganin inhibits the reaction [Lipopolysaccharides results in increased expression of STAT3 protein] |
CTD |
PMID:35279615 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
loganin inhibits the reaction [Bleomycin results in increased expression of TGFB1 mRNA] |
CTD |
PMID:35279615 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO EXP |
loganin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA] |
CTD |
PMID:35279615 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfsf11 |
TNF superfamily member 11 |
decreases expression |
ISO |
loganin results in decreased expression of TNFSF11 mRNA |
CTD |
PMID:20966881 |
|
NCBI chr15:53,673,850...53,705,325
Ensembl chr15:53,673,877...53,705,445
|
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions decreases phosphorylation |
ISO |
[luteolin-7-glucoside co-treated with Hydrogen Peroxide] results in increased phosphorylation of AKT1 protein luteolin-7-glucoside results in decreased phosphorylation of AKT1 protein |
CTD |
PMID:31157476 PMID:34165247 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
ISO |
luteolin-7-glucoside results in increased expression of BAX protein |
CTD |
PMID:34165247 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions decreases expression |
ISO |
luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of BCL2 protein]; luteolin-7-glucoside inhibits the reaction [Hydrogen Peroxide results in decreased expression of BCL2 protein] luteolin-7-glucoside results in decreased expression of BCL2 protein |
CTD |
PMID:31157476 PMID:31381935 PMID:34165247 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
decreases expression |
ISO |
luteolin-7-glucoside results in decreased expression of BCL2L1 protein |
CTD |
PMID:34165247 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Bid |
BH3 interacting domain death agonist |
increases expression |
ISO |
luteolin-7-glucoside results in increased expression of BID protein alternative form |
CTD |
PMID:34165247 |
|
NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases cleavage |
ISO |
benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone inhibits the reaction [luteolin-7-glucoside results in increased cleavage of CASP3 protein]; luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of CASP3 protein modified form]; luteolin-7-glucoside inhibits the reaction [Hydrogen Peroxide results in increased cleavage of CASP3 protein] |
CTD |
PMID:31157476 PMID:31381935 PMID:34165247 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
increases cleavage |
ISO |
luteolin-7-glucoside results in increased cleavage of CASP8 protein |
CTD |
PMID:34165247 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
increases cleavage |
ISO |
luteolin-7-glucoside results in increased cleavage of CASP9 protein |
CTD |
PMID:34165247 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
luteolin-7-glucoside inhibits the reaction [Hydrogen Peroxide results in decreased activity of CAT protein] |
CTD |
PMID:31157476 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccna2 |
cyclin A2 |
decreases expression |
ISO |
luteolin-7-glucoside results in decreased expression of CCNA2 protein |
CTD |
PMID:34165247 |
|
NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577
|
|
G |
Ccnb1 |
cyclin B1 |
decreases expression |
ISO |
luteolin-7-glucoside results in decreased expression of CCNB1 protein |
CTD |
PMID:34165247 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
decreases phosphorylation |
ISO |
luteolin-7-glucoside results in decreased phosphorylation of CDK1 protein |
CTD |
PMID:34165247 |
|
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
decreases expression |
ISO |
luteolin-7-glucoside results in decreased expression of CDK2 protein |
CTD |
PMID:34165247 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression |
ISO |
luteolin-7-glucoside results in increased expression of CDKN1A protein |
CTD |
PMID:34165247 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions increases activity |
ISO |
1,3-bis(4-hydroxyphenyl)-4-methyl-5-(4-(2-piperidinylethoxy)phenol)-1H-pyrazole inhibits the reaction [luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of ESR1 protein]]; Fulvestrant inhibits the reaction [luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of ESR1 protein]]; luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of ESR1 protein] luteolin-7-glucoside results in increased activity of ESR1 protein |
CTD |
PMID:31381935 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions increases activity |
ISO |
4-(2-phenyl-5,7-bis(trifluoromethyl)pyrazolo(1,5-a)pyrimidin-3-yl)phenol inhibits the reaction [luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of ESR2 protein]]; Fulvestrant inhibits the reaction [luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of ESR2 protein]]; luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of ESR2 protein] luteolin-7-glucoside results in increased activity of ESR2 protein |
CTD |
PMID:31381935 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Fas |
Fas cell surface death receptor |
increases expression |
ISO |
luteolin-7-glucoside results in increased expression of FAS protein |
CTD |
PMID:34165247 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
1,3-bis(4-hydroxyphenyl)-4-methyl-5-(4-(2-piperidinylethoxy)phenol)-1H-pyrazole inhibits the reaction [luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of FOS protein]]; 4-(2-phenyl-5,7-bis(trifluoromethyl)pyrazolo(1,5-a)pyrimidin-3-yl)phenol inhibits the reaction [luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of FOS protein]]; Fulvestrant inhibits the reaction [luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of FOS protein]]; luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of FOS protein] |
CTD |
PMID:31381935 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
luteolin-7-glucoside inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of IL6 protein] |
CTD |
PMID:11123379 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
decreases phosphorylation multiple interactions |
ISO |
luteolin-7-glucoside results in decreased phosphorylation of MAPK1 protein 1,3-bis(4-hydroxyphenyl)-4-methyl-5-(4-(2-piperidinylethoxy)phenol)-1H-pyrazole inhibits the reaction [luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of MAPK1 protein]]; 4-(2-phenyl-5,7-bis(trifluoromethyl)pyrazolo(1,5-a)pyrimidin-3-yl)phenol inhibits the reaction [luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of MAPK1 protein]]; Fulvestrant inhibits the reaction [luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of MAPK1 protein]]; luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of MAPK1 protein] |
CTD |
PMID:31381935 PMID:34165247 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions decreases phosphorylation |
ISO |
1,3-bis(4-hydroxyphenyl)-4-methyl-5-(4-(2-piperidinylethoxy)phenol)-1H-pyrazole inhibits the reaction [luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of MAPK3 protein]]; 4-(2-phenyl-5,7-bis(trifluoromethyl)pyrazolo(1,5-a)pyrimidin-3-yl)phenol inhibits the reaction [luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of MAPK3 protein]]; Fulvestrant inhibits the reaction [luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of MAPK3 protein]]; luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of MAPK3 protein] luteolin-7-glucoside results in decreased phosphorylation of MAPK3 protein |
CTD |
PMID:31381935 PMID:34165247 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage multiple interactions |
ISO |
luteolin-7-glucoside results in increased cleavage of PARP1 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [luteolin-7-glucoside results in increased cleavage of PARP1 protein]; benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone inhibits the reaction [luteolin-7-glucoside results in increased cleavage of PARP1 protein]; pyrazolanthrone inhibits the reaction [luteolin-7-glucoside results in increased cleavage of PARP1 protein]; SB 203580 promotes the reaction [luteolin-7-glucoside results in increased cleavage of PARP1 protein]; U 0126 inhibits the reaction [luteolin-7-glucoside results in increased cleavage of PARP1 protein] |
CTD |
PMID:34165247 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Ripk1 |
receptor interacting serine/threonine kinase 1 |
increases expression |
ISO |
luteolin-7-glucoside results in increased expression of RIPK1 protein |
CTD |
PMID:34165247 |
|
NCBI chr17:30,839,639...30,871,824
Ensembl chr17:30,839,650...30,871,824
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
ISO |
1,3-bis(4-hydroxyphenyl)-4-methyl-5-(4-(2-piperidinylethoxy)phenol)-1H-pyrazole inhibits the reaction [luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of STAT3 protein]]; 4-(2-phenyl-5,7-bis(trifluoromethyl)pyrazolo(1,5-a)pyrimidin-3-yl)phenol inhibits the reaction [luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of STAT3 protein]]; Fulvestrant inhibits the reaction [luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of STAT3 protein]]; luteolin-7-glucoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of STAT3 protein] |
CTD |
PMID:31381935 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
luteolin-7-glucoside inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of TNF protein] |
CTD |
PMID:11123379 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfrsf1a |
TNF receptor superfamily member 1A |
increases expression |
ISO |
luteolin-7-glucoside results in increased expression of TNFRSF1A protein |
CTD |
PMID:34165247 |
|
NCBI chr 4:158,150,815...158,163,592
Ensembl chr 4:158,150,820...158,163,591
|
|
|
G |
Aqp3 |
aquaporin 3 (Gill blood group) |
multiple interactions |
ISO |
[malvidin-3-glucoside co-treated with petunidin-3-glucoside] results in increased expression of AQP3 mRNA |
CTD |
PMID:33294640 |
|
NCBI chr 5:56,239,200...56,244,718
Ensembl chr 5:56,239,201...56,244,720
|
|
G |
Car1 |
carbonic anhydrase 1 |
decreases activity |
ISO |
malvidin-3-glucoside results in decreased activity of CA1 protein |
CTD |
PMID:28445001 |
|
NCBI chr 2:86,829,436...86,872,209
Ensembl chr 2:86,861,897...86,872,208
|
|
G |
Car2 |
carbonic anhydrase 2 |
decreases activity |
ISO |
malvidin-3-glucoside results in decreased activity of CA2 protein |
CTD |
PMID:28445001 |
|
NCBI chr 2:86,741,625...86,756,766
Ensembl chr 2:86,741,626...86,756,818
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
malvidin-3-glucoside inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] |
CTD |
PMID:23731018 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Pde5a |
phosphodiesterase 5A |
decreases activity |
ISO |
malvidin-3-glucoside results in decreased activity of PDE5A protein |
CTD |
PMID:15769121 |
|
NCBI chr 2:210,858,515...211,003,480
Ensembl chr 2:210,858,063...210,999,701
|
|
G |
Sele |
selectin E |
multiple interactions |
ISO |
malvidin-3-glucoside inhibits the reaction [TNF protein results in increased expression of SELE protein] |
CTD |
PMID:30611791 |
|
NCBI chr13:76,402,841...76,412,741
Ensembl chr13:76,403,304...76,412,741
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
malvidin-3-glucoside inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein] malvidin-3-glucoside inhibits the reaction [TNF protein results in increased expression of SELE protein] |
CTD |
PMID:23731018 PMID:30611791 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Car1 |
carbonic anhydrase 1 |
decreases activity |
ISO |
malvin results in decreased activity of CA1 protein |
CTD |
PMID:28445001 |
|
NCBI chr 2:86,829,436...86,872,209
Ensembl chr 2:86,861,897...86,872,208
|
|
G |
Car2 |
carbonic anhydrase 2 |
decreases activity |
ISO |
malvin results in decreased activity of CA2 protein |
CTD |
PMID:28445001 |
|
NCBI chr 2:86,741,625...86,756,766
Ensembl chr 2:86,741,626...86,756,818
|
|
|
G |
Ikbkb |
inhibitor of nuclear factor kappa B kinase subunit beta |
multiple interactions |
ISO |
monotropein inhibits the reaction [Lipopolysaccharides results in increased activity of IKBKB protein] |
CTD |
PMID:23261679 |
|
NCBI chr16:69,319,487...69,373,251
Ensembl chr16:69,319,554...69,373,250
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
monotropein inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; monotropein inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein] |
CTD |
PMID:23261679 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
ISO |
monotropein inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein] |
CTD |
PMID:23261679 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO |
monotropein inhibits the reaction [Dextran Sulfate affects the localization of NFKB1 protein]; monotropein inhibits the reaction [Lipopolysaccharides affects the localization of NFKB1 protein] |
CTD |
PMID:23261679 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions decreases degradation |
ISO |
monotropein inhibits the reaction [Dextran Sulfate results in increased phosphorylation of NFKBIA protein]; monotropein inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein] monotropein results in decreased degradation of NFKBIA protein |
CTD |
PMID:23261679 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
monotropein inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 protein]; monotropein inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; monotropein inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] |
CTD |
PMID:23261679 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
monotropein inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 protein]; monotropein inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]; monotropein inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein] |
CTD |
PMID:23261679 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
monotropein inhibits the reaction [Dextran Sulfate affects the localization of RELA protein]; monotropein inhibits the reaction [Lipopolysaccharides affects the localization of RELA protein] |
CTD |
PMID:23261679 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
monotropein inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; monotropein inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein] |
CTD |
PMID:23261679 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Hprt1 |
hypoxanthine phosphoribosyltransferase 1 |
increases mutagenesis |
ISO |
1-methoxy-3-indolylmethylglucosinolate metabolite results in increased mutagenesis of HPRT1 gene |
CTD |
PMID:20846518 |
|
NCBI chr X:132,736,175...132,768,149
Ensembl chr X:132,736,096...132,768,154
|
|
G |
Sult1a1 |
sulfotransferase family 1A member 1 |
increases response to substance |
ISO |
SULT1A1 protein results in increased susceptibility to 1-methoxy-3-indolylmethylglucosinolate metabolite |
CTD |
PMID:20846518 |
|
NCBI chr 1:181,272,022...181,276,750
Ensembl chr 1:181,272,023...181,275,562
|
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
multiple interactions |
ISO |
[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in decreased expression of ABCA1 mRNA |
CTD |
PMID:36464106 |
|
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions |
ISO |
[Cephalothin co-treated with Neomycin] results in increased expression of ABCB11 mRNA; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of ABCB11 mRNA |
CTD |
PMID:24657338 PMID:36464106 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions |
ISO |
[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of ABCB1A mRNA |
CTD |
PMID:36464106 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
multiple interactions |
ISO |
[Cephalothin co-treated with Neomycin] results in increased expression of ABCC2 mRNA; [Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of ABCC2 mRNA]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of ABCC2 mRNA |
CTD |
PMID:24657338 PMID:36464106 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
multiple interactions |
ISO |
[Cephalothin co-treated with Neomycin] results in increased expression of ABCC3 mRNA; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of ABCC3 mRNA |
CTD |
PMID:24657338 PMID:36464106 |
|
NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions |
ISO |
[Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of ABCG2 mRNA]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of ABCG2 mRNA |
CTD |
PMID:36464106 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Abcg5 |
ATP binding cassette subfamily G member 5 |
multiple interactions |
ISO |
[Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in decreased expression of ABCG5 mRNA]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in decreased expression of ABCG5 mRNA |
CTD |
PMID:36464106 |
|
NCBI chr 6:9,965,118...9,990,563
Ensembl chr 6:9,965,118...9,990,563
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
multiple interactions |
ISO |
[Vancomycin co-treated with Neomycin co-treated with Metronidazole co-treated with elemicin] results in increased expression of ACACA mRNA |
CTD |
PMID:34979169 |
|
NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
|
|
G |
Acat2 |
acetyl-CoA acetyltransferase 2 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ACAT2 protein |
CTD |
PMID:30545405 |
|
NCBI chr 1:47,695,833...47,713,879
Ensembl chr 1:47,695,788...47,752,821
|
|
G |
Acat2l1 |
acetyl-CoA acetyltransferase 2-like 1 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ACAT2L1 protein |
CTD |
PMID:30545405 |
|
NCBI chr 1:47,803,822...47,829,012
Ensembl chr 1:47,803,813...47,829,151
|
|
G |
Ace2 |
angiotensin converting enzyme 2 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ACE2 protein |
CTD |
PMID:30545405 |
|
NCBI chr X:30,293,597...30,340,961
Ensembl chr X:30,293,589...30,340,977
|
|
G |
Ada |
adenosine deaminase |
decreases activity multiple interactions |
ISO |
Neomycin results in decreased activity of ADA protein Tetrachlorodibenzodioxin inhibits the reaction [Neomycin results in decreased activity of ADA protein] |
CTD |
PMID:7853360 |
|
NCBI chr 3:152,398,745...152,422,854
Ensembl chr 3:152,398,747...152,447,088
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
multiple interactions |
ISO |
[Vancomycin co-treated with Neomycin co-treated with Metronidazole co-treated with elemicin] results in increased expression of ADIPOQ mRNA |
CTD |
PMID:34979169 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Ahsg |
alpha-2-HS-glycoprotein |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of AHSG protein |
CTD |
PMID:30545405 |
|
NCBI chr11:78,121,388...78,127,998
Ensembl chr11:78,117,918...78,145,999
|
|
G |
Aldoa |
aldolase, fructose-bisphosphate A |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ALDOA protein |
CTD |
PMID:30545405 |
|
NCBI chr 1:181,402,275...181,407,476
Ensembl chr 1:181,402,275...181,406,182
|
|
G |
Aldob |
aldolase, fructose-bisphosphate B |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ALDOB protein |
CTD |
PMID:30545405 |
|
NCBI chr 5:63,889,045...63,902,086
Ensembl chr 5:63,889,046...63,902,116
|
|
G |
Apaf1 |
apoptotic peptidase activating factor 1 |
increases expression multiple interactions |
ISO |
Neomycin results in increased expression of APAF1 mRNA peoniflorin inhibits the reaction [Neomycin results in increased expression of APAF1 mRNA] |
CTD |
PMID:29292089 |
|
NCBI chr 7:25,494,143...25,579,540
Ensembl chr 7:25,494,609...25,579,540
|
|
G |
Arg2 |
arginase 2 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of ARG2 protein |
CTD |
PMID:30545405 |
|
NCBI chr 6:97,936,002...97,961,379
Ensembl chr 6:97,936,002...97,961,378
|
|
G |
Arpc3 |
actin related protein 2/3 complex, subunit 3 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ARPC3 protein |
CTD |
PMID:30545405 |
|
NCBI chr12:34,172,780...34,186,651
Ensembl chr12:34,172,780...34,186,651
|
|
G |
Asah1 |
N-acylsphingosine amidohydrolase 1 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of ASAH1 protein |
CTD |
PMID:30545405 |
|
NCBI chr16:50,966,404...50,997,827
Ensembl chr16:50,966,229...51,008,233
|
|
G |
Atp1a1 |
ATPase Na+/K+ transporting subunit alpha 1 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ATP1A1 protein |
CTD |
PMID:30545405 |
|
NCBI chr 2:189,020,722...189,048,826
Ensembl chr 2:189,020,722...189,048,837
|
|
G |
Atp2a3 |
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 3 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ATP2A3 protein |
CTD |
PMID:30545405 |
|
NCBI chr10:57,581,742...57,612,758
Ensembl chr10:57,582,128...57,612,748
|
|
G |
Atp5mf |
ATP synthase membrane subunit f |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ATP5MF protein |
CTD |
PMID:30545405 |
|
NCBI chr12:9,421,665...9,428,236
Ensembl chr12:9,421,579...9,428,236
|
|
G |
Atp5pd |
ATP synthase peripheral stalk subunit d |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ATP5PD protein |
CTD |
PMID:30545405 |
|
NCBI chr10:100,657,700...100,662,960
Ensembl chr10:100,657,708...100,663,479
|
|
G |
Atp5pf |
ATP synthase peripheral stalk subunit F6 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ATP5PF protein |
CTD |
PMID:30545405 |
|
NCBI chr11:23,881,594...23,889,581
Ensembl chr11:23,881,592...23,889,119
|
|
G |
B3galt5 |
Beta-1,3-galactosyltransferase 5 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of B3GALT5 protein |
CTD |
PMID:30545405 |
|
NCBI chr11:35,584,273...35,630,922
Ensembl chr11:35,585,220...35,630,917
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression |
ISO |
peoniflorin inhibits the reaction [Neomycin results in increased expression of BAX mRNA] |
CTD |
PMID:29292089 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcat1 |
branched chain amino acid transaminase 1 |
decreases expression |
ISO |
Neomycin results in decreased expression of BCAT1 mRNA |
CTD |
PMID:30626089 |
|
NCBI chr 4:177,964,834...178,046,573
Ensembl chr 4:177,964,834...178,046,597
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions decreases expression |
ISO |
peoniflorin inhibits the reaction [Neomycin results in decreased expression of BCL2 mRNA]; peoniflorin inhibits the reaction [Neomycin results in decreased expression of BCL2 protein] Neomycin results in decreased expression of BCL2 mRNA; Neomycin results in decreased expression of BCL2 protein |
CTD |
PMID:29292089 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases expression affects cleavage |
ISO |
BIX 01294 affects the reaction [Neomycin affects the cleavage of CASP3 protein]; peoniflorin inhibits the reaction [Neomycin results in increased expression of CASP3 mRNA]; peoniflorin inhibits the reaction [Neomycin results in increased expression of CASP3 protein modified form] Neomycin results in increased expression of CASP3 mRNA; Neomycin results in increased expression of CASP3 protein modified form |
CTD |
PMID:23429292 PMID:29292089 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
increases expression multiple interactions |
ISO |
Neomycin results in increased expression of CASP9 mRNA; Neomycin results in increased expression of CASP9 protein modified form peoniflorin inhibits the reaction [Neomycin results in increased expression of CASP9 mRNA]; peoniflorin inhibits the reaction [Neomycin results in increased expression of CASP9 protein modified form] |
CTD |
PMID:29292089 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Casr |
calcium-sensing receptor |
multiple interactions |
ISO EXP |
CASR protein promotes the reaction [Neomycin results in increased phosphorylation of and results in increased activity of MAPK1 protein]; CASR protein promotes the reaction [Neomycin results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Neomycin binds to and results in increased activity of CASR protein [Neomycin binds to and results in increased activity of CASR protein] which results in increased abundance of Calcium; [Neomycin binds to and results in increased activity of CASR protein] which results in increased abundance of Inositol Phosphates; Neomycin binds to and results in increased activity of CASR protein |
CTD |
PMID:10231437 PMID:17537980 |
|
NCBI chr11:64,235,251...64,304,811
Ensembl chr11:64,235,251...64,304,811
|
|
G |
Ccng2 |
cyclin G2 |
increases expression |
ISO |
Neomycin results in increased expression of CCNG2 mRNA |
CTD |
PMID:30626089 |
|
NCBI chr14:14,804,321...14,812,819
Ensembl chr14:14,804,322...14,812,830
|
|
G |
Cd86 |
CD86 molecule |
increases expression |
ISO |
Neomycin results in increased expression of CD86 protein |
CTD |
PMID:19665512 |
|
NCBI chr11:64,142,193...64,200,816
Ensembl chr11:64,163,828...64,200,818
|
|
G |
Cdh1 |
cadherin 1 |
decreases expression |
ISO |
Neomycin results in decreased expression of CDH1 protein |
CTD |
PMID:15953529 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Clca4 |
chloride channel accessory 4 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of CLCA4 protein |
CTD |
PMID:30545405 |
|
NCBI chr 2:233,883,625...233,904,993
Ensembl chr 2:233,883,851...233,903,089
|
|
G |
Cldn5 |
claudin 5 |
multiple interactions |
ISO |
[Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in decreased expression of CLDN5 mRNA]; [Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in decreased expression of CLDN5 protein] |
CTD |
PMID:35390362 |
|
NCBI chr11:82,212,822...82,214,248
Ensembl chr11:82,211,475...82,214,992
|
|
G |
Cldn7 |
claudin 7 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of CLDN7 protein |
CTD |
PMID:30545405 |
|
NCBI chr10:54,689,684...54,692,177
Ensembl chr10:54,689,987...54,692,171
|
|
G |
Cmbl |
carboxymethylenebutenolidase homolog |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of CMBL protein |
CTD |
PMID:30545405 |
|
NCBI chr 2:82,569,257...82,591,007
Ensembl chr 2:82,571,888...82,591,009
|
|
G |
Cndp2 |
carnosine dipeptidase 2 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of CNDP2 protein |
CTD |
PMID:30545405 |
|
NCBI chr18:78,039,924...78,057,030
Ensembl chr18:78,039,932...78,056,922
|
|
G |
Cox5a |
cytochrome c oxidase subunit 5A |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of COX5A protein |
CTD |
PMID:30545405 |
|
NCBI chr 8:57,922,374...57,933,781
Ensembl chr 8:57,922,290...57,933,781
|
|
G |
Cox6b1 |
cytochrome c oxidase subunit 6B1 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of COX6B1 protein |
CTD |
PMID:30545405 |
|
NCBI chr 1:85,875,080...85,884,081
Ensembl chr 1:85,875,109...85,884,001 Ensembl chr 2:85,875,109...85,884,001
|
|
G |
Cox7a2 |
cytochrome c oxidase subunit 7A2 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of COX7A2 protein |
CTD |
PMID:30545405 |
|
NCBI chr 8:80,716,824...80,720,922
Ensembl chr14:51,301,168...51,301,633 Ensembl chr 8:51,301,168...51,301,633
|
|
G |
Csf2 |
colony stimulating factor 2 |
multiple interactions |
ISO |
[Ampicillin co-treated with Vancomycin co-treated with Neomycin co-treated with Metronidazole] inhibits the reaction [Dextran Sulfate results in increased expression of CSF2 protein]; [Ampicillin co-treated with Vancomycin co-treated with Neomycin co-treated with Metronidazole] results in decreased expression of CSF2 protein |
CTD |
PMID:31442584 |
|
NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199
|
|
G |
Cth |
cystathionine gamma-lyase |
multiple interactions decreases expression |
ISO |
Plant Oils inhibits the reaction [Neomycin results in decreased expression of CTH mRNA] |
CTD |
PMID:30626089 |
|
NCBI chr 2:246,975,888...247,002,234
Ensembl chr 2:246,975,894...247,002,234
|
|
G |
Ctsa |
cathepsin A |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of CTSA protein |
CTD |
PMID:30545405 |
|
NCBI chr 3:153,569,106...153,574,983
Ensembl chr 3:153,568,381...153,576,215
|
|
G |
Cxcl9 |
C-X-C motif chemokine ligand 9 |
multiple interactions |
ISO |
[Vancomycin co-treated with Neomycin co-treated with Cilastatin, Imipenem Drug Combination] inhibits the reaction [Doxorubicin results in increased expression of CXCL9 mRNA]; [Vancomycin co-treated with Neomycin co-treated with Cilastatin, Imipenem Drug Combination] inhibits the reaction [Nanotubes, Carbon promotes the reaction [Doxorubicin results in increased expression of CXCL9 mRNA]] |
CTD |
PMID:32068018 |
|
NCBI chr14:15,722,868...15,727,779
Ensembl chr14:15,722,908...15,728,435
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of CYP1A2 mRNA |
CTD |
PMID:30545405 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp27a1 |
cytochrome P450, family 27, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
[Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in decreased expression of CYP27A1 mRNA]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in decreased expression of CYP27A1 mRNA |
CTD |
PMID:36464106 |
|
NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551
|
|
G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of CYP2C11 mRNA |
CTD |
PMID:30545405 |
|
NCBI chr 1:236,762,719...236,799,069
Ensembl chr 1:236,762,842...236,799,066
|
|
G |
Cyp2d2 |
cytochrome P450, family 2, subfamily d, polypeptide 2 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of CYP2D2 mRNA |
CTD |
PMID:30545405 |
|
NCBI chr 7:113,935,138...113,939,209
Ensembl chr 7:113,935,138...113,939,209
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of CYP2E1 mRNA |
CTD |
PMID:30545405 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of CYP3A2 mRNA |
CTD |
PMID:30545405 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
multiple interactions |
ISO |
[Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in decreased expression of CYP7A1 mRNA]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in decreased expression of CYP7A1 mRNA |
CTD |
PMID:36464106 |
|
NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688
|
|
G |
Cyp7b1 |
cytochrome P450 family 7 subfamily B member 1 |
multiple interactions |
ISO |
[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in decreased expression of CYP7B1 mRNA |
CTD |
PMID:36464106 |
|
NCBI chr 2:100,502,791...100,669,713
Ensembl chr 2:100,502,791...100,669,698
|
|
G |
Cyp8b1 |
cytochrome P450 family 8 subfamily B member 1 |
multiple interactions |
ISO |
[Cephalothin co-treated with Neomycin] results in decreased expression of CYP8B1 mRNA; [Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in decreased expression of CYP8B1 mRNA]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in decreased expression of CYP8B1 mRNA |
CTD |
PMID:24657338 PMID:36464106 |
|
NCBI chr 8:121,578,123...121,580,093
Ensembl chr 8:121,557,062...121,580,166
|
|
G |
Epcam |
epithelial cell adhesion molecule |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of EPCAM protein |
CTD |
PMID:30545405 |
|
NCBI chr 6:6,880,142...6,896,103
Ensembl chr 6:6,878,237...6,896,127
|
|
G |
Etfa |
electron transfer flavoprotein subunit alpha |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ETFA protein |
CTD |
PMID:30545405 |
|
NCBI chr 8:55,835,115...55,891,890
Ensembl chr 8:55,835,134...55,891,969
|
|
G |
Ezr |
ezrin |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of EZR protein |
CTD |
PMID:30545405 |
|
NCBI chr 1:46,967,961...47,011,505
Ensembl chr 1:46,967,658...47,011,505
|
|
G |
Fasn |
fatty acid synthase |
multiple interactions |
ISO |
[Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of FASN mRNA]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of FASN mRNA; [Vancomycin co-treated with Neomycin co-treated with Metronidazole] inhibits the reaction [elemicin results in increased expression of FASN mRNA] |
CTD |
PMID:34979169 PMID:36464106 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Fgf19 |
fibroblast growth factor 19 |
multiple interactions |
ISO |
[Cephalothin co-treated with Neomycin] results in increased expression of FGF15 mRNA |
CTD |
PMID:24657338 |
|
NCBI chr 1:200,056,526...200,060,980
Ensembl chr 1:200,056,644...200,060,287
|
|
G |
Foxo1 |
forkhead box O1 |
multiple interactions increases expression |
ISO |
Plant Oils inhibits the reaction [Neomycin results in increased expression of FOXO1 mRNA] |
CTD |
PMID:30626089 |
|
NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790
|
|
G |
Gadd45g |
growth arrest and DNA-damage-inducible, gamma |
increases expression multiple interactions |
ISO |
Neomycin results in increased expression of GADD45G mRNA Plant Oils inhibits the reaction [Neomycin results in increased expression of GADD45G mRNA] |
CTD |
PMID:30626089 |
|
NCBI chr17:13,376,842...13,378,587
Ensembl chr17:13,376,839...13,378,610
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
multiple interactions |
ISO |
[Vancomycin co-treated with Neomycin co-treated with Metronidazole] promotes the reaction [Zinc Oxide analog results in increased expression of GCLM protein] |
CTD |
PMID:36535435 |
|
NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
|
|
G |
Gfpt2 |
glutamine-fructose-6-phosphate transaminase 2 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of GFPT2 protein |
CTD |
PMID:30545405 |
|
NCBI chr10:34,115,005...34,161,329
Ensembl chr10:34,115,052...34,161,329
|
|
G |
Gipc2 |
GIPC PDZ domain containing family, member 2 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of GIPC2 protein |
CTD |
PMID:30545405 |
|
NCBI chr 2:241,030,764...241,110,236
Ensembl chr 2:241,030,770...241,110,236
|
|
G |
Gng12 |
G protein subunit gamma 12 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of GNG12 protein |
CTD |
PMID:30545405 |
|
NCBI chr 4:96,011,118...96,134,767
Ensembl chr 4:96,010,952...96,134,712
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
ISO |
[Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased activity of GPT protein]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased activity of GPT protein; [Vancomycin co-treated with Neomycin co-treated with Metronidazole] inhibits the reaction [elemicin results in increased activity of GPT protein] |
CTD |
PMID:34979169 PMID:36464106 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gpt2 |
glutamic--pyruvic transaminase 2 |
decreases expression |
ISO |
Neomycin results in decreased expression of GPT2 mRNA |
CTD |
PMID:30626089 |
|
NCBI chr19:21,526,800...21,561,314
Ensembl chr19:21,517,621...21,560,610
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of GPX1 protein |
CTD |
PMID:30545405 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gsta3 |
glutathione S-transferase alpha 3 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of GSTA3 mRNA |
CTD |
PMID:30545405 |
|
NCBI chr 9:23,658,574...23,684,240
Ensembl chr 9:23,658,574...23,684,240
|
|
G |
Gstm2 |
glutathione S-transferase mu 2 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of GSTM2 mRNA |
CTD |
PMID:30545405 |
|
NCBI chr 2:195,624,015...195,628,774
Ensembl chr 2:195,544,426...195,628,961
|
|
G |
Hexb |
hexosaminidase subunit beta |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of HEXB protein |
CTD |
PMID:30545405 |
|
NCBI chr 2:28,483,997...28,504,165
Ensembl chr 2:28,484,012...28,504,223
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
multiple interactions |
ISO |
[Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of HMGCR mRNA]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of HMGCR mRNA |
CTD |
PMID:36464106 |
|
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
ISO |
[Vancomycin co-treated with Neomycin co-treated with Metronidazole] promotes the reaction [Zinc Oxide analog results in increased expression of HMOX1 protein] |
CTD |
PMID:36535435 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hnrnph2 |
heterogeneous nuclear ribonucleoprotein H2 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of HNRNPH2 protein |
CTD |
PMID:30545405 |
|
NCBI chr X:97,780,890...97,786,846
Ensembl chr X:97,780,785...97,787,041
|
|
G |
Hp |
haptoglobin |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of HP protein |
CTD |
PMID:30545405 |
|
NCBI chr19:37,539,626...37,544,178
Ensembl chr19:37,539,627...37,544,523
|
|
G |
Hspd1 |
heat shock protein family D (Hsp60) member 1 |
multiple interactions |
EXP |
Neomycin inhibits the reaction [Adenosine Triphosphate results in increased expression of HSPD1 protein] |
CTD |
PMID:16178011 |
|
NCBI chr 9:56,579,195...56,590,011
Ensembl chr 9:56,579,201...56,589,662
|
|
G |
Htr4 |
5-hydroxytryptamine receptor 4 |
multiple interactions |
ISO |
[Vancomycin co-treated with Neomycin co-treated with Metronidazole] promotes the reaction [Zinc Oxide results in increased expression of HTR4 mRNA]; [Vancomycin co-treated with Neomycin co-treated with Metronidazole] results in increased expression of HTR4 mRNA |
CTD |
PMID:36535435 |
|
NCBI chr18:55,765,981...55,949,921
Ensembl chr18:55,766,725...55,949,321
|
|
G |
Il18 |
interleukin 18 |
multiple interactions |
ISO |
[Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in increased secretion of IL18 protein] |
CTD |
PMID:35390362 |
|
NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
[Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in increased expression of and results in increased secretion of IL1B protein]; [Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in increased expression of IL1B mRNA]; [Vancomycin co-treated with Neomycin co-treated with Cilastatin, Imipenem Drug Combination] inhibits the reaction [Doxorubicin results in increased expression of IL1B protein]; [Vancomycin co-treated with Neomycin co-treated with Cilastatin, Imipenem Drug Combination] inhibits the reaction [Nanotubes, Carbon promotes the reaction [Doxorubicin results in increased expression of IL1B protein]] |
CTD |
PMID:32068018 PMID:35390362 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
[Ampicillin co-treated with Vancomycin co-treated with Neomycin co-treated with Metronidazole] inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; [Ampicillin co-treated with Vancomycin co-treated with Neomycin co-treated with Metronidazole] results in decreased expression of IL6 protein; Dextran Sulfate inhibits the reaction [[Ampicillin co-treated with Vancomycin co-treated with Neomycin co-treated with Metronidazole] results in decreased expression of IL6 protein] |
CTD |
PMID:31442584 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Inhba |
inhibin subunit beta A |
increases expression |
ISO |
Neomycin results in increased expression of INHBA mRNA |
CTD |
PMID:30626089 |
|
NCBI chr17:49,091,635...49,111,573
Ensembl chr17:49,095,920...49,108,982
|
|
G |
Ins2 |
insulin 2 |
multiple interactions |
EXP |
Neomycin inhibits the reaction [INS protein results in increased uptake of cobaltous chloride] |
CTD |
PMID:14622148 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Irs2 |
insulin receptor substrate 2 |
increases expression |
ISO |
Neomycin results in increased expression of IRS2 mRNA |
CTD |
PMID:30626089 |
|
NCBI chr16:78,488,249...78,512,482
Ensembl chr16:78,485,045...78,512,482
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases expression |
EXP |
3,9-bis((ethylthio)methyl)-K-252a inhibits the reaction [Neomycin results in increased expression of JUN protein modified form] |
CTD |
PMID:10627579 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Klf2 |
KLF transcription factor 2 |
increases expression |
ISO |
Neomycin results in increased expression of KLF2 mRNA |
CTD |
PMID:30626089 |
|
NCBI chr16:17,521,107...17,523,739
Ensembl chr16:17,514,552...17,523,944
|
|
G |
Kng2 |
kininogen 2 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of MAP1 protein |
CTD |
PMID:30545405 |
|
NCBI chr11:77,913,876...77,936,247
Ensembl chr11:77,909,612...78,002,971
|
|
G |
Krt16 |
keratin 16 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of KRT16 protein |
CTD |
PMID:30545405 |
|
NCBI chr10:85,168,357...85,171,816
Ensembl chr10:85,066,802...85,171,799
|
|
G |
Ldlr |
low density lipoprotein receptor |
multiple interactions |
ISO |
[Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of LDLR mRNA]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of LDLR mRNA |
CTD |
PMID:36464106 |
|
NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580
|
|
G |
Lep |
leptin |
multiple interactions |
ISO |
[Vancomycin co-treated with Neomycin co-treated with Metronidazole co-treated with elemicin] results in increased expression of LEP mRNA |
CTD |
PMID:34979169 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Lpin1 |
lipin 1 |
multiple interactions |
ISO |
[Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of LPIN1 mRNA]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of LPIN1 mRNA |
CTD |
PMID:36464106 |
|
NCBI chr 6:39,309,198...39,417,034
Ensembl chr 6:39,312,748...39,417,097
|
|
G |
Lyz2 |
lysozyme 2 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of LYZ2 protein |
CTD |
PMID:30545405 |
|
NCBI chr 7:52,906,810...52,912,154
Ensembl chr 7:52,906,811...52,912,106
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases expression |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Neomycin results in increased phosphorylation of and results in increased activity of MAPK1 protein]; CASR protein promotes the reaction [Neomycin results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Neomycin results in increased phosphorylation of and results in increased activity of MAPK1 protein peoniflorin inhibits the reaction [Neomycin results in increased expression of MAPK1 protein modified form] |
CTD |
PMID:17537980 PMID:29292089 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases expression |
ISO EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Neomycin results in increased phosphorylation of and results in increased activity of MAPK3 protein]; CASR protein promotes the reaction [Neomycin results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Neomycin results in increased phosphorylation of and results in increased activity of MAPK3 protein [Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of MAPK3 protein Neomycin results in increased expression of MAPK3 protein modified form peoniflorin inhibits the reaction [Neomycin results in increased expression of MAPK3 protein modified form] |
CTD |
PMID:17537980 PMID:29292089 PMID:30545405 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mlxip |
MLX interacting protein |
multiple interactions |
ISO |
[Vancomycin co-treated with Neomycin co-treated with Metronidazole] inhibits the reaction [elemicin results in increased expression of MLXIP mRNA] |
CTD |
PMID:34979169 |
|
NCBI chr12:33,128,524...33,192,300
Ensembl chr12:33,128,520...33,192,374
|
|
G |
Mthfd2 |
methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase |
multiple interactions decreases expression |
ISO |
Plant Oils inhibits the reaction [Neomycin results in decreased expression of MTHFD2 mRNA] |
CTD |
PMID:30626089 |
|
NCBI chr 4:115,811,135...115,822,663
Ensembl chr 4:115,811,139...115,822,608
|
|
G |
Myd88 |
MYD88, innate immune signal transduction adaptor |
multiple interactions |
ISO |
[Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in increased expression of MYD88 mRNA]; [Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in increased expression of MYD88 protein] |
CTD |
PMID:35390362 |
|
NCBI chr 8:119,074,439...119,078,508
Ensembl chr 8:119,074,437...119,079,415
|
|
G |
Myh14 |
myosin heavy chain 14 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of MYH14 protein |
CTD |
PMID:30545405 |
|
NCBI chr 1:95,096,266...95,158,861
Ensembl chr 1:95,096,266...95,158,836
|
|
G |
Ndufa13 |
NADH:ubiquinone oxidoreductase subunit A13 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of NDUFA13 protein |
CTD |
PMID:30545405 |
|
NCBI chr16:19,526,633...19,533,567
Ensembl chr16:19,526,565...19,535,726
|
|
G |
Ndufab1 |
NADH:ubiquinone oxidoreductase subunit AB1 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of NDUFAB1 protein |
CTD |
PMID:30545405 |
|
NCBI chr 1:176,644,696...176,658,131
Ensembl chr 1:176,644,703...176,658,099
|
|
G |
Nog |
noggin |
increases expression |
ISO |
Neomycin results in increased expression of NOG mRNA |
CTD |
PMID:30626089 |
|
NCBI chr10:74,128,712...74,130,339
Ensembl chr10:74,128,712...74,130,339
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
[Vancomycin co-treated with Neomycin co-treated with Cilastatin, Imipenem Drug Combination] inhibits the reaction [Doxorubicin results in increased expression of NOS2 mRNA]; [Vancomycin co-treated with Neomycin co-treated with Cilastatin, Imipenem Drug Combination] inhibits the reaction [Nanotubes, Carbon promotes the reaction [Doxorubicin results in increased expression of NOS2 mRNA]] |
CTD |
PMID:32068018 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Npc1l1 |
NPC1 like intracellular cholesterol transporter 1 |
multiple interactions |
ISO |
[Cephalothin co-treated with Neomycin] results in increased expression of NPC1L1 mRNA |
CTD |
PMID:24657338 |
|
NCBI chr14:81,071,448...81,091,113
Ensembl chr14:81,071,451...81,091,113
|
|
G |
Npc2 |
NPC intracellular cholesterol transporter 2 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of NPC2 protein |
CTD |
PMID:30545405 |
|
NCBI chr 6:104,397,239...104,418,161
Ensembl chr 6:104,378,644...104,418,155
|
|
G |
Nr5a2 |
nuclear receptor subfamily 5, group A, member 2 |
multiple interactions |
ISO |
[Cephalothin co-treated with Neomycin] results in increased expression of NR5A2 mRNA |
CTD |
PMID:24657338 |
|
NCBI chr13:48,313,634...48,433,494
Ensembl chr13:48,316,301...48,433,326
|
|
G |
Ocln |
occludin |
multiple interactions |
ISO |
[Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in decreased expression of OCLN mRNA]; [Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in decreased expression of OCLN protein] |
CTD |
PMID:35390362 |
|
NCBI chr 2:31,657,217...31,707,466
Ensembl chr 2:31,657,220...31,764,150
|
|
G |
Pdxkl1 |
pyridoxal kinase like 1 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of PDXK protein |
CTD |
PMID:30545405 |
|
NCBI chr20:10,162,934...10,192,572
Ensembl chr20:10,164,099...10,192,739
|
|
G |
Pfn1 |
profilin 1 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of PFN1 protein |
CTD |
PMID:30545405 |
|
NCBI chr10:55,365,263...55,367,968
Ensembl chr10:55,365,262...55,527,631
|
|
G |
Pgam1 |
phosphoglycerate mutase 1 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of PGAM1 protein |
CTD |
PMID:30545405 |
|
NCBI chr 1:240,723,832...240,731,443
Ensembl chr 1:240,723,920...240,738,452
|
|
G |
Pmm2 |
phosphomannomutase 2 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of PMM2 protein |
CTD |
PMID:30545405 |
|
NCBI chr10:6,961,521...6,982,913
Ensembl chr10:6,961,709...6,983,098
|
|
G |
Ppp1ca |
protein phosphatase 1 catalytic subunit alpha |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of PPP1CA protein |
CTD |
PMID:30545405 |
|
NCBI chr 1:201,485,117...201,488,734
Ensembl chr 1:201,485,085...201,497,327
|
|
G |
Ppp1cb |
protein phosphatase 1 catalytic subunit beta |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of PPP1CB protein |
CTD |
PMID:30545405 |
|
NCBI chr 6:23,958,813...23,992,841
Ensembl chr 6:23,960,998...23,992,824
|
|
G |
Ppp1cc |
protein phosphatase 1 catalytic subunit gamma |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of PPP1CC protein |
CTD |
PMID:30545405 |
|
NCBI chr12:34,383,072...34,400,553
Ensembl chr12:34,383,072...34,400,553
|
|
G |
Psat1 |
phosphoserine aminotransferase 1 |
multiple interactions decreases expression |
ISO |
Plant Oils inhibits the reaction [Neomycin results in decreased expression of PSAT1 mRNA] |
CTD |
PMID:30626089 |
|
NCBI chr 1:213,196,709...213,218,564
Ensembl chr 1:213,196,709...213,218,682
|
|
G |
Psma3 |
proteasome 20S subunit alpha 3 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of PSMA3 protein |
CTD |
PMID:30545405 |
|
NCBI chr 6:89,483,741...89,503,775
Ensembl chr 6:89,483,727...89,504,965
|
|
G |
Psph |
phosphoserine phosphatase |
decreases expression multiple interactions |
ISO |
Neomycin results in decreased expression of PSPH mRNA Plant Oils inhibits the reaction [Neomycin results in decreased expression of PSPH mRNA] |
CTD |
PMID:30626089 |
|
NCBI chr12:26,882,524...26,905,084
Ensembl chr12:26,883,133...26,905,074
|
|
G |
Ralb |
RAS like proto-oncogene B |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of RALB protein |
CTD |
PMID:30545405 |
|
NCBI chr13:30,588,036...30,624,199
Ensembl chr13:30,588,033...30,624,202
|
|
G |
Ran |
RAN, member RAS oncogene family |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of RAN protein |
CTD |
PMID:30545405 |
|
NCBI chr12:27,674,049...27,678,598
Ensembl chr12:27,674,050...27,678,276
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
[Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in increased expression of RELA mRNA]; [Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in increased expression of RELA protein] |
CTD |
PMID:35390362 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rida |
reactive intermediate imine deaminase A homolog |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of RIDA protein |
CTD |
PMID:30545405 |
|
NCBI chr 7:65,691,429...65,705,257
Ensembl chr 7:65,691,435...65,705,716
|
|
G |
Rpl30 |
ribosomal protein L30 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of RPL30 protein |
CTD |
PMID:30545405 |
|
NCBI chr 7:65,648,266...65,651,401
Ensembl chr 7:65,645,991...65,651,363 Ensembl chr10:65,645,991...65,651,363 Ensembl chr10:65,645,991...65,651,363
|
|
G |
Rpn2 |
ribophorin II |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of RPN2 protein |
CTD |
PMID:30545405 |
|
NCBI chr 3:145,941,787...145,989,271
Ensembl chr 3:145,941,839...145,989,543
|
|
G |
Rps23 |
ribosomal protein S23 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of RPS23 protein |
CTD |
PMID:30545405 |
|
NCBI chr 2:22,079,339...22,080,909
Ensembl chr 2:22,079,302...22,080,918
|
|
G |
Rps27l |
ribosomal protein S27-like |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of RPS27L protein |
CTD |
PMID:30545405 |
|
NCBI chr 8:67,562,483...67,567,418
Ensembl chr 8:67,562,483...67,567,418
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
affects phosphorylation |
ISO |
Neomycin affects the phosphorylation of RPS6KB1 protein |
CTD |
PMID:16537399 |
|
NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
|
|
G |
RT1-DMb |
RT1 class II, locus DMb |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of RT1-DMB protein |
CTD |
PMID:30545405 |
|
NCBI chr20:4,693,102...4,700,340
Ensembl chr20:4,693,103...4,700,340
|
|
G |
S100a10 |
S100 calcium binding protein A10 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of S100A10 protein |
CTD |
PMID:30545405 |
|
NCBI chr 2:179,221,012...179,229,659
Ensembl chr 2:179,220,887...179,229,661
|
|
G |
S100a11 |
S100 calcium binding protein A11 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of S100A11 protein |
CTD |
PMID:30545405 |
|
NCBI chr 2:179,191,688...179,197,098
Ensembl chr 2:179,191,715...179,197,044
|
|
G |
Scarb2 |
scavenger receptor class B, member 2 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of SCARB2 protein |
CTD |
PMID:30545405 |
|
NCBI chr14:15,558,271...15,609,813
Ensembl chr14:15,558,236...15,609,813
|
|
G |
Serpinb6a |
serpin family B member 6A |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of SERPINB6 protein |
CTD |
PMID:30545405 |
|
NCBI chr17:30,871,468...30,989,703
Ensembl chr17:30,871,468...31,014,427
|
|
G |
Shmt2 |
serine hydroxymethyltransferase 2 |
decreases expression multiple interactions |
ISO EXP |
Neomycin results in decreased expression of SHMT2 mRNA [Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of SHMT2 protein |
CTD |
PMID:30545405 PMID:30626089 |
|
NCBI chr 7:63,358,961...63,364,293
Ensembl chr 7:63,358,961...63,364,236
|
|
G |
Slc10a1 |
solute carrier family 10 member 1 |
multiple interactions |
ISO |
[Cephalothin co-treated with Neomycin] results in increased expression of SLC10A1 mRNA |
CTD |
PMID:24657338 |
|
NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670
|
|
G |
Slc22a7 |
solute carrier family 22 member 7 |
multiple interactions |
ISO |
[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of SLC22A7 mRNA |
CTD |
PMID:36464106 |
|
NCBI chr 9:14,547,073...14,554,354
Ensembl chr 9:14,547,849...14,553,921
|
|
G |
Slc3a1 |
solute carrier family 3 member 1 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of SLC3A1 protein |
CTD |
PMID:30545405 |
|
NCBI chr 6:9,608,169...9,641,881
Ensembl chr 6:9,608,178...9,641,907
|
|
G |
Slc51b |
SLC51 subunit beta |
multiple interactions |
ISO |
[Cephalothin co-treated with Neomycin] results in decreased expression of SLC51B mRNA |
CTD |
PMID:24657338 |
|
NCBI chr 8:65,931,891...65,939,953
Ensembl chr 8:65,931,890...65,940,145
|
|
G |
Slco1b2 |
solute carrier organic anion transporter family member 1B2 |
multiple interactions |
ISO |
[Cephalothin co-treated with Neomycin] results in increased expression of SLCO1B2 mRNA |
CTD |
PMID:24657338 |
|
NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981
|
|
G |
Smad6 |
SMAD family member 6 |
increases expression |
ISO |
Neomycin results in increased expression of SMAD6 mRNA |
CTD |
PMID:30626089 |
|
NCBI chr 8:64,450,114...64,519,673
Ensembl chr 8:64,450,114...64,519,763
|
|
G |
Smad9 |
SMAD family member 9 |
increases expression |
ISO |
Neomycin results in increased expression of SMAD9 mRNA |
CTD |
PMID:30626089 |
|
NCBI chr 2:138,956,326...139,006,315
Ensembl chr 2:138,986,471...139,006,307
|
|
G |
Smpd2 |
sphingomyelin phosphodiesterase 2 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of SMPD2 protein |
CTD |
PMID:30545405 |
|
NCBI chr20:44,986,229...44,989,343
Ensembl chr20:44,986,231...44,989,441
|
|
G |
Sqle |
squalene epoxidase |
multiple interactions |
ISO |
[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of SQLE mRNA |
CTD |
PMID:36464106 |
|
NCBI chr 7:90,867,973...90,883,623
Ensembl chr 7:90,868,011...90,883,618
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions |
ISO |
[Vancomycin co-treated with Neomycin co-treated with Metronidazole] promotes the reaction [Zinc Oxide analog results in increased expression of SQSTM1 protein] |
CTD |
PMID:36535435 |
|
NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions |
ISO |
[Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of SREBF1 mRNA]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of SREBF1 mRNA |
CTD |
PMID:36464106 |
|
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
|
|
G |
Srebf2 |
sterol regulatory element binding transcription factor 2 |
multiple interactions |
ISO |
[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of SREBF2 mRNA |
CTD |
PMID:36464106 |
|
NCBI chr 7:113,663,202...113,720,850
Ensembl chr 7:113,663,202...113,720,848
|
|
G |
Sst |
somatostatin |
multiple interactions |
ISO |
[Vancomycin co-treated with Neomycin co-treated with Metronidazole] promotes the reaction [Zinc Oxide results in increased expression of SST mRNA]; [Vancomycin co-treated with Neomycin co-treated with Metronidazole] results in increased expression of SST mRNA |
CTD |
PMID:36535435 |
|
NCBI chr11:76,956,896...76,958,173
Ensembl chr11:76,956,896...76,958,173
|
|
G |
Sstr2 |
somatostatin receptor 2 |
multiple interactions |
ISO |
[Vancomycin co-treated with Neomycin co-treated with Metronidazole] promotes the reaction [Zinc Oxide results in increased expression of SSTR2 mRNA] |
CTD |
PMID:36535435 |
|
NCBI chr10:98,664,204...98,671,370
Ensembl chr10:98,664,216...98,674,351
|
|
G |
Tars1 |
threonyl-tRNA synthetase 1 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of TARS1 protein |
CTD |
PMID:30545405 |
|
NCBI chr 2:60,368,893...60,387,715
Ensembl chr 2:60,367,796...60,387,717
|
|
G |
Tgfb2 |
transforming growth factor, beta 2 |
increases expression multiple interactions |
ISO |
Neomycin results in increased expression of TGFB2 mRNA Plant Oils inhibits the reaction [Neomycin results in increased expression of TGFB2 mRNA] |
CTD |
PMID:30626089 |
|
NCBI chr13:98,160,075...98,261,771
Ensembl chr13:98,160,087...98,261,405
|
|
G |
Tjp1 |
tight junction protein 1 |
multiple interactions |
ISO |
[Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in decreased expression of TJP1 mRNA]; [Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in decreased expression of TJP1 protein] |
CTD |
PMID:35390362 |
|
NCBI chr 1:118,849,838...119,094,492
Ensembl chr 1:118,849,838...119,094,432
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions |
ISO |
[Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in increased expression of TLR4 mRNA]; [Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in increased expression of TLR4 protein]; TLR4 gene mutant form results in decreased susceptibility to [Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] |
CTD |
PMID:35390362 |
|
NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
|
|
G |
Tm9sf2 |
transmembrane 9 superfamily member 2 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of TM9SF2 protein |
CTD |
PMID:30545405 |
|
NCBI chr15:99,201,556...99,254,054
Ensembl chr15:99,201,489...99,254,049
|
|
G |
Tmed10 |
transmembrane p24 trafficking protein 10 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of TMED10 protein |
CTD |
PMID:30545405 |
|
NCBI chr 6:104,991,843...105,026,705
Ensembl chr 6:104,991,838...105,026,753
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
[Ampicillin co-treated with Vancomycin co-treated with Neomycin co-treated with Metronidazole] inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; [Ampicillin co-treated with Vancomycin co-treated with Neomycin co-treated with Metronidazole] results in decreased expression of TNF protein; [Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in increased expression of and results in increased secretion of TNF protein]; [Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in increased expression of TNF mRNA]; [Vancomycin co-treated with Neomycin co-treated with Cilastatin, Imipenem Drug Combination] inhibits the reaction [Doxorubicin results in increased expression of TNF protein]; [Vancomycin co-treated with Neomycin co-treated with Cilastatin, Imipenem Drug Combination] inhibits the reaction [Nanotubes, Carbon promotes the reaction [Doxorubicin results in increased expression of TNF protein]]; Dextran Sulfate inhibits the reaction [[Ampicillin co-treated with Vancomycin co-treated with Neomycin co-treated with Metronidazole] results in decreased expression of TNF protein] |
CTD |
PMID:31442584 PMID:32068018 PMID:35390362 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Traf6 |
TNF receptor associated factor 6 |
multiple interactions |
ISO |
[Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in increased expression of TRAF6 mRNA]; [Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in increased expression of TRAF6 protein] |
CTD |
PMID:35390362 |
|
NCBI chr 3:87,963,517...87,988,316
Ensembl chr 3:87,963,514...87,983,507
|
|
G |
Tubal3 |
tubulin, alpha-like 3 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of TUBAL3 protein |
CTD |
PMID:30545405 |
|
NCBI chr17:66,323,733...66,332,423
Ensembl chr17:66,323,733...66,335,355
|
|
G |
Twf1 |
twinfilin actin-binding protein 1 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of TWF1 protein |
CTD |
PMID:30545405 |
|
NCBI chr 7:125,715,938...125,727,834
Ensembl chr 7:125,716,015...125,727,894
|
|
G |
Txn1 |
thioredoxin 1 |
multiple interactions |
ISO |
[Vancomycin co-treated with Neomycin co-treated with Metronidazole] promotes the reaction [Zinc Oxide analog results in increased expression of TXN1 protein] |
CTD |
PMID:36535435 |
|
NCBI chr 5:72,712,334...72,724,564
Ensembl chr 5:72,711,933...72,724,629
|
|
G |
Txndc5 |
thioredoxin domain containing 5 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of TXNDC5 protein |
CTD |
PMID:30545405 |
|
NCBI chr17:26,289,880...26,318,025
Ensembl chr17:26,289,880...26,318,025
|
|
G |
Uqcrc1 |
ubiquinol-cytochrome c reductase core protein 1 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of UQCRC1 protein |
CTD |
PMID:30545405 |
|
NCBI chr 8:109,589,735...109,601,481
Ensembl chr 8:109,589,706...109,601,480
|
|
G |
Uqcrfs1 |
ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of UQCRFS1 protein |
CTD |
PMID:30545405 |
|
NCBI chr17:33,977,908...33,982,478
Ensembl chr17:33,977,921...33,982,479
|
|
G |
Uqcrh |
ubiquinol-cytochrome c reductase hinge protein |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of UQCRH protein |
CTD |
PMID:30545405 |
|
NCBI chr 5:129,545,978...129,554,173
Ensembl chr 5:129,545,984...129,554,242
|
|
G |
Vdr |
vitamin D receptor |
multiple interactions |
ISO |
[Cephalothin co-treated with Neomycin] results in increased expression of VDR mRNA |
CTD |
PMID:24657338 |
|
NCBI chr 7:128,987,981...129,037,677
Ensembl chr 7:128,987,981...129,037,677
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
increases transport |
EXP ISO |
ABCB11 protein results in increased transport of notoginsenoside R1 |
CTD |
PMID:25297453 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases expression multiple interactions |
ISO |
notoginsenoside R1 results in increased expression of ABCB1 mRNA notoginsenoside R1 results in increased expression of ABCB1A mRNA NR1I2 protein promotes the reaction [notoginsenoside R1 results in increased expression of ABCB1 mRNA] |
CTD |
PMID:25472953 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
increases transport |
ISO |
ABCC1 protein results in increased transport of notoginsenoside R1 |
CTD |
PMID:25297453 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
increases transport |
EXP ISO |
ABCC2 protein results in increased transport of notoginsenoside R1 |
CTD |
PMID:25297453 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
increases transport |
EXP ISO |
ABCG2 protein results in increased transport of notoginsenoside R1 |
CTD |
PMID:25297453 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
increases phosphorylation multiple interactions |
ISO |
notoginsenoside R1 results in increased phosphorylation of AKT1 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [notoginsenoside R1 results in increased phosphorylation of AKT1 protein]; notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate results in decreased phosphorylation of AKT1 protein] |
CTD |
PMID:33689844 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Apoe |
apolipoprotein E |
multiple interactions |
ISO |
notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in decreased abundance of Glutathione]; notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in decreased expression of MIR20A mRNA]; notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased abundance of Cholesterol]; notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased abundance of Triglycerides]; notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased expression of IFNG protein]; notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased expression of IL2 protein]; notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased expression of IL6 protein]; notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased expression of MIR126A mRNA]; notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased expression of MIR21A mRNA]; notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased expression of TNF protein] |
CTD |
PMID:24933211 |
|
NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
ISO EXP |
notoginsenoside R1 inhibits the reaction [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in increased expression of APP protein modified form] notoginsenoside R1 inhibits the reaction [APP protein modified form results in decreased expression of BCL2 protein]; notoginsenoside R1 inhibits the reaction [APP protein modified form results in increased cleavage of CASP3 protein]; notoginsenoside R1 inhibits the reaction [APP protein modified form results in increased expression of BAX protein]; notoginsenoside R1 inhibits the reaction [APP protein modified form results in increased phosphorylation of MAPK1 protein]; notoginsenoside R1 inhibits the reaction [APP protein modified form results in increased phosphorylation of MAPK3 protein]; notoginsenoside R1 inhibits the reaction [APP protein modified form results in increased phosphorylation of MAPK8 protein]; notoginsenoside R1 inhibits the reaction [APP protein modified form results in increased phosphorylation of MAPK9 protein] |
CTD |
PMID:24975829 PMID:25714973 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Atp5f1d |
ATP synthase F1 subunit delta |
multiple interactions |
EXP |
15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid inhibits the reaction [notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in decreased expression of ATP5F1D protein]]; notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in decreased expression of ATP5F1D protein] |
CTD |
PMID:25305180 |
|
NCBI chr 7:9,560,604...9,565,919
Ensembl chr 7:9,560,608...9,565,929
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate results in increased expression of BAX protein]]; 3-(2,4-dichloro-5-methoxyphenyl)-2-sulfanyl-4(3H)-quinazolinone inhibits the reaction [notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate results in increased expression of BAX protein]]; Cyclosporine inhibits the reaction [notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate results in increased expression of BAX protein]]; notoginsenoside R1 inhibits the reaction [Excitatory Amino Acid Agonists results in increased expression of BAX protein]; notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate results in increased expression of BAX protein] notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in increased expression of BAX protein]; notoginsenoside R1 inhibits the reaction [APP protein modified form results in increased expression of BAX protein] |
CTD |
PMID:19224577 PMID:24975829 PMID:25305180 PMID:33689844 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions increases expression |
ISO EXP |
notoginsenoside R1 inhibits the reaction [Excitatory Amino Acid Agonists results in decreased expression of BCL2 protein]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein] notoginsenoside R1 results in increased expression of BCL2 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid inhibits the reaction [notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in decreased expression of BCL2 protein]]; notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in decreased expression of BCL2 protein]; notoginsenoside R1 inhibits the reaction [APP protein modified form results in decreased expression of BCL2 protein] |
CTD |
PMID:19224577 PMID:20023602 PMID:23170834 PMID:24975829 PMID:25305180 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
multiple interactions increases expression |
ISO |
fulvestrant inhibits the reaction [notoginsenoside R1 results in increased expression of BGLAP mRNA] |
CTD |
PMID:26362186 |
|
NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495
|
|
G |
Bid |
BH3 interacting domain death agonist |
multiple interactions |
ISO |
notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of BID protein modified form] |
CTD |
PMID:23170834 |
|
NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate results in increased cleavage of CASP3 protein]]; 3-(2,4-dichloro-5-methoxyphenyl)-2-sulfanyl-4(3H)-quinazolinone inhibits the reaction [notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate results in increased cleavage of CASP3 protein]]; Cyclosporine inhibits the reaction [notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate results in increased cleavage of CASP3 protein]]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased activity of CASP3 protein]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of CASP3 protein modified form]; notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate results in increased cleavage of CASP3 protein] 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid inhibits the reaction [notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in increased cleavage of CASP3 protein]]; notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in increased activity of CASP3 protein]; notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in increased cleavage of CASP3 protein]; notoginsenoside R1 inhibits the reaction [APP protein modified form results in increased cleavage of CASP3 protein]; notoginsenoside R1 inhibits the reaction [Hydrogen Peroxide results in increased activity of CASP3 protein]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased activity of CASP3 protein] |
CTD |
PMID:23170834 PMID:24437944 PMID:24720662 PMID:24975829 PMID:25305180 PMID:25738436 PMID:33689844 More...
|
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased activity of CASP8 protein] |
CTD |
PMID:23170834 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
ISO |
notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased activity of CASP9 protein] |
CTD |
PMID:23170834 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
notoginsenoside R1 inhibits the reaction [Streptozocin results in decreased activity of CAT protein] |
CTD |
PMID:25503068 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 protein] |
CTD |
PMID:23170834 PMID:25472953 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Chat |
choline O-acetyltransferase |
increases expression |
ISO |
notoginsenoside R1 results in increased expression of CHAT |
CTD |
PMID:25714973 |
|
NCBI chr16:7,657,362...7,717,093
Ensembl chr16:7,657,362...7,717,093
|
|
G |
Chuk |
component of inhibitor of nuclear factor kappa B kinase complex |
multiple interactions |
ISO |
notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of CHUK protein modified form] |
CTD |
PMID:25472953 |
|
NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
decreases activity |
EXP |
notoginsenoside R1 results in decreased activity of CYP1A2 protein |
CTD |
PMID:25834921 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
increases expression |
ISO |
notoginsenoside R1 results in increased expression of CYP3A4 mRNA |
CTD |
PMID:25472953 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions increases expression |
ISO EXP |
notoginsenoside R1 results in increased phosphorylation of and results in increased activity of ESR1 protein notoginsenoside R1 results in increased expression of ESR1; notoginsenoside R1 results in increased expression of ESR1 mRNA; notoginsenoside R1 results in increased expression of ESR1 protein [1,3-bis(4-hydroxyphenyl)-4-methyl-5-(4-(2-piperidinylethoxy)phenol)-1H-pyrazole results in decreased activity of ESR1 protein] which results in decreased susceptibility to notoginsenoside R1; [notoginsenoside R1 co-treated with Lipopolysaccharides] results in increased expression of ESR1 protein; fulvestrant inhibits the reaction [[notoginsenoside R1 co-treated with Lipopolysaccharides] results in increased expression of ESR1 protein] |
CTD |
PMID:23170834 PMID:24720662 PMID:25738436 PMID:26362186 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
increases expression |
EXP |
notoginsenoside R1 results in increased expression of ESR2 |
CTD |
PMID:24720662 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
F3 |
coagulation factor III, tissue factor |
multiple interactions |
ISO |
notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of F3 mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of F3 protein] |
CTD |
PMID:9102164 |
|
NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668
|
|
G |
Fas |
Fas cell surface death receptor |
multiple interactions |
ISO |
notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of FAS mRNA] |
CTD |
PMID:23170834 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Fn1 |
fibronectin 1 |
multiple interactions |
ISO |
notoginsenoside R1 inhibits the reaction [Hydrogen Peroxide results in increased expression of and results in increased secretion of FN1 protein]; notoginsenoside R1 inhibits the reaction [Hydrogen Peroxide results in increased expression of FN1 mRNA]; notoginsenoside R1 inhibits the reaction [TNF protein results in increased expression of and results in increased secretion of FN1 protein]; notoginsenoside R1 inhibits the reaction [TNF protein results in increased expression of FN1 mRNA] |
CTD |
PMID:16632126 |
|
NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
multiple interactions increases expression |
EXP |
Cycloheximide inhibits the reaction [notoginsenoside R1 results in increased expression of GCLC protein]; Dactinomycin inhibits the reaction [notoginsenoside R1 results in increased expression of GCLC protein]; fulvestrant inhibits the reaction [notoginsenoside R1 results in increased expression of GCLC protein]; NFE2L2 promotes the reaction [notoginsenoside R1 results in increased expression of GCLC protein]; notoginsenoside R1 promotes the reaction [Hydrogen Peroxide results in increased expression of GCLC protein] |
CTD |
PMID:24437944 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Grin1 |
glutamate ionotropic receptor NMDA type subunit 1 |
multiple interactions |
ISO |
[GRIN1 protein co-treated with GRIN2B protein] results in increased susceptibility to notoginsenoside R1 |
CTD |
PMID:19224577 |
|
NCBI chr 3:8,103,680...8,130,603
Ensembl chr 3:8,103,680...8,130,603
|
|
G |
Grin2b |
glutamate ionotropic receptor NMDA type subunit 2B |
multiple interactions |
ISO |
[GRIN1 protein co-treated with GRIN2B protein] results in increased susceptibility to notoginsenoside R1 |
CTD |
PMID:19224577 |
|
NCBI chr 4:168,580,824...169,044,110
Ensembl chr 4:168,599,546...169,042,279
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions increases expression |
ISO EXP |
fulvestrant inhibits the reaction [notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in decreased expression of GSK3B protein modified form]]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in decreased expression of GSK3B protein modified form]; wortmannin inhibits the reaction [notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in decreased expression of GSK3B protein modified form]] notoginsenoside R1 results in increased expression of GSK3B protein modified form |
CTD |
PMID:23170834 PMID:24720662 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression |
ISO EXP |
[astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] results in increased expression of HMOX1 mRNA; [astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] results in increased expression of HMOX1 protein notoginsenoside R1 results in increased expression of HMOX1; notoginsenoside R1 results in increased expression of HMOX1 protein Cycloheximide inhibits the reaction [notoginsenoside R1 results in increased expression of HMOX1 protein]; Dactinomycin inhibits the reaction [notoginsenoside R1 results in increased expression of HMOX1 protein]; fulvestrant inhibits the reaction [notoginsenoside R1 results in increased expression of HMOX1 protein]; NFE2L2 promotes the reaction [notoginsenoside R1 results in increased expression of HMOX1 protein]; notoginsenoside R1 promotes the reaction [Hydrogen Peroxide results in increased expression of HMOX1 protein] |
CTD |
PMID:24437944 PMID:24720662 PMID:25422538 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO |
notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of ICAM1 mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of ICAM1 mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of ICAM1 protein] |
CTD |
PMID:23170834 PMID:25472953 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Ide |
insulin degrading enzyme |
multiple interactions increases expression |
ISO |
2-chloro-5-nitrobenzanilide inhibits the reaction [notoginsenoside R1 results in increased expression of IDE] |
CTD |
PMID:25714973 |
|
NCBI chr 1:235,002,984...235,102,448
Ensembl chr 1:234,995,351...235,102,440
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased expression of IFNG protein]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of IFNG mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IFNG mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IFNG protein] |
CTD |
PMID:23170834 PMID:24933211 PMID:25472953 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Ikbkb |
inhibitor of nuclear factor kappa B kinase subunit beta |
multiple interactions |
ISO |
notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of IKBKB protein modified form] |
CTD |
PMID:25472953 |
|
NCBI chr16:69,319,487...69,373,251
Ensembl chr16:69,319,554...69,373,250
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
ISO |
notoginsenoside R1 promotes the reaction [Lipopolysaccharides results in increased expression of IL10 protein] |
CTD |
PMID:23170834 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il15 |
interleukin 15 |
multiple interactions |
ISO |
notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL15 mRNA] |
CTD |
PMID:25472953 |
|
NCBI chr19:25,640,025...25,706,818
Ensembl chr19:25,640,251...25,706,820
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions |
ISO |
notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of IL1A mRNA] |
CTD |
PMID:25472953 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO EXP |
notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of IL1B mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein] 1,3-bis(4-hydroxyphenyl)-4-methyl-5-(4-(2-piperidinylethoxy)phenol)-1H-pyrazole inhibits the reaction [notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]]; Fulvestrant inhibits the reaction [notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA] |
CTD |
PMID:23170834 PMID:25472953 PMID:25738436 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il2 |
interleukin 2 |
multiple interactions |
ISO |
notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased expression of IL2 protein]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of IL2 mRNA] |
CTD |
PMID:24933211 PMID:25472953 |
|
NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO EXP |
notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased expression of IL6 protein]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]; notoginsenoside R1 inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IL6 protein] 1,3-bis(4-hydroxyphenyl)-4-methyl-5-(4-(2-piperidinylethoxy)phenol)-1H-pyrazole inhibits the reaction [notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]]; Fulvestrant inhibits the reaction [notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein] |
CTD |
PMID:17655881 PMID:23170834 PMID:24933211 PMID:25472953 PMID:25738436 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ilk |
integrin-linked kinase |
multiple interactions |
EXP |
notoginsenoside R1 inhibits the reaction [Streptozocin results in increased activity of ILK protein] |
CTD |
PMID:25503068 |
|
NCBI chr 1:160,088,839...160,095,140
Ensembl chr 1:160,088,897...160,095,140
|
|
G |
Itga3 |
integrin subunit alpha 3 |
multiple interactions |
ISO |
notoginsenoside R1 inhibits the reaction [Glucose results in decreased expression of ITGA3 mRNA]; notoginsenoside R1 inhibits the reaction [Glucose results in decreased expression of ITGA3 protein]; notoginsenoside R1 inhibits the reaction [Streptozocin results in decreased expression of ITGA3 mRNA]; notoginsenoside R1 inhibits the reaction [Streptozocin results in decreased expression of ITGA3 protein] |
CTD |
PMID:25503068 |
|
NCBI chr10:79,990,160...80,022,206
Ensembl chr10:79,990,161...80,022,118
|
|
G |
Itgam |
integrin subunit alpha M |
multiple interactions |
EXP |
notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of ITGAM protein] |
CTD |
PMID:17655881 |
|
NCBI chr 1:182,659,047...182,709,501
Ensembl chr 1:182,659,000...182,709,503
|
|
G |
Itgb1 |
integrin subunit beta 1 |
multiple interactions |
ISO |
notoginsenoside R1 inhibits the reaction [Glucose results in decreased expression of ITGB1 mRNA]; notoginsenoside R1 inhibits the reaction [Glucose results in decreased expression of ITGB1 protein]; notoginsenoside R1 inhibits the reaction [Streptozocin results in decreased expression of ITGB1 mRNA]; notoginsenoside R1 inhibits the reaction [Streptozocin results in decreased expression of ITGB1 protein] |
CTD |
PMID:25503068 |
|
NCBI chr19:56,705,123...56,753,199
Ensembl chr19:56,705,171...56,753,195
|
|
G |
Itgb2 |
integrin subunit beta 2 |
decreases expression multiple interactions |
ISO EXP |
notoginsenoside R1 results in decreased expression of ITGB2 protein notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of ITGB2 protein] |
CTD |
PMID:17655881 PMID:18176958 |
|
NCBI chr20:11,061,394...11,097,656
Ensembl chr20:11,061,430...11,097,600
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation |
ISO EXP |
notoginsenoside R1 inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK1 protein]; notoginsenoside R1 inhibits the reaction [TNF protein results in increased phosphorylation of MAPK1 protein] fulvestrant inhibits the reaction [notoginsenoside R1 results in increased phosphorylation of MAPK1 protein]; notoginsenoside R1 inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in increased expression of MAPK1 mRNA]; notoginsenoside R1 inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in increased phosphorylation of MAPK1 protein]; notoginsenoside R1 inhibits the reaction [APP protein modified form results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:16458614 PMID:16632126 PMID:24437944 PMID:24975829 PMID:25004876 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
EXP ISO |
fulvestrant inhibits the reaction [notoginsenoside R1 results in increased phosphorylation of MAPK3 protein]; notoginsenoside R1 inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in increased expression of MAPK3 mRNA]; notoginsenoside R1 inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in increased phosphorylation of MAPK3 protein]; notoginsenoside R1 inhibits the reaction [APP protein modified form results in increased phosphorylation of MAPK3 protein] notoginsenoside R1 inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK3 protein]; notoginsenoside R1 inhibits the reaction [TNF protein results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:16458614 PMID:16632126 PMID:24437944 PMID:24975829 PMID:25004876 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
EXP |
notoginsenoside R1 inhibits the reaction [APP protein modified form results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:24975829 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
multiple interactions |
EXP |
notoginsenoside R1 inhibits the reaction [APP protein modified form results in increased phosphorylation of MAPK9 protein] |
CTD |
PMID:24975829 |
|
NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178
|
|
G |
Mir126a |
microRNA 126a |
multiple interactions |
ISO |
notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased expression of MIR126A mRNA] |
CTD |
PMID:24933211 |
|
NCBI chr 3:9,415,063...9,415,180
Ensembl chr 3:9,415,063...9,415,180
|
|
G |
Mir20a |
microRNA 20a |
multiple interactions |
ISO |
notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in decreased expression of MIR20A mRNA] |
CTD |
PMID:24933211 |
|
NCBI chr15:92,181,084...92,181,168
Ensembl chr15:92,181,084...92,181,168
|
|
G |
Mir21 |
microRNA 21 |
multiple interactions |
ISO |
notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased expression of MIR21A mRNA] |
CTD |
PMID:24933211 |
|
NCBI chr10:71,405,257...71,405,348
Ensembl chr10:71,405,257...71,405,348
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions decreases expression |
ISO EXP |
notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; notoginsenoside R1 inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased activity of MPO protein] notoginsenoside R1 results in decreased expression of MPO protein |
CTD |
PMID:20023602 PMID:25472953 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
affects localization multiple interactions |
ISO EXP |
notoginsenoside R1 affects the localization of NFE2L2 protein NFE2L2 promotes the reaction [notoginsenoside R1 results in increased expression of GCLC protein]; NFE2L2 promotes the reaction [notoginsenoside R1 results in increased expression of HMOX1 protein]; NFE2L2 promotes the reaction [notoginsenoside R1 results in increased expression of NQO1 protein]; notoginsenoside R1 promotes the reaction [Hydrogen Peroxide affects the localization of NFE2L2 protein] 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate results in decreased expression of and affects the localization of NFE2L2 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [notoginsenoside R1 results in increased expression of and affects the localization of NFE2L2 protein]; [astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] affects the localization of NFE2L2 protein; notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate results in decreased expression of and affects the localization of NFE2L2 protein]; notoginsenoside R1 results in increased expression of and affects the localization of NFE2L2 protein |
CTD |
PMID:24437944 PMID:24720662 PMID:25422538 PMID:33689844 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO EXP |
notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased degradation of NFKBIA protein]; notoginsenoside R1 promotes the reaction [Lipopolysaccharides results in increased expression of NFKBIA mRNA] fulvestrant inhibits the reaction [notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in decreased expression of NFKBIA protein]]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased phosphorylation of NFKBIA protein]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in decreased expression of NFKBIA protein]; wortmannin inhibits the reaction [notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in decreased expression of NFKBIA protein]] |
CTD |
PMID:9102164 PMID:23170834 PMID:25472953 PMID:25738436 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO EXP |
notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] [notoginsenoside R1 results in increased phosphorylation of and results in increased activity of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide; notoginsenoside R1 results in increased phosphorylation of and results in increased activity of NOS2 protein |
CTD |
PMID:23170834 PMID:25472953 PMID:26045775 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nos3 |
nitric oxide synthase 3 |
multiple interactions |
ISO |
notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in decreased expression of NOS3 protein] |
CTD |
PMID:23170834 |
|
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions increases expression |
EXP |
Cycloheximide inhibits the reaction [notoginsenoside R1 results in increased expression of NQO1 protein]; Dactinomycin inhibits the reaction [notoginsenoside R1 results in increased expression of NQO1 protein]; fulvestrant inhibits the reaction [notoginsenoside R1 results in increased expression of NQO1 protein]; NFE2L2 promotes the reaction [notoginsenoside R1 results in increased expression of NQO1 protein]; notoginsenoside R1 promotes the reaction [Hydrogen Peroxide results in increased expression of NQO1 protein] |
CTD |
PMID:24437944 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
multiple interactions increases activity increases response to substance |
ISO |
notoginsenoside R1 binds to and results in increased activity of NR1I2 protein; NR1I2 protein promotes the reaction [notoginsenoside R1 results in increased expression of ABCB1 mRNA]; NR1I2 protein promotes the reaction [notoginsenoside R1 results in increased expression of UGT1A1 mRNA] notoginsenoside R1 results in increased activity of NR1I2 protein NR1I2 protein results in increased susceptibility to notoginsenoside R1 |
CTD |
PMID:25472953 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
ISO |
notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of PARP1 protein modified form] |
CTD |
PMID:23170834 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Plat |
plasminogen activator, tissue type |
increases expression multiple interactions |
ISO |
notoginsenoside R1 results in increased expression of PLAT mRNA; notoginsenoside R1 results in increased expression of PLAT protein notoginsenoside R1 results in increased expression of [PLAT protein binds to SERPINE1 protein] |
CTD |
PMID:8018658 PMID:9220151 |
|
NCBI chr16:69,240,582...69,265,177
Ensembl chr16:69,240,585...69,268,223
|
|
G |
Plau |
plasminogen activator, urokinase |
increases expression |
ISO |
notoginsenoside R1 results in increased expression of PLAU mRNA; notoginsenoside R1 results in increased expression of PLAU protein |
CTD |
PMID:9220151 |
|
NCBI chr15:3,456,230...3,462,732
Ensembl chr15:3,456,232...3,462,775
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions increases expression |
ISO |
2-chloro-5-nitrobenzanilide inhibits the reaction [notoginsenoside R1 results in increased expression of PPARG] |
CTD |
PMID:25714973 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppp1r12a |
protein phosphatase 1, regulatory subunit 12A |
multiple interactions |
EXP |
15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid inhibits the reaction [notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in increased phosphorylation of PPP1R12A protein]]; notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in increased phosphorylation of PPP1R12A protein] |
CTD |
PMID:25305180 |
|
NCBI chr 7:43,482,808...43,593,689
Ensembl chr 7:43,482,803...43,593,425
|
|
G |
Psen1 |
presenilin 1 |
multiple interactions |
ISO |
notoginsenoside R1 inhibits the reaction [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in increased expression of APP protein modified form] |
CTD |
PMID:25714973 |
|
NCBI chr 6:103,323,052...103,375,088
Ensembl chr 6:103,323,120...103,371,650
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA] |
CTD |
PMID:25472953 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO EXP |
notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of RELA protein modified form]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of RELA protein modified form] 1,3-bis(4-hydroxyphenyl)-4-methyl-5-(4-(2-piperidinylethoxy)phenol)-1H-pyrazole inhibits the reaction [notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of and affects the localization of RELA protein]]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of and affects the localization of RELA protein] |
CTD |
PMID:23170834 PMID:25472953 PMID:25738436 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rock1 |
Rho-associated coiled-coil containing protein kinase 1 |
multiple interactions |
EXP |
notoginsenoside R1 inhibits the reaction [[Oxygen co-treated with [Oxygen deficiency co-treated with Glucose deficiency]] results in increased expression of ROCK1 protein] |
CTD |
PMID:25305180 |
|
NCBI chr18:1,114,532...1,236,345
Ensembl chr18:1,115,905...1,235,571
|
|
G |
Runx2 |
RUNX family transcription factor 2 |
increases expression multiple interactions |
ISO |
notoginsenoside R1 results in increased expression of RUNX2 mRNA fulvestrant inhibits the reaction [notoginsenoside R1 results in increased expression of RUNX2 mRNA] |
CTD |
PMID:26362186 |
|
NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167
|
|
G |
Sele |
selectin E |
decreases expression |
ISO |
notoginsenoside R1 results in decreased expression of SELE protein |
CTD |
PMID:18176958 |
|
NCBI chr13:76,402,841...76,412,741
Ensembl chr13:76,403,304...76,412,741
|
|
G |
Serpine1 |
serpin family E member 1 |
multiple interactions decreases activity |
ISO |
notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of SERPINE1 mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of SERPINE1 protein]; notoginsenoside R1 inhibits the reaction [TNF protein results in increased expression of and results in increased secretion of SERPINE1 protein]; notoginsenoside R1 inhibits the reaction [TNF protein results in increased expression of SERPINE1 mRNA]; notoginsenoside R1 results in increased expression of [PLAT protein binds to SERPINE1 protein] notoginsenoside R1 results in decreased activity of SERPINE1 protein |
CTD |
PMID:8018658 PMID:9102164 PMID:16458614 |
|
NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
|
|
G |
Slco1b2 |
solute carrier organic anion transporter family member 1B2 |
multiple interactions |
EXP ISO |
SLCO1B2 protein binds to and results in increased transport of notoginsenoside R1 SLCO1B3 protein binds to and results in increased transport of notoginsenoside R1 |
CTD |
PMID:25297453 |
|
NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981
|
|
G |
Sp7 |
Sp7 transcription factor |
multiple interactions increases expression |
ISO |
fulvestrant inhibits the reaction [notoginsenoside R1 results in increased expression of SP7 mRNA] |
CTD |
PMID:26362186 |
|
NCBI chr 7:133,484,609...133,494,788
Ensembl chr 7:133,484,609...133,494,847
|
|
G |
Sparc |
secreted protein acidic and cysteine rich |
multiple interactions increases expression |
ISO |
fulvestrant inhibits the reaction [notoginsenoside R1 results in increased expression of SPARC mRNA] |
CTD |
PMID:26362186 |
|
NCBI chr10:39,516,394...39,538,252
Ensembl chr10:39,516,406...39,538,396
|
|
G |
Sqstm1 |
sequestosome 1 |
affects localization multiple interactions |
ISO |
notoginsenoside R1 affects the localization of SQSTM1 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [notoginsenoside R1 affects the localization of SQSTM1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate affects the localization of SQSTM1 protein]]; notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate affects the localization of SQSTM1 protein] |
CTD |
PMID:33689844 |
|
NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions decreases expression |
ISO EXP |
notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; notoginsenoside R1 inhibits the reaction [TNF protein results in increased expression of and results in increased secretion of FN1 protein]; notoginsenoside R1 inhibits the reaction [TNF protein results in increased expression of and results in increased secretion of SERPINE1 protein]; notoginsenoside R1 inhibits the reaction [TNF protein results in increased expression of FN1 mRNA]; notoginsenoside R1 inhibits the reaction [TNF protein results in increased expression of SERPINE1 mRNA]; notoginsenoside R1 inhibits the reaction [TNF protein results in increased phosphorylation of MAPK1 protein]; notoginsenoside R1 inhibits the reaction [TNF protein results in increased phosphorylation of MAPK3 protein] notoginsenoside R1 results in decreased expression of TNF 1,3-bis(4-hydroxyphenyl)-4-methyl-5-(4-(2-piperidinylethoxy)phenol)-1H-pyrazole inhibits the reaction [notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]; fulvestrant inhibits the reaction [notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA] notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased expression of TNF protein]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of TNF mRNA]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; notoginsenoside R1 inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of TNF protein] |
CTD |
PMID:9102164 PMID:16458614 PMID:16632126 PMID:20023602 PMID:23170834 PMID:24933211 PMID:25472953 PMID:25738436 More...
|
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfrsf1a |
TNF receptor superfamily member 1A |
multiple interactions |
ISO |
notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of TNFRSF1A mRNA] |
CTD |
PMID:23170834 |
|
NCBI chr 4:158,150,815...158,163,592
Ensembl chr 4:158,150,820...158,163,591
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
ISO |
notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of TRP53 mRNA]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of TRP53 protein] |
CTD |
PMID:23170834 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
increases expression multiple interactions |
ISO |
notoginsenoside R1 results in increased expression of UGT1A1 mRNA NR1I2 protein promotes the reaction [notoginsenoside R1 results in increased expression of UGT1A1 mRNA] |
CTD |
PMID:25472953 |
|
NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
multiple interactions |
ISO |
notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of VCAM1 protein] |
CTD |
PMID:23170834 |
|
NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958
|
|
|
G |
Ace |
angiotensin I converting enzyme |
multiple interactions |
EXP |
oleuropein inhibits the reaction [Isoproterenol results in increased activity of ACE protein] |
CTD |
PMID:26056852 |
|
NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
ISO |
oleuropein inhibits the reaction [Rotenone results in increased expression of ACTA2 protein] |
CTD |
PMID:36774383 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
multiple interactions |
EXP |
oleuropein inhibits the reaction [Cholesterol, Dietary results in decreased secretion of ADIPOQ protein] |
CTD |
PMID:27019295 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
oleuropein inhibits the reaction [Rotenone results in decreased phosphorylation of AKT1 protein]; oleuropein inhibits the reaction [TNF protein results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:34126350 PMID:36774383 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
EXP ISO |
oleuropein inhibits the reaction [Acrolein results in increased expression of BAX mRNA]; oleuropein inhibits the reaction [Acrolein results in increased expression of BAX protein] oleuropein inhibits the reaction [Rotenone results in increased expression of BAX protein] |
CTD |
PMID:29414845 PMID:36774383 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
EXP ISO |
oleuropein inhibits the reaction [Acrolein results in decreased expression of BCL2 mRNA]; oleuropein inhibits the reaction [Acrolein results in decreased expression of BCL2 protein]; oleuropein inhibits the reaction [decamethrin results in decreased expression of BCL2 protein] oleuropein affects the reaction [Rotenone results in decreased expression of BCL2 protein] |
CTD |
PMID:28595958 PMID:29414845 PMID:36774383 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
multiple interactions |
ISO |
oleuropein affects the reaction [Rotenone results in decreased expression of BDNF protein] |
CTD |
PMID:36774383 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
oleuropein inhibits the reaction [Rotenone results in increased cleavage of CASP3 protein] |
CTD |
PMID:36774383 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cat |
catalase |
increases activity multiple interactions |
EXP ISO |
oleuropein results in increased activity of CAT protein oleuropein inhibits the reaction [Rotenone results in decreased activity of CAT protein] oleuropein inhibits the reaction [decamethrin results in decreased activity of CAT protein] |
CTD |
PMID:18823963 PMID:28595958 PMID:36774383 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
ISO |
oleuropein inhibits the reaction [Rotenone results in decreased phosphorylation of CREB1 protein] |
CTD |
PMID:36774383 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Csf1r |
colony stimulating factor 1 receptor |
multiple interactions |
ISO |
oleuropein inhibits the reaction [TNF protein results in increased export of CSF1R protein] |
CTD |
PMID:34126350 |
|
NCBI chr18:54,546,673...54,590,418
Ensembl chr18:54,546,659...54,590,415
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
decreases activity |
ISO |
oleuropein results in decreased activity of CYP19A1 protein |
CTD |
PMID:17910019 |
|
NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions |
EXP |
oleuropein inhibits the reaction [Acrolein results in increased expression of DDIT3 protein] |
CTD |
PMID:29414845 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Fasn |
fatty acid synthase |
multiple interactions |
EXP |
oleuropein inhibits the reaction [Cholesterol, Dietary results in increased expression of FASN protein] |
CTD |
PMID:27019295 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
EXP |
oleuropein inhibits the reaction [Cholesterol, Dietary results in increased activity of GPT protein]; oleuropein inhibits the reaction [decamethrin results in increased expression of GPT protein]; oleuropein inhibits the reaction [Isoproterenol results in increased expression of and results in increased secretion of GPT protein] |
CTD |
PMID:26056852 PMID:27019295 PMID:28595958 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions |
ISO |
oleuropein inhibits the reaction [Rotenone results in decreased expression of and results in decreased phosphorylation of GSK3B protein] |
CTD |
PMID:36774383 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
EXP |
oleuropein inhibits the reaction [Acrolein results in increased expression of HSPA5 protein] |
CTD |
PMID:29414845 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO |
oleuropein inhibits the reaction [Lipopolysaccharides results in increased expression of ICAM1 protein] |
CTD |
PMID:12615669 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
oleuropein inhibits the reaction [TNF protein results in increased export of IL6 protein] |
CTD |
PMID:34126350 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ldha |
lactate dehydrogenase A |
multiple interactions |
EXP |
oleuropein inhibits the reaction [Isoproterenol results in increased expression of and results in increased secretion of LDHA protein] |
CTD |
PMID:26056852 |
|
NCBI chr 1:97,371,823...97,381,247
Ensembl chr 1:97,366,021...97,433,472
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
oleuropein inhibits the reaction [TNF protein results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:34126350 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
oleuropein inhibits the reaction [TNF protein results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:34126350 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
ISO |
oleuropein inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP9 mRNA]; oleuropein inhibits the reaction [Tetradecanoylphorbol Acetate results in increased secretion of MMP9 protein] |
CTD |
PMID:22595400 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
EXP |
oleuropein inhibits the reaction [Doxorubicin results in increased expression of NOS2 protein] |
CTD |
PMID:17223128 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Ntrk2 |
neurotrophic receptor tyrosine kinase 2 |
multiple interactions |
ISO |
oleuropein inhibits the reaction [Rotenone results in decreased expression of and results in decreased phosphorylation of NTRK2 protein] |
CTD |
PMID:36774383 |
|
NCBI chr17:5,558,992...5,870,299
Ensembl chr17:5,559,043...5,869,136
|
|
G |
Pnlip |
pancreatic lipase |
multiple interactions |
EXP |
oleuropein inhibits the reaction [Isoproterenol results in increased activity of PNLIP protein] |
CTD |
PMID:26056852 |
|
NCBI chr 1:257,774,012...257,811,656
Ensembl chr 1:257,798,581...257,811,654
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
EXP |
oleuropein inhibits the reaction [Cholesterol, Dietary results in increased expression of PPARG protein] |
CTD |
PMID:27019295 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO EXP |
oleuropein inhibits the reaction [[Tetradecanoylphorbol Acetate results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; oleuropein inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 mRNA] oleuropein inhibits the reaction [decamethrin results in increased expression of PTGS2 protein] |
CTD |
PMID:22595400 PMID:28595958 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
oleuropein inhibits the reaction [Tetradecanoylphorbol Acetate results in increased localization of and results in increased activity of RELA protein] |
CTD |
PMID:22595400 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Sele |
selectin E |
multiple interactions |
ISO |
oleuropein inhibits the reaction [Lipopolysaccharides results in increased expression of SELE protein] |
CTD |
PMID:12615669 |
|
NCBI chr13:76,402,841...76,412,741
Ensembl chr13:76,403,304...76,412,741
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions |
EXP |
oleuropein inhibits the reaction [Cholesterol, Dietary results in increased expression of SREBF1 protein] |
CTD |
PMID:27019295 |
|
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
|
|
G |
Th |
tyrosine hydroxylase |
multiple interactions |
ISO |
oleuropein inhibits the reaction [Rotenone results in decreased expression of TH protein] |
CTD |
PMID:36774383 |
|
NCBI chr 1:198,071,500...198,078,832
Ensembl chr 1:198,071,503...198,109,767
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
oleuropein inhibits the reaction [TNF protein results in increased expression of VCAM1 protein] oleuropein inhibits the reaction [TNF protein results in increased export of CSF1R protein]; oleuropein inhibits the reaction [TNF protein results in increased export of IL6 protein]; oleuropein inhibits the reaction [TNF protein results in increased phosphorylation of AKT1 protein]; oleuropein inhibits the reaction [TNF protein results in increased phosphorylation of MAPK1 protein]; oleuropein inhibits the reaction [TNF protein results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:12615669 PMID:34126350 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnnt1 |
troponin T1, slow skeletal type |
multiple interactions |
EXP |
oleuropein inhibits the reaction [Isoproterenol results in increased expression of and results in increased secretion of TNNT1 protein] |
CTD |
PMID:26056852 |
|
NCBI chr 1:69,306,362...69,316,721
Ensembl chr 1:69,306,362...69,316,721
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
EXP |
oleuropein inhibits the reaction [decamethrin results in increased expression of TP53 protein] |
CTD |
PMID:28595958 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
multiple interactions |
ISO |
oleuropein inhibits the reaction [Lipopolysaccharides results in increased expression of VCAM1 mRNA]; oleuropein inhibits the reaction [Lipopolysaccharides results in increased expression of VCAM1 protein]; oleuropein inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of VCAM1 protein]; oleuropein inhibits the reaction [TNF protein results in increased expression of VCAM1 protein] |
CTD |
PMID:12615669 |
|
NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958
|
|
|
G |
Car1 |
carbonic anhydrase 1 |
decreases activity |
ISO |
pelargonidin-3-glucoside results in decreased activity of CA1 protein |
CTD |
PMID:28445001 |
|
NCBI chr 2:86,829,436...86,872,209
Ensembl chr 2:86,861,897...86,872,208
|
|
G |
Car2 |
carbonic anhydrase 2 |
decreases activity |
ISO |
pelargonidin-3-glucoside results in decreased activity of CA2 protein |
CTD |
PMID:28445001 |
|
NCBI chr 2:86,741,625...86,756,766
Ensembl chr 2:86,741,626...86,756,818
|
|
|
G |
Car1 |
carbonic anhydrase 1 |
decreases activity |
ISO |
pelargonidin-3-glucoside results in decreased activity of CA1 protein |
CTD |
PMID:28445001 |
|
NCBI chr 2:86,829,436...86,872,209
Ensembl chr 2:86,861,897...86,872,208
|
|
G |
Car2 |
carbonic anhydrase 2 |
decreases activity |
ISO |
pelargonidin-3-glucoside results in decreased activity of CA2 protein |
CTD |
PMID:28445001 |
|
NCBI chr 2:86,741,625...86,756,766
Ensembl chr 2:86,741,626...86,756,818
|
|
|
G |
Aqp3 |
aquaporin 3 (Gill blood group) |
multiple interactions |
ISO |
[malvidin-3-glucoside co-treated with petunidin-3-glucoside] results in increased expression of AQP3 mRNA |
CTD |
PMID:33294640 |
|
NCBI chr 5:56,239,200...56,244,718
Ensembl chr 5:56,239,201...56,244,720
|
|
|
G |
Abat |
4-aminobutyrate aminotransferase |
decreases expression |
ISO |
Phlorhizin results in decreased expression of ABAT mRNA |
CTD |
PMID:22538082 |
|
NCBI chr10:6,996,688...7,092,835
Ensembl chr10:6,999,819...7,092,835
|
|
G |
Acaa1b |
acetyl-Coenzyme A acyltransferase 1B |
increases expression |
ISO |
Phlorhizin results in increased expression of ACAA1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 8:118,872,996...118,881,852
Ensembl chr 8:118,872,997...118,881,825
|
|
G |
Acaa2 |
acetyl-CoA acyltransferase 2 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of ACAA2 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr18:68,345,136...68,373,246
Ensembl chr18:68,345,012...68,373,249
|
|
G |
Acad8 |
acyl-CoA dehydrogenase family, member 8 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of ACAD8 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 8:25,382,271...25,406,404
Ensembl chr 8:25,382,273...25,406,414
|
|
G |
Acad9 |
acyl-CoA dehydrogenase family, member 9 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of ACAD9 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 2:118,943,170...118,966,150
Ensembl chr 2:118,943,174...118,966,547
|
|
G |
Acadl |
acyl-CoA dehydrogenase, long chain |
decreases expression |
ISO |
Phlorhizin results in decreased expression of ACADL mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 9:68,333,981...68,372,149
Ensembl chr 9:68,333,980...68,372,220
|
|
G |
Acadm |
acyl-CoA dehydrogenase medium chain |
decreases expression |
ISO |
Phlorhizin results in decreased expression of ACADM mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 2:242,858,865...242,883,036
Ensembl chr 2:242,858,865...242,883,147
|
|
G |
Acat1 |
acetyl-CoA acetyltransferase 1 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of ACAT1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 8:53,979,813...54,008,861
Ensembl chr 8:53,979,813...54,008,855
|
|
G |
Aco1 |
aconitase 1 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of ACO1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 5:55,259,841...55,315,872
Ensembl chr 5:55,259,827...55,316,391
|
|
G |
Acox1 |
acyl-CoA oxidase 1 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of ACOX1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr10:101,406,197...101,431,252
Ensembl chr10:101,406,197...101,431,232
|
|
G |
Acox2 |
acyl-CoA oxidase 2 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of ACOX2 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr15:16,660,584...16,692,160
Ensembl chr15:16,660,272...16,692,160
|
|
G |
Acsl1 |
acyl-CoA synthetase long-chain family member 1 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of ACSL1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr16:45,755,246...45,821,541
Ensembl chr16:45,755,254...45,821,541
|
|
G |
Actb |
actin, beta |
increases expression |
ISO |
Phlorhizin results in increased expression of ACTB mRNA |
CTD |
PMID:22538082 |
|
NCBI chr12:11,663,112...11,666,697
Ensembl chr12:11,663,109...11,672,877
|
|
G |
Adh5 |
alcohol dehydrogenase 5 (class III), chi polypeptide |
decreases expression |
ISO |
Phlorhizin results in decreased expression of ADH5 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 2:226,975,184...226,987,591
Ensembl chr 2:226,947,466...226,987,591
|
|
G |
Adhfe1 |
alcohol dehydrogenase, iron containing, 1 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of ADHFE1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 5:9,705,966...9,732,580
Ensembl chr 5:9,705,970...9,732,517
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
multiple interactions |
ISO |
2,2-bis(4-glycidyloxyphenyl)propane affects the reaction [[cobaltous chloride co-treated with Phlorhizin] affects the expression of ADIPOQ mRNA]; 2,2-bis(4-glycidyloxyphenyl)propane affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Phlorhizin] affects the expression of ADIPOQ mRNA]; [cobaltous chloride co-treated with Phlorhizin] affects the expression of ADIPOQ mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Phlorhizin] affects the expression of ADIPOQ mRNA |
CTD |
PMID:32408695 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Akr1a1 |
aldo-keto reductase family 1 member A1 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of AKR1A1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 5:130,092,945...130,130,277
Ensembl chr 5:130,092,732...130,113,674
|
|
G |
Akr7a2 |
aldo-keto reductase family 7, member A2 |
increases expression |
ISO |
Phlorhizin results in increased expression of AKR7A2 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 5:151,552,375...151,560,914
Ensembl chr 5:151,552,343...151,560,909
|
|
G |
Alb |
albumin |
multiple interactions |
ISO |
Phlorhizin inhibits the reaction [Glucose results in decreased uptake of ALB protein] |
CTD |
PMID:16313995 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Aldh2 |
aldehyde dehydrogenase 2 family member |
decreases expression increases expression |
ISO |
Phlorhizin results in decreased expression of ALDH2 mRNA Phlorhizin results in increased expression of ALDH2 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr12:34,949,549...34,982,527
Ensembl chr12:34,901,219...34,982,521
|
|
G |
Aldh3a2 |
aldehyde dehydrogenase 3 family, member A2 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of ALDH3A2 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr10:45,928,313...45,949,366
Ensembl chr10:45,908,524...45,949,281
|
|
G |
Aldh4a1 |
aldehyde dehydrogenase 4 family, member A1 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of ALDH4A1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 5:151,880,002...151,905,491
Ensembl chr 5:151,830,701...151,925,345
|
|
G |
Aldh6a1 |
aldehyde dehydrogenase 6 family, member A1 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of ALDH6A1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 6:104,077,975...104,098,636
Ensembl chr 6:104,077,979...104,098,656
|
|
G |
Aldh7a1 |
aldehyde dehydrogenase 7 family, member A1 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of ALDH7A1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr18:50,003,242...50,042,193
Ensembl chr18:50,009,934...50,042,193
|
|
G |
Anapc2 |
anaphase promoting complex subunit 2 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of ANAPC2 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 3:8,086,434...8,098,182
Ensembl chr 3:8,086,462...8,098,178
|
|
G |
Anapc5 |
anaphase-promoting complex subunit 5 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of ANAPC5 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr12:33,748,709...33,781,709
Ensembl chr12:33,748,735...33,781,781
|
|
G |
Aox1 |
aldehyde oxidase 1 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of AOX1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 9:59,579,621...59,658,772
Ensembl chr 9:59,579,649...59,658,770
|
|
G |
Aph1b |
aph-1 homolog B, gamma secretase subunit |
increases expression |
ISO |
Phlorhizin results in increased expression of APH1B mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 8:67,429,198...67,454,735
Ensembl chr 8:67,429,198...67,450,243
|
|
G |
App |
amyloid beta precursor protein |
decreases expression |
ISO |
Phlorhizin results in decreased expression of APP mRNA |
CTD |
PMID:22538082 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Atf3 |
activating transcription factor 3 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of ATF3 mRNA |
CTD |
PMID:16123366 |
|
NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631
|
|
G |
Atp2a2 |
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2 |
increases expression |
ISO |
Phlorhizin results in increased expression of ATP2A2 mRNA |
CTD |
PMID:16123366 |
|
NCBI chr12:34,072,710...34,122,142
Ensembl chr12:34,072,683...34,122,101
|
|
G |
Atp5f1a |
ATP synthase F1 subunit alpha |
decreases expression |
ISO |
Phlorhizin results in decreased expression of ATP5F1A mRNA |
CTD |
PMID:22538082 |
|
NCBI chr18:71,292,406...71,300,342
Ensembl chr18:71,292,374...71,300,794
|
|
G |
Atp5f1c |
ATP synthase F1 subunit gamma |
increases expression |
ISO |
Phlorhizin results in increased expression of ATP5F1C mRNA |
CTD |
PMID:22538082 |
|
NCBI chr17:68,423,927...68,446,169
Ensembl chr17:68,423,909...68,608,367
|
|
G |
Auh |
AU RNA binding methylglutaconyl-CoA hydratase |
decreases expression |
ISO |
Phlorhizin results in decreased expression of AUH mRNA |
CTD |
PMID:22538082 |
|
NCBI chr17:12,329,522...12,424,882
Ensembl chr17:12,329,524...12,424,896
|
|
G |
B2m |
beta-2 microglobulin |
increases expression |
ISO |
Phlorhizin results in increased expression of B2M mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 3:109,095,740...109,101,764
Ensembl chr 3:109,095,729...109,101,766
|
|
G |
Bad |
BCL2-associated agonist of cell death |
multiple interactions |
ISO |
[2,2-bis(4-glycidyloxyphenyl)propane co-treated with Phlorhizin] promotes the reaction [[cobaltous chloride co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of BAD protein] |
CTD |
PMID:32408695 |
|
NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823
|
|
G |
Bag1 |
BAG cochaperone 1 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of BAG1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 5:56,068,494...56,081,075
Ensembl chr 5:56,068,494...56,081,075
|
|
G |
Bckdhb |
branched chain keto acid dehydrogenase E1 subunit beta |
decreases expression |
ISO |
Phlorhizin results in decreased expression of BCKDHB mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 8:84,845,264...85,027,812
Ensembl chr 8:84,845,264...85,027,812
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions |
ISO |
[2,2-bis(4-glycidyloxyphenyl)propane co-treated with Phlorhizin] promotes the reaction [[cobaltous chloride co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of BCL2L1 protein] |
CTD |
PMID:32408695 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Birc6 |
baculoviral IAP repeat-containing 6 |
increases expression |
ISO |
Phlorhizin results in increased expression of BIRC6 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 6:20,722,922...20,916,396
Ensembl chr 6:20,722,922...20,916,434
|
|
G |
Cat |
catalase |
increases expression |
ISO |
Phlorhizin results in increased expression of CAT mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
2,2-bis(4-glycidyloxyphenyl)propane affects the reaction [[cobaltous chloride co-treated with Phlorhizin] affects the expression of CCL2 mRNA]; 2,2-bis(4-glycidyloxyphenyl)propane affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Phlorhizin] affects the expression of CCL2 mRNA]; [cobaltous chloride co-treated with Phlorhizin] affects the expression of CCL2 mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Phlorhizin] affects the expression of CCL2 mRNA |
CTD |
PMID:32408695 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Cct7 |
chaperonin containing TCP1 subunit 7 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of CCT7 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 4:117,989,232...118,006,478
Ensembl chr 4:117,989,232...118,006,580
|
|
G |
Chrm2 |
cholinergic receptor, muscarinic 2 |
multiple interactions |
EXP |
Phlorhizin inhibits the reaction [Streptozocin results in increased expression of CHRM2 mRNA]; Phlorhizin inhibits the reaction [Streptozocin results in increased expression of CHRM2 protein] |
CTD |
PMID:18715473 |
|
NCBI chr 4:65,015,408...65,149,104
Ensembl chr 4:65,014,144...65,149,103
|
|
G |
Clybl |
citramalyl-CoA lyase |
decreases expression |
ISO |
Phlorhizin results in decreased expression of CLYBL mRNA |
CTD |
PMID:22538082 |
|
NCBI chr15:99,283,644...99,505,697
Ensembl chr15:99,283,650...99,505,695
|
|
G |
Cox15 |
cytochrome c oxidase assembly homolog COX15 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of COX15 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 1:242,605,588...242,622,279
Ensembl chr 1:242,605,588...242,622,261
|
|
G |
Cox17 |
cytochrome c oxidase copper chaperone COX17 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of COX17 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr11:62,400,733...62,406,507
|
|
G |
Cox7c |
cytochrome c oxidase subunit 7C |
increases expression |
ISO |
Phlorhizin results in increased expression of COX7C mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 2:16,841,771...16,843,796
Ensembl chr 2:16,840,837...16,843,760
|
|
G |
Cox8a |
cytochrome c oxidase subunit 8A |
decreases expression |
ISO |
Phlorhizin results in decreased expression of COX8A mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 1:204,402,118...204,404,439
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
decreases expression |
ISO |
Phlorhizin results in decreased expression of CPT1A mRNA |
CTD |
PMID:16123366 PMID:22538082 |
|
NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Cpt2 |
carnitine palmitoyltransferase 2 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of CPT2 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 5:122,664,677...122,682,126
Ensembl chr 5:122,664,677...122,682,095
|
|
G |
Crebbp |
CREB binding protein |
decreases expression |
ISO |
Phlorhizin results in decreased expression of CREBBP mRNA |
CTD |
PMID:22538082 |
|
NCBI chr10:11,335,551...11,461,888
Ensembl chr10:11,335,953...11,461,888
|
|
G |
Cs |
citrate synthase |
decreases expression |
ISO |
Phlorhizin results in decreased expression of CS mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 7:758,074...791,421
Ensembl chr 7:758,345...791,421
|
|
G |
Cul1 |
cullin 1 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of CUL1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 4:76,551,952...76,625,830
Ensembl chr 4:76,551,983...76,627,980
|
|
G |
Cyb5r3 |
cytochrome b5 reductase 3 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of CYB5R3 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 7:114,306,686...114,324,247
Ensembl chr 7:114,306,685...114,324,298
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of CYP1A2 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of CYP2B6 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
increases expression |
ISO |
Phlorhizin results in increased expression of CYP2D6 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
decreases expression increases expression |
ISO |
Phlorhizin results in decreased expression of CYP3A7 mRNA Phlorhizin results in increased expression of CYP3A7 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422
|
|
G |
Cyp4f1 |
cytochrome P450, family 4, subfamily f, polypeptide 1 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of CYP4F12 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 7:12,010,850...12,022,497
Ensembl chr 7:12,010,852...12,022,046
|
|
G |
Dhrs4 |
dehydrogenase/reductase 4 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of DHRS4 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr15:28,966,544...28,978,135
Ensembl chr15:28,966,553...28,978,127
|
|
G |
Dld |
dihydrolipoamide dehydrogenase |
decreases expression |
ISO |
Phlorhizin results in decreased expression of DLD mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 6:47,904,153...47,924,814
Ensembl chr 6:47,903,914...47,924,795
|
|
G |
Dnaja2 |
DnaJ heat shock protein family (Hsp40) member A2 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of DNAJA2 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr19:21,497,792...21,516,904
Ensembl chr19:21,497,729...21,516,901
|
|
G |
Dnaja3 |
DnaJ heat shock protein family (Hsp40) member A3 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of DNAJA3 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr10:10,854,732...10,880,171
Ensembl chr10:10,854,732...10,880,161
|
|
G |
Dnajb1 |
DnaJ heat shock protein family (Hsp40) member B1 |
decreases expression increases expression |
ISO |
Phlorhizin results in decreased expression of DNAJB1 mRNA Phlorhizin results in increased expression of DNAJB1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr19:24,522,731...24,526,419
Ensembl chr19:24,522,717...24,526,458
|
|
G |
Dnajb4 |
DnaJ heat shock protein family (Hsp40) member B4 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of DNAJB4 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 2:241,129,346...241,159,272
Ensembl chr 2:241,130,340...241,159,089
|
|
G |
Dnajb6 |
DnaJ heat shock protein family (Hsp40) member B6 |
increases expression |
ISO |
Phlorhizin results in increased expression of DNAJB6 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 4:5,452,683...5,556,679
Ensembl chr 4:5,452,683...5,556,659
|
|
G |
Dnajc1 |
DnaJ heat shock protein family (Hsp40) member C1 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of DNAJC1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr17:80,955,209...81,112,025
Ensembl chr17:80,955,237...81,111,988
|
|
G |
Dnajc13 |
DnaJ heat shock protein family (Hsp40) member C13 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of DNAJC13 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 8:104,767,785...104,877,317
Ensembl chr 8:104,767,788...104,877,317
|
|
G |
Dnajc14 |
DnaJ heat shock protein family (Hsp40) member C14 |
increases expression |
ISO |
Phlorhizin results in increased expression of DNAJC14 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 7:1,233,856...1,247,349
Ensembl chr 7:1,235,162...1,248,645
|
|
G |
Dnajc19 |
DnaJ heat shock protein family (Hsp40) member C19 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of DNAJC19 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 2:116,923,272...116,945,312
Ensembl chr 2:116,923,272...116,945,264
|
|
G |
Dnajc3 |
DnaJ heat shock protein family (Hsp40) member C3 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of DNAJC3 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr15:96,025,605...96,068,585
Ensembl chr15:96,025,624...96,065,181
|
|
G |
Dnajc4 |
DnaJ heat shock protein family (Hsp40) member C4 |
increases expression |
ISO |
Phlorhizin results in increased expression of DNAJC4 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 1:204,178,189...204,182,412
Ensembl chr 1:204,178,191...204,182,387
|
|
G |
Dnajc5 |
DnaJ heat shock protein family (Hsp40) member C5 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of DNAJC5 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 3:168,621,905...168,656,570
Ensembl chr 3:168,621,969...168,655,935
|
|
G |
Echs1 |
enoyl-CoA hydratase, short chain 1 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of ECHS1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 1:194,895,036...194,903,863
Ensembl chr 1:194,895,036...194,903,884
|
|
G |
Ep300 |
E1A binding protein p300 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of EP300 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 7:113,108,476...113,178,529
Ensembl chr 7:113,106,247...113,136,088 Ensembl chr 7:113,106,247...113,136,088
|
|
G |
Ephx1 |
epoxide hydrolase 1 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of EPHX1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr13:92,714,315...92,744,105
Ensembl chr13:92,714,315...92,790,235
|
|
G |
Fas |
Fas cell surface death receptor |
decreases expression |
ISO |
Phlorhizin results in decreased expression of FAS mRNA |
CTD |
PMID:16123366 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Fbxw7 |
F-box and WD repeat domain containing 7 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of FBXW7 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 2:170,149,706...170,311,536
Ensembl chr 2:170,149,694...170,309,941
|
|
G |
Fh |
fumarate hydratase |
decreases expression |
ISO |
Phlorhizin results in decreased expression of FH mRNA |
CTD |
PMID:22538082 |
|
NCBI chr13:87,524,331...87,550,215
Ensembl chr13:87,524,337...87,550,266
|
|
G |
Fis1 |
fission, mitochondrial 1 |
increases expression |
ISO |
Phlorhizin results in increased expression of FIS1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr12:19,708,560...19,723,392
Ensembl chr12:19,708,558...19,723,377
|
|
G |
Fkbp5 |
FKBP prolyl isomerase 5 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of FKBP5 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr20:6,457,207...6,575,404
Ensembl chr20:6,457,216...6,541,674
|
|
G |
Fmo1 |
flavin containing dimethylaniline monoxygenase 1 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of FMO1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr13:75,182,184...75,214,439
Ensembl chr13:75,182,176...75,214,647
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
multiple interactions |
EXP |
Phlorhizin inhibits the reaction [Streptozocin results in increased expression of G6PC1 mRNA] |
CTD |
PMID:12446591 |
|
NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
decreases expression |
ISO |
Phlorhizin results in decreased expression of GCLC mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
decreases expression |
ISO |
Phlorhizin results in decreased expression of GCLM mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
|
|
G |
Glrx2 |
glutaredoxin 2 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of GLRX2 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr13:55,481,875...55,504,737
Ensembl chr13:55,482,694...55,492,831
|
|
G |
Gpd2 |
glycerol-3-phosphate dehydrogenase 2 |
increases expression decreases expression |
ISO |
Phlorhizin results in increased expression of GPD2 mRNA Phlorhizin results in decreased expression of GPD2 mRNA |
CTD |
PMID:16123366 PMID:22538082 |
|
NCBI chr 3:41,800,552...41,937,729
Ensembl chr 3:41,801,930...41,936,901
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of GPX1 mRNA |
CTD |
PMID:16123366 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gpx7 |
glutathione peroxidase 7 |
increases expression |
ISO |
Phlorhizin results in increased expression of GPX7 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 5:123,145,151...123,153,141
Ensembl chr 5:123,144,331...123,153,004
|
|
G |
Gsta5 |
glutathione S-transferase alpha 5 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of GSTA5 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 8:79,105,561...79,117,472
Ensembl chr 8:79,105,661...79,117,472
|
|
G |
Gstk1 |
glutathione S-transferase kappa 1 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of GSTK1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 4:71,118,979...71,123,298
Ensembl chr 4:71,118,896...71,123,292
|
|
G |
Gstm1 |
glutathione S-transferase mu 1 |
decreases expression increases expression |
ISO |
Phlorhizin results in decreased expression of GSTM1 mRNA; Phlorhizin results in decreased expression of GSTM5 mRNA Phlorhizin results in increased expression of GSTM5 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411
|
|
G |
Gstm2 |
glutathione S-transferase mu 2 |
increases expression |
ISO |
Phlorhizin results in increased expression of GSTM2 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 2:195,624,015...195,628,774
Ensembl chr 2:195,544,426...195,628,961
|
|
G |
Gstm4 |
glutathione S-transferase mu 4 |
increases expression |
ISO |
Phlorhizin results in increased expression of GSTM4 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 2:195,667,940...195,685,315
Ensembl chr 2:195,680,004...195,685,323
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
increases expression |
ISO |
Phlorhizin results in increased expression of GSTP1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
|
|
G |
Gstt1 |
glutathione S-transferase theta 1 |
decreases expression increases expression |
ISO |
Phlorhizin results in decreased expression of GSTT1 mRNA Phlorhizin results in increased expression of GSTT1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr20:12,856,613...12,873,586
Ensembl chr20:12,856,669...12,873,585
|
|
G |
Hacd3 |
3-hydroxyacyl-CoA dehydratase 3 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of HACD3 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 8:65,501,240...65,538,507
Ensembl chr 8:65,501,240...65,538,507
|
|
G |
Hadhb |
hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit beta |
increases expression |
ISO |
Phlorhizin results in increased expression of HADHB mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 6:26,153,572...26,187,668
Ensembl chr 6:26,153,578...26,184,869
|
|
G |
Herpud1 |
homocysteine inducible ER protein with ubiquitin like domain 1 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of HERPUD1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr19:10,598,411...10,609,002
Ensembl chr19:10,598,417...10,618,424
|
|
G |
Hibadh |
3-hydroxyisobutyrate dehydrogenase |
decreases expression |
ISO |
Phlorhizin results in decreased expression of HIBADH mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 4:81,649,180...81,747,244
Ensembl chr 4:81,649,175...81,780,617
|
|
G |
Hmgcs1 |
3-hydroxy-3-methylglutaryl-CoA synthase 1 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of HMGCS1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 2:51,649,368...51,667,100
Ensembl chr 2:51,649,497...51,667,100
|
|
G |
Hmox1 |
heme oxygenase 1 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of HMOX1 mRNA |
CTD |
PMID:16123366 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hras |
HRas proto-oncogene, GTPase |
increases expression |
ISO |
Phlorhizin results in increased expression of HRAS mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 1:196,290,127...196,299,823
Ensembl chr 1:196,296,263...196,300,615
|
|
G |
Hsd17b10 |
hydroxysteroid (17-beta) dehydrogenase 10 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of HSD17B10 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr X:21,089,142...21,091,603
Ensembl chr X:21,089,122...21,109,488
|
|
G |
Hsd17b4 |
hydroxysteroid (17-beta) dehydrogenase 4 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of HSD17B4 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr18:43,328,903...43,417,950
Ensembl chr18:43,328,824...43,417,952
|
|
G |
Hsp90aa1 |
heat shock protein 90 alpha family class A member 1 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of HSP90AA1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 6:129,702,376...129,707,907
Ensembl chr 6:129,702,383...129,707,268
|
|
G |
Hsp90ab1 |
heat shock protein 90 alpha family class B member 1 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of HSP90AB1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 9:15,432,986...15,438,358
Ensembl chr 9:15,433,691...15,438,488
|
|
G |
Hspa13 |
heat shock protein family A (Hsp70) member 13 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of HSPA13 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr11:14,375,669...14,389,853
Ensembl chr11:14,373,275...14,389,895
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
increases expression |
ISO |
Phlorhizin results in increased expression of HSPA5 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Hspa8 |
heat shock protein family A (Hsp70) member 8 |
increases expression |
ISO |
Phlorhizin results in increased expression of HSPA8 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 8:41,183,397...41,187,260
Ensembl chr 8:41,183,264...41,187,259
|
|
G |
Hspa9 |
heat shock protein family A (Hsp70) member 9 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of HSPA9 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr18:26,536,131...26,554,294
Ensembl chr18:26,535,798...26,554,292
|
|
G |
Hspb1 |
heat shock protein family B (small) member 1 |
increases expression |
ISO |
Phlorhizin results in increased expression of HSPB1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr12:20,794,014...20,795,675
Ensembl chr12:20,794,028...20,795,743
|
|
G |
Hspb8 |
heat shock protein family B (small) member 8 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of HSPB8 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr12:40,176,405...40,205,002
Ensembl chr12:40,176,532...40,191,185
|
|
G |
Hspd1 |
heat shock protein family D (Hsp60) member 1 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of HSPD1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 9:56,579,195...56,590,011
Ensembl chr 9:56,579,201...56,589,662
|
|
G |
Hspe1 |
heat shock protein family E (Hsp10) member 1 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of HSPE1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 9:56,589,912...56,593,000
Ensembl chr 9:56,589,789...56,593,089
|
|
G |
Htra2 |
HtrA serine peptidase 2 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of HTRA2 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 4:115,556,914...115,560,202
Ensembl chr 4:115,556,916...115,560,095
|
|
G |
Id1 |
inhibitor of DNA binding 1 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of ID1 mRNA |
CTD |
PMID:16123366 |
|
NCBI chr 3:141,210,666...141,212,420
Ensembl chr 3:141,211,267...141,212,419
|
|
G |
Idh2 |
isocitrate dehydrogenase (NADP(+)) 2 |
increases expression |
ISO |
Phlorhizin results in increased expression of IDH2 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025
|
|
G |
Idh3a |
isocitrate dehydrogenase (NAD(+)) 3 catalytic subunit alpha |
decreases expression |
ISO |
Phlorhizin results in decreased expression of IDH3A mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 8:54,971,694...54,991,085
Ensembl chr 8:54,971,740...54,991,084
|
|
G |
Idh3b |
isocitrate dehydrogenase (NAD(+)) 3 non-catalytic subunit beta |
decreases expression |
ISO |
Phlorhizin results in decreased expression of IDH3B mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 3:117,481,845...117,486,909
Ensembl chr 3:117,481,845...117,486,982
|
|
G |
Idh3g |
isocitrate dehydrogenase (NAD(+)) 3 non-catalytic subunit gamma |
decreases expression |
ISO |
Phlorhizin results in decreased expression of IDH3G mRNA |
CTD |
PMID:22538082 |
|
NCBI chr X:151,515,244...151,524,175
Ensembl chr X:151,515,247...151,524,171
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
2,2-bis(4-glycidyloxyphenyl)propane affects the reaction [[cobaltous chloride co-treated with Phlorhizin] affects the expression of IL1B mRNA]; [cobaltous chloride co-treated with Phlorhizin] affects the expression of IL1B mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Phlorhizin] affects the expression of IL1B mRNA |
CTD |
PMID:32408695 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
2,2-bis(4-glycidyloxyphenyl)propane affects the reaction [[cobaltous chloride co-treated with Phlorhizin] affects the expression of IL6 mRNA]; 2,2-bis(4-glycidyloxyphenyl)propane affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Phlorhizin] affects the expression of IL6 mRNA]; [cobaltous chloride co-treated with Phlorhizin] affects the expression of IL6 mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Phlorhizin] affects the expression of IL6 mRNA |
CTD |
PMID:32408695 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ivd |
isovaleryl-CoA dehydrogenase |
decreases expression |
ISO |
Phlorhizin results in decreased expression of IVD mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 3:105,851,710...105,872,144
Ensembl chr 3:105,851,683...105,872,575
|
|
G |
Junb |
JunB proto-oncogene, AP-1 transcription factor subunit |
decreases expression |
ISO |
Phlorhizin results in decreased expression of JUNB mRNA |
CTD |
PMID:22538082 |
|
NCBI chr19:23,176,265...23,178,049
Ensembl chr19:23,176,294...23,178,035
|
|
G |
Jund |
JunD proto-oncogene, AP-1 transcription factor subunit |
increases expression |
ISO |
Phlorhizin results in increased expression of JUND mRNA |
CTD |
PMID:22538082 |
|
NCBI chr16:18,734,121...18,735,799
Ensembl chr16:18,734,122...18,735,799
|
|
G |
Kcnj11 |
potassium inwardly-rectifying channel, subfamily J, member 11 |
increases expression |
ISO |
Phlorhizin results in increased expression of KCNJ11 mRNA |
CTD |
PMID:16123366 |
|
NCBI chr 1:96,591,048...96,594,574
Ensembl chr 1:96,591,049...96,594,082
|
|
G |
Keap1 |
Kelch-like ECH-associated protein 1 |
increases expression |
ISO |
Phlorhizin results in increased expression of KEAP1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862
|
|
G |
Kras |
KRAS proto-oncogene, GTPase |
decreases expression |
ISO |
Phlorhizin results in decreased expression of KRAS mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 4:178,185,418...178,218,484
|
|
G |
Lep |
leptin |
multiple interactions |
ISO |
2,2-bis(4-glycidyloxyphenyl)propane affects the reaction [[cobaltous chloride co-treated with Phlorhizin] affects the expression of LEP mRNA]; [2,2-bis(4-glycidyloxyphenyl)propane co-treated with lipopolysaccharide, E coli O55-B5 co-treated with Phlorhizin] affects the expression of LEP mRNA; [cobaltous chloride co-treated with Phlorhizin] affects the expression of LEP mRNA |
CTD |
PMID:32408695 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Maf |
MAF bZIP transcription factor |
decreases expression |
ISO |
Phlorhizin results in decreased expression of MAF mRNA |
CTD |
PMID:22538082 |
|
NCBI chr19:43,353,867...43,713,162
Ensembl chr19:43,360,342...43,712,365
|
|
G |
Mafg |
MAF bZIP transcription factor G |
decreases expression |
ISO |
Phlorhizin results in decreased expression of MAFG mRNA |
CTD |
PMID:22538082 |
|
NCBI chr10:105,903,307...105,911,808
Ensembl chr10:105,903,237...105,912,026
|
|
G |
Maob |
monoamine oxidase B |
decreases expression |
ISO |
Phlorhizin results in decreased expression of MAOB mRNA |
CTD |
PMID:22538082 |
|
NCBI chr X:5,907,327...6,010,996
Ensembl chr X:5,907,266...6,011,003
|
|
G |
Map2k2 |
mitogen activated protein kinase kinase 2 |
increases expression |
ISO |
Phlorhizin results in increased expression of MAP2K2 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 7:8,590,729...8,610,279
Ensembl chr 7:8,580,905...8,610,243
|
|
G |
Map2k6 |
mitogen-activated protein kinase kinase 6 |
increases expression |
ISO |
Phlorhizin results in increased expression of MAP2K6 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr10:95,373,304...95,490,406
Ensembl chr10:95,373,204...95,488,293
|
|
G |
Map2k7 |
mitogen activated protein kinase kinase 7 |
increases expression |
ISO |
Phlorhizin results in increased expression of MAP2K7 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr12:2,591,312...2,600,534
Ensembl chr12:2,591,219...2,604,222
|
|
G |
Map3k7 |
mitogen activated protein kinase kinase kinase 7 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of MAP3K7 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 5:46,356,973...46,415,597
Ensembl chr 5:46,357,931...46,415,597
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases expression |
ISO |
Phlorhizin results in increased expression of MAPK3 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of MAPK9 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178
|
|
G |
Mccc2 |
methylcrotonyl-CoA carboxylase subunit 2 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of MCCC2 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 2:31,304,927...31,375,978
Ensembl chr 2:31,304,932...31,375,972
|
|
G |
Mdm2 |
MDM2 proto-oncogene |
decreases expression |
ISO |
Phlorhizin results in decreased expression of MDM2 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915
|
|
G |
Med20 |
mediator complex subunit 20 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of MED20 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 9:13,370,146...13,382,756
Ensembl chr 9:13,370,146...13,382,476
|
|
G |
Mgst1 |
microsomal glutathione S-transferase 1 |
increases expression |
ISO |
Phlorhizin results in increased expression of MGST1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 4:171,029,666...171,044,893
Ensembl chr 4:171,029,630...171,044,892
|
|
G |
Mmut |
methylmalonyl-CoA mutase |
decreases expression |
ISO |
Phlorhizin results in decreased expression of MMUT mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 9:19,928,720...19,956,985
Ensembl chr 9:19,928,727...19,957,046
|
|
G |
Myl9 |
myosin light chain 9 |
decreases phosphorylation |
EXP |
Phlorhizin results in decreased phosphorylation of MYL9 protein |
CTD |
PMID:17272349 |
|
NCBI chr 3:145,281,943...145,288,333
Ensembl chr 3:145,281,937...145,288,333
|
|
G |
Ndufa12 |
NADH:ubiquinone oxidoreductase subunit A12 |
increases expression |
ISO |
Phlorhizin results in increased expression of NDUFA12 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 7:28,771,330...28,798,316
Ensembl chr 7:28,771,330...28,798,315
|
|
G |
Ndufa2 |
NADH:ubiquinone oxidoreductase subunit A2 |
increases expression |
ISO |
Phlorhizin results in increased expression of NDUFA2 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr18:28,355,774...28,357,863
Ensembl chr18:28,355,774...28,358,076
|
|
G |
Ndufa3 |
NADH:ubiquinone oxidoreductase subunit A3 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of NDUFA3 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 1:65,597,567...65,600,197
Ensembl chr 1:65,597,578...65,600,235
|
|
G |
Ndufa7 |
NADH:ubiquinone oxidoreductase subunit A7 |
increases expression |
ISO |
Phlorhizin results in increased expression of NDUFA7 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 7:14,609,283...14,622,064
Ensembl chr 7:14,609,146...14,631,976
|
|
G |
Ndufab1 |
NADH:ubiquinone oxidoreductase subunit AB1 |
increases expression |
ISO |
Phlorhizin results in increased expression of NDUFAB1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 1:176,644,696...176,658,131
Ensembl chr 1:176,644,703...176,658,099
|
|
G |
Ndufaf1 |
NADH:ubiquinone oxidoreductase complex assembly factor 1 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of NDUFAF1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 3:106,639,025...106,650,549
Ensembl chr 3:106,639,851...106,650,212
|
|
G |
Ndufb6 |
NADH:ubiquinone oxidoreductase subunit B6 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of NDUFB6 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 5:55,400,543...55,410,110
Ensembl chr 5:55,400,543...55,410,181
|
|
G |
Ndufs1 |
NADH:ubiquinone oxidoreductase core subunit S1 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of NDUFS1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 9:64,546,430...64,579,751
Ensembl chr 9:64,546,225...64,579,893
|
|
G |
Ndufs4 |
NADH:ubiquinone oxidoreductase subunit S4 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of NDUFS4 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 2:45,951,327...46,061,829
Ensembl chr 2:45,951,313...46,061,846
|
|
G |
Ndufs5 |
NADH:ubiquinone oxidoreductase subunit S5 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of NDUFS5 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 5:135,974,029...135,979,705
Ensembl chr 5:135,974,034...135,979,603 Ensembl chr14:135,974,034...135,979,603 Ensembl chr 2:135,974,034...135,979,603
|
|
G |
Ndufs8 |
NADH:ubiquinone oxidoreductase core subunit S8 |
increases expression |
ISO |
Phlorhizin results in increased expression of NDUFS8 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 1:201,140,585...201,144,573
Ensembl chr 1:201,140,585...201,144,511
|
|
G |
Nedd4 |
NEDD4 E3 ubiquitin protein ligase |
decreases expression |
ISO |
Phlorhizin results in decreased expression of NEDD4 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 8:73,384,095...73,468,951
Ensembl chr 8:73,383,695...73,468,951
|
|
G |
Neurod1 |
neuronal differentiation 1 |
increases expression |
ISO |
Phlorhizin results in increased expression of NEUROD1 mRNA |
CTD |
PMID:16123366 |
|
NCBI chr 3:64,359,554...64,363,526
Ensembl chr 3:64,359,395...64,363,649
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of NFE2L2 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO |
[Phlorhizin co-treated with 2,2-bis(4-glycidyloxyphenyl)propane co-treated with cobaltous chloride] affects the expression of NFKB1 mRNA |
CTD |
PMID:32408695 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nkx6-1 |
NK6 homeobox 1 |
increases expression |
ISO |
Phlorhizin results in increased expression of NKX6-1 mRNA |
CTD |
PMID:16123366 |
|
NCBI chr14:7,969,756...7,976,689
Ensembl chr14:7,969,756...7,976,681
|
|
G |
Nos3 |
nitric oxide synthase 3 |
multiple interactions decreases expression |
ISO |
Phlorhizin inhibits the reaction [Hydrogen Peroxide results in increased expression of NOS3 mRNA] Phlorhizin results in decreased expression of NOS3 mRNA |
CTD |
PMID:20021702 |
|
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Nras |
NRAS proto-oncogene, GTPase |
decreases expression |
ISO |
Phlorhizin results in decreased expression of NRAS mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 2:190,582,885...190,593,509
Ensembl chr 2:190,582,918...190,591,626
|
|
G |
Ogdh |
oxoglutarate dehydrogenase |
decreases expression |
ISO |
Phlorhizin results in decreased expression of OGDH mRNA |
CTD |
PMID:22538082 |
|
NCBI chr14:81,150,021...81,217,479
Ensembl chr14:81,150,091...81,217,479
|
|
G |
Park7 |
Parkinsonism associated deglycase |
increases expression |
ISO |
Phlorhizin results in increased expression of PARK7 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 5:161,353,718...161,376,993
Ensembl chr 5:161,353,719...161,376,970
|
|
G |
Pc |
pyruvate carboxylase |
increases expression decreases expression |
ISO |
Phlorhizin results in increased expression of PCX mRNA Phlorhizin results in decreased expression of PC mRNA |
CTD |
PMID:16123366 PMID:22538082 |
|
NCBI chr 1:201,799,374...201,898,412
Ensembl chr 1:201,804,267...201,898,380
|
|
G |
Pcca |
propionyl-CoA carboxylase subunit alpha |
decreases expression |
ISO |
Phlorhizin results in decreased expression of PCCA mRNA |
CTD |
PMID:22538082 |
|
NCBI chr15:99,627,955...99,969,555
Ensembl chr15:99,627,982...99,968,266
|
|
G |
Pck1 |
phosphoenolpyruvate carboxykinase 1 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of PCK1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 3:161,930,256...161,936,205
Ensembl chr 3:161,930,256...161,936,191
|
|
G |
Pecr |
peroxisomal trans-2-enoyl-CoA reductase |
increases expression decreases expression |
ISO |
Phlorhizin results in increased expression of PECR mRNA Phlorhizin results in decreased expression of PECR mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 9:73,897,877...73,926,511
Ensembl chr 9:73,897,880...73,926,511
|
|
G |
Pik3c2a |
phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 alpha |
decreases expression |
ISO |
Phlorhizin results in decreased expression of PIK3C2A mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 1:170,577,942...170,684,353
Ensembl chr 1:170,577,942...170,683,472
|
|
G |
Pik3c3 |
phosphatidylinositol 3-kinase, catalytic subunit type 3 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of PIK3C3 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr18:21,845,282...21,934,387
Ensembl chr18:21,845,295...21,929,048
|
|
G |
Pink1 |
PTEN induced kinase 1 |
increases expression |
ISO |
Phlorhizin results in increased expression of PINK1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 5:150,530,523...150,542,635
Ensembl chr 5:150,530,523...150,542,635
|
|
G |
Prdx1 |
peroxiredoxin 1 |
increases expression |
ISO |
Phlorhizin results in increased expression of PRDX1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 5:130,147,258...130,162,856
Ensembl chr 5:130,147,204...130,162,856
|
|
G |
Prdx5 |
peroxiredoxin 5 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of PRDX5 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 1:204,099,826...204,103,589
Ensembl chr 1:204,099,826...204,114,268
|
|
G |
Prkch |
protein kinase C, eta |
increases expression |
ISO |
Phlorhizin results in increased expression of PRKCH mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 6:92,292,000...92,490,663
Ensembl chr 6:92,292,000...92,490,654
|
|
G |
Prkci |
protein kinase C, iota |
decreases expression |
ISO |
Phlorhizin results in decreased expression of PRKCI mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 2:112,321,919...112,382,305
Ensembl chr 2:112,321,929...112,382,352
|
|
G |
Prkd3 |
protein kinase D3 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of PRKD3 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 6:16,032,507...16,108,444
Ensembl chr 6:16,032,585...16,108,443
|
|
G |
Psma4 |
proteasome 20S subunit alpha 4 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of PSMA4 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 8:55,340,431...55,347,893
Ensembl chr 8:55,340,386...55,347,890
|
|
G |
Psmb1 |
proteasome 20S subunit beta 1 |
increases expression |
ISO |
Phlorhizin results in increased expression of PSMB1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 1:56,442,432...56,463,544
Ensembl chr 1:56,420,618...56,463,560
|
|
G |
Psmb2 |
proteasome 20S subunit beta 2 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of PSMB2 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 5:138,970,564...139,002,715
Ensembl chr 5:138,970,533...139,021,137
|
|
G |
Psmc1 |
proteasome 26S subunit, ATPase 1 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of PSMC1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 6:119,392,833...119,405,233
Ensembl chr 6:119,392,855...119,410,123
|
|
G |
Psmc4 |
proteasome 26S subunit, ATPase 4 |
increases expression decreases expression |
ISO |
Phlorhizin results in increased expression of PSMC4 mRNA Phlorhizin results in decreased expression of PSMC4 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 1:83,349,127...83,357,497
Ensembl chr 1:83,348,592...83,357,494
|
|
G |
Psmc6 |
proteasome 26S subunit, ATPase 6 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of PSMC6 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr15:18,542,585...18,564,057
Ensembl chr15:18,542,563...18,564,055
|
|
G |
Psmd10 |
proteasome 26S subunit, non-ATPase 10 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of PSMD10 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr X:104,656,809...104,665,122
Ensembl chr X:104,656,812...104,665,097
|
|
G |
Psmd12 |
proteasome 26S subunit, non-ATPase 12 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of PSMD12 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr10:92,438,223...92,457,323
Ensembl chr10:92,438,298...92,457,287
|
|
G |
Psmd14 |
proteasome 26S subunit, non-ATPase 14 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of PSMD14 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 3:46,254,338...46,347,076
Ensembl chr 3:46,254,330...46,347,076
|
|
G |
Psmd4 |
proteasome 26S subunit ubiquitin receptor, non-ATPase 4 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of PSMD4 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 2:182,598,934...182,608,250
Ensembl chr 2:182,598,934...182,608,194
|
|
G |
Psmd6 |
proteasome 26S subunit, non-ATPase 6 |
increases expression |
ISO |
Phlorhizin results in increased expression of PSMD6 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr15:11,102,174...11,112,180
Ensembl chr15:11,102,180...11,205,620
|
|
G |
Psmd7 |
proteasome 26S subunit, non-ATPase 7 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of PSMD7 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr19:35,494,317...35,501,605
Ensembl chr19:35,494,316...35,501,588
|
|
G |
Psmd9 |
proteasome 26S subunit, non-ATPase 9 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of PSMD9 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr12:33,337,182...33,357,468
|
|
G |
Raf1 |
Raf-1 proto-oncogene, serine/threonine kinase |
decreases expression |
ISO |
Phlorhizin results in decreased expression of RAF1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 4:148,679,534...148,740,265
Ensembl chr 4:148,679,530...148,740,317
|
|
G |
Rdh14 |
retinol dehydrogenase 14 |
increases expression |
ISO |
Phlorhizin results in increased expression of RDH14 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 6:33,156,569...33,161,712
Ensembl chr 6:33,156,569...33,161,712
|
|
G |
S100a6 |
S100 calcium binding protein A6 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of S100A6 mRNA |
CTD |
PMID:16123366 |
|
NCBI chr 2:176,100,619...176,102,181
Ensembl chr 2:176,100,899...176,102,180
|
|
G |
Sdha |
succinate dehydrogenase complex flavoprotein subunit A |
decreases expression |
ISO |
Phlorhizin results in decreased expression of SDHA mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 1:28,935,965...28,960,936
Ensembl chr 1:28,940,164...28,961,535
|
|
G |
Sdhb |
succinate dehydrogenase complex iron sulfur subunit B |
increases expression |
ISO |
Phlorhizin results in increased expression of SDHB mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 5:153,264,906...153,285,570
Ensembl chr 5:153,264,899...153,314,293
|
|
G |
Sds |
serine dehydratase |
decreases expression |
ISO |
Phlorhizin results in decreased expression of SDS mRNA |
CTD |
PMID:22538082 |
|
NCBI chr12:36,083,226...36,090,540
Ensembl chr12:36,083,229...36,088,203
|
|
G |
Slc2a2 |
solute carrier family 2 member 2 |
increases expression |
ISO |
Phlorhizin results in increased expression of SLC2A2 mRNA |
CTD |
PMID:16123366 |
|
NCBI chr 2:111,609,798...111,639,930
Ensembl chr 2:111,611,774...111,639,933
|
|
G |
Slc35a2 |
solute carrier family 35 member A2 |
increases expression |
ISO |
Phlorhizin results in increased expression of SLC35A2 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr X:14,608,145...14,616,937
Ensembl chr X:14,608,055...14,616,678
|
|
G |
Slc5a1 |
solute carrier family 5 member 1 |
multiple interactions decreases activity affects binding |
ISO EXP |
Phlorhizin inhibits the reaction [[Sodium co-treated with SLC5A1 protein] results in increased uptake of methylglucoside]; Phlorhizin inhibits the reaction [SLC5A1 protein results in increased uptake of methylglucoside] [Phlorhizin results in decreased activity of SLC5A1 protein] which results in decreased uptake of spiraeoside [Phlorhizin results in decreased activity of SLC5A1 protein] which results in decreased uptake of Glucose SLC5A1 protein binds to Phlorhizin |
CTD |
PMID:12663055 PMID:12927799 PMID:16300400 PMID:17288452 PMID:17983207 |
|
NCBI chr14:77,553,990...77,618,589
Ensembl chr14:77,553,843...77,618,547
|
|
G |
Slc5a2 |
solute carrier family 5 member 2 |
decreases activity |
ISO |
Phlorhizin results in decreased activity of SLC5A2 protein |
CTD |
PMID:21128592 |
|
NCBI chr 1:182,847,185...182,853,309
Ensembl chr 1:182,847,106...182,853,306
|
|
G |
Sod1 |
superoxide dismutase 1 |
increases expression |
ISO |
Phlorhizin results in increased expression of SOD1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sod2 |
superoxide dismutase 2 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of SOD2 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Stip1 |
stress-induced phosphoprotein 1 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of STIP1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 1:204,209,433...204,228,452
Ensembl chr 1:204,178,932...204,228,476
|
|
G |
Sucla2 |
succinate-CoA ligase ADP-forming subunit beta |
decreases expression |
ISO |
Phlorhizin results in decreased expression of SUCLA2 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr15:48,752,356...48,805,495
Ensembl chr15:48,752,312...48,805,138
|
|
G |
Suclg2 |
succinate-CoA ligase GDP-forming subunit beta |
decreases expression |
ISO |
Phlorhizin results in decreased expression of SUCLG2 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 4:128,067,031...128,337,146
Ensembl chr 4:128,067,033...128,337,170
|
|
G |
Sugt1 |
SGT1 homolog, MIS12 kinetochore complex assembly cochaperone |
decreases expression |
ISO |
Phlorhizin results in decreased expression of SUGT1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr15:54,991,419...55,032,244
Ensembl chr15:54,990,672...55,069,150
|
|
G |
Txn1 |
thioredoxin 1 |
decreases expression increases expression |
ISO |
Phlorhizin results in decreased expression of TXN mRNA Phlorhizin results in increased expression of TXN mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 5:72,712,334...72,724,564
Ensembl chr 5:72,711,933...72,724,629
|
|
G |
Txn2 |
thioredoxin 2 |
increases expression |
ISO |
Phlorhizin results in increased expression of TXN2 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 7:109,496,772...109,510,378
Ensembl chr 7:109,496,761...109,510,359
|
|
G |
Ubb |
ubiquitin B |
increases expression |
ISO |
Phlorhizin results in increased expression of UBB mRNA |
CTD |
PMID:22538082 |
|
NCBI chr10:47,247,630...47,249,335
Ensembl chr10:47,245,637...47,249,333
|
|
G |
Ubc |
ubiquitin C |
decreases expression |
ISO |
Phlorhizin results in decreased expression of UBC mRNA |
CTD |
PMID:22538082 |
|
NCBI chr12:31,239,149...31,243,924
Ensembl chr12:31,239,152...31,243,925
|
|
G |
Ube2b |
ubiquitin-conjugating enzyme E2B |
decreases expression |
ISO |
Phlorhizin results in decreased expression of UBE2B mRNA |
CTD |
PMID:22538082 |
|
NCBI chr10:36,248,434...36,263,379
Ensembl chr10:36,248,438...36,264,665
|
|
G |
Ube2f |
ubiquitin-conjugating enzyme E2F (putative) |
decreases expression |
ISO |
Phlorhizin results in decreased expression of UBE2F mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 9:91,845,975...91,881,145
Ensembl chr 9:91,845,987...91,880,594
|
|
G |
Ube2h |
ubiquitin-conjugating enzyme E2H |
decreases expression |
ISO |
Phlorhizin results in decreased expression of UBE2H mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 4:58,834,674...58,930,156
Ensembl chr 4:58,834,674...58,930,156
|
|
G |
Ube2i |
ubiquitin-conjugating enzyme E2I |
decreases expression |
ISO |
Phlorhizin results in decreased expression of UBE2I mRNA |
CTD |
PMID:22538082 |
|
NCBI chr10:14,277,749...14,294,681
Ensembl chr10:69,701,618...69,702,443 Ensembl chr10:69,701,618...69,702,443
|
|
G |
Ube2l3 |
ubiquitin-conjugating enzyme E2L 3 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of UBE2L3 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr11:83,797,722...83,838,862
Ensembl chr11:83,797,722...83,838,862
|
|
G |
Ube2m |
ubiquitin-conjugating enzyme E2M |
increases expression |
ISO |
Phlorhizin results in increased expression of UBE2M mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 1:73,662,576...73,666,113
Ensembl chr 1:73,662,576...73,666,026
|
|
G |
Ube2n |
ubiquitin-conjugating enzyme E2N |
decreases expression |
ISO |
Phlorhizin results in decreased expression of UBE2N mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 7:30,154,330...30,184,373
Ensembl chr 7:30,154,616...30,184,355
|
|
G |
Ube2q1 |
ubiquitin conjugating enzyme E2 Q1 |
increases expression |
ISO |
Phlorhizin results in increased expression of UBE2Q1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 2:175,198,793...175,209,152
Ensembl chr 2:175,198,873...175,207,942
|
|
G |
Ube2r2 |
ubiquitin-conjugating enzyme E2R 2 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of UBE2R2 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 5:56,286,604...56,345,160
Ensembl chr 5:56,286,725...56,345,513
|
|
G |
Ube2v2 |
ubiquitin conjugating enzyme E2 V2 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of UBE2V2 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr11:85,304,528...85,338,430
Ensembl chr11:85,304,526...85,336,369
|
|
G |
Ube4a |
ubiquitination factor E4A |
increases expression |
ISO |
Phlorhizin results in increased expression of UBE4A mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 8:45,236,022...45,278,129
Ensembl chr 8:45,236,026...45,278,038
|
|
G |
Ubr2 |
ubiquitin protein ligase E3 component n-recognin 2 |
increases expression |
ISO |
Phlorhizin results in increased expression of UBR2 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 9:13,982,427...14,062,315
Ensembl chr 9:13,982,329...14,062,139
|
|
G |
Uchl3 |
ubiquitin C-terminal hydrolase L3 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of UCHL3 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr15:78,485,304...78,527,355
Ensembl chr15:78,485,315...78,527,355 Ensembl chr 3:78,485,315...78,527,355
|
|
G |
Uchl5 |
ubiquitin C-terminal hydrolase L5 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of UCHL5 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr13:55,520,722...55,556,503
Ensembl chr13:55,520,729...55,556,502
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
decreases activity |
ISO |
Phlorhizin results in decreased activity of UGT1A1 protein |
CTD |
PMID:35868516 |
|
NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a2 |
UDP glucuronosyltransferase 1 family, polypeptide A2 |
decreases activity |
ISO |
Phlorhizin results in decreased activity of UGT1A3 protein |
CTD |
PMID:35868516 |
|
NCBI chr 9:88,791,216...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a9 |
UDP glucuronosyltransferase family 1 member A9 |
decreases activity |
ISO |
Phlorhizin results in decreased activity of UGT1A9 protein |
CTD |
PMID:35868516 |
|
NCBI chr 9:88,696,981...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt2b1 |
UDP glucuronosyltransferase 2 family, polypeptide B1 |
decreases activity |
ISO |
Phlorhizin results in decreased activity of UGT2B17 protein |
CTD |
PMID:35868516 |
|
NCBI chr14:21,024,035...21,035,784
Ensembl chr14:21,024,006...21,035,986
|
|
G |
Ugt2b7 |
UDP glucuronosyltransferase family 2 member B7 |
decreases activity |
ISO |
Phlorhizin results in decreased activity of UGT2B7 protein |
CTD |
PMID:35868516 |
|
NCBI chr14:20,896,682...20,919,604
Ensembl chr14:20,896,682...20,919,604
|
|
G |
Uqcrc2 |
ubiquinol cytochrome c reductase core protein 2 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of UQCRC2 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 1:175,167,933...175,198,499
Ensembl chr 1:175,167,894...175,199,453
|
|
G |
Usp1 |
ubiquitin specific peptidase 1 |
increases expression |
ISO |
Phlorhizin results in increased expression of USP1 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 5:113,587,564...113,598,934
Ensembl chr 5:113,587,564...113,598,932
|
|
G |
Usp14 |
ubiquitin specific peptidase 14 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of USP14 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr18:1,018,111...1,057,727
Ensembl chr18:1,019,400...1,057,519
|
|
G |
Usp19 |
ubiquitin specific peptidase 19 |
increases expression |
ISO |
Phlorhizin results in increased expression of USP19 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 8:109,190,727...109,201,761
Ensembl chr 8:109,190,724...109,201,741
|
|
G |
Usp24 |
ubiquitin specific peptidase 24 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of USP24 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 5:121,080,687...121,210,321
Ensembl chr 5:121,080,470...121,210,311
|
|
G |
Usp33 |
ubiquitin specific peptidase 33 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of USP33 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 2:241,283,209...241,328,479
Ensembl chr 2:241,292,985...241,328,479
|
|
G |
Usp4 |
ubiquitin specific peptidase 4 |
increases expression |
ISO |
Phlorhizin results in increased expression of USP4 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 8:109,035,402...109,079,382
Ensembl chr 8:109,036,099...109,080,427
|
|
G |
Usp45 |
ubiquitin specific peptidase 45 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of USP45 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr 5:35,318,621...35,392,090
Ensembl chr 5:35,318,635...35,389,420
|
|
G |
Usp46 |
ubiquitin specific peptidase 46 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of USP46 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr14:34,150,055...34,219,227
Ensembl chr14:34,150,004...34,219,227
|
|
G |
Usp7 |
ubiquitin specific peptidase 7 |
decreases expression |
ISO |
Phlorhizin results in decreased expression of USP7 mRNA |
CTD |
PMID:22538082 |
|
NCBI chr10:6,880,684...6,925,355
Ensembl chr10:6,828,795...6,925,355
|
|
G |
Usp9x |
ubiquitin specific peptidase 9, X-linked |
decreases expression |
ISO |
Phlorhizin results in decreased expression of USP9X mRNA |
CTD |
PMID:22538082 |
|
NCBI chr X:9,588,825...9,726,993
Ensembl chr X:9,588,825...9,696,711
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO |
2,2-bis(4-glycidyloxyphenyl)propane affects the reaction [[cobaltous chloride co-treated with lipopolysaccharide, E coli O55-B5 co-treated with Phlorhizin] results in increased expression of VEGFA mRNA]; 2,2-bis(4-glycidyloxyphenyl)propane affects the reaction [[cobaltous chloride co-treated with Phlorhizin] affects the expression of VEGFA mRNA]; [cobaltous chloride co-treated with lipopolysaccharide, E coli O55-B5 co-treated with Phlorhizin] results in increased expression of VEGFA mRNA; [cobaltous chloride co-treated with Phlorhizin] affects the expression of VEGFA mRNA |
CTD |
PMID:32408695 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Xiap |
X-linked inhibitor of apoptosis |
decreases expression |
ISO |
Phlorhizin results in decreased expression of XIAP mRNA |
CTD |
PMID:22538082 |
|
NCBI chr X:120,890,537...120,938,413
Ensembl chr X:120,897,907...120,934,700
|
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression |
ISO |
isosalipurposide results in increased expression of HMOX1 protein |
CTD |
PMID:26028482 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
MAPK1 protein affects the reaction [isosalipurposide affects the localization of NFE2L2 protein] |
CTD |
PMID:26028482 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
MAPK3 protein affects the reaction [isosalipurposide affects the localization of NFE2L2 protein] |
CTD |
PMID:26028482 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
affects localization multiple interactions |
ISO |
isosalipurposide affects the localization of NFE2L2 protein MAPK1 protein affects the reaction [isosalipurposide affects the localization of NFE2L2 protein]; MAPK3 protein affects the reaction [isosalipurposide affects the localization of NFE2L2 protein] |
CTD |
PMID:26028482 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
|
G |
Trpa1 |
transient receptor potential cation channel, subfamily A, member 1 |
increases activity multiple interactions |
ISO |
picrocrocin results in increased activity of TRPA1 protein 2-(1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-7H-purin-7-yl)-N-(4-isopropylphenyl)acetamide inhibits the reaction [picrocrocin results in increased activity of TRPA1 protein] |
CTD |
PMID:30636360 |
|
NCBI chr 5:4,379,862...4,434,133
Ensembl chr 5:4,379,999...4,433,570
|
|
|
G |
Acat2 |
acetyl-CoA acetyltransferase 2 |
multiple interactions |
ISO |
[isoquercitrin co-treated with Hydrogen Peroxide] results in increased expression of ACAT2 mRNA |
CTD |
PMID:18032389 |
|
NCBI chr 1:47,695,833...47,713,879
Ensembl chr 1:47,695,788...47,752,821
|
|
G |
Akr7a3 |
aldo-keto reductase family 7 member A3 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with oxfendazole co-treated with isoquercitrin] results in increased expression of AKR7A3 mRNA |
CTD |
PMID:20033131 |
|
NCBI chr 5:151,590,968...151,601,394
Ensembl chr 5:151,584,479...151,601,394
|
|
G |
Apoa1 |
apolipoprotein A1 |
increases secretion |
ISO |
isoquercitrin results in increased secretion of APOA1 protein |
CTD |
PMID:24963805 |
|
NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035
|
|
G |
Atf6 |
activating transcription factor 6 |
increases expression |
EXP |
isoquercitrin results in increased expression of ATF6 mRNA |
CTD |
PMID:30365939 |
|
NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177
|
|
G |
Atxn2 |
ataxin 2 |
multiple interactions |
EXP |
isoquercitrin inhibits the reaction [Oxidopamine results in increased expression of ATXN2 mRNA] |
CTD |
PMID:25129099 |
|
NCBI chr12:34,754,132...34,851,175
Ensembl chr12:34,754,137...34,851,479
|
|
G |
Atxn3 |
ataxin 3 |
multiple interactions |
EXP |
isoquercitrin inhibits the reaction [Oxidopamine results in increased expression of ATXN3 mRNA] |
CTD |
PMID:25129099 |
|
NCBI chr 6:121,072,228...121,107,902
Ensembl chr 6:121,074,448...121,107,902
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression |
ISO |
isoquercitrin results in decreased expression of BCL2 mRNA |
CTD |
PMID:30597948 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Casp3 |
caspase 3 |
affects expression |
ISO |
isoquercitrin affects the expression of CASP3 mRNA |
CTD |
PMID:30597948 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
decreases expression |
ISO |
isoquercitrin results in decreased expression of CASP8 mRNA |
CTD |
PMID:30597948 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with Dietary Fats co-treated with Canrenoic Acid co-treated with isoquercitrin analog] results in increased expression of CAT mRNA; isoquercitrin inhibits the reaction [Streptozocin results in decreased activity of CAT protein] |
CTD |
PMID:30298849 PMID:30817903 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
EXP |
isoquercitrin inhibits the reaction [[Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of CCL2 mRNA] |
CTD |
PMID:21295105 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions |
EXP |
isoquercitrin inhibits the reaction [Carrageenan results in increased expression of CCL5 protein] |
CTD |
PMID:14654164 |
|
NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Cdkn2b |
cyclin-dependent kinase inhibitor 2B |
multiple interactions |
EXP |
isoquercitrin inhibits the reaction [[Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of CDKN2B mRNA] |
CTD |
PMID:21295105 |
|
NCBI chr 5:104,009,839...104,019,082
Ensembl chr 5:104,010,680...104,019,050
|
|
G |
Ctnnb1 |
catenin beta 1 |
affects expression |
ISO |
isoquercitrin affects the expression of CTNNB1 mRNA |
CTD |
PMID:30597948 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
multiple interactions |
EXP |
isoquercitrin inhibits the reaction [Carrageenan results in increased expression of CXCL2 protein] |
CTD |
PMID:14654164 |
|
NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions decreases activity |
EXP ISO |
[Diethylnitrosamine co-treated with oxfendazole co-treated with isoquercitrin] results in increased expression of CYP1A1 mRNA isoquercitrin results in decreased activity of CYP1A1 protein |
CTD |
PMID:16271822 PMID:20033131 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with oxfendazole co-treated with isoquercitrin] results in increased expression of CYP1A2 mRNA |
CTD |
PMID:20033131 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
decreases activity |
ISO |
isoquercitrin results in decreased activity of CYP1B1 protein |
CTD |
PMID:16271822 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp2b2 |
cytochrome P450, family 2, subfamily b, polypeptide 2 |
multiple interactions |
EXP |
isoquercitrin inhibits the reaction [[Diethylnitrosamine co-treated with oxfendazole] results in increased expression of CYP2B2 mRNA] |
CTD |
PMID:20033131 |
|
NCBI chr 1:81,594,534...81,608,567
Ensembl chr 1:81,594,555...81,608,566
|
|
G |
Cyp51 |
cytochrome P450, family 51 |
multiple interactions |
ISO |
[isoquercitrin co-treated with Hydrogen Peroxide] results in increased expression of CYP51A1 mRNA |
CTD |
PMID:18032389 |
|
NCBI chr 4:30,036,956...30,055,410
Ensembl chr 4:30,036,865...30,055,410
|
|
G |
Dhcr7 |
7-dehydrocholesterol reductase |
multiple interactions |
ISO |
[isoquercitrin co-treated with Hydrogen Peroxide] results in increased expression of DHCR7 mRNA |
CTD |
PMID:18032389 |
|
NCBI chr 1:199,015,081...199,031,055
Ensembl chr 1:199,015,081...199,031,055
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; isoquercitrin inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; isoquercitrin inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; isoquercitrin inhibits the reaction [EGF protein results in increased phosphorylation of PTK2 protein] |
CTD |
PMID:26109002 |
|
NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein] |
CTD |
PMID:26109002 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Egln1 |
egl-9 family hypoxia-inducible factor 1 |
multiple interactions |
EXP |
isoquercitrin inhibits the reaction [Oxidopamine results in increased expression of EGLN1 mRNA] |
CTD |
PMID:25129099 |
|
NCBI chr19:52,867,900...52,907,308
Ensembl chr19:52,869,486...52,907,777
|
|
G |
Fdft1 |
farnesyl diphosphate farnesyl transferase 1 |
multiple interactions |
ISO |
[isoquercitrin co-treated with Hydrogen Peroxide] results in increased expression of FDFT1 mRNA |
CTD |
PMID:18032389 |
|
NCBI chr15:37,412,143...37,440,198
Ensembl chr15:37,412,146...37,440,287
|
|
G |
Fdps |
farnesyl diphosphate synthase |
multiple interactions |
ISO |
[isoquercitrin co-treated with Hydrogen Peroxide] results in increased expression of FDPS mRNA |
CTD |
PMID:18032389 |
|
NCBI chr 2:174,497,402...174,507,031
Ensembl chr 2:174,486,665...174,507,776
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
EXP |
[isoquercitrin analog co-treated with Propylthiouracil] results in decreased expression of FOS mRNA |
CTD |
PMID:31068541 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Gpx2 |
glutathione peroxidase 2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with oxfendazole co-treated with isoquercitrin] results in increased expression of GPX2 mRNA |
CTD |
PMID:20033131 |
|
NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877
|
|
G |
Gria3 |
glutamate ionotropic receptor AMPA type subunit 3 |
multiple interactions |
EXP |
isoquercitrin analog inhibits the reaction [Propylthiouracil results in increased expression of GRIA3 mRNA] |
CTD |
PMID:31068541 |
|
NCBI chr X:120,238,515...120,504,106
Ensembl chr X:120,238,534...120,504,096
|
|
G |
Gsta5 |
glutathione S-transferase alpha 5 |
multiple interactions |
EXP |
[isoquercitrin co-treated with oxfendazole co-treated with Diethylnitrosamine] results in increased expression of GSTA5 mRNA; isoquercitrin inhibits the reaction [[Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of GSTA5 mRNA] |
CTD |
PMID:20033131 PMID:20045035 |
|
NCBI chr 8:79,105,561...79,117,472
Ensembl chr 8:79,105,661...79,117,472
|
|
G |
Gstm1 |
glutathione S-transferase mu 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with oxfendazole co-treated with isoquercitrin] results in increased expression of GSTM1 mRNA; isoquercitrin inhibits the reaction [[Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of GSTM1 mRNA] |
CTD |
PMID:20033131 PMID:20045035 |
|
NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
multiple interactions |
ISO |
[isoquercitrin co-treated with Hydrogen Peroxide] results in increased expression of HMGCR mRNA |
CTD |
PMID:18032389 |
|
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Hmgcs1 |
3-hydroxy-3-methylglutaryl-CoA synthase 1 |
multiple interactions |
ISO |
[isoquercitrin co-treated with Hydrogen Peroxide] results in increased expression of HMGCS1 mRNA |
CTD |
PMID:18032389 |
|
NCBI chr 2:51,649,368...51,667,100
Ensembl chr 2:51,649,497...51,667,100
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
EXP |
isoquercitrin inhibits the reaction [beta-Naphthoflavone results in increased expression of HMOX1 protein]; isoquercitrin inhibits the reaction [Streptozocin results in increased expression of HMOX1 mRNA] |
CTD |
PMID:21295105 PMID:30817903 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Ibsp |
integrin-binding sialoprotein |
increases expression |
EXP |
isoquercitrin results in increased expression of IBSP mRNA |
CTD |
PMID:30365939 |
|
NCBI chr14:5,439,825...5,452,570
Ensembl chr14:5,439,829...5,452,693
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions |
EXP |
[isoquercitrin analog co-treated with Propylthiouracil] results in increased expression of IL1A mRNA; [isoquercitrin co-treated with Diethylnitrosamine co-treated with beta-Naphthoflavone] results in decreased expression of IL1A mRNA |
CTD |
PMID:21295105 PMID:31068541 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP |
isoquercitrin inhibits the reaction [Streptozocin results in increased expression of IL1B mRNA] |
CTD |
PMID:30817903 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP |
isoquercitrin inhibits the reaction [Streptozocin results in increased expression of IL6 mRNA] |
CTD |
PMID:30817903 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ins1 |
insulin 1 |
multiple interactions |
EXP |
isoquercitrin inhibits the reaction [Streptozocin results in increased expression of INS1 protein] |
CTD |
PMID:30817903 |
|
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Insig1 |
insulin induced gene 1 |
multiple interactions |
ISO |
[isoquercitrin co-treated with Hydrogen Peroxide] results in increased expression of INSIG1 mRNA |
CTD |
PMID:18032389 |
|
NCBI chr 4:7,315,494...7,323,972
Ensembl chr 4:7,315,495...7,323,952
|
|
G |
Jak1 |
Janus kinase 1 |
increases expression |
ISO |
isoquercitrin results in increased expression of JAK1 mRNA |
CTD |
PMID:30597948 |
|
NCBI chr 5:115,780,248...115,888,841
Ensembl chr 5:115,780,248...115,888,926
|
|
G |
Jak2 |
Janus kinase 2 |
increases expression |
ISO |
isoquercitrin results in increased expression of JAK2 mRNA |
CTD |
PMID:30597948 |
|
NCBI chr 1:226,995,334...227,054,381
Ensembl chr 1:226,995,334...227,054,189
|
|
G |
Keap1 |
Kelch-like ECH-associated protein 1 |
multiple interactions |
EXP |
isoquercitrin inhibits the reaction [Streptozocin results in decreased expression of KEAP1 mRNA] |
CTD |
PMID:30817903 |
|
NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862
|
|
G |
Lct |
lactase |
multiple interactions |
EXP |
[migalastat results in decreased activity of LCT protein] which results in decreased hydrolysis of isoquercitrin |
CTD |
PMID:12663055 |
|
NCBI chr13:39,781,929...39,824,456
Ensembl chr13:39,781,929...39,824,456
|
|
G |
Ldlr |
low density lipoprotein receptor |
multiple interactions |
ISO |
[isoquercitrin co-treated with Hydrogen Peroxide] results in increased expression of LDLR mRNA |
CTD |
PMID:18032389 |
|
NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:26109002 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:26109002 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mcl1 |
MCL1 apoptosis regulator, BCL2 family member |
affects expression |
ISO |
isoquercitrin affects the expression of MCL1 mRNA |
CTD |
PMID:30597948 |
|
NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303
|
|
G |
Me1 |
malic enzyme 1 |
multiple interactions |
EXP |
isoquercitrin inhibits the reaction [[Diethylnitrosamine co-treated with oxfendazole] results in increased expression of ME1 mRNA] |
CTD |
PMID:20033131 |
|
NCBI chr 8:87,549,043...87,660,251
Ensembl chr 8:87,549,043...87,660,304
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions |
ISO |
isoquercitrin results in decreased expression of and results in decreased activity of MMP2 protein |
CTD |
PMID:18715546 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
ISO |
isoquercitrin results in decreased expression of and results in decreased activity of MMP9 protein |
CTD |
PMID:18715546 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
EXP |
isoquercitrin inhibits the reaction [Streptozocin results in increased expression of NFE2L2 mRNA] |
CTD |
PMID:30817903 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
EXP |
[isoquercitrin analog co-treated with Propylthiouracil] results in decreased expression of NFKB1 mRNA |
CTD |
PMID:31068541 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
EXP |
isoquercitrin inhibits the reaction [[Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of NFKBIA mRNA] |
CTD |
PMID:20045035 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
EXP |
isoquercitrin inhibits the reaction [[Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of NOS2 mRNA] |
CTD |
PMID:21295105 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with oxfendazole co-treated with isoquercitrin] results in increased expression of NQO1 mRNA; isoquercitrin analog inhibits the reaction [Propylthiouracil results in increased expression of NQO1 mRNA] |
CTD |
PMID:20033131 PMID:31068541 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr3c2 |
nuclear receptor subfamily 3, group C, member 2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with Dietary Fats co-treated with Canrenoic Acid co-treated with isoquercitrin analog] results in increased expression of NR3C2 mRNA |
CTD |
PMID:30298849 |
|
NCBI chr19:30,715,634...31,059,885
Ensembl chr19:30,715,648...31,059,885
|
|
G |
Nsf |
N-ethylmaleimide sensitive factor, vesicle fusing ATPase |
multiple interactions |
EXP |
isoquercitrin inhibits the reaction [Oxidopamine results in decreased expression of NSF mRNA] |
CTD |
PMID:25129099 |
|
NCBI chr10:88,727,912...88,857,375
Ensembl chr10:88,727,912...88,857,386
|
|
G |
Nsg1 |
neuronal vesicle trafficking associated 1 |
multiple interactions |
EXP |
isoquercitrin inhibits the reaction [Oxidopamine results in decreased expression of NSG1 mRNA] |
CTD |
PMID:25129099 |
|
NCBI chr14:72,648,771...72,670,521
Ensembl chr14:72,648,741...72,670,514
|
|
G |
Opa1 |
OPA1, mitochondrial dynamin like GTPase |
multiple interactions |
EXP |
isoquercitrin inhibits the reaction [Oxidopamine results in decreased expression of OPA1 mRNA] |
CTD |
PMID:25129099 |
|
NCBI chr11:71,108,100...71,185,170
Ensembl chr11:71,109,873...71,185,109
|
|
G |
Otx2 |
orthodenticle homeobox 2 |
multiple interactions |
EXP |
isoquercitrin analog inhibits the reaction [Propylthiouracil results in increased expression of OTX2 mRNA] |
CTD |
PMID:31068541 |
|
NCBI chr15:21,942,233...21,953,034
Ensembl chr15:21,943,191...21,953,416
|
|
G |
Park7 |
Parkinsonism associated deglycase |
multiple interactions |
EXP |
isoquercitrin inhibits the reaction [Oxidopamine results in increased expression of PARK7 mRNA] |
CTD |
PMID:25129099 |
|
NCBI chr 5:161,353,718...161,376,993
Ensembl chr 5:161,353,719...161,376,970
|
|
G |
Pik3ca |
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha |
affects expression |
ISO |
isoquercitrin affects the expression of PIK3CA mRNA |
CTD |
PMID:30597948 |
|
NCBI chr 2:115,175,275...115,249,034
Ensembl chr 2:115,174,984...115,249,032
|
|
G |
Pik3r1 |
phosphoinositide-3-kinase regulatory subunit 1 |
increases expression |
ISO |
isoquercitrin results in increased expression of PIK3R1 mRNA |
CTD |
PMID:30597948 |
|
NCBI chr 2:32,878,942...32,963,668
Ensembl chr 2:32,882,032...32,963,631
|
|
G |
Ppid |
peptidylprolyl isomerase D |
multiple interactions |
EXP |
isoquercitrin inhibits the reaction [Oxidopamine results in increased expression of PPID mRNA] |
CTD |
PMID:25129099 |
|
NCBI chr 2:164,727,803...164,740,168
Ensembl chr 2:164,727,779...164,740,221
|
|
G |
Prkn |
parkin RBR E3 ubiquitin protein ligase |
multiple interactions |
EXP |
isoquercitrin inhibits the reaction [Oxidopamine results in increased expression of PRKN mRNA] |
CTD |
PMID:25129099 |
|
NCBI chr 1:48,688,651...49,882,520
Ensembl chr 1:48,690,556...49,882,555
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP |
isoquercitrin inhibits the reaction [[Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of PTGS2 mRNA]; isoquercitrin inhibits the reaction [[Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of PTGS2 protein]; isoquercitrin inhibits the reaction [Carrageenan results in increased expression of PTGS2 mRNA]; isoquercitrin inhibits the reaction [Streptozocin results in increased expression of PTGS2 mRNA] |
CTD |
PMID:14654164 PMID:20045035 PMID:30817903 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Ptk2 |
protein tyrosine kinase 2 |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [EGF protein results in increased phosphorylation of PTK2 protein] |
CTD |
PMID:26109002 |
|
NCBI chr 7:105,126,725...105,331,848
Ensembl chr 7:105,126,728...105,331,783
|
|
G |
Relb |
RELB proto-oncogene, NF-kB subunit |
increases expression |
ISO |
isoquercitrin results in increased expression of RELB mRNA |
CTD |
PMID:30597948 |
|
NCBI chr 1:79,257,738...79,285,490
Ensembl chr 1:79,257,725...79,285,507
|
|
G |
Runx2 |
RUNX family transcription factor 2 |
increases expression |
EXP |
isoquercitrin results in increased expression of RUNX2 mRNA |
CTD |
PMID:30365939 |
|
NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167
|
|
G |
Sc5d |
sterol-C5-desaturase |
multiple interactions |
ISO |
[isoquercitrin co-treated with Hydrogen Peroxide] results in increased expression of SC5D mRNA |
CTD |
PMID:18032389 |
|
NCBI chr 8:42,629,649...42,641,257
Ensembl chr 8:42,632,672...42,641,273
|
|
G |
Serpine1 |
serpin family E member 1 |
multiple interactions |
EXP |
isoquercitrin inhibits the reaction [[Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of SERPINE1 mRNA] |
CTD |
PMID:20045035 |
|
NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
|
|
G |
Slc5a1 |
solute carrier family 5 member 1 |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [SLC5A1 protein results in increased uptake of methylglucoside] |
CTD |
PMID:17495124 |
|
NCBI chr14:77,553,990...77,618,589
Ensembl chr14:77,553,843...77,618,547
|
|
G |
Sqle |
squalene epoxidase |
multiple interactions |
ISO |
[isoquercitrin co-treated with Hydrogen Peroxide] results in increased expression of SQLE mRNA |
CTD |
PMID:18032389 |
|
NCBI chr 7:90,867,973...90,883,623
Ensembl chr 7:90,868,011...90,883,618
|
|
G |
Srebf2 |
sterol regulatory element binding transcription factor 2 |
multiple interactions |
ISO |
[isoquercitrin co-treated with Hydrogen Peroxide] results in increased cleavage of and results in increased activity of SREBF2 protein; [isoquercitrin co-treated with Hydrogen Peroxide] results in increased expression of SREBF2 mRNA; SREBF2 protein affects the susceptibility to [isoquercitrin co-treated with Hydrogen Peroxide] |
CTD |
PMID:18032389 |
|
NCBI chr 7:113,663,202...113,720,850
Ensembl chr 7:113,663,202...113,720,848
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
increases expression |
ISO |
isoquercitrin results in increased expression of STAT3 mRNA |
CTD |
PMID:30597948 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Stat6 |
signal transducer and activator of transcription 6 |
increases expression |
ISO |
isoquercitrin results in increased expression of STAT6 mRNA |
CTD |
PMID:30597948 |
|
NCBI chr 7:63,480,229...63,497,551
Ensembl chr 7:63,479,642...63,498,495
|
|
G |
Stub1 |
STIP1 homology and U-box containing protein 1 |
multiple interactions |
EXP |
isoquercitrin inhibits the reaction [Oxidopamine results in increased expression of STUB1 mRNA] |
CTD |
PMID:25129099 |
|
NCBI chr10:14,850,765...14,853,046
Ensembl chr10:14,850,765...14,853,046
|
|
G |
Th |
tyrosine hydroxylase |
multiple interactions |
EXP |
isoquercitrin promotes the reaction [Oxidopamine results in decreased expression of TH mRNA] |
CTD |
PMID:25129099 |
|
NCBI chr 1:198,071,500...198,078,832
Ensembl chr 1:198,071,503...198,109,767
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
increases expression |
ISO |
isoquercitrin results in increased expression of TIMP1 protein |
CTD |
PMID:18715546 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP |
isoquercitrin inhibits the reaction [[Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of TNF mRNA]; isoquercitrin inhibits the reaction [Carrageenan results in increased expression of TNF protein]; isoquercitrin inhibits the reaction [Streptozocin results in increased expression of TNF mRNA] |
CTD |
PMID:14654164 PMID:21295105 PMID:30817903 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfrsf1a |
TNF receptor superfamily member 1A |
multiple interactions |
EXP |
isoquercitrin inhibits the reaction [[Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of TNFRSF1A protein] |
CTD |
PMID:21295105 |
|
NCBI chr 4:158,150,815...158,163,592
Ensembl chr 4:158,150,820...158,163,591
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
EXP |
isoquercitrin inhibits the reaction [Streptozocin results in increased expression of TP53 mRNA] |
CTD |
PMID:30817903 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tradd |
TNFRSF1A-associated via death domain |
multiple interactions |
EXP |
isoquercitrin inhibits the reaction [[Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of TRADD protein] |
CTD |
PMID:21295105 |
|
NCBI chr19:33,136,148...33,142,714
Ensembl chr19:33,136,138...33,142,638
|
|
G |
Txn1 |
thioredoxin 1 |
multiple interactions |
EXP |
isoquercitrin analog inhibits the reaction [Propylthiouracil results in increased expression of TXN1 mRNA] |
CTD |
PMID:31068541 |
|
NCBI chr 5:72,712,334...72,724,564
Ensembl chr 5:72,711,933...72,724,629
|
|
G |
Tyk2 |
tyrosine kinase 2 |
affects expression |
ISO |
isoquercitrin affects the expression of TYK2 mRNA |
CTD |
PMID:30597948 |
|
NCBI chr 8:19,641,881...19,667,157
Ensembl chr 8:19,641,884...19,667,044
|
|
G |
Uchl1 |
ubiquitin C-terminal hydrolase L1 |
multiple interactions |
EXP |
isoquercitrin inhibits the reaction [Oxidopamine results in increased expression of UCHL1 mRNA] |
CTD |
PMID:25129099 |
|
NCBI chr14:41,485,031...41,495,590
Ensembl chr14:41,485,031...41,495,590
|
|
|
G |
Acat2 |
acetyl-CoA acetyltransferase 2 |
multiple interactions |
ISO |
[isoquercitrin co-treated with Hydrogen Peroxide] results in increased expression of ACAT2 mRNA |
CTD |
PMID:18032389 |
|
NCBI chr 1:47,695,833...47,713,879
Ensembl chr 1:47,695,788...47,752,821
|
|
G |
Akr7a3 |
aldo-keto reductase family 7 member A3 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with oxfendazole co-treated with isoquercitrin] results in increased expression of AKR7A3 mRNA |
CTD |
PMID:20033131 |
|
NCBI chr 5:151,590,968...151,601,394
Ensembl chr 5:151,584,479...151,601,394
|
|
G |
Apoa1 |
apolipoprotein A1 |
increases secretion |
ISO |
isoquercitrin results in increased secretion of APOA1 protein |
CTD |
PMID:24963805 |
|
NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035
|
|
G |
Atf6 |
activating transcription factor 6 |
increases expression |
EXP |
isoquercitrin results in increased expression of ATF6 mRNA |
CTD |
PMID:30365939 |
|
NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177
|
|
G |
Atxn2 |
ataxin 2 |
multiple interactions |
EXP |
isoquercitrin inhibits the reaction [Oxidopamine results in increased expression of ATXN2 mRNA] |
CTD |
PMID:25129099 |
|
NCBI chr12:34,754,132...34,851,175
Ensembl chr12:34,754,137...34,851,479
|
|
G |
Atxn3 |
ataxin 3 |
multiple interactions |
EXP |
isoquercitrin inhibits the reaction [Oxidopamine results in increased expression of ATXN3 mRNA] |
CTD |
PMID:25129099 |
|
NCBI chr 6:121,072,228...121,107,902
Ensembl chr 6:121,074,448...121,107,902
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression |
ISO |
isoquercitrin results in decreased expression of BCL2 mRNA |
CTD |
PMID:30597948 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Casp3 |
caspase 3 |
affects expression |
ISO |
isoquercitrin affects the expression of CASP3 mRNA |
CTD |
PMID:30597948 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
decreases expression |
ISO |
isoquercitrin results in decreased expression of CASP8 mRNA |
CTD |
PMID:30597948 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with Dietary Fats co-treated with Canrenoic Acid co-treated with isoquercitrin analog] results in increased expression of CAT mRNA; isoquercitrin inhibits the reaction [Streptozocin results in decreased activity of CAT protein] |
CTD |
PMID:30298849 PMID:30817903 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
EXP |
isoquercitrin inhibits the reaction [[Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of CCL2 mRNA] |
CTD |
PMID:21295105 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions |
EXP |
isoquercitrin inhibits the reaction [Carrageenan results in increased expression of CCL5 protein] |
CTD |
PMID:14654164 |
|
NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Cdkn2b |
cyclin-dependent kinase inhibitor 2B |
multiple interactions |
EXP |
isoquercitrin inhibits the reaction [[Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of CDKN2B mRNA] |
CTD |
PMID:21295105 |
|
NCBI chr 5:104,009,839...104,019,082
Ensembl chr 5:104,010,680...104,019,050
|
|
G |
Ctnnb1 |
catenin beta 1 |
affects expression |
ISO |
isoquercitrin affects the expression of CTNNB1 mRNA |
CTD |
PMID:30597948 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
multiple interactions |
EXP |
isoquercitrin inhibits the reaction [Carrageenan results in increased expression of CXCL2 protein] |
CTD |
PMID:14654164 |
|
NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
decreases activity multiple interactions |
ISO EXP |
isoquercitrin results in decreased activity of CYP1A1 protein [Diethylnitrosamine co-treated with oxfendazole co-treated with isoquercitrin] results in increased expression of CYP1A1 mRNA |
CTD |
PMID:16271822 PMID:20033131 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with oxfendazole co-treated with isoquercitrin] results in increased expression of CYP1A2 mRNA |
CTD |
PMID:20033131 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
decreases activity |
ISO |
isoquercitrin results in decreased activity of CYP1B1 protein |
CTD |
PMID:16271822 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp2b2 |
cytochrome P450, family 2, subfamily b, polypeptide 2 |
multiple interactions |
EXP |
isoquercitrin inhibits the reaction [[Diethylnitrosamine co-treated with oxfendazole] results in increased expression of CYP2B2 mRNA] |
CTD |
PMID:20033131 |
|
NCBI chr 1:81,594,534...81,608,567
Ensembl chr 1:81,594,555...81,608,566
|
|
G |
Cyp51 |
cytochrome P450, family 51 |
multiple interactions |
ISO |
[isoquercitrin co-treated with Hydrogen Peroxide] results in increased expression of CYP51A1 mRNA |
CTD |
PMID:18032389 |
|
NCBI chr 4:30,036,956...30,055,410
Ensembl chr 4:30,036,865...30,055,410
|
|
G |
Dhcr7 |
7-dehydrocholesterol reductase |
multiple interactions |
ISO |
[isoquercitrin co-treated with Hydrogen Peroxide] results in increased expression of DHCR7 mRNA |
CTD |
PMID:18032389 |
|
NCBI chr 1:199,015,081...199,031,055
Ensembl chr 1:199,015,081...199,031,055
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; isoquercitrin inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; isoquercitrin inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; isoquercitrin inhibits the reaction [EGF protein results in increased phosphorylation of PTK2 protein] |
CTD |
PMID:26109002 |
|
NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein] |
CTD |
PMID:26109002 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Egln1 |
egl-9 family hypoxia-inducible factor 1 |
multiple interactions |
EXP |
isoquercitrin inhibits the reaction [Oxidopamine results in increased expression of EGLN1 mRNA] |
CTD |
PMID:25129099 |
|
NCBI chr19:52,867,900...52,907,308
Ensembl chr19:52,869,486...52,907,777
|
|
G |
Fdft1 |
farnesyl diphosphate farnesyl transferase 1 |
multiple interactions |
ISO |
[isoquercitrin co-treated with Hydrogen Peroxide] results in increased expression of FDFT1 mRNA |
CTD |
PMID:18032389 |
|
NCBI chr15:37,412,143...37,440,198
Ensembl chr15:37,412,146...37,440,287
|
|
G |
Fdps |
farnesyl diphosphate synthase |
multiple interactions |
ISO |
[isoquercitrin co-treated with Hydrogen Peroxide] results in increased expression of FDPS mRNA |
CTD |
PMID:18032389 |
|
NCBI chr 2:174,497,402...174,507,031
Ensembl chr 2:174,486,665...174,507,776
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
EXP |
[isoquercitrin analog co-treated with Propylthiouracil] results in decreased expression of FOS mRNA |
CTD |
PMID:31068541 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Gpx2 |
glutathione peroxidase 2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with oxfendazole co-treated with isoquercitrin] results in increased expression of GPX2 mRNA |
CTD |
PMID:20033131 |
|
NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877
|
|
G |
Gria3 |
glutamate ionotropic receptor AMPA type subunit 3 |
multiple interactions |
EXP |
isoquercitrin analog inhibits the reaction [Propylthiouracil results in increased expression of GRIA3 mRNA] |
CTD |
PMID:31068541 |
|
NCBI chr X:120,238,515...120,504,106
Ensembl chr X:120,238,534...120,504,096
|
|
G |
Gsta5 |
glutathione S-transferase alpha 5 |
multiple interactions |
EXP |
[isoquercitrin co-treated with oxfendazole co-treated with Diethylnitrosamine] results in increased expression of GSTA5 mRNA; isoquercitrin inhibits the reaction [[Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of GSTA5 mRNA] |
CTD |
PMID:20033131 PMID:20045035 |
|
NCBI chr 8:79,105,561...79,117,472
Ensembl chr 8:79,105,661...79,117,472
|
|
G |
Gstm1 |
glutathione S-transferase mu 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with oxfendazole co-treated with isoquercitrin] results in increased expression of GSTM1 mRNA; isoquercitrin inhibits the reaction [[Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of GSTM1 mRNA] |
CTD |
PMID:20033131 PMID:20045035 |
|
NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
multiple interactions |
ISO |
[isoquercitrin co-treated with Hydrogen Peroxide] results in increased expression of HMGCR mRNA |
CTD |
PMID:18032389 |
|
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Hmgcs1 |
3-hydroxy-3-methylglutaryl-CoA synthase 1 |
multiple interactions |
ISO |
[isoquercitrin co-treated with Hydrogen Peroxide] results in increased expression of HMGCS1 mRNA |
CTD |
PMID:18032389 |
|
NCBI chr 2:51,649,368...51,667,100
Ensembl chr 2:51,649,497...51,667,100
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
EXP |
isoquercitrin inhibits the reaction [beta-Naphthoflavone results in increased expression of HMOX1 protein]; isoquercitrin inhibits the reaction [Streptozocin results in increased expression of HMOX1 mRNA] |
CTD |
PMID:21295105 PMID:30817903 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Ibsp |
integrin-binding sialoprotein |
increases expression |
EXP |
isoquercitrin results in increased expression of IBSP mRNA |
CTD |
PMID:30365939 |
|
NCBI chr14:5,439,825...5,452,570
Ensembl chr14:5,439,829...5,452,693
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions |
EXP |
[isoquercitrin analog co-treated with Propylthiouracil] results in increased expression of IL1A mRNA; [isoquercitrin co-treated with Diethylnitrosamine co-treated with beta-Naphthoflavone] results in decreased expression of IL1A mRNA |
CTD |
PMID:21295105 PMID:31068541 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP |
isoquercitrin inhibits the reaction [Streptozocin results in increased expression of IL1B mRNA] |
CTD |
PMID:30817903 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP |
isoquercitrin inhibits the reaction [Streptozocin results in increased expression of IL6 mRNA] |
CTD |
PMID:30817903 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ins1 |
insulin 1 |
multiple interactions |
EXP |
isoquercitrin inhibits the reaction [Streptozocin results in increased expression of INS1 protein] |
CTD |
PMID:30817903 |
|
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Insig1 |
insulin induced gene 1 |
multiple interactions |
ISO |
[isoquercitrin co-treated with Hydrogen Peroxide] results in increased expression of INSIG1 mRNA |
CTD |
PMID:18032389 |
|
NCBI chr 4:7,315,494...7,323,972
Ensembl chr 4:7,315,495...7,323,952
|
|
G |
Jak1 |
Janus kinase 1 |
increases expression |
ISO |
isoquercitrin results in increased expression of JAK1 mRNA |
CTD |
PMID:30597948 |
|
NCBI chr 5:115,780,248...115,888,841
Ensembl chr 5:115,780,248...115,888,926
|
|
G |
Jak2 |
Janus kinase 2 |
increases expression |
ISO |
isoquercitrin results in increased expression of JAK2 mRNA |
CTD |
PMID:30597948 |
|
NCBI chr 1:226,995,334...227,054,381
Ensembl chr 1:226,995,334...227,054,189
|
|
G |
Keap1 |
Kelch-like ECH-associated protein 1 |
multiple interactions |
EXP |
isoquercitrin inhibits the reaction [Streptozocin results in decreased expression of KEAP1 mRNA] |
CTD |
PMID:30817903 |
|
NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862
|
|
G |
Lct |
lactase |
multiple interactions |
EXP |
[migalastat results in decreased activity of LCT protein] which results in decreased hydrolysis of isoquercitrin |
CTD |
PMID:12663055 |
|
NCBI chr13:39,781,929...39,824,456
Ensembl chr13:39,781,929...39,824,456
|
|
G |
Ldlr |
low density lipoprotein receptor |
multiple interactions |
ISO |
[isoquercitrin co-treated with Hydrogen Peroxide] results in increased expression of LDLR mRNA |
CTD |
PMID:18032389 |
|
NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:26109002 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:26109002 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mcl1 |
MCL1 apoptosis regulator, BCL2 family member |
affects expression |
ISO |
isoquercitrin affects the expression of MCL1 mRNA |
CTD |
PMID:30597948 |
|
NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303
|
|
G |
Me1 |
malic enzyme 1 |
multiple interactions |
EXP |
isoquercitrin inhibits the reaction [[Diethylnitrosamine co-treated with oxfendazole] results in increased expression of ME1 mRNA] |
CTD |
PMID:20033131 |
|
NCBI chr 8:87,549,043...87,660,251
Ensembl chr 8:87,549,043...87,660,304
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions |
ISO |
isoquercitrin results in decreased expression of and results in decreased activity of MMP2 protein |
CTD |
PMID:18715546 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
ISO |
isoquercitrin results in decreased expression of and results in decreased activity of MMP9 protein |
CTD |
PMID:18715546 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
EXP |
isoquercitrin inhibits the reaction [Streptozocin results in increased expression of NFE2L2 mRNA] |
CTD |
PMID:30817903 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
EXP |
[isoquercitrin analog co-treated with Propylthiouracil] results in decreased expression of NFKB1 mRNA |
CTD |
PMID:31068541 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
EXP |
isoquercitrin inhibits the reaction [[Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of NFKBIA mRNA] |
CTD |
PMID:20045035 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
EXP |
isoquercitrin inhibits the reaction [[Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of NOS2 mRNA] |
CTD |
PMID:21295105 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with oxfendazole co-treated with isoquercitrin] results in increased expression of NQO1 mRNA; isoquercitrin analog inhibits the reaction [Propylthiouracil results in increased expression of NQO1 mRNA] |
CTD |
PMID:20033131 PMID:31068541 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr3c2 |
nuclear receptor subfamily 3, group C, member 2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with Dietary Fats co-treated with Canrenoic Acid co-treated with isoquercitrin analog] results in increased expression of NR3C2 mRNA |
CTD |
PMID:30298849 |
|
NCBI chr19:30,715,634...31,059,885
Ensembl chr19:30,715,648...31,059,885
|
|
G |
Nsf |
N-ethylmaleimide sensitive factor, vesicle fusing ATPase |
multiple interactions |
EXP |
isoquercitrin inhibits the reaction [Oxidopamine results in decreased expression of NSF mRNA] |
CTD |
PMID:25129099 |
|
NCBI chr10:88,727,912...88,857,375
Ensembl chr10:88,727,912...88,857,386
|
|
G |
Nsg1 |
neuronal vesicle trafficking associated 1 |
multiple interactions |
EXP |
isoquercitrin inhibits the reaction [Oxidopamine results in decreased expression of NSG1 mRNA] |
CTD |
PMID:25129099 |
|
NCBI chr14:72,648,771...72,670,521
Ensembl chr14:72,648,741...72,670,514
|
|
G |
Opa1 |
OPA1, mitochondrial dynamin like GTPase |
multiple interactions |
EXP |
isoquercitrin inhibits the reaction [Oxidopamine results in decreased expression of OPA1 mRNA] |
CTD |
PMID:25129099 |
|
NCBI chr11:71,108,100...71,185,170
Ensembl chr11:71,109,873...71,185,109
|
|
G |
Otx2 |
orthodenticle homeobox 2 |
multiple interactions |
EXP |
isoquercitrin analog inhibits the reaction [Propylthiouracil results in increased expression of OTX2 mRNA] |
CTD |
PMID:31068541 |
|
NCBI chr15:21,942,233...21,953,034
Ensembl chr15:21,943,191...21,953,416
|
|
G |
Park7 |
Parkinsonism associated deglycase |
multiple interactions |
EXP |
isoquercitrin inhibits the reaction [Oxidopamine results in increased expression of PARK7 mRNA] |
CTD |
PMID:25129099 |
|
NCBI chr 5:161,353,718...161,376,993
Ensembl chr 5:161,353,719...161,376,970
|
|
G |
Pik3ca |
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha |
affects expression |
ISO |
isoquercitrin affects the expression of PIK3CA mRNA |
CTD |
PMID:30597948 |
|
NCBI chr 2:115,175,275...115,249,034
Ensembl chr 2:115,174,984...115,249,032
|
|
G |
Pik3r1 |
phosphoinositide-3-kinase regulatory subunit 1 |
increases expression |
ISO |
isoquercitrin results in increased expression of PIK3R1 mRNA |
CTD |
PMID:30597948 |
|
NCBI chr 2:32,878,942...32,963,668
Ensembl chr 2:32,882,032...32,963,631
|
|
G |
Ppid |
peptidylprolyl isomerase D |
multiple interactions |
EXP |
isoquercitrin inhibits the reaction [Oxidopamine results in increased expression of PPID mRNA] |
CTD |
PMID:25129099 |
|
NCBI chr 2:164,727,803...164,740,168
Ensembl chr 2:164,727,779...164,740,221
|
|
G |
Prkn |
parkin RBR E3 ubiquitin protein ligase |
multiple interactions |
EXP |
isoquercitrin inhibits the reaction [Oxidopamine results in increased expression of PRKN mRNA] |
CTD |
PMID:25129099 |
|
NCBI chr 1:48,688,651...49,882,520
Ensembl chr 1:48,690,556...49,882,555
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP |
isoquercitrin inhibits the reaction [[Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of PTGS2 mRNA]; isoquercitrin inhibits the reaction [[Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of PTGS2 protein]; isoquercitrin inhibits the reaction [Carrageenan results in increased expression of PTGS2 mRNA]; isoquercitrin inhibits the reaction [Streptozocin results in increased expression of PTGS2 mRNA] |
CTD |
PMID:14654164 PMID:20045035 PMID:30817903 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Ptk2 |
protein tyrosine kinase 2 |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [EGF protein results in increased phosphorylation of PTK2 protein] |
CTD |
PMID:26109002 |
|
NCBI chr 7:105,126,725...105,331,848
Ensembl chr 7:105,126,728...105,331,783
|
|
G |
Relb |
RELB proto-oncogene, NF-kB subunit |
increases expression |
ISO |
isoquercitrin results in increased expression of RELB mRNA |
CTD |
PMID:30597948 |
|
NCBI chr 1:79,257,738...79,285,490
Ensembl chr 1:79,257,725...79,285,507
|
|
G |
Runx2 |
RUNX family transcription factor 2 |
increases expression |
EXP |
isoquercitrin results in increased expression of RUNX2 mRNA |
CTD |
PMID:30365939 |
|
NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167
|
|
G |
Sc5d |
sterol-C5-desaturase |
multiple interactions |
ISO |
[isoquercitrin co-treated with Hydrogen Peroxide] results in increased expression of SC5D mRNA |
CTD |
PMID:18032389 |
|
NCBI chr 8:42,629,649...42,641,257
Ensembl chr 8:42,632,672...42,641,273
|
|
G |
Serpine1 |
serpin family E member 1 |
multiple interactions |
EXP |
isoquercitrin inhibits the reaction [[Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of SERPINE1 mRNA] |
CTD |
PMID:20045035 |
|
NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
|
|
G |
Slc5a1 |
solute carrier family 5 member 1 |
multiple interactions |
ISO |
isoquercitrin inhibits the reaction [SLC5A1 protein results in increased uptake of methylglucoside] |
CTD |
PMID:17495124 |
|
NCBI chr14:77,553,990...77,618,589
Ensembl chr14:77,553,843...77,618,547
|
|
G |
Sqle |
squalene epoxidase |
multiple interactions |
ISO |
[isoquercitrin co-treated with Hydrogen Peroxide] results in increased expression of SQLE mRNA |
CTD |
PMID:18032389 |
|
NCBI chr 7:90,867,973...90,883,623
Ensembl chr 7:90,868,011...90,883,618
|
|
G |
Srebf2 |
sterol regulatory element binding transcription factor 2 |
multiple interactions |
ISO |
[isoquercitrin co-treated with Hydrogen Peroxide] results in increased cleavage of and results in increased activity of SREBF2 protein; [isoquercitrin co-treated with Hydrogen Peroxide] results in increased expression of SREBF2 mRNA; SREBF2 protein affects the susceptibility to [isoquercitrin co-treated with Hydrogen Peroxide] |
CTD |
PMID:18032389 |
|
NCBI chr 7:113,663,202...113,720,850
Ensembl chr 7:113,663,202...113,720,848
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
increases expression |
ISO |
isoquercitrin results in increased expression of STAT3 mRNA |
CTD |
PMID:30597948 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Stat6 |
signal transducer and activator of transcription 6 |
increases expression |
ISO |
isoquercitrin results in increased expression of STAT6 mRNA |
CTD |
PMID:30597948 |
|
NCBI chr 7:63,480,229...63,497,551
Ensembl chr 7:63,479,642...63,498,495
|
|
G |
Stub1 |
STIP1 homology and U-box containing protein 1 |
multiple interactions |
EXP |
isoquercitrin inhibits the reaction [Oxidopamine results in increased expression of STUB1 mRNA] |
CTD |
PMID:25129099 |
|
NCBI chr10:14,850,765...14,853,046
Ensembl chr10:14,850,765...14,853,046
|
|
G |
Th |
tyrosine hydroxylase |
multiple interactions |
EXP |
isoquercitrin promotes the reaction [Oxidopamine results in decreased expression of TH mRNA] |
CTD |
PMID:25129099 |
|
NCBI chr 1:198,071,500...198,078,832
Ensembl chr 1:198,071,503...198,109,767
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
increases expression |
ISO |
isoquercitrin results in increased expression of TIMP1 protein |
CTD |
PMID:18715546 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP |
isoquercitrin inhibits the reaction [[Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of TNF mRNA]; isoquercitrin inhibits the reaction [Carrageenan results in increased expression of TNF protein]; isoquercitrin inhibits the reaction [Streptozocin results in increased expression of TNF mRNA] |
CTD |
PMID:14654164 PMID:21295105 PMID:30817903 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfrsf1a |
TNF receptor superfamily member 1A |
multiple interactions |
EXP |
isoquercitrin inhibits the reaction [[Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of TNFRSF1A protein] |
CTD |
PMID:21295105 |
|
NCBI chr 4:158,150,815...158,163,592
Ensembl chr 4:158,150,820...158,163,591
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
EXP |
isoquercitrin inhibits the reaction [Streptozocin results in increased expression of TP53 mRNA] |
CTD |
PMID:30817903 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tradd |
TNFRSF1A-associated via death domain |
multiple interactions |
EXP |
isoquercitrin inhibits the reaction [[Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of TRADD protein] |
CTD |
PMID:21295105 |
|
NCBI chr19:33,136,148...33,142,714
Ensembl chr19:33,136,138...33,142,638
|
|
G |
Txn1 |
thioredoxin 1 |
multiple interactions |
EXP |
isoquercitrin analog inhibits the reaction [Propylthiouracil results in increased expression of TXN1 mRNA] |
CTD |
PMID:31068541 |
|
NCBI chr 5:72,712,334...72,724,564
Ensembl chr 5:72,711,933...72,724,629
|
|
G |
Tyk2 |
tyrosine kinase 2 |
affects expression |
ISO |
isoquercitrin affects the expression of TYK2 mRNA |
CTD |
PMID:30597948 |
|
NCBI chr 8:19,641,881...19,667,157
Ensembl chr 8:19,641,884...19,667,044
|
|
G |
Uchl1 |
ubiquitin C-terminal hydrolase L1 |
multiple interactions |
EXP |
isoquercitrin inhibits the reaction [Oxidopamine results in increased expression of UCHL1 mRNA] |
CTD |
PMID:25129099 |
|
NCBI chr14:41,485,031...41,495,590
Ensembl chr14:41,485,031...41,495,590
|
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [spiraeoside inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein]]; spiraeoside inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein] |
CTD |
PMID:32602595 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Ap5m1 |
adaptor related protein complex 5 subunit mu 1 |
decreases expression |
ISO |
spiraeoside results in decreased expression of AP5M1 protein |
CTD |
PMID:34116102 |
|
NCBI chr15:22,355,478...22,385,222
Ensembl chr15:22,355,500...22,377,750
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [spiraeoside inhibits the reaction [Glucose results in increased expression of BAX protein]]; spiraeoside inhibits the reaction [Glucose results in increased expression of BAX protein] |
CTD |
PMID:32602595 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions decreases expression |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [spiraeoside inhibits the reaction [Glucose results in decreased expression of BCL2 protein]]; spiraeoside inhibits the reaction [Glucose results in decreased expression of BCL2 protein] spiraeoside results in decreased expression of BCL2 protein |
CTD |
PMID:32602595 PMID:34116102 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bid |
BH3 interacting domain death agonist |
decreases expression |
ISO |
spiraeoside results in decreased expression of BID protein |
CTD |
PMID:34116102 |
|
NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720
|
|
G |
Casp3 |
caspase 3 |
decreases expression |
ISO |
spiraeoside results in decreased expression of CASP3 protein |
CTD |
PMID:34116102 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
decreases expression |
ISO |
spiraeoside results in decreased expression of CASP9 protein |
CTD |
PMID:34116102 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [spiraeoside inhibits the reaction [Glucose results in increased activity of CAT protein]]; spiraeoside inhibits the reaction [Glucose results in increased activity of CAT protein] |
CTD |
PMID:32602595 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
decreases expression |
ISO |
spiraeoside results in decreased expression of CDK2 protein |
CTD |
PMID:34116102 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cryz |
crystallin zeta |
increases activity |
ISO |
spiraeoside results in increased activity of CRYZ protein |
CTD |
PMID:8968052 |
|
NCBI chr 2:243,552,037...243,580,369
Ensembl chr 2:243,552,119...243,579,758
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [spiraeoside inhibits the reaction [Glucose results in decreased expression of HMOX1 protein]]; spiraeoside inhibits the reaction [Glucose results in decreased expression of HMOX1 protein] |
CTD |
PMID:32602595 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Lct |
lactase |
multiple interactions |
EXP |
[migalastat results in decreased activity of LCT protein] which results in decreased hydrolysis of spiraeoside |
CTD |
PMID:12663055 |
|
NCBI chr13:39,781,929...39,824,456
Ensembl chr13:39,781,929...39,824,456
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [spiraeoside inhibits the reaction [Glucose results in decreased expression of NFE2L2 protein]]; spiraeoside inhibits the reaction [Glucose results in decreased expression of NFE2L2 protein] |
CTD |
PMID:32602595 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Plcg2 |
phospholipase C, gamma 2 |
decreases phosphorylation |
ISO |
spiraeoside results in decreased phosphorylation of PLCG2 protein |
CTD |
PMID:15613018 |
|
NCBI chr19:45,547,416...45,683,930
Ensembl chr19:45,547,416...45,683,930
|
|
G |
Slc5a1 |
solute carrier family 5 member 1 |
multiple interactions |
EXP ISO |
[Phlorhizin results in decreased activity of SLC5A1 protein] which results in decreased uptake of spiraeoside spiraeoside inhibits the reaction [SLC5A1 protein results in increased uptake of methylglucoside] |
CTD |
PMID:12663055 PMID:17495124 |
|
NCBI chr14:77,553,990...77,618,589
Ensembl chr14:77,553,843...77,618,547
|
|
G |
Syk |
spleen associated tyrosine kinase |
decreases phosphorylation |
ISO |
spiraeoside results in decreased phosphorylation of SYK protein |
CTD |
PMID:15613018 |
|
NCBI chr17:12,604,615...12,678,437
Ensembl chr17:12,604,619...12,661,410
|
|
|
G |
Ace |
angiotensin I converting enzyme |
decreases expression |
ISO |
rebaudioside A results in decreased expression of ACE mRNA |
CTD |
PMID:31655124 |
|
NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131
|
|
G |
Acox1 |
acyl-CoA oxidase 1 |
multiple interactions |
ISO |
rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of ACOX1 mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr10:101,406,197...101,431,252
Ensembl chr10:101,406,197...101,431,232
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
EXP |
rebaudioside A inhibits the reaction [Thioacetamide results in increased expression of ACTA2 protein] |
CTD |
PMID:30883860 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Agtr1a |
angiotensin II receptor, type 1a |
increases expression |
ISO |
rebaudioside A results in increased expression of AGTR1 mRNA |
CTD |
PMID:31655124 |
|
NCBI chr17:34,173,446...34,226,892
Ensembl chr17:34,174,429...34,226,946
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
increases expression |
ISO |
rebaudioside A results in increased expression of ALOX5 mRNA |
CTD |
PMID:31655124 |
|
NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
decreases expression |
ISO |
rebaudioside A results in decreased expression of BAX mRNA |
CTD |
PMID:31655124 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Calca |
calcitonin-related polypeptide alpha |
increases expression |
ISO |
rebaudioside A results in increased expression of CALCA mRNA |
CTD |
PMID:31655124 |
|
NCBI chr 1:168,878,212...168,883,176
Ensembl chr 1:168,878,214...168,883,105
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of CAT mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cav1 |
caveolin 1 |
decreases expression |
ISO |
rebaudioside A results in decreased expression of CAV1 mRNA |
CTD |
PMID:31655124 |
|
NCBI chr 4:45,640,624...45,673,708
Ensembl chr 4:45,634,918...45,673,705
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
decreases expression |
ISO |
rebaudioside A results in decreased expression of CCL2 mRNA |
CTD |
PMID:31655124 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Cflar |
CASP8 and FADD-like apoptosis regulator |
decreases expression |
ISO |
rebaudioside A results in decreased expression of CFLAR mRNA |
CTD |
PMID:31655124 |
|
NCBI chr 9:60,185,338...60,236,173
Ensembl chr 9:60,185,452...60,237,034
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
multiple interactions |
ISO |
rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of CPT1A mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Dgat2 |
diacylglycerol O-acyltransferase 2 |
multiple interactions |
ISO |
rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of DGAT2 mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr 1:153,454,078...153,484,432
Ensembl chr 1:153,454,080...153,484,428
|
|
G |
Edn1 |
endothelin 1 |
decreases expression |
ISO |
rebaudioside A results in decreased expression of EDN1 mRNA |
CTD |
PMID:31655124 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Ednra |
endothelin receptor type A |
increases expression |
ISO |
rebaudioside A results in increased expression of EDNRA mRNA |
CTD |
PMID:31655124 |
|
NCBI chr19:30,233,540...30,303,727
Ensembl chr19:30,233,571...30,297,049
|
|
G |
F2r |
coagulation factor II (thrombin) receptor |
decreases expression |
ISO |
rebaudioside A results in decreased expression of F2R mRNA |
CTD |
PMID:31655124 |
|
NCBI chr 2:26,869,343...26,885,856
Ensembl chr 2:26,868,404...26,885,870
|
|
G |
Faslg |
Fas ligand |
increases expression |
ISO |
rebaudioside A results in increased expression of FASLG mRNA |
CTD |
PMID:31655124 |
|
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Fgf1 |
fibroblast growth factor 1 |
increases expression |
ISO |
rebaudioside A results in increased expression of FGF1 mRNA |
CTD |
PMID:31655124 |
|
NCBI chr18:30,686,555...30,772,667
Ensembl chr18:30,686,581...30,772,357
|
|
G |
Flt1 |
Fms related receptor tyrosine kinase 1 |
decreases expression |
ISO |
rebaudioside A results in decreased expression of FLT1 mRNA |
CTD |
PMID:31655124 |
|
NCBI chr12:7,296,899...7,468,626
Ensembl chr12:7,297,292...7,468,626
|
|
G |
Foxo1 |
forkhead box O1 |
multiple interactions |
ISO |
rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of FOXO1 mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
multiple interactions |
ISO |
rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of G6PC1 mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
EXP |
rebaudioside A inhibits the reaction [Thioacetamide results in increased expression of IL10 protein] |
CTD |
PMID:30883860 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP |
rebaudioside A inhibits the reaction [Thioacetamide results in increased expression of IL6 protein] |
CTD |
PMID:30883860 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Insr |
insulin receptor |
multiple interactions |
ISO |
rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of INSR mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr12:1,193,193...1,330,976
Ensembl chr12:1,197,100...1,330,883
|
|
G |
Irs1 |
insulin receptor substrate 1 |
multiple interactions |
ISO |
rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of IRS1 mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr 9:83,552,964...83,605,797
Ensembl chr 9:83,548,944...83,606,122
|
|
G |
Irs2 |
insulin receptor substrate 2 |
multiple interactions |
ISO |
rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of IRS2 mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr16:78,488,249...78,512,482
Ensembl chr16:78,485,045...78,512,482
|
|
G |
Itgav |
integrin subunit alpha V |
decreases expression |
ISO |
rebaudioside A results in decreased expression of ITGAV mRNA |
CTD |
PMID:31655124 |
|
NCBI chr 3:68,838,514...68,926,653
Ensembl chr 3:68,838,189...68,926,639
|
|
G |
Kit |
KIT proto-oncogene receptor tyrosine kinase |
decreases expression |
ISO |
rebaudioside A results in decreased expression of KIT mRNA |
CTD |
PMID:31655124 |
|
NCBI chr14:32,547,459...32,624,694
Ensembl chr14:32,548,877...32,624,652
|
|
G |
Ldlr |
low density lipoprotein receptor |
multiple interactions |
ISO |
rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of ACOX1 mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of CAT mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of CPT1A mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of DGAT2 mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of FOXO1 mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of G6PC1 mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of INSR mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of IRS1 mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of IRS2 mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of LIPC mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of MTOR mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of NFKB1 mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of NFKBIA mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PCK1 mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PPARA mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PPARD mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PPARG mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PPARGC1A mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of SCD1 mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of SIRT1 mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of SLC27A1 mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of SLC2A2 mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of SOD2 mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580
|
|
G |
Lep |
leptin |
multiple interactions |
ISO |
rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of ACOX1 mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of CAT mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of CPT1A mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of DGAT2 mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of FOXO1 mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of G6PC1 mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of INSR mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of IRS1 mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of IRS2 mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of LIPC mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of MTOR mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of NFKB1 mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of NFKBIA mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PCK1 mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PPARA mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PPARD mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PPARG mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PPARGC1A mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of SCD1 mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of SIRT1 mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of SLC27A1 mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of SLC2A2 mRNA]; rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of SOD2 mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Lipc |
lipase C, hepatic type |
multiple interactions |
ISO |
rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of LIPC mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr 8:71,509,633...71,635,663
Ensembl chr 8:71,509,635...71,635,464
|
|
G |
Mmp13 |
matrix metallopeptidase 13 |
multiple interactions |
EXP |
rebaudioside A inhibits the reaction [Thioacetamide results in increased expression of MMP13 protein] |
CTD |
PMID:30883860 |
|
NCBI chr 8:4,497,960...4,508,239
Ensembl chr 8:4,497,960...4,508,239
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions |
EXP |
rebaudioside A inhibits the reaction [Thioacetamide results in increased activity of MMP2 protein] |
CTD |
PMID:30883860 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
increases expression multiple interactions |
ISO EXP |
rebaudioside A results in increased expression of MMP9 mRNA rebaudioside A inhibits the reaction [Thioacetamide results in increased activity of MMP9 protein] |
CTD |
PMID:30883860 PMID:31655124 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
multiple interactions |
ISO |
rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of MTOR mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
EXP |
rebaudioside A inhibits the reaction [Thioacetamide results in decreased expression of NFE2L2 protein] |
CTD |
PMID:30883860 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO |
rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of NFKB1 mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of NFKBIA mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Pck1 |
phosphoenolpyruvate carboxykinase 1 |
multiple interactions |
ISO |
rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PCK1 mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr 3:161,930,256...161,936,205
Ensembl chr 3:161,930,256...161,936,191
|
|
G |
Pf4 |
platelet factor 4 |
increases expression |
ISO |
rebaudioside A results in increased expression of PF4 mRNA |
CTD |
PMID:31655124 |
|
NCBI chr14:17,298,304...17,299,220
Ensembl chr14:17,298,308...17,299,365
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PPARA mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Ppard |
peroxisome proliferator-activated receptor delta |
multiple interactions |
ISO |
rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PPARD mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr20:6,298,785...6,363,970
Ensembl chr20:6,298,785...6,363,968
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
ISO |
rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PPARG mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
multiple interactions |
ISO |
rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PPARGC1A mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
decreases expression |
ISO |
rebaudioside A results in decreased expression of PTGS2 mRNA |
CTD |
PMID:31655124 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
rebaudioside A inhibits the reaction [Thioacetamide results in increased expression of RELA protein] |
CTD |
PMID:30883860 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Scd |
stearoyl-CoA desaturase |
multiple interactions |
ISO |
rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of SCD1 mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562
|
|
G |
Sele |
selectin E |
decreases expression |
ISO |
rebaudioside A results in decreased expression of SELE mRNA |
CTD |
PMID:31655124 |
|
NCBI chr13:76,402,841...76,412,741
Ensembl chr13:76,403,304...76,412,741
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions |
ISO |
rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of SIRT1 mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260
|
|
G |
Slc27a1 |
solute carrier family 27 member 1 |
multiple interactions |
ISO |
rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of SLC27A1 mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr16:18,278,984...18,300,173
Ensembl chr16:18,278,984...18,296,063
|
|
G |
Slc2a2 |
solute carrier family 2 member 2 |
multiple interactions |
ISO |
rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of SLC2A2 mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr 2:111,609,798...111,639,930
Ensembl chr 2:111,611,774...111,639,933
|
|
G |
Smad7 |
SMAD family member 7 |
multiple interactions |
EXP |
rebaudioside A inhibits the reaction [Thioacetamide results in decreased expression of SMAD7 protein] |
CTD |
PMID:30883860 |
|
NCBI chr18:68,988,429...69,016,774
Ensembl chr18:68,988,429...69,016,765
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions |
ISO |
rebaudioside A affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of SOD2 mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
EXP |
rebaudioside A inhibits the reaction [Thioacetamide results in increased expression of TGFB1 protein] |
CTD |
PMID:30883860 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP |
rebaudioside A inhibits the reaction [Thioacetamide results in increased expression of TNF protein] |
CTD |
PMID:30883860 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfsf10 |
TNF superfamily member 10 |
decreases expression |
ISO |
rebaudioside A results in decreased expression of TNFSF10 mRNA |
CTD |
PMID:31655124 |
|
NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135
|
|
|
G |
Alb |
albumin |
multiple interactions |
ISO |
ALB protein binds to and affects the transport of salicin |
CTD |
PMID:8831264 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Tas2r118 |
taste receptor, type 2, member 118 |
multiple interactions increases activity |
ISO |
4-((diethylamino)sulfonyl)benzoic acid inhibits the reaction [salicin results in increased activity of TAS2R16 protein]; Probenecid inhibits the reaction [salicin results in increased activity of TAS2R16 protein] |
CTD |
PMID:21629661 |
|
NCBI chr 4:52,449,208...52,450,107
Ensembl chr 4:52,449,208...52,450,107
|
|
|
G |
Ide |
insulin degrading enzyme |
multiple interactions |
ISO |
scopolin binds to and affects the activity of IDE protein |
CTD |
PMID:23146021 |
|
NCBI chr 1:235,002,984...235,102,448
Ensembl chr 1:234,995,351...235,102,440
|
|
G |
Urod |
uroporphyrinogen decarboxylase |
multiple interactions |
ISO |
scopolin binds to and affects the activity of UROD protein |
CTD |
PMID:23209648 |
|
NCBI chr 5:130,464,695...130,468,783
Ensembl chr 5:130,455,217...130,468,808
|
|
|
G |
Akr7a3 |
aldo-keto reductase family 7 member A3 |
increases activity |
EXP |
sinigrin results in increased activity of AKR7A3 protein |
CTD |
PMID:9328168 |
|
NCBI chr 5:151,590,968...151,601,394
Ensembl chr 5:151,584,479...151,601,394
|
|
G |
Gsta5 |
glutathione S-transferase alpha 5 |
increases activity |
EXP |
sinigrin results in increased activity of GSTA5 protein |
CTD |
PMID:9328168 |
|
NCBI chr 8:79,105,561...79,117,472
Ensembl chr 8:79,105,661...79,117,472
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
sinigrin inhibits the reaction [TNF protein affects the localization of RELA protein] |
CTD |
PMID:28483571 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
sinigrin inhibits the reaction [TNF protein affects the localization of RELA protein]; sinigrin inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]; sinigrin inhibits the reaction [TNF protein results in increased expression of VCAM1 protein] |
CTD |
PMID:28483571 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
multiple interactions |
ISO |
sinigrin inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]; sinigrin inhibits the reaction [TNF protein results in increased expression of VCAM1 protein] |
CTD |
PMID:28483571 |
|
NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958
|
|
|
G |
Ace |
angiotensin I converting enzyme |
decreases expression |
ISO |
stevioside results in decreased expression of ACE mRNA |
CTD |
PMID:31655124 |
|
NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131
|
|
G |
Ache |
acetylcholinesterase |
multiple interactions |
EXP |
stevioside inhibits the reaction [Scopolamine results in increased activity of ACHE protein] |
CTD |
PMID:20871768 |
|
NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Acox1 |
acyl-CoA oxidase 1 |
multiple interactions |
ISO |
stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of ACOX1 mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr10:101,406,197...101,431,252
Ensembl chr10:101,406,197...101,431,232
|
|
G |
Acp5 |
acid phosphatase 5, tartrate resistant |
decreases secretion |
EXP |
stevioside results in decreased secretion of ACP5 protein |
CTD |
PMID:21089163 |
|
NCBI chr 8:20,663,984...20,670,604
Ensembl chr 8:20,663,985...20,667,929
|
|
G |
Agtr1a |
angiotensin II receptor, type 1a |
increases expression |
ISO |
stevioside results in increased expression of AGTR1 mRNA |
CTD |
PMID:31655124 |
|
NCBI chr17:34,173,446...34,226,892
Ensembl chr17:34,174,429...34,226,946
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
increases expression |
ISO |
stevioside results in increased expression of ALOX5 mRNA |
CTD |
PMID:31655124 |
|
NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
decreases expression |
ISO |
stevioside results in decreased expression of BAX mRNA |
CTD |
PMID:31655124 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Calca |
calcitonin-related polypeptide alpha |
increases expression |
ISO |
stevioside results in increased expression of CALCA mRNA |
CTD |
PMID:31655124 |
|
NCBI chr 1:168,878,212...168,883,176
Ensembl chr 1:168,878,214...168,883,105
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of CAT mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
decreases expression |
ISO |
stevioside results in decreased expression of CCL2 mRNA |
CTD |
PMID:31655124 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Cflar |
CASP8 and FADD-like apoptosis regulator |
decreases expression |
ISO |
stevioside results in decreased expression of CFLAR mRNA |
CTD |
PMID:31655124 |
|
NCBI chr 9:60,185,338...60,236,173
Ensembl chr 9:60,185,452...60,237,034
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
multiple interactions |
ISO |
stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of CPT1A mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases expression |
ISO |
stevioside results in increased expression of CYP1A1 mRNA |
CTD |
PMID:28887089 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
increases expression |
ISO |
stevioside results in increased expression of CYP1A2 mRNA; stevioside results in increased expression of CYP1A2 protein |
CTD |
PMID:28887089 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
increases expression |
ISO |
stevioside results in increased expression of CYP1B1 mRNA |
CTD |
PMID:28887089 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
decreases expression |
ISO |
stevioside results in decreased expression of CYP2C9 mRNA |
CTD |
PMID:28887089 |
|
NCBI chr 1:236,762,719...236,799,069
Ensembl chr 1:236,762,842...236,799,066
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions increases expression |
ISO |
stevioside binds to and results in decreased activity of CYP3A4 protein stevioside results in increased expression of CYP3A4 mRNA; stevioside results in increased expression of CYP3A4 protein |
CTD |
PMID:28887089 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Dgat2 |
diacylglycerol O-acyltransferase 2 |
multiple interactions |
ISO |
stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of DGAT2 mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr 1:153,454,078...153,484,432
Ensembl chr 1:153,454,080...153,484,428
|
|
G |
Edn1 |
endothelin 1 |
decreases expression |
ISO |
stevioside results in decreased expression of EDN1 mRNA |
CTD |
PMID:31655124 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Ednra |
endothelin receptor type A |
increases expression |
ISO |
stevioside results in increased expression of EDNRA mRNA |
CTD |
PMID:31655124 |
|
NCBI chr19:30,233,540...30,303,727
Ensembl chr19:30,233,571...30,297,049
|
|
G |
F2r |
coagulation factor II (thrombin) receptor |
decreases expression |
ISO |
stevioside results in decreased expression of F2R mRNA |
CTD |
PMID:31655124 |
|
NCBI chr 2:26,869,343...26,885,856
Ensembl chr 2:26,868,404...26,885,870
|
|
G |
Faslg |
Fas ligand |
increases expression |
ISO |
stevioside results in increased expression of FASLG mRNA |
CTD |
PMID:31655124 |
|
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Fgf1 |
fibroblast growth factor 1 |
increases expression |
ISO |
stevioside results in increased expression of FGF1 mRNA |
CTD |
PMID:31655124 |
|
NCBI chr18:30,686,555...30,772,667
Ensembl chr18:30,686,581...30,772,357
|
|
G |
Flt1 |
Fms related receptor tyrosine kinase 1 |
decreases expression |
ISO |
stevioside results in decreased expression of FLT1 mRNA |
CTD |
PMID:31655124 |
|
NCBI chr12:7,296,899...7,468,626
Ensembl chr12:7,297,292...7,468,626
|
|
G |
Foxo1 |
forkhead box O1 |
multiple interactions |
ISO |
stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of FOXO1 mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
multiple interactions |
ISO |
stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of G6PC1 mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804
|
|
G |
Insr |
insulin receptor |
multiple interactions |
ISO |
stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of INSR mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr12:1,193,193...1,330,976
Ensembl chr12:1,197,100...1,330,883
|
|
G |
Irs1 |
insulin receptor substrate 1 |
multiple interactions |
ISO |
stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of IRS1 mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr 9:83,552,964...83,605,797
Ensembl chr 9:83,548,944...83,606,122
|
|
G |
Irs2 |
insulin receptor substrate 2 |
multiple interactions |
ISO |
stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of IRS2 mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr16:78,488,249...78,512,482
Ensembl chr16:78,485,045...78,512,482
|
|
G |
Itgav |
integrin subunit alpha V |
decreases expression |
ISO |
stevioside results in decreased expression of ITGAV mRNA |
CTD |
PMID:31655124 |
|
NCBI chr 3:68,838,514...68,926,653
Ensembl chr 3:68,838,189...68,926,639
|
|
G |
Kit |
KIT proto-oncogene receptor tyrosine kinase |
decreases expression |
ISO |
stevioside results in decreased expression of KIT mRNA |
CTD |
PMID:31655124 |
|
NCBI chr14:32,547,459...32,624,694
Ensembl chr14:32,548,877...32,624,652
|
|
G |
Ldlr |
low density lipoprotein receptor |
multiple interactions |
ISO |
stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of ACOX1 mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of CAT mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of CPT1A mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of DGAT2 mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of FOXO1 mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of G6PC1 mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of INSR mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of IRS1 mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of IRS2 mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of LIPC mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of MTOR mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of NFKB1 mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of NFKBIA mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PCK1 mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PLIN2 mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PPARA mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PPARD mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PPARG mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PPARGC1A mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of SCD1 mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of SIRT1 mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of SLC27A1 mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of SLC2A2 mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of SOD2 mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580
|
|
G |
Lep |
leptin |
multiple interactions |
ISO |
stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of ACOX1 mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of CAT mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of CPT1A mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of DGAT2 mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of FOXO1 mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of G6PC1 mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of INSR mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of IRS1 mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of IRS2 mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of LIPC mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of MTOR mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of NFKB1 mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of NFKBIA mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PCK1 mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PLIN2 mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PPARA mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PPARD mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PPARG mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PPARGC1A mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of SCD1 mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of SIRT1 mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of SLC27A1 mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of SLC2A2 mRNA]; stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of SOD2 mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Lipc |
lipase C, hepatic type |
multiple interactions |
ISO |
stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of LIPC mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr 8:71,509,633...71,635,663
Ensembl chr 8:71,509,635...71,635,464
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
increases expression |
ISO |
stevioside results in increased expression of MMP9 mRNA |
CTD |
PMID:31655124 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
multiple interactions |
ISO |
stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of MTOR mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO |
stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of NFKB1 mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of NFKBIA mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Pck1 |
phosphoenolpyruvate carboxykinase 1 |
multiple interactions |
ISO |
stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PCK1 mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr 3:161,930,256...161,936,205
Ensembl chr 3:161,930,256...161,936,191
|
|
G |
Pf4 |
platelet factor 4 |
increases expression |
ISO |
stevioside results in increased expression of PF4 mRNA |
CTD |
PMID:31655124 |
|
NCBI chr14:17,298,304...17,299,220
Ensembl chr14:17,298,308...17,299,365
|
|
G |
Plin2 |
perilipin 2 |
multiple interactions |
ISO |
stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PLIN2 mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr 5:101,156,648...101,211,738
Ensembl chr 5:101,154,411...101,242,319
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PPARA mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Ppard |
peroxisome proliferator-activated receptor delta |
multiple interactions |
ISO |
stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PPARD mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr20:6,298,785...6,363,970
Ensembl chr20:6,298,785...6,363,968
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
ISO |
stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PPARG mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
multiple interactions |
ISO |
stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of PPARGC1A mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
decreases expression |
ISO |
stevioside results in decreased expression of PTGS2 mRNA |
CTD |
PMID:31655124 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Scd |
stearoyl-CoA desaturase |
multiple interactions |
ISO |
stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of SCD1 mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562
|
|
G |
Sele |
selectin E |
decreases expression |
ISO |
stevioside results in decreased expression of SELE mRNA |
CTD |
PMID:31655124 |
|
NCBI chr13:76,402,841...76,412,741
Ensembl chr13:76,403,304...76,412,741
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions |
ISO |
stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of SIRT1 mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260
|
|
G |
Slc27a1 |
solute carrier family 27 member 1 |
multiple interactions |
ISO |
stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of SLC27A1 mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr16:18,278,984...18,300,173
Ensembl chr16:18,278,984...18,296,063
|
|
G |
Slc2a2 |
solute carrier family 2 member 2 |
multiple interactions |
ISO |
stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of SLC2A2 mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr 2:111,609,798...111,639,930
Ensembl chr 2:111,611,774...111,639,933
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions |
ISO |
stevioside affects the reaction [[LEP protein co-treated with LDLR protein] affects the expression of SOD2 mRNA] |
CTD |
PMID:25554529 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Tnfsf10 |
TNF superfamily member 10 |
decreases expression |
ISO |
stevioside results in decreased expression of TNFSF10 mRNA |
CTD |
PMID:31655124 |
|
NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135
|
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
ISO |
syringin results in increased expression of BAX protein |
CTD |
PMID:35580997 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression |
ISO |
syringin results in decreased expression of BCL2 protein |
CTD |
PMID:35580997 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
decreases expression |
ISO |
syringin results in decreased expression of BIRC5 protein |
CTD |
PMID:35580997 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Ccl11 |
C-C motif chemokine ligand 11 |
multiple interactions |
ISO |
syringin inhibits the reaction [Ovalbumin results in increased expression of CCL11 protein] |
CTD |
PMID:33146439 |
|
NCBI chr10:67,028,328...67,032,929
Ensembl chr10:67,028,328...67,032,926
|
|
G |
Ccnd1 |
cyclin D1 |
increases expression |
ISO |
syringin results in increased expression of CCND1 protein |
CTD |
PMID:35580997 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Cdh1 |
cadherin 1 |
increases expression |
ISO |
syringin results in increased expression of CDH1 protein |
CTD |
PMID:35580997 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
syringin inhibits the reaction [Ovalbumin results in increased expression of IFNG protein] |
CTD |
PMID:33146439 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il13 |
interleukin 13 |
multiple interactions |
ISO |
syringin inhibits the reaction [Ovalbumin results in increased expression of IL13 protein] |
CTD |
PMID:33146439 |
|
NCBI chr10:37,790,130...37,792,687
Ensembl chr10:37,790,130...37,792,737
|
|
G |
Il4 |
interleukin 4 |
multiple interactions |
ISO |
syringin inhibits the reaction [Ovalbumin results in increased expression of IL4 protein] |
CTD |
PMID:33146439 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il5 |
interleukin 5 |
multiple interactions |
ISO |
syringin inhibits the reaction [Ovalbumin results in increased expression of IL5 protein] |
CTD |
PMID:33146439 |
|
NCBI chr10:37,874,342...37,877,213
Ensembl chr10:37,874,342...37,877,213
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
syringin inhibits the reaction [Ovalbumin results in increased expression of IL6 protein] |
CTD |
PMID:33146439 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
ISO |
syringin inhibits the reaction [Ovalbumin results in increased activity of MPO protein] |
CTD |
PMID:33146439 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
syringin inhibits the reaction [Ovalbumin results in increased expression of and results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:33146439 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
increases phosphorylation |
ISO |
syringin results in increased phosphorylation of PPARA protein |
CTD |
PMID:23691032 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Prkaa1 |
protein kinase AMP-activated catalytic subunit alpha 1 |
decreases phosphorylation |
ISO |
syringin results in decreased phosphorylation of PRKAA1 protein |
CTD |
PMID:23691032 |
|
NCBI chr 2:54,240,298...54,275,978
Ensembl chr 2:54,240,137...54,275,978
|
|
G |
Prkaa2 |
protein kinase AMP-activated catalytic subunit alpha 2 |
decreases phosphorylation |
ISO |
syringin results in decreased phosphorylation of PRKAA2 protein |
CTD |
PMID:23691032 |
|
NCBI chr 5:119,807,992...119,879,987
Ensembl chr 5:119,813,226...119,879,543
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
syringin inhibits the reaction [Ovalbumin results in increased expression of and results in increased phosphorylation of RELA protein] |
CTD |
PMID:33146439 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Sqstm1 |
sequestosome 1 |
decreases expression |
ISO |
syringin results in decreased expression of SQSTM1 protein |
CTD |
PMID:35580997 |
|
NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
syringin inhibits the reaction [Ovalbumin results in increased expression of TNF protein] |
CTD |
PMID:33146439 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tp53 |
tumor protein p53 |
increases expression |
ISO |
syringin results in increased expression of TP53 protein |
CTD |
PMID:35580997 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
|
G |
Acadm |
acyl-CoA dehydrogenase medium chain |
multiple interactions |
ISO |
tectoridin inhibits the reaction [Ethanol results in decreased expression of ACADM mRNA] |
CTD |
PMID:20637825 |
|
NCBI chr 2:242,858,865...242,883,036
Ensembl chr 2:242,858,865...242,883,147
|
|
G |
Acox1 |
acyl-CoA oxidase 1 |
multiple interactions |
ISO |
tectoridin inhibits the reaction [Ethanol results in decreased expression of ACOX1 mRNA] |
CTD |
PMID:20637825 |
|
NCBI chr10:101,406,197...101,431,252
Ensembl chr10:101,406,197...101,431,232
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
multiple interactions |
ISO |
tectoridin inhibits the reaction [Ethanol results in decreased expression of CPT1A mRNA] |
CTD |
PMID:20637825 |
|
NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Dgat1 |
diacylglycerol O-acyltransferase 1 |
multiple interactions |
ISO |
tectoridin inhibits the reaction [Ethanol results in increased expression of DGAT1 mRNA] |
CTD |
PMID:20637825 |
|
NCBI chr 7:108,223,860...108,235,413
Ensembl chr 7:108,218,524...108,234,299
|
|
G |
Dgat2 |
diacylglycerol O-acyltransferase 2 |
multiple interactions |
ISO |
tectoridin inhibits the reaction [Ethanol results in increased expression of DGAT2 mRNA] |
CTD |
PMID:20637825 |
|
NCBI chr 1:153,454,078...153,484,432
Ensembl chr 1:153,454,080...153,484,428
|
|
G |
Dpp4 |
dipeptidylpeptidase 4 |
multiple interactions |
ISO |
[Xiao-Ke-An results in increased abundance of tectoridin] which results in decreased activity of DPP4 protein |
CTD |
PMID:32535096 |
|
NCBI chr 3:46,962,233...47,043,870
Ensembl chr 3:46,962,243...47,043,901
|
|
G |
Gpam |
glycerol-3-phosphate acyltransferase, mitochondrial |
multiple interactions |
ISO |
tectoridin inhibits the reaction [Ethanol results in increased expression of GPAM mRNA] |
CTD |
PMID:20637825 |
|
NCBI chr 1:254,106,323...254,170,755
Ensembl chr 1:254,106,331...254,142,639
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
tectoridin inhibits the reaction [Ethanol results in decreased expression of PPARA mRNA] |
CTD |
PMID:20637825 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
decreases response to substance |
ISO |
ABCC1 results in decreased susceptibility to Teniposide |
CTD |
PMID:8968083 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Ar |
androgen receptor |
multiple interactions |
ISO |
Teniposide binds to and results in decreased activity of AR protein |
CTD |
PMID:25752796 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression |
ISO |
Teniposide results in increased expression of CDKN1A mRNA; Teniposide results in increased expression of CDKN1A protein |
CTD |
PMID:25914138 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
decreases methylation multiple interactions |
ISO |
CYP3A4 protein results in decreased methylation of Teniposide Cyclosporine inhibits the reaction [CYP3A4 protein results in decreased methylation of Teniposide]; Dexamethasone inhibits the reaction [CYP3A4 protein results in decreased methylation of Teniposide]; Erythromycin inhibits the reaction [CYP3A4 protein results in decreased methylation of Teniposide]; Midazolam inhibits the reaction [CYP3A4 protein results in decreased methylation of Teniposide] |
CTD |
PMID:8114683 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
decreases methylation |
ISO |
CYP3A5 protein results in decreased methylation of Teniposide |
CTD |
PMID:8114683 |
|
NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions |
ISO |
Teniposide binds to and results in decreased activity of ESR1 protein |
CTD |
PMID:25752796 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions |
ISO |
Teniposide binds to and results in decreased activity of ESR2 protein |
CTD |
PMID:25752796 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
decreases response to substance |
ISO |
FGF2 protein results in decreased susceptibility to Teniposide |
CTD |
PMID:20221717 |
|
NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
multiple interactions |
ISO |
Teniposide inhibits the reaction [GSTP1 protein results in increased metabolism of 1-chloro-2,4-dinitrobenzene-glutathione conjugate] |
CTD |
PMID:23769903 |
|
NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
|
|
G |
Mir135b |
microRNA 135b |
decreases response to substance |
ISO |
MIR135B mRNA results in decreased susceptibility to Teniposide |
CTD |
PMID:27570640 |
|
NCBI chr13:43,638,857...43,638,953
Ensembl chr13:43,638,857...43,638,953
|
|
G |
Mir196b |
microRNA 196b |
decreases response to substance |
ISO |
MIR196B mRNA results in decreased susceptibility to Teniposide |
CTD |
PMID:27570640 |
|
NCBI chr 4:81,330,487...81,330,571
Ensembl chr 4:81,330,487...81,330,571
|
|
G |
Mttp |
microsomal triglyceride transfer protein |
decreases expression multiple interactions |
ISO |
Teniposide results in decreased expression of MTTP mRNA Teniposide promotes the reaction [CETP protein results in decreased expression of MTTP mRNA] |
CTD |
PMID:25914138 |
|
NCBI chr 2:226,613,090...226,654,239
Ensembl chr 2:226,613,090...226,654,239
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
decreases expression |
ISO |
Teniposide results in decreased expression of MYC mRNA; Teniposide results in decreased expression of MYC protein |
CTD |
PMID:11585056 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Nr1h2 |
nuclear receptor subfamily 1, group H, member 2 |
multiple interactions affects localization affects response to substance |
ISO |
NR1H2 mutant form inhibits the reaction [Teniposide results in increased expression of CETP mRNA]; Teniposide promotes the reaction [NR1H2 protein results in increased expression of CETP mRNA] Teniposide affects the localization of NR1H2 protein NR1H2 protein affects the susceptibility to Teniposide |
CTD |
PMID:25914138 |
|
NCBI chr 1:95,041,967...95,047,358
Ensembl chr 1:95,041,967...95,047,377
|
|
G |
Nr1h3 |
nuclear receptor subfamily 1, group H, member 3 |
multiple interactions increases expression affects response to substance |
ISO |
NR1H3 mutant form inhibits the reaction [Teniposide results in increased expression of CETP mRNA]; Teniposide promotes the reaction [NR1H3 protein results in increased expression of CETP mRNA]; Teniposide results in increased expression of and affects the localization of NR1H3 protein Teniposide results in increased expression of NR1H3 mRNA NR1H3 protein affects the susceptibility to Teniposide |
CTD |
PMID:25914138 |
|
NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722
|
|
G |
Nrip1 |
nuclear receptor interacting protein 1 |
decreases expression |
ISO |
Teniposide results in decreased expression of NRIP1 mRNA; Teniposide results in decreased expression of NRIP1 protein |
CTD |
PMID:25914138 |
|
NCBI chr11:14,895,843...14,979,490
Ensembl chr11:14,895,553...14,981,761
|
|
G |
Odc1 |
ornithine decarboxylase 1 |
decreases expression |
ISO |
Teniposide results in decreased expression of ODC1 protein |
CTD |
PMID:11585056 |
|
NCBI chr 6:40,329,831...40,336,444
Ensembl chr 6:40,329,964...40,336,440
|
|
G |
Pgr |
progesterone receptor |
multiple interactions |
ISO |
Teniposide binds to and results in decreased activity of PGR protein |
CTD |
PMID:25752796 |
|
NCBI chr 8:6,072,673...6,131,552
Ensembl chr 8:6,072,673...6,131,344
|
|
G |
Rxra |
retinoid X receptor alpha |
multiple interactions |
ISO |
Teniposide promotes the reaction [RXRA protein results in increased expression of CETP mRNA]; Tretinoin promotes the reaction [Teniposide promotes the reaction [RXRA protein results in increased expression of CETP mRNA]] |
CTD |
PMID:25914138 |
|
NCBI chr 3:10,989,832...11,076,366
Ensembl chr 3:10,989,832...11,073,712
|
|
G |
Slco2b1 |
solute carrier organic anion transporter family, member 2b1 |
multiple interactions |
ISO |
Teniposide inhibits the reaction [SLCO2B1 protein results in increased uptake of Cascade Blue] |
CTD |
PMID:30863990 |
|
NCBI chr 1:153,959,288...154,007,294
Ensembl chr 1:153,959,293...154,007,353
|
|
G |
Thra |
thyroid hormone receptor alpha |
multiple interactions |
ISO |
Teniposide binds to and results in decreased activity of THRA protein |
CTD |
PMID:25752796 |
|
NCBI chr10:83,701,885...83,729,408
Ensembl chr10:83,700,755...83,729,936
|
|
G |
Thrb |
thyroid hormone receptor beta |
multiple interactions |
ISO |
Teniposide binds to and results in decreased activity of THRB protein |
CTD |
PMID:25752796 |
|
NCBI chr15:7,685,180...8,031,920
Ensembl chr15:7,685,180...7,882,916
|
|
G |
Top2a |
DNA topoisomerase II alpha |
multiple interactions |
ISO |
TOP2A results in decreased susceptibility to [Cisplatin co-treated with Teniposide] |
CTD |
PMID:11325482 |
|
NCBI chr10:83,945,731...83,976,874
Ensembl chr10:83,945,735...83,976,874
|
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
affects export |
ISO |
ABCC2 protein affects the export of polydatin |
CTD |
PMID:15686436 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions |
ISO |
polydatin inhibits the reaction [potassium oxonate results in increased expression of ABCG2 protein] |
CTD |
PMID:22865646 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Agt |
angiotensinogen |
multiple interactions |
EXP |
polydatin inhibits the reaction [AGT protein modified form results in increased expression of CYBB mRNA]; polydatin inhibits the reaction [AGT protein modified form results in increased expression of CYBB protein]; polydatin inhibits the reaction [AGT protein modified form results in increased expression of MYH7 mRNA]; polydatin inhibits the reaction [AGT protein modified form results in increased expression of NOX4 mRNA]; polydatin inhibits the reaction [AGT protein modified form results in increased expression of NOX4 protein]; polydatin inhibits the reaction [AGT protein modified form results in increased expression of NPPA mRNA]; polydatin inhibits the reaction [AGT protein modified form results in increased expression of TGFB1 protein] |
CTD |
PMID:25488910 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Ahr |
aryl hydrocarbon receptor |
decreases localization multiple interactions |
ISO |
polydatin results in decreased localization of AHR protein polydatin promotes the reaction [6-formylindolo(3,2-b)carbazole results in increased localization of AHR protein] |
CTD |
PMID:21756928 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Arnt |
aryl hydrocarbon receptor nuclear translocator |
increases localization |
ISO |
polydatin results in increased localization of ARNT protein |
CTD |
PMID:21756928 |
|
NCBI chr 2:182,997,731...183,056,584
Ensembl chr 2:182,997,736...183,056,580
|
|
G |
Atg5 |
autophagy related 5 |
multiple interactions |
ISO |
polydatin inhibits the reaction [Rotenone results in decreased expression of ATG5 protein] |
CTD |
PMID:31926197 |
|
NCBI chr20:47,798,217...47,889,216
Ensembl chr20:47,798,290...47,889,209
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO |
cyclopamine inhibits the reaction [polydatin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of BCL2 mRNA]]; polydatin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of BCL2 mRNA] polydatin inhibits the reaction [Dopamine results in decreased expression of BCL2 protein] |
CTD |
PMID:27481074 PMID:28980048 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Cat |
catalase |
multiple interactions |
ISO EXP |
cyclopamine inhibits the reaction [polydatin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in decreased activity of CAT protein]]; polydatin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in decreased activity of CAT protein] polydatin inhibits the reaction [Arsenic Trioxide results in decreased activity of CAT protein] |
CTD |
PMID:27481074 PMID:29130132 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions decreases secretion decreases expression |
ISO |
polydatin inhibits the reaction [leptomycin B results in increased secretion of CCL2 protein]; polydatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of CCL2 mRNA]; polydatin inhibits the reaction [PD168393 results in increased expression of CCL2 mRNA] polydatin results in decreased secretion of CCL2 protein polydatin results in decreased expression of CCL2 mRNA |
CTD |
PMID:21756928 PMID:21967610 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions |
ISO |
cyclopamine inhibits the reaction [polydatin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CCND1 mRNA]]; polydatin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CCND1 mRNA] |
CTD |
PMID:27481074 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccnd2 |
cyclin D2 |
multiple interactions |
ISO |
cyclopamine inhibits the reaction [polydatin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CCND2 mRNA]]; polydatin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CCND2 mRNA] |
CTD |
PMID:27481074 |
|
NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
multiple interactions decreases secretion decreases expression |
ISO |
[polydatin co-treated with TGFA protein] results in increased expression of CXCL10 mRNA; polydatin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased secretion of CXCL10 protein]; polydatin inhibits the reaction [PD168393 results in increased expression of CXCL10 mRNA] polydatin results in decreased secretion of CXCL10 protein polydatin results in decreased expression of CXCL10 mRNA |
CTD |
PMID:21756928 PMID:21967610 |
|
NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975
|
|
G |
Cybb |
cytochrome b-245 beta chain |
multiple interactions |
EXP |
polydatin inhibits the reaction [AGT protein modified form results in increased expression of CYBB mRNA]; polydatin inhibits the reaction [AGT protein modified form results in increased expression of CYBB protein] |
CTD |
PMID:25488910 |
|
NCBI chr X:13,358,101...13,392,570
Ensembl chr X:13,359,430...13,392,586
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases expression |
ISO |
polydatin results in increased expression of CYP1A1 mRNA |
CTD |
PMID:21756928 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
ISO |
polydatin inhibits the reaction [TGFA protein affects the localization of EGFR protein] |
CTD |
PMID:21967610 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions |
ISO |
ESR2 gene mutant form inhibits the reaction [polydatin results in increased expression of SOD2 protein] |
CTD |
PMID:24361291 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
G6pd |
glucose-6-phosphate dehydrogenase |
decreases activity |
ISO |
polydatin results in decreased activity of G6PD protein |
CTD |
PMID:25130191 |
|
NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801
|
|
G |
Gli1 |
GLI family zinc finger 1 |
multiple interactions |
ISO |
cyclopamine inhibits the reaction [polydatin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of GLI1 mRNA]]; cyclopamine inhibits the reaction [polydatin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased localization of GLI1 protein]]; polydatin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of GLI1 mRNA]; polydatin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased localization of GLI1 protein] |
CTD |
PMID:27481074 |
|
NCBI chr 7:63,156,926...63,169,579
Ensembl chr 7:63,156,926...63,169,251
|
|
G |
Hlcs |
holocarboxylase synthetase |
decreases activity |
ISO |
polydatin results in decreased activity of HLCS protein |
CTD |
PMID:26303405 |
|
NCBI chr11:33,455,806...33,635,197
Ensembl chr11:33,455,809...33,624,222
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
polydatin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of MAPK1 protein]; polydatin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of MAPK3 protein]; polydatin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of RELA protein]; polydatin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased secretion of CXCL10 protein]; polydatin promotes the reaction [[TNF protein co-treated with IFNG protein] results in increased secretion of CXCL8 protein] |
CTD |
PMID:21756928 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP |
polydatin inhibits the reaction [Arsenic Trioxide results in increased expression of IL1B mRNA] |
CTD |
PMID:29130132 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il4 |
interleukin 4 |
multiple interactions |
EXP |
polydatin inhibits the reaction [OVAL protein results in increased secretion of IL4 protein] |
CTD |
PMID:23840142 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il6 |
interleukin 6 |
multiple interactions decreases expression |
ISO |
polydatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL6 mRNA] polydatin results in decreased expression of IL6 mRNA |
CTD |
PMID:21756928 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Keap1 |
Kelch-like ECH-associated protein 1 |
multiple interactions |
ISO |
polydatin inhibits the reaction [Hydrogen Peroxide results in increased expression of KEAP1 protein] polydatin inhibits the reaction [TSHR protein results in increased expression of KEAP1 protein] |
CTD |
PMID:31705858 |
|
NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862
|
|
G |
Lct |
lactase |
increases hydrolysis |
EXP |
LCT protein results in increased hydrolysis of polydatin analog |
CTD |
PMID:17009167 |
|
NCBI chr13:39,781,929...39,824,456
Ensembl chr13:39,781,929...39,824,456
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation decreases phosphorylation |
ISO |
polydatin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [polydatin results in increased phosphorylation of MAPK1 protein] polydatin results in decreased phosphorylation of MAPK1 protein |
CTD |
PMID:21756928 PMID:28980048 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation decreases phosphorylation |
ISO |
polydatin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [polydatin results in increased phosphorylation of MAPK3 protein] polydatin results in decreased phosphorylation of MAPK3 protein |
CTD |
PMID:21756928 PMID:28980048 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk7 |
mitogen-activated protein kinase 7 |
multiple interactions increases phosphorylation |
ISO |
XMD 8-92 inhibits the reaction [polydatin results in increased phosphorylation of MAPK7 protein] |
CTD |
PMID:28980048 |
|
NCBI chr10:46,170,264...46,176,262
Ensembl chr10:46,170,167...46,176,267
|
|
G |
Mfn2 |
mitofusin 2 |
multiple interactions |
ISO |
polydatin inhibits the reaction [Rotenone results in increased expression of MFN2 protein] |
CTD |
PMID:31926197 |
|
NCBI chr 5:158,304,285...158,335,502
Ensembl chr 5:158,304,287...158,335,342
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
multiple interactions |
ISO |
polydatin inhibits the reaction [Rotenone results in increased phosphorylation of MTOR protein] |
CTD |
PMID:31926197 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Myh7 |
myosin heavy chain 7 |
multiple interactions |
EXP |
polydatin inhibits the reaction [AGT protein modified form results in increased expression of MYH7 mRNA] |
CTD |
PMID:25488910 |
|
NCBI chr15:28,446,550...28,469,888
Ensembl chr15:28,446,550...28,468,217
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
ISO |
[polydatin co-treated with Hydrogen Peroxide] results in increased expression of NFE2L2 protein; NFE2L2 protein affects the reaction [[polydatin co-treated with Hydrogen Peroxide] results in increased expression of NFE2L2 protein]; NFE2L2 protein affects the reaction [polydatin inhibits the reaction [Hydrogen Peroxide results in decreased expression of NQO1 protein]] polydatin inhibits the reaction [TSHR protein results in decreased expression of NFE2L2 protein] |
CTD |
PMID:31705858 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nox4 |
NADPH oxidase 4 |
multiple interactions |
EXP |
polydatin inhibits the reaction [AGT protein modified form results in increased expression of NOX4 mRNA]; polydatin inhibits the reaction [AGT protein modified form results in increased expression of NOX4 protein] |
CTD |
PMID:25488910 |
|
NCBI chr 1:140,900,886...141,078,844
Ensembl chr 1:140,901,097...141,077,406
|
|
G |
Nppa |
natriuretic peptide A |
multiple interactions |
EXP |
polydatin inhibits the reaction [2,2'-dipyridyl disulfide results in increased expression of NPPA protein]; polydatin inhibits the reaction [AGT protein modified form results in increased expression of NPPA mRNA]; polydatin inhibits the reaction [Phenylephrine results in increased expression of NPPA protein] |
CTD |
PMID:25449040 PMID:25488910 |
|
NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
ISO |
polydatin inhibits the reaction [TSHR protein results in decreased expression of NQO1 protein] NFE2L2 protein affects the reaction [polydatin inhibits the reaction [Hydrogen Peroxide results in decreased expression of NQO1 protein]]; polydatin inhibits the reaction [Hydrogen Peroxide results in decreased expression of NQO1 protein] |
CTD |
PMID:31705858 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Orai1 |
ORAI calcium release-activated calcium modulator 1 |
affects response to substance |
ISO |
ORAI1 protein affects the susceptibility to polydatin |
CTD |
PMID:22959927 |
|
NCBI chr12:33,533,151...33,548,361
Ensembl chr12:33,534,344...33,548,405
|
|
G |
Park7 |
Parkinsonism associated deglycase |
multiple interactions |
ISO |
[PRKN protein affects the susceptibility to polydatin] which results in increased expression of PARK7 protein; polydatin inhibits the reaction [Rotenone results in increased expression of PARK7 protein] |
CTD |
PMID:31926197 |
|
NCBI chr 5:161,353,718...161,376,993
Ensembl chr 5:161,353,719...161,376,970
|
|
G |
Pde5a |
phosphodiesterase 5A |
decreases activity |
ISO |
polydatin results in decreased activity of PDE5A protein |
CTD |
PMID:15769121 |
|
NCBI chr 2:210,858,515...211,003,480
Ensembl chr 2:210,858,063...210,999,701
|
|
G |
Ppargc1b |
PPARG coactivator 1 beta |
decreases expression |
ISO |
polydatin results in decreased expression of PPARGC1B protein |
CTD |
PMID:31926197 |
|
NCBI chr18:54,758,891...54,861,103
Ensembl chr18:54,758,902...54,861,194
|
|
G |
Ppp1r12a |
protein phosphatase 1, regulatory subunit 12A |
multiple interactions |
EXP |
polydatin inhibits the reaction [2,2'-dipyridyl disulfide results in increased phosphorylation of PPP1R12A protein]; polydatin inhibits the reaction [Phenylephrine results in increased phosphorylation of PPP1R12A protein] |
CTD |
PMID:25449040 |
|
NCBI chr 7:43,482,808...43,593,689
Ensembl chr 7:43,482,803...43,593,425
|
|
G |
Prkn |
parkin RBR E3 ubiquitin protein ligase |
multiple interactions affects response to substance |
ISO |
[PRKN protein affects the susceptibility to polydatin] which results in increased expression of PARK7 protein |
CTD |
PMID:31926197 |
|
NCBI chr 1:48,688,651...49,882,520
Ensembl chr 1:48,690,556...49,882,555
|
|
G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
decreases activity |
ISO |
polydatin results in decreased activity of PTGS1 protein |
CTD |
PMID:11962253 |
|
NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions decreases activity |
ISO |
[polydatin co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of PTGS2 mRNA polydatin results in decreased activity of PTGS2 protein |
CTD |
PMID:11962253 PMID:21756928 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO EXP |
polydatin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of RELA protein]; polydatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of RELA protein] polydatin inhibits the reaction [Arsenic Trioxide results in increased expression of RELA mRNA] |
CTD |
PMID:21756928 PMID:29130132 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rhoa |
ras homolog family member A |
multiple interactions |
EXP |
polydatin inhibits the reaction [Phenylephrine results in increased activity of RHOA protein] |
CTD |
PMID:25449040 |
|
NCBI chr 8:108,991,926...109,025,746
Ensembl chr 8:108,991,954...109,025,746
|
|
G |
Shh |
sonic hedgehog signaling molecule |
multiple interactions |
ISO |
polydatin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of and results in increased secretion of SHH protein] |
CTD |
PMID:27481074 |
|
NCBI chr 4:6,954,017...6,963,170
Ensembl chr 4:6,954,017...6,963,170
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions |
ISO |
polydatin inhibits the reaction [Rotenone results in decreased expression of SIRT1 protein] |
CTD |
PMID:31926197 |
|
NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260
|
|
G |
Slc22a1 |
solute carrier family 22 member 1 |
multiple interactions |
ISO |
polydatin inhibits the reaction [potassium oxonate results in decreased expression of SLC22A1 protein] |
CTD |
PMID:22865646 |
|
NCBI chr 1:48,076,657...48,103,679
Ensembl chr 1:48,076,666...48,103,678
|
|
G |
Slc22a12 |
solute carrier family 22 member 12 |
multiple interactions |
ISO |
polydatin inhibits the reaction [potassium oxonate results in increased expression of SLC22A12 protein] |
CTD |
PMID:22865646 |
|
NCBI chr 1:203,845,039...203,852,496
Ensembl chr 1:203,845,048...203,853,555
|
|
G |
Slc22a4 |
solute carrier family 22 member 4 |
multiple interactions |
ISO |
polydatin inhibits the reaction [potassium oxonate results in decreased expression of SLC22A4 protein] |
CTD |
PMID:22865646 |
|
NCBI chr10:38,133,333...38,179,932
Ensembl chr10:38,133,322...38,179,720
|
|
G |
Slc22a5 |
solute carrier family 22 member 5 |
multiple interactions |
ISO |
polydatin inhibits the reaction [potassium oxonate results in decreased expression of SLC22A5 protein] |
CTD |
PMID:22865646 |
|
NCBI chr10:38,008,303...38,035,474
Ensembl chr10:38,008,311...38,035,309
|
|
G |
Slc22a6 |
solute carrier family 22 member 6 |
multiple interactions |
ISO |
polydatin inhibits the reaction [potassium oxonate results in decreased expression of SLC22A6 protein] |
CTD |
PMID:22865646 |
|
NCBI chr 1:205,522,579...205,531,179
Ensembl chr 1:205,522,729...205,531,173
|
|
G |
Slc2a9 |
solute carrier family 2 member 9 |
multiple interactions |
ISO |
polydatin inhibits the reaction [potassium oxonate results in increased expression of SLC2A9 protein] |
CTD |
PMID:22865646 |
|
NCBI chr14:72,328,334...72,461,981
Ensembl chr14:72,328,320...72,461,981
|
|
G |
Slc5a1 |
solute carrier family 5 member 1 |
affects uptake |
ISO |
SLC5A1 protein affects the uptake of polydatin |
CTD |
PMID:15686436 |
|
NCBI chr14:77,553,990...77,618,589
Ensembl chr14:77,553,843...77,618,547
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions increases expression |
ISO |
polydatin results in increased expression of and results in increased activity of SOD2 protein polydatin results in increased expression of SOD2 protein ESR2 gene mutant form inhibits the reaction [polydatin results in increased expression of SOD2 protein]; fulvestrant inhibits the reaction [polydatin results in increased expression of SOD2 protein] |
CTD |
PMID:24361291 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions |
ISO |
polydatin promotes the reaction [Rotenone results in decreased expression of SQSTM1 protein] |
CTD |
PMID:31926197 |
|
NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Tgfa |
transforming growth factor alpha |
multiple interactions |
ISO |
[polydatin co-treated with TGFA protein] results in increased expression of CXCL10 mRNA; [polydatin co-treated with TGFA protein] results in increased expression of CXCL8 mRNA; polydatin inhibits the reaction [TGFA protein affects the localization of EGFR protein] |
CTD |
PMID:21756928 PMID:21967610 |
|
NCBI chr 4:118,618,043...118,700,897
Ensembl chr 4:118,618,269...118,700,894
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
EXP |
polydatin inhibits the reaction [AGT protein modified form results in increased expression of TGFB1 protein] |
CTD |
PMID:25488910 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions decreases expression |
ISO EXP |
polydatin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of MAPK1 protein]; polydatin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of MAPK3 protein]; polydatin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of RELA protein]; polydatin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased secretion of CXCL10 protein]; polydatin promotes the reaction [[TNF protein co-treated with IFNG protein] results in increased secretion of CXCL8 protein] polydatin inhibits the reaction [Arsenic Trioxide results in increased expression of TNF mRNA] polydatin results in decreased expression of TNF mRNA |
CTD |
PMID:21756928 PMID:29130132 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
EXP |
polydatin inhibits the reaction [Arsenic Trioxide results in increased expression of TP53 mRNA] |
CTD |
PMID:29130132 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tshr |
thyroid stimulating hormone receptor |
multiple interactions |
ISO |
polydatin inhibits the reaction [TSHR protein results in decreased expression of NFE2L2 protein]; polydatin inhibits the reaction [TSHR protein results in decreased expression of NQO1 protein]; polydatin inhibits the reaction [TSHR protein results in increased expression of KEAP1 protein] |
CTD |
PMID:31705858 |
|
NCBI chr 6:110,341,585...110,475,297
Ensembl chr 6:110,341,581...110,474,538
|
|
G |
Tug1 |
taurine up-regulated 1 |
decreases expression |
ISO |
polydatin results in decreased expression of TUG1 mRNA |
CTD |
PMID:30974157 |
|
NCBI chr14:78,519,894...78,526,927
Ensembl chr14:78,522,506...78,526,927
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
increases hydrolysis |
ISO |
UGT1A1 protein results in increased hydrolysis of polydatin metabolite |
CTD |
PMID:17009167 |
|
NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ulk1 |
unc-51 like autophagy activating kinase 1 |
multiple interactions |
ISO |
polydatin inhibits the reaction [Rotenone results in increased phosphorylation of ULK1 protein] |
CTD |
PMID:31926197 |
|
NCBI chr12:45,851,710...45,877,966
Ensembl chr12:45,851,710...45,877,966
|
|
G |
Umod |
uromodulin |
multiple interactions |
ISO |
polydatin inhibits the reaction [potassium oxonate results in increased expression of and results in decreased secretion of UMOD protein] |
CTD |
PMID:22865646 |
|
NCBI chr 1:173,816,341...173,829,681
Ensembl chr 1:173,816,339...173,830,302
|
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
rhapontin inhibits the reaction [Streptozocin results in decreased activity of CAT protein] |
CTD |
PMID:32662907 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
EXP |
rhapontin inhibits the reaction [Streptozocin results in decreased expression of HMOX1 mRNA]; rhapontin inhibits the reaction [Streptozocin results in decreased expression of HMOX1 protein] |
CTD |
PMID:32662907 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
EXP |
rhapontin inhibits the reaction [Streptozocin results in decreased expression of IL10 mRNA]; rhapontin inhibits the reaction [Streptozocin results in decreased expression of IL10 protein] |
CTD |
PMID:32662907 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Ins1 |
insulin 1 |
multiple interactions |
EXP |
rhapontin inhibits the reaction [Streptozocin results in decreased expression of INS1 protein] |
CTD |
PMID:32662907 |
|
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Keap1 |
Kelch-like ECH-associated protein 1 |
multiple interactions |
EXP |
rhapontin inhibits the reaction [Streptozocin results in increased expression of KEAP1 mRNA]; rhapontin inhibits the reaction [Streptozocin results in increased expression of KEAP1 protein] |
CTD |
PMID:32662907 |
|
NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions |
EXP |
rhapontin inhibits the reaction [Streptozocin results in increased expression of MMP2 mRNA] |
CTD |
PMID:32662907 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
EXP |
rhapontin inhibits the reaction [Streptozocin results in decreased expression of NFE2L2 mRNA]; rhapontin inhibits the reaction [Streptozocin results in decreased expression of NFE2L2 protein] |
CTD |
PMID:32662907 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
EXP |
rhapontin inhibits the reaction [Streptozocin results in decreased expression of NQO1 mRNA] |
CTD |
PMID:32662907 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
multiple interactions |
EXP |
rhapontin inhibits the reaction [Streptozocin results in decreased expression of TIMP1 mRNA] |
CTD |
PMID:32662907 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP |
rhapontin inhibits the reaction [Streptozocin results in increased expression of TNF mRNA] |
CTD |
PMID:32662907 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
EXP |
trilobatin inhibits the reaction [Hydrogen Peroxide affects the localization of BAX protein] |
CTD |
PMID:30104959 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
EXP |
trilobatin inhibits the reaction [Hydrogen Peroxide results in decreased expression of BCL2 protein] |
CTD |
PMID:30104959 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
NFE2L2 protein affects the reaction [trilobatin inhibits the reaction [Isoflurane results in decreased activity of CAT protein]]; trilobatin inhibits the reaction [Isoflurane results in decreased activity of CAT protein] |
CTD |
PMID:32663520 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Esrra |
estrogen related receptor, alpha |
multiple interactions |
EXP |
trilobatin inhibits the reaction [Hydrogen Peroxide results in decreased expression of ESRRA protein] |
CTD |
PMID:30104959 |
|
NCBI chr 1:204,104,100...204,114,182
Ensembl chr 1:204,104,101...204,114,268
|
|
G |
Foxo3 |
forkhead box O3 |
multiple interactions |
EXP |
trilobatin inhibits the reaction [Hydrogen Peroxide results in decreased expression of FOXO3 protein] |
CTD |
PMID:30104959 |
|
NCBI chr20:45,669,708...45,764,606
Ensembl chr20:45,672,995...45,764,561
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions |
EXP |
trilobatin inhibits the reaction [Hydrogen Peroxide results in decreased expression of GPX1 protein] |
CTD |
PMID:30104959 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
ISO EXP |
trilobatin promotes the reaction [Isoflurane results in increased expression of HMOX1 mRNA]; trilobatin promotes the reaction [Isoflurane results in increased expression of HMOX1 protein] trilobatin inhibits the reaction [Hydrogen Peroxide results in decreased expression of HMOX1 protein] |
CTD |
PMID:30104959 PMID:32663520 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Idh2 |
isocitrate dehydrogenase (NADP(+)) 2 |
multiple interactions |
EXP |
trilobatin inhibits the reaction [Hydrogen Peroxide results in decreased activity of IDH2 protein]; trilobatin inhibits the reaction [Hydrogen Peroxide results in decreased expression of IDH2 protein] |
CTD |
PMID:30104959 |
|
NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
trilobatin inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; trilobatin inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein] |
CTD |
PMID:25053100 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
trilobatin inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; trilobatin inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]; trilobatin inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein] |
CTD |
PMID:25053100 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Keap1 |
Kelch-like ECH-associated protein 1 |
multiple interactions |
EXP |
trilobatin inhibits the reaction [Hydrogen Peroxide results in increased expression of KEAP1 protein] |
CTD |
PMID:30104959 |
|
NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862
|
|
G |
Mt-atp6 |
mitochondrially encoded ATP synthase membrane subunit 6 |
multiple interactions |
EXP |
trilobatin inhibits the reaction [Hydrogen Peroxide results in decreased expression of ATP6 mRNA] |
CTD |
PMID:30104959 |
|
NCBI chr MT:7,919...8,599 NCBI chr MT:7,919...8,599 NCBI chr MT:7,919...8,599
Ensembl chr MT:7,919...8,599
|
|
G |
Mt-co1 |
mitochondrially encoded cytochrome c oxidase I |
multiple interactions |
EXP |
trilobatin inhibits the reaction [Hydrogen Peroxide results in decreased expression of COX1 mRNA] |
CTD |
PMID:30104959 |
|
NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867
Ensembl chr MT:5,323...6,867
|
|
G |
Mt-cyb |
mitochondrially encoded cytochrome b |
multiple interactions |
EXP |
trilobatin inhibits the reaction [Hydrogen Peroxide results in decreased expression of CYTB mRNA] |
CTD |
PMID:30104959 |
|
NCBI chr MT:14,136...15,278 NCBI chr MT:14,136...15,278 NCBI chr MT:14,136...15,278
Ensembl chr MT:14,136...15,278
|
|
G |
Mt-nd2 |
mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 2 |
multiple interactions |
EXP |
trilobatin inhibits the reaction [Hydrogen Peroxide results in decreased expression of ND2 mRNA] |
CTD |
PMID:30104959 |
|
NCBI chr MT:3,904...4,942 NCBI chr MT:3,904...4,942 NCBI chr MT:3,904...4,942
Ensembl chr MT:3,904...4,942
|
|
G |
Mt-nd5 |
mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 5 |
multiple interactions |
EXP |
trilobatin inhibits the reaction [Hydrogen Peroxide results in decreased expression of ND5 mRNA] |
CTD |
PMID:30104959 |
|
NCBI chr MT:11,736...13,565 NCBI chr MT:11,736...13,565 NCBI chr MT:11,736...13,565
Ensembl chr MT:11,736...13,565
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
EXP ISO |
trilobatin promotes the reaction [Hydrogen Peroxide affects the localization of NFE2L2 protein] NFE2L2 protein affects the reaction [trilobatin inhibits the reaction [Isoflurane results in decreased activity of CAT protein]]; trilobatin promotes the reaction [Isoflurane results in increased expression of NFE2L2 protein] |
CTD |
PMID:30104959 PMID:32663520 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
trilobatin inhibits the reaction [Lipopolysaccharides results in increased degradation of NFKBIA protein] |
CTD |
PMID:25053100 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
EXP ISO |
trilobatin inhibits the reaction [Hydrogen Peroxide results in decreased expression of NQO1 protein] trilobatin promotes the reaction [Isoflurane results in increased expression of NQO1 mRNA]; trilobatin promotes the reaction [Isoflurane results in increased expression of NQO1 protein] |
CTD |
PMID:30104959 PMID:32663520 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
multiple interactions |
EXP |
trilobatin inhibits the reaction [Hydrogen Peroxide results in decreased expression of PPARGC1A protein] |
CTD |
PMID:30104959 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
trilobatin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of RELA protein] |
CTD |
PMID:25053100 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Sirt3 |
sirtuin 3 |
multiple interactions |
EXP |
trilobatin inhibits the reaction [Hydrogen Peroxide results in decreased expression of SIRT3 mRNA]; trilobatin inhibits the reaction [Hydrogen Peroxide results in decreased expression of SIRT3 protein] |
CTD |
PMID:30104959 |
|
NCBI chr 1:195,942,066...195,964,472
Ensembl chr 1:195,942,073...195,964,808
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions |
EXP |
trilobatin inhibits the reaction [Hydrogen Peroxide results in decreased activity of SOD2 protein]; trilobatin inhibits the reaction [Hydrogen Peroxide results in increased acetylation of SOD2 protein] |
CTD |
PMID:30104959 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
trilobatin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; trilobatin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; trilobatin inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein] |
CTD |
PMID:25053100 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Ucp2 |
uncoupling protein 2 |
multiple interactions |
EXP |
trilobatin inhibits the reaction [Hydrogen Peroxide results in increased expression of UCP2 protein] |
CTD |
PMID:30104959 |
|
NCBI chr 1:154,839,242...154,845,612
Ensembl chr 1:154,839,209...154,845,611
|
|